PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ALTER, MJ; MARGOLIS, HS; KRAWCZYNSKI, K; JUDSON, FN; MARES, A; ALEXANDER, WJ; HU, PY; MILLER, JK; GERBER, MA; SAMPLINER, RE; MEEKS, EL; BEACH, MJ				ALTER, MJ; MARGOLIS, HS; KRAWCZYNSKI, K; JUDSON, FN; MARES, A; ALEXANDER, WJ; HU, PY; MILLER, JK; GERBER, MA; SAMPLINER, RE; MEEKS, EL; BEACH, MJ			THE NATURAL-HISTORY OF COMMUNITY-ACQUIRED HEPATITIS-C IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; ACUTE NON-A; CHRONIC LIVER-DISEASE; POSTTRANSFUSION HEPATITIS; VIRAL-HEPATITIS; VIRUS-INFECTION; EPIDEMIOLOGY; TRANSMISSION; ANTIBODIES; REGIONS	Background. Chronic liver disease develops in more than half of patients with post-transfusion hepatitis C, but little is known about the natural history of community-acquired hepatitis C. Methods. In 1985 and 1986 we identified adults with acute non-A, non-B hepatitis in four counties in the United States and followed them prospectively. We used three markers to detect hepatitis C virus (HCV) infection in stored samples of serum: antibody to HCV (anti-HCV) detected by second-generation serologic assays; HCV RNA detected by polymerase-chain-reaction assay; and antibody to HCV antigen (anti-HCVAg) detected by fluorescent-antibody-blocking assay. Results. Of 130 patients with non-A, non-B hepatitis, 106 (82 percent) had HCV infection, 93 were positive for anti-HCV, and 13 were positive only for HCV RNA or anti-HCVAg. Chronic hepatitis developed in 60 (62 percent) of 97 HCV-infected patients followed for 9 to 48 months, with no relation to the risk factors for infection. Ten of the 30 patients who had liver biopsies had chronic active hepatitis. In samples collected 42 to 48 months after the onset of hepatitis, HCV RNA was detected in 12 of 13 tested patients with chronic hepatitis and in all 15 tested patients with hepatitis that had resolved. Anti-HCV persisted in all but two of the initially positive patients, for a rate of antibody loss of 0.6 per 100 person-years. Conclusions. Patients with community-acquired hepatitis C have a high rate of chronic hepatitis. HCV may be a major cause of chronic liver disease in the United States, and in most patients HCV infection seems to persist for at least several years, even in the absence of active liver disease.	DENVER PUBL HLTH, DENVER, CO USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80262 USA; TACOMA PIERCE CTY DEPT HLTH, TACOMA, WA USA; JEFFERSON CTY DEPT HLTH, BIRMINGHAM, AL USA; PINELLAS CTY DEPT HLTH, ST PETERSBURG, FL USA; TULANE UNIV, SCH MED, DEPT PATHOL, NEW ORLEANS, LA 70112 USA; UNIV ARIZONA, ARIZONA HLTH SCI CTR, DEPT MED, TUCSON, AZ 85724 USA; VET AFFAIRS MED CTR, TUCSON, AZ USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Tulane University; University of Arizona; University of Arizona Health Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System	ALTER, MJ (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, HEPATITIS BRANCH, ATLANTA, GA 30333 USA.				PHS HHS [224-90-1002, 224-85-1001] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALTER HJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P396; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; [Anonymous], 1977, LANCET, V2, P914; BEACH MJ, 1992, J MED VIROL, V36, P226, DOI 10.1002/jmv.1890360314; BORTOLOTTI F, 1991, J HEPATOL, V12, P176, DOI 10.1016/0168-8278(91)90935-5; BRADLEY DW, 1983, J INFECT DIS, V148, P254, DOI 10.1093/infdis/148.2.254; GERBER MA, 1992, MODERN PATHOL, V5, P483; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; INOUE Y, 1991, NATURE, V353, P609, DOI 10.1038/353609a0; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MATHIESON RD, 1986, AM J CLIN PATHOL, V85, P353, DOI 10.1093/ajcp/85.3.353; MCHUTCHISON JG, 1991, GASTROENTEROLOGY, V101, P1117, DOI 10.1016/0016-5085(91)90742-4; MIMMS L, 1990, LANCET, V336, P1590, DOI 10.1016/0140-6736(90)93377-2; NAGATA A, 1985, AM J GASTROENTEROL, V80, P298; NORKRANS G, 1979, SCAND J INFECT DIS, V11, P259, DOI 10.3109/inf.1979.11.issue-4.01; PEREZROMERO M, 1990, ANN INTERN MED, V113, P411, DOI 10.7326/0003-4819-113-5-411; RAKELA J, 1979, GASTROENTEROLOGY, V77, P1200; RIESTRA S, 1990, ANN INTERN MED, V113, P411; SAMPLINER RE, 1984, J MED VIROL, V13, P125, DOI 10.1002/jmv.1890130203; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; 1986, MMWR MORB MORTAL WKL, V35, P655	29	1540	1573	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1899	1905		10.1056/NEJM199212313272702	http://dx.doi.org/10.1056/NEJM199212313272702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1280771				2022-12-28	WOS:A1992KE50500002
J	GOTTLIEB, DJ				GOTTLIEB, DJ			CALCIUM-CHANNEL BLOCKERS IN PRIMARY PULMONARY-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											GOTTLIEB, DJ (corresponding author), BOSTON UNIV,SCH MED,BOSTON,MA 02118, USA.							RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203	1	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1458	1458						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX479	1285785				2022-12-28	WOS:A1992JX47900018
J	IHDE, DC				IHDE, DC			DRUG-THERAPY - CHEMOTHERAPY OF LUNG-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SMALL-CELL-CARCINOMA; CROSS-RESISTANT CHEMOTHERAPY; COOPERATIVE-ONCOLOGY-GROUP; ALTERNATING COMBINATION CHEMOTHERAPY; LYMPH-NODE METASTASES; RANDOMIZED TRIAL; BRONCHOGENIC-CARCINOMA; STAGE-III; INDUCTION CHEMOTHERAPY; RADIATION-THERAPY				IHDE, DC (corresponding author), NCI, OFF DIRECTOR, BLDG 31, RM 11A48, BETHESDA, MD 20892 USA.							ALBERTO P, 1976, CANCER, V38, P2208, DOI 10.1002/1097-0142(197612)38:6<2208::AID-CNCR2820380603>3.0.CO;2-H; [Anonymous], MANUAL STAGING CANC; BATIST G, 1986, J CLIN ONCOL, V4, P982, DOI 10.1200/JCO.1986.4.6.982; BONOMI PD, 1989, J CLIN ONCOL, V7, P1602, DOI 10.1200/JCO.1989.7.11.1602; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BORK E, 1991, J CLIN ONCOL, V9, P1627, DOI 10.1200/JCO.1991.9.9.1627; BROWER M, 1983, AM J MED, V75, P993, DOI 10.1016/0002-9343(83)90880-X; BUNN PA, 1987, ANN INTERN MED, V106, P655, DOI 10.7326/0003-4819-106-5-655; CARNEY DN, 1990, SEMIN ONCOL, V17, P49; CELLERINO R, 1991, J CLIN ONCOL, V9, P1453, DOI 10.1200/JCO.1991.9.8.1453; CHABNER BA, 1990, J NATL CANCER I, V82, P1083, DOI 10.1093/jnci/82.13.1083; CHANG A, 1992, P AN M AM SOC CLIN, V11, P293; COHEN MH, 1977, CANCER TREAT REP, V61, P349; COHEN MH, 1979, CANCER TREAT REP, V63, P163; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; DAVIS S, 1980, CANCER TREAT REP, V64, P685; DAVIS S, 1981, CANCER TREAT REP, V65, P955; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; DONNADIEU N, 1991, LUNG CANCER, V7, P243; DURRANT KR, 1971, LANCET, V1, P715; EAGAN RT, 1977, CANCER TREAT REP, V61, P1339; EDMONSON JH, 1976, CANCER TREAT REP, V60, P925; EINHORN LH, 1982, CANCER TREAT REP, V66, P2005; EINHORN LH, 1988, J CLIN ONCOL, V6, P451, DOI 10.1200/JCO.1988.6.3.451; ELLIOTT JA, 1984, CANCER TREAT REV, V11, P103, DOI 10.1016/0305-7372(84)90002-1; ELLIOTT JA, 1984, EUR J CANCER CLIN ON, V20, P1025, DOI 10.1016/0277-5379(84)90104-4; ETTINGER DS, 1990, J CLIN ONCOL, V8, P230, DOI 10.1200/JCO.1990.8.2.230; EVANS WK, 1987, ANN INTERN MED, V107, P451, DOI 10.7326/0003-4819-107-4-451; FELD R, 1984, J CLIN ONCOL, V2, P1352, DOI 10.1200/JCO.1984.2.12.1352; FINKELSTEIN DM, 1986, J CLIN ONCOL, V4, P702, DOI 10.1200/JCO.1986.4.5.702; FUKUOKA M, 1991, J NATL CANCER I, V83, P855, DOI 10.1093/jnci/83.12.855; FUKUOKA M, 1992, J CLIN ONCOL, V10, P16, DOI 10.1200/JCO.1992.10.1.16; GANDARA DR, 1991, P AN M AM SOC CLIN, V10, P246; GANZ PA, 1989, CANCER, V63, P1271, DOI 10.1002/1097-0142(19890401)63:7<1271::AID-CNCR2820630707>3.0.CO;2-6; GIACCONE G, 1988, J CLIN ONCOL, V6, P1264, DOI 10.1200/JCO.1988.6.8.1264; GOLDIE JH, 1982, CANCER TREAT REP, V66, P439; GRALLA RJ, 1981, ANN INTERN MED, V95, P414, DOI 10.7326/0003-4819-95-4-414; GRANT SC, 1992, J CLIN ONCOL, V10, P484, DOI 10.1200/JCO.1992.10.3.484; GREEN RA, 1969, AM J MED, V46, P516, DOI 10.1016/0002-9343(69)90071-0; HOLMES EC, 1986, J CLIN ONCOL, V4, P710, DOI 10.1200/JCO.1986.4.5.710; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUMBLET Y, 1987, J CLIN ONCOL, V5, P1864, DOI 10.1200/JCO.1987.5.12.1864; IHDE DC, 1986, J CLIN ONCOL, V4, P1443, DOI 10.1200/JCO.1986.4.10.1443; IHDE DC, 1991, CURR PROB CANCER, V15, P109, DOI 10.1016/0147-0272(91)90012-Y; IHDE DC, 1991, CURR PROB CANCER, V15, P61; IHDE DC, 1991, P AN M AM SOC CLIN, V10, P240; JACKSON DV, 1988, J CLIN ONCOL, V6, P1161, DOI 10.1200/JCO.1988.6.7.1161; JOHNSON BE, 1990, J CLIN ONCOL, V8, P396, DOI 10.1200/JCO.1990.8.3.396; JOHNSON DH, 1990, J CLIN ONCOL, V8, P1613, DOI 10.1200/JCO.1990.8.10.1613; JOHNSON DH, 1990, ANN INTERN MED, V113, P33, DOI 10.7326/0003-4819-113-1-33; JOHNSON DH, 1987, J CLIN ONCOL, V5, P703, DOI 10.1200/JCO.1987.5.5.703; JOHNSON DH, 1987, J CLIN ONCOL, V5, P1731, DOI 10.1200/JCO.1987.5.11.1731; JOHNSON DH, 1992, P AN M AM SOC CLIN, V11, P288; JOHNSON RK, 1990, J NATL CANCER I, V82, P1082, DOI 10.1093/jnci/82.13.1082; KANASA S, 1991, CANCER, V67, P2443; KLASA RJ, 1991, J CLIN ONCOL, V9, P499, DOI 10.1200/JCO.1991.9.3.499; KLASTERSKY J, 1986, J CLIN ONCOL, V4, P1780, DOI 10.1200/JCO.1986.4.12.1780; KRIS MG, 1990, P AN M AM SOC CLIN, V9, P229; LAD T, 1988, J CLIN ONCOL, V6, P9; LECHEVALIER T, 1991, JNCI-J NATL CANCER I, V83, P417, DOI 10.1093/jnci/83.6.417; LECHEVALIER T, 1992, J NATL CANCER I, V84, P58; LEE JS, 1989, J CLIN ONCOL, V7, P916, DOI 10.1200/JCO.1989.7.7.916; LOWENBRAUN S, 1984, CANCER, V54, P2344, DOI 10.1002/1097-0142(19841201)54:11<2344::AID-CNCR2820541106>3.0.CO;2-C; LOWENBRAUN S, 1979, CANCER, V44, P406, DOI 10.1002/1097-0142(197908)44:2<406::AID-CNCR2820440206>3.0.CO;2-1; LUEDKE DW, 1990, J CLIN ONCOL, V8, P886, DOI 10.1200/JCO.1990.8.5.886; MARTINI N, 1983, ANN SURG, V198, P386, DOI 10.1097/00000658-198309000-00015; MARTINI N, 1988, ANN THORAC SURG, V45, P370, DOI 10.1016/S0003-4975(98)90007-8; MATTSON K, 1988, EUR J CANCER CLIN ON, V24, P477, DOI 10.1016/S0277-5379(98)90020-7; MCCRACKEN JD, 1990, J CLIN ONCOL, V8, P892, DOI 10.1200/JCO.1990.8.5.892; MEHTA C, 1982, P AM ASSOC CANC RES, V23, P155; MINNA JD, 1989, CANCER PRINCIPLES PR, V1, P591; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; MOUNTAIN CF, 1983, SEMIN ONCOL, V10, P71; MURPHY WK, 1992, P AN M AM SOC CLIN, V11, P294; MURRAY N, 1991, P AN M AM SOC CLIN, V10, P243; OCONNELL JP, 1986, J CLIN ONCOL, V4, P1604, DOI 10.1200/JCO.1986.4.11.1604; OSTERLIND K, 1983, CANCER RES, V43, P6085; OSTERLIND K, 1986, J CLIN ONCOL, V4, P1044, DOI 10.1200/JCO.1986.4.7.1044; PEREZ CA, 1984, J CLIN ONCOL, V2, P1200, DOI 10.1200/JCO.1984.2.11.1200; PEREZ CA, 1987, CANCER, V59, P1874, DOI 10.1002/1097-0142(19870601)59:11<1874::AID-CNCR2820591106>3.0.CO;2-Z; PERRY MC, 1987, NEW ENGL J MED, V316, P912, DOI 10.1056/NEJM198704093161504; PETROVICH Z, 1978, CANCER, V42, P1129, DOI 10.1002/1097-0142(197809)42:3<1129::AID-CNCR2820420315>3.0.CO;2-F; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; RIES LAG, 1991, NIH912789 PUBL; ROSSO R, 1990, TCANCER, V65, P130; ROTH BJ, 1992, J CLIN ONCOL, V10, P282, DOI 10.1200/JCO.1992.10.2.282; RUCKDESCHEL JC, 1986, J CLIN ONCOL, V4, P14, DOI 10.1200/JCO.1986.4.1.14; SCHAAKEKONING C, 1992, NEW ENGL J MED, V326, P524, DOI 10.1056/NEJM199202203260805; SHIELDS TW, 1977, CANCER, V40, P2057, DOI 10.1002/1097-0142(197711)40:5<2057::AID-CNCR2820400510>3.0.CO;2-O; SHIELDS TW, 1982, CANCER, V50, P1713, DOI 10.1002/1097-0142(19821101)50:9<1713::AID-CNCR2820500910>3.0.CO;2-B; SIKIC BI, 1991, J NATL CANCER I, V83, P738, DOI 10.1093/jnci/83.11.738; SKARIN A, 1989, J SURG ONCOL, V40, P266, DOI 10.1002/jso.2930400413; SMITH IE, 1985, CANCER TREAT REP, V69, P43; SORENSEN JB, 1987, J CLIN ONCOL, V5, P1169, DOI 10.1200/JCO.1987.5.8.1169; SPIRO SG, 1983, THORAX, V38, P501, DOI 10.1136/thx.38.7.501; SPIRO SG, 1989, BRIT J CANCER, V59, P578, DOI 10.1038/bjc.1989.117; SPITZER G, 1986, J CLIN ONCOL, V4, P4, DOI 10.1200/JCO.1986.4.1.4; SPLINTER TAW, 1988, P AN M AM SOC CLIN, V7, P202; TAYLOR SG, 1987, ANN THORAC SURG, V43, P87, DOI 10.1016/S0003-4975(10)60173-7; VALDIVIESO M, 1984, AM J MED, V76, P405, DOI 10.1016/0002-9343(84)90658-2; VERONESI A, 1988, AM J CLIN ONCOL-CANC, V11, P566, DOI 10.1097/00000421-198810000-00012; VIALLET J, 1991, CRIT REV ONCOL HEMAT, V11, P109, DOI 10.1016/1040-8428(91)90002-T; WEIDEN PL, 1991, J NATL CANCER I, V83, P266, DOI 10.1093/jnci/83.4.266; WEISENBURGER TH, 1986, NEW ENGL J MED, V315, P1377; WOODS RL, 1990, BRIT J CANCER, V61, P608, DOI 10.1038/bjc.1990.135; 1989, RESPIR MED, V83, P51	106	410	414	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1434	1441						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX479	1328881				2022-12-28	WOS:A1992JX47900006
J	GIANNINI, G; CLEMENTI, E; CECI, R; MARZIALI, G; SORRENTINO, V				GIANNINI, G; CLEMENTI, E; CECI, R; MARZIALI, G; SORRENTINO, V			EXPRESSION OF A RYANODINE RECEPTOR-CA2+ CHANNEL THAT IS REGULATED BY TGF-BETA	SCIENCE			English	Article							INOSITOL TRISPHOSPHATE; FUNCTIONAL EXPRESSION; CELL-PROLIFERATION; CALCIUM RELEASE; FLUCTUATIONS; INHIBITION; STORE; CDNA; DNA	Ryanodine receptors (RyRs) are intracellular channels that release calcium ions from the sarcoplasmic reticulum (SR) in response to either plasma membrane depolarization (in skeletal muscle) or increases in the concentration of intracellular free Ca2+ (in the heart). A gene (beta-4) encoding a ryanodine receptor (similar to, but distinct from, the muscle RyRs) was identified. The beta-4 gene was expressed in all tissues investigated, with the exception of heart. Treatment of mink lung epithelial cells (Mv1Lu) with transforming growth factor beta (TGF-beta) induced expression of the beta-4 gene together with the release of Ca2+ in response to ryanodine (but not in response to caffeine, the other drug active on muscle RyRs). This ryanodine receptor may be important in the regulation of intracellular Ca2+ homeostasis.	EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY; UNIV MILAN,DEPT PHARMACOL,I-20122 MILAN,ITALY; UNIV MILAN,IST SCI SAN RAFFAELE,I-20122 MILAN,ITALY	European Molecular Biology Laboratory (EMBL); University of Milan; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Giannini, Giuseppe/B-5672-2013; Sorrentino, Vincenzo/A-4793-2014; Marziali, Giovanna/J-9808-2016	Giannini, Giuseppe/0000-0003-0299-4056; Sorrentino, Vincenzo/0000-0002-8573-8631; Marziali, Giovanna/0000-0001-7450-1017; Ceci, Roberta/0000-0002-8900-8839				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CHEEK TR, 1991, BIOCHEM J, V275, P697, DOI 10.1042/bj2750697; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GIANNINI G, UNPUB; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTTSU K, 1990, J BIOL CHEM, V265, P13472; ROBERTS AB, 1990, HDB EXPT PHARM, V95, pCH8; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; VABREEMEN C, 1989, ANN REV PHYSL, V51, P315; VOLPE P, 1991, EMBO J, V10, P3183, DOI 10.1002/j.1460-2075.1991.tb04880.x; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	33	256	260	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					91	94		10.1126/science.1320290	http://dx.doi.org/10.1126/science.1320290			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1320290				2022-12-28	WOS:A1992JC16500037
J	GULYAS, KD; DONAHUE, TF				GULYAS, KD; DONAHUE, TF			SSL2, A SUPPRESSOR OF A STEM-LOOP MUTATION IN THE HIS4 LEADER ENCODES THE YEAST HOMOLOG OF HUMAN ERCC-3	CELL			English	Article							TRANSLATIONAL INITIATOR REGION; EUKARYOTIC MESSENGER-RNA; EXCISION REPAIR GENE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; BINDING-PROTEIN; BIOLOGICAL CHARACTERIZATION; SECONDARY STRUCTURE; PUTATIVE HELICASES; MOLECULAR-CLONING	Reversion of haploid, His4- yeast containing a stem-loop mutation in the 5' UTR that blocks HIS4 translation initiation identified four unlinked suppressor genes, SSL1-SSL4, which restore His4+ expression. The SSL2 gene encodes an essential 95 kd protein with ATP-dependent helicase motifs. SSL2 protein is 54% identical to the protein encoded by the human gene, ERCC-3, for which a defective form causes xeroderma pigmentosum and Cockayne's syndrome. An SSL2 allele made to resemble the defective ERCC-3 gene confers UV light hypersensitivity to yeast cells. Hence, SSL2 is the functional homolog of ERCC-3. However, the SSL2 suppressor gene does not restore HIS4 expression by removal of the stem-loop from DNA or the mRNA. We propose that SSL2 and ERCC-3 may have two functions, one defined by a UV repair defect, and a second essential function that is related to gene expression.			GULYAS, KD (corresponding author), INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032263, T32GM007757] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32263, GM07757] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CHANG TH, 1990, P NATL ACAD SCI USA, V87, P1571, DOI 10.1073/pnas.87.4.1571; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DONAHUE TF, 1982, GENE, V18, P47, DOI 10.1016/0378-1119(82)90055-5; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DONAHUE TF, 1988, MOL CELL BIOL, V8, P2955, DOI 10.1128/MCB.8.7.2955; DONAHUE TF, 1983, CELL, V32, P89, DOI 10.1016/0092-8674(83)90499-3; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FINK GR, 1974, GENETICS, V77, P231; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1980, CELL, V22, P7, DOI 10.1016/0092-8674(80)90148-8; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Maniatis T., 1982, MOL CLONING; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; NAUMOVSKI L, 1985, MOL CELL BIOL, V5, P17, DOI 10.1128/MCB.5.1.17; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; REYNOLDS P, 1985, NUCLEIC ACIDS RES, V13, P2357, DOI 10.1093/nar/13.7.2357; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUBY SW, 1991, TRENDS GENET, V7, P79; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ PJ, 1988, GENETICS, V120, P681; SCHMID SR, 1991, MOL CELL BIOL, V11, P3463, DOI 10.1128/MCB.11.7.3463; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P5125, DOI 10.1093/nar/14.13.5125; SHERMAN F, 1981, MOL BIOL YEAST SACCH, P301; SHERMAN F, 1972, METHODS YEAST GENETI; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SONG JM, 1990, J BACTERIOL, V172, P6620, DOI 10.1128/jb.172.12.6620-6630.1990; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; VALAVICIUS BC, 1990, GENETICS, V124, P483; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WEBER CA, 1988, MOL CELL BIOL, V8, P1137, DOI 10.1128/MCB.8.3.1137; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, MOL CELL BIOL, V10, P2570, DOI 10.1128/MCB.10.6.2570; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WILLIAMS NP, 1989, P NATL ACAD SCI USA, V86, P7515, DOI 10.1073/pnas.86.19.7515; WINSTON F, 1983, METHOD ENZYMOL, V101, P211	60	138	140	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					1031	1042		10.1016/0092-8674(92)90621-I	http://dx.doi.org/10.1016/0092-8674(92)90621-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1318786				2022-12-28	WOS:A1992HY79200014
J	HARDING, FA; MCARTHUR, JG; GROSS, JA; RAULET, DH; ALLISON, JP				HARDING, FA; MCARTHUR, JG; GROSS, JA; RAULET, DH; ALLISON, JP			CD28-MEDIATED SIGNALING CO-STIMULATES MURINE T-CELLS AND PREVENTS INDUCTION OF ANERGY IN T-CELL CLONES	NATURE			English	Article							HUMAN-LYMPHOCYTES; ANTIGEN; ACTIVATION; EXPRESSION; PATHWAY; COMPLEX	OCCUPANCY of the T-cell antigen receptor is insufficient to induce T-cell activation optimally; a second co-stimulatory signal is required 1. Exposure of T-cell clones to complexes of antigen with major histocompatibility complex molecules in the absence of the co-stimulatory signal induces a state of clonal anergy. This requirement for two stimuli for T-cell activation could have an important role in vivo in establishing peripheral tolerance to antigens not encountered in the thymus 1,2. The receptor on T cells required for the co-stimulatory stimulus involved in the prevention of anergy has not been identified. The human T-cell antigen CD28 provides a signal that can synergize with T-cell antigen receptor stimulation in activating T cells to proliferate and secrete lymphokines 3-6. Here we report that a monoclonal antibody against the murine homologue of CD28 (ref. 7; J.A.G. et al., manuscript in preparation) can provide a co-stimulatory signal to naive CD4+ T cells and to T-cell clones. Moreover, we demonstrate that this costimulatory signal can block the induction of anergy in T-cell clones.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; UNIV WASHINGTON,DEPT IMMUNOL SL05,SEATTLE,WA 98195	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle				Allison, James/0000-0001-8980-5697; Raulet, David/0000-0002-1257-8649				FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GROSS JA, 1990, J IMMUNOL, V144, P3201; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HANSEN JA, 1980, IMMUNOGENETICS, V10, P247, DOI 10.1007/BF01561573; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MARTIN PJ, 1986, J IMMUNOL, V136, P3282; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; WEISS A, 1986, J IMMUNOL, V137, P819	17	1556	1666	0	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					607	609		10.1038/356607a0	http://dx.doi.org/10.1038/356607a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1313950				2022-12-28	WOS:A1992HP03100050
J	CHEN, L; KRAUSE, M; DRAPER, B; WEINTRAUB, H; FIRE, A				CHEN, L; KRAUSE, M; DRAPER, B; WEINTRAUB, H; FIRE, A			BODY-WALL MUSCLE FORMATION IN CAENORHABDITIS-ELEGANS EMBRYOS THAT LACK THE MYOD HOMOLOG HLH-1	SCIENCE			English	Article							MYOSIN HEAVY-CHAIN; LOCALIZATION; EXPRESSION; GENE; IDENTIFICATION; ACTIVATION; ISOFORMS; LINEAGE	The myoD family of DNA binding proteins has been implicated in the control of myogenesis in a variety of organisms. Searches for homologs in the nematode Caenorhabditis elegans yielded only one gene, designated hlh-1, expressed in body-wall muscle cells and their precursors. To assess the role of hlh-1 in C. elegans myogenesis, genetic deficiencies spanning the hlh-1 locus were isolated after gamma irradiation. Embryos homozygous for these deficiencies exhibited extensive body-wall muscle differentiation, including expression of several characteristic myofilament proteins and weak contracile behavior. Thus, zygotic hlh-1 expression was not required for body-wall muscle precursors to adopt muscle cell fates.	CARNEGIE INST WASHINGTON,115 W UNIV PKWY,BALTIMORE,MD 21210; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT ZOOL,SEATTLE,WA 98195	Carnegie Institution for Science; Johns Hopkins University; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle				Krause, Michael/0000-0001-6127-3940; Draper, Bruce W/0000-0002-4397-7749; Fire, Andrew/0000-0001-6217-8312	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037706] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM037706] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDIZZI JP, 1987, J CELL BIOL, V105, P2763, DOI 10.1083/jcb.105.6.2763; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; EDGLEY ML, 1990, GENETIC MAPS, V5, P3111; EPSTEIN HF, 1974, J MOL BIOL, V90, P291, DOI 10.1016/0022-2836(74)90374-X; FRANCIS GR, 1985, J CELL BIOL, V101, P1532, DOI 10.1083/jcb.101.4.1532; GOH PY, 1991, DEVELOPMENT, V111, P667; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HARVEY RP, 1990, DEVELOPMENT, V108, P669; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE MO, UNPUB; MERRILL PT, 1988, DEVELOPMENT, V104, P495; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MILLER DM, 1986, P NATL ACAD SCI USA, V83, P2305, DOI 10.1073/pnas.83.8.2305; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; MOERMAN DG, 1988, GENE DEV, V2, P93, DOI 10.1101/gad.2.1.93; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; ROSENBLUTH RE, 1985, GENETICS, V109, P493; RUPP A, 1991, CELL, V65, P927; STORFER F, 1990, THESIS U COLORADO BO; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TAPSCOTT S, UNPUB; THAYER M, 1991, CELL, V65, P927; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; Waterston R., 1988, NEMATODE C ELEGANS, P281; WATERSTON RH, 1989, EMBO J, V8, P3429, DOI 10.1002/j.1460-2075.1989.tb08507.x; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	30	81	88	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					240	243		10.1126/science.1314423	http://dx.doi.org/10.1126/science.1314423			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1314423				2022-12-28	WOS:A1992HM89600035
J	MILLAR, JBA; RUSSELL, P				MILLAR, JBA; RUSSELL, P			THE CDC25 M-PHASE INDUCER - AN UNCONVENTIONAL PROTEIN PHOSPHATASE	CELL			English	Review							FISSION YEAST CDC25; MITOTIC INDUCER; MITOSIS; DIVISION; P80CDC25; HOMOLOG		UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,DEPT CELL BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; Scripps Institution of Oceanography	MILLAR, JBA (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,DEPT MOLEC BIOL,LA JOLLA,CA 92093, USA.			Millar, Jonathan/0000-0002-9930-3989				AGLAKTIONOV K, 1991, CELL, V67, P1181; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; NAGATA A, 1991, NEW BIOL, V3, P959; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0	22	246	255	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					407	410		10.1016/0092-8674(92)90177-E	http://dx.doi.org/10.1016/0092-8674(92)90177-E			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1310893				2022-12-28	WOS:A1992HD39800001
J	SUTTER, RW; COCHI, SL				SUTTER, RW; COCHI, SL			PERTUSSIS HOSPITALIZATIONS AND MORTALITY IN THE UNITED-STATES, 1985-1988 - EVALUATION OF THE COMPLETENESS OF NATIONAL REPORTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WHOOPING-COUGH; SURVEILLANCE; TRANSMISSION; EPIDEMIC	Objective. - To determine the magnitude of hospitalizations for pertussis and pertussis mortality and to estimate the total burden of clinically significant pertussis in the United States. Design. - Capture-recapture methods for estimating population size from independent surveillance systems were used to analyze morbidity and mortality data from case report forms received at the Centers for Disease Control (CDC) from the states, and compared these data with pertussis hospitalizations compiled from a database of US hospitals participating in the Commission on Professional and Hospital Activities-Professional Activities Survey (CPHA-PAS) and death certificate reports compiled by the National Center for Health Statistics (NCHS). Population Studied. - All pertussis hospitalizations and pertussis-related deaths in the United States, 1985 through 1988. Results. - We estimated that 13 557 pertussis hospitalizations (95% confidence interval [CI], 12953 to 14162) and 98 pertussis deaths had occurred during the 4-year study period (an average of more than 3300 hospitalizations and 25 deaths per year). The completeness of reporting hospitalizations to the CDC was 32% and to the CPHA-PAS, 23%, while the completeness of reporting pertussis deaths to the CDC was 33% and to NCHS, 23%. Patients who were hospitalized with per-tussis and reported to CDC were at a higher risk for developing pneumonia (31.0% vs 20.0%, relative risk [RR], 1.6; 95% CI, 1.4 to 1.7), seizures (3.7% vs 2.1 %; RR, 1.9; 95% CI, 1.4 to 2.5) and encephalitis (1.2% vs 0.2%; RR, 5.3; 95% CI, 2.4 to 11.6) compared with patients recorded in the CPHA-PAS system. Conclusions. - Our study suggests that there is substantial underreporting of pertussis, that severe complications of pertussis (including hospitalizations) are reported preferentially to the CDC, and that the national health impact of pertussis based on these indicators is considerably higher than previously published reports have suggested.			SUTTER, RW (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,INFORMAT SERV,MAILSTOP E07,ATLANTA,GA 30333, USA.							[Anonymous], 1951, U CALIFORNIA PUBLICA; BIELLIK RJ, 1988, J INFECT DIS, V157, P1134, DOI 10.1093/infdis/157.6.1134; BIELLIK RJ, 1989, 29TH INT C ANT AG CH, P145; BOWIE C, 1990, LANCET, V335, P397, DOI 10.1016/0140-6736(90)90220-Y; BROOME CV, 1981, J INFECT DIS, V144, P187, DOI 10.1093/infdis/144.2.187; CHERRY JD, 1990, JAMA-J AM MED ASSOC, V263, P1679; COCHI SL, 1989, AM J EPIDEMIOL, V129, P349, DOI 10.1093/oxfordjournals.aje.a115138; Cormack R. M., 1969, Oceanogr. mar. Biol., V6, P455; EDDINS DL, 1985, 20TH IMM C P DALL, P51; GRIFFITH AH, 1989, VACCINE, V7, P199, DOI 10.1016/0264-410X(89)90229-6; HALPERIN SA, 1989, J PEDIATR-US, V115, P686, DOI 10.1016/S0022-3476(89)80643-2; HICKS T, 1987, PERTUSSIS HAWAII COM; JENKINSON D, 1983, BRIT MED J, V287, P185, DOI 10.1136/bmj.287.6386.185; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; MILLER CL, 1976, BRIT MED J, P117; MORTIMER EA, 1990, J INFECT DIS, V161, P473, DOI 10.1093/infdis/161.3.473; NKOWANE BM, 1986, AM J DIS CHILD, V140, P433, DOI 10.1001/archpedi.1986.02140190043021; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; POLLOCK TM, 1984, ARCH DIS CHILD, V59, P162, DOI 10.1136/adc.59.2.162; SACKS JJ, 1985, AM J PUBLIC HEALTH, V75, P1420, DOI 10.2105/AJPH.75.12.1420; SNEDEOR GW, 1989, STATISTICAL METHODS; SUTTER RW, 1990, AM J EPIDEMIOL, V131, P132, DOI 10.1093/oxfordjournals.aje.a115466; WASSILAK S, 1983, 18TH P IMM C ATL GA, P37; 1987, PEDIATRIC LENGTH STA; 1988, PEDIATRIC LENGTH STA; 1985, MMWR, V34, P399; 1991, REPORT COMMITTEE INF, P358; 1991, MMWR, V40, P1; 1989, STATE IMMUNIZATION R; 1987, VITAL STATISTICS US, V2; 1989, PEDIATRIC LENGTH STA; 1977, INT CLASSIFICATION D; 1985, MMWR, V34, P390; 1983, MMWR, V32, P297; 1987, VERSION 6; 1990, MMWR, V38, P51; 1988, CATALOGUE PUBLIC USE; 1953, REPORTED INCIDENCE S; 1986, PEDIATRIC LENGTH STA	40	139	141	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1992	267	3					386	391		10.1001/jama.267.3.386	http://dx.doi.org/10.1001/jama.267.3.386			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY437	1309387				2022-12-28	WOS:A1992GY43700036
J	BELHAM, NDN				BELHAM, NDN			THE PRACTICAL PHYSICS OF HEARING-AIDS	BRITISH MEDICAL JOURNAL			English	Article											BELHAM, NDN (corresponding author), 7 BINYON CLOSE,EVESHAM WR11 5EY,WORCS,ENGLAND.							Terman F.E., 1955, RADIO ENG; 1991, ELECTRONICS MAPLIN M	2	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1569	1570		10.1136/bmj.305.6868.1569	http://dx.doi.org/10.1136/bmj.305.6868.1569			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286391	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100028
J	CANBY, S				CANBY, S			THE PHYSICIANS DUEL	BRITISH MEDICAL JOURNAL			English	Editorial Material											CANBY, S (corresponding author), BRITISH MUSEUM,DEPT ORIENTAL ANTIQUITIES,LONDON WC1B 3DG,ENGLAND.							NIZAMI GANJEH, KHAMSEH	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1544	1544		10.1136/bmj.305.6868.1544	http://dx.doi.org/10.1136/bmj.305.6868.1544			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286379	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100016
J	LOUDON, I				LOUDON, I			THE TRANSFORMATION OF MATERNAL MORTALITY	BRITISH MEDICAL JOURNAL			English	Article																		BAIRD D, 1960, LANCET, V2, P609; BAIRD D, 1960, LANCET, V2, P557; BRECKINRIDGE M, 1927, AM J PUBLIC HEALTH, V17, P1141; BRECKINRIDGE M, 1981, WIDE NEIGHBORHOODS; Crawford MD, 1932, LANCET, V1, P1239; DEAVITT N, 1979, WOMEN HLTH, V4, P169; DEAVITT N, 1979, WOMEN HLTH, V4, P81; DeLee JB, 1920, AM J OBSTET GYNECOL, V1, P34, DOI 10.1016/S0002-9378(20)90067-4; DeLee JB, 1933, J AMER MED ASSOC, V100, P6, DOI 10.1001/jama.1933.02740010008002; DELEE JB, 1920, AM J OBSTET GYNECOL, V1, P77; DeLee Joseph B., 1916, AM J OBST, V73, P407; DULEY L, 1992, BRIT J OBSTET GYNAEC, V99, P547, DOI 10.1111/j.1471-0528.1992.tb13818.x; FINDLEY P, 1918, NW MED, V17, P67; Kosmak GW, 1927, J AMER MED ASSOC, V89, P2009, DOI 10.1001/jama.1927.02690240001001; Levy J, 1923, AM J PUBLIC HEALTH, V13, P88, DOI 10.2105/AJPH.13.2.88; Levy Julius, 1918, AM J OBSTET, V77, P41; LOUDON I, 1990, BRIT MED J, V301, P703, DOI 10.1136/bmj.301.6754.703; LOUDON I, 1986, BMJ-BRIT MED J, V293, P606, DOI 10.1136/bmj.293.6547.606; LOUDON I, 1987, BMJ-BRIT MED J, V295, P485, DOI 10.1136/bmj.295.6596.485; Loudon I., 1992, DEATH CHILDBIRTH INT; MENDENHALL DR, 1929, MIDWIFERY DENMARK; PORGES RF, 1985, AM J OBSTET GYNECOL, V152, P642, DOI 10.1016/S0002-9378(85)80037-5; TANDY EC, 1935, CHILDRENS BUREAU PUB, V229; WILLIAMS JW, 1992, N Y STATE J MED, V22, P493; WOODBURY RM, 1926, CHILDRENS BUREAU PUB, V152; Young J, 1936, AM J OBSTET GYNECOL, V31, P198, DOI 10.1016/S0002-9378(36)90430-1; 1933, FETAL NEWBORN MATERN; MH66586688 PUBL REC; MH66909192 PUBL REC; 1933, MATERNAL MORTALITY N; 1981, REPORTS HLTH SOCIAL, V34; 1877, 38TH GEN REG OFF REP, P234; 1933, CHILDRENS BUREAU PUB, V221; 1932, FINAL REPORT DEP COM; 1941, PUBLIC HLTH REPORTS, V56, P855; 1878, 39TH GEN REG OFF REP, P242	36	38	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1557	1560		10.1136/bmj.305.6868.1557	http://dx.doi.org/10.1136/bmj.305.6868.1557			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286386	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992KD77100023
J	KOCH, AE; POLVERINI, PJ; KUNKEL, SL; HARLOW, LA; DIPIETRO, LA; ELNER, VM; ELNER, SG; STRIETER, RM				KOCH, AE; POLVERINI, PJ; KUNKEL, SL; HARLOW, LA; DIPIETRO, LA; ELNER, VM; ELNER, SG; STRIETER, RM			INTERLEUKIN-8 AS A MACROPHAGE-DERIVED MEDIATOR OF ANGIOGENESIS	SCIENCE			English	Article							SYNOVIAL TISSUE MACROPHAGES; TUMOR NECROSIS FACTOR; MESSENGER-RNA; NEUTROPHIL; PEPTIDE; NEOVASCULARIZATION; PURIFICATION; INHIBITION; INDUCTION; MONOCYTES	Angiogenic factors produced by monocytes-macrophages are involved in the pathogenesis of chronic inflammatory disorders characterized by persistent angiogenesis. The possibility was tested that interleukin-8 (IL-8), which is a cytokine that is chemotactic for lymphocytes and neutrophils, is also angiogenic. Human recombinant IL-8 was potently angiogenic when implanted in the rat cornea and induced proliferation and chemotaxis of human umbilical vein endothelial cells. Angiogenic activity present in the conditioned media of inflamed human rheumatoid synovial tissue macrophages or lipopolysaccharide-stimulated blood monocytes was equally blocked by antibodies to either IL-8 or tumor necrosis factor-alpha. An IL-8 antisense oligonucleotide specifically blocked the production of monocyte-induced angiogenic activity. These data suggest a function for macrophage-derived IL-8 in angiogenesis-dependent disorders such as rheumatoid arthritis, tumor growth, and wound repair.	UNIV MICHIGAN,DEPT OPHTHALMOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT MED,DIV PULM,ANN ARBOR,MI 48109; LAKESIDE VET ADM MED CTR,CHICAGO,IL 60611; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; LOYOLA UNIV,MED CTR,DEPT SURG,MAYWOOD,IL 60153	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Loyola University Chicago	KOCH, AE (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ARTHRIT & CONNECT TISSUE DIS SECT,WARD BLDG 3-315,CHICAGO,IL 60611, USA.		Koch, Alisa E/B-6894-2011; Polverini, Peter/AAJ-8392-2020; Huang, H/E-9490-2010		NHLBI NIH HHS [HL39926] Funding Source: Medline; NIAMS NIH HHS [AR30692, AR41492] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041492, P60AR030692] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BRENNAN FM, 1990, EUR J IMMUNOL, V20, P2141, DOI 10.1002/eji.1830200938; DEMARCO D, 1991, BIOCHEM BIOPH RES CO, V174, P411, DOI 10.1016/0006-291X(91)91431-B; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH AE, 1988, BIOCHEM BIOPH RES CO, V154, P205, DOI 10.1016/0006-291X(88)90671-7; KOCH AE, 1986, ARTHRITIS RHEUM, V29, P471, DOI 10.1002/art.1780290403; KOCH AE, 1991, J IMMUNOL, V147, P2187; KOCH AE, 1986, J LEUKOCYTE BIOL, V39, P233, DOI 10.1002/jlb.39.2.233; KOCH AE, 1988, J RHEUMATOL, V15, P1058; KOCH AE, 1991, AGENTS ACTIONS, V34, P350, DOI 10.1007/BF01988728; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEICHL P, 1992, ANN RHEUM DIS, V51, P19, DOI 10.1136/ard.51.1.19; POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0; POLVERINI PJ, 1989, CYTOKINES, P54; SCHRODER JM, 1986, J INVEST DERMATOL, V87, P53, DOI 10.1111/1523-1747.ep12523566; SELTZ M, 1991, J CLIN INVEST, V87, P463; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; STOECKLE M Y, 1990, New Biologist, V2, P313; VISSERS MCM, 1988, J IMMUNOL METHODS, V110, P203, DOI 10.1016/0022-1759(88)90104-4; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355	27	1858	1934	1	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1798	1801		10.1126/science.1281554	http://dx.doi.org/10.1126/science.1281554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1281554				2022-12-28	WOS:A1992KB96400040
J	BOCSKEI, Z; GROOM, CR; FLOWER, DR; WRIGHT, CE; PHILLIPS, SEV; CAVAGGIONI, A; FINDLAY, JBC; NORTH, ACT				BOCSKEI, Z; GROOM, CR; FLOWER, DR; WRIGHT, CE; PHILLIPS, SEV; CAVAGGIONI, A; FINDLAY, JBC; NORTH, ACT			PHEROMONE BINDING TO 2 RODENT URINARY PROTEINS REVEALED BY X-RAY CRYSTALLOGRAPHY	NATURE			English	Article							NASAL-MUCOSA; RESOLUTION; REFINEMENT; CRYSTALLIZATION; SEQUENCE; REGION	THE principal protein excreted in male rat urine, urinary alpha2-globulin and the homologous mouse protein, major urinary protein, have been well characterized, although their functions remain unclear. Male rat urine affects the behaviour and sexual response of female rats1, leading to the proposal that rodent urinary proteins are responsible for binding pheromones and their subsequent release from drying urine2. Urinary alpha2-globulin is also involved in hyaline droplet nephropathy, an important toxicological syndrome in male rats resulting from exposure to a number of industrial chemicals and characterized by the accumulation of liganded urinary alpha2-globulin in lysosomes in the kidney, followed by the induction of renal cancer3. We now report the three-dimensional structures of mouse major urinary protein (at 2.4 angstrom resolution) and rat urinary alpha2-globulin (at 2.8 angstrom resolution). The results corroborate the role of these proteins in pheromone transport and elaborate the structural basis of ligand binding.	UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV PARMA,IST FISIOL UMANA,I-43100 PARMA,ITALY	University of Leeds; University of Parma			Flower, Darren/F-1263-2010	Flower, Darren/0000-0002-8542-7067; Phillips, Simon/0000-0001-8922-0250; Groom, Colin/0000-0001-8921-9575	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BACCHINI A, IN PRESS EXPERIMENTI; BOCSKEI Z, 1991, J MOL BIOL, V218, P699, DOI 10.1016/0022-2836(91)90258-8; BORGHOFF SJ, 1990, ANNU REV PHARMACOL, V30, P349, DOI 10.1146/annurev.pa.30.040190.002025; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAVAGGIONI A, 1990, COMP BIOCHEM PHYS B, V96, P513, DOI 10.1016/0305-0491(90)90049-Y; CAVAGGIONI A, 1987, FEBS LETT, V212, P225, DOI 10.1016/0014-5793(87)81349-2; CHERFILS J, 1988, J APPL CRYSTALLOGR, V21, P985, DOI 10.1107/S002188988800932X; CLARK AJ, 1985, EMBO J, V4, P3159, DOI 10.1002/j.1460-2075.1985.tb04059.x; CLARK AJ, 1984, EMBO J, V3, P1045, DOI 10.1002/j.1460-2075.1984.tb01925.x; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; Cowley J. J., 1978, Biological determinants of sexual behaviour., P87; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; FLOWER DR, 1991, J MOL GRAPHICS, V9, P257, DOI 10.1016/0263-7855(91)80021-Q; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUBER R, 1987, J MOL BIOL, V195, P423, DOI 10.1016/0022-2836(87)90661-9; ICHIYOSHI Y, 1987, BIOCHIM BIOPHYS ACTA, V910, P43, DOI 10.1016/0167-4781(87)90093-5; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KIMURA H, 1991, J BIOL CHEM, V266, P5963; NORTH ACT, 1991, BIOCH SOC S, V57, P35; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PARRYSMITH DJ, 1991, COMPUT APPL BIOSCI, V7, P233; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; TIRINDELLI R, 1989, EUR J BIOCHEM, V185, P569, DOI 10.1111/j.1432-1033.1989.tb15151.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90	27	354	365	2	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					186	188		10.1038/360186a0	http://dx.doi.org/10.1038/360186a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1279439				2022-12-28	WOS:A1992JX75200069
J	MUSACCHIO, A; NOBLE, M; PAUPTIT, R; WIERENGA, R; SARASTE, M				MUSACCHIO, A; NOBLE, M; PAUPTIT, R; WIERENGA, R; SARASTE, M			CRYSTAL-STRUCTURE OF A SRC-HOMOLOGY-3 (SH3) DOMAIN	NATURE			English	Article							PHOSPHOLIPASE-C; ALPHA-SPECTRIN; PROTEIN; SRC; SIMILARITY; REFINEMENT; SEQUENCES; ELEMENTS; ERRORS; BRAIN	THE Src-homologous SH3 domain is a small domain present in a large number of proteins that are involved in signal transduction, such as the Src protein tyrosine kinase, or in membrane-cytoskeleton interactions, but the function of SH3 is still unknown (reviewed in refs 1-3). Here we report the three-dimensional structure at 1.8 angstrom resolution of the SH3 domain of the cytoskeletal protein spectrin expressed in Escherichia coli. The domain is a compact beta-barrel made of five antiparallel beta-strands. The amino acids that are conserved in the SH3 sequences are located close to each other on one side of the molecule. This surface is rich in aromatic and carboxylic amino acids, and is distal to the region of the molecule where the N and C termini reside and where SH3 inserts into the alpha-spectrin chain. We suggest that a protein ligand binds to this conserved surface of SH3.	EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)				Musacchio, Andrea/0000-0003-2362-8784; Noble, Martin/0000-0002-3595-9807				ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; Bennett V, 1990, CURR OPIN CELL BIOL, V2, P51, DOI 10.1016/S0955-0674(05)80030-4; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1988, ONCOGENE, V3, P491; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SAHR KE, 1990, J BIOL CHEM, V265, P4434; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; 1979, CCP4 PACKAGE	35	415	426	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					851	855		10.1038/359851a0	http://dx.doi.org/10.1038/359851a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279434				2022-12-28	WOS:A1992JV77700071
J	MIICK, SM; MARTINEZ, GV; FIORI, WR; TODD, AP; MILLHAUSER, GL				MIICK, SM; MARTINEZ, GV; FIORI, WR; TODD, AP; MILLHAUSER, GL			SHORT ALANINE-BASED PEPTIDES MAY FORM 3(10)-HELICES AND NOT ALPHA-HELICES IN AQUEOUS-SOLUTION	NATURE			English	Article							RIBONUCLEASE-A; PROTEINS; RESONANCE; SPECTRA; ANALOG	SHORT alanine peptides, containing 16 or 17 residues, appear to form alpha-helices in aqueous solution1-4. But the main spectroscopic analyses used on helical peptides (circular dichroism5 and nuclear magnetic resonance6-8) cannot distinguish between an alpha-helix (in which the ith residue is hydrogen-bonded to residue i + 4; ref. 9) a nd the next most common peptide helix, the 3(10)-helix10 (i --> i + 3 hydrogen-bonding). To address this problem we have designed single and doubly spin-labelled analogues of alanine-based peptides in which the nitroxide spin label forms an unbranched side chain extending from the sulphur atom of a cysteine residue. Here we report the circular dichroism, Fourier-transform infrared and electron-spin resonance spectra of these peptides under helix-forming conditions. The infrared absorbance gives an amide I' band with a frequency that is substantially different from that observed for alpha-helices. The electron-spin resonance spectra of doubly labelled helices show that the ranking of distances between side chains, around a single turn (residues 4-8), is inconsistent with an alpha-helical structure. Our experiments suggest that the more likely peptide geometry is a 3(10)-helix.	UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz								BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BRADLEY EK, 1990, J MOL BIOL, V215, P607, DOI 10.1016/S0022-2836(05)80172-X; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; DWIVEDI AM, 1984, BIOPOLYMERS, V23, P2025, DOI 10.1002/bip.360231016; FALLE HR, 1966, MOL PHYS, V11, P49, DOI 10.1080/00268976600100841; GAUTAM B, 1991, BIOPOLYMERS, V31, P1763; KARLE IL, 1990, BIOCHEMISTRY-US, V29, P6747, DOI 10.1021/bi00481a001; KENNEDY DF, 1991, BIOCHEMISTRY-US, V30, P6541, DOI 10.1021/bi00240a026; KRYSTEK SR, 1992, FEBS LETT, V299, P255, DOI 10.1016/0014-5793(92)80127-3; LEMAIRE H, 1968, MOL PHYS, V14, P441, DOI 10.1080/00268976800100551; LUCKHURST GR, 1976, SPIN LABELING THEORY, pCH4; MALCOLM BR, 1983, BIOPOLYMERS, V22, P319, DOI 10.1002/bip.360220140; MANNING MC, 1991, BIOPOLYMERS, V31, P569, DOI 10.1002/bip.360310511; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MERUTKA G, 1990, BIOCHEMISTRY-US, V29, P7511, DOI 10.1021/bi00484a021; MIICK SM, 1991, BIOCHEMISTRY-US, V30, P9498, DOI 10.1021/bi00103a016; OSTERHOUT JJ, 1989, BIOCHEMISTRY-US, V28, P7059, DOI 10.1021/bi00443a042; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PRESTRELSKI SJ, 1991, INT J PEPT PROT RES, V37, P508; TIRADORIVES J, 1991, BIOCHEMISTRY-US, V30, P3864, DOI 10.1021/bi00230a009; TODD AP, 1991, BIOCHEMISTRY-US, V30, P5515, DOI 10.1021/bi00236a026; TONIOLO C, 1991, TRENDS BIOCHEM SCI, V16, P350; Voet D VJ, 1990, BIOCHEMISTRY; WURTHRICH K, 1986, NMR PROTEINS NUCLEIC	25	213	213	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					653	655		10.1038/359653a0	http://dx.doi.org/10.1038/359653a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1328890				2022-12-28	WOS:A1992JT82400063
J	MISIANI, R; BELLAVITA, P; FENILI, D; BORELLI, G; MARCHESI, D; MASSAZZA, M; VENDRAMIN, G; COMOTTI, B; TANZI, E; SCUDELLER, G; ZANETTI, A				MISIANI, R; BELLAVITA, P; FENILI, D; BORELLI, G; MARCHESI, D; MASSAZZA, M; VENDRAMIN, G; COMOTTI, B; TANZI, E; SCUDELLER, G; ZANETTI, A			HEPATITIS-C VIRUS-INFECTION IN PATIENTS WITH ESSENTIAL MIXED CRYOGLOBULINEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C; CRYOGLOBULINEMIA; GLOMERULONEPHRITIS; HEPATITIS ANTIBODIES; RHEUMATOID FACTOR	LONG-TERM; B VIRUS; GLOMERULONEPHRITIS; VASCULITIS	Objective: To study the association between hepatitis C virus (HCV) infection and essential mixed cryoglobulinemia. Setting: Wards and clinics of the Ospedali Riuniti di Bergamo and Ospedale di Treviglio e Caravaggio, Italy. Patients: Fifty-one patients with essential mixed cryoglobulinemia associated with glomerulonephritis and 45 controls with noncryoglobulinemic glomerulopathies. Measurements: Antibodies to hepatitis C virus (anti-HCV) in sera from patients with essential mixed cryoglobulinemia and from controls, using two enzyme-linked immunosorbent assays (C100 ELISA and c22/c200 ELISA) and a recombinant immunoblot assay (4-RIBA); cryoprecipitate anti-HCV before and after use of dithiothreitol, a substance able to destroy IgM antibodies with rheumatoid factor activity, in patients with essential mixed cryoglobulinemia; serum HCV RNA by polymerase chain reaction in patients with essential mixed cryoglobulinemia. Results: In patients with essential mixed cryoglobulinemia, the c22/c200 ELISA detected anti-HCV in 98% of serum samples (95% Cl, 90% to 100%), whereas the rate of reactivity remained at 2% (Cl, 0% to 12%) in the control group (P < 0.0001). These results were confirmed by the 4-RIBA in 66% of patients with essential mixed cryoglobulinemia. The study of cryoprecipitate by c100 ELISA showed anti-HCV in 41% (Cl, 28% to 56%) of patients. After dithiothreitol, the rate of reactivity increased to 94% (Cl, 84% to 99%; P < 0.0001 by the McNemar paired chi-square test), suggesting that the elimination of rheumatoid factor leads to unmasking of anti-HCV in cryoprecipitate. Polymerase chain reaction detected HCV RNA in 13 of 16 sera from patients with essential mixed cryoglobulinemia. Conclusions: The extremely high prevalence of anti-HCV in serum and cryoprecipitate along with the frequently associated serum HCV RNA suggests a close relation between essential mixed cryoglobulinemia and chronic HCV infection.	OSPED RIUNITI BERGAMO, DEPT IMMUNOHEMATOL, LARGO BAROZZI 1, I-24100 BERGAMO, ITALY; OSPED TREVIGLIO & CARAVAGGIO, TREVIGLIO, SPAIN; UNIV MILAN, I-20122 MILAN, ITALY; UNIV CAMERINO, I-62032 CAMERINO, ITALY	Ospedali Riuniti di Bergamo; University of Milan; University of Camerino			Tanzi, Elisabetta/M-9066-2016	Tanzi, Elisabetta/0000-0002-4119-701X				BONOMO L, 1987, AM J MED, V83, P726, DOI 10.1016/0002-9343(87)90904-1; BONOMO L, 1971, CLIN EXP IMMUNOL, V9, P175; BOUDART D, 1990, LANCET, V336, P63, DOI 10.1016/0140-6736(90)91585-X; CASATO M, 1991, LANCET, V337, P1047, DOI 10.1016/0140-6736(91)92715-E; CORDONNIER D, 1975, AM J MED, V59, P867, DOI 10.1016/0002-9343(75)90480-5; CREAM JJ, 1971, BRIT J DERMATOL, V84, P48, DOI 10.1111/j.1365-2133.1971.tb14196.x; DURAND JM, 1991, LANCET, V337, P499, DOI 10.1016/0140-6736(91)93443-D; DUSSAIX E, 1990, LANCET, V335, P1160, DOI 10.1016/0140-6736(90)91163-5; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; HOUGHTON M, 1989, Patent No. 883109225; HURWITZ D, 1975, CLIN EXP IMMUNOL, V19, P131; JORI GP, 1977, GUT, V18, P245, DOI 10.1136/gut.18.3.245; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; LEVO Y, 1977, ANN INTERN MED, V87, P287, DOI 10.7326/0003-4819-87-3-287; MAGGIORE Q, 1982, KIDNEY INT, V21, P387, DOI 10.1038/ki.1982.34; Masson P L, 1981, Methods Enzymol, V74 Pt C, P106; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MCINTOSH RM, 1976, Q J MED, V45, P23; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MELTZER M, 1966, AM J MED, V40, P828, DOI 10.1016/0002-9343(66)90199-9; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; POPP JW, 1980, ANN INTERN MED, V92, P379, DOI 10.7326/0003-4819-92-3-379; REALDI G, 1974, Z IMMUNITATSFORSCH, V147, P114; Riethmuller G, 1966, Clin Exp Immunol, V1, P337; SINICO RA, 1988, KIDNEY INT, V34, P109, DOI 10.1038/ki.1988.152; SPALLUTO JL, 1962, AM J MED, V32, P142; TARANTINO A, 1978, CLIN EXP IMMUNOL, V32, P77; THEILMANN L, 1990, LANCET, V335, P1345; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I	31	518	523	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					573	577		10.7326/0003-4819-117-7-573	http://dx.doi.org/10.7326/0003-4819-117-7-573			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1326246				2022-12-28	WOS:A1992JQ22600005
J	STEINBERG, D; FERRUCCI, JT; HARRIS, NL; BLOCH, KJ; KADISON, P				STEINBERG, D; FERRUCCI, JT; HARRIS, NL; BLOCH, KJ; KADISON, P			A 49-YEAR-OLD WOMAN WITH PERIPHERAL NEUROPATHY, HEPATOSPLENOMEGALY, AND INTERMITTENT ABDOMINAL-PAIN - SYNDROME OF POLYNEUROPATHY, ORGANOMEGALY, ENDOCRINOPATHY, M COMPONENT, AND SKIN CHANGES (POEMS) - ATYPICAL LYMPHOID HYPERPLASIA WITH SOME FEATURES OF ANGIOFOLLICULAR HYPERPLASIA, SUGGESTIVE OF FOLLICULAR LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							PLASMA-CELL DYSCRASIA; NODE HYPERPLASIA; MYELOID METAPLASIA; M PROTEIN; DISEASE; NEUROPATHY; PATIENT; LESIONS		HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	STEINBERG, D (corresponding author), LAHEY CLIN FDN, HEMATOL SECT, BOSTON, MA 02215 USA.							BARDWICK PA, 1980, MEDICINE, V59, P311, DOI 10.1097/00005792-198007000-00006; BITTER MA, 1985, CANCER, V56, P188, DOI 10.1002/1097-0142(19850701)56:1<188::AID-CNCR2820560132>3.0.CO;2-Z; BOURDETTE DN, 1984, NEUROLOGY, V34, P532, DOI 10.1212/WNL.34.4.532; BOURONCLE BA, 1962, AM J MED SCI, V243, P697, DOI 10.1097/00000441-196206000-00001; CASTLEMAN B, 1956, CANCER, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4; CROW RS, 1956, BRIT MED J, V2, P802, DOI 10.1136/bmj.2.4996.802; DELANEY P, 1977, ANN INTERN MED, V87, P336, DOI 10.7326/0003-4819-87-3-336; DONAGHY M, 1989, J NEUROL SCI, V89, P253, DOI 10.1016/0022-510X(89)90027-0; DRIEDGER H, 1980, MEDICINE, V59, P301, DOI 10.1097/00005792-198007000-00005; FAM AG, 1986, ARTHRITIS RHEUM, V29, P233, DOI 10.1002/art.1780290212; FEDDERSEN RM, 1989, J AM ACAD DERMATOL, V21, P1061, DOI 10.1016/S0190-9622(89)70296-6; FRIZZERA G, 1988, SEMIN DIAGN PATHOL, V5, P346; FUKATSU A, 1991, CLIN NEPHROL, V36, P76; GABA AR, 1978, AM J CLIN PATHOL, V69, P86; GALLAGHER JC, 1991, ANN INTERN MED, V114, P520; GIUSEFFI V, 1991, NEUROLOGY, V41, P239, DOI 10.1212/WNL.41.2_Part_1.239; IMAWARI M, 1974, ANN INTERN MED, V81, P490, DOI 10.7326/0003-4819-81-4-490; ISHIKAWA O, 1987, BRIT J DERMATOL, V117, P523, DOI 10.1111/j.1365-2133.1987.tb04933.x; JACKSON A, 1990, POSTGRAD MED J, V66, P761, DOI 10.1136/pgmj.66.779.761; KANITAKIS J, 1988, ARCH DERMATOL, V124, P695, DOI 10.1001/archderm.124.5.695; KELLER AR, 1972, CANCER-AM CANCER SOC, V29, P670, DOI 10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#; KELLY JJ, 1983, NEUROLOGY, V33, P202, DOI 10.1212/WNL.33.2.202; KELLY JJ, 1985, MUSCLE NERVE, V8, P138, DOI 10.1002/mus.880080210; KYLE RA, 1983, MAYO CLIN PROC, V58, P665; LOEB JM, 1989, GASTROENTEROLOGY, V96, P247, DOI 10.1016/0016-5085(89)90789-0; LORINCZ AL, 1985, DERMATOLOGY, V2, P1273; MALLORY A, 1968, ANN INTERN MED, V69, P305, DOI 10.7326/0003-4819-69-2-305; MEISEL S, 1988, CHEST, V93, P1306, DOI 10.1378/chest.93.6.1306; MITCHELL MC, 1982, MEDICINE, V61, P199, DOI 10.1097/00005792-198207000-00001; MORROW JS, 1982, ARCH INTERN MED, V142, P1231, DOI 10.1001/archinte.142.6.1231; MUHLBAUER JE, 1982, JAMA-J AM MED ASSOC, V247, P3095, DOI 10.1001/jama.247.22.3095; MYERS BM, 1991, AM J MED, V90, P646; NAKANISHI T, 1984, NEUROLOGY, V34, P712, DOI 10.1212/WNL.34.6.712; OSSIAS AL, 1973, BRIT J HAEMATOL, V25, P179, DOI 10.1111/j.1365-2141.1973.tb01728.x; PITCOCK JA, 1962, ANN INTERN MED, V57, P73, DOI 10.7326/0003-4819-57-1-73; SAIKAWA S, 1980, Medical Journal of Kagoshima University, V32, P219; SCHAUMBURG HH, 1992, DISORDERS PERIPHERAL, V36; SCHEINKER I, 1938, NEUROLOGY, V147, P247; SHELLEY WB, 1987, ARCH DERMATOL, V123, P85, DOI 10.1001/archderm.123.1.85; Shimpo S, 1968, Nihon Rinsho, V26, P2444; SILVERSTEIN MN, 1974, ARCH INTERN MED, V134, P113, DOI 10.1001/archinte.134.1.113; STEWART PM, 1989, SCOT MED J, V34, P520, DOI 10.1177/003693308903400504; TSUJIMURA T, 1988, ACTA PATHOL JAPON, V38, P1337; VARKI A, 1983, MEDICINE, V62, P353, DOI 10.1097/00005792-198311000-00002; VIARD JP, 1988, AM J MED, V84, P524, DOI 10.1016/0002-9343(88)90277-X; WILLIAMS ME, 1985, ARCH INTERN MED, V145, P1308, DOI 10.1001/archinte.145.7.1308; YIANNIKAS C, 1983, NEUROLOGY, V33, P139, DOI 10.1212/WNL.33.2.139; 1984, NEW ENGL J MED, V311, P388	48	10	10	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					1014	1021						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1325606				2022-12-28	WOS:A1992JQ22500008
J	MIZUUCHI, M; BAKER, TA; MIZUUCHI, K				MIZUUCHI, M; BAKER, TA; MIZUUCHI, K			ASSEMBLY OF THE ACTIVE FORM OF THE TRANSPOSASE-MU DNA COMPLEX - A CRITICAL CONTROL POINT IN MU-TRANSPOSITION	CELL			English	Article							STRAND-TRANSFER-REACTION; INTEGRATION HOST FACTOR; BACTERIOPHAGE-MU; PHAGE-MU; B-PROTEIN; SITE; ENHANCER; ENDS; TRANSPOSOSOMES; RECOMBINATION	Discovery and characterization of a new intermediate in Mu DNA transposition allowed assembly of the transposition machinery to be separated from the chemical steps of recombination. This stable intermediate, which accumulates in the presence of Ca2+, consists of the two ends of the Mu DNA synapsed by a tetramer of the Mu transposase. Within this stable synaptic complex (SSC), the recombination sites are engaged but not yet cleaved. Thus, the SSC is structurally related to both the cleaved donor and strand transfer complexes, but precedes them on the transposition pathway. Once the active protein-DNA complex is constructed, it is conserved throughout transposition. The participation of internal sequence elements and accessory factors exclusively during SSC assembly allows recombination to be controlled prior to the irreversible chemical steps.			MIZUUCHI, M (corresponding author), NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; Cox M. M., 1989, MOBILE DNA, P661; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Furth M., 1983, LAMBDA 2, P145; GROENEN MAM, 1985, P NATL ACAD SCI USA, V82, P2087, DOI 10.1073/pnas.82.7.2087; HARSHEY RM, 1985, P NATL ACAD SCI USA, V82, P7676, DOI 10.1073/pnas.82.22.7676; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LABHART P, 1985, NUCLEIC ACIDS RES, V13, P8999, DOI 10.1093/nar/13.24.8999; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI M, 1986, NUCLEIC ACIDS RES, V14, P3813, DOI 10.1093/nar/14.9.3813; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MOSKOWITZ IPG, 1991, GENE DEV, V5, P1635, DOI 10.1101/gad.5.9.1635; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; THOMPSON JF, 1989, MOBILE DNA, P1; WEISBERG RA, 1983, LAMBDA, V2, P211	39	151	155	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					303	311		10.1016/0092-8674(92)90104-K	http://dx.doi.org/10.1016/0092-8674(92)90104-K			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1322248				2022-12-28	WOS:A1992JE75700013
J	HOSFORD, DA; CLARK, S; CAO, Z; WILSON, WA; LIN, FH; MORRISETT, RA; HUIN, A				HOSFORD, DA; CLARK, S; CAO, Z; WILSON, WA; LIN, FH; MORRISETT, RA; HUIN, A			THE ROLE OF GABA(B) RECEPTOR ACTIVATION IN ABSENCE SEIZURES OF LETHARGIC (IH/IH) MICE	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; PETIT-MAL EPILEPSY; THALAMIC NUCLEI; CALCIUM CURRENT; NEURONS; CAT; ELECTROPHYSIOLOGY; ETHOSUXIMIDE; POTENTIALS; RELEASE	Lethargic (lh/lh) mice, which function as an animal model of absence seizures, have spontaneous seizures that have behavioral and electrographic features and anticonvulsant sensitivity similar to those of human absence seizures. Antagonists of the gamma-aminobutyric acid(B) (GABA(B)) receptor suppressed these seizures in lethargic mice, whereas agonists of GABA(B) receptors exacerbated them. Furthermore, GABA(B) receptor binding and synaptically evoked GABA(B) receptor-mediated inhibition of N-methyl-D-aspartate responses were selectively increased in lh/lh mice. Therefore, enhanced GABA(B) receptor-mediated synaptic responses may underlie absence seizures in lh/lh mice, and GABA(B) receptor antagonists hold promise as anticonvulsants for absence seizures.	UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; VET ADM MED CTR,DURHAM,NC 27705	University of Nebraska System; University of Nebraska Medical Center; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	HOSFORD, DA (corresponding author), DUKE UNIV,MED CTR,DEPT MED NEUROL,DURHAM,NC 27710, USA.			Clark PharmBS PhD, Suzanne/0000-0002-7018-1113				BUZSAKI G, 1990, NEUROSCIENCE, V36, P1, DOI 10.1016/0306-4522(90)90345-5; CLARK S, 1991, EPILEPSIA S3, V32, P66; Cochran W.G, 1957, STAT METHODS, V6th ed; COULTER DA, 1989, ANN NEUROL, V25, P582, DOI 10.1002/ana.410250610; CRUNELLI V, 1988, J PHYSIOL-LONDON, V399, P153; CRUNELLI V, 1991, TRENDS NEUROSCI, V14, P16, DOI 10.1016/0166-2236(91)90178-W; CRUNELLI V, 1989, J PHYSIOL-LONDON, V413, P543, DOI 10.1113/jphysiol.1989.sp017668; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DESCHENES M, 1984, J NEUROPHYSIOL, V51, P1196, DOI 10.1152/jn.1984.51.6.1196; Dickie MM, 1964, MOUSE NEWS LETT, V30, P31; DUNG HC, 1971, TEX REP BIOL MED, V29, P273; HELLER AH, 1983, EPILEPSIA, V25, P25; HOSFORD D A, 1991, Society for Neuroscience Abstracts, V17, P170; JASPER HH, 1946, P ASS RES NERV MENT, V26, P272; KABRA PM, 1977, CLIN CHEM, V23, P1284; KARLSSON G, 1990, GABAB RECEPTORS IN MAMMALIAN FUNCTION, P349; KELLY KM, 1990, NEUROSCI LETT, V116, P233, DOI 10.1016/0304-3940(90)90416-7; KERR DIB, 1988, NEUROSCI LETT, V92, P92, DOI 10.1016/0304-3940(88)90748-3; KRALL RL, 1978, EPILEPSIA, V19, P409, DOI 10.1111/j.1528-1157.1978.tb04507.x; LIU Z, 1992, NEUROSCIENCE, V48, P87, DOI 10.1016/0306-4522(92)90340-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIRSKY AF, 1986, J CLIN NEUROPHYSIOL, V3, P179; MORRISETT RA, 1991, J NEUROSCI, V11, P203; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; Noebels J L, 1986, Adv Neurol, V44, P97; OLPE HR, 1990, EUR J PHARMACOL, V187, P27, DOI 10.1016/0014-2999(90)90337-6; PELLEGRINI A, 1979, EXP NEUROL, V66, P285, DOI 10.1016/0014-4886(79)90081-5; ROY JP, 1984, J NEUROPHYSIOL, V51, P1220, DOI 10.1152/jn.1984.51.6.1220; SHEN C, 1985, J NEUROSCI, V5, P2696; Sidman RL, 1965, CATALOG NEUROLOGICAL, P34; SNEAD OC, 1992, EUR J PHARMACOL, V213, P343, DOI 10.1016/0014-2999(92)90623-C; SNEAD OC, 1991, SOC NEUR ABSTR, V17, P506; SNEAD OC, 1991, EPILEPSIA S3, V32, P66; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; TAYLOR SM, 1985, EUR J PHARMACOL, V118, P163, DOI 10.1016/0014-2999(85)90675-2; WALDMEIER PC, 1988, N-S ARCH PHARMACOL, V337, P289; WILLIAMS D, 1953, BRAIN, V76, P50, DOI 10.1093/brain/76.1.50; YEH GC, 1989, P NATL ACAD SCI USA, V86, P8157, DOI 10.1073/pnas.86.20.8157	38	289	295	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					398	401		10.1126/science.1321503	http://dx.doi.org/10.1126/science.1321503			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1321503				2022-12-28	WOS:A1992JD67400037
J	FERNS, MJ; HALL, ZW				FERNS, MJ; HALL, ZW			HOW MANY AGRINS DOES IT TAKE TO MAKE A SYNAPSE	CELL			English	Review							ACETYLCHOLINE-RECEPTOR CLUSTERS; TORPEDO ELECTRIC ORGAN; CULTURED MUSCLE-CELLS; NEUROMUSCULAR-JUNCTION; MOTOR NEURONS; MOLECULES; COMPONENTS; MEMBRANE; PROTEIN; NERVE				FERNS, MJ (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Ferns, Michael/0000-0002-1545-3024				ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P757, DOI 10.1113/jphysiol.1977.sp011880; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092-8674(91)90364-5; COHEN MW, 1992, IN PRESS J NEUROSCI; FALLON JR, 1989, J CELL BIOL, V108, P1527, DOI 10.1083/jcb.108.4.1527; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FRANK E, 1979, J CELL BIOL, V83, P143, DOI 10.1083/jcb.83.1.143; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GODFREY EW, 1991, EXP CELL RES, V195, P99, DOI 10.1016/0014-4827(91)90504-N; GODFREY EW, 1988, DEV BIOL, V130, P471, DOI 10.1016/0012-1606(88)90343-0; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; LIETH E, 1992, DEV BIOL, V149, P41, DOI 10.1016/0012-1606(92)90262-F; MAGILLSOLC C, 1990, J EXP BIOL, V153, P1; MAGILLSOLC C, 1988, J CELL BIOL, V107, P1825, DOI 10.1083/jcb.107.5.1825; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; NASTUK MA, 1991, NEURON, V7, P807, DOI 10.1016/0896-6273(91)90283-6; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; RUPP F, 1992, IN PRESS J NEUROSCI; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1989, J NEUROSCI, V9, P1294	27	37	37	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					1	3		10.1016/0092-8674(92)90525-H	http://dx.doi.org/10.1016/0092-8674(92)90525-H			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1320460				2022-12-28	WOS:A1992JC95700001
J	WILLETT, F; CURZEN, N; ADAMS, J; ARMITAGE, M				WILLETT, F; CURZEN, N; ADAMS, J; ARMITAGE, M			CORONARY VASOSPASM INDUCED BY SUBCUTANEOUS SUMATRIPTAN	BRITISH MEDICAL JOURNAL			English	Letter											WILLETT, F (corresponding author), ROYAL BOURNEMOUTH HOSP,BOURNEMOUTH,ENGLAND.		curzen, nick/AAD-8161-2020					PEARCE JMS, 1991, BRIT MED J, V303, P1491, DOI 10.1136/bmj.303.6816.1491; 1991, NEW ENGL J MED, V325, P322; 1991, NEW ENGL J MED, V325, P316	3	83	83	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1415	1415		10.1136/bmj.304.6839.1415	http://dx.doi.org/10.1136/bmj.304.6839.1415			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1320974	Green Published, Bronze			2022-12-28	WOS:A1992HX08200020
J	KANO, M; REXHAUSEN, U; DREESSEN, J; KONNERTH, A				KANO, M; REXHAUSEN, U; DREESSEN, J; KONNERTH, A			SYNAPTIC EXCITATION PRODUCES A LONG-LASTING REBOUND POTENTIATION OF INHIBITORY SYNAPTIC SIGNALS IN CEREBELLAR PURKINJE-CELLS	NATURE			English	Article							GABAA RECEPTOR FUNCTION; PATCH-CLAMP; TERM DEPRESSION; PLASTICITY; DENDRITES; SYNAPSES; NEURONS; INVITRO; SLICES; RAT	PERSISTENT changes in synaptic efficacy are thought to underlie the formation of learning and memory in the brain 1. High-frequency activation of an afferent excitatory fibre system can induce long-term potentiation 2,3, and conjunctive activation of two distinct excitatory synaptic inputs to the cerebellar Purkinje cells can lead to long-term depression of the synaptic activity of one of the inputs 4. Here we report a new form of neural plasticity in which activation of an excitatory synaptic input can induce a potentiation of inhibitory synaptic signals to the same cell. In cerebellar Purkinje cells stimulation of the excitatory climbing fibre synapses is followed by a long-lasting (up to 75 min) potentiation of gamma-aminobutyric acid A (GABA(A)) receptor-mediated inhibitory postsynaptic currents (i.p.s.cs), a phenomenon that we term rebound potentiation. Using whole-cell patch-clamp recordings in combination with fluorometric video imaging of intracellular calcium ion concentration, we find that a climbing fibre-induced transient increase in postsynaptic calcium concentration triggers the induction of rebound potentiation: Because the response of Purkinje cells to bath-applied exogenous GABA is also potentiated after climbing fibre-stimulation with a time course similar to that of the rebound potentiation of i.p.s.cs, we conclude that the potentiation is caused by a calcium-dependent upregulation of postsynaptic GABA(A) receptor function. We propose that rebound potentiation is a mechanism by which in vivo block of climbing fibre activity induces an increase in excitability in Purkinje cells 5,6. Moreover, rebound potentiation of i.p.s.cs is a cellular mechanism which, in addition to the long-term depression of parallel fibre synaptic activity 4, may have an important role for motor learning in the cerebellum.	MAX PLANCK INST BIOPHYS CHEM,FASSBERG,W-3400 GOTTINGEN,GERMANY	Max Planck Society				Kano, Masanobu/0000-0002-0725-3292				BENEDETTI F, 1984, EXP BRAIN RES, V55, P368; CHEN QX, 1990, J PHYSIOL-LONDON, V420, P207, DOI 10.1113/jphysiol.1990.sp017908; CHEUN J E, 1991, Society for Neuroscience Abstracts, V17, P602; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; ECCLES JC, 1966, J PHYSIOL-LONDON, V182, P268, DOI 10.1113/jphysiol.1966.sp007824; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRISON NL, 1989, NEUROSCI LETT, V105, P137, DOI 10.1016/0304-3940(89)90025-6; INOUE M, 1986, NATURE, V324, P156, DOI 10.1038/324156a0; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Ito M, 1990, Neuroreport, V1, P129; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KANO M, 1988, NEUROSCI RES, V5, P544, DOI 10.1016/0168-0102(88)90041-7; KNOPFEL T, 1991, EUR J NEUROSCI, V3, P343, DOI 10.1111/j.1460-9568.1991.tb00821.x; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; KONNERTH A, IN PRESS P NATN ACAD; KUBA K, 1990, PROG NEUROBIOL, V34, P197, DOI 10.1016/0301-0082(90)90012-6; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; LLANO I, 1991, NEURON, V7, P577, DOI 10.1016/0896-6273(91)90370-F; LLANO I, 1991, NEURON, V6, P565, DOI 10.1016/0896-6273(91)90059-9; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; MARCHENKO SM, 1991, BRAIN RES, V546, P355, DOI 10.1016/0006-8993(91)91502-R; MONTAROLO PG, 1982, J PHYSIOL-LONDON, V332, P187, DOI 10.1113/jphysiol.1982.sp014409; MOUGINOT D, 1991, J PHYSL, V427, P109; MULLE C, 1992, NEURON, V8, P135, DOI 10.1016/0896-6273(92)90115-T; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; ROSS WN, 1987, J PHYSIOL-LONDON, V389, P319, DOI 10.1113/jphysiol.1987.sp016659	32	312	315	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					601	604		10.1038/356601a0	http://dx.doi.org/10.1038/356601a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1313949				2022-12-28	WOS:A1992HP03100048
J	PATERSON, Y				PATERSON, Y			MAPPING ANTIBODY-BINDING SITES ON PROTEIN ANTIGENS	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; CYTOCHROME-C; COMPLEX; EXCHANGE; NMR	The large surfaces of protein antigens that interact with antibody-combining sites can be determined using deuterium-exchange labelling and two-dimensional H-1 nuclear magnetic resonance (NMR). This technique may also be applied to other protein-protein interactions to identify key residues that contribute to the affinity.			PATERSON, Y (corresponding author), UNIV PENN, SCH MED, DEPT MICROBIOL, 209 JOHNSON PAVIL, PHILADELPHIA, PA 19104 USA.			Paterson, Yvonne/0000-0002-9406-4958				AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENTLEY GA, 1989, COLD SH Q B, V54, P239; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; JEMMERSON R, 1986, SCIENCE, V232, P1001, DOI 10.1126/science.2422757; MARKLEY JL, 1989, METHOD ENZYMOL, V176, P12; MYLVAGANAM SE, 1991, J MOL BIOL, V221, P455, DOI 10.1016/0022-2836(91)80066-4; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PATERSON Y, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P177; PATERSON Y, 1990, SCIENCE, V249, P755, DOI 10.1126/science.1697101; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0	14	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 2	1992	356	6368					456	457		10.1038/356456a0	http://dx.doi.org/10.1038/356456a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1313552				2022-12-28	WOS:A1992HL83000072
J	DEVRIES, C; ESCOBEDO, JA; UENO, H; HOUCK, K; FERRARA, N; WILLIAMS, LT				DEVRIES, C; ESCOBEDO, JA; UENO, H; HOUCK, K; FERRARA, N; WILLIAMS, LT			THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR	SCIENCE			English	Article							PERMEABILITY FACTOR; CELL MITOGEN; AMINO-ACID; FAMILY; EXPRESSION; SEQUENCE; SECRETE; FLT	The fms-like tyrosine kinase (Flt) is a transmembrane receptor in the tyrosine kinase family. Expression of flt complementary DNA in COS cells conferred specific, high-affinity binding of vascular endothelial growth factor, also known as vascular permeability factor (VEGF-VPF), a factor that induces vascular permeability when injected in the guinea pig skin and stimulates endothelial cell proliferation. Expression of Flt in Xenopus laevis oocytes caused the oocytes to release calcium in response to VEGF-VPF. These findings show that flt encodes a receptor for VEGF-VPF.	UNIV CALIF SAN FRANCISCO,DEPT MED,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Roche Holding; Genentech			Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249	NHLBI NIH HHS [R01 HL-32898, P01 HL-43821] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898, P01HL043821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BETSHOLTZ C, 1990, NATURE, V344, P299, DOI 10.1038/344299a0; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; CRISCUOLO GR, 1988, J NEUROSURG, V69, P254, DOI 10.3171/jns.1988.69.2.0254; DEVRIES CAM, UNPUB; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V127, P121, DOI 10.1002/jcp.1041270116; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEUNG DW, 1991, METHOD ENZYMOL, V198, P391; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; OLANDER V, 1991, BIOCHEM BIOPH RES CO, V175, P68; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; SATOH H, 1987, JPN J CANCER RES, V78, P772; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1990, CANCER RES, V50, P1774; SHIBUYA M, 1990, ONCOGENE, V5, P519; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; YARDEN Y, 1988, ANN REV BIOCH, V57	31	1830	1996	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					989	991		10.1126/science.1312256	http://dx.doi.org/10.1126/science.1312256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1312256				2022-12-28	WOS:A1992HE60500042
J	BENGAL, E; RANSONE, L; SCHARFMANN, R; DWARKI, VJ; TAPSCOTT, SJ; WEINTRAUB, H; VERMA, IM				BENGAL, E; RANSONE, L; SCHARFMANN, R; DWARKI, VJ; TAPSCOTT, SJ; WEINTRAUB, H; VERMA, IM			FUNCTIONAL ANTAGONISM BETWEEN C-JUN AND MYOD PROTEINS - A DIRECT PHYSICAL ASSOCIATION	CELL			English	Article							LEUCINE ZIPPER DOMAIN; DNA-BINDING PROTEINS; MYOGENIC DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; AUTO-REGULATION; FOS; CELLS; MYC; ENHANCER; ELEMENT	The product of the proto-oncogene Jun inhibits myogenesis. Constitutive expression of Jun in myoblasts interferes with the expression and the function of MyoD protein. In transient transfection assays Jun inhibits transactivation of the MyoD promoter, the muscle creatine kinase enhancer, and a reporter gene linked to MyoD DNA-binding sites. Conversely, MyoD suppresses the transactivation by Jun of genes linked to an AP-1 site. We demonstrate that both in vivo and in vitro MyoD and Jun proteins physically interact. Mutational analysis suggests that this interaction occurs via the leucine zipper domain of Jun and the helix-loop-helix region of MyoD.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	BENGAL, E (corresponding author), SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186, USA.		scharfmann, raphael/L-3296-2017	Scharfmann, Raphael/0000-0001-7619-337X	NATIONAL CANCER INSTITUTE [F32CA008585] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08585-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JONAT G, 1990, CELL, V62, P1189; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SU HY, 1991, ONCOGENE, V6, P1759; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	44	409	411	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					507	519		10.1016/0092-8674(92)90187-H	http://dx.doi.org/10.1016/0092-8674(92)90187-H			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1310896				2022-12-28	WOS:A1992HD39800011
J	FRASER, I				FRASER, I			LEARNING SURGERY IN PARIS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1548	1549		10.1136/bmj.305.6868.1548	http://dx.doi.org/10.1136/bmj.305.6868.1548			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KD771	1286382	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992KD77100019
J	JONES, PF				JONES, PF			2 19TH-CENTURY SURGEONS	BRITISH MEDICAL JOURNAL			English	Editorial Material									UNIV ABERDEEN,ABERDEEN AB9 1FX,SCOTLAND	University of Aberdeen	JONES, PF (corresponding author), 7 PK RD,CULTS AB1 9HR,ABERDEEN,SCOTLAND.							BULLOCH W, 1929, LANCET, V1, P309; Fisher R. B., 1977, J LISTER 1827 1912; Keith William, 1844, Edinb Med Surg J, V61, P396; Keith William, 1844, Edinb Med Surg J, V61, P123; Lister J, 1867, LANCET, V90, P353, DOI [10.1016/S0140-6736(02)51827-4, DOI 10.1016/S0140-6736(02)51827-4]; MACKENZIE H, 1953, CITY ABERDEEN 3RD ST; Ogston A., 1880, ARCH KLIN CHIR, V25, P588; OGSTON A, 1943, A OGSTON KCVO, P98; OGSTON A, 1943, A OGSTON KCVO, P93; Ogston Alexander, 1877, Edinb Med J, V22, P782	10	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1546	1548		10.1136/bmj.305.6868.1546	http://dx.doi.org/10.1136/bmj.305.6868.1546			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286381	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100018
J	KIRKER, S				KIRKER, S			CONVULSIONS AT CHRISTMAS	BRITISH MEDICAL JOURNAL			English	Article											KIRKER, S (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BENNETT DR, 1963, NEUROLOGY, V13, P953, DOI 10.1212/WNL.13.11.953; GUNDERSO.CH, 1973, NEUROLOGY, V23, P678, DOI 10.1212/WNL.23.7.678	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1580	1580		10.1136/bmj.305.6868.1580	http://dx.doi.org/10.1136/bmj.305.6868.1580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286400	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100038
J	KNEEBONE, RL				KNEEBONE, RL			MUSIC MAKING	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1567	1568		10.1136/bmj.305.6868.1567	http://dx.doi.org/10.1136/bmj.305.6868.1567			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286389	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992KD77100026
J	ROBERTS, RW; CROTHERS, DM				ROBERTS, RW; CROTHERS, DM			STABILITY AND PROPERTIES OF DOUBLE AND TRIPLE HELICES - DRAMATIC EFFECTS OF RNA OR DNA BACKBONE COMPOSITION	SCIENCE			English	Article							RIBONUCLEASE-H; HYBRID; INHIBITION; OLIGONUCLEOTIDE; TRANSCRIPTION; POLYMERASE; PROMOTER; BINDING; R(GCG)D(TATACGC); CLEAVAGE	Studies of a series of short oligonucleotide double and triple helices containing either all RNA, all DNA, or a mixture of the two show strand-dependent variation in their stability and structure. The variation in stability for both groups falls over a range of greater than 10 kilocalories per mole. In forming the triple helix, RNA is favored on both pyrimidine strands, whereas DNA is favored on the purine strand. In general, relatively unstable duplexes form particularly stable triplexes and vice versa. Structural data indicate that the strands in hybrid helices adopt a conformation that is intermediate between molecules containing all DNA and all RNA. Thus, RNA-DNA hybrids were not forced into the conformation of the RNA (A-form). The provocative stability of the triplex with an RNA third strand + DNA duplex points to novel antisense strategies and opens the possibility of an in vivo role of these structures. Overall, the data emphasize the fundamental role of sugars in determining the properties of nucleic acid complexes.			ROBERTS, RW (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.				NIAMS NIH HHS [GAR21966] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOTT S, 1986, J MOL BIOL, V188, P631, DOI 10.1016/S0022-2836(86)80011-0; ARNOTT S, 1976, NUCLEIC ACIDS RES, V3, P2459, DOI 10.1093/nar/3.10.2459; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BIRG F, 1990, NUCLEIC ACIDS RES, V18, P2901, DOI 10.1093/nar/18.10.2901; CHAMBERLIN MJ, 1965, FED PROC, V24, P1446; CHOU SH, 1989, BIOCHEMISTRY-US, V28, P2435, DOI 10.1021/bi00432a014; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; GRAY DM, 1980, NUCLEIC ACIDS RES, V8, P3695, DOI 10.1093/nar/8.16.3695; HAASNOOT CAG, 1983, J BIOMOL STRUCT DYN, V1, P131, DOI 10.1080/07391102.1983.10507430; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEHRMAN EA, 1977, NUCLEIC ACIDS RES, V4, P1381, DOI 10.1093/nar/4.5.1381; MACAYA R, 1992, J MOL BIOL, V225, P755, DOI 10.1016/0022-2836(92)90399-5; MACAYA RF, 1992, J AM CHEM SOC, V114, P781, DOI 10.1021/ja00028a067; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MELLEMA JR, 1983, NUCLEIC ACIDS RES, V11, P5717, DOI 10.1093/nar/11.16.5717; MILLER HI, 1973, J BIOL CHEM, V248, P2621; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; ROBERTS RL, UNPUB; ROBERTS RW, 1991, P NATL ACAD SCI USA, V88, P9397, DOI 10.1073/pnas.88.21.9397; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0; WETMUR JG, 1991, CRIT REV BIOCHEM MOL, V26, P227, DOI 10.3109/10409239109114069; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	39	444	475	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1463	1466		10.1126/science.1279808	http://dx.doi.org/10.1126/science.1279808			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279808				2022-12-28	WOS:A1992JZ62500022
J	FISHER, AR; BAILEY, CR; SHANNON, CN; WIELOGORSKI, AK				FISHER, AR; BAILEY, CR; SHANNON, CN; WIELOGORSKI, AK			HEPARIN RESISTANCE AFTER APROTININ	LANCET			English	Letter							BLOOD				FISHER, AR (corresponding author), BROOK GEN HOSP,CARDIOTHORAC UNIT,LONDON SE18 4LW,ENGLAND.			Bailey, Craig/0000-0002-7084-3842				BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364; HORKAY F, 1992, 12TH ANN SAN DIEG CA, P188; HUNT BJ, 1992, J THORAC CARDIOV SUR, V104, P211; ROYSTON D, 1987, LANCET, V2, P1289	4	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1230	1231		10.1016/0140-6736(92)92935-9	http://dx.doi.org/10.1016/0140-6736(92)92935-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1279335				2022-12-28	WOS:A1992JY38600042
J	QUINTON, PM; REDDY, MM				QUINTON, PM; REDDY, MM			CONTROL OF CFTR CHLORIDE CONDUCTANCE BY ATP LEVELS THROUGH NONHYDROLYTIC BINDING	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CHANNEL	SITE-SPECIFIC mutation1 and membrane reconstitution2 experiments provide compelling evidence that the product of the gene which is at fault in the disease cystic fibrosis, termed the cystic fibrosis transmembrane conductance regulator (CFTR)3, is a small-conductance chloride channel activated by phosphorylation4. As transport of chloride ions is passive, the predicted presence of two nucleotide-binding domains in CFTR seems as puzzling as a report5 that ATP hydrolysis is essential to activate the channel. We now find that in the sweat duct, which expresses high levels of CFTR6 and has a very high Cl- conductance7, intracellular concentrations of ATP must be about normal (5 mM)8 for activation of this conductance, apparently by a non-hydrolytic, perhaps allosteric, mechanism. This passive dependence on ATP should mean that even a modest depletion of cell energy levels will significantly lower the energy demands of electrolyte transport by decreasing chloride conductance. We believe this direct coupling between cellular ATP levels and chloride channel activity is an adaptive mechanism to protect the tissue from damage resulting from excessive energy depletion9.			QUINTON, PM (corresponding author), UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521, USA.							ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; ATKINSON DE, 1977, METABOLISM ITS REGUL; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; KARTNER N, IN PRESS NATURE GENE; QUINTON PM, 1991, ADV EXP MED BIOL, V290, P159; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; RIORDAN JR, 1989, SCIENCE, V245, P1066; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4	17	164	165	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					79	81		10.1038/360079a0	http://dx.doi.org/10.1038/360079a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1279436				2022-12-28	WOS:A1992JW71700060
J	VILLAR, J; FARNOT, U; BARROS, F; VICTORA, C; LANGER, A; BELIZAN, JM				VILLAR, J; FARNOT, U; BARROS, F; VICTORA, C; LANGER, A; BELIZAN, JM			A RANDOMIZED TRIAL OF PSYCHOSOCIAL SUPPORT DURING HIGH-RISK PREGNANCIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BIRTH-WEIGHT; HEALTH-EDUCATION; PRENATAL-CARE; FETAL GROWTH; SUPPLEMENTATION; LABOR; DELIVERY; WOMEN	Background. It is often suggested that psychological and social support and health education for women at high risk for delivering a low-birth-weight infant can improve the outcomes of pregnancy, but the evidence is inconclusive. We undertook this prospective trial to evaluate a program of home visits designed to provide psychosocial support during pregnancy. Methods. At four centers in Latin America, 2235 women at higher-than-average risk for delivering a low-birth-weight infant were recruited before the 20th week of pregnancy. The women were randomly assigned either to an intervention group (n = 1115) that received four to six home visits from a nurse or social worker in addition to routine prenatal care or to a control group (n = 1120) that received only routine prenatal care (with a mean of eight prenatal visits). The principal measures of outcome were low birth weight (<2500 g), preterm delivery (<37 weeks of gestation), and specified categories of maternal and neonatal morbidity. Results. The women who received the home visits as well as routine prenatal care had outcomes that differed little from those of the women who received only routine care. The risks of low birth weight (odds ratio for the intervention group as compared with the control group, 0.93; 95 percent confidence interval, 0.68 to 1.28), preterm delivery (odds ratio, 0.88; 95 percent confidence interval, 0.67 to 1.16), and intrauterine growth retardation (odds ratio, 1.08; 95 percent confidence interval, 0.83 to 1.40) were similar in the two groups. There was no evidence that the intervention had any significant effect on the type of delivery, the length of hospital stay, perinatal mortality, or neonatal morbidity in the first 40 days. There was no protective effect of the psychosocial-support program even among the mothers at highest risk. Conclusions. Interventions designed to provide psychosocial support and health education during high-risk pregnancies are unlikely to improve maternal health or to reduce the incidence of low birth weight among infants.	CTR ROSARINO ESTUDIOS PERINATALES,ROSARIO,ARGENTINA; MINIST PUBL HLTH CUBA,HOSP AMER ARIAS,HAVANA,CUBA; UNIV FED PELOTAS,CTR PERQUISAS EPIDEMIOL,PELOTAS,BRAZIL; NATL INST HLTH,CTR INVEST SALUD PUBL,CUERNAVAVA,MEXICO; NATL INST PERINATOL,MEXICO CITY,MEXICO	Universidade Federal de Pelotas			Victora, Cesar G/D-4476-2013; Victora, Cesar Gomes/Y-2455-2019; Barros, Fernando C/D-4857-2013	Victora, Cesar G/0000-0002-2465-2180; Victora, Cesar Gomes/0000-0002-2465-2180; Belizan, Jose/0000-0002-8412-3010				BARROS F C, 1985, World Health Forum, V6, P322; Barros F C, 1990, Paediatr Perinat Epidemiol, V4, P205, DOI 10.1111/j.1365-3016.1990.tb00639.x; Belizan J M, 1989, Bull Pan Am Health Organ, V23, P414; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BERKOWITZ GS, 1983, J PSYCHOSOM RES, V27, P283, DOI 10.1016/0022-3999(83)90050-8; BLONDEL B, 1990, EUR J OBSTET GYN R B, V34, P47, DOI 10.1016/0028-2243(90)90006-M; BRYCE RL, 1991, BRIT J OBSTET GYNAEC, V98, P1001, DOI 10.1111/j.1471-0528.1991.tb15338.x; CHALMERS TC, 1988, DATA ANAL CLIN MED Q, P75; ELBOURNE D, 1989, EFFECTIVE CARE PREGN, V1, P221; HEINS HC, 1990, OBSTET GYNECOL, V75, P341; KENNELL J, 1991, JAMA-J AM MED ASSOC, V265, P2197, DOI 10.1001/jama.265.17.2197; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; LANGER A, IN PRESS SOC SCI MED; LOEVINSOHN BP, 1990, INT J EPIDEMIOL, V19, P788, DOI 10.1093/ije/19.4.788; MACARTHUR C, 1987, BRIT J OBSTET GYNAEC, V94, P295, DOI 10.1111/j.1471-0528.1987.tb03094.x; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; Olds D, 1986, PEDIATRICS, V78, P138; OLDS DL, 1986, PEDIATRICS, V77, P16; PRENTICE AM, 1983, LANCET, V1, P489; SOSA R, 1980, NEW ENGL J MED, V303, P597, DOI 10.1056/NEJM198009113031101; Spielberger CD, 1971, INTERAM J PSYCHOL, V5, P145; SUSSER M, 1991, AM J CLIN NUTR, V53, P1384, DOI 10.1093/ajcn/53.6.1384; VILLAR J, 1982, AM J OBSTET GYNECOL, V143, P793, DOI 10.1016/0002-9378(82)90012-6; VILLAR J, 1988, PEDIATRICS, V81, P51; WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624; 1991, LANCET, V338, P155	26	121	122	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1266	1271		10.1056/NEJM199210293271803	http://dx.doi.org/10.1056/NEJM199210293271803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1303639	Bronze			2022-12-28	WOS:A1992JV25900003
J	ROWLAND, AS; BAIRD, DD; WEINBERG, CR; SHORE, DL; SHY, CM; WILCOX, AJ				ROWLAND, AS; BAIRD, DD; WEINBERG, CR; SHORE, DL; SHY, CM; WILCOX, AJ			REDUCED FERTILITY AMONG WOMEN EMPLOYED AS DENTAL ASSISTANTS EXPOSED TO HIGH-LEVELS OF NITROUS-OXIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPRAGUE-DAWLEY RATS; SPONTANEOUS-ABORTION; DELAYED CONCEPTION; CIGARETTE-SMOKING; ANESTHETIC-GASES; PREGNANCY; EXPOSURES; WORKPLACE; DENTISTS; TOXICITY	Background. Fertility is reduced in female rats exposed to levels of nitrous oxide similar to those found in some dental offices. Epidemiologic studies have suggested an association between exposure to mixed anesthetic gases and impaired fertility. We investigated the effects of occupational exposure to nitrous oxide on the fertility of female dental assistants. Methods. Screening questionnaires were mailed to 7000 female dental assistants, ages 18 to 39, registered by the California Department of Consumer Affairs. Sixty-nine percent responded. Four hundred fifty-nine women were determined to be eligible, having become pregnant during the previous four years for reasons unrelated to the failure of birth control, and 91 percent of these women completed telephone interviews. Detailed information was collected on exposure to nitrous oxide and fertility (measured by the number of menstrual cycles without contraception that the women required to become pregnant). Results. After controlling for covariates, we found that women exposed to high levels of nitrous oxide were significantly less fertile than women who were unexposed or exposed to lower levels of nitrous oxide. The effect was evident only in the 19 women with five or more hours of exposure per week. These women were only 41 percent (95 percent confidence interval, 23 to 74 percent; P<0.003) as likely as unexposed women to conceive during each menstrual cycle. Conclusions. Occupational exposure to high levels of nitrous oxide may adversely affect a woman's ability to become pregnant.	NIEHS,DIV BIOMETRY & RISK ASSESSMENT,STAT & BIOMATH BRANCH,RES TRIANGLE PK,NC 27709; UNIV N CAROLINA,SCH PUBL HLTH,DEPT EPIDEMIOL,CHAPEL HILL,NC 27514	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	ROWLAND, AS (corresponding author), NIEHS,EPIDEMIOL BRANCH,A3-05,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Wilcox, Allen J/C-7723-2019; Baird, Donna D/D-5214-2017; Rowland, Andy/AAH-4049-2019	Wilcox, Allen J/0000-0002-3376-1311; Baird, Donna D/0000-0002-5544-2653; Weinberg, Clarice/0000-0002-7713-8556				AXELSSON G, 1982, INT J EPIDEMIOL, V11, P250, DOI 10.1093/ije/11.3.250; BAIRD DD, 1985, JAMA-J AM MED ASSOC, V253, P2979, DOI 10.1001/jama.253.20.2979; BAIRD DD, 1986, AM J EPIDEMIOL, V124, P470, DOI 10.1093/oxfordjournals.aje.a114417; BARLOW SM, 1982, REPRODUCTIVE HAZARDS, P386; COATE WB, 1979, ANESTHESIOLOGY, V50, P310, DOI 10.1097/00000542-197904000-00006; COHEN EN, 1971, ANESTHESIOLOGY, V35, P343; COHEN EN, 1980, J AM DENT ASSOC, V101, P21, DOI 10.14219/jada.archive.1980.0345; COHEN EN, 1975, J AM DENT ASSOC, V90, P1291, DOI 10.14219/jada.archive.1975.0270; FERSTANDIG LL, 1978, ANESTH ANALG, V57, P328; FUJINAGA M, 1991, TERATOLOGY, V43, P151, DOI 10.1002/tera.1420430207; HENRY RJ, 1991, J DENT RES, V70, P1286, DOI 10.1177/00220345910700091001; JASTAK JT, 1989, INT ANESTHESIOL CLIN, V27, P92, DOI 10.1097/00004311-198902720-00005; KNILLJON.RP, 1972, LANCET, V1, P1326; KUGEL G, 1989, Journal of Dental Research, V68, P313; Kugel G, 1990, Anesth Prog, V37, P176; LEMASTERS GK, 1989, J CLIN EPIDEMIOL, V42, P975, DOI 10.1016/0895-4356(89)90162-5; LINN S, 1982, JAMA-J AM MED ASSOC, V247, P629; MAZZE RI, 1988, TERATOLOGY, V38, P121, DOI 10.1002/tera.1420380204; MAZZE RI, 1987, BRIT J ANAESTH, V59, P1291, DOI 10.1093/bja/59.10.1291; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; McGlothlin JD, 1988, STUDY PROTOCOL CONTR; NUNN JF, 1985, NITROUS OXIDE N2O, P211; RACHOOTIN P, 1983, J OCCUP ENVIRON MED, V25, P394; ROYSTON BD, 1988, ANESTHESIOLOGY, V68, P213, DOI 10.1097/00000542-198802000-00006; SPENCE AA, 1977, JAMA-J AM MED ASSOC, V238, P955, DOI 10.1001/jama.238.9.955; SURUDA AJ, 1990, J OCCUP ENVIRON MED, V32, P682; SWEENEY B, 1985, BRIT MED J, V291, P567, DOI 10.1136/bmj.291.6495.567; TIETZE C, 1968, INT J FERTIL, V13, P385; VESSEY MP, 1978, ANAESTHESIA, V33, P430, DOI 10.1111/j.1365-2044.1978.tb12461.x; WEINBERG CR, 1989, AM J EPIDEMIOL, V129, P1072, DOI 10.1093/oxfordjournals.aje.a115211; WEINBERG CR, IN PRESS STAT MED; WHITCHER CE, 1977, J AM DENT ASSOC, V95, P763, DOI 10.14219/jada.archive.1977.0493; 1977, DHEW NIOSH77140 NAT; 1992, EMPLOY EARN, V39, P185; 1981, DENTISTS DESK REFERE, P23	35	221	222	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					993	997		10.1056/NEJM199210013271405	http://dx.doi.org/10.1056/NEJM199210013271405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1298226				2022-12-28	WOS:A1992JQ22500005
J	MARTINI, CJM				MARTINI, CJM			GRADUATE MEDICAL-EDUCATION IN THE CHANGING ENVIRONMENT OF MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											MARTINI, CJM (corresponding author), AMER MED ASSOC,MED EDUC GRP,515 N STATE ST,CHICAGO,IL 60610, USA.							CROWLEY AE, 1982, JAMA-J AM MED ASSOC, V248, P3248; ROWLEY BD, 1991, JAMA-J AM MED ASSOC, V266, P933, DOI 10.1001/jama.266.7.933; 1992, 1992 ABMS AM BOARD M; 1992, ABMS RECORD, V1, P1	4	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1097	1105		10.1001/jama.268.9.1097	http://dx.doi.org/10.1001/jama.268.9.1097			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1302468				2022-12-28	WOS:A1992JK68100006
J	STODDARD, BL; KOSHLAND, DE				STODDARD, BL; KOSHLAND, DE			PREDICTION OF THE STRUCTURE OF A RECEPTOR PROTEIN COMPLEX USING A BINARY DOCKING METHOD	NATURE			English	Article							MALTOSE-BINDING; ASPARTATE; CHEMORECEPTOR; CHEMOTAXIS	TO validate procedures of rational drug design, it is important to develop computational methods that predict binding sites between a protein and a ligand molecule. Many small molecules have been tested using such programs, but examination of protein-protein and peptide-protein interactions has been sparse. We were able to test such applications once the structures of both the maltose-binding protein1 (MBP) and the ligand-binding domain of the aspartate receptor2, which binds MBP, became available. Here we predict the binding site of MBP to its receptor using a 'binary docking' technique in which two MBP octapeptide sequences containing mutations that eliminate maltose chemotaxis are independently docked to the receptor. The peptides in the docked solutions superimpose on their original positions in the structure of MBP and allow the formation of an MBP-receptor complex. The consistency of the computational and biological results supports this approach for predicting protein-protein and peptide-protein interactions.			STODDARD, BL (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,DIV BIOCHEM,534 BARKER HALL,BERKELEY,CA 94720, USA.							FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GARDINA P, 1992, J BACTERIOL, V174, P1528, DOI 10.1128/jb.174.5.1528-1536.1992; GASTEIGER J, 1978, TETRAHEDRON LETT, V34, P3181; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GOODSELL D, 1991, PROTEIN-STRUCT FUNCT, V8, P195; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOSSMANN M, 1988, J BACTERIOL, V170, P4516, DOI 10.1128/jb.170.10.4516-4521.1988; MANSON MD, 1986, J BACTERIOL, V165, P34, DOI 10.1128/jb.165.1.34-40.1986; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MOWBRAY SL, 1987, CELL, V50, P171, DOI 10.1016/0092-8674(87)90213-3; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202	12	67	68	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					774	776		10.1038/358774a0	http://dx.doi.org/10.1038/358774a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1324436				2022-12-28	WOS:A1992JK69900059
J	BERSTEIN, G; BLANK, JL; JHON, DY; EXTON, JH; RHEE, SG; ROSS, EM				BERSTEIN, G; BLANK, JL; JHON, DY; EXTON, JH; RHEE, SG; ROSS, EM			PHOSPHOLIPASE C-BETA-1 IS A GTPASE-ACTIVATING PROTEIN FOR GQ/11, ITS PHYSIOLOGICAL REGULATOR	CELL			English	Article								Purified M1 muscarinic cholinergic receptor and G(q/11) were coreconstituted in lipid vesicles. Addition of purified phospholipase C-beta-1 (PLC-beta-1) further stimulated the receptor-promoted steady-state GTPase activity of G(q/11) up to 20-fold. Stimulation depended upon receptor-mediated GTP-GDP exchange. Addition of PLC-beta-1 caused a rapid burst of hydrolysis of G(q/11)-bound GTP that was at least 50-fold faster than in its absence. Thus, PLC-beta-1 stimulates hydrolysis of G(q/11)-bound GTP and acts as a GTPase-activating protein (GAP) for its physiologic regulator, G(q/11). GTPase-stimulating activity was specific both for PLC-beta-1 and G(g/11). Such GAP activity by an effector coupled to a trimeric G protein can reconcile slow GTP hydrolysis by pure G proteins in vitro with fast physiologic deactivation of G protein-mediated signaling.	VANDERBILT UNIV, MED CTR,SCH MED,HOWARD HUGHES MED INST, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA; NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	Howard Hughes Medical Institute; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	BERSTEIN, G (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				FIC NIH HHS [TW04475] Funding Source: Medline; NIGMS NIH HHS [GM30355] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CASSEL D, 1977, J CYCLIC NUCL PROT, V3, P393; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1985, J BIOL CHEM, V260, P7927; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MAY DC, 1985, J BIOL CHEM, V260, P5829; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NAVON SE, 1984, J BIOL CHEM, V259, P6686; PARK D, 1992, IN PRESS J BIOL CHEM; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEDERSEN SE, 1982, P NATL ACAD SCI-BIOL, V79, P7228, DOI 10.1073/pnas.79.23.7228; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; ROSS EM, 1991, BETA ADRENERGIC RECE, P125; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUH PG, 1988, J BIOL CHEM, V263, P14497; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VUONG TM, 1990, NATURE, V346, P71, DOI 10.1038/346071a0; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	45	350	354	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					411	418		10.1016/0092-8674(92)90165-9	http://dx.doi.org/10.1016/0092-8674(92)90165-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322796				2022-12-28	WOS:A1992JH12400006
J	CENCIARELLI, C; HOU, D; HSU, KC; RELLAHAN, BL; WIEST, DL; SMITH, HT; FRIED, VA; WEISSMAN, AM				CENCIARELLI, C; HOU, D; HSU, KC; RELLAHAN, BL; WIEST, DL; SMITH, HT; FRIED, VA; WEISSMAN, AM			ACTIVATION-INDUCED UBIQUITINATION OF THE T-CELL ANTIGEN RECEPTOR	SCIENCE			English	Article							ZETA-CHAIN; COMPLEX; PHOSPHORYLATION; IDENTIFICATION; POLYPEPTIDE; DEGRADATION; COMPONENT; ANTIBODY; PROTEIN; SUBUNIT	The zeta-subunit of the T cell antigen receptor (TCR) exists primarily as a disulfide-linked homodimer. This receptor subunit is important in TCR-mediated signal transduction and is a substrate for a TCR-activated protein tyrosine kinase. The zeta-chain was found to undergo ubiquitination in response to receptor engagement. This posttranslational modification occurred in normal T cells and tumor lines. Both nonphosphorylated and phosphorylated zeta-molecules were modified, and at least one other TCR subunit, CD3-delta, was also ubiquitinated after activation of the receptor. These findings suggest an expanded role for ubiquitination in transmembrane receptor function.	NCI,DIV CANC BIOL DIAG & CTR,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); New York Medical College				Wiest, David/0000-0002-0792-3188				ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; CENCIARELLI C, UNPUB; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1990, New Biologist, V2, P227; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; Fried V A, 1989, Prog Clin Biol Res, V317, P733; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORI S, 1992, J BIOL CHEM, V267, P6429; MURTI KG, 1988, P NATL ACAD SCI USA, V85, P3019, DOI 10.1073/pnas.85.9.3019; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PATEL MD, 1987, J BIOL CHEM, V262, P5831; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P6396; Weissman A M, 1989, Year Immunol, V4, P74; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1986, NATURE, V324, P480, DOI 10.1038/324480a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	32	197	198	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					795	797		10.1126/science.1323144	http://dx.doi.org/10.1126/science.1323144			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323144				2022-12-28	WOS:A1992JG85100034
J	KREISS, J; NGUGI, E; HOLMES, K; NDINYAACHOLA, J; WAIYAKI, P; ROBERTS, PL; RUMINJO, I; SAJABI, R; KIMATA, J; FLEMING, TR; ANZALA, A; HOLTON, D; PLUMMER, F				KREISS, J; NGUGI, E; HOLMES, K; NDINYAACHOLA, J; WAIYAKI, P; ROBERTS, PL; RUMINJO, I; SAJABI, R; KIMATA, J; FLEMING, TR; ANZALA, A; HOLTON, D; PLUMMER, F			EFFICACY OF NONOXYNOL-9 CONTRACEPTIVE SPONGE USE IN PREVENTING HETEROSEXUAL ACQUISITION OF HIV IN NAIROBI PROSTITUTES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; CLINICAL-TRIAL; INFECTION; INACTIVATION; TRANSMISSION; INVITRO; CONDOMS; AFRICA; MEN	Objective.-To determine the efficacy of the nonoxynol 9 contraceptive sponge in preventing sexual acquisition of the human immunodeficiency virus (HIV). Design.-Prospective, randomized placebo-controlled trial. Setting.-Research clinic for prostitutes in Nairobi, Kenya. Patients and Interventions.-One hundred thirty-eight HIV-seronegative women were enrolled, of whom 74 were assigned to nonoxynol 9 sponge use and 64 to placebo use. These two groups did not significantly differ with respect to demographic characteristics, sexual practices, or prevalence of genital infections at enrollment, except for a lower number of sex partners per week and a higher initial prevalence of genital ulcers among women assigned to nonoxynol 9 sponge use. Among the 116 women who returned for follow-up, the mean durations of follow-up were 14 and 17 months for the two groups, respectively. Main Outcome Measure.-HIV seroconversion. Results.-Nonoxynol 9 sponge use was associated with an increased frequency of genital ulcers (relative risk [RR], 3.3; P<.0001) and vulvitis (RR, 3.3; P<.0001) and a reduced risk of gonococcal cervicitis (RR, 0.4; P<.0001). Twenty-seven (45%) of 60 women in the nonoxynol 9 sponge group and 20 (36%) of 56 women in the placebo group developed HIV antibodies. The hazard ratio for the association between nonoxynol 9 sponge use and HIV seroconversion was 1.7 (95% confidence interval [CI], 0.9 to 3.0). Using multivariate analysis to control for the presence of genital ulcers at enrollment, the adjusted hazard ratio for the association between nonoxynol 9 sponge use and seroconversion was 1.6 (95% CI, 0.8 to 2.8). Conclusions.-Genital ulcers and vulvitis occurred with increased frequency in nonoxynol 9 sponge users. We were unable to demonstrate that nonoxynol 9 sponge use was effective in reducing the risk of HIV infection among highly exposed women.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV NAIROBI,DEPT COMMUNITY HLTH,NAIROBI,KENYA; UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA; UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG R3T 2N2,MANITOBA,CANADA; KENYA GOVT MED RES CTR,CTR MICROBIOL RES,NAIROBI,KENYA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Nairobi; University of Nairobi; University of Manitoba; Kenya Medical Research Institute			, Holmes/K-6215-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI025024] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-25024] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRD KD, 1991, AIDS, V5, P791, DOI 10.1097/00002030-199107000-00001; CAMERON DW, 1989, LANCET, V2, P403; CHVAPIL M, 1980, FERTIL STERIL, V33, P445; HICKS DR, 1985, LANCET, V2, P1422; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; HOOTON TM, 1991, JAMA-J AM MED ASSOC, V265, P64, DOI 10.1001/jama.265.1.64; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; LAGA M, 1986, LANCET, V2, P1145; LOUV WC, 1988, J INFECT DIS, V158, P518, DOI 10.1093/infdis/158.3.518; MALKOVSKY M, 1988, LANCET, V1, P645; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; NIRUTHISARD S, 1991, SEX TRANSM DIS, V18, P176, DOI 10.1097/00007435-199107000-00010; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; POLSKY B, 1988, LANCET, V1, P1456; ROSENBERG MJ, 1987, JAMA-J AM MED ASSOC, V257, P2308, DOI 10.1001/jama.257.17.2308; STAMM WE, 1988, JAMA-J AM MED ASSOC, V260, P1429, DOI 10.1001/jama.260.10.1429; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; VOELLER B, 1989, CONTRACEPTION, V39, P95, DOI 10.1016/0010-7824(89)90018-8; WHITE N, 1988, NATURE, V335, P19, DOI 10.1038/335019a0; 1990, POPUL REP H, P1; 1990, LANCET, V335, P1497; 1989, MMWR, V38, P353; 1989, MMWR, V38, P1	24	371	383	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					477	482		10.1001/jama.268.4.477	http://dx.doi.org/10.1001/jama.268.4.477			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JD472	1320133				2022-12-28	WOS:A1992JD47200021
J	WILLIAMS, ME; BRUST, PF; FELDMAN, DH; PATTHI, S; SIMERSON, S; MAROUFI, A; MCCUE, AF; VELICELEBI, G; ELLIS, SB; HARPOLD, MM				WILLIAMS, ME; BRUST, PF; FELDMAN, DH; PATTHI, S; SIMERSON, S; MAROUFI, A; MCCUE, AF; VELICELEBI, G; ELLIS, SB; HARPOLD, MM			STRUCTURE AND FUNCTIONAL EXPRESSION OF AN OMEGA-CONOTOXIN SENSITIVE HUMAN N-TYPE CALCIUM-CHANNEL	SCIENCE			English	Article							CHICK SENSORY NEURONS; CURRENTS; PEPTIDES; REQUIREMENTS; BINDING; PROBES; BRAIN; GVIA	N-type calcium channels are omega-conotoxin (omega-CgTx)-sensitive, voltage-dependent ion channels involved in the control of neurotransmitter release from neurons. Multiple subtypes of voltage-dependent calcium channel complexes exist, and it is the alpha-1 subunit of the complex that forms the pore through which calcium enters the cell. The primary structures of human neuronal calcium channel alpha-1B subunits were deduced by the characterization of overlapping complementary DNAs. Two forms (alpha-1B-1 and alpha-1B-2) were identified in human neuroblastoma (IMR32) cells and in the central nervous system, but not in skeletal muscle or aorta tissues. The alpha-1B-1 subunit directs the recombinant expression of N-type calcium channel activity when it is transiently co-expressed with human neuronal beta-2 and alpha-2b subunits in mammalian HEK293 cells. The recombinant channel was irreversibly blocked by omega-CgTx but was insensitive to dihydropyridines. The alpha-1B-1-alpha-2b-beta-2-transfected cells displayed a single class of saturable, high-affinity (dissociation constant = 55 pM) omega-CgTx binding sites. Co-expression of the beta-2 subunit was necessary for N-type channel activity, whereas the alpha-2b subunit appeared to modulate the expression of the channel. The heterogeneity of alpha-1B subunits, along with the heterogeneity of alpha-2 and beta-subunits, is consistent with multiple, biophysically distinct N-type calcium channels.	SIBIA INC,505 COAST BLVD S,LA JOLLA,CA 92037									AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CARBONE E, 1990, PFLUG ARCH EUR J PHY, V416, P170, DOI 10.1007/BF00370239; COHEN MW, 1991, J NEUROSCI, V11, P1032; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; JONES SW, 1989, J GEN PHYSIOL, V94, P169, DOI 10.1085/jgp.94.1.169; KIM HL, 1992, P NATL ACAD SCI USA, V89, P3251, DOI 10.1073/pnas.89.8.3251; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PLUMMER MR, 1991, NATURE, V351, P657, DOI 10.1038/351657a0; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHER E, 1988, FEBS LETT, V235, P178, DOI 10.1016/0014-5793(88)81258-4; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STANLEY EF, 1991, J NEUROSCI, V11, P985; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; SWANDULLA D, 1991, TRENDS NEUROSCI, V14, P46, DOI 10.1016/0166-2236(91)90018-P; TARELLI FT, 1991, BRAIN RES, V547, P331, DOI 10.1016/0006-8993(91)90981-Z; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	43	463	485	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					389	395		10.1126/science.1321501	http://dx.doi.org/10.1126/science.1321501			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1321501				2022-12-28	WOS:A1992JD67400035
J	LITTLER, E; STUART, AD; CHEE, MS				LITTLER, E; STUART, AD; CHEE, MS			HUMAN CYTOMEGALOVIRUS UL97 OPEN READING FRAME ENCODES A PROTEIN THAT PHOSPHORYLATES THE ANTIVIRAL NUCLEOSIDE ANALOG GANCICLOVIR	NATURE			English	Article							HERPES-SIMPLEX VIRUS; EPSTEIN-BARR VIRUS; THYMIDINE KINASE; IDENTIFICATION; HERPESVIRUSES	HUMAN cytomegalovirus(HCMV, a betaherpes virus) is the cause of serious disease in immunologically compromised individuals, including those with acquired immunodeficiency syndome 1. One of the compounds used in the chemotherapy of HCMV infections is the nucleoside analogue 9-(1,3-dihydroxy-2-propoxymethyl)-guanine (ganciclovir). The mechanism of action of this drug is dependent on the formation of the nucleoside triphosphate, which is a strong inhibitor of the viral DNA polymerase 2-4. Thymidine kinase, which is encoded by many of the herpesviruses, catalyses the initial phosphorylation of ganciclovir. But there is no evidence for the coding of this enzyme by HCMV 2,5,6, and DNA sequence analysis of the HCMV genome has shown that there is no open reading frame characteristic of a herpesvirus thymidine kinase 7. Here we present biochemical and immunological evidence that the HCMV UL97 open reading frame codes for a protein capable of phosphorylating ganciclovir. This protein seems to be responsible for the selectivity of ganciclovir and will be useful tool in the understanding and refinement of the antiviral activity of new selective anti-HCMV compounds.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology	LITTLER, E (corresponding author), WELLCOME RES LABS, DEPT MOLEC SCI, LANGLEY COURT, BECKENHAM BR3 3BS, KENT, ENGLAND.							BIRON KK, 1986, P NATL ACAD SCI USA, V83, P8769, DOI 10.1073/pnas.83.22.8769; BIRON KK, 1985, P NATL ACAD SCI USA, V82, P2473, DOI 10.1073/pnas.82.8.2473; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEE MS, 1989, J GEN VIROL, V70, P1151, DOI 10.1099/0022-1317-70-5-1151; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ERTL PF, 1991, J GEN VIROL, V72, P1729, DOI 10.1099/0022-1317-72-7-1729; ESTES JE, 1977, J VIROL, V24, P13, DOI 10.1128/JVI.24.1.13-21.1977; FREITAS VR, 1985, ANTIMICROB AGENTS CH, V28, P240, DOI 10.1128/AAC.28.2.240; FYFE JA, 1978, J BIOL CHEM, V253, P8721; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LITTLER E, 1988, J VIROL, V62, P3892, DOI 10.1128/JVI.62.10.3892-3895.1988; LITTLER E, 1990, J VIROL, V64, P714, DOI 10.1128/JVI.64.2.714-722.1990; MACHER AM, 1983, NEW ENGL J MED, V309, P1454; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SMITH RF, 1989, J VIROL, V63, P450, DOI 10.1128/JVI.63.1.450-455.1989; STANAT SC, 1991, ANTIMICROB AGENTS CH, V35, P2191, DOI 10.1128/AAC.35.11.2191; SULLIVAN V, 1992, NATURE, V358, P162, DOI 10.1038/358162a0	18	322	336	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					160	162		10.1038/358160a0	http://dx.doi.org/10.1038/358160a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1319559				2022-12-28	WOS:A1992JC58300055
J	RIPSIN, CM; KEENAN, JM; JACOBS, DR; ELMER, PJ; WELCH, RR; VANHORN, L; LIU, K; TURNBULL, WH; THYE, FW; KESTIN, M; HEGSTED, M; DAVIDSON, DM; DAVIDSON, MH; DUGAN, LD; DEMARKWAHNEFRIED, W; BELING, S				RIPSIN, CM; KEENAN, JM; JACOBS, DR; ELMER, PJ; WELCH, RR; VANHORN, L; LIU, K; TURNBULL, WH; THYE, FW; KESTIN, M; HEGSTED, M; DAVIDSON, DM; DAVIDSON, MH; DUGAN, LD; DEMARKWAHNEFRIED, W; BELING, S			OAT PRODUCTS AND LIPID LOWERING - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SERUM-CHOLESTEROL; HYPERCHOLESTEROLEMIC MEN; CLINICAL-TRIALS; BLOOD-PRESSURE; BRAN; FIBER; DIETS; YOUNG; FAT	Objectives.-To test the a prior hypothesis that consumption of oats will lower the blood total cholesterol level and to assess modifiers and confounders of this association. Data-Sources.-A computerized literature (MEDLINE) search and the Quaker Oats Co identified published and unpublished trials as of March 1991. Raw data were requested for all trials. Study Selection.-Trials were included in summary effect size estimates if they were randomized and controlled, if a formal assessment of diet and body weight changes occurred, and, if raw data were not received, if there was enough information in the published report to perform calculations. Data Synthesis.-Twenty trials were identified. Using the methods of DerSimonian and Laird, a summary effect size for change in blood total cholesterol level of -0.13 mmol/L (-5.9 mg/dL) (95% confidence interval [CI], -0.19 to -0.017 mmol/L [-8.4 to -3.3 mg/dL]) was calculated for the 10 trials meeting the inclusion criteria. The summary effect size for trials using wheat control groups was -0.11 mmol/L (-4.4 mg/dL) (95% CI, -0.21 to -0.01 mmol/L [-8.3 to -0.138 mg/dL]). Calculation of Keys scores demonstrated that substituting carbohydrates for dietary fats and cholesterol did not account for the majority of blood cholesterol reduction. Larger reductions were seen in trials in which subjects had initially higher blood cholesterol levels (greater-than-or-equal-to 5.9 mmol/L [greater-than-or-equal-to 229 mg/dL]), particularly when a dose of 3 g or more of soluble fiber was employed. Conclusion.-This analysis supports the hypothesis that incorporating oat products into the diet causes a modest reduction in blood cholesterol level.	UNIV MINNESOTA, DEPT FAMILY PRACTICE & COMMUNITY HLTH, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DIV EPIDEMIOL, MINNEAPOLIS, MN 55455 USA; UNIV ULSTER, DEPT BIOL & BIOMED SCI, JORDANSTOWN, NORTH IRELAND; NORTHWESTERN UNIV, SCH MED, DEPT COMMUNITY HLTH & PREVENT MED, CHICAGO, IL 60611 USA; UNIV LONDON KINGS COLL, DEPT NUTR & DIETET, LONDON WC2R 2LS, ENGLAND; VIRGINIA POLYTECH INST & STATE UNIV, DEPT HUMAN NUTR & FOODS, BLACKSBURG, VA 24061 USA; FRED HUTCHINSON CANC RES CTR, CANC PREVENT RES PROGRAM, SEATTLE, WA 98104 USA; UNIV CALIF IRVINE, CTR AGR, SCH HUMAN ECOL, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT MED, PREVENT CARDIOL PROGRAM, IRVINE, CA 92717 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO CTR CLIN RES, CHICAGO, IL 60612 USA; DUKE UNIV, DUKE COMPREHENS CANC CTR, CANC CONTROL RES PROGRAM, DURHAM, NC 27706 USA; CANYON RANCH HLTH CTR, LENOX, MA USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Ulster University; Northwestern University; University of London; King's College London; Virginia Polytechnic Institute & State University; Fred Hutchinson Cancer Center; University of California System; University of California Irvine; University of California System; University of California Irvine; Rush University; Duke University			Welch, Robert W/B-5034-2009	Jacobs, David/0000-0002-7232-0543				ANDERSON JT, 1979, PREV MED, V8, P525, DOI 10.1016/0091-7435(79)90328-1; ANDERSON JW, 1990, ADV EXP MED BIOL, V270, P17; ANDERSON JW, 1991, AM J CLIN NUTR, V54, P678, DOI 10.1093/ajcn/54.4.678; ANDERSON JW, 1984, J CAN DIET ASSOC, V45, P140; ANDERSON JW, 1988, AM J CLIN NUTR, V48, P749, DOI 10.1093/ajcn/48.3.749; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; CHALMERS TC, 1987, NEW ENGL J MED, V316, P49; CLIFTON PM, 1990, ARTERIOSCLEROSIS, V10, P394, DOI 10.1161/01.ATV.10.3.394; DAVIDSON MH, 1991, JAMA-J AM MED ASSOC, V265, P1833, DOI 10.1001/jama.265.14.1833; DEMARKWAHNEFRIED W, 1990, J AM DIET ASSOC, V90, P223; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GOLD KV, 1988, WESTERN J MED, V148, P299; GROOT APD, 1963, LANCET, V2, P303, DOI 10.1016/S0140-6736(63)90210-1; HEGSTED M, 1989, FASEB J, pA368; IRWIG L, 1991, JAMA-J AM MED ASSOC, V266, P1678, DOI 10.1001/jama.266.12.1678; KEENAN JM, 1991, J FAM PRACTICE, V33, P600; KESTIN M, 1990, AM J CLIN NUTR, V52, P661, DOI 10.1093/ajcn/52.4.661; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; KIRBY RW, 1981, AM J CLIN NUTR, V34, P824, DOI 10.1093/ajcn/34.5.824; MCMICHAEL AJ, 1983, AM J EPIDEMIOL, V118, P620, DOI 10.1093/oxfordjournals.aje.a113672; O'BRIEN L T, 1985, Journal of Applied Nutrition, V37, P26; OAKES M, 1986, STATISTICAL INFERENC, P157; OKELL RT, 1988, MO MED, V85, P72; Reynolds HR, 1989, J AM DIET ASSOC, V89, pA112; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SLAVIN JL, 1987, J AM DIET ASSOC, V87, P1164; STEWART LM, 1990, J HUM NUTR DIET, V3, P436; STORCH K, 1984, CLIN RES, V32, pA740; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; TOPPING DL, 1990, ROY SOC CH, V83, P300, DOI 10.1533/9781845698195.6.300; Turnbull WH, 1989, J CLIN NUTR GASTROEN, V1, P15; Turnbull WH., 1987, J CLIN NUTR GASTROEN, V2, P177; VANHORN L, 1991, AM J PUBLIC HEALTH, V81, P183, DOI 10.2105/AJPH.81.2.183; VANHORN LV, 1988, PREV MED, V17, P759; VANHORN LV, 1986, J AM DIET ASSOC, V86, P377; WELCH RW, 1991, J CEREAL SCI, V13, P173, DOI 10.1016/S0733-5210(09)80034-9; WELCH RW, 1990, P NUTR SOC, V49, pA50; YACH D, 1990, S AFR MED J, V78, P94; 1987, PHYSL EFFECTS HLTH C; 1988, SAS STAT USERS GUIDE	43	345	358	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3317	3325		10.1001/jama.267.24.3317	http://dx.doi.org/10.1001/jama.267.24.3317			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1317928				2022-12-28	WOS:A1992HY94400032
J	SOUHAMI, R				SOUHAMI, R			CURRENT ISSUES IN CANCER .2. LUNG-CANCER	BRITISH MEDICAL JOURNAL			English	Article							SMALL-CELL-CARCINOMA; RANDOMIZED TRIAL; CHEMOTHERAPY; RADIATION				SOUHAMI, R (corresponding author), UNIV COLL & MIDDLESEX SCH MED,LONDON W1P 8DT,ENGLAND.							CARNEY DN, 1988, SEMIN ONCOL, V15, P199; CULLEN MH, 1988, BRIT J CANCER, V58, P359, DOI 10.1038/bjc.1988.219; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; DOLL R, 1990, EUR J CANCER, V26, P500; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KRIS MG, 1987, SURG CLIN N AM, V67, P1051; LECHEVALIER T, 1991, JNCI-J NATL CANCER I, V83, P417, DOI 10.1093/jnci/83.6.417; LINNOILA RI, 1988, AM J CLIN PATHOL, V90, P641, DOI 10.1093/ajcp/90.6.641; OSTERLIND K, 1986, EUR J CANCER CLIN ON, V22, P589, DOI 10.1016/0277-5379(86)90048-9; PERRY MC, 1987, NEW ENGL J MED, V316, P912, DOI 10.1056/NEJM198704093161504; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; SOUHAMI RL, 1990, BRIT J CANCER, V61, P584, DOI 10.1038/bjc.1990.131; SOUHAMI RL, 1985, CANCER RES, V45, P2878; SPIRO SG, 1989, BRIT J CANCER, V59, P578, DOI 10.1038/bjc.1989.117; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; 1989, BRIT J CANCER, V59, P584; 1975, CANCER, V36, P914; 1986, NEW ENGL J MED, V315, P1377; 1991, BRIT J CANCER, V63, P265	20	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1298	1301		10.1136/bmj.304.6837.1298	http://dx.doi.org/10.1136/bmj.304.6837.1298			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1318766	Green Published, Bronze			2022-12-28	WOS:A1992HV08600030
J	MASLANSKI, JA; LESHKO, L; BUSA, WB				MASLANSKI, JA; LESHKO, L; BUSA, WB			LITHIUM-SENSITIVE PRODUCTION OF INOSITOL PHOSPHATES DURING AMPHIBIAN EMBRYONIC MESODERM INDUCTION	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; EARLY XENOPUS EMBRYOS; LAEVIS EMBRYOS; ACTIVIN-A; IDENTIFICATION; DIACYLGLYCEROL; COMPETENCE; PATTERN; BRAIN; EGG	Mesoderm induction and body axis determination in frog (Xenopus) embryos are thought to involve growth factor-mediated cell-cell signaling, but the signal transduction pathways are unknown. Li+, which inhibits the polyphosphoinositide (PI) cycle signal transduction pathway in many cells, also disrupts axis determination and mesoderm induction. Amounts of the PI cycle-derived second messenger, inositol 1,4,5-trisphosphate, increased during mesoderm induction in normal embryos; addition of Li+ inhibited the embryonic inositol monophosphatase and reversed this increase. Embryonic PI cycle activity thus shows characteristics that indicate it may function in mesoderm induction and axis determination.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University					NICHD NIH HHS [HD27546, HD22879] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022879, R29HD022879, R01HD027546] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; AULT KT, UNPUB; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; COOKE J, 1991, CURR TOP DEV BIOL, V25, P45; DALE L, 1987, DEVELOPMENT, V100, P279; GERHART J, 1989, DEVELOPMENT, V107, P37; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GRUNZ H, 1986, ROUX ARCH DEV BIOL, V195, P467, DOI 10.1007/BF00375751; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; JONES EA, 1987, DEVELOPMENT, V101, P557; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Maslanski J. A., 1990, METHODS INOSITIDE RE, P113; MASLANSKI JA, UNPUB; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; SHEPARD TH, 1986, CATALOG TERATOGENIC, pR21; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SLACK JMW, 1991, DEVELOPMENT, V113, P661; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0	33	89	89	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					243	245		10.1126/science.1314424	http://dx.doi.org/10.1126/science.1314424			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1314424				2022-12-28	WOS:A1992HM89600036
J	STIRLING, CJ; HEWITT, EW				STIRLING, CJ; HEWITT, EW			THE SACCHAROMYCES-CEREVISIAE SEC65 GENE ENCODES A COMPONENT OF YEAST SIGNAL RECOGNITION PARTICLE WITH HOMOLOGY TO HUMAN SRP19	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; PROTEIN; DNA; EXPRESSION; SEQUENCE; SUBUNIT; GROWTH; SYSTEM; RNA	TRANSLOCATION of proteins across the endoplasmic reticulum (ER) membrane represents the first step in the eukaryotic secretory pathway. In mammalian cells, the targeting of secretory and membrane protein precursors to the ER is mediated by signal recognition particle (SRP), a cytosolic ribonucleoprotein complex comprising a molecule of 7SL RNA and six polypeptide subunits (relative molecular masses 9, 14, 19, 54, 68 and 72K) 1. In Saccharomyces cerevisiae, a homologue of the 54K subunit (SRP54) 2,3 co-purifies with a small cytoplasmic RNA, scR1 (refs 4,5). Genetic data indicate that SRP54 and scR1 are involved in translocation in vivo, suggesting the existence of an SRP-like activity in yeast 5,6. Whether this activity requires additional components similar to those found in mammalian SRP is not known. We have recently reported a genetic selection that led to the isolation of a yeast mutant, sec65-1, which is conditionally defective in the insertion of integral membrane proteins into the ER7. Here we report the cloning and sequencing of the SEC65 gene, which encodes a 31.2K protein with significant sequence similarity to the 19K subunit of human SRP (SRP19) 8. We also report the cloning of a multicopy suppressor of sec65-1, and its identification as the previously defined SRP54 gene, providing genetic evidence for an interaction between these gene products in vivo.			STIRLING, CJ (corresponding author), UNIV MANCHESTER,DEPT BIOCHEM & MOLEC BIOL,MANCHESTER M13 9PT,LANCS,ENGLAND.			Hewitt, Eric/0000-0002-6238-6303				AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; AMAYA Y, 1991, FEBS LETT, V283, P325, DOI 10.1016/0014-5793(91)80619-E; DEMONTIGNY J, 1989, MOL GEN GENET, V215, P455, DOI 10.1007/BF00427043; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; HANN BC, 1992, NATURE, V356, P532, DOI 10.1038/356532a0; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; SIKORSKI RS, 1989, GENETICS, V122, P19; STIRLING CJ, IN PRESS MOL BIOL CE; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WOODS A, 1989, J CELL SCI, V93, P491	20	88	90	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					534	537		10.1038/356534a0	http://dx.doi.org/10.1038/356534a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1313948				2022-12-28	WOS:A1992HN23100063
J	MACDONALD, F; MORTON, DG; RINDL, PM; HAYDON, J; CULLEN, R; GIBSON, J; NEOPTOLEMOS, JP; KEIGHLEY, MRB; MCKEOWN, CM; HULTEN, M				MACDONALD, F; MORTON, DG; RINDL, PM; HAYDON, J; CULLEN, R; GIBSON, J; NEOPTOLEMOS, JP; KEIGHLEY, MRB; MCKEOWN, CM; HULTEN, M			PREDICTIVE DIAGNOSIS OF FAMILIAL ADENOMATOUS POLYPOSIS WITH LINKED DNA MARKERS - POPULATION BASED STUDY	BRITISH MEDICAL JOURNAL			English	Article							COLORECTAL-CANCER; CHROMOSOME-5; LOCALIZATION; GENE; LINKAGE; COLI	Objectives-To evaluate the use of polymorphic DNA probes linked to the APC gene in the presymptomatic diagnosis of familial adenomatous polyposis. Design-Four DNA probes were tested on an unselected population of patients at risk of familial adenomatous polyposis. Subjects-The first 47 families notified to the West Midlands familial adenomatous polyposis register. Plus five families sent to our hospital as part of the West of Britain DNA consortium. Main outcome measures-The proportion of families and family members in whom DNA testing could be used to adjust the estimate of risk. Results-Only 17 families on the register (containing 46% (74/162) of the population at risk) had a suitable pedigree structure for DNA analysis. DNA was analysed in 12 of these families plus the five families from the West of Britain consortium. At least one probe was informative in 27 of the 33 subjects born with 50% risk, but the most informative probe (pi-227) was the one with the highest recombination rate (10%). Flanking markers were informative in only four of the 33 subjects. Conclusions-These findings confirm the potential for accurate predictive diagnosis of familial adenomatous polyposis with polymorphic DNA probes, but such an approach is currently limited to about one third of affected families. A combined approach to presymptomatic diagnosis, which includes DNA testing and indirect ophthalmoscopy, is advocated.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT SURG,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; E BIRMINGHAM DIST GEN HOSP,DEPT OPHTHALMOL,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND; E BIRMINGHAM DIST GEN HOSP,DEPT CLIN GENET,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND	University of Birmingham	MACDONALD, F (corresponding author), E BIRMINGHAM DIST GEN HOSP,REG GENET SERV,DNA LAB,BIRMINGHAM B9 52T,ENGLAND.		Neoptolemos, John/HGU-7742-2022; Neoptolemos, John P/G-4488-2010	Neoptolemos, John/0000-0002-6201-7399; Gibson, Jonathan M/0000-0002-9281-5244				BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BREUKEL C, 1991, NUCLEIC ACIDS RES, V19, P685, DOI 10.1093/nar/19.3.685-a; BULOW S, 1987, DAN MED BULL, V34, P1; BURN J, 1989, J MED GENET, V26, P207; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; CACHONGONZALEZ MB, 1991, J MED GENET, V28, P681, DOI 10.1136/jmg.28.10.681; CHAPMAN PD, 1989, BRIT MED J, V298, P353, DOI 10.1136/bmj.298.6670.353; DUNLOP MG, 1990, AM J HUM GENET, V47, P982; DUNLOP MG, 1991, LANCET, V337, P313, DOI 10.1016/0140-6736(91)90940-Q; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GOPS CMJ, 1991, HUM GENET, V86, P365; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KHAN PM, 1988, HUM GENET, V79, P183, DOI 10.1007/BF00280563; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MURDAY V, 1989, CANCER SURV, V8, P139; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; REED TE, 1955, AM J HUM GENET, V7, P236; ROMEO G, 1986, LANCET, V2, P8; Sambrook J, 1989, MOL CLONING LABORATO; SOLOMON E, 1990, NATURE, V343, P412, DOI 10.1038/343412a0; TOPS CMJ, 1989, LANCET, V2, P1361	24	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					869	872		10.1136/bmj.304.6831.869	http://dx.doi.org/10.1136/bmj.304.6831.869			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1327364	Green Published, Bronze			2022-12-28	WOS:A1992HM83500021
J	SHAM, JSK; CLEEMANN, L; MORAD, M				SHAM, JSK; CLEEMANN, L; MORAD, M			GATING OF THE CARDIAC CA2+ RELEASE CHANNEL - THE ROLE OF NA+ CURRENT AND NA+-CA2+ EXCHANGE	SCIENCE			English	Article							SODIUM-CALCIUM EXCHANGE; SARCOPLASMIC-RETICULUM; GUINEA-PIG; ACTIVATES CONTRACTION; VENTRICULAR MYOCYTES; CA-2+ RELEASE; PURKINJE-CELL; HEART-MUSCLE; VOLTAGE; INACTIVATION	In cardiac myocytes, calcium influx through the calcium channel is the primary pathway for triggering calcium release. Recently it has been suggested that the calcium-induced calcium release mechanism can also be activated indirectly by the sodium current, which elevates the sodium concentration under the cell membrane, thereby favoring the entry of "trigger" calcium via the sodium-calcium exchanger. To test this hypothesis, sodium current was suppressed by reducing the external sodium concentration or applying tetrodotoxin. At potentials positive to -30 millivolts, calcium release was unaffected. A small calcium release at more negative potentials could be attributed to partial activation of calcium channels, because it was unaltered by replacement of sodium with lithium and was blocked by cadmium. Thus, sodium influx or its accumulation does not initiate calcium release. In addition, sodium-calcium exchange-related calcium release at potentials positive to +80 millivolts has slower kinetics than calcium channel-induced release. Therefore, only the calcium channel gates the fast release of calcium from the sarcoplasmic reticulum in the range of the action potential.	UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania				Sham, James/0000-0002-3571-8712	NHLBI NIH HHS [HL-16152, HL-07400] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADRIAN RH, 1973, J PHYSIOL-LONDON, V235, P103, DOI 10.1113/jphysiol.1973.sp010380; Baker P F, 1972, Prog Biophys Mol Biol, V24, P177, DOI 10.1016/0079-6107(72)90007-7; BERS DM, 1990, AM J PHYSIOL, V258, pC944, DOI 10.1152/ajpcell.1990.258.5.C944; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; BROWN AM, 1981, J PHYSIOL-LONDON, V318, P455; CALLEWAERT G, 1988, P NATL ACAD SCI USA, V85, P2009, DOI 10.1073/pnas.85.6.2009; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; HILLE B, 1972, J GEN PHYSIOL, V59, P637, DOI 10.1085/jgp.59.6.637; JOHNSON EA, 1991, SCIENCE, V251, P1370, DOI 10.1126/science.1848371; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; MORAD M, 1983, NATURE, V304, P635, DOI 10.1038/304635a0; NABAUER M, 1990, AM J PHYSIOL, V258, pC189, DOI 10.1152/ajpcell.1990.258.1.C189; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; NILIUS B, 1988, J PHYSIOL-LONDON, V399, P537; PEACHEY LD, 1973, STRUCTURE FUNCTION M, V3, P1; VALDEOLMILLOS M, 1989, PFLUG ARCH EUR J PHY, V413, P676, DOI 10.1007/BF00581820	26	149	154	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1992	255	5046					850	853		10.1126/science.1311127	http://dx.doi.org/10.1126/science.1311127			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1311127				2022-12-28	WOS:A1992HD54800038
J	ZHANG, XK; HOFFMANN, B; TRAN, PBV; GRAUPNER, G; PFAHL, M				ZHANG, XK; HOFFMANN, B; TRAN, PBV; GRAUPNER, G; PFAHL, M			RETINOID X-RECEPTOR IS AN AUXILIARY PROTEIN FOR THYROID-HORMONE AND RETINOIC ACID RECEPTORS	NATURE			English	Article							RESPONSE ELEMENT; HUMAN TESTIS; BINDING; GENE; IDENTIFICATION; SUPERFAMILY; ENHANCE	THYROID hormones and retinoic acid function through nuclear receptors that belong to the steroid/thyroid-hormone receptor superfamily (reviewed in refs 1-4). Thyroid hormone receptors (TRs) and retinoic acid receptors (RARs) require auxiliary nuclear proteins for efficient DNA binding 5-10. Here we report that retinoid X receptors RXR-alpha (ref. 11) is one of these nuclear proteins. RXR-alpha interacts both with TRs and with RARs, forming heterodimers in solution that strongly interact with a variety of T3/retinoic acid response elements. Transfection experiments show that RXR-alpha can greatly enhance the transcriptional activity of TR and RAR at low retinoic acid concentrations that do not significantly activate RXR-alpha itself. Thus, RXR-alpha enhances the transcriptional activity of other receptors and its own ligand sensitivity by heterodimer formation. Our studies reveal a new subclass of receptors and a regulatory pathway controlling nuclear receptor activities by heterodimer formation.	LA JOLLA CANC RES FDN,CTR CANC,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HUSHMAN M, 1991, MOL CELL BIOL, V11, P4097; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; PFAHL M, 1990, METHOD ENZYMOL, V153, P256; PFAHL M, 1992, RETINOIDS NORMAL DEV, P51; ROSEN ED, 1991, MOL CELL ENDOCRINOL, V78, pC83, DOI 10.1016/0303-7207(91)90175-R; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1991, NEW BIOL, V3, P1	29	934	968	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					441	446		10.1038/355441a0	http://dx.doi.org/10.1038/355441a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1310350				2022-12-28	WOS:A1992HB53000068
J	BENNETT, JDC				BENNETT, JDC			GEDROITS,VERA - MILITARY SURGEON, POET, AND AUTHOR	BRITISH MEDICAL JOURNAL			English	Item About an Individual											BENNETT, JDC (corresponding author), QUEEN ELIZABETH MIL HOSP,DEPT EAR NOSE & THROAT SURG,LONDON SE18 4QH,ENGLAND.							BENNETT JDC, 1991, J ROY SOC MED, V84, P554, DOI 10.1177/014107689108400917; BOTKINE T, 1980, TEMPS TSARS, P132; FRASER J, 1942, SURGERY MODERN WARFA, V1, P392; GEDROITS S, 1910, POEMS FAIRYTALES; GEDROITS VI, PUBLICATION LIST; KAWECKI B, 1977, Z WEDROWEK WILENSKIE; MARCOU D, 1905, ARCH GENERALES MED, V2, P2836; METS AG, 1989, BIOGRAPHICAL DICT GR, V1, P535; MOCKLER GHG, 1906, RUSSOJAPANESE WAR JO, P100; MYSYROWICZ L, 1977, REV TRIMETRIELLE SOC, V34, P207; 1904, BMJ, V2, P457; 1897, CATALOGUE ETUDIANTS, V13; 1905, J R ARMY MED CORPS, V4, P393	13	7	7	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1532	1534		10.1136/bmj.305.6868.1532	http://dx.doi.org/10.1136/bmj.305.6868.1532			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286373	Green Published, Bronze			2022-12-28	WOS:A1992KD77100010
J	THIBAULT, GE				THIBAULT, GE			THINGS ARE SELDOM WHAT THEY SEEM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HEPATOCELLULAR-CARCINOMA; TRANSPLANTATION; HYPERCALCEMIA; CIRRHOSIS; PROGNOSIS; HEPATOMA				THIBAULT, GE (corresponding author), VET AFFAIRS MED CTR,1400 VFW PKWY,BOSTON,MA 02132, USA.							BUSCARINI L, 1991, ONCOLOGY-BASEL, V48, P26; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; IKEDA T, 1988, CANCER, V61, P1813, DOI 10.1002/1097-0142(19880501)61:9<1813::AID-CNCR2820610915>3.0.CO;2-U; KASSIANIDES C, 1987, GASTROENTEROL CLIN N, V16, P553; KNILLJONES RP, 1970, NEW ENGL J MED, V282, P704, DOI 10.1056/NEJM197003262821302; LEE FI, 1966, GUT, V7, P77, DOI 10.1136/gut.7.1.77; MARGOLIS S, 1972, MEDICINE, V51, P381, DOI 10.1097/00005792-197209000-00003; MILLER WJ, 1991, AM J ROENTGENOL, V157, P303, DOI 10.2214/ajr.157.2.1649550; NOMURA F, 1989, CANCER, V64, P1700, DOI 10.1002/1097-0142(19891015)64:8<1700::AID-CNCR2820640824>3.0.CO;2-Z; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; SIEGLER M, 1975, NEW ENGL J MED, V293, P853, DOI 10.1056/NEJM197510232931705; SOX HC, 1986, ANN INTERN MED, V104, P60, DOI 10.7326/0003-4819-104-1-60; ZAMAN SN, 1985, LANCET, V1, P1357	14	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1992	327	23					1663	1666		10.1056/NEJM199212033272308	http://dx.doi.org/10.1056/NEJM199212033272308			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA260	1279423				2022-12-28	WOS:A1992KA26000008
J	FIGUERAS, A; MORALESOLIVAS, FJ; CAPELLA, D; PALOP, V; LAPORTE, JR				FIGUERAS, A; MORALESOLIVAS, FJ; CAPELLA, D; PALOP, V; LAPORTE, JR			BOVINE GANGLIOSIDES AND ACUTE MOTOR POLYNEUROPATHY	BRITISH MEDICAL JOURNAL			English	Article									UNIV AUTONOMA BARCELONA,CSU VALL DHEBRON,INST CATALA FARMACOL,SERV FARMACOL CLIN,E-08035 BARCELONA,SPAIN; UNIV VALENCIA,FAC MED,DEPT FARMACOL,VALENCIA,SPAIN; CTR FARMACOVIGILANCIA COMUNITAT VALENCIANA,VALENCIA,SPAIN	Autonomous University of Barcelona; University of Valencia			Figueras, Albert/I-7421-2013; Laporte, Joan-Ramon/A-1302-2011; Figueras, Albert/H-7743-2012	Figueras, Albert/0000-0002-2740-2013; Figueras, Albert/0000-0002-2740-2013				BRADLEY WG, 1990, MUSCLE NERVE, V13, P853; LATOV N, 1991, LANCET, V338, P757, DOI 10.1016/0140-6736(91)91475-A; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; SCHONHOFER PS, 1991, LANCET, V338, P757; 1985, LANCET, V1, P1137	5	70	71	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1330	1331		10.1136/bmj.305.6865.1330	http://dx.doi.org/10.1136/bmj.305.6865.1330			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1309191	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992KA77300022
J	FABER, DS; YOUNG, WS; LEGENDRE, P; KORN, H				FABER, DS; YOUNG, WS; LEGENDRE, P; KORN, H			INTRINSIC QUANTAL VARIABILITY DUE TO STOCHASTIC PROPERTIES OF RECEPTOR-TRANSMITTER INTERACTIONS	SCIENCE			English	Article							CENTRAL INHIBITORY SYNAPSE; LONG-TERM POTENTIATION; GLYCINE RECEPTORS; CENTRAL NEURON; NEUROMUSCULAR SYNAPSE; HIPPOCAMPAL SLICES; CHANNEL ACTIVATION; SPINAL-CORD; TRANSMISSION; ACETYLCHOLINE	Synaptic events at the neuromuscular junction are integer multiples of a quantum, the postsynaptic response to transmitter released from one presynaptic vesicle. At central synapses where quanta are small, it has been suggested they are invariant due to occupation of all postsynaptic receptors, a concept neglecting inherent fluctuations in channel behavior. If this did occur, the quantal release model would not apply there and could not be used to localize sites of synaptic modification. Monte Carlo simulations of quanta include transmitter diffusion and interactions with postsynaptic receptors that are treated probabilistically. These models suggest that when there are few postsynaptic channels available at a synapse, their stochastic behavior produces significant intrinsic variance in response amplitude and kinetics, and saturation does not occur. These results were confirmed by analysis of inhibitory quanta in embryonic and adult Mauthner cells involving a small and large number of channels, respectively. The findings apply to excitatory synapses as well.	SUNY BUFFALO, NEUROBIOL LAB, BUFFALO, NY 14214 USA; INST PASTEUR, INSERM, U261, DEPT BIOTECHNOL, F-75724 PARIS 15, FRANCE	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris					NINDS NIH HHS [NS21848] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021848] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKAGI H, 1988, SCIENCE, V242, P270, DOI 10.1126/science.2845580; BARTOL TM, 1991, BIOPHYS J, V59, P1290, DOI 10.1016/S0006-3495(91)82344-X; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BUSCH C, 1990, COLD SH Q B, V55, P69; DIAMOND J, 1973, J PHYSIOL-LONDON, V232, P113, DOI 10.1113/jphysiol.1973.sp010259; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; EDWARDS FR, 1976, J PHYSIOL-LONDON, V259, P689, DOI 10.1113/jphysiol.1976.sp011489; FABER DS, 1988, P NATL ACAD SCI USA, V85, P8708, DOI 10.1073/pnas.85.22.8708; FABER DS, 1985, P NATL ACAD SCI USA, V82, P3504, DOI 10.1073/pnas.82.10.3504; FABER DS, 1991, BIOPHYS J, V60, P1288, DOI 10.1016/S0006-3495(91)82162-2; FABER DS, 1980, SCIENCE, V208, P612, DOI 10.1126/science.6245449; FABER DS, 1988, J NEUROPHYSIOL, V60, P1982, DOI 10.1152/jn.1988.60.6.1982; FABER DS, 1982, J NEUROPHYSIOL, V48, P654, DOI 10.1152/jn.1982.48.3.654; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; HARTZELL HC, 1975, J PHYSIOL-LONDON, V251, P427, DOI 10.1113/jphysiol.1975.sp011102; JACK JJB, 1981, J PHYSIOL-LONDON, V321, P65, DOI 10.1113/jphysiol.1981.sp013972; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KORN H, 1990, J NEUROPHYSIOL, V63, P198, DOI 10.1152/jn.1990.63.1.198; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KORN H, 1991, NATURE, V350, P282, DOI 10.1038/350282a0; KORN H, 1987, P NATL ACAD SCI USA, V84, P5981, DOI 10.1073/pnas.84.16.5981; KUFFLER SW, 1975, J PHYSIOL-LONDON, V251, P465, DOI 10.1113/jphysiol.1975.sp011103; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; Legendre P., 1992, Society for Neuroscience Abstracts, V18, P1357; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MARGAROLI A, 1992, NATURE, V357, P134; ROBINSON HPC, 1991, BIOPHYS J, V59, P295, DOI 10.1016/S0006-3495(91)82223-8; ROPERT N, 1990, J PHYSIOL-LONDON, V428, P287; SEITANIDOU T, 1988, J NEUROSCI, V8, P4319; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; SOLODKIN M, 1991, J NEUROPHYSIOL, V65, P927, DOI 10.1152/jn.1991.65.4.927; TRILLER A, 1982, J NEUROPHYSIOL, V48, P708, DOI 10.1152/jn.1982.48.3.708; TWYMAN RE, 1991, J PHYSIOL-LONDON, V435, P303, DOI 10.1113/jphysiol.1991.sp018512; VRENSEN G, 1980, BRAIN RES, V184, P23, DOI 10.1016/0006-8993(80)90585-5; YOUNG AB, 1973, P NATL ACAD SCI USA, V70, P2832, DOI 10.1073/pnas.70.10.2832	43	155	155	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1992	258	5087					1494	1498		10.1126/science.1279813	http://dx.doi.org/10.1126/science.1279813			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279813				2022-12-28	WOS:A1992JZ62500032
J	GAUR, A; WIERS, B; LIU, A; ROTHBARD, J; FATHMAN, CG				GAUR, A; WIERS, B; LIU, A; ROTHBARD, J; FATHMAN, CG			AMELIORATION OF AUTOIMMUNE ENCEPHALOMYELITIS BY MYELIN BASIC-PROTEIN SYNTHETIC PEPTIDE INDUCED ANERGY	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; T-CELL TOLERANCE; MULTIPLE-SCLEROSIS; MONOCLONAL-ANTIBODY; ANTIGEN; DETERMINANT; EPITOPES; MICE; PREVENTION; REVERSAL	Experimental autoimmune encephalomyelitis (EAE), a demyelinating disease of the central nervous system that can be induced in susceptible strains of mice by immunization with myelin basic protein (MBP) or its immunodominant T cell determinants, serves as a model of human multiple sclerosis. Tolerance to MBP in adult mice was induced by intraperitoneal injection of synthetic peptides of immunodominant determinants of MBP and prevented MBP-induced EAE. Furthermore, tolerance-inducing regimens of peptides administered to mice after the disease had begun (10 days after induction with MBP) blocked the progression and decreased the severity of EAE. Peptide-induced tolerance resulted from the induction of anergy in proliferative, antigen-specific T cells.	STANFORD UNIV,MED CTR,SCH MED,DIV IMMUNOL & RHEUMATOL,STANFORD,CA 94305; IMMULOG PHARMACEUT CORP,PALO ALTO,CA 94304	Stanford University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027989] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27989] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALVORD EC, 1965, ANN NY ACAD SCI, V1220, P333; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; CAMPBELL B, 1973, ARCH NEUROL-CHICAGO, V29, P10, DOI 10.1001/archneur.1973.00490250028003; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; DEMAGISTRIS TM, 1992, CELL, V68, P625; DRISCOLL BF, 1976, J IMMUNOL, V117, P110; DRISCOLL BF, 1974, J IMMUNOL, V112, P392; EYLAR EH, 1972, NATURE, V236, P74, DOI 10.1038/236074a0; FRITZ RB, 1983, J IMMUNOL, V130, P191; GAMMON G, 1986, NATURE, V319, P413, DOI 10.1038/319413a0; HAFLER DA, 1988, J EXP MED, V167, P1313, DOI 10.1084/jem.167.4.1313; HASHIM GA, 1973, ARCH BIOCHEM BIOPHYS, V156, P287, DOI 10.1016/0003-9861(73)90367-6; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; KONO DH, 1988, J EXP MED, V168, P213, DOI 10.1084/jem.168.1.213; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; MARTIN R, 1992, J IMMUNOL, V148, P1359; OKI A, 1985, J EXP MED, V161, P897, DOI 10.1084/jem.161.5.897; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; SMILEK DE, 1991, P NATL ACAD SCI USA, V88, P9633, DOI 10.1073/pnas.88.21.9633; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WALDOR MK, 1985, SCIENCE, V227, P415, DOI 10.1126/science.3155574; WISNIEWSKI HM, 1977, ANN NEUROL, V1, P144, DOI 10.1002/ana.410010207; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943; ZAMVIL SS, 1988, J EXP MED, V167, P1586, DOI 10.1084/jem.167.5.1586; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0; ZAMVIL SS, 1988, J EXP MED, V168, P1181, DOI 10.1084/jem.168.3.1181	29	239	249	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1491	1494		10.1126/science.1279812	http://dx.doi.org/10.1126/science.1279812			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279812				2022-12-28	WOS:A1992JZ62500031
J	MARTIN, DH; MROCZKOWSKI, TF; DALU, ZA; MCCARTY, J; JONES, RB; HOPKINS, SJ; JOHNSON, RB				MARTIN, DH; MROCZKOWSKI, TF; DALU, ZA; MCCARTY, J; JONES, RB; HOPKINS, SJ; JOHNSON, RB			A CONTROLLED TRIAL OF A SINGLE DOSE OF AZITHROMYCIN FOR THE TREATMENT OF CHLAMYDIAL URETHRITIS AND CERVICITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVITRO ACTIVITY; TRACHOMATIS INFECTIONS; UREAPLASMA-UREALYTICUM; ERYTHROMYCIN	Background. Currently, there is no single-dose therapy that is effective in the treatment of urethral or endocervical infections with Chlamydia trachomatis. Azithromycin is a new azalide antibiotic that has substantial activity against C. trachomatis, is concentrated intracellularly, and has a long half-life in serum and tissue. Methods. We conducted a trial in which 299 female patients and 158 male patients with uncomplicated genital infection and a positive C. trachomatis antigen test were randomly assigned to receive either azithromycin (1 g once orally) or doxycycline (100 mg orally twice daily for seven days). Only patients subsequently determined to have a culture positive for C. trachomatis at base line were included in the evaluation of efficacy. Results. Among the patients who could be evaluated, 5 of the 141 patients (4 percent) treated with azithromycin did not respond to treatment, as compared with 3 of the 125 patients (2 percent) treated with doxycycline (difference between groups, 2 percent; 95 percent confidence interval, 0 to 6 percent). Of the patients evaluated 21 to 35 days after treatment, none of 112 treated with azithromycin and 1 of 102 treated with doxycycline had a positive culture. The rates of bacteriologic cure were similar for the 98 female patients (97 percent) and the 43 male patients (95 percent) treated with azithromycin. Seventeen percent of the patients who received azithromycin and 20 percent of those treated with doxycycline had mild-to-moderate drug-related side effects, mainly gastrointestinal symptoms. Conclusions. A single 1-g dose of azithromycin is as effective for the treatment of uncomplicated genital chlamydial infections as a standard seven-day course of doxycycline.	ST LOUIS HLTH DEPT, ST LOUIS, MO USA; CALIF MED RES GRP, FRESNO, CA USA; INDIANA UNIV, SCH MED, INDIANAPOLIS, IN 46202 USA; PFIZER INC, CENT RES, GROTON, CT 06340 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Pfizer	MARTIN, DH (corresponding author), LOUISIANA STATE UNIV, MED CTR, DEPT MED, INFECT DIS SECT, 1542 TULANE AVE, NEW ORLEANS, LA 70112 USA.							BALDWIN DR, 1990, EUR RESPIR J, V3, P886; Bell T A, 1987, Semin Adolesc Med, V3, P153; BOWIE WR, 1977, J CLIN INVEST, V59, P735, DOI 10.1172/JCI108694; CHOW JM, 1990, JAMA-J AM MED ASSOC, V263, P3164, DOI 10.1001/jama.263.23.3164; CRAMER JA, 1990, ARCH INTERN MED, V150, P1509, DOI 10.1001/archinte.150.7.1509; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; FOULDS G, 1990, J ANTIMICROB CHEMOTH, V25, P73, DOI 10.1093/jac/25.suppl_A.73; GLADUE RP, 1990, ANTIMICROB AGENTS CH, V34, P1056, DOI 10.1128/AAC.34.6.1056; HAMMERSCHLAG MR, 1989, J PEDIATR-US, V114, P727, DOI 10.1016/S0022-3476(89)80128-3; JONES RB, 1990, J INFECT DIS, V162, P1309, DOI 10.1093/infdis/162.6.1309; KARAM GH, 1986, J INFECT DIS, V154, P900, DOI 10.1093/infdis/154.5.900; KROHN K, 1991, EUR J CLIN MICROBIOL, V10, P864, DOI 10.1007/BF01975844; PATTON DL, 1990, CHLAMYDIAL INFECTION, P223; RENAUDIN H, 1990, EUR J CLIN MICROBIOL, V9, P838, DOI 10.1007/BF01967388; RYAN RW, 1986, 26TH INT C ANT AG CH, P267; RYLANDER M, 1988, SCAND J INFECT DIS, P12; SCIEUX C, 1990, J ANTIMICROB CHEMOTH, V25, P7, DOI 10.1093/jac/25.suppl_A.7; SHEPARD MK, 1989, FERTIL STERIL, V52, P232; SLANEY L, 1990, J ANTIMICROB CHEMOTH, V25, P1; STAMM WE, 1987, AM J MED, V82, P307; STEINGRIMSSON O, 1990, J ANTIMICROB CHEMOTH, V25, P109, DOI 10.1093/jac/25.suppl_A.109; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070	22	219	229	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					921	925		10.1056/NEJM199209243271304	http://dx.doi.org/10.1056/NEJM199209243271304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP014	1325036	Bronze			2022-12-28	WOS:A1992JP01400004
J	ARTALEJO, CR; ROSSIE, S; PERLMAN, RL; FOX, AP				ARTALEJO, CR; ROSSIE, S; PERLMAN, RL; FOX, AP			VOLTAGE-DEPENDENT PHOSPHORYLATION MAY RECRUIT CA2+ CURRENT FACILITATION IN CHROMAFFIN CELLS	NATURE			English	Article							CARDIAC CALCIUM-CHANNEL; RABBIT SKELETAL-MUSCLE; PROTEIN KINASE-C; OKADAIC ACID; POTENT INHIBITORS; PHOSPHATASE-2A; RECEPTOR	BOVINE chromaffin cells have two components of whole-cell Ca2+ current: 'standard' Ca2+ currents that are activated by brief depolarizations, and 'facilitation' Ca2+ currents, which are normally quiescent but can be activated by large pre-depolarizations or by repetitive depolarizations to physiological potentials 1-5. The activation of protein kinase A can also stimulate Ca2+ current facilitation, indicating that phosphorylation can play a part in facilitation 6. Here we investigate the role of protein phosphorylation in the recruitment of facilitation Ca2+ currents by pre-pulses or repetitive depolarizations. We find that recruitment of facilitation by depolarization is a rapid first-order process which is suppressed by inhibitors of protein phosphorylation or by injection of phosphatase 2A into cells. Recruitment of facilitation Ca2+ current by voltage is normally reversible but phosphatase inhibitors render it irreversible. Our results indicate that recruitment of these Ca2+ currents by pre-pulses or repetitive depolarizations involves voltage-dependent phosphorylation of the facilitation Ca2+ channel or a closely associated regulatory protein. Voltage-dependent phosphorylation may therefore be a mechanism by which membrane potential can modulate ion channel activity.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,JOSEPH P KENNEDY JR MENTAL RETARDAT RES CTR,CHICAGO,IL 60637; UNIV AUTONOMA MADRID,FAC MED,DEPT FARMACOL,E-28029 MADRID,SPAIN; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	University of Chicago; University of Chicago; University of Chicago; Autonomous University of Madrid; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Perlman, Robert/GZH-2102-2022					ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; AMADOR M, 1991, NEUROSCI LETT, V124, P251, DOI 10.1016/0304-3940(91)90106-4; ARTALEJO CR, 1991, J PHYSIOL-LONDON, V432, P681, DOI 10.1113/jphysiol.1991.sp018406; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; ARTALEJO CR, 1991, J PHYSIOL-LONDON, V444, P213, DOI 10.1113/jphysiol.1991.sp018874; CHUNG S, 1991, SCIENCE, V253, P56; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1988, METHOD ENZYMOL, V159, P390; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HAAVIK J, 1989, FEBS LETT, V251, P36, DOI 10.1016/0014-5793(89)81424-3; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HESCHELER J, 1987, EUR J BIOCHEM, V165, P261, DOI 10.1111/j.1432-1033.1987.tb11436.x; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOSHI T, 1984, P NATL ACAD SCI-BIOL, V81, P5871, DOI 10.1073/pnas.81.18.5871; HOSHI T, 1987, J NEUROSCI, V7, P571; IMAGAWA T, 1987, J BIOL CHEM, V262, P8333; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; NESTLER EJ, 1989, BASIC NEUROCHEMISTRY; TESSMER GW, 1977, J BIOL CHEM, V252, P5666; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999; YOUNT RG, 1975, ADV ENZYMOL, V34, P1	24	127	128	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					63	66		10.1038/358063a0	http://dx.doi.org/10.1038/358063a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1319555				2022-12-28	WOS:A1992JB34100054
J	SCHOFIELD, PF; JONES, DJ				SCHOFIELD, PF; JONES, DJ			ABC OF COLORECTAL DISEASES - COLORECTAL NEOPLASIA .1. BENIGN COLONIC TUMORS	BRITISH MEDICAL JOURNAL			English	Article									HOPE HOSP,DEPT GEN SURG,SALFORD M6 8HD,LANCS,ENGLAND		SCHOFIELD, PF (corresponding author), WITHINGTON HOSP,MANCHESTER M20 8LR,LANCS,ENGLAND.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1498	1500		10.1136/bmj.304.6840.1498	http://dx.doi.org/10.1136/bmj.304.6840.1498			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1319254	Bronze, Green Published			2022-12-28	WOS:A1992HY55300030
J	KULHANJIAN, JA; SOROUSH, V; AU, DS; BRONZAN, RN; YASUKAWA, LL; WEYLMAN, LE; ARVIN, AM; PROBER, CG				KULHANJIAN, JA; SOROUSH, V; AU, DS; BRONZAN, RN; YASUKAWA, LL; WEYLMAN, LE; ARVIN, AM; PROBER, CG			IDENTIFICATION OF WOMEN AT UNSUSPECTED RISK OF PRIMARY INFECTION WITH HERPES-SIMPLEX VIRUS TYPE-2 DURING PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENITAL HERPES; DELIVERY; INFANTS; ACQUISITION; CULTURES; PARTNER	Background. Primary infections with herpes simplex virus type 2 (HSV-2) acquired by women during pregnancy account for about half of the morbidity and mortality from HSV-2 among neonates. The other half results from reactivation of old infections. Better methods are needed to identify which women are at risk for primary HSV-2 infection. Methods. We prospectively studied HSV-2 infections among pregnant women who were patients in private obstetrical practices. Using an enzyme-linked immunosorbent assay that detects type-specific antibodies to HSV-2 glycoprotein G, we determined the prevalence at base line of HSV-2 infections among pregnant women and their husbands, the frequency of discordance for infection between partners, and the risk of seroconversion during pregnancy among the seronegative women whose husbands were seropositive. Results. The seroprevalence of HSV-2 was 32 percent among the 277 women followed throughout their pregnancies and 25 percent among the 190 husbands studied. Two thirds of the HSV-2-seropositive women had no history of genital herpes. Of the 190 couples, 139 (73 percent) were serologically concordant for HSV-2 antibodies (57 percent being seronegative and 16 percent being seropositive), whereas 51 couples (27 percent) were discordant, despite having been sexually intimate for a mean of 6.1 years. Eighteen women who were seronegative for HSV-2 (9.5 percent) had seropositive partners, of whom 10 (56 percent) had no history of genital herpes. Thus, approximately 5 percent of these pregnant women had an unsuspected risk of contracting a primary HSV-2 infection. One of the 18 seronegative women with a seropositive husband seroconverted to HSV-2 during pregnancy; none of the other women seroconverted. Conclusions. In this study about 10 percent of pregnant women were at risk of contracting a primary HSV-2 infection from their HSV-2-seropositive husbands. In addition, about a third of these women were seropositive for HSV-2 and thus at risk for asymptomatic, reactivated infections. Serologic testing of couples can identify women who are at risk for primary or reactivated HSV-2 infections during pregnancy.	STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,DIV INFECT DIS,RM A367,STANFORD,CA 94305	Stanford University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016080] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16080] Funding Source: Medline; PHS HHS [A1008844] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADLERSTORTHZ K, 1985, AM J OBSTET GYNECOL, V151, P582, DOI 10.1016/0002-9378(85)90143-7; ARVIN AM, 1986, NEW ENGL J MED, V315, P796, DOI 10.1056/NEJM198609253151303; BOUCHER FD, 1990, PEDIATR INFECT DIS J, V9, P499, DOI 10.1097/00006454-199007000-00009; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BROWN ZA, 1987, NEW ENGL J MED, V317, P1246, DOI 10.1056/NEJM198711123172002; FRENKEL LM, 1987, PEDIATR RES, V21, pA325; HARDY DA, 1990, J INFECT DIS, V162, P1031, DOI 10.1093/infdis/162.5.1031; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; PROBER CG, 1988, NEW ENGL J MED, V318, P887, DOI 10.1056/NEJM198804073181404; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STAVRAKY KM, 1983, AM J EPIDEMIOL, V118, P109, DOI 10.1093/oxfordjournals.aje.a113612; SULLENDER WM, 1988, J INFECT DIS, V157, P164, DOI 10.1093/infdis/157.1.164; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109	19	123	125	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					916	920		10.1056/NEJM199204023261403	http://dx.doi.org/10.1056/NEJM199204023261403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1311799	Bronze			2022-12-28	WOS:A1992HL26100003
J	MORABIA, A; WYNDER, EL				MORABIA, A; WYNDER, EL			RELATION OF BRONCHIOLOALVEOLAR CARCINOMA TO TOBACCO	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUNG-CANCER; CIGARETTE SMOKERS	Objective - To determine whether bronchioalveolar carcinoma is related to tobacco use. Design - Case-control study. Setting - 11 teaching hospitals of Chicago, Long Island, New York, and Philadelphia, 1977-89. Subjects - 87 patients with histologically diagnosed bronchioloalveolar carcinoma (cases) and 286 non-cancer and 297 cancer patients matched to cases on age, sex, race, hospital, and date of admission. Results - 10% of male cases and 25% of female cases had never smoked. Relative risks of bronchioloalveolar carcinoma (as estimated by the relative odds) were greater for subjects who started smoking at a younger age, smoked for a longer time, or smoked more cigarettes per day. Relative risks decreased proportionally to the duration of smoking cessation. Conclusion - Smoking plays an important part in the aetiology of bronchioloalveolar carcinoma but is not the only potential cause because of the large proportion of never smokers among patients with this disease.	AMER HLTH FDN, 320 E43RD ST, NEW YORK, NY 10017 USA	American Health Foundation								Breslow N, 1980, STATISTICAL METHODS, V32; CLAYTON F, 1988, PATHOL ANNU, V23, P361; EDWARDS CW, 1984, THORAX, V39, P166, DOI 10.1136/thx.39.3.166; FEINSTEI.AR, 1970, AM REV RESPIR DIS, V101, P671; GEDDES DM, 1987, BRIT MED J, V294, P3, DOI 10.1136/bmj.294.6563.3; GRECO RJ, 1986, ANN THORAC SURG, V41, P652, DOI 10.1016/S0003-4975(10)63082-2; GROVER FL, 1989, ANN SURG, V209, P779, DOI 10.1097/00000658-198906000-00016; HOIDAL JR, 1981, AM REV RESPIR DIS, V123, P85; HOIDAL JR, 1982, AM REV RESPIR DIS, V126, P548; IVES JC, 1983, AM REV RESPIR DIS, V128, P195, DOI 10.1164/arrd.1983.128.1.195; JONES JG, 1980, LANCET, V1, P66; LIEBOW A A, 1960, Adv Intern Med, V10, P329; MANNING JT, 1984, CANCER-AM CANCER SOC, V54, P525, DOI 10.1002/1097-0142(19840801)54:3<525::AID-CNCR2820540324>3.0.CO;2-X; MORABIA A, 1991, CANCER, V68, P2074, DOI 10.1002/1097-0142(19911101)68:9<2074::AID-CNCR2820680939>3.0.CO;2-X; ROSENOW EC, 1979, CA-CANCER J CLIN, V29, P233, DOI 10.3322/canjclin.29.4.233; SCHRAUFNAGEL D, 1982, AM REV RESPIR DIS, V125, P74; STANLEY KE, 1981, J NATL CANCER I, V66, P989, DOI 10.1093/jnci/66.6.989; VINCENT RG, 1977, CANCER, V39, P1647, DOI 10.1002/1097-0142(197704)39:4<1647::AID-CNCR2820390439>3.0.CO;2-H; WYNDER EL, 1977, CANCER RES, V37, P4608; 1984, DATA NATIONAL HLTH I	20	42	43	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 29	1992	304	6826					541	543		10.1136/bmj.304.6826.541	http://dx.doi.org/10.1136/bmj.304.6826.541			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1313719	Green Published, Bronze			2022-12-28	WOS:A1992HG59900019
J	BREATHNACH, AS; JENKINS, DR; PEDLER, SJ				BREATHNACH, AS; JENKINS, DR; PEDLER, SJ			STETHOSCOPES AS POSSIBLE VECTORS OF INFECTION BY STAPHYLOCOCCI	BRITISH MEDICAL JOURNAL			English	Article											BREATHNACH, AS (corresponding author), ROYAL VICTORIA INFIRM,DEPT CLIN MICROBIOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							AYCLIFF GA, 1992, CONTROL HOSPITAL INF, P78; AYCLIFFE GA, 1990, J HOSP INFECT, V16, P351; GERKEN A, 1972, LANCET, V1, P1214; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; Waldvogel F. A., 1990, PRINCIPLES PRACTICES, P1489	5	58	60	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1573	1574		10.1136/bmj.305.6868.1573	http://dx.doi.org/10.1136/bmj.305.6868.1573			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286393	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KD77100030
J	LAMONT, T				LAMONT, T			THE AMAZONS WITHIN - WOMEN IN THE BMA 100 YEARS AGO	BRITISH MEDICAL JOURNAL			English	Item About an Individual											LAMONT, T (corresponding author), BRITISH MED ASSOC,BOARD SCI & EDUC,LONDON WC1H 9JR,ENGLAND.							ANDERSON LG, 1939, EG ANDERSON; [Anonymous], 1892, BMJ-BRIT MED J, V2, P262; [Anonymous], 1892, BMJ-BRIT MED J, V2, P383; BLAKE C, 1991, CHARGE PARASOLS WOME; MUIRHEADLITTLE E, 1932, HIST BMA, V1; 1878, BMJ, V2, P253; 1878, BMJ, V1, P175; 1878, BMJ, V1, P234; 1861, LANCET, V2, P16	9	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1529	1532		10.1136/bmj.305.6868.1529	http://dx.doi.org/10.1136/bmj.305.6868.1529			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286372	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100009
J	HANVEY, JC; PEFFER, NJ; BISI, JE; THOMSON, SA; CADILLA, R; JOSEY, JA; RICCA, DJ; HASSMAN, CF; BONHAM, MA; AU, KG; CARTER, SG; BRUCKENSTEIN, DA; BOYD, AL; NOBLE, SA; BABISS, LE				HANVEY, JC; PEFFER, NJ; BISI, JE; THOMSON, SA; CADILLA, R; JOSEY, JA; RICCA, DJ; HASSMAN, CF; BONHAM, MA; AU, KG; CARTER, SG; BRUCKENSTEIN, DA; BOYD, AL; NOBLE, SA; BABISS, LE			ANTISENSE AND ANTIGENE PROPERTIES OF PEPTIDE NUCLEIC-ACIDS	SCIENCE			English	Article							TRIPLE-HELIX FORMATION; RNASE-H; INHIBITION; DNA; OLIGONUCLEOTIDES; TRANSCRIPTION; TRANSLATION; INVITRO	Peptide nucleic acids (PNAs) are polyamide oligomers that can strand invade duplex DNA, causing displacement of one DNA strand and formation of a D-loop. Binding of either a T10 PNA or a mixed sequence 15-mer PNA to the transcribed strand of a G-free transcription cassette caused 90 to 100 percent site-specific termination of pol II transcription elongation. When a T10 PNA was bound on the nontranscribed strand, site-specific inhibition never exceeded 50 percent. Binding of PNAs to RNA resulted in site-specific termination of both reverse transcription and in vitro translation, precisely at the position of the PNA . RNA heteroduplex. Nuclear microinjection of cells constitutively expressing SV40 large T antigen (T Ag) with either a 15-mer or 20-mer PNA targeted to the T Ag messenger RNA suppressed T Ag expression. This effect was specific in that there was no reduction in beta-galactosidase expression from a coinjected expression vector and no inhibition of T Ag expression after microinjection of a 10-mer PNA.	GLAXO INC,RES INST,DEPT CELL BIOL,5 MOORE DR,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT MED CHEM,RES TRIANGLE PK,NC 27709; HOOD COLL,DEPT BIOL,FREDERICK,MD 21701	GlaxoSmithKline; GlaxoSmithKline								BOIZIAU C, 1991, NUCLEIC ACIDS RES, V19, P1113, DOI 10.1093/nar/19.5.1113; BOIZIAU C, 1992, P NATL ACAD SCI USA, V89, P768, DOI 10.1073/pnas.89.2.768; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; TITUS DE, 1991, PROMEGA PROTOCOLS AP, P59; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WICKSTROM E, 1991, PROSPECTS ANTISENSE; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	19	466	573	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1481	1485		10.1126/science.1279811	http://dx.doi.org/10.1126/science.1279811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279811				2022-12-28	WOS:A1992JZ62500028
J	SPERA, RV; FARBER, BF				SPERA, RV; FARBER, BF			MULTIPLY-RESISTANT ENTEROCOCCUS-FAECIUM - THE NOSOCOMIAL PATHOGEN OF THE 1990S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VANCOMYCIN		N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT MED,DIV INFECT DIS & IMMUNOL,MANHASSET,NY 11030	Cornell University; Northwell Health; North Shore University Hospital								HANDWERGER S, 1992, CLIN INFECT DIS, V14, P655, DOI 10.1093/clinids/14.3.655; JACOBY GA, 1991, NEW ENGL J MED, V324, P601, DOI 10.1056/NEJM199102283240906; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; MURRAY BE, 1991, J INFECT DIS, V163, P1185, DOI 10.1093/infdis/163.6.1185; RAMPHAL R, 1992, ANTIMICROB AGENTS CH, V36, P1062, DOI 10.1128/AAC.36.5.1062; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; UTTLEY AHC, 1989, EPIDEMIOL INFECT, V103, P173, DOI 10.1017/S0950268800030478; VANDERAUWERA P, 1990, 30TH INT C ANT AG CH; WADE J, 1991, LANCET, V337, P1616, DOI 10.1016/0140-6736(91)93320-9	12	75	78	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2563	2564		10.1001/jama.268.18.2563	http://dx.doi.org/10.1001/jama.268.18.2563			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1308665				2022-12-28	WOS:A1992JW61600030
J	NAGEL, G; HWANG, TC; NASTIUK, KL; NAIRN, AC; GADSBY, DC				NAGEL, G; HWANG, TC; NASTIUK, KL; NAIRN, AC; GADSBY, DC			THE PROTEIN KINASE-A-REGULATED CARDIAC CL- CHANNEL RESEMBLES THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	NATURE			English	Article							CFTR CHLORIDE CHANNEL; AUTONOMIC REGULATION; MYOCYTES; GENE; EXPRESSION; CELLS; PHOSPHORYLATION; IDENTIFICATION; ADRENALINE; ACID	STIMULATION of beta-adrenoceptors in cardiac ventricular myocytes activates a strong chloride ion conductance1-5 as a result of phosphorylation by cyclic AMP-dependent protein kinase (PKA)2,4. This Cl- conductance, which is time- and voltage-independent1-5, counters2,5 the tendency of the simultaneously enhanced Ca2+ channel current to prolong the ventricular action potential. Using inside-out giant patches6 excised from guinea-pig myocytes, we show here that phosphorylation by the PKA catalytic subunit plus Mg-ATP elicits discrete Cl- channel currents. In almost symmetrical Cl- solutions (approximately 150 mM), unitary current amplitude scales with membrane potential, and reverses sign near 0 mV, to yield a single channel conductance of approximately 12 pS. Opening of the phosphorylated channels requires hydrolysable nucleoside triphosphate, indicating that phosphorylation by PKA is necessary, but not sufficient, for channel activation. The properties of these PKA-regulated cardiac Cl- channels are very similar, if not identical, to those of the cystic fibrosis transmembrane conductance regulator (CFTR)7, the epithelial cell Cl- channel whose regulation is defective in patients with cystic fibrosis. The full cardiological impact of these Cl- channels and of their possible malfunction in patients with cystic fibrosis remains to be determined.	ROCKEFELLER UNIV,CARDIAC MEMBRANE PHYSIOL LAB,1230 YORK AVE,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Rockefeller University; Rockefeller University				Nairn, Angus/0000-0002-7075-0195; Nagel, Georg/0000-0001-8174-8712				AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAHINSKI A, 1989, NATURE, V340, P718, DOI 10.1038/340718a0; BENSON LN, 1984, AM REV RESPIR DIS, V130, P987; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHERON G, 1984, ACTA PAEDIATR SCAND, V73, P697, DOI 10.1111/j.1651-2227.1984.tb09999.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; EHARA T, 1990, NATURE, V347, P284, DOI 10.1038/347284a0; HARVEY RD, 1990, J GEN PHYSIOL, V95, P1077, DOI 10.1085/jgp.95.6.1077; HARVEY RD, 1989, SCIENCE, V244, P983, DOI 10.1126/science.2543073; Hilgemann D, 1991, SODIUM PUMP RECENT D, P543; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HWANG TC, 1992, J GEN PHYSIOL, V99, P465, DOI 10.1085/jgp.99.4.465; Hwang Tzyh-Chang, 1992, Journal of General Physiology, V100, p69A; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; MATSUOKA S, 1990, J PHYSIOL-LONDON, V425, P579, DOI 10.1113/jphysiol.1990.sp018119; OVERHOLT J L, 1992, Biophysical Journal, V61, pA442; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J, 1989, MOL CLONING LABORATO; SULLIVAN MM, 1986, CHEST, V90, P239, DOI 10.1378/chest.90.2.239; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417	30	162	165	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					81	84		10.1038/360081a0	http://dx.doi.org/10.1038/360081a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1279437				2022-12-28	WOS:A1992JW71700061
J	BURNETT, SD; WOOLF, CM; YUDKIN, JS				BURNETT, SD; WOOLF, CM; YUDKIN, JS			DEVELOPING A DISTRICT DIABETIC REGISTER	BRITISH MEDICAL JOURNAL			English	Article							CARE	Objectives-To compile a district wide diabetic register of all diabetic patients registered with general practitioners in the catchment area of a single district general hospital and to compare different approaches to identifying patients. Design-Information for a register was obtained from general practitioners' practice registers, the Prescription Pricing Authority, and hospital diabetic clinic records. Setting-Catchment area of an inner London district general hospital with a large diabetic clinic. Subjects-All patients with a diagnosis of diabetes resident in or attending general practitioners or hospital clinics in the district or its catchment area. Main outcome measures-Prevalence of diabetes, population of patients elicited by different approaches, proportion attending the local district general hospital, cost of using prescription returns for identifying diabetic patients. Results-4674 patients with diabetes were identified from all sources of information, which corresponds to a mean of 22.4 patients per general practitioner and the prevalence of known diabetes of 1.17%. 39.4% of patients identified had Prescription Pricing Authority returns and 42.8% of patients appeared on practices' diabetic registers. Only 56.5% of patients identified attended the district general hospital. For practices where all sources of information were available, practice registers included 60.4% of all patients, and prescription returns and the clinic register identified 64.9% and 40.6% respectively. The cost of using prescription returns to identify patients not detected in other ways was Pound 6-37 per patient. Conclusion-The task of developing district diabetic registers may prove, even in one cross sectional attempt, a major task in many inner city health districts.			BURNETT, SD (corresponding author), WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,DEPT MED,LONDON N19 5NF,ENGLAND.		Yudkin, John S/C-1988-2008					COULTER A, 1989, J EPIDEMIOL COMMUN H, V43, P25, DOI 10.1136/jech.43.1.25; HURWITZ B, 1990, DIABETES CLIN MANAGE, P110; JONES RB, 1989, PRACTICAL DIABETES, V3, P129; KOPELMAN P, 1990, DIABETIC MED, V7, P558, DOI 10.1111/j.1464-5491.1990.tb01446.x; MCMAHON C, 1991, DIABETIC MED, V8, P770, DOI 10.1111/j.1464-5491.1991.tb01698.x; NABARRO J, 1987, J ROY COLL GEN PRACT, V37, P389; YUDKIN JS, 1980, J EPIDEMIOL COMMUN H, V34, P277, DOI 10.1136/jech.34.4.277; 1991, RECOMMENDATIONS DIAB	8	30	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					627	630		10.1136/bmj.305.6854.627	http://dx.doi.org/10.1136/bmj.305.6854.627			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1294089	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JN69800022
J	WILLARD, JE; LANGE, RA; HILLIS, LD				WILLARD, JE; LANGE, RA; HILLIS, LD			CURRENT CONCEPTS - THE USE OF ASPIRIN IN ISCHEMIC-HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY-ARTERY BYPASS; ACUTE MYOCARDIAL-INFARCTION; LOW-DOSE ASPIRIN; UNSTABLE ANGINA-PECTORIS; VEIN-GRAFT PATENCY; TRANS-LUMINAL ANGIOPLASTY; CYCLIC BLOOD-FLOW; RANDOMIZED TRIAL; ANTIPLATELET THERAPY; PLATELET-AGGREGATION		UNIV TEXAS, SW MED CTR,DEPT INTERNAL MED,DIV CARDIOVASC, RM CS7 102, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Lange, Richard/AAM-9594-2021					AMBROSE JA, 1985, J AM COLL CARDIOL, V5, P609, DOI 10.1016/S0735-1097(85)80384-3; [Anonymous], 1980, LANCET, V1, P1172; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P316; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1980, CIRCULATION, V62, P449; ASHTON JH, 1986, CIRCULATION, V73, P572, DOI 10.1161/01.CIR.73.3.572; BARNATHAN ES, 1987, CIRCULATION, V76, P125, DOI 10.1161/01.CIR.76.1.125; BLOCK PC, 1981, NEW ENGL J MED, V305, P382, DOI 10.1056/NEJM198108133050706; BORIEN JR, 1968, LANCET, V1, P799; BRADEN GA, 1991, CIRCULATION, V84, P679, DOI 10.1161/01.CIR.84.2.679; BREDDIN K, 1980, CIRCULATION, V62, P63; BREZINSKI DA, 1988, CIRCULATION, V78, P35, DOI 10.1161/01.CIR.78.1.35; BROWN BG, 1985, CIRCULATION, V72, P138, DOI 10.1161/01.CIR.72.1.138; BUSH LR, 1984, CIRCULATION, V69, P1161, DOI 10.1161/01.CIR.69.6.1161; BUSH LR, 1984, CIRC RES, V55, P642, DOI 10.1161/01.RES.55.5.642; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CHESEBRO JH, 1982, NEW ENGL J MED, V307, P73, DOI 10.1056/NEJM198207083070201; CHESEBRO JH, 1984, NEW ENGL J MED, V310, P209, DOI 10.1056/NEJM198401263100401; CHESEBRO JH, 1989, CIRCULATION S2, V80, P266; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEGAETANO G, 1985, CIRCULATION, V72, P1185, DOI 10.1161/01.CIR.72.6.1185; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; EICHHORN EJ, 1991, J AM COLL CARDIOL, V17, P43, DOI 10.1016/0735-1097(91)90702-B; ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436; ELWOOD PC, 1980, CIRCULATION, V62, P53; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FAXON DP, 1982, ARTERIOSCLEROSIS, V2, P125, DOI 10.1161/01.ATV.2.2.125; FITZGERALD DJ, 1988, CIRCULATION, V77, P142, DOI 10.1161/01.CIR.77.1.142; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FITZGERALD DJ, 1986, J CLIN INVEST, V77, P496, DOI 10.1172/JCI112329; FITZGERALD GA, 1987, NEW ENGL J MED, V316, P1247; FOLTS JD, 1976, CIRCULATION, V54, P365, DOI 10.1161/01.CIR.54.3.365; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GOLDMAN S, 1989, CIRCULATION, V80, P1190, DOI 10.1161/01.CIR.80.5.1190; GOLDMAN S, 1988, CIRCULATION, V77, P1324, DOI 10.1161/01.CIR.77.6.1324; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HIRSH PD, 1981, NEW ENGL J MED, V304, P687; HOLMES DR, 1981, BRIT HEART J, V45, P411; ISHIKAWA K, 1991, CIRCULATION S2, V84, P367; KALLMAN R, 1987, THROMB RES, V45, P355, DOI 10.1016/0049-3848(87)90224-6; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; KOSTER JK, 1981, ARTERY, V9, P405; KRUSKAL JB, 1987, NEW ENGL J MED, V317, P1361, DOI 10.1056/NEJM198711263172201; LAM JYT, 1987, CIRCULATION, V75, P243, DOI 10.1161/01.CIR.75.1.243; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LIMET R, 1987, J THORAC CARDIOV SUR, V94, P773; LORENZ RL, 1984, LANCET, V1, P1261; LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; MANSON JE, 1990, AM J MED, V89, P772, DOI 10.1016/0002-9343(90)90220-8; MAYER JE, 1981, ANN THORAC SURG, V31, P204, DOI 10.1016/S0003-4975(10)60927-7; MCBRIDE W, 1988, NEW ENGL J MED, V318, P1734, DOI 10.1056/NEJM198806303182606; MCENANY MT, 1982, J THORAC CARDIOV SUR, V83, P81; MILLER KP, 1988, MED CLIN N AM, V72, P117, DOI 10.1016/S0025-7125(16)30788-X; MONCADA S, 1979, FED PROC, V38, P66; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; PANTELY GA, 1979, NEW ENGL J MED, V301, P962, DOI 10.1056/NEJM197911013011803; PATRONO C, 1980, THROMB RES, V17, P317, DOI 10.1016/0049-3848(80)90066-3; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PICK R, 1979, J CLIN INVEST, V63, P158, DOI 10.1172/JCI109272; PRESTON FE, 1981, NEW ENGL J MED, V304, P76, DOI 10.1056/NEJM198101083040203; RAJAH SM, 1985, J THORAC CARDIOV SUR, V90, P373; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROTH GJ, 1975, J CLIN INVEST, V56, P624, DOI 10.1172/JCI108132; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SHARMA GVRK, 1983, CIRCULATION, V68, P218; SHERMAN CT, 1986, NEW ENGL J MED, V315, P913, DOI 10.1056/NEJM198610093151501; SMITH JB, 1971, NATURE-NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0; SPRAY TL, 1977, AM HEART J, V94, P500, DOI 10.1016/S0002-8703(77)80046-X; STEELE PM, 1985, CIRC RES, V57, P105, DOI 10.1161/01.RES.57.1.105; The Aspirin Myocardial Infarction Study: final results, 1980, CIRCULATION S5, V62, pV79; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THEROUX P, 1987, CIRCULATION, V75, P156, DOI 10.1161/01.CIR.75.1.156; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VIOLI F, 1989, Journal of the American College of Cardiology, V13, p238A; WALLENTIN L, 1990, LANCET, V336, P827; WHITE CW, 1987, CIRCULATION, V76, P400; WILLERSON JT, 1986, J AM COLL CARDIOL, V8, P245, DOI 10.1016/S0735-1097(86)80121-8; WILLICH SN, 1989, CIRCULATION, V80, P853, DOI 10.1161/01.CIR.80.4.853; ZACK PM, 1984, AM HEART J, V108, P1408, DOI 10.1016/0002-8703(84)90684-7; ZUCKER MB, 1978, CURR THER RES CLIN E, V23, P194; 1980, CIRCULATION S5, V5, P79; 1980, CIRCULATION S5, V62, P59	87	154	157	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					175	181						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1285747				2022-12-28	WOS:A1992JD31900008
J	BENNETT, MK; CALAKOS, N; SCHELLER, RH				BENNETT, MK; CALAKOS, N; SCHELLER, RH			SYNTAXIN - A SYNAPTIC PROTEIN IMPLICATED IN DOCKING OF SYNAPTIC VESICLES AT PRESYNAPTIC ACTIVE ZONES	SCIENCE			English	Article							INTEGRAL MEMBRANE-PROTEIN; CALCIUM CHANNELS; OMEGA-CONOTOXIN; IDENTIFICATION; SYNAPTOPHYSIN; NEURONS; ORGANIZATION; BRAIN	Synaptic vesicles store neurotransmitters that are released during calcium-regulated exocytosis. The specificity of neurotransmitter release requires the localization of both synaptic vesicles and calcium channels to the presynaptic active zone. Two 35-kilodalton proteins (p35 or syntaxins) were identified that interact with the synaptic vesicle protein p65 (synaptotagmin). The p35 proteins are expressed only in the nervous system, are 84 percent identical, include carboxyl-terminal membrane anchors, and are concentrated on the plasma membrane at synaptic sites. An antibody to p35 immunoprecipitated solubilized N-type calcium channels. The p35 proteins may function in docking synaptic vesicles near calcium channels at presynaptic active zones.	STANFORD UNIV, MED CTR, BECKMAN CTR MOLEC & GENET MED, STANFORD, CA 94305 USA	Stanford University					PHS HHS [2T32G07365] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MA, UNPUB; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CALAKOS N, UNPUB; CHARRIAUTMARLANGUE C, 1991, P NATL ACAD SCI USA, V88, P10232, DOI 10.1073/pnas.88.22.10232; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEUSER JE, 1977, HDB PHYSL NERVOUS SY, V1, pCH8; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HUTTNER WB, 1983, J CELL BIOL, V96, P1373; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REYNOLDS IJ, 1986, P NATL ACAD SCI USA, V83, P8804, DOI 10.1073/pnas.83.22.8804; SAISU H, 1991, BIOCHEM BIOPH RES CO, V181, P59, DOI 10.1016/S0006-291X(05)81381-6; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	43	1101	1119	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1992	257	5067					255	259		10.1126/science.1321498	http://dx.doi.org/10.1126/science.1321498			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321498				2022-12-28	WOS:A1992JC58500043
J	REYES, H; REISZPORSZASZ, S; HANKINSON, O				REYES, H; REISZPORSZASZ, S; HANKINSON, O			IDENTIFICATION OF THE AH RECEPTOR NUCLEAR TRANSLOCATOR PROTEIN (ARNT) AS A COMPONENT OF THE DNA-BINDING FORM OF THE AH RECEPTOR	SCIENCE			English	Article							XENOBIOTIC RESPONSIVE ELEMENTS; HEAT-SHOCK PROTEIN; DIOXIN RECEPTOR; GLUCOCORTICOID RECEPTOR; MUTAGENIC ACTIVATION; CARCINOGENIC ARYLAMINES; AROMATIC-AMINES; MOUSE-LIVER; P-450C GENE; RAT-LIVER	The Ah (dioxin) receptor binds a number of widely disseminated environmental pollutants, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and polycyclic aromatic hydrocarbons, and mediates their carcinogenic effects. The ligand-bound receptor activates Cyp1a1 gene transcription through interaction with specific DNA sequences, termed xenobiotic responsive elements (XREs). The Ah receptor nuclear translocator protein (Arnt) is required for Ah receptor function. Arnt is now shown to be a structural component of the XRE binding form of the Ah receptor. Furthermore, Arnt and the ligand-binding subunit of the receptor were extracted as a complex from the nuclei of cells treated with ligand. Arnt contains a basic helix-loop-helix motif, which may be responsible for interacting with both the XRE and the ligand-binding subunit.	UNIV CALIF LOS ANGELES,DEPT PATHOL LAB MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NCI NIH HHS [CA 28868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA T, 1990, CANCER RES, V50, P2060; BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696; COON MJ, 1983, SOMATIC CELL GENET, V9, P497; COON MJ, 1980, MICROSOMES DRUG OXID, P1149; COON MJ, 1981, SOMATIC CELL GENET, V7, P373; CULLITON BJ, 1991, NATURE, V352, P753, DOI 10.1038/352753a0; CUTHILL S, 1987, J BIOL CHEM, V262, P3477; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DEGAWA M, 1989, CARCINOGENESIS, V10, P1119, DOI 10.1093/carcin/10.6.1119; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1986, J BIOL CHEM, V261, P3987; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1986, EUR J BIOCHEM, V155, P223, DOI 10.1111/j.1432-1033.1986.tb09480.x; DENISON MS, 1988, J BIOL CHEM, V263, P17221; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HANKINSON O, UNPUB; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HENRY EC, 1989, BIOCHEMISTRY-US, V28, P6430, DOI 10.1021/bi00441a041; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; KARENLAMPI SO, 1988, J BIOL CHEM, V263, P10111; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OKEY AB, 1980, J BIOL CHEM, V255, P1415; PERDEW GH, 1988, J BIOL CHEM, V263, P9848; PERDEW GH, 1987, J BIOL CHEM, V262, P13802; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLAND A, 1984, BANBURY REPORT, V18, P109; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; REYES H, UNPUB; ROBERTS L, 1991, SCIENCE, V251, P624, DOI 10.1126/science.1846976; ROBERTS L, 1991, SCIENCE, V251, P866, DOI 10.1126/science.2000488; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SNYDERWINE EG, 1989, J NATL CANCER I, V81, P223, DOI 10.1093/jnci/81.3.223; WATSON AJ, 1992, J BIOL CHEM, V267, P6874; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	45	726	749	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1193	1195		10.1126/science.256.5060.1193	http://dx.doi.org/10.1126/science.256.5060.1193			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1317062				2022-12-28	WOS:A1992HV19200033
J	COHEN, J; SCHAMROTH, A; NAZARETH, I; JOHNSON, M; GRAHAM, S; THOMSON, D				COHEN, J; SCHAMROTH, A; NAZARETH, I; JOHNSON, M; GRAHAM, S; THOMSON, D			PROBLEM DRUG-USE IN A CENTRAL LONDON GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							NATIONAL SURVEY; OPIATE MISUSE; PRACTITIONERS; ADDICTION	Objective - To describe the profile of problem drug users presenting in general practice and to determine whether they can be cared for in general practice. Design - Study of consultations by problem drug users. Setting - Central London general practice. Subjects - 150 problem drug users presenting over two years. Main outcome measures - Stopping drug use, alterations in lifestyle, obtaining paid work, and stopping drug related crime. Results - Of the 150 patients, 111 were men and 39 women, and 106 were unemployed. 121 patients used heroin, 112 of whom injected. 145 patients accepted a methadone reduction programme and 81 completed it. A further 25 were stabilised on reducing doses of methadone, until places became available for them as inpatients at drug dependency units or rehabilitation projects. Conclusion - Withdrawal programmes for patients who misuse drugs can be successfully managed in general practice.			COHEN, J (corresponding author), WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,DEPT PRIMARY HLTH CARE,LONDON N19 5NF,ENGLAND.			Nazareth, Irwin/0000-0003-2146-9628				COHEN J, 1990, DRUG ALCOHOL DEPEN, V25, P315, DOI 10.1016/0376-8716(90)90157-A; COOK CCH, 1987, J ROY SOC MED, V80, P782, DOI 10.1177/014107688708001222; GLANZ A, 1986, BRIT MED J, V293, P543, DOI 10.1136/bmj.293.6546.543; GLANZ A, 1986, BRIT MED J, V293, P486, DOI 10.1136/bmj.293.6545.486; MARTIN E, 1987, J ROY SOC MED, V80, P305, DOI 10.1177/014107688708000516; NEVILLE RG, 1988, BRIT MED J, V296, P755, DOI 10.1136/bmj.296.6624.755; PARKER J, 1987, J ROY COLL GEN PRACT, V37, P260; ROBERTSON JR, 1985, BRIT MED J, V290, P34, DOI 10.1136/bmj.290.6461.34; SKIDMORE CA, 1987, J ROY COLL GEN PRACT, V37, P397; SKIDMORE CA, 1990, BRIT MED J, V300, P219, DOI 10.1136/bmj.300.6719.219	10	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1158	1160		10.1136/bmj.304.6835.1158	http://dx.doi.org/10.1136/bmj.304.6835.1158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1327365	Bronze, Green Published			2022-12-28	WOS:A1992HT23200027
J	BERKENSTAM, A; RUIZ, MDV; BARETTINO, D; HORIKOSHI, M; STUNNENBERG, HG				BERKENSTAM, A; RUIZ, MDV; BARETTINO, D; HORIKOSHI, M; STUNNENBERG, HG			COOPERATIVITY IN TRANSACTIVATION BETWEEN RETINOIC ACID RECEPTOR AND TFIID REQUIRES AN ACTIVITY ANALOGOUS TO E1A	CELL			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; TATA-BOX; BINDING-PROTEIN; BETA-GENE; ACTIVATION; ALPHA; CELLS; DIFFERENTIATION; IDENTIFICATION	In embryonal carcinoma (EC) cells retinoic acid (RA) strongly induces transcription from the RA receptor beta-2 (RAR-beta-2) promoter through an RA response element (RARE) located in close proximity to the TATA box. Here we demonstrate that recombinant human TATA box-binding protein, hTFIID, and RAR functionally cooperate in transactivation of the RAR-beta-2 promoter in EC cells in a strictly RA-dependent manner. We demonstrate that the core domain of hTFIID is sufficient to mediate RAR-dependent transcription and that Drosophila, but not yeast, TFIID can substitute for hTFIID. In COS cells ectopic expression of the E1A protein is a prerequisite for hTFIID and RAR to cooperate in transactivation. We propose a model for transcriptional regulation of the RAR-beta-2 promoter in EC cells in which RAR, following activation by RA, functionally interacts with hTFIID via an E1A-like activity present in EC cells.	ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University	BERKENSTAM, A (corresponding author), EUROPEAN MOLEC BIOL LAB, GENE EXPRESS PROGRAM, MEYERHOFSTR 1, W-6900 HEIDELBERG, GERMANY.		Berkenstam, Anders/E-7136-2012; Stunnenberg, Hendrik G./D-6875-2012; Vivanco, Maria/G-2393-2011	Stunnenberg, Hendrik G./0000-0002-0066-1576; Vivanco, Maria/0000-0002-9540-247X				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DIGNAM JD, 1983, NUCL ACIDS RES, V11; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; RUI MDM, 1991, EMBO J, V10, P3829; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TOMIC M, 1990, NUCLEIC ACIDS RES, V18, P1656, DOI 10.1093/nar/18.6.1656; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	59	125	127	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					401	412		10.1016/0092-8674(92)90443-G	http://dx.doi.org/10.1016/0092-8674(92)90443-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1316240				2022-12-28	WOS:A1992HT07800004
J	MERIGAN, TC; RENLUND, DG; KEAY, S; BRISTOW, MR; STARNES, V; OCONNELL, JB; RESTA, S; DUNN, D; GAMBERG, P; RATKOVEC, RM; RICHENBACHER, WE; MILLAR, RC; DUMOND, C; DEAMOND, B; SULLIVAN, V; CHENEY, T; BUHLES, W; STINSON, EB				MERIGAN, TC; RENLUND, DG; KEAY, S; BRISTOW, MR; STARNES, V; OCONNELL, JB; RESTA, S; DUNN, D; GAMBERG, P; RATKOVEC, RM; RICHENBACHER, WE; MILLAR, RC; DUMOND, C; DEAMOND, B; SULLIVAN, V; CHENEY, T; BUHLES, W; STINSON, EB			A CONTROLLED TRIAL OF GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER HEART-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-INFECTION; RECIPIENTS; PNEUMONIA; IMMUNOGLOBULIN; COMBINATION	Background. Because of the immunosuppression required, heart-transplant recipients frequently have complications caused by cytomegalovirus (CMV), including pneumonia, esophagitis, gastritis, and a syndrome of fever, hepatitis, and leukopenia. We undertook a controlled trial to evaluate the prophylactic administration of ganciclovir to prevent CMV-induced disease after heart transplantation. Methods. This randomized, double-blind, placebo-controlled trial was conducted at four centers. Before randomization, the patients were stratified into two groups: those who were seropositive for CMV before transplantation and those who were seronegative but who received hearts from seropositive donors. Ganciclovir was given intravenously at a dose of 5 mg per kilogram of body weight every 12 hours from postoperative day 1 through day 14, then at a dose of 6 mg per kilogram each day for 5 days per week until day 28. Results. Among the seropositive patients, CMV illness occurred during the first 120 days after heart transplantation in 26 of 56 patients given placebo (46 percent), as compared with 5 of 56 patients treated with ganciclovir (9 percent) (P < 0.001). Among 37 seronegative patients, CMV illness was frequent in both groups (placebo, 29 percent; ganciclovir, 35 percent; P not significant). From day 15 through day 60, the patients who took ganciclovir had significantly fewer urine cultures positive for CMV, but by day 90 there was no difference. More of the ganciclovir-treated patients had serum creatinine concentrations greater-than-or-equal-to 220-mu-mol per liter (2.5 mg per deciliter) (18 percent vs. 4 percent in the placebo group), but those elevations were transient. Conclusions. The prophylactic administration of ganciclovir after heart transplantation is safe, and in CMV-seropositive patients it reduces the incidence of CMV-induced illness.	SALT LAKE CITY VET AFFAIRS HOSP,SALT LAKE CITY,UT; STANFORD UNIV,MED CTR,SCH MED,DEPT CARDIOTHORAC SURG,STANFORD,CA 94305; UNIV UTAH,LATTER DAY ST HOSP,MED CTR,DEPT MED,SALT LAKE CITY,UT 84143; UNIV UTAH,LATTER DAY ST HOSP,MED CTR,DEPT SURG,SALT LAKE CITY,UT 84143; SYNTEX INC,INST CLIN MED,PALO ALTO,CA 94304; SYNTEX INC,INST RES DATA MANAGEMENT,PALO ALTO,CA 94304	US Department of Veterans Affairs; Stanford University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Syntex Corporation; Syntex Corporation	MERIGAN, TC (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV INFECT DIS,STANFORD,CA 94305, USA.		Merigan, Thomas/AGQ-7464-2022; bristow, michael r/G-7850-2011		NIAID NIH HHS [AI-05629-28] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI005629, R37AI005629] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUHLES WC, 1988, REV INFECT DIS, V10, pS495; DUMMER JS, 1985, J INFECT DIS, V152, P1182, DOI 10.1093/infdis/152.6.1182; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; LASKE A, 1991, TRANSPLANT P, V23, P1170; MATTHEWS T, 1988, REV INFECT DIS, V10, pS490; MERTZ GJ, 1988, JAMA-J AM MED ASSOC, V260, P201, DOI 10.1001/jama.260.2.201; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POLLARD RB, 1982, AM J MED, V73, P679, DOI 10.1016/0002-9343(82)90410-7; RAND KH, 1978, NEW ENGL J MED, V298, P951, DOI 10.1056/NEJM197804272981705; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; SCHMIDT GM, 1988, TRANSPLANTATION, V46, P905; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; 1985, SAS USERS GUIDE STAT; 1986, NEW ENGL J MED, V314, P801	15	321	323	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1182	1186		10.1056/NEJM199204303261803	http://dx.doi.org/10.1056/NEJM199204303261803			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1313549	Bronze			2022-12-28	WOS:A1992HR00800003
J	BUSTELO, XR; LEDBETTER, JA; BARBACID, M				BUSTELO, XR; LEDBETTER, JA; BARBACID, M			PRODUCT OF VAV PROTOONCOGENE DEFINES A NEW CLASS OF TYROSINE PROTEIN-KINASE SUBSTRATES	NATURE			English	Article							SEQUENCE	SEVERAL proteins implicated in the regulation of cellular responses to mitogenic stimuli contain a common non-catalytic domain, SH2 (for src-homologous domain 2), that mediates their interaction with activated tyrosine protein kinases. Here we report that p95vav, a proto-oncogene product specifically expressed in cells of the haematopoietic system, contains an SH2 domain and is a substrate for tyrosine protein kinases. Exposure of quiescent NIH3T3 cells ectopically expressing p95vav to either epidermal or platelet-derived growth factors induces the rapid phosphorylation of this protein on tyrosine residues. Activation of the receptors for these growth factors by their cognate ligand results in their association with p95vav, a process mediated by its SH2 domain. In T cells, co-activation of the T-cell receptor and the accessory CD4 cell-surface protein also results in the phosphorylation of the endogenous p95vav protein in tyrosine residues. Phosphorylation of p95vav is rapid, transient and precedes the appearance of most other phosphotyrosine-containing proteins. In addition to the SH2 domain, p95vav contains structural motifs not found in other tyrosine kinase substrates. One such motif is a helix-loop-helix/leucine zipper-like domain which shares some sequence similarity with these motifs in the Myc and Max proteins. Deletion of the helix-loop-helix-like motif causes oncogenic activation of p95vav. These results indicate that p95vav is a new type of signal transduction molecule and suggest a possible role for this protein in the transduction of tyrosine phosphorylation signalling into transcriptional events.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, POB 4000, PRINCETON, NJ 08543 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC SCI, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb			Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072				AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEDBETTER JA, 1991, BLOOD, V77, P1271; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEFTON BM, 1991, ONCOGENE, V6, P683	21	297	298	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					68	71		10.1038/356068a0	http://dx.doi.org/10.1038/356068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1311423				2022-12-28	WOS:A1992HG60200058
J	SIDRANSKY, D; MIKKELSEN, T; SCHWECHHEIMER, K; ROSENBLUM, ML; CAVANEE, W; VOGELSTEIN, B				SIDRANSKY, D; MIKKELSEN, T; SCHWECHHEIMER, K; ROSENBLUM, ML; CAVANEE, W; VOGELSTEIN, B			CLONAL EXPANSION OF P53 MUTANT-CELLS IS ASSOCIATED WITH BRAIN-TUMOR PROGRESSION	NATURE			English	Article							CHROMOSOME-17; MUTATIONS	TUMOUR progression is a fundamental feature of the biology of cancer 1. Cancers do not arise de novo in their final form, but begin as small, indolent growths, which gradually acquire characteristics associated with malignancy. In the brain, for example, low-grade tumours (astrocytomas) evolve into faster growing, more dysplastic and invasive high-grade tumours (glioblastomaS) 2,3. To define the genetic events underlying brain tumour progression, we analysed the p53 gene in ten primary brain tumour pairs. Seven pairs consisted of tumours that were high grade both at presentation and recurrence (group A) and three pairs consisted of low-grade tumours that had progressed to higher grade tumours (group B). In group A pairs, four of the recurrent tumours contained a p53 gene mutation; in three of them, the same mutation was found in the primary tumour. In group B pairs, progression to high grade was associated with a p53 gene mutation. A subpopulation of cells were present in the low-grade tumours that contained the same p53 gene mutation predominant in the cells of the recurrent tumours that had progressed to glioblastoma. Thus, the histological progression of brain tumours was associated with a clonal expansion of cells that had previously acquired a mutation in the p53 gene, endowing them with a selective growth advantage. These experimental observations strongly support Nowell's clonal evolution model of tumour progression 4.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; LUDWIG INST CANC RES,MONTREAL H3A 1A1,QUEBEC,CANADA; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT NEUROL SURG,BRAIN TUMOR RES CTR,SAN FRANCISCO,CA 94143; UNIV FREIBURG,INST PATHOL,NEUROPATOL ABT,W-7800 FREIBURG,GERMANY	Johns Hopkins University; Ludwig Institute for Cancer Research; University of California System; University of California San Francisco; University of Freiburg								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIGNER SH, 1988, CANCER RES, V48, P405; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULDS L, 1975, NEOPLASTIC DEV, V2; FOULDS L, 1969, NEOPLASTIC DEV, V1; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JAMES CD, 1988, CANCER RES, V48, P5546; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; RUSSELL DS, 1977, PATHOL TUMOURS NER, P226; SCHERER JH, 1940, AM J CANCER, V40, P159; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123	15	675	682	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					846	848		10.1038/355846a0	http://dx.doi.org/10.1038/355846a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1311419				2022-12-28	WOS:A1992HF63600062
J	DURKOP, H; LATZA, U; HUMMEL, M; EITELBACH, F; SEED, B; STEIN, H				DURKOP, H; LATZA, U; HUMMEL, M; EITELBACH, F; SEED, B; STEIN, H			MOLECULAR-CLONING AND EXPRESSION OF A NEW MEMBER OF THE NERVE GROWTH-FACTOR RECEPTOR FAMILY THAT IS CHARACTERISTIC FOR HODGKINS-DISEASE	CELL			English	Article							TUMOR-NECROSIS-FACTOR; STERNBERG-REED CELLS; MONOCLONAL-ANTIBODY; POINT MUTATIONS; LYMPHOID-CELLS; KI-1 ANTIGEN; PROTEIN; LINES; TRANSLOCATION; EFFICIENCY	In man, Hodgkin's disease (HD) represents the most frequent lymphoma entity whose pathogenesis is still unknown. In order to contribute to the characterization of the molecular mechanisms of this disease, cDNAs coding for the HD characteristic antigen CD30 were cloned from expression libraries of the human HUT-102 cell line using the monoclonal antibodies Ki-1 and Ber-H2. The open reading frame of the cDNA that can be translated from two mRNA species of 2.6 kb, and 3.8 kb, respectively, predicts a 595 amino acid protein with leader, extracellular, single transmembrane, and intracellular domains. When expressed in COS-1 cells, the cDNA presented properties comparable to native CD30 antigen. The CD30 extracellular domain proved to be homologous to members of the nerve growth factor receptor superfamily. Six cysteine-rich motifs could be recognized within the putative ligand-binding domain.	FREE UNIV BERLIN,KLINIKUM STEGLITZ,INST PATHOL,W-1000 BERLIN 45,GERMANY; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Free University of Berlin; Harvard University; Massachusetts General Hospital								ANDREESEN R, 1984, BLOOD, V63, P1299; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOYLSTON AW, 1985, EUR J IMMUNOL, V15, P738, DOI 10.1002/eji.1830150719; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DIEHL V, 1982, CANCER TREAT REP, V66, P615; DIEHL V, 1981, J CANCER RES CLIN, V101, P111, DOI 10.1007/BF00405072; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ESCHENFELDT WH, 1987, METHOD ENZYMOL, V152, P335; FROESE P, 1987, J IMMUNOL, V139, P2081; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUEBLER U, 1983, GENE, V25, P263; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN H, 1990, RES IMMUNOL, V141, P13, DOI 10.1016/0923-2494(90)90098-J; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES DB, 1985, HEMATOL ONCOL, V3, P133, DOI 10.1002/hon.2900030205; KAMESAKI H, 1986, BLOOD, V68, P285; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MATSUI M, 1990, ONCOGENE, V5, P249; MCMICHAEL AJ, 1987, LEUKOCYTE TYPING 3; MORGAN R, 1989, BLOOD, V73, P2155; NAWROCKI JF, 1988, J IMMUNOL, V141, P672; OTSU M, 1987, MOL CELL BIOL, V7, P708, DOI 10.1128/MCB.7.2.708; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RAGSDALE C, 1991, NATURE, V350, P660, DOI 10.1038/350660a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAADT M, 1980, INT J CANCER, V26, P723, DOI 10.1002/ijc.2910260605; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; SCHWARTING R, 1989, LEUCOCYTE TYPING 4, P419; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, BLOOD, V66, P848; STEIN H, 1989, CANCER RES, V117, P15; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SWAN D, 1972, P NATL ACAD SCI USA, V69, P1408; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VONHEINJE G, 1985, NUCLEIC ACIDS RES, V14, P483	63	605	650	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1992	68	3					421	427		10.1016/0092-8674(92)90180-K	http://dx.doi.org/10.1016/0092-8674(92)90180-K			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1310894				2022-12-28	WOS:A1992HD39800004
J	ANDERSON, RGW; KAMEN, BA; ROTHBERG, KG; LACEY, SW				ANDERSON, RGW; KAMEN, BA; ROTHBERG, KG; LACEY, SW			POTOCYTOSIS - SEQUESTRATION AND TRANSPORT OF SMALL MOLECULES BY CAVEOLAE	SCIENCE			English	Editorial Material							FOLATE BINDING-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; PLASMALEMMAL VESICLES; MA104 CELLS; RECEPTOR; MEMBRANE; SURFACE; INTERNALIZATION; ACCUMULATION; ENDOCYTOSIS		UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ANDERSON, RGW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235, USA.							ANDERSON RGW, 1991, INTRACELLULAR TRAFFI; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; Darnell J., 1990, MOL CELL BIOL; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GUILLOT FL, 1990, MICROVASC RES, V39, P1, DOI 10.1016/0026-2862(90)90055-V; JEMMERSON R, 1985, J HISTOCHEM CYTOCHEM, V33, P1227, DOI 10.1177/33.12.4067276; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MATO JM, 1987, J BIOL CHEM, V262, P2131; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PETERS KR, 1985, J CELL BIOL, V101, P2233, DOI 10.1083/jcb.101.6.2233; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; ROTHBERG KG, IN PRESS CELL; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SALTIEL AR, 1987, ENDOCRINOLOGY, V120, P967, DOI 10.1210/endo-120-3-967; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SMITH RM, 1990, ENDOCRINOLOGY, V126, P1551, DOI 10.1210/endo-126-3-1551; SUZUKI S, 1989, CELL TISSUE RES, V257, P237, DOI 10.1007/BF00261826; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VANDENBOSCH RA, 1988, EMBO J, V7, P3345, DOI 10.1002/j.1460-2075.1988.tb03206.x; VILLALBA M, 1988, BIOCHIM BIOPHYS ACTA, V968, P69, DOI 10.1016/0167-4889(88)90045-6; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	30	712	739	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					410	411		10.1126/science.1310359	http://dx.doi.org/10.1126/science.1310359			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1310359				2022-12-28	WOS:A1992HA59000026
J	LEID, M; KASTNER, P; LYONS, R; NAKSHATRI, H; SAUNDERS, M; ZACHAREWSKI, T; CHEN, JY; STAUB, A; GARNIER, JM; MADER, S; CHAMBON, P				LEID, M; KASTNER, P; LYONS, R; NAKSHATRI, H; SAUNDERS, M; ZACHAREWSKI, T; CHEN, JY; STAUB, A; GARNIER, JM; MADER, S; CHAMBON, P			PURIFICATION, CLONING, AND RXR IDENTITY OF THE HELA-CELL FACTOR WITH WHICH RAR OR TR HETERODIMERIZES TO BIND TARGET SEQUENCES EFFICIENTLY	CELL			English	Article							RETINOIC-ACID RECEPTOR; THYROID-HORMONE RECEPTORS; MOUSE ESTROGEN-RECEPTOR; VITAMIN-D RECEPTOR; V-ERB-A; RESPONSE ELEMENT; NUCLEAR RECEPTOR; BETA-GENE; EXPRESSION; PROTEIN	We have purified and cloned a HeLa cell nuclear protein that strongly stimulates binding of retinoic acid and thyroid hormone receptors (RARs and TRs) to resPonse elements. The purified protein is a human retinoid X receptor-beta (hRXR-beta). Three murine members of the RXR family (mRXR-alpha, beta, and gamma) have also been cloned, and their interactions with RARs and TRs have been investigated. Under conditions where RAR, RXR, and TR bound poorly as homodimers to various response elements, strongly cooperative RAR-RXR and TR-RXR binding was observed. The binding efficiency was dependent on the sequence, relative orientation, and spacing of the repeated motifs of response elements. We show also that unstable RAR-RXR heterodimers were formed in solution, and that C-terminal sequences and the DNA-binding domains of both receptors were required for efficient formation of stable heterodimers on response elements. These findings suggest a convergence of the signaling pathways of some members of the nuclear receptor superfamily.	FAC MED STRASBOURG,INST CHIM BIOL,INSERM,U184,F-67085 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	LEID, M (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE.			Nakshatri, Harikrishna/0000-0001-8876-0052				Abate C, 1990, Semin Cancer Biol, V1, P19; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DESBOIS C, 1991, ONCOGENE, V6, P2129; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1992, IN PRESS EMBO J; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; LINSTEDT AD, 1986, J STEROID BIOCHEM, V24, P677, DOI 10.1016/0022-4731(86)90842-3; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PERLMAN AJ, 1982, J BIOL CHEM, V257, P930; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; ROWE A, 1991, DEVELOPMENT, V111, P771; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Ruberte E., 1991, SEMIN DEV BIOL, V2, P153; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SKAFAR DF, 1991, BIOCHEMISTRY-US, V30, P6148, DOI 10.1021/bi00239a010; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	98	1206	1252	0	40	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					377	395		10.1016/0092-8674(92)90478-U	http://dx.doi.org/10.1016/0092-8674(92)90478-U			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310259				2022-12-28	WOS:A1992HB35300016
J	SIMS, SR				SIMS, SR			GRENFELL,WILFRED - AN ATHLETIC MISSIONARY	BRITISH MEDICAL JOURNAL			English	Item About an Individual																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1527	1529		10.1136/bmj.305.6868.1527	http://dx.doi.org/10.1136/bmj.305.6868.1527			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286371	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100008
J	CARMIGNOTO, G; VICINI, S				CARMIGNOTO, G; VICINI, S			ACTIVITY-DEPENDENT DECREASE IN NMDA RECEPTOR RESPONSES DURING DEVELOPMENT OF THE VISUAL-CORTEX	SCIENCE			English	Article							MUSCLE ACETYLCHOLINE-RECEPTOR; MONOCULAR DEPRIVATION; NEURONS; PLASTICITY; GLYCINE; PERIOD	Plasticity of the developing visual system has been regarded as the best model for changes of neuronal connections under the influence of the environment. N-methyl-D-aspartate (NMDA) receptors are crucial for experience-dependent synaptic modifications that occur in the developing visual cortex. NMDA-mediated excitatory postsynaptic currents (EPSCs) in layer IV neurons of the visual cortex lasted longer in young rats than in adult rats, and the duration of the EPSCs became progressively shorter, in parallel with the developmental reduction in synaptic plasticity. This decrease in NMDA receptor-mediated EPSC duration is delayed when the animals are reared in the dark, a condition that prolongs developmental plasticity, and is prevented by treatment with tetrodotoxin, a procedure that inhibits neural activity. Application of L-glutamate to outside-out patches excised from layer IV neurons of young, but not of adult, rats activated prolonged bursts of NMDA channel openings. A modification of the NMDA receptor gating properties may therefore account for the age-dependent decline of visual cortical plasticity.			CARMIGNOTO, G (corresponding author), GEORGETOWN UNIV,SCH MED,FIDIA,GEORGETOWN INST NEUROSCI,3900 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.		Carmignoto, Giorgio/A-8375-2018	Carmignoto, Giorgio/0000-0003-3063-6774; Vicini, Stefano/0000-0001-8671-5194	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS028130] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS 28130-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERARDI N, 1991, J PHYSIOL-LONDON, V434, P14; CRONLYDILLON J, 1979, J PHYSIOL-LONDON, V293, P469, DOI 10.1113/jphysiol.1979.sp012901; DAW NW, 1992, J NEUROPHYSIOL, V67, P197, DOI 10.1152/jn.1992.67.1.197; DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; FOX K, 1989, J NEUROSCI, V9, P2443; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KATZ LC, 1992, ANNU REV NEUROSCI, V15, P31; KLECKNER NW, 1991, MOL BRAIN RES, V11, P151; KONNERTH A, 1990, EXP BRAIN RES, V81, P209; LESTER RAJ, 1992, J NEUROSCI, V12, P635; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; OLSON CR, 1980, EXP BRAIN RES, V39, P17; PARNAVELAS JG, 1976, EXP NEUROL, V51, P637, DOI 10.1016/0014-4886(76)90186-2; RAUSCHECKER JP, 1991, PHYSIOL REV, V71, P587, DOI 10.1152/physrev.1991.71.2.587; STAFFORD CA, 1984, OPHTHAL PHYSL OPT, V4, P95, DOI 10.1016/0275-5408(84)90059-0; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; VICINI S, 1985, J NEUROSCI, V5, P2212; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WITZEMANN V, 1987, FEBS LETT, V223, P104, DOI 10.1016/0014-5793(87)80518-5	28	606	612	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					1007	1011		10.1126/science.1279803	http://dx.doi.org/10.1126/science.1279803			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1279803				2022-12-28	WOS:A1992JW79600039
J	PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; QUAN, S; SAYRE, KR; JOHNSON, PJ; WILBER, JC; LEVEY, AS				PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; QUAN, S; SAYRE, KR; JOHNSON, PJ; WILBER, JC; LEVEY, AS			PREVALENCE OF HEPATITIS-C VIRUS-RNA IN ORGAN DONORS POSITIVE FOR HEPATITIS-C ANTIBODY AND IN THE RECIPIENTS OF THEIR ORGANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; CHRONIC NON-A; LONG-TERM; LIVER-DISEASE; RENAL-TRANSPLANTATION; VIRAL-HEPATITIS; SGOT ACTIVITY; TRANSMISSION; SERUM; COMPLICATIONS	Background. There is a high prevalence of liver disease among the recipients of organs from donors with antibodies to hepatitis C virus (HCV). We undertook a study to determine the frequency of persistent HCV infection, as indicated by the presence of HCV RNA, among both cadaveric organ donors positive for antibodies to HCV (anti-HCV) and the recipients of organs from these donors. Methods. Serum samples from donors and recipients were tested for HCV RNA with the reverse transcriptase polymerase chain reaction, with use of primers from the 5' untranslated region of the HCV genome, and for anti-HCV with the first-generation enzyme-linked immunosorbent assay (ELISA) and two second-generation tests. Results. HCV RNA was detected in 9 of the 11 organ donors (82 percent) with a positive first-generation ELISA for anti-HCV. Among the organ recipients, the prevalence of HCV RNA increased after transplantation: 7 of 26 patients (27 percent) had positive samples before transplantation, as compared with 23 of 24 patients (96 percent) after transplantation (P<0.001). Among 13 recipients who were HCV RNA-negative before receiving organs from the nine HCV RNA-positive donors, HCV infection was detected in all 13 after transplantation, and anti-HCV developed in 8 (62 percent). On the basis of a positive test for HCV RNA, the maximal sensitivity of the three anti-HCV tests was 57 percent (positive in 4 of 7 patients with end-stage organ failure) before transplantation and 70 percent (positive in 16 of 23 patients) after transplantation. Conclusions. Nearly all the recipients of organs from anti-HCV-positive donors become infected with HCV. The current tests for anti-HCV antibodies underestimate the incidence of transmission and the prevalence of HCV infection among immunosuppressed organ recipients.	NEW ENGLAND ORGAN BANK INC,1 GATEWAY CTR,WASHINGTON ST & NEWTON CORNER,NEWTON,MA 02158; ORTHO DIAGNOST SYST INC,RARITAN,NJ; CHIRON CORP,EMERYVILLE,CA	Novartis								ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRAUN WE, 1990, KIDNEY INT, V37, P1363, DOI 10.1038/ki.1990.123; CHA TA, 1991, J CLIN MICROBIOL, V29, P2528, DOI 10.1128/JCM.29.11.2528-2534.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COHEN GA, 1976, ANN INTERN MED, V84, P275, DOI 10.7326/0003-4819-84-3-275; Debure A, 1988, Adv Nephrol Necker Hosp, V17, P375; DIETHELM AG, 1992, NEW ENGL J MED, V326, P410, DOI 10.1056/NEJM199202063260612; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; EVANS CS, 1992, TRANSFUSION, V32, P408, DOI 10.1046/j.1537-2995.1992.32592327712.x; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HESS G, 1989, LANCET, V2, P987; KORETZ RL, 1985, GASTROENTEROLOGY, V88, P1251, DOI 10.1016/S0016-5085(85)80087-1; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAQUAGLIA MP, 1981, TRANSPLANTATION, V32, P504, DOI 10.1097/00007890-198112000-00011; MAHONY JF, 1989, TRANSPLANT P, V21, P1433; PEREIRA BJG, 1991, NEW ENGL J MED, V325, P454, DOI 10.1056/NEJM199108153250702; PEREIRA BJG, 1992, 11 ANN M AM SOC TRAN, P322; PEREZROMERO M, 1990, ANN INTERN MED, V113, P411, DOI 10.7326/0003-4819-113-5-411; PIRSCH JD, 1992, NEW ENGL J MED, V326, P412; RAKELA J, 1979, GASTROENTEROLOGY, V77, P1200; REALDI G, 1982, GUT, V23, P270, DOI 10.1136/gut.23.4.270; RIESTRA S, 1990, ANN INTERN MED, V113, P411; ROTH D, 1991, Journal of the American Society of Nephrology, V2, P815; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; WARNOCK LG, 1974, CLIN CHEM, V20, P1213; WEIR MR, 1985, KIDNEY INT, V28, P839, DOI 10.1038/ki.1985.206; WOLF PL, 1972, CLIN CHEM, V18, P567; 1991, MMWR MORB MORTAL W S, V40, P1	32	235	236	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					910	915		10.1056/NEJM199209243271302	http://dx.doi.org/10.1056/NEJM199209243271302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP014	1325035				2022-12-28	WOS:A1992JP01400002
J	DENT, P; HASER, W; HAYSTEAD, TAJ; VINCENT, LA; ROBERTS, TM; STURGILL, TW				DENT, P; HASER, W; HAYSTEAD, TAJ; VINCENT, LA; ROBERTS, TM; STURGILL, TW			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE BY V-RAF IN NIH 3T3 CELLS AND INVITRO	SCIENCE			English	Article							GROWTH; DEFINITION	Mitogen-activated protein (MAP) kinases are 42- and 44-kD serine-threonine protein kinases that are activated by tyrosine and threonine phosphorylation in cells stimulated with mitogens and growth factors. MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p37(22W)) of the c-Raf-1 protein kinase. The v-Raf proteins purified from cells infected with ECl 2 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro. Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p37(22W)) also activated MAP kinase kinase in vitro. These findings suggest that one function of c-Raf-1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase.	UNIV VIRGINIA,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Virginia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA050661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; NCI NIH HHS [CA50661] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline; NIDDK NIH HHS [DK41077] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALLEMAIN GL, 1992, J MOL CELL BIOL, V12, P2222; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DENT P, UNPUB; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GALLEGO C, IN PRESS P NATL ACAD; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HASER W, UNPUB; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SEGER R, 1992, J BIOL CHEM, V267, P14373; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701	27	666	683	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1404	1407		10.1126/science.1326789	http://dx.doi.org/10.1126/science.1326789			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1326789				2022-12-28	WOS:A1992JL61200035
J	THIBAULT, GE				THIBAULT, GE			RARE X RARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CARDIAC AMYLOIDOSIS; ANGINA-PECTORIS; FEATURES; ARTERIES				THIBAULT, GE (corresponding author), VET AFFAIRS MED CTR,1400 VFW PKY,BOSTON,MA 02132, USA.							BARBOUR DJ, 1988, AM J CARDIOL, V62, P1134, DOI 10.1016/0002-9149(88)90567-X; FALK RH, 1987, AM J CARDIOL, V59, P418, DOI 10.1016/0002-9149(87)90948-9; GERTZ MA, 1985, AM J CARDIOL, V55, P1645, DOI 10.1016/0002-9149(85)90995-6; GERTZ MA, 1989, MAYO CLIN PROC, V64, P1505, DOI 10.1016/S0025-6196(12)65706-1; KASSIRER JP, 1991, LEARNING CLIN REASON, P187; KYLE RA, 1983, MAYO CLIN PROC, V58, P665; PASTERNAK RC, 1980, AM J MED, V68, P813, DOI 10.1016/0002-9343(80)90199-0; PATEL VL, 1986, COGNITIVE SCI, V10, P91, DOI 10.1016/S0364-0213(86)80010-6; SAFFITZ JE, 1983, AM J CARDIOL, V51, P1234, DOI 10.1016/0002-9149(83)90379-X; SALTISSI S, 1984, BRIT HEART J, V52, P233; SMITH RRL, 1979, AM J CARDIOL, V44, P413, DOI 10.1016/0002-9149(79)90389-8; VOYTOVICH AE, 1985, J MED EDUC, V60, P302	12	10	10	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					714	717		10.1056/NEJM199209033271008	http://dx.doi.org/10.1056/NEJM199209033271008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1294080				2022-12-28	WOS:A1992JL23500008
J	WELLS, AU; CHUNG, KF; STAMP, TCB; STUDD, JW; BARNES, PJ; DENISON, DM; MITCHELL, DN; GEDDES, DM				WELLS, AU; CHUNG, KF; STAMP, TCB; STUDD, JW; BARNES, PJ; DENISON, DM; MITCHELL, DN; GEDDES, DM			BROMPTON GRAND ROUND - CORTICOSTEROID INDUCED OSTEOPOROSIS IN SEVERE MENSTRUAL ASTHMA	BRITISH MEDICAL JOURNAL			English	Discussion							PAGETS-DISEASE; BONE; ESTROGEN; THERAPY		ROYAL NATL ORTHOPAED HOSP,LONDON W1N 6AD,ENGLAND; UNIV LONDON KINGS COLL HOSP,THORAC MED,LONDON SE5 8RX,ENGLAND; UNIV LONDON KINGS COLL HOSP,CLIN PHYSIOL,LONDON SE5 8RX,ENGLAND	University of London; University College London; Royal National Orthopaedic Hospital NHS Trust; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	WELLS, AU (corresponding author), ROYAL BROMPTON & NATL HEART HOSP,THORAC MED,LONDON SW3 6HP,ENGLAND.			Barnes, Peter/0000-0002-5122-4018				ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; BARNES PJ, 1989, BRIT MED J, V299, P695, DOI 10.1136/bmj.299.6701.695; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BEYNON HLC, 1988, LANCET, V2, P370; BIJVOET OLM, 1980, ARTHRITIS RHEUM, V23, P1193, DOI 10.1002/art.1780231018; CANALIS E, 1990, OSTEOPRESS, P243; FLEISCH H, 1980, ARTHRITIS RHEUM-US, V23, P1162, DOI 10.1002/art.1780231014; Gennari C, 1986, Clin Rheum Dis, V12, P637; MAGOS A, 1985, BRIT J HOSP MED, V33, P68; MANNING P, 1990, OSTEOPOROSIS 1990, P1585; PACKE GE, 1990, OSTEOPOROSIS, P1635; POUW EM, 1991, BRIT MED J, V302, P627, DOI 10.1136/bmj.302.6777.627; RAISZ LG, 1990, OSTEOPOROSIS, P253; ROSS RK, 1981, LANCET, V1, P858; SAVVAS M, 1989, BRIT J OBSTET GYNAEC, V96, P392; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; STUDD J, 1989, LANCET, V1, P850; VALKEMA R, 1989, J BONE MINER RES  S1, V4, P370; VALKEMA R, 1990, OSTEOPOROSIS 1987, P836	19	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					413	415		10.1136/bmj.305.6850.413	http://dx.doi.org/10.1136/bmj.305.6850.413			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1301023	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JK31400023
J	MITCHELL, CJ; NIEBYLSKI, ML; SMITH, GC; KARABATSOS, N; MARTIN, D; MUTEBI, JP; CRAIG, GB; MAHLER, MJ				MITCHELL, CJ; NIEBYLSKI, ML; SMITH, GC; KARABATSOS, N; MARTIN, D; MUTEBI, JP; CRAIG, GB; MAHLER, MJ			ISOLATION OF EASTERN EQUINE ENCEPHALITIS-VIRUS FROM AEDES-ALBOPICTUS IN FLORIDA	SCIENCE			English	Article							ENCEPHALOMYELITIS VIRUS; UNITED-STATES; MOSQUITOS; IDENTIFICATION; ARBOVIRUS; SKUSE	Fourteen strains of eastern equine encephalitis (EEE) virus were isolated from Aedes albopictus mosquitoes collected in Polk County, Florida. These are the first isolations of an arbovirus of proven public health and veterinary importance from naturally infected Ae. albopictus in the United States since established populations of this introduced mosquito were first discovered in 1985. The widespread distribution of Ae. albopictus in Florida and in other areas of the United States where EEE is endemic raises concern that this species may become an epizootic and epidemic vector of EEE virus.	POLK CTY ENVIRONM OPERAT DIV, BARTOW, FL 33830 USA; UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN 46556 USA	University of Notre Dame	MITCHELL, CJ (corresponding author), CTR DIS CONTROL, CTR INFECT DIS, DIV VECTOR BORNE INFECT DIS, FT COLLINS, CO 80522 USA.							BIRCH WE, 1991, MMWR-MORBID MORTAL W, V40, P533; Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P121; CRAVEN RB, 1988, J AM MOSQUITO CONTR, V4, P138; FERREIRA JA, UNPUB; Ferreira Neto J. A., 1987, Cadernos de Saude Publica, V3, P56, DOI 10.1590/S0102-311X1987000100006; FORATTINI OP, 1986, REV SAUDE PUBL, V20, P244, DOI 10.1590/S0034-89101986000300009; FRANCY DB, 1990, SCIENCE, V250, P1738, DOI 10.1126/science.2270489; JUMALI, 1979, AM J TROP MED HYG, V28, P717; METSELAAR D, 1980, B WORLD HEALTH ORGAN, V58, P937; MITCHELL CJ, 1987, AM J TROP MED HYG, V36, P107, DOI 10.4269/ajtmh.1987.36.107; MITCHELL CJ, 1991, J AM MOSQUITO CONTR, V7, P446; MITCHELL CJ, 1990, J AM MOSQUITO CONTR, V6, P523; Morris C. D., 1988, The arboviruses: epidemiology and ecology. Volume III., P1; NASCI RS, 1981, MOSQ NEWS, V41, P808; NEILL SU, COMMUNICATION; OMEARA GF, COMMUNICATION; REITER P, 1987, J AM MOSQUITO CONTR, V3, P494; ROEHRIG JT, 1990, AM J TROP MED HYG, V42, P394, DOI 10.4269/ajtmh.1990.42.394; SAVAGE HM, IN PRESS J MED ENTOM; Scott T. W., 1989, Advances in Virus Research, V37, P277, DOI 10.1016/S0065-3527(08)60838-6; SCOTT TW, 1990, J AM MOSQUITO CONTR, V6, P274; SHROYER DA, 1986, J AM MOSQUITO CONTR, V2, P424; SHROYER DA, 1991, AM MOSQ CONTROL ASS, V7, P446; SPRENGER D, 1986, J AM MOSQUITO CONTR, V2, P217; Tsai T F, 1991, Infect Dis Clin North Am, V5, P73; WELLINGS FM, 1972, AM J TROP MED HYG, V21, P201, DOI 10.4269/ajtmh.1972.21.201	26	131	135	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1992	257	5069					526	527		10.1126/science.1321985	http://dx.doi.org/10.1126/science.1321985			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1321985				2022-12-28	WOS:A1992JE75500027
J	WEINTRAUB, SJ; PRATER, CA; DEAN, DC				WEINTRAUB, SJ; PRATER, CA; DEAN, DC			RETINOBLASTOMA PROTEIN SWITCHES THE E2F SITE FROM POSITIVE TO NEGATIVE ELEMENT	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; GENE-PRODUCT; TRANSCRIPTION FACTOR; CELL-CYCLE; EXPRESSION; PROMOTER; BINDING	ORIGINALLY E2F sites were identified as elements in the promoters of adenovirus early genes that are necessary for activation of these genes by the early protein E1a (ref. 1). E2F promoter elements have been shown to be important for transcriptional activation of several genes critical for progression through the cell cycle2-4. During the G1 phase of the cell cycle, the E2F protein forms a complex with the cell-cycle protein Rb (ref. 5) and it has been suggested that this binding of Rb to E2F inactivates E2F (ref. 5). Here we show that Rb-E2F is an active complex that, when bound to the E2F site, inhibits the activity of other promoter elements and thus silences transcription. We propose that the ability of this complex to inhibit transcription is integral to the function of Rb and provide evidence that E2F is a positive element in the absence of an active form of Rb. It has been shown that binding of Rb to E2F depends on the phosphorylation state of Rb (only the underphosphorylated form binds)5 and that the phosphorylation state of Rb changes during progression through the cell cycle6,7. We therefore suggest that the E2F site alternates between a positive and negative element with the phosphorylation/dephosphorylation cycle of Rb. This cyclic activity may be responsible for activating and then inhibiting genes during the cell cycle.	WASHINGTON UNIV,SCH MED,DEPT MED,660 S EUCLID,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; HEARING P, 1983, CELL, V33, P692; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	20	640	656	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					259	261		10.1038/358259a0	http://dx.doi.org/10.1038/358259a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1321348				2022-12-28	WOS:A1992JD58700061
J	LEE, KF; LI, E; HUBER, LJ; LANDIS, SC; SHARPE, AH; CHAO, MV; JAENISCH, R				LEE, KF; LI, E; HUBER, LJ; LANDIS, SC; SHARPE, AH; CHAO, MV; JAENISCH, R			TARGETED MUTATION OF THE GENE ENCODING THE LOW AFFINITY NGF RECEPTOR P75 LEADS TO DEFICITS IN THE PERIPHERAL SENSORY NERVOUS-SYSTEM	CELL			English	Article							GROWTH-FACTOR RECEPTORS; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; SYMPATHETIC NEURONS; FACTOR FAMILY; CHICK-EMBRYO; SUBSTANCE-P; EXPRESSION; CELLS; BRAIN	We have generated mice carrying a mutation of the gene encoding the low affinity NGF receptor p75NGFR by targeted mutation in embryonic stem cells. Mice homozygous for the mutation were viable and fertile. Immunohistochemical analyses of the footpad skin of mutant mice revealed markedly decreased sensory innervation by calcitonin gene-related peptide- and substance P-immunoreactive fibers. The defective innervation was correlated with loss of heat sensitivity and associated with the development of ulcers in the distal extremities. Complicated by secondary bacterial infection, the ulcers progressed to toenail and hair loss. Crossing a human transgene encoding p75NGFR into the mutant animals rescued the absent heat sensitivity and the occurrence of skin ulcers and increased the density of neuropeptide-immunoreactive sensory innervation of footpad skin. The mutation in the gene encoding p75NGFR did not decrease the size of sympathetic ganglia or the density of sympathetic innervation of the iris or salivary gland. Our results suggest that p75NGFR has an important role in the development and function of sensory neurons.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT CELL BIOL & ANAT, NEW YORK, NY 10021 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT NEUROSCI, CLEVELAND, OH 44106 USA	Massachusetts Institute of Technology (MIT); Cornell University; Case Western Reserve University	LEE, KF (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Chao, Moses/0000-0002-6969-3744	NICHD NIH HHS [HD 23315] Funding Source: Medline; NINDS NIH HHS [NS 21072, NS 023678] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD023315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021072, R01NS023678] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; ADAMS RD, 1989, PRINCIPLES NEUROLOGY, P1028; ALOE L, 1981, NATURE, V291, P413, DOI 10.1038/291413a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P55; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BYERS MR, 1990, DEVELOPMENT, V109, P461; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HAEGERSTRAND A, 1990, P NATL ACAD SCI USA, V87, P3299, DOI 10.1073/pnas.87.9.3299; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1983, NEUROSCIENCE, V8, P631, DOI 10.1016/0306-4522(83)90204-X; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Levi-Montalcini R, 1990, PROG NEUROENDOCRINOL, V3, P1; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LINDBERGER M, 1989, J NEUROL SCI, V93, P289, DOI 10.1016/0022-510X(89)90198-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; PATIL N, 1990, NEURON, V4, P437, DOI 10.1016/0896-6273(90)90056-L; PEARSON J, 1982, NATURE, V295, P61, DOI 10.1038/295061a0; PERSSON H, 1990, SCIENCE, V247, P704, DOI 10.1126/science.2154035; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RITTER AM, 1991, NATURE, V350, P500, DOI 10.1038/350500a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROHRER H, 1988, DEVELOPMENT, V103, P545; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; SCHOTZINGER RJ, 1990, NEURON, V5, P91, DOI 10.1016/0896-6273(90)90037-G; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SEHESTED M, 1981, VIRCHOWS ARCH A, V391, P217, DOI 10.1007/BF00437598; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P1950, DOI 10.1073/pnas.83.6.1950; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONBARTHELD CS, 1991, DEVELOPMENT, V113, P455; WAKADE AR, 1984, NEUROSCI LETT, V45, P71, DOI 10.1016/0304-3940(84)90331-8; WEIHER H, 1990, CELL, V62, P425, DOI 10.1016/0092-8674(90)90008-3; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WYATT S, 1990, NEURON, V4, P421, DOI 10.1016/0896-6273(90)90054-J; YAN H, 1991, J BIOL CHEM, V266, P12099; YAN Q, 1988, J NEUROSCI, V8, P3481; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	85	863	880	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					737	749		10.1016/0092-8674(92)90286-L	http://dx.doi.org/10.1016/0092-8674(92)90286-L			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1317267				2022-12-28	WOS:A1992HW83800005
J	KLIEWER, SA; UMESONO, K; MANGELSDORF, DJ; EVANS, RM				KLIEWER, SA; UMESONO, K; MANGELSDORF, DJ; EVANS, RM			RETINOID X-RECEPTOR INTERACTS WITH NUCLEAR RECEPTORS IN RETINOIC ACID, THYROID-HORMONE AND VITAMIN-D3 SIGNALING	NATURE			English	Article							RESPONSE ELEMENT; BETA-GENE; IDENTIFICATION; BINDING; COMPLEXES; SEQUENCE; PROTEIN	CELLULAR responsiveness to retinoic acid and its metabolites is conferred through two structurally and pharmacologically distinct 1 families of receptors: the retinoic acid receptors (RAR) 2,3 and the retinoid X receptors (RXR) 1. Here we report that the transcriptional activity of RAR and RXR can be reciprocally modulated by direct interactions between the two proteins. RAR and RXR have a high degree of cooperativity in binding to target DNA, consistent with previous reports indicating that the binding of either RAR or RXR to their cognate response elements is enhanced by factors present in nuclear extracts 4,5. RXR also interacts directly with and enhances the binding of nuclear receptors conferring responsiveness to vitamin D3 and thyroid hormone T3; the DNA-binding activities of these receptors are also stimulated by the presence of nuclear extracts 6-9. Together these data indicate that RXR has a central role in multiple hormonal signalling pathways.	HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Howard Hughes Medical Institute	KLIEWER, SA (corresponding author), SALK INST BIOL STUDIES,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Mangelsdorf, David/0000-0002-4355-0796	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y	21	1357	1386	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					446	449		10.1038/355446a0	http://dx.doi.org/10.1038/355446a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1310351	Green Accepted			2022-12-28	WOS:A1992HB53000069
J	LEVIN, AA; STURZENBECKER, LJ; KAZMER, S; BOSAKOWSKI, T; HUSELTON, C; ALLENBY, G; SPECK, J; KRATZEISEN, C; ROSENBERGER, M; LOVEY, A; GRIPPO, JF				LEVIN, AA; STURZENBECKER, LJ; KAZMER, S; BOSAKOWSKI, T; HUSELTON, C; ALLENBY, G; SPECK, J; KRATZEISEN, C; ROSENBERGER, M; LOVEY, A; GRIPPO, JF			9-CIS RETINOIC ACID STEREOISOMER BINDS AND ACTIVATES THE NUCLEAR RECEPTOR RXR-ALPHA	NATURE			English	Article							THYROID-HORMONE; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; ANALOGS; CELLS	VITAMIN-A (retinol) and its natural derivatives are required for many physiological processes 1-3. The activity of retinoids is thought to be mediated by interactions with two subfamilies of nuclear retinoic acid receptors, RAR and RXR. The RARs bind all-trans retinoic acid (t-RA) with high affinity and alter gene expression as a consequence of this direct ligand interaction 4-10. RXR-alpha is activated by t-RA, yet has little binding affinity for this ligand (ref. 11). t-RA may be converted to a more proximate ligand that directly binds and activates RXR-alpha, and we have developed a method of nuclear receptor-dependent ligand trapping to test this hypothesis. Here we report the identification of a stereoisomer of retinoic acid, 9-cis retinoic acid, which directly binds and activates RXR-alpha. These results suggest a new role for isomerization in the physiology of natural retinoids.	HOFFMANN LA ROCHE INC,DEPT MED CHEM,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT DRUG METAB,NUTLEY,NJ 07110	Roche Holding; Roche Holding	LEVIN, AA (corresponding author), HOFFMANN LA ROCHE INC,DEPT TOXICOL & PATHOL,NUTLEY,NJ 07110, USA.							ALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605; ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CAVEY MT, 1990, ANAL BIOCHEM, V186, P19, DOI 10.1016/0003-2697(90)90565-Q; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COWARD WA, 1969, BRIT J NUTR, V23, P619, DOI 10.1079/BJN19690069; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DELEENHEER AP, 1990, METHOD ENZYMOL, V189, P104; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; GARLAND WA, 1991, TRAC-TREND ANAL CHEM, V10, P177, DOI 10.1016/0165-9936(91)85018-M; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUSELTON CA, 1990, LIQUID CROMATOGRAPHY, P166; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; NAPOLI JL, 1986, METHOD ENZYMOL, V123, P112, DOI 10.1016/S0076-6879(86)23015-3; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHULE R, 1991, P NATL ACAD SCI USA, V88, P6092; THAILER C, 1987, NATURE, V327, P625; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, NEW BIOL, V3, P169	35	1231	1290	6	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1992	355	6358					359	361		10.1038/355359a0	http://dx.doi.org/10.1038/355359a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1309942				2022-12-28	WOS:A1992HA59100071
J	FEINMESSER, R; MIYAZAKI, I; CHEUNG, R; FREEMAN, JL; NOYEK, AM; DOSCH, HM				FEINMESSER, R; MIYAZAKI, I; CHEUNG, R; FREEMAN, JL; NOYEK, AM; DOSCH, HM			DIAGNOSIS OF NASOPHARYNGEAL CARCINOMA BY DNA AMPLIFICATION OF TISSUE OBTAINED BY FINE-NEEDLE ASPIRATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; BURKITTS-LYMPHOMA; CELLS; ANTIBODIES; EXPRESSION; SEROLOGY; GENOMES; NODES	Background. In nasopharyngeal carcinoma the primary lesion is often difficult to find. Metastatic lesions occur frequently but are difficult to distinguish from other head and neck tumors. The viral genome of the Epstein-Barr virus (EBV) can be identified in the cells of this carcinoma. Methods. We used the polymerase chain reaction (PCR) to test for the presence of EBV genomes in 15 samples of metastatic squamous-cell carcinoma of the neck obtained by fine-needle aspiration and in 26 samples obtained by biopsy of lymph nodes. For controls we used disease-free lymph nodes from 10 patients with various head and neck tumors, tonsillar tissue from 46 subjects, blood from 59 EBV-seropositive blood donors, and mononuclear cells from 8 patients with fatal lymphoproliferative lesions. Results. Of the 41 malignant lesions examined, only the nine nasopharyngeal carcinomas (one primary lesion and eight metastases) contained EBV genomes. None of the 20 nodes with other types of cancer, the 10 disease-free nodes, or any of the 105 normal control samples contained detectable EBV. In two patients with suspected metastases from occult primary tumors, the presence of EBV was predictive of nasopharyngeal carcinoma; in both cases overt nasopharyngeal carcinoma developed within one year. Conclusions. In patients with suspected nasopharyngeal carcinoma, fine-needle aspiration can provide tissue for diagnosis by DNA amplification of EBV genomes. The presence of EBV in metastases from an occult primary tumor is predictive of the development of overt nasopharyngeal carcinoma.	HOSP SICK CHILDREN,RES INST,DIV IMMUNOL & CANC,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; MT SINAI HOSP,DEPT OTOLARYNGOL,TORONTO M5G 1X5,ONTARIO,CANADA; BEILINSON MED CTR,TEL AVIV,ISRAEL	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Rabin Medical Center								AMMATUNA P, 1988, MICROBIOLOGICA, V11, P89; ARRAND JR, 1989, J VIROL, V63, P983, DOI 10.1128/JVI.63.2.983-986.1989; Atichartakarn V, 1985, Southeast Asian J Trop Med Public Health, V16, P619; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; CAI WM, 1983, INT J RADIAT ONCOL, V9, P1763, DOI 10.1016/0360-3016(83)90341-3; CHAN MKM, 1989, ACTA CYTOL, V33, P344; DOSCH HM, 1990, INT IMMUNOL, V2, P833, DOI 10.1093/intimm/2.9.833; DOSCH HM, 1991, INT IMMUNOL, V3, P731, DOI 10.1093/intimm/3.7.731; FEDDER M, 1985, AM J MED, V79, P365, DOI 10.1016/0002-9343(85)90315-8; FRABLE MS, 1982, LARYNGOSCOPE, V92, P1414; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; HENLE W, 1973, JNCI-J NATL CANCER I, V51, P361; HERBST H, 1990, AM J PATHOL, V137, P13; HO JHC, 1978, INT J RADIAT ONCOL, V4, P182; JESSE RH, 1973, CANCER, V31, P854, DOI 10.1002/1097-0142(197304)31:4<854::AID-CNCR2820310414>3.0.CO;2-D; KLINE TS, 1980, ARCH PATHOL LAB MED, V104, P117; Levine P H, 1981, Cancer Detect Prev, V4, P307; LINZ U, 1990, BIOTECHNIQUES, V9, P286; MACCOMB WS, 1972, AM J SURG, V124, P441, DOI 10.1016/0002-9610(72)90064-5; NEEL HB, 1983, OTOLARYNG HEAD NECK, V91, P255, DOI 10.1177/019459988309100310; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PEARSON GR, 1983, CANCER, V51, P260, DOI 10.1002/1097-0142(19830115)51:2<260::AID-CNCR2820510216>3.0.CO;2-#; PEIPER SC, 1990, ARCH PATHOL LAB MED, V114, P711; ROBINSON D W, 1959, Plast Reconstr Surg Transplant Bull, V23, P27, DOI 10.1097/00006534-195901000-00004; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; SMITH PE, 1967, AM J SURG, V113, P633, DOI 10.1016/0002-9610(67)90309-1; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WOLF H, 1973, NATURE-NEW BIOL, V244, P245, DOI 10.1038/newbio244245a0; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	32	128	129	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					17	21		10.1056/NEJM199201023260103	http://dx.doi.org/10.1056/NEJM199201023260103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX315	1309196	Bronze			2022-12-28	WOS:A1992GX31500003
J	JAMES, JIP				JAMES, JIP			A SURGEON IN YUGOSLAVIA IN THE WORLD-WAR-II	BRITISH MEDICAL JOURNAL			English	Editorial Material											JAMES, JIP (corresponding author), UNIV EDINBURGH,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1545	1546		10.1136/bmj.305.6868.1545	http://dx.doi.org/10.1136/bmj.305.6868.1545			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286380	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KD77100017
J	BORDER, WA; NOBLE, NA; YAMAMOTO, T; HARPER, JR; YAMAGUCHI, Y; PIERSCHBACHER, MD; RUOSLAHTI, E				BORDER, WA; NOBLE, NA; YAMAMOTO, T; HARPER, JR; YAMAGUCHI, Y; PIERSCHBACHER, MD; RUOSLAHTI, E			NATURAL INHIBITOR OF TRANSFORMING GROWTH-FACTOR-BETA PROTECTS AGAINST SCARRING IN EXPERIMENTAL KIDNEY-DISEASE	NATURE			English	Article							EXPERIMENTAL GLOMERULONEPHRITIS; EXTRACELLULAR-MATRIX; RAT GLOMERULUS; FIBRONECTIN	THE central pathological feature of human kidney disease that leads to kidney failure is the accumulation of extracellular matrix in glomeruli. Overexpression of transforming growth factor-beta (TGF-beta) underlies the accumulation of pathological matrix in experimental glomerulonephritis1. Administration of an antibody raised against TGF-beta to glomerulonephritic rats suppresses glomerular matrix production and prevents matrix accumulation in the injured glomeruli2. One of the matrix components induced by TGF-beta, the proteoglycan decorin, can bind TGF-beta and neutralize its biological activity3, so decorin may be a natural regulator of TGF-beta (refs 3, 4). We tested whether decorin could antagonize the action of TGF-beta in vivo using the experimental glomerulonephritis model1. We report here that administration of decorin inhibits the increased production of extracellular matrix and attenuates manifestations of disease, confirming our hypothesis. On the basis of our results, decorin may eventually prove to be clinically useful in diseases associated with overproduction of TGF-beta.	TELIOS PHARMACEUT INC,SAN DIEGO,CA 92121; LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute	BORDER, WA (corresponding author), UNIV UTAH,SCH MED,DIV NEPHROL,SALT LAKE CITY,UT 84132, USA.							BALZA E, 1988, FEBS LETT, V228, P42, DOI 10.1016/0014-5793(88)80580-5; BORDER WA, 1988, KIDNEY INT, V34, P419, DOI 10.1038/ki.1988.197; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BORDER WA, 1990, KIDNEY INT, V37, P289; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065; COURTOY PJ, 1980, J CELL BIOL, V87, P691, DOI 10.1083/jcb.87.3.691; COURTOY PJ, 1982, J HISTOCHEM CYTOCHEM, V30, P874, DOI 10.1177/30.9.7130672; GINSBERG JM, 1992, J CLIN INVEST, V90, P1; KULOZIK M, 1990, J CLIN INVEST, V86, P917, DOI 10.1172/JCI114793; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; OOMURA A, 1989, VIRCHOWS ARCH A, V415, P151, DOI 10.1007/BF00784353; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; ROBERTS AB, 1989, HDB EXPT PHARM, P419; WANG A, 1991, J BIOL CHEM, V266, P15598; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	16	958	1012	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					361	364		10.1038/360361a0	http://dx.doi.org/10.1038/360361a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1280332				2022-12-28	WOS:A1992JZ63000057
J	DAUBE, SS; VONHIPPEL, PH				DAUBE, SS; VONHIPPEL, PH			FUNCTIONAL TRANSCRIPTION ELONGATION COMPLEXES FROM SYNTHETIC RNA-DNA BUBBLE DUPLEXES	SCIENCE			English	Article							TERNARY COMPLEXES; CHAIN ELONGATION; POLYMERASE-II; BINDING; INITIATION; HOLOENZYME; TEMPLATE; PROTEIN; INVITRO; VIEW	A synthetic RNA-DNA bubble duplex construct intended to mimic the nucleic acid frame-work of a functional transcription elongation complex was designed and assembled. The construct consisted of a double-stranded DNA duplex of variable length (the template and nontemplate strands) containing an internal noncomplementary DNA "bubble" sequence. The 3' end of an RNA oligonucleotide that is partially complementary to the template DNA strand was hybridized within the DNA bubble to form an RNA-DNA duplex with a noncomplementary 5'-terminal RNA tail. The addition of either Escherichia coli or T7 RNA polymerase to this construct formed a complex that synthesized RNA with good efficiency from the hybridized RNA primer in a template-directed and processive manner, and displayed other features of a normal promoter-initiated transcription elongation complex. Other such constructs can be designed to examine many of the functional and regulatory properties of transcription systems.	UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon	DAUBE, SS (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R37GM015792, R01GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; CHAMBERLIN MJ, 1973, J BIOL CHEM, V148, P2235; DAUBE SS, UNPUB; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEE DN, IN PRESS J MOL BIOL; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; Maniatis T., 1982, MOL CLONING; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; REDDY MK, 1992, J BIOL CHEM, V267, P14157; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SIPPEL A, 1968, BIOCHIM BIOPHYS ACTA, V157, P218, DOI 10.1016/0005-2787(68)90286-4; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WARSHAW MM, 1970, BIOPOLYMERS, V9, P1079, DOI 10.1002/bip.1970.360090910; WEBSTER KR, 1991, BIOTECHNIQUES, V11, P658; WHEELER AR, 1987, BIOCHEMISTRY-US, V26, P3322, DOI 10.1021/bi00386a012; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	28	92	108	3	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 20	1992	258	5086					1320	1324		10.1126/science.1280856	http://dx.doi.org/10.1126/science.1280856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1280856				2022-12-28	WOS:A1992JY95800026
J	HORAK, ER; LEEK, R; KLENK, N; LEJEUNE, S; SMITH, K; STUART, N; GREENALL, M; STEPNIEWSKA, K; HARRIS, AL				HORAK, ER; LEEK, R; KLENK, N; LEJEUNE, S; SMITH, K; STUART, N; GREENALL, M; STEPNIEWSKA, K; HARRIS, AL			ANGIOGENESIS, ASSESSED BY PLATELET ENDOTHELIAL-CELL ADHESION MOLECULE ANTIBODIES, AS INDICATOR OF NODE METASTASES AND SURVIVAL IN BREAST-CANCER	LANCET			English	Article							TUMOR ANGIOGENESIS; ANTIGEN	Animal models suggest a role for new vessel formation (angiogenesis) in tumours with metastatic potential, and there is some evidence that this is true for human tumours. What is needed is a sensitive and specific label for endothelial cells, and one candidate would be a monoclonal antibody to platelet/endothelial cell adhesion molecule (PECAM). We have counted microvessels in 103 primary breast cancers using the JC70 antibody to PECAM (or CD31). We compared our findings with various pathological indicators (lymph node status and tumour grade, size, and type and markers (oestrogen receptor, and c-erbB-2 expression and detection of mutant p53). Tumours showed significantly higher vascularisation than normal breast tissue and the number of blood vessels/mm2 was significantly associated with node metastasis. Only 2 out of 50 tumours with 99 vessel/mm2 or less were node positive whereas 31 out of 39 tumours with counts above 140/mm2 were positive (p<0.0001). Tumour size and grade also correlated with node metastasis and vascularisation also increased with the size of the primary and with poor differentiation. However, within each subgroup of size or differentiation tumours without node involvement had much lower vascular counts, and multivariate analysis showed that vascular count alone explains the association of size and grade with node metastasis. Other markers, conventional or novel, did not correlate with vascularisation. Even with the short follow-up in this series, vascular counts correlated with early death. These results suggest that angiogenesis is closely linked to metastasis, that it is acquired at a critical density of vessels, and that this process occurs as tumours enlarge or become more poorly differentiated. Counting of newly formed microvessels stained with endothelium-specific antibodies may prove to be a useful tool in the early detection of metastatic potential and in the selection of patients for whom anti-angiogenesis drugs might be beneficial.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,MOLEC ONCOL LAB,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL & BACTERIOL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT SURG,OXFORD OX3 9DU,ENGLAND; IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC1,ENGLAND	University of Oxford; University of Oxford; University of Oxford			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Stepniewska, Kasia/0000-0002-1713-6209; Leek, Russell/0000-0002-8038-8660				ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; BICKNELL R, 1991, EUR J CANCER, V27, P781, DOI 10.1016/0277-5379(91)90189-K; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GANNON JV, 1990, EMBO J, V9, P3927; Gatter KC, 1984, RECENT ADV HISTOPATH, P35; Goldmann E, 1907, LANCET, V2, P1236; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; HORAK E, 1991, ONCOGENE, V6, P2277; JENSEN HM, 1982, SCIENCE, V218, P293, DOI 10.1126/science.6181563; KUZU I, 1992, J CLIN PATHOL, V45, P143, DOI 10.1136/jcp.45.2.143; LIOTTA LA, 1974, CANCER RES, V34, P997; MAHADEVAN V, 1990, ACTA ONCOL, V29, P97, DOI 10.3109/02841869009089997; MASON DY, 1989, J CLIN PATHOL, V42, P1194, DOI 10.1136/jcp.42.11.1194; NICHOLSON S, 1989, LANCET, V1, P182; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; SCHLINGEMANN RO, 1990, LAB INVEST, V62, P690; SCHMIDT JG, 1992, LANCET, V339, P810, DOI 10.1016/0140-6736(92)91937-4; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; STARKEY JR, 1988, INT J CANCER, V42, P48, DOI 10.1002/ijc.2910420110; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	21	810	868	0	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1120	1124		10.1016/0140-6736(92)93150-L	http://dx.doi.org/10.1016/0140-6736(92)93150-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1279332				2022-12-28	WOS:A1992JX13400003
J	KOUTSKY, LA; HOLMES, KK; CRITCHLOW, CW; STEVENS, CE; PAAVONEN, J; BECKMANN, AM; DEROUEN, TA; GALLOWAY, DA; VERNON, D; KIVIAT, NB				KOUTSKY, LA; HOLMES, KK; CRITCHLOW, CW; STEVENS, CE; PAAVONEN, J; BECKMANN, AM; DEROUEN, TA; GALLOWAY, DA; VERNON, D; KIVIAT, NB			A COHORT STUDY OF THE RISK OF CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE-2 OR GRADE-3 IN RELATION TO PAPILLOMAVIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS TYPE-1; CANCER; WOMEN; HERPES; ANTIBODIES	Background Human papillomavirus (HPV) has been associated with cervical intraepithelial neoplasia, but the temporal relation between the infection and the neoplasia remains unclear, as does the relative importance of the specific type of HPV, other sexually transmitted diseases, and other risk factors. Methods. We studied prospectively a cohort of 241 women who presented for evaluation of sexually transmitted disease and had negative cervical cytologic tests. The women were followed every four months with cytologic and colposcopic examinations of the uterine cervix and tests for HPV DNA and other sexually transmitted diseases. Results. Cervical intraepithelial neoplasia grade 2 or 3 was confirmed by biopsy in 28 women. On the basis of survival analysis, the cumulative incidence of cervical intraepithelial neoplasia at two years was 28 percent among women with a positive test for HPV and 3 percent among those without detectable HPV DNA. The risk was highest among those with HPV type 16 or 18 infection (adjusted relative risk as compared with that in women without HPV infection, 11; 95 percent confidence interval, 4.6 to 26; attributable risk, 52 percent). All 24 cases of cervical intraepithelial neoplasia grade 2 or 3 among HPV-positive women were detected within 24 months after the first positive test for HPV. After adjustment for the presence of HPV infection, the development of cervical intraepithelial neoplasia was also associated with younger age at first intercourse, the presence of serum antibodies to Chlamydia trachomatis, the presence of serum antibodies to cytomegalovirus, and cervical infection with Neisseria gonorrhoeae. Conclusions. Cervical intraepithelial neoplasia is a common and apparently early manifestation of cervical infection by HPV, particularly types 16 and 18.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT BIOSTAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT OBSTET & GYNECOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT PATHOL, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, DEPT TUMOR BIOL, SEATTLE, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center			, Holmes/K-6215-2019		NATIONAL CANCER INSTITUTE [R01CA034493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024756, P01AI012192] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34493] Funding Source: Medline; NIAID NIH HHS [AI 12192, AI 24756] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; Breslow N E, 1987, IARC Sci Publ, P1; CAMPION MJ, 1986, LANCET, V2, P237; CUZICK J, 1989, BRIT J CANCER, V60, P238, DOI 10.1038/bjc.1989.261; DEVILLIERS EM, 1987, LANCET, V2, P703; DONNAN SPB, 1989, INT J EPIDEMIOL, V18, P32, DOI 10.1093/ije/18.1.32; HARRIS RWC, 1980, BRIT J CANCER, V42, P359, DOI 10.1038/bjc.1980.246; KIVIAT NB, 1989, J INFECT DIS, V159, P293, DOI 10.1093/infdis/159.2.293; KIVIAT NB, 1992, INT J GYNECOL PATHOL, V11, P197, DOI 10.1097/00004347-199207000-00005; Koss L. G, 1979, DIAGNOSTIC CYTOLOGY; KOSS LG, 1989, JAMA-J AM MED ASSOC, V261, P737, DOI 10.1001/jama.261.5.737; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LORINCZ A, 1990, SEXUALLY TRANSMITTED, P953; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; LORINCZ AT, 1990, AM J OBSTET GYNECOL, V162, P645, DOI 10.1016/0002-9378(90)90974-C; LORINCZ AT, 1986, VIRAL ETIOLOGY CERVI, P225; MCDOUGALL JK, 1986, CIBA F SYMP, V120, P86; Paavonen J, 1988, Obstet Gynecol Surv, V43, P373, DOI 10.1097/00006254-198807000-00001; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; PRATILI M A, 1986, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V15, P45; REEVES WC, 1987, INT J CANCER, V40, P450, DOI 10.1002/ijc.2910400403; REID R, 1987, AM J OBSTET GYNECOL, V156, P212, DOI 10.1016/0002-9378(87)90241-9; RITTER DB, 1988, AM J OBSTET GYNECOL, V159, P1517, DOI 10.1016/0002-9378(88)90587-X; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P35; SLATTERY ML, 1989, AM J EPIDEMIOL, V130, P248, DOI 10.1093/oxfordjournals.aje.a115331; SMILEY L, 1990, SEXUALLY TRANSMITTED, P415; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; STAMM WE, 1990, SEXUALLY TRANSMITTED, P917; SYRJANEN K, 1987, PAPILLOMAVIRUSES, V5, P281; WILLETT GD, 1989, INT J GYNECOL PATHOL, V8, P18, DOI 10.1097/00004347-198903000-00003; ZANINETTI P, 1986, INT J EPIDEMIOL, V15, P477, DOI 10.1093/ije/15.4.477; ZUNZUNEGUI MV, 1986, AM J EPIDEMIOL, V123, P302, DOI 10.1093/oxfordjournals.aje.a114238	33	763	795	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1272	1278		10.1056/NEJM199210293271804	http://dx.doi.org/10.1056/NEJM199210293271804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1328880				2022-12-28	WOS:A1992JV25900004
J	MCCONNELL, HM; OWICKI, JC; PARCE, JW; MILLER, DL; BAXTER, GT; WADA, HG; PITCHFORD, S				MCCONNELL, HM; OWICKI, JC; PARCE, JW; MILLER, DL; BAXTER, GT; WADA, HG; PITCHFORD, S			THE CYTOSENSOR MICROPHYSIOMETER - BIOLOGICAL APPLICATIONS OF SILICON TECHNOLOGY	SCIENCE			English	Article							CELL-AFFECTING AGENTS	A silicon-based device, dubbed a microphysiometer, can be used to detect and monitor the response of cells to a variety of chemical substances, especially ligands for specific plasma membrane receptors. The microphysiometer measures the rate of proton excretion from 104 to 106 cells. This article gives an overview of experiments currently being carried out with this instrument with emphasis on receptors with seven transmembrane helices and tyrosine kinase receptors. As a scientific instrument, the microphysiometer can be thought of as serving two distinct functions. In terms of detecting specific molecules, selected biological cells in this instrument serve as detectors and amplifiers. The microphysiometer can also investigate cell function and biochemistry. A major application of this instrument may prove to be screening for new receptor ligands. In this respect, the microphysiometer appears to offer significant advantages over other techniques.	MOLEC DEVICES CORP,4700 BOHANNAN DR,MENLO PK,CA 94025; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University								BAXTER GW, UNPUB; BRIGGS J, 1991, ANAL CHEM, V63, P850, DOI 10.1021/ac00009a003; FRASER CM, 1989, MOL PHARMACOL, V36, P840; HAFEMAN DG, 1988, SCIENCE, V240, P1182, DOI 10.1126/science.3375810; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; INDELICATO SR, 1991, 5TH INT C IMM TAMP; McConnell HM, 1991, CURR OPIN STRUC BIOL, V1, P647, DOI 10.1016/S0959-440X(05)80091-0; MILLER DL, 1991, FASEB J, V5, pA1014; NAG B, 1992, J IMMUNOL, V148, P2040; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PARCE JW, 1990, ANN BIOL CLIN-PARIS, V48, P639; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; RALEYSUSMAN KM, 1992, J NEUROSCI, V12, P773; RICE PA, 1991, FASEB J, V5, pA1014; RICE PA, 1991, THESIS STANFORD U ST; ROSSER M P, 1991, Society for Neuroscience Abstracts, V17, P818; SALON J A, 1991, Society for Neuroscience Abstracts, V17, P86; WADA HG, IN PRESS J CELL PHYS; WADA HG, 1990, MAY NAT I ALL INF DI	20	564	651	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1906	1912		10.1126/science.1329199	http://dx.doi.org/10.1126/science.1329199			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1329199				2022-12-28	WOS:A1992JP59400023
J	JOHNSON, E				JOHNSON, E			EVIDENCE OF SUBSTANCE-ABUSE FOUND WITH POSTTRAUMATIC-STRESS-DISORDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							COTTLER LB, 1992, AM J PSYCHIAT, V149, P664	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1518	1518						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1325568				2022-12-28	WOS:A1992JN25600006
J	VANDUIJN, NP; BROUWER, HJ; LAMBERTS, H				VANDUIJN, NP; BROUWER, HJ; LAMBERTS, H			USE OF SYMPTOMS AND SIGNS TO DIAGNOSE MAXILLARY SINUSITIS IN GENERAL-PRACTICE - COMPARISON WITH ULTRASONOGRAPHY	BRITISH MEDICAL JOURNAL			English	Article							SINUSES	Objective-To establish the incidence of maxillary sinusitis in general practice and the predictive value of symptoms and signs. Design-Population based study. Setting-9 general practices with 15 220 patients aged 15 years and older on the list. Patients-400 patients with 441 episodes in whom practitioners intended to confirm or to exclude sinusitis. Main outcome measures-Results of ultrasonography and signs and symptoms associated with positive results. Results-212 of the 441 episodes were confirmed by ultrasonography. 15.7 episodes occurred per 1000 adults per year. The five symptoms beginning with common cold (beta-coefficient=1.035), purulent rhinorrhoea (0.996), pain at bending (0.950), unilateral maxillary pain (0.640), and pain in teeth (0.606) were associated with positive results on ultrasonography. General practitioners' clinical diagnoses were correct in 177 episodes, false positive in 88, false negative in 22, and uncertain in 154. With an algorithm using the five weighted symptoms 243 of the diagnoses would have been correct, but 110 would remain uncertain and 44 cases would have been missed. Conclusion-The five symptoms algorithm would improve diagnostic accuracy of general practitioners, but incorrect and uncertain diagnoses cannot be avoided.			VANDUIJN, NP (corresponding author), UNIV AMSTERDAM,DEPT GEN PRACTICE,MEIBERGDREEF 15,1105 AZ AMSTERDAM,NETHERLANDS.							Albert A., 1987, MULTIVARIATE INTERPR; AXELSSON A, 1976, ORL J OTO-RHINO-LARY, V38, P298, DOI 10.1159/000275288; AXELSSON A, 1972, ACTA OTO-LARYNGOL, V74, P118, DOI 10.3109/00016487209128430; AXELSSON A, 1983, ANN OTO RHINOL LARYN, V92, P75, DOI 10.1177/000348948309200118; BAUER WJ, 1983, LARYNG RHINOL OTOL V, V62, P443, DOI 10.1055/s-2007-1008469; BERG O, 1988, ACTA OTO-LARYNGOL, V105, P343, DOI 10.3109/00016488809097017; BERG O, 1981, ANN OTO RHINOL LARYN, V90, P272, DOI 10.1177/000348948109000316; DAVIDSON TM, 1989, HEAD NECK-J SCI SPEC, V11, P405, DOI 10.1002/hed.2880110505; ILLUM P, 1972, ACTA OTO-LARYNGOL, V74, P287, DOI 10.3109/00016487209128452; JANNERT M, 1982, ACTA OTOLARYNGOL S, V389, P29; Lamberts H, 1991, REASON ENCOUNTER EPI; LAMBERTS H, 1991, HUIS HUISARTS VERSLA; LLOYD GAS, 1991, J LARYNGOL OTOL, V105, P181, DOI 10.1017/S0022215100115300; MCNEILL RA, 1963, J LARYNGOL OTOL, V72, P1009; Otten F W, 1984, Ned Tijdschr Geneeskd, V128, P1941; OTTEN FWA, 1990, CLIN OTOLARYNGOL, V16, P285; Revonta M, 1980, Acta Otolaryngol Suppl, V370, P1; SAVOLAINEN S, 1989, ALLERGY, V44, P116, DOI 10.1111/j.1398-9995.1989.tb02234.x; SUOMPAA J, 1989, J LARYNGOL OTOL, V103, P765; VAINIOMATTILA J, 1974, ACTA OTOLARYNGOL S S, V318, P1; van den Hoogen H.J.M, 1985, MORBIDITY FIGURES GE; VUORINEN P, 1962, J Laryngol Otol, V76, P359, DOI 10.1017/S0022215100059442; YLIKOSKI J, 1989, ORL J OTO-RHINO-LARY, V51, P175, DOI 10.1159/000276054; 1986, MORBIDITY STATISTICS	24	75	76	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					684	687		10.1136/bmj.305.6855.684	http://dx.doi.org/10.1136/bmj.305.6855.684			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1298231	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JP51100020
J	LEVEY, GS				LEVEY, GS			INTERNAL-MEDICINE AND THE TRAINING OF INTERNATIONAL MEDICAL GRADUATES - A TIME FOR OPEN DISCUSSION AND NEW APPROACHES	ANNALS OF INTERNAL MEDICINE			English	Note						FOREIGN MEDICAL GRADUATES; INTERNSHIP AND RESIDENCY; EDUCATION, MEDICAL, GRADUATE; CLINICAL COMPETENCE; FINANCING, GOVERNMENT	STANDARDIZED PATIENTS; UNITED-STATES; RESIDENTS; MANPOWER; PROGRAMS	The number of foreign national medical graduates entering internal medicine residency training programs in the United States has doubled since 1986. A rigorous, standardized preresidency evaluation of the basic clinical skills and language abilities of international medical graduates should be implemented. Those found to have significant deficits should undertake a preparatory curriculum designed to meet special educational needs before entry into the formal training program. A relevant curriculum might include formal lectures, reading assignments, physical diagnosis sessions, language classes, patient encounter sessions, and a tutorial on U.S. medical culture that includes medical ethics and the basics of our health care system. All or only some of these may be required for any given individual. The Educational Commission for Foreign Medical Graduates (ECFMG) could provide many of the methods needed for an evaluation program and work collaboratively with program directors. This new approach to training of international medical graduates will require an evaluation system to measure its effectiveness. Important questions about the funding of graduate medical education for international medical graduates must also be addressed.			LEVEY, GS (corresponding author), MERCK & CO INC, MED & SCI AFFAIRS, POB 2000 33-73, RAHWAY, NJ 07065 USA.							ANDERSEN RM, 1990, ANN INTERN MED, V113, P243, DOI 10.7326/0003-4819-113-3-243; ANDERSEN RM, 1989, ANN INTERN MED, V110, P922, DOI 10.7326/0003-4819-110-11-922; ANDERSEN RM, 1992, ANN INTERN MED, V117, P243, DOI 10.7326/0003-4819-117-3-243; BABBOTT D, 1991, ANN INTERN MED, V114, P16, DOI 10.7326/0003-4819-114-1-16; BOGDONOFF MD, 1991, ANN INTERN MED, V114, P426, DOI 10.7326/0003-4819-114-5-426; ETZEL SI, 1989, JAMA-J AM MED ASSOC, V262, P1029, DOI 10.1001/jama.262.8.1029; FRIEDMAN M, 1991, ACAD MED, V66, pS61, DOI 10.1097/00001888-199109000-00042; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; STILLMAN P, 1991, ANN INTERN MED, V114, P393, DOI 10.7326/0003-4819-114-5-393; STILLMAN PL, 1991, ACAD MED, V66, pS25, DOI 10.1097/00001888-199109000-00030; TARLOV AR, 1978, ANN INTERN MED, V88, P413, DOI 10.7326/0003-4819-88-3-413; 1981, HRA81561 PUBL; 1992, STATISTICAL INFORMAT	13	16	16	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					403	407		10.7326/0003-4819-117-5-403	http://dx.doi.org/10.7326/0003-4819-117-5-403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1303634				2022-12-28	WOS:A1992JK67800010
J	LITWIN, MS				LITWIN, MS			ODE TO JOY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIANS ROLE; DEATH; DECISION MAKING; COMMUNICATION; INTERNSHIP AND RESIDENCY		In this personal account of a surgical intern's first encounter with the death of a patient, the author presents the unique perspective of a fledgling physician confronting one of the most difficult situations in medicine.			LITWIN, MS (corresponding author), UNIV CALIF LOS ANGELES, ROBERT WOOD JOHNSON CLIN SCH PROGRAM, B-973 FACTOR BLDG, LOS ANGELES, CA 90024 USA.		Xypolia, Ilia/A-4948-2016	Xypolia, Ilia/0000-0002-6398-089X; Litwin, Mark/0000-0002-2318-344X					0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					337	337		10.7326/0003-4819-117-4-337	http://dx.doi.org/10.7326/0003-4819-117-4-337			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1302467				2022-12-28	WOS:A1992JH46400012
J	EHRMANN, DA; ROSENFIELD, RL; BARNES, RB; BRIGELL, DF; SHEIKH, Z				EHRMANN, DA; ROSENFIELD, RL; BARNES, RB; BRIGELL, DF; SHEIKH, Z			DETECTION OF FUNCTIONAL OVARIAN HYPERANDROGENISM IN WOMEN WITH ANDROGEN EXCESS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH FACTOR-I; POLYCYSTIC OVARIES; IDIOPATHIC HIRSUTISM; LUTEINIZING HORMONE; DISEASE; DEXAMETHASONE; RESPONSES; PATHOGENESIS; SECRETION; CELLS	Background. Distinguishing between ovarian and adrenal causes of androgen excess may be difficult. We have found that women with the polycystic ovary syndrome have supranormal plasma 17-hydroxyprogesterone responses to the gonadotropin-releasing hormone agonist nafarelin. We determined the usefulness of testing with nafarelin to distinguish ovarian causes of hyperandrogenism in women. Methods. We studied 40 consecutive women with hyperandrogenism who had oligomenorrhea, hirsutism, or acne. All 40 underwent testing with nafarelin, dexamethasone, and corticotropin with measurement of circulating concentrations of gonadotropins and steroid hormones, and 19 underwent ovarian ultrasonography. Results. The plasma 17-hydroxyprogesterone response to nafarelin was supranormal in 23 of the 40 women (58 percent), and the plasma androgen response to corticotropin was elevated in 23; 13 women had both abnormalities. Only one woman had conclusive evidence of a steroidogenic block; she had nonclassic adrenal 21-hydroxylase deficiency. Of the 23 women with abnormal responses to nafarelin, only 11 (48 percent) had elevated base-line serum luteinizing hormone concentrations. Of the 13 women with abnormal responses to nafarelin who underwent ultrasonography, 7 (54 percent) had polycystic ovaries. Peak plasma 17-hydroxyprogesterone concentrations after nafarelin administration correlated closely with plasma free testosterone concentrations after dexamethasone administration (r = 0.75, P<0.001). Conclusions. Approximately half of women with oligomenorrhea, hirsutism, or acne have an abnormal response to the gonadotropin-releasing hormone agonist nafarelin, suggesting an ovarian cause of their androgen excess.	UNIV CHICAGO,PRITZKER SCH MED,DEPT OBSTET GYNECOL,CHICAGO,IL 60637	University of Chicago	EHRMANN, DA (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,DEPT MED,ENDOCRINOL SECT,5841 S MARYLAND AVE,MC 1027,CHICAGO,IL 60637, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007011] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00055] Funding Source: Medline; NICHD NIH HHS [HD-06308] Funding Source: Medline; NIDDK NIH HHS [DK-07011-17] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM GE, 1976, OBSTET GYNECOL, V47, P395; ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; BARNES R, 1989, ANN INTERN MED, V110, P386, DOI 10.7326/0003-4819-110-5-386; BARNES RB, 1989, NEW ENGL J MED, V320, P559, DOI 10.1056/NEJM198903023200904; BERGER MJ, 1975, FERTIL STERIL, V26, P619; CARA JF, 1988, ENDOCRINOLOGY, V123, P733, DOI 10.1210/endo-123-2-733; CHANG RJ, 1983, J CLIN ENDOCR METAB, V56, P897, DOI 10.1210/jcem-56-5-897; DAVOREN JB, 1986, ENDOCRINOLOGY, V118, P888, DOI 10.1210/endo-118-2-888; ELDARGEVA T, 1990, NEW ENGL J MED, V323, P855, DOI 10.1056/NEJM199009273231302; EMANS SJ, 1988, J PEDIATR-US, V112, P821, DOI 10.1016/S0022-3476(88)83217-7; ERICKSON GF, 1985, ENDOCR REV, V6, P371, DOI 10.1210/edrv-6-3-371; FAUSER BCJM, 1991, J CLIN ENDOCR METAB, V73, P811, DOI 10.1210/jcem-73-4-811; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; HAGUE WM, 1989, CLIN ENDOCRINOL, V30, P355, DOI 10.1111/j.1365-2265.1989.tb00433.x; HATCH R, 1981, AM J OBSTET GYNECOL, V140, P815, DOI 10.1016/0002-9378(81)90746-8; HERNANDEZ ER, 1990, ENDOCRINOLOGY, V127, P2804, DOI 10.1210/endo-127-6-2804; HILLIER SG, 1991, MOL CELL ENDOCRINOL, V75, pR1, DOI 10.1016/0303-7207(91)90234-J; HILLIER SG, 1991, J CLIN ENDOCR METAB, V72, P1206, DOI 10.1210/jcem-72-6-1206; JIALAL I, 1987, J CLIN ENDOCR METAB, V64, P1066, DOI 10.1210/jcem-64-5-1066; JUDD HL, 1973, AM J OBSTET GYNECOL, V117, P976, DOI 10.1016/0002-9378(73)90071-9; KIRSCHNER MA, 1976, NEW ENGL J MED, V294, P637, DOI 10.1056/NEJM197603182941204; MULHERON GW, 1991, ENDOCRINOLOGY, V129, P368, DOI 10.1210/endo-129-1-368; NEW MI, 1983, J CLIN ENDOCR METAB, V57, P320, DOI 10.1210/jcem-57-2-320; POLSON DW, 1988, LANCET, V1, P870; RITTMASTER RS, 1990, J CLIN ENDOCR METAB, V70, P1096, DOI 10.1210/jcem-70-4-1096; ROSENFIELD RL, 1990, FERTIL STERIL, V53, P785; ROSENFIELD RL, 1985, J CLIN ENDOCR METAB, V60, P585, DOI 10.1210/jcem-60-3-585; Rosenfield RL, 1992, POLYCYSTIC OVARY SYN, P83; SIEGEL SF, 1990, NEW ENGL J MED, V323, P849, DOI 10.1056/NEJM199009273231301; Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181, DOI 10.1016/S0002-9378(15)30642-6; STEWART PM, 1990, LANCET, V335, P431, DOI 10.1016/0140-6736(90)90664-Q; Timor-Tritsch IE, 1988, TRANSVAGINAL SONOGRA; WALDSTREICHER J, 1988, J CLIN ENDOCR METAB, V66, P165, DOI 10.1210/jcem-66-1-165; YEH HC, 1987, RADIOLOGY, V163, P111, DOI 10.1148/radiology.163.1.3547491; YEN SSC, 1970, J CLIN ENDOCR METAB, V30, P435, DOI 10.1210/jcem-30-4-435	35	268	279	2	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					157	162		10.1056/NEJM199207163270304	http://dx.doi.org/10.1056/NEJM199207163270304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1319000				2022-12-28	WOS:A1992JD31900004
J	HAMM, CW; RAVKILDE, J; GERHARDT, W; JORGENSEN, P; PEHEIM, E; LJUNGDAHL, L; GOLDMANN, B; KATUS, HA				HAMM, CW; RAVKILDE, J; GERHARDT, W; JORGENSEN, P; PEHEIM, E; LJUNGDAHL, L; GOLDMANN, B; KATUS, HA			THE PROGNOSTIC VALUE OF SERUM TROPONIN-T IN UNSTABLE ANGINA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CREATINE KINASE-MB; HIGH-RISK SUBGROUP; PLATELET ACTIVATION; SKELETAL-MUSCLE; PECTORIS; IDENTIFICATION; THROMBUS; ISCHEMIA; DEATH	Background. Cardiac troponin T is a regulatory contractile protein not normally found in blood. Its detection in the circulation has been shown to be a sensitive and specific marker for myocardial cell damage. We used a newly developed enzyme immunoassay for troponin T to determine whether its presence in the serum of patients with unstable angina was a prognostic indicator. Methods. We screened 109 patients with unstable angina (25 with accelerated or subacute angina and 84 with acute angina at rest) for serum creatine kinase activity, creatine kinase isoenzyme MB activity, and troponin T every eight hours for two days after admission to the hospital. The outcomes of interest during the hospitalization were death and myocardial infarction. Results. Troponin T was detected (range, 0.20 to 3.64-mu-g per liter; mean, 0.78; median, 0.50) in the serum of 33 of the 84 patients (39 percent) with acute angina at rest. Only three of these patients had elevated creatine kinase MB activity (two were positive for troponin T, and one was negative). Of the 33 patients who were positive for troponin T, 10 (30 percent) had myocardial infarction (3 after coronary-artery bypass surgery), and 5 of these died during hospitalization. In contrast, only 1 of the 51 patients with angina at rest who were negative for troponin T had an acute myocardial infarction (P<0.001), and this patient died (P = 0.03). Thus, 10 of the 11 patients with myocardial infarctions had detectable levels of troponin T; only 1 had elevated creatine kinase MB activity. Troponin T was not detected in any of the 25 patients with accelerated or subacute angina, and none of these patients died. Conclusions. Cardiac troponin T in serum appears to be a more sensitive indicator of myocardial-cell injury than serum creatine kinase MB activity, and its detection in the circulation may be a useful prognostic indicator in patients with unstable angina.	AARHUS UNIV HOSP,DEPT INTERNAL MED,DK-8000 AARHUS,DENMARK; UNIV HOSP HEIDELBERG,DEPT MED,HEIDELBERG,GERMANY; ODENSE UNIV HOSP,DEPT CLIN CHEM,DK-5000 ODENSE,DENMARK; UNIV BERN,INSELSPITAL,DEPT CLIN CHEM,CH-3010 BERN,SWITZERLAND; NYA LASARETTET,DEPT CLIN CHEM,HELSINGBORG,SWEDEN; NYA LASARETTET,DEPT CARDIOL,HELSINGBORG,SWEDEN	Aarhus University; Ruprecht Karls University Heidelberg; University of Southern Denmark; Odense University Hospital; University of Bern; University Hospital of Bern	HAMM, CW (corresponding author), UNIV HAMBURG,KRANKENHAUS EPPENDORF,DEPT CARDIOL,MED CLIN,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161				ARMSTRONG PW, 1982, AM J CARDIOL, V49, P1849, DOI 10.1016/0002-9149(82)90201-6; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BRESNAHAN DR, 1985, J AM COLL CARDIOL, V6, P285, DOI 10.1016/S0735-1097(85)80161-3; BRIGGS MM, 1989, J MOL BIOL, V206, P245, DOI 10.1016/0022-2836(89)90538-X; CUMMINS P, 1987, EUR J CLIN INVEST, V17, P317, DOI 10.1111/j.1365-2362.1987.tb02194.x; DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418; DONSKY MS, 1976, BRIT HEART J, V38, P257; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141; GAZES PC, 1973, CIRCULATION, V48, P331, DOI 10.1161/01.CIR.48.2.331; GERHARDT W, 1982, CLIN CHEM, V28, P277; GERHARDT W, 1991, CLIN CHEM, V37, P1405; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; HAMM CW, 1987, J AM COLL CARDIOL, V10, P998, DOI 10.1016/S0735-1097(87)80336-4; HAMM CW, 1987, DEUT MED WOCHENSCHR, V112, P1812, DOI 10.1055/s-2008-1068333; HOLMES DR, 1981, BRIT HEART J, V45, P411; HORDER M, 1979, SCAND J CLIN LAB INV, V39, P1, DOI 10.3109/00365517909104932; HORDER M, 1990, BIOCH CLIN, V14, P77; JORGENSEN PJ, 1990, CLIN CHEM, V36, P1502; JULIAN DG, 1985, UNSTABLE ANGINA CURR, P65; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KATUS HA, 1992, CLIN CHEM, V38, P386; KATUS HA, 1991, AM J CARDIOL, V67, P1360, DOI 10.1016/0002-9149(91)90466-X; KATUS HA, 1988, J AM COLL CARDIOL, V11, P487, DOI 10.1016/0735-1097(88)91521-5; KATUS HA, 1990, UNSTABLE ANGINA /, P92; KRUSKAL JB, 1987, NEW ENGL J MED, V317, P1361, DOI 10.1056/NEJM198711263172201; MESSMER BJ, 1990, UNSTABLE ANGINA /, P245; MULCAHY R, 1981, AM J CARDIOL, V48, P525, DOI 10.1016/0002-9149(81)90083-7; NAUNHEIM KS, 1989, ANN THORAC SURG, V47, P569, DOI 10.1016/0003-4975(89)90435-9; NORDLANDER R, 1979, BRIT HEART J, V41, P647; OLSON HG, 1981, CIRCULATION, V64, P674, DOI 10.1161/01.CIR.64.4.674; PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795; SCLAROVSKY S, 1988, AM HEART J, V116, P933, DOI 10.1016/0002-8703(88)90143-3; VETROVEC GW, 1981, AM HEART J, V102, P1202, DOI 10.1016/0002-8703(81)90653-0; VONARNIM T, 1988, EUR HEART J, V9, P435; WHITE RD, 1985, AM J CARDIOL, V55, P1478, DOI 10.1016/0002-9149(85)90957-9; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; WURZBURG U, 1977, J CLIN CHEM CLIN BIO, V15, P131; ZACK PM, 1984, AM HEART J, V108, P1408, DOI 10.1016/0002-8703(84)90684-7; 1971, ISCHAEMIC HEART DISE	41	864	892	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					146	150		10.1056/NEJM199207163270302	http://dx.doi.org/10.1056/NEJM199207163270302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1290492				2022-12-28	WOS:A1992JD31900002
J	BICKMORE, WA; OGHENE, K; LITTLE, MH; SEAWRIGHT, A; VANHEYNINGEN, V; HASTIE, ND				BICKMORE, WA; OGHENE, K; LITTLE, MH; SEAWRIGHT, A; VANHEYNINGEN, V; HASTIE, ND			MODULATION OF DNA-BINDING SPECIFICITY BY ALTERNATIVE SPLICING OF THE WILMS-TUMOR WT1 GENE TRANSCRIPT	SCIENCE			English	Article							EARLY GROWTH-RESPONSE; FINGER; PROTEIN; SEQUENCES; DELETION; GENOME; LOCUS; EGR-1	The technique of whole-genome polymerase chain reaction was used to study the DNA binding properties of the product of the wt1 gene. The zinc finger region of this gene is alternatively spliced such that the major transcript encodes a protein with three extra amino acids between the third and fourth fingers. The minor form of the protein binds specifically to DNA. It is now shown that the major form of wt1 messenger RNA encodes a protein that binds to DNA with a specificity that differs from that of the minor form. Therefore, alternative splicing within the DNA binding domain of a transcription factor can generate proteins with distinct DNA binding specificities and probably different physiological targets.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Bickmore, Wendy A/C-7314-2013; Little, Melissa H/A-6170-2010; van Heyningen, Veronica/B-8039-2008; VAN HEYNINGEN, Veronica/GYE-0531-2022	Bickmore, Wendy A/0000-0001-6660-7735; Little, Melissa H/0000-0003-0380-2263; van Heyningen, Veronica/0000-0003-0359-0141; 	MRC [MC_U127527199] Funding Source: UKRI; Medical Research Council [MC_U127527199] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BORDEREAUX D, 1990, ONCOGENE, V5, P925; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUFF V, 1990, AM J HUM GENET, V47, P28; KENT JF, UNPUB; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; LITT M, 1989, AM J HUM GENET, V44, P397; LITTLE MH, IN PRESS P NATL ACAD; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIYAGAWA K, UNPUB; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283	23	225	229	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					235	237		10.1126/science.1321494	http://dx.doi.org/10.1126/science.1321494			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321494				2022-12-28	WOS:A1992JC58500037
J	SENGUPTA, DJ; BOROWIEC, JA				SENGUPTA, DJ; BOROWIEC, JA			STRAND-SPECIFIC RECOGNITION OF A SYNTHETIC DNA-REPLICATION FORK BY THE SV40 LARGE TUMOR-ANTIGEN	SCIENCE			English	Article							LARGE T-ANTIGEN; SIMIAN VIRUS-40 DNA; TERMINATION FACTOR-RHO; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; UNWINDING ACTIVITY; HELICASE ACTIVITY; ORIGIN; INVITRO; BINDING	The mechanism by which DNA helicases unwind DNA was tested; an "unwinding complex" between the SV40 large tumor antigen (T antigen) and a DNA molecule designed to resemble a replication fork was probed. In an adenosine triphosphate (ATP)-dependent reaction, T antigen quantitatively recognized this synthetic replication fork and bound the DNA primarily as a hexamer. The T antigen bound only one of the two strands at the fork, an asymmetric interaction consistent with the 3' --> 5' directionality of the DNA helicase activity of T antigen. Binding to chemically modified DNA substrates indicated that the DNA helicase recognized the DNA primarily through the sugar-phosphate backbone. Ethylation of six top strand phosphates at the junction of single-stranded and double-stranded DNA inhibited the DNA helicase activity of T antigen. Neither a 3' single-stranded end on the DNA substrate nor ATP hydrolysis was required for T antigen to bind the replication fork. These data suggest that T antigen can directly bind the replication fork through recognition of a fork-specific structure.			SENGUPTA, DJ (corresponding author), NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016, USA.				NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029963] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA 16087] Funding Source: Medline; NIAID NIH HHS [AI29963] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI K, 1981, J BIOL CHEM, V256, P5247; AUBORN KJ, 1988, J VIROL, V62, P2204, DOI 10.1128/JVI.62.6.2204-2208.1988; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1989, UCLA S MOL CELL BIOL, V127, P315; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GOETZ GS, 1988, J BIOL CHEM, V263, P383; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Maniatis T., 1982, MOL CLONING; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; ODA T, 1972, J MOL BIOL, V71, P799; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STAHL H, 1983, J VIROL, V47, P65, DOI 10.1128/JVI.47.1.65-76.1983; STAHL H, 1985, J VIROL, V54, P473, DOI 10.1128/JVI.54.2.473-482.1985; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TJIAN R, 1981, CELL, V26, P1, DOI 10.1016/0092-8674(81)90026-X; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WIEKOWSKI M, 1987, J VIROL, V61, P411, DOI 10.1128/JVI.61.2.411-418.1987; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989	46	64	65	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1656	1661		10.1126/science.256.5064.1656	http://dx.doi.org/10.1126/science.256.5064.1656			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1319087				2022-12-28	WOS:A1992HZ17400038
J	HSU, VW; SHAH, N; KLAUSNER, RD				HSU, VW; SHAH, N; KLAUSNER, RD			A BREFELDIN-A-LIKE PHENOTYPE IS INDUCED BY THE OVEREXPRESSION OF A HUMAN ERD-2-LIKE PROTEIN, ELP-1	CELL			English	Article							LUMINAL ER PROTEINS; ENDOPLASMIC-RETICULUM; GOLGI PROTEINS; TRANSPORT; SYSTEM; PATHWAY; GENE; IDENTIFICATION; EXPRESSION; RETENTION	Brefeldin A (BFA) is a unique drug affecting the molecular mechanisms that regulate membrane traffic and organelle structure. BFA's ability to alter retrograde traffic from the Golgi to the endoplasmic reticulum (ER) led us to ask whether the ERD-2 retrieval receptor, proposed to return escaped ER resident proteins from the Golgi, might either interfere with or mimic the effects of the drug. When either human ERD-2 or a novel human homolog (referred to as ELP-1) is overexpressed in a variety of cell types, the effects are phenotypically indistinguishable from the addition of BFA. These include the redistribution of the Golgi coat protein, beta-COP, to the cytosol, the loss of the Golgi apparatus as a distinct organelle, the mixing of this organelle with the ER, the addition of complex oligosaccharides to resident ER glycoproteins, and the block of anterograde traffic. Thus, these receptors may provide signals that regulate retrograde traffic between the Golgi and the ER.			HSU, VW (corresponding author), NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA.							ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOW SH, 1991, J BIOL CHEM, V266, P17729; Maniatis T., 1982, MOL CLONING; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKANO A, 1985, BIOCHIM BIOPHYS ACTA, V845, P324, DOI 10.1016/0167-4889(85)90195-8; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1991, CELL, V64, P1183; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZUBER C, 1991, P NATL ACAD SCI USA, V88, P9818, DOI 10.1073/pnas.88.21.9818	46	124	125	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					625	635		10.1016/0092-8674(92)90226-3	http://dx.doi.org/10.1016/0092-8674(92)90226-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1316805	Green Published, Bronze			2022-12-28	WOS:A1992HV08900007
J	HALL, A				HALL, A			SIGNAL TRANSDUCTION THROUGH SMALL GTPASES - A TALE OF 2 GAPS	CELL			English	Review							PROTEINS				HALL, A (corresponding author), INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND.							BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GEORGE JM, 1992, MOL BRAIN RES, V12, P323, DOI 10.1016/0169-328X(92)90134-W; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL A, 1992, IN PRESS MOL BIOL CE; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; IMAI Y, 1991, MOL CELL BIOL, V11, P3088, DOI 10.1128/MCB.11.6.3088; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	18	124	127	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					389	391		10.1016/0092-8674(92)90441-E	http://dx.doi.org/10.1016/0092-8674(92)90441-E			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1316238				2022-12-28	WOS:A1992HT07800002
J	PENG, CK; BULDYREV, SV; GOLDBERGER, AL; HAVLIN, S; SCIORTINO, F; SIMONS, M; STANLEY, HE				PENG, CK; BULDYREV, SV; GOLDBERGER, AL; HAVLIN, S; SCIORTINO, F; SIMONS, M; STANLEY, HE			LONG-RANGE CORRELATIONS IN NUCLEOTIDE-SEQUENCES	NATURE			English	Article							PIECES; GENES	DNA SEQUENCES have been analysed using models, such as an n-step Markov chain, that incorporate the possibility of short-range nucleotide correlations 1. We propose here a method for studying the stochastic properties of nucleotide sequences by constructing a 1:1 map of the nucleotide sequence onto a walk, which we term a 'DNA walk'. We then use the mapping to provide a quantitative measure of the correlation between nucleotides over long distances along the DNA chain. Thus we uncover in the nucleotide sequence a remarkably long-range power law correlation that implies a new scale-invariant property of DNA. We find such long-range correlations in intron-containing genes and in nontranscribed regulatory DNA sequences, but not in complementary DNA sequences or intron-less genes.	BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV CARDIOVASC,BOSTON,MA 02215; NIH,DIV COMP RES & TECHNOL,PHYS SCI LAB,BETHESDA,MD 20892; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Institutes of Health (NIH) - USA; Massachusetts Institute of Technology (MIT)	PENG, CK (corresponding author), BOSTON UNIV,CTR POLYMER STUDIES,BOSTON,MA 02215, USA.		Peng, Chung-Kang/N-1308-2019; Sciortino, Francesco/B-4768-2012; Havlin, Shlomo/ABF-1527-2020; Peng, Chung-Kang/E-1489-2011; Buldyrev, Sergey V/I-3933-2015; Simons, Michael/G-8553-2014	Peng, Chung-Kang/0000-0003-3666-9833; Peng, Chung-Kang/0000-0003-3666-9833; Simons, Michael/0000-0003-0348-7734; Buldyrev, Sergey/0000-0002-3008-1070; SCIORTINO, Francesco/0000-0002-2418-2713				BAK P, 1987, PHYS REV LETT, V59, P381, DOI 10.1103/PhysRevLett.59.381; DARNELL JE, 1978, SCIENCE, V202, P1257, DOI 10.1126/science.364651; DOOLITTLE WF, 1978, NATURE, V272, P581, DOI 10.1038/272581a0; DOOLITTLE WF, 1990, INTERVENING SEQUENCE, P42; DUTTA P, 1981, REV MOD PHYS, V53, P497, DOI 10.1103/RevModPhys.53.497; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; LI W, 1991, SFI9102 SANT FE I TE; MONTROLL EW, 1984, NONEQUILIBRIUM PHENO, V2, P1; SHLESINGER MF, 1988, ANNU REV PHYS CHEM, V39, P269, DOI 10.1146/annurev.physchem.39.1.269; STANLEY HE, 1971, INTRO PHASE TRANSITI, P120; [No title captured]	11	1148	1188	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					168	170		10.1038/356168a0	http://dx.doi.org/10.1038/356168a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1301010				2022-12-28	WOS:A1992HH73100065
J	TONGLET, R; BOURDOUX, P; MINGA, T; ERMANS, AM				TONGLET, R; BOURDOUX, P; MINGA, T; ERMANS, AM			EFFICACY OF LOW ORAL DOSES OF IODIZED OIL IN THE CONTROL OF IODINE DEFICIENCY IN ZAIRE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDEMIC GOITER	Background. About one billion people worldwide are at risk for iodine deficiency. Despite existing programs of prophylaxis, the prevention of iodine deficiency is still a challenge throughout the developing world. We studied the efficacy of low doses of iodized oil in an area of severe iodine deficiency in Zaire. Methods. Seventy-five subjects with visible goiter were randomly assigned to receive a single oral dose of placebo or either 0.1 or 0.25 ml of iodized oil, corresponding to 0, 47, and 118 mg of iodine, respectively. The mean ages of the subjects in the three groups were 23, 22, and 22 years, respectively, and the ratios of males to females were 0.25, 0.32, and 0.19. Efficacy was assessed by evaluating goiter size and measuring urinary iodine and serum thyroid hormone concentrations for 12 months. Results. Goiter size decreased in most of the subjects who received either dose of iodized oil. Their urinary iodine concentrations were normal for six to nine months and their serum thyroxine and thyrotropin concentrations were nearly all normal throughout the study period. There were no side effects, even in subjects whose serum thyroxine concentrations had initially been low. In the placebo group, neither goiter size nor any of the biochemical values changed. Conclusions. The oral administration of a single small dose of iodized oil is capable of correcting iodine deficiency for about a year. This method of supplementation is likely to be more effective, efficient, and acceptable than the administration of either intramuscular or large oral doses of iodized oil.	UNIV LIBRE BRUXELLES, CTR SCI & MED, B-1050 BRUSSELS, BELGIUM; ZONE SANTE RURALE KIROTSHE, NORD KIVU, DEM REP CONGO; UNIV LIBRE BRUXELLES, HOP ST PIERRE, DEPT NUCL MED, B-1000 BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel								[Anonymous], 1986, LANCET, V2, P433; BOUKIS MA, 1983, J CLIN ENDOCR METAB, V57, P859, DOI 10.1210/jcem-57-4-859; BOURDOUX P, 1982, CLIN EVALUATION FREE, P241; BOURDOUX P, 1989, 1989 AOTA S IOD DEF, P45; BOURDOUX P, 1985, SERONO S, V22, P145; BOURDOUX PP, 1990, J ENDOCRINOL INVEST, V13, P77, DOI 10.1007/BF03348591; DELANGE F, 1974, MONOGR PAEDIATR, V2, P1; Delange F, 1986, PAHO WHO SCI PUBLICA, P373; DELRAY FE, 1984, ENDOCRINOLOGIA, V31, P61; ELTOM M, 1985, J CLIN ENDOCR METAB, V61, P1112, DOI 10.1210/jcem-61-6-1112; ERMANS AM, 1969, SCI PUBLICATION, V193, P101; GARDNER MJ, 1989, BRIT MED J, P1; LAGASSE R, 1980, IDRC MONOGRAPH E, V13, P45; MABERLY GF, 1982, CLIN ENDOCRINOL, V17, P253, DOI 10.1111/j.1365-2265.1982.tb01587.x; MAHMOUD I, 1986, EXP MOL PATHOL, V44, P259, DOI 10.1016/0014-4800(86)90040-7; MAHMOUD I, 1986, FRONTIERS THYROIDOLO, V2, P967; MCLENNAN R, 1974, SCI PUBLICATION PAN, V292, P195; PHILLIPS DIW, 1989, INT J EPIDEMIOL, V18, P907, DOI 10.1093/ije/18.4.907; PHILLIPS DIW, 1988, INT J EPIDEMIOL, V17, P142, DOI 10.1093/ije/17.1.142; Sandell E. B., 1937, MICROCHIM ACTA, V1, P9, DOI [10.1007/BF01476194, DOI 10.1007/BF01476194]; SUZUKI H, 1965, ACTA ENDOCRINOL-COP, V50, P161, DOI 10.1530/acta.0.0500161; THILLY C, 1984, ANN ENDOCRINOL-PARIS, V45, P87; THILLY CH, 1973, J CLIN ENDOCR METAB, V36, P1196, DOI 10.1210/jcem-36-6-1196; THILLY CH, 1980, IDRC MONOGRAPH E, V13, P37; WEI J, 1985, NUTR REP INT, V31, P1085; WILS W, 1986, B ACAD R SCI OUTREME, V2, P7; WOLFF J, 1969, AM J MED, V47, P101, DOI 10.1016/0002-9343(69)90245-9	27	75	77	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					236	241		10.1056/NEJM199201233260405	http://dx.doi.org/10.1056/NEJM199201233260405			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1309390	Bronze			2022-12-28	WOS:A1992HA43100005
J	WEI, JY				WEI, JY			MECHANISMS OF DISEASE - AGE AND THE CARDIOVASCULAR-SYSTEM	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONGESTIVE HEART-FAILURE; BLOOD-PRESSURE; EXCITATION-CONTRACTION; ELDERLY PATIENTS; CARDIAC-MUSCLE; EXERCISE; RATS; MYOCARDIUM; STATES; STRESS		GERIATR RES EDUC & CLIN CTR,BOSTON,MA; BROCKTON W ROXBURY VET AFFAIRS MED CTR,BOSTON,MA; BETH ISRAEL HOSP,BOSTON,MA 02215	Geriatric Research Education & Clinical Center; Harvard University; Harvard University; Beth Israel Deaconess Medical Center	WEI, JY (corresponding author), HARVARD UNIV,SCH MED,DIV AGING,643 HUNTINGTON AVE,BOSTON,MA 02115, USA.			Wei, Jeanne/0000-0002-1861-3329				AGUIRRE FV, 1989, AM J CARDIOL, V63, P1098, DOI 10.1016/0002-9149(89)90085-4; AROESTY JM, 1985, CIRCULATION, V71, P889, DOI 10.1161/01.CIR.71.5.889; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; CLARK BA, 1991, AM J HYPERTENS, V4, P500, DOI 10.1093/ajh/4.6.500; CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812; Davies MJ., 1976, CARDIOLOGY OLD AGE, P57; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FORMAN DE, 1992, J GERONTOL, V47, pM56, DOI 10.1093/geronj/47.2.M56; FORMAN DE, 1991, JAMA-J AM MED ASSOC, V266, P2222, DOI 10.1001/jama.1991.03470160054021; GOLDBERG ID, 1984, ANN NY ACAD SCI, V435, P422, DOI 10.1111/j.1749-6632.1984.tb13840.x; GWATHMEY JK, 1990, J APPL PHYSIOL, V69, P1366, DOI 10.1152/jappl.1990.69.4.1366; HACHAMOVITCH R, 1989, AM J PHYSIOL, V256, pH66, DOI 10.1152/ajpheart.1989.256.1.H66; HAUSDORFF JM, 1992, AM J CARDIOL, V70, P1064, DOI 10.1016/0002-9149(92)90362-3; ISOYAMA S, 1988, J CLIN INVEST, V81, P1850, DOI 10.1172/JCI113530; Kannel W B, 1989, Cardiol Clin, V7, P1; KOOBS DH, 1978, ARCH PATHOL LAB MED, V102, P66; KRUMHOLZ HM, 1991, ACUTE MYOCARDIAL INF, P101; LARSON EB, 1987, ARCH INTERN MED, V147, P353, DOI 10.1001/archinte.147.2.353; LARSSON B, 1984, EUR HEART J, V5, P31, DOI 10.1093/eurheartj/5.suppl_E.31; LI YX, 1986, AM J PHYSIOL, V251, pH12, DOI 10.1152/ajpheart.1986.251.1.H12; LIE JT, 1988, MAYO CLIN PROC, V63, P552, DOI 10.1016/S0025-6196(12)64885-X; LIPSITZ LA, 1983, NEW ENGL J MED, V309, P81, DOI 10.1056/NEJM198307143090205; LIPSITZ LA, 1990, J AM GERIATR SOC, V38, P103, DOI 10.1111/j.1532-5415.1990.tb03469.x; LUCHI RJ, 1982, J AM GERIATR SOC, V30, P700, DOI 10.1111/j.1532-5415.1982.tb01983.x; MANNING WJ, 1991, AM J CARDIOL, V67, P894, DOI 10.1016/0002-9149(91)90628-X; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; NICHOLS WW, 1985, AM J CARDIOL, V55, P1179, DOI 10.1016/0002-9149(85)90659-9; NIXON JV, 1985, AM J CARDIOL, V56, P932, DOI 10.1016/0002-9149(85)90407-2; OGAWA T, 1992, CIRCULATION, V86, P494, DOI 10.1161/01.CIR.86.2.494; OLIVETTI G, 1991, CIRC RES, V68, P1560, DOI 10.1161/01.RES.68.6.1560; OROURKE RA, 1987, J AM COLL CARDIOL, V10, pA52, DOI 10.1016/S0735-1097(87)80449-7; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; RODRIGUES EA, 1987, EUR HEART J, V8, P624, DOI 10.1093/oxfordjournals.eurheartj.a062332; SARTORI MP, 1987, AM J CARDIOL, V59, P1179, DOI 10.1016/0002-9149(87)90871-X; SHANNON RP, 1984, SEMIN NEPHROL, V4, P346; SHANNON RP, 1986, HYPERTENSION, V8, P438, DOI 10.1161/01.HYP.8.5.438; SHANNON RP, 1991, AM J CARDIOL, V67, P1110, DOI 10.1016/0002-9149(91)90874-K; SIEGEL JS, 1980, NIH80969 US DEP HLTH, P289; SORBINI CA, 1968, RESPIRATION, V25, P3, DOI 10.1159/000192549; STRATTON JR, 1992, CIRCULATION, V86, P504, DOI 10.1161/01.CIR.86.2.504; TAKAHASHI T, 1992, J CLIN INVEST, V89, P939, DOI 10.1172/JCI115675; TSUNODA K, 1986, J CLIN ENDOCR METAB, V62, P384; WEI JY, 1989, CIRCULATION, V80, P171; WEI JY, 1987, J GERONTOL, V42, P11, DOI 10.1093/geronj/42.1.11; WEI JY, 1984, AM J PHYSIOL, V246, pH784, DOI 10.1152/ajpheart.1984.246.6.H784; WEI JY, 1987, CURR PROB CARDIOLOGY, V12, P1; WEI JY, 1983, AM J PHYSIOL, V245, pR18, DOI 10.1152/ajpregu.1983.245.1.R18; WEI JY, 1989, J CLIN INVEST, V83, P778, DOI 10.1172/JCI113957; WEI JY, 1990, MERCK MANUAL GERIATR, P380; WHITE WB, 1989, AM J CARDIOL, V63, P1343, DOI 10.1016/0002-9149(89)91046-1; WITTELS EH, 1990, AM J CARDIOL, V65, P432, DOI 10.1016/0002-9149(90)90806-C; YIN FCP, 1980, AGING-US, V12, P137; YUSUF S, 1989, HYPERTENSION, V0013	53	337	348	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1735	1739						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KA897	1304738				2022-12-28	WOS:A1992KA89700008
J	NORD, E				NORD, E			AN ALTERNATIVE TO QALYS - THE SAVED YOUNG LIFE EQUIVALENT (SAVE)	BRITISH MEDICAL JOURNAL			English	Article							HEALTH STATES; COST-EFFECTIVENESS; CARE; UTILITIES; QUALITY				NORD, E (corresponding author), NATL INST PUBL HLTH,GEITMYRSVEIEN 75,N-0462 OSLO,NORWAY.							Ashmore M, 1989, HLTH EFFICIENCY SOCI; Broome J, 1988, PHILOS MED WELFARE, P57; CARRHILL RA, 1989, SOC SCI MED, V29, P469, DOI 10.1016/0277-9536(89)90296-7; CHIANG CL, 1965, PHS PUBLICATION 2, V1000; Culyer AJ, 1971, SOCIAL TRENDS, V2, P31; DAHL G, 1992, J NORWEGIAN ASS DISA, V1, P26; DRUMMOND MF, 1991, OXFORD REV EC POL, V5, P59; FLETCHER A, 1991, J HYPERTENS, P9193; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; KAPLAN RM, 1979, MED CARE, V17, P501, DOI 10.1097/00005650-197905000-00005; KAPLAN RM, 1988, HEALTH SERV RES, V23, P203; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; MOONEY G, 1991, PROVIDING HEALTH CARE : THE ECONOMICS OF ALTERNATIVE SYSTEMS OF FINANCE AND DELIVERY, P120; MORRIS J, 1989, CATEGORY RATING METH; MULKAY M, 1987, SOCIOLOGY, V21, P541, DOI 10.1177/0038038587021004004; MULLEY AG, 1989, MED CARE, V27, pS269, DOI 10.1097/00005650-198903001-00021; NORD E, 1989, HEALTH POLICY, V13, P189, DOI 10.1016/0168-8510(89)90092-4; Nord E, 1991, Int J Health Plann Manage, V6, P234, DOI 10.1002/hpm.4740060308; NORD E, 1992, SOC SCI MED, V34, P559, DOI 10.1016/0277-9536(92)90211-8; NORD E, 1991, HEALTH POLICY, V18, P25, DOI 10.1016/0168-8510(91)90141-J; NORD E, IN PRESS J MED ETHIC; NORD E, 1992, EUROQOL C P, P87; PATRICK DL, 1973, HEALTH SERV RES, V8, P229; RICHARDSON J, 1991, 12TH P AUSTR C HLTH, P80; ROSSER RM, 1972, INT J EPIDEMIOL, V1, P361, DOI 10.1093/ije/1.4.361; SINTONEN H, 1981, SOC SCI MED-MED ECON, V15, P55, DOI 10.1016/0160-7995(81)90019-8; SMITH A, 1987, LANCET, V1, P1134; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; WAGSTAFF A, 1991, J HEALTH ECON, V10, P21, DOI 10.1016/0167-6296(91)90015-F; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WILLIAMS A, 1987, WORLD HOSPITALS, V13, P34; Williams A, 1988, PHILOS MED WELFARE; 1990, HLTH POLICY, V16, P199; 1987, RETNINGSLINJER PRIOR, P23	36	51	50	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1992	305	6858					875	877		10.1136/bmj.305.6858.875	http://dx.doi.org/10.1136/bmj.305.6858.875			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JT777	1301030	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JT77700033
J	HEGDE, RS; GROSSMAN, SR; LAIMINS, LA; SIGLER, PB				HEGDE, RS; GROSSMAN, SR; LAIMINS, LA; SIGLER, PB			CRYSTAL-STRUCTURE AT 1.7-ANGSTROM OF THE BOVINE PAPILLOMAVIRUS-1 E2 DNA-BINDING DOMAIN BOUND TO ITS DNA TARGET	NATURE			English	Article							PROTEIN STRUCTURES; TERMINAL DOMAIN; NUCLEIC-ACIDS; REPRESSOR; RECOGNITION; RESOLUTION; COMPLEX; OPERATOR; ACTIVATION; E2-PROTEIN	The dominant transcriptional regulator of the papillomaviruses, E2, binds to its specific DNA target through a previously unobserved dimeric antiparallel beta-barrel. The DNA is severely but smoothly bent over the barrel by the interaction of successive major grooves with a pair of symmetrically disposed alpha-helices. The specific interface is an 'interwoven' network of interactions where the identifying base pairs of the target contact more than one amino-acid side chain and the discriminating amino acids interact with more than one base pair.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	Yale University; University of Chicago; Howard Hughes Medical Institute; University of Chicago	HEGDE, RS (corresponding author), YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510, USA.							ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BLUNDELL TL, 1971, NATURE, V231, P506, DOI 10.1038/231506a0; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BRUNGER AT, 1990, XPLOR VERSION 2 1 MA; DOSTATNI N, 1988, EMBO J, V7, P3807, DOI 10.1002/j.1460-2075.1988.tb03265.x; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HANDSCHUMACHER MD, 1983, ACCESS YALE U; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MCBRIDE AA, 1988, EMBO J, V7, P533, DOI 10.1002/j.1460-2075.1988.tb02842.x; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; MCBRIDE AA, 1989, COMMON MECHANISMS TR, P115; MONINI P, 1991, J VIROL, V65, P2124, DOI 10.1128/JVI.65.4.2124-2130.1991; MOSKALUK C, 1988, P NATL ACAD SCI USA, V85, P1826, DOI 10.1073/pnas.85.6.1826; OHLENDORF DH, 1982, NATURE, V298, P718, DOI 10.1038/298718a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SOUSA R, 1990, BIOCHIM BIOPHYS ACTA, V1032, P19, DOI 10.1016/0304-419X(90)90010-X; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; USTAV M, 1991, EMBO J, V10, P445; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	40	309	317	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					505	512		10.1038/359505a0	http://dx.doi.org/10.1038/359505a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1328886				2022-12-28	WOS:A1992JR85900050
J	MIYAKE, M; TAKI, T; HITOMI, S; HAKOMORI, S				MIYAKE, M; TAKI, T; HITOMI, S; HAKOMORI, S			CORRELATION OF EXPRESSION OF H/LE(Y)/LE(B) ANTIGENS WITH SURVIVAL IN PATIENTS WITH CARCINOMA OF THE LUNG	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-EMBRYOS; CARBOHYDRATE; BLADDER; CANCERS	Background. The level of expression of H/Le(y)/Le(b) antigens is high in various histologic types of lung cancer, a feature that may be related to deletion of A and B blood-group antigens. We evaluated the possibility that expression of this antigen, which can be defined by the monoclonal antibody MIA-15-5, might be of prognostic value, as suggested by our previous observation that MIA-15-5 inhibits tumor-cell motility and metastasis. Methods. We used MIA-15-5 to stain tissue sections from 149 patients with primary lung cancer whose clinico-pathological histories were well documented. The survival curves for patients whose tumors stained positively were compared with the curves for those whose tumors stained negatively. Multivariate analyses were performed with a Cox proportional-hazards regression model. Results. Among the 149 patients studied, five-year survival in the 91 patients with MIA-positive tumors was significantly lower than survival in the 58 with MIA-negative tumors (20.9 percent vs. 58.6 percent, P<0.001). Among the 67 patients with squamous-cell carcinoma, the rates also differed significantly (10.5 percent vs. 62.1 percent, P<0.001). The difference in survival between patients with MIA-positive tumors and those with MIA-negative tumors was significant among patients with blood groups A and AB (P<0.001), but not among those with blood group B or 0 (P = 0.071 and 0.068, respectively). Multivariate analysis with the Cox regression model indicated that positivity best correlated with five-year mortality, followed by lymph-node status (N stage) and tumor size (T stage), whereas sex, age, and blood group did not correlate with mortality. Conclusions. Positivity for MIA (i.e., immunohistologic staining by MIA-15-5, which defines H/Le(y)/Le(b) antigens) is inversely correlated with survival among patients with primary lung cancer and may be of prognostic value.	KYOTO UNIV, CHEST DIS RES INST, DEPT THORAC SURG, KYOTO 606, JAPAN; UNIV WASHINGTON, INST BIOMEMBRANE, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOBIOL, SEATTLE, WA 98195 USA	Kyoto University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	MIYAKE, M (corresponding author), KITANO HOSP, TAZUKE KOFUKAI MED RES INST, DEPT THORAC SURG, KITA KIE, OSAKA 530, JAPAN.				NCI NIH HHS [CA-42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1982, AM J CLIN PATHOL, V77, P123; COON JS, 1985, CANCER, V56, P797, DOI 10.1002/1097-0142(19850815)56:4<797::AID-CNCR2820560417>3.0.CO;2-H; COX DR, 1972, J R STAT SOC B, V34, P187; DABELSTEEN E, 1983, CANCER RES, V43, P1451; DABELSTEEN E, 1975, ACTA PATH MICRO IM A, VA 83, P292; DAVIDSOHN I, 1969, ARCH PATHOL, V87, P306; DAVIDSOHN I, 1966, ARCH PATHOL, V81, P381; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; HAKOMORI S, 1974, ANTIGENS, V2, P79; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hermanek P, 1987, TNM CLASSIFICATION M, P69; ITAI S, 1990, CANCER RES, V50, P7603; ITZKOWITZ SH, 1990, CANCER-AM CANCER SOC, V66, P1960, DOI 10.1002/1097-0142(19901101)66:9<1960::AID-CNCR2820660919>3.0.CO;2-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAY HE, 1961, J NATL CANCER I, V26, P1349; KOVARIK S, 1968, ARCH PATHOL, V86, P12; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASAMUNE H, 1952, Tohoku J Exp Med, V56, P37; MASAMUNE H, 1958, TOHOKU J EXP MED, V8, P81; MIYAKE M, 1991, BIOCHEMISTRY-US, V30, P3328, DOI 10.1021/bi00227a023; MIYAKE M, 1988, CANCER RES, V48, P7150; ORNTOFT TF, 1989, INT J CANCER, V43, P774, DOI 10.1002/ijc.2910430505; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P1079; SILLETTI S, 1991, CANCER RES, V51, P3507; STANFORD DR, 1986, INT J CANCER, V37, P435, DOI 10.1002/ijc.2910370316; STELLNER K, 1973, BIOCHEM BIOPH RES CO, V55, P439, DOI 10.1016/0006-291X(73)91106-6	27	232	249	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					14	18		10.1056/NEJM199207023270103	http://dx.doi.org/10.1056/NEJM199207023270103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1317941				2022-12-28	WOS:A1992JA76100003
J	TRAVERS, AA				TRAVERS, AA			THE REPROGRAMMING OF TRANSCRIPTIONAL COMPETENCE	CELL			English	Review							POSITION-EFFECT VARIEGATION; DROSOPHILA; PROTEIN				TRAVERS, AA (corresponding author), MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND.							ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EPSTEIN H, 1992, J CELL SCI, V101, P463; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E	18	67	73	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					573	575		10.1016/0092-8674(92)90218-2	http://dx.doi.org/10.1016/0092-8674(92)90218-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1316804				2022-12-28	WOS:A1992HV08900001
J	GOESSLING, LS; DANIELSMCQUEEN, S; BHATTACHARYYAPAKRASI, M; LIN, JJ; THACH, RE				GOESSLING, LS; DANIELSMCQUEEN, S; BHATTACHARYYAPAKRASI, M; LIN, JJ; THACH, RE			ENHANCED DEGRADATION OF THE FERRITIN REPRESSOR PROTEIN DURING INDUCTION OF FERRITIN MESSENGER-RNA TRANSLATION	SCIENCE			English	Article							ELEMENT-BINDING-PROTEIN; ELECTROPHORETIC TRANSFER; AFFINITY PURIFICATION; POLYACRYLAMIDE GELS; CHELATABLE IRON; HEPATOMA-CELLS; RABBIT LIVER; HEMIN; EXPRESSION; NITROCELLULOSE	Induction of ferritin synthesis in cultured cells by heme or iron is accompanied by degradation of the ferritin repressor protein (FRP). Intermediates in the degradative pathway apparently include FRP covalently linked in larger aggregates. The effect of iron on FRP degradation is enhanced by porphyrin precursors but is decreased by inhibitors of porphyrin synthesis, which implies that heme is an active agent. These results suggest that translational induction in this system may be caused by enhanced repressor degradation. While unique among translational regulatory systems, this process is common to a variety of other biosynthetic control mechanisms.	WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Washington University (WUSTL)					NIAID NIH HHS [AI 20484] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020484] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS ML, 1989, BIOCHIM BIOPHYS ACTA, V1012, P243, DOI 10.1016/0167-4889(89)90104-3; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOTTOMLEY SS, 1985, J BIOL CHEM, V260, P6811; BROWN PH, 1989, J BIOL CHEM, V264, P13383; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANG CS, 1982, J BIOL CHEM, V257, P3650; CHERNIK RJ, 1989, HEPATOLOGY, V10, P359; CIECHANOVER A, 1990, P NATL ACAD SCI USA, V63, P1129; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DANIELSMCQUEEN S, UNPUB; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EISENSTEIN RS, 1991, ENZYME BASEL, V44, P42; GOESSLING LS, UNPUB; HARFORD JB, 1991, ENZYME, V44, P28; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; IWASA F, 1989, BIOCHEM J, V262, P807, DOI 10.1042/bj2620807; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; LAWSON TG, 1989, J VIROL, V63, P5013, DOI 10.1128/JVI.63.12.5013-5022.1989; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6068, DOI 10.1073/pnas.88.14.6068; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; LIN JJ, 1990, BIOCHIM BIOPHYS ACTA, V1050, P146, DOI 10.1016/0167-4781(90)90156-V; LIN JJ, 1991, ENZYME, V44, P59; MULLEREBERHARD U, 1988, J BIOL CHEM, V263, P14753; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; ROBERTS JW, 1981, NATURE, V290, P422, DOI 10.1038/290422a0; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROUAULT T, 1985, J BIOL CHEM, V260, P4862; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SWENSON GR, 1991, BIOL MET, V4, P48, DOI 10.1007/BF01135557; THEIL EC, 1991, ENZYME, V44, P68; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WALDEN WE, 1987, GENE, V61, P317, DOI 10.1016/0378-1119(87)90195-8; WARD JH, 1984, J BIOL CHEM, V259, P3235; ZHENG L, COMMUNICATION	42	48	47	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					670	673		10.1126/science.1316633	http://dx.doi.org/10.1126/science.1316633			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1316633				2022-12-28	WOS:A1992HR18500034
J	LIN, AY; IHDE, DC				LIN, AY; IHDE, DC			RECENT DEVELOPMENTS IN THE TREATMENT OF LUNG-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPY ONCOLOGY GROUP; LYMPH-NODE METASTASES; SMALL-CELL CARCINOMA; RADIATION-THERAPY; RANDOMIZED TRIAL; STAGE-II; CHEMOTHERAPY; RADIOTHERAPY; IRRADIATION; SURVIVAL		NCI,OSN,MED ONCOL BRANCH,BLDG 31,ROOM 11A48,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA								BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BORK E, 1986, J CLIN ONCOL, V4, P524, DOI 10.1200/JCO.1986.4.4.524; BROOKS BJ, 1986, J CLIN ONCOL, V4, P200, DOI 10.1200/JCO.1986.4.2.200; BUNN PA, 1987, ANN INTERN MED, V106, P655, DOI 10.7326/0003-4819-106-5-655; CORTESE DA, 1983, J THORAC CARDIOV SUR, V86, P373; COX JD, 1990, J CLIN ONCOL, V8, P1543, DOI 10.1200/JCO.1990.8.9.1543; CULLEN JW, 1989, CANCER PRINCIPLES PR, P181; DEVESA SS, 1990, J NATL CANCER I, V6, P162; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; EINHORN LH, 1988, J CLIN ONCOL, V6, P451, DOI 10.1200/JCO.1988.6.3.451; ERRETT LE, 1985, J THORAC CARDIOV SUR, V90, P656; FELD R, 1984, J CLIN ONCOL, V2, P1352, DOI 10.1200/JCO.1984.2.12.1352; GARFINKEL L, 1991, CA-CANCER J CLIN, V41, P137, DOI 10.3322/canjclin.41.3.137; HOLMES EC, 1986, J CLIN ONCOL, V4, P710, DOI 10.1200/JCO.1986.4.5.710; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; IHDE DC, 1991, P AN M AM SOC CLIN, V10, P240; JOHNSON BE, 1990, J CLIN ONCOL, V8, P396, DOI 10.1200/JCO.1990.8.3.396; LAD T, 1988, J CLIN ONCOL, V6, P9; MARTINI N, 1983, ANN SURG, V198, P386, DOI 10.1097/00000658-198309000-00015; MARTINI N, 1988, ANN THORAC SURG, V45, P370, DOI 10.1016/S0003-4975(98)90007-8; MCCRACKEN JD, 1990, J CLIN ONCOL, V8, P892, DOI 10.1200/JCO.1990.8.5.892; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; OSTERLIND K, 1986, J CLIN ONCOL, V4, P1044, DOI 10.1200/JCO.1986.4.7.1044; PEREZ CA, 1984, J CLIN ONCOL, V2, P1200, DOI 10.1200/JCO.1984.2.11.1200; PEREZ CA, 1987, CANCER, V59, P1874, DOI 10.1002/1097-0142(19870601)59:11<1874::AID-CNCR2820591106>3.0.CO;2-Z; PERRY MC, 1987, NEW ENGL J MED, V316, P912, DOI 10.1056/NEJM198704093161504; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; RIES LAG, 1991, NCI NIH912789 PUBL; SPIRO SG, 1989, BRIT J CANCER, V59, P578, DOI 10.1038/bjc.1989.117; TURRISI AT, 1988, INT J RADIAT ONCOL, V15, P183, DOI 10.1016/0360-3016(88)90364-1; WEISENBURGER TH, 1986, NEW ENGL J MED, V315, P1377	32	14	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1661	1664		10.1001/jama.267.12.1661	http://dx.doi.org/10.1001/jama.267.12.1661			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1311778				2022-12-28	WOS:A1992HJ59700035
J	ATSUMI, T; MCCARTER, L; IMAE, Y				ATSUMI, T; MCCARTER, L; IMAE, Y			POLAR AND LATERAL FLAGELLAR MOTORS OF MARINE VIBRIO ARE DRIVEN BY DIFFERENT ION-MOTIVE FORCES	NATURE			English	Article							SWARMER CELL-DIFFERENTIATION; NA+ PUMP; ALKALOPHILIC BACILLUS; PROTONMOTIVE FORCE; PARAHAEMOLYTICUS; ALGINOLYTICUS; AMILORIDE; MOTILITY	VARIOUS species of marine Vibrio produce two distinct types of flagella, each adapted for a different type of motility 1. A single, sheathed polar flagellum is suited for swimming in liquid medium, and numerous unsheathed lateral flagella, which are produced only under viscous conditions, are suited for swarming over viscous surfaces 2,3. Both types of flagella are driven by reversible motors embedded in the cytoplasmic membrane. Here we report that the energy source for the polar flagellar motor of Vibrio parahaemolyticus is the sodium-motive force, whereas the lateral flagellar motors are driven by the proton-motive force. This is evidence that two distinct types of flagella powered by different energy sources are functionally active in one cell.	NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN; THE AGOURON INST,LA JOLLA,CA 92037	Nagoya University								ALLEN RD, 1971, J BACTERIOL, V107, P295, DOI 10.1128/JB.107.1.295-302.1971; ATSUMI T, 1990, J BACTERIOL, V172, P1634, DOI 10.1128/jb.172.3.1634-1639.1990; CHERNYAK BV, 1983, FEBS LETT, V164, P38, DOI 10.1016/0014-5793(83)80014-3; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; MANSON MD, 1977, P NATL ACAD SCI USA, V74, P3060, DOI 10.1073/pnas.74.7.3060; MATSUURA S, 1977, FEBS LETT, V82, P187, DOI 10.1016/0014-5793(77)80581-4; MCCARTER L, 1988, CELL, V54, P345, DOI 10.1016/0092-8674(88)90197-3; MCCARTER L, 1990, MOL MICROBIOL, V4, P1057, DOI 10.1111/j.1365-2958.1990.tb00678.x; SUGIYAMA S, 1988, J BIOL CHEM, V263, P8215; TOKUDA H, 1988, J BIOCHEM-TOKYO, V103, P650, DOI 10.1093/oxfordjournals.jbchem.a122323; TOKUDA H, 1982, J BIOL CHEM, V257, P7; TSUCHIYA T, 1985, J BACTERIOL, V162, P794, DOI 10.1128/JB.162.2.794-798.1985; YOSHIDA S, 1990, J BIOL CHEM, V265, P20346	13	196	206	2	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					182	184		10.1038/355182a0	http://dx.doi.org/10.1038/355182a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1309599				2022-12-28	WOS:A1992GY62900065
J	FIORE, MC; JORENBY, DE; BAKER, TB; KENFORD, SL				FIORE, MC; JORENBY, DE; BAKER, TB; KENFORD, SL			TOBACCO DEPENDENCE AND THE NICOTINE PATCH - CLINICAL GUIDELINES FOR EFFECTIVE USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SMOKING-CESSATION; CIGARETTE-SMOKING; CHEWING-GUM; PHYSICIAN INTERVENTION; REPLACEMENT THERAPY; RANDOMIZED TRIAL; POLACRILEX GUM; QUIT SMOKING; WITHDRAWAL; ADVICE	Objective.-A comprehensive review of transdermal nicotine treatment for tobacco dependence, with recommendations derived from the research literature. Data Sources.-English-language clinical trials. Study Selection.-Clinical trials using placebo-controlled, double-blind methodology (11 studies) with at least 6 months of follow-up after treatment (eight studies) and biochemical verification of smoking status. Data Synthesis.-Nicotine patches produce end-of-treatment smoking cessation rates that range from 18% to 77%; these rates are about twice those of placebo-treated subjects. Nicotine patches produced 6-month abstinence rates of 22% to 42%, while placebo patches produced quit rates of 5% to 28%. Nicotine patches appear to reduce some, but not all, nicotine withdrawal symptoms. For instance, while the patch reduces craving for cigarettes and negative moods, it does not appear to reduce hunger or weight gain. The clinical trials literature suggests that proper adjuvant smoking cessation counseling is crucial in determining successful long-term outcome with the nicotine patch, and suggests that 6 to 8 weeks of patch therapy may be an adequate duration for most patients. Conclusions.-Nicotine patches are an effective aid to tobacco dependence treatment. However, success rates vary greatly across research studies and may be influenced highly by the nature and intensity of adjuvant smoking cessation counseling. More research is needed to identify optimal duration, dosage, and individualization of patch therapy. The impact of nicotine patches (more than 5 million users with $1 billion in sales for 1992) also raises important ethical and public health issues.			FIORE, MC (corresponding author), UNIV WISCONSIN,SCH MED,CTR TOBACCO RES & INTERVENT,ROOM 7275 MSC,1300 UNIV AVE,MADISON,WI 53706, USA.							ABELIN T, 1989, LANCET, V1, P7; ANDA RF, 1987, JAMA-J AM MED ASSOC, V257, P1916; BENOWITZ NL, 1987, CLIN PHARMACOL THER, V41, P467, DOI 10.1038/clpt.1987.58; BENOWITZ NL, 1991, CLIN PHARMACOL THER, V50, P286, DOI 10.1038/clpt.1991.138; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BENOWITZ NL, 1986, NEW ENGL J MED, V315, P1310, DOI 10.1056/NEJM198611203152102; BENOWITZ NL, 1991, JAMA-J AM MED ASSOC, V266, P3174, DOI 10.1001/jama.266.22.3174; BLUM A, 1992, TOBACCO CONTROL, V1, P11; BRANDON TH, 1990, ADDICT BEHAV, V15, P1; BUCHKREMER G, 1991, PHARMACOPSYCHIATRY, V24, P96, DOI 10.1055/s-2007-1014448; BURNS D, 1992, TOBACCO USE CALIFORN; COHEN SJ, 1987, AM J PUBLIC HEALTH, V77, P313, DOI 10.2105/AJPH.77.3.313; CUMMINGS SR, 1989, ANN INTERN MED, V110, P640, DOI 10.7326/0003-4819-110-8-640; CUMMINGS SR, 1988, JAMA-J AM MED ASSOC, V260, P1565, DOI 10.1001/jama.260.11.1565; DAUGHTON DM, 1991, ARCH INTERN MED, V151, P749, DOI 10.1001/archinte.151.4.749; DICLEMENTE CL, 1991, J CONSULT CLIN PSYCH, V592, P95; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P3149, DOI 10.1001/jama.266.22.3149; DUBOIS JP, 1989, METHOD FIND EXP CLIN, V11, P187; EICHELBERG D, 1989, METHOD FIND EXP CLIN, V11, P223; ELIXHAUSER A, 1990, Journal of Public Health Policy, V11, P218, DOI 10.2307/3342753; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; FAGERSTROM KO, 1990, GLOBAL WAR, P687; FIORE M, 1988, SMOKING HLTH 1987, P189; FIORE MC, 1991, JAMA-J AM MED ASSOC, V266, P3183, DOI 10.1001/jama.266.22.3183; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; FRANK E, 1991, JAMA-J AM MED ASSOC, V266, P3139, DOI 10.1001/jama.266.22.3139; GILPIN E, 1992, TOBACCO CONTROL, V0001; GLYNN TJ, 1990, PHYS NIH903064 US DE; GRITZ ER, 1991, BRIT J ADDICT, V86, P57; HAJEK P, 1988, JAMA-J AM MED ASSOC, V260, P1593, DOI 10.1001/jama.260.11.1593; HATZIANDREU EJ, 1990, J NATL CANCER I, V82, P1402, DOI 10.1093/jnci/82.17.1402; HENNINGFIELD JE, 1990, JAMA-J AM MED ASSOC, V264, P1560, DOI 10.1001/jama.264.12.1560; HENNINGFIELD JE, 1988, NICOTINE REPLACEMENT, P35; HOLAHAN CJ, 1990, J PERS SOC PSYCHOL, V58, P909, DOI 10.1037/0022-3514.58.5.909; HUBER GL, 1989, SEMIN RESPIR MED, V10, P297, DOI 10.1055/s-2007-1006184; HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289; HUGHES JR, 1991, ARCH GEN PSYCHIAT, V48, P52; HURT RD, 1992, MED CLIN N AM, V76, P495, DOI 10.1016/S0025-7125(16)30364-9; HURT RD, 1990, MAYO CLIN PROC, V65, P1529, DOI 10.1016/S0025-6196(12)62186-7; HWANG S, 1992, WALL STREET J   0522, P1; KNOTT VJ, 1977, PSYCHOPHYSIOLOGY, V14, P150, DOI 10.1111/j.1469-8986.1977.tb03367.x; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2883; LAM W, 1987, LANCET, V2, P27; LANDO HA, 1992, AM J PUBLIC HEALTH, V82, P41, DOI 10.2105/AJPH.82.1.41; MCNABB ME, 1982, JAMA-J AM MED ASSOC, V248, P865, DOI 10.1001/jama.248.7.865; MULLIGAN SC, 1990, CLIN PHARMACOL THER, V47, P331, DOI 10.1038/clpt.1990.36; OCKENE JK, 1987, PREV MED, V16, P723, DOI 10.1016/0091-7435(87)90054-5; ORLEANS CT, 1985, ANNU REV MED, V36, P51; ORLEANS CT, 1991, J CONSULT CLIN PSYCH, V59, P439, DOI 10.1037/0022-006X.59.3.439; PEDERSON LL, 1982, PREV MED, V11, P71, DOI 10.1016/0091-7435(82)90006-8; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; RENNARD S, 1991, CHEST, V100, pS5; ROSE JE, 1990, CLIN PHARMACOL THER, V47, P323, DOI 10.1038/clpt.1990.35; RUSSELL MAH, 1991, BRIT J ADDICT, V86, P653; RUSSELL MAH, 1978, DRUG METAB REV, V8, P29, DOI 10.3109/03602537808993776; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; Sachs D.P., 1989, CURR PULMONOL, V10, P141; SCHNEIDER NG, 1990, J AM DENT ASSOC S, pS7; SCHWARTZ JL, 1987, REV EVALUATION SMOKI; SCHWID SR, 1992, AM J CLIN NUTR, V55, P878, DOI 10.1093/ajcn/55.4.878; SHERIN K, 1982, POSTGRAD MED, V11, P71; TAYLOR P, 1990, P166; TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; TONNESEN P, 1988, NEW ENGL J MED, V318, P15, DOI 10.1056/NEJM198801073180104; WACK JT, 1982, AM J CLIN NUTR, V35, P366, DOI 10.1093/ajcn/35.2.366; WILSON DM, 1988, JAMA-J AM MED ASSOC, V260, P1570, DOI 10.1001/jama.260.11.1570; WISE RA, 1988, J ABNORM PSYCHOL, V97, P118, DOI 10.1037/0021-843X.97.2.118; ZELMAN DC, IN PRESS J CONSULT C; ZINSER MC, IN PRESS J ABNORM PS; 1992, PROSTEP NICOTINE TRA; 1992, HABITROL NICOTINE TR; 1992, NICOTROL NICOTINE TR; 1991, NICODERM NICOTINE TR; 1988, CDC888406 US DEP HLT; 1992, MED LETT DRUGS THER, V34, P37; 1990, CDC908416 US HLTH HU; 1991, JAMA-J AM MED ASSOC, V266, P3133; 1992, MMWR, V41, P354; 1991, ACCREDITATION MANUAL, V1; 1989, CDC898411 US DEP HLT	81	171	172	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2687	2694		10.1001/jama.268.19.2687	http://dx.doi.org/10.1001/jama.268.19.2687			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JX680	1304736				2022-12-28	WOS:A1992JX68000031
J	JOHNSON, E				JOHNSON, E			RECALL OF DRINKING PATTERNS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							GLADSJO JA, 1992, ADDICT BEHAV, V17, P347, DOI 10.1016/0306-4603(92)90040-3	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1518	1518						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1325568				2022-12-28	WOS:A1992JN25600005
J	FREMONT, DH; MATSUMURA, M; STURA, EA; PETERSON, PA; WILSON, IA				FREMONT, DH; MATSUMURA, M; STURA, EA; PETERSON, PA; WILSON, IA			CRYSTAL-STRUCTURES OF 2 VIRAL PEPTIDES IN COMPLEX WITH MURINE MHC CLASS-I H-2K(B)	SCIENCE			English	Article							ANTIGEN-BINDING SITE; T-CELL RECOGNITION; HISTOCOMPATIBILITY ANTIGEN; MOLECULES; RECEPTOR; RESOLUTION; ANTIBODY; HLA-B27; HLA-A2	The x-ray structures of a murine MHC class I molecule (H-2K(b)) were determined in complex with two different viral peptides, derived from the vesicular stomatitis virus nucleoprotein(52-59), VSV-8, and the Sendai virus nucleoprotein(324-332), SEV-9. The H-2K(b) complexes were refined at 2.3 angstrom for VSV-8 and 2.5 angstrom for SEV-9. The structure of H-2K(b) exhibits a high degree of similarity with human HLA class I, although the individual domains can have slightly altered dispositions. Both peptides bind in extended conformations with most of their surfaces buried in the H-2K(b) binding groove. The nonamer peptide maintains the same amino- and carboxyl-terminal interactions as the octamer primarily by the insertion of a bulge in the center of an otherwise beta-conformation. Most of the specific interactions are between side-chain atoms of H-2K(b) and main-chain atoms of peptide. This binding scheme accounts in large part for the enormous diversity of peptide sequences that bind with high affinity to class I molecules. Small but significant conformational changes in H-2K(b) are associated with peptide binding, and these synergistic movements may be an integral part of the T cell receptor recognition process.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego			Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118; Fremont, Daved/0000-0002-8544-2689	NCI NIH HHS [CA-97489, CA-09523] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUESTONE JA, UNPUB; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHEN Y, TUBES WERE GENERATED; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CONNOLLY ML, CALCULATE SOLVENT AC; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FILMAN D, PROGRAM HARADA; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREMONT DH, CALCULATE PSEUDO ROT; FREMONT DH, UNPUB; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HARADA Y, 1981, ACTA CRYSTALLOGR A, V37, P398, DOI 10.1107/S0567739481000867; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JACKSON MR, IN PRESS P NATL ACAD; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, IN PRESS CELL; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MATSUMURA M, IN PRESS J BIOL CHEM; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROGNAN D, 1992, PROTEINS, V13, P70, DOI 10.1002/prot.340130107; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHIBATA K, 1992, P NATL ACAD SCI USA, V89, P3135, DOI 10.1073/pnas.89.7.3135; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STURA EA, IN PRESS J MOL BIOL; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, J BIOL CHEM, V266, P3357; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VANBLEEK GM, 1990, NATURE, V348, P213; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; WILSON IA, 1991, METHOD ENZYMOL, V203, P153	59	892	925	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					919	927		10.1126/science.1323877	http://dx.doi.org/10.1126/science.1323877			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1323877				2022-12-28	WOS:A1992JH82700024
J	MCGEE, HM; HORGAN, JH				MCGEE, HM; HORGAN, JH			CARDIAC REHABILITATION PROGRAMS - ARE WOMEN LESS LIKELY TO ATTEND	BRITISH MEDICAL JOURNAL			English	Article							EXERCISE				MCGEE, HM (corresponding author), BEAUMONT HOSP,DEPT CARDIOL,POB 1297,DUBLIN 9,IRELAND.		McGee, Hannah M/D-6480-2012	McGee, Hannah M/0000-0003-1417-993X				OCALLAGHAN WG, 1984, EUR HEART J, V5, P649, DOI 10.1093/oxfordjournals.eurheartj.a061721; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE MB, 1980, AM HEART J, V338, P1366; OLDRIDGE NB, 1978, CAN MED ASSOC J, V118, P361; 1991, LANCET, V338, P1366	5	52	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					283	284		10.1136/bmj.305.6848.283-a	http://dx.doi.org/10.1136/bmj.305.6848.283-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1285764	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JG74000018
J	DOEBBELING, BN; STANLEY, GL; SHEETZ, CT; PFALLER, MA; HOUSTON, AK; ANNIS, L; LI, N; WENZEL, RP				DOEBBELING, BN; STANLEY, GL; SHEETZ, CT; PFALLER, MA; HOUSTON, AK; ANNIS, L; LI, N; WENZEL, RP			COMPARATIVE EFFICACY OF ALTERNATIVE HAND-WASHING AGENTS IN REDUCING NOSOCOMIAL INFECTIONS IN INTENSIVE-CARE UNITS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL-ACQUIRED INFECTIONS; ATTRIBUTABLE MORTALITY; CLINICAL-TRIALS; RISK-FACTORS; TRANSMISSION; DISINFECTION; DURATION	Background. Effective hand-washing can prevent nosocomial infections, particularly in high-risk areas of the hospital. There are few clinical studies of the efficacy of specific hand-cleansing agents in preventing the transmission of pathogens from health care workers to patients. Methods. For eight months, we conducted a prospective multiple-crossover trial involving 1894 adult patients in three intensive care units (ICUs). In a given month, the ICU used a hand-washing system involving either chlorhexidine, a broad-spectrum antimicrobial agent, or 60 percent isopropyl alcohol with the optional use of a nonmedicated soap; in alternate months the other system was used. Rates of nosocomial infection and hand-washing compliance were monitored prospectively. Results. When chlorhexidine was used, there were 152 nosocomial infections, as compared with 202 when the combination of alcohol and soap was used (adjusted incidence-density ratio [IDR], 0.73; 95 percent confidence interval, 0.59 to 0.90). The largest reduction with chlorhexidine was in gastrointestinal infections (IDR, 0.19; 95 percent confidence interval, 0.05 to 0.64). When chlorhexidine was available, the rates of nosocomial infection declined in each of the ICUs, and health care workers washed their hands more often than when alcohol and soap were used (relative risk, 1.28; 95 percent confidence interval, 1.02 to 1.60). The total volume of alcohol and soap used was 46 percent that of chlorhexidine (P<0.001). Conclusions. A hand-disinfection system using an antimicrobial agent (chlorhexidine) reduces the rate of nosocomial infections more effectively than one using alcohol and soap. The improvement may be explained at least in part by better compliance with hand-washing instructions when chlorhexidine was used.	UNIV IOWA, COLL MED,DEPT INTERNAL MED, DIV GEN MED CLIN EPIDEMIOL & HLTH SERV RES,C41,GH, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PATHOL, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PREVENT MED & ENVIRONM HLTH, IOWA CITY, IA 52242 USA; UNIV IOWA HOSP & CLIN, PROGRAM EPIDEMIOL, IOWA CITY, IA 52242 USA; VET AFFAIRS MED CTR, IOWA CITY, IA USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System			Doebbeling, Bradley/C-6620-2009; Doebbeling, Bradley/L-9155-2019; Doebbeling, Bradley/AAC-1063-2022	Doebbeling, Bradley/0000-0003-3504-3468				ALBERT RK, 1981, NEW ENGL J MED, V304, P1465, DOI 10.1056/NEJM198106113042404; AYLIFFE GAJ, 1988, J HOSP INFECT, V11, P226, DOI 10.1016/0195-6701(88)90101-6; BAUER TM, 1990, J HOSP INFECT, V15, P301, DOI 10.1016/0195-6701(90)90087-5; BLACK RE, 1981, AM J EPIDEMIOL, V113, P445, DOI 10.1093/oxfordjournals.aje.a113112; BRODERICK A, 1990, AM J EPIDEMIOL, V131, P734, DOI 10.1093/oxfordjournals.aje.a115558; CASEWELL M, 1977, BRIT MED J, V2, P1315, DOI 10.1136/bmj.2.6098.1315; DASCHNER FD, 1988, J HOSP INFECT, V11, P227, DOI 10.1016/0195-6701(88)90192-2; DOEBBELING BN, 1990, J THORAC CARDIOV SUR, V99, P981; FRAPPIER-DAVIGNON L, 1959, Can Med Assoc J, V81, P531; FREEMAN J, 1978, J INFECT DIS, V138, P811, DOI 10.1093/infdis/138.6.811; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GOLDMANN DA, 1983, J INFECT DIS, V147, P635, DOI 10.1093/infdis/147.4.635; GRAHAM M, 1990, AM J INFECT CONTROL, V18, P77, DOI 10.1016/0196-6553(90)90085-7; HOOTON TM, 1981, AM J MED, V70, P960, DOI 10.1016/0002-9343(81)90562-3; Horan T., 1988, Antimicrobic Newsletter, V5, P65, DOI 10.1016/0738-1751(88)90027-5; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P285; LAFORCE FM, 1981, AM J MED, V70, P664, DOI 10.1016/0002-9343(81)90593-3; LARSON E, 1988, INFECT CONT HOSP EP, V9, P28, DOI 10.1086/645729; LARSON E, 1990, INFECT CONT HOSP EP, V11, P63; LARSON E, 1988, AM J INFECT CONTROL, V16, P253, DOI 10.1016/S0196-6553(88)80005-1; LARSON EL, 1986, ANTIMICROB AGENTS CH, V30, P542, DOI 10.1128/AAC.30.4.542; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MAKI D, 1982, 22ND INT C ANT AG CH, P188; MASSANARI RM, 1984, AM J INFECT CONTROL, V12, P247; MAYER JA, 1986, INFECT CONT HOSP EP, V7, P259, DOI 10.1017/S0195941700064171; MORRISON AJ, 1984, INFECT CONTROL, V7, P268; MORTIMER EA, 1966, BMJ-BRIT MED J, V1, P319, DOI 10.1136/bmj.1.5483.319; OJAJARVI J, 1980, J HYG-CAMBRIDGE, V85, P193, DOI 10.1017/S0022172400063221; OJAJARVI J, 1981, J HYG-CAMBRIDGE, V86, P275, DOI 10.1017/S0022172400069023; PLATT R, 1983, LANCET, V1, P893; QURAISHI ZA, 1984, AM J INFECT CONTROL, V12, P83, DOI 10.1016/0196-6553(84)90021-X; ROTTER ML, 1984, INFECT CONT HOSP EP, V5, P18, DOI 10.1017/S0195941700058744; Semmelweis I., 1983, ETIOLOGY CONCEPT PRO; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; SLAUGHTER FG, 1950, IMMORTAL MAGYAR SEMM, P3; STAMM WE, 1978, ANN INTERN MED, V89, P764, DOI 10.7326/0003-4819-89-5-764; STEERE AC, 1975, ANN INTERN MED, V83, P683, DOI 10.7326/0003-4819-83-5-683; SULLIVAN KM, 1988, DEPID; WENZEL RP, 1976, AM J EPIDEMIOL, V104, P645, DOI 10.1093/oxfordjournals.aje.a112343; WENZEL RP, 1988, INT J EPIDEMIOL, V17, P225, DOI 10.1093/ije/17.1.225; WENZEL RP, 1983, INFECT CONT HOSP EP, V4, P371, DOI 10.1017/S0195941700059774; WENZEL RP, 1981, REV INFECT DIS, V3, P701; WENZEL RP, 1985, AM J MED, V78, P3, DOI 10.1016/0002-9343(85)90356-0; WEY SB, 1988, ARCH INTERN MED, V148, P2642, DOI 10.1001/archinte.148.12.2642; YOUNG LS, 1981, AM J MED, V70, P398, DOI 10.1016/0002-9343(81)90779-8	45	340	347	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1992	327	2					88	93		10.1056/NEJM199207093270205	http://dx.doi.org/10.1056/NEJM199207093270205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC214	1285746	Bronze			2022-12-28	WOS:A1992JC21400005
J	VARSHAVSKY, A				VARSHAVSKY, A			THE N-END RULE	CELL			English	Review							SHORT-LIVED PROTEIN; DEPENDENT PROTEOLYTIC SYSTEM; UBIQUITIN-CONJUGATING ENZYME; REPAIR GENE RAD6; ESCHERICHIA-COLI; TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CELL-CYCLE; AMINO-ACID				VARSHAVSKY, A (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.							ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; BALZI E, 1990, J BIOL CHEM, V265, P7464; BANUETT F, 1986, J MOL BIOL, V187, P213, DOI 10.1016/0022-2836(86)90229-9; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BOND JS, 1987, MOL ASPECTS MED, V9, P173, DOI 10.1016/0098-2997(87)90021-5; BUSCH H, 1984, METHOD ENZYMOL, V106, P238; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1985, P NATL ACAD SCI USA, V82, P1341, DOI 10.1073/pnas.82.5.1341; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DEDUVE C, 1969, LYSOSOMES BIOLOGY PA, V1, P3; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DERBYSHIRE KM, 1990, P NATL ACAD SCI USA, V87, P4048, DOI 10.1073/pnas.87.11.4048; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; DUNTEN RL, 1991, J BIOL CHEM, V266, P3260; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FERBER S, 1987, NATURE, V326, P808, DOI 10.1038/326808a0; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P1; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GROSSMAN AD, 1987, GENE DEV, V1, P179, DOI 10.1101/gad.1.2.179; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HO YS, 1988, GENE DEV, V2, P184, DOI 10.1101/gad.2.2.184; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES EW, 1991, J BIOL CHEM, V266, P7963; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MADURA K, 1990, NUCLEIC ACIDS RES, V18, P771, DOI 10.1093/nar/18.4.771; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MEYER EM, 1986, J BIOL CHEM, V261, P4365; MIZUSAWA S, 1983, P NATL ACAD SCI-BIOL, V80, P358, DOI 10.1073/pnas.80.2.358; MURTI KG, 1988, P NATL ACAD SCI USA, V85, P3019, DOI 10.1073/pnas.85.9.3019; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Olson TS, 1989, CURR OPIN CELL BIOL, V1, P1194, DOI 10.1016/S0955-0674(89)80071-7; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; OTA IM, 1992, P NATL ACAD SCI USA, V89, P2355, DOI 10.1073/pnas.89.6.2355; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; Pringle J R, 1975, Methods Cell Biol, V12, P233; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REISS Y, 1988, J BIOL CHEM, V263, P2693; Rivett AJ, 1990, CURR OPIN CELL BIOL, V2, P1143, DOI 10.1016/0955-0674(90)90168-E; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHANKLIN J, 1989, BIOCHEMISTRY-US, V28, P6028, DOI 10.1021/bi00440a046; SHARON G, 1991, J BIOL CHEM, V266, P15890; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SIMPSON MV, 1953, J BIOL CHEM, V201, P143; SOFFER RL, 1980, TRANSFER RNA BIOL AS, P493; SOKOLIK CW, 1991, J BIOL CHEM, V266, P9100; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STRAUSS EG, 1988, VIROLOGY, V164, P265, DOI 10.1016/0042-6822(88)90644-7; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; VARSHAVSKY A, 1988, N END RULE PROTEIN T, P287; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILKINSON KD, 1980, J BIOL CHEM, V255, P7529; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	92	438	455	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					725	735		10.1016/0092-8674(92)90285-K	http://dx.doi.org/10.1016/0092-8674(92)90285-K			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1317266				2022-12-28	WOS:A1992HW83800004
J	THOMPSON, AM				THOMPSON, AM			THE OXIDIZING CAPACITY OF THE EARTHS ATMOSPHERE - PROBABLE PAST AND FUTURE CHANGES	SCIENCE			English	Article							ACID DEPOSITION MODEL; TROPOSPHERIC OZONE PRODUCTION; CLIMATE CHANGE; HYDROGEN-PEROXIDE; SULFUR-DIOXIDE; SURFACE OZONE; METHANE; CHEMISTRY; OXIDANTS; MECHANISMS	The principal oxidants in the lower atmosphere are ozone (O3) and two by-products of O3 photodissociation, the hydroxyl radical (OH) and hydrogen peroxide (H2O2). A number of critical atmospheric chemical problems depend on the earth's "oxidizing capacity," which is essentially the global burden of these oxidants. There is limited direct evidence for changes in the earth's oxidizing capacity since recent preindustrial times when, because of industrial and population growth, increasing amounts of O3 precursor trace gases (carbon monoxide, nitrogen oxides, and hydrocarbons) have been released into the atmosphere. The concentrations of O3 and possibly H2O2 have increased over large regions. Models predict that tropospheric O3 will increase approximately 0.3 to 1% per year over the next 50 years with both positive and negative trends possible for OH and H2O2. Models and the observational network for oxidants are improving, but validation of global models is still at an early stage.			THOMPSON, AM (corresponding author), NASA, GODDARD SPACE FLIGHT CTR, ATMOSPHERES LAB, GREENBELT, MD 20771 USA.		Thompson, Anne M/C-3649-2014; Thompson, Anne Mee/V-5862-2019	Thompson, Anne M/0000-0002-7829-0920; Thompson, Anne Mee/0000-0002-7829-0920				ATHERTON CS, 1990, J GEOPHYS RES-ATMOS, V95, P14027, DOI 10.1029/JD095iD09p14027; ATKINSON R, 1989, MONOGRAPH AM I PHYSI, V1; BECK JP, 1992, ATMOS ENVIRON A-GEN, V26, P17, DOI 10.1016/0960-1686(92)90257-L; BLAKE DR, 1986, J ATMOS CHEM, V4, P43, DOI 10.1007/BF00053772; BOJKOV RD, 1986, J CLIM APPL METEOROL, V25, P343, DOI 10.1175/1520-0450(1986)025<0343:SODTSH>2.0.CO;2; BRUHL C, 1989, GEOPHYS RES LETT, V16, P703, DOI 10.1029/GL016i007p00703; BRUHL C, 1991, JUN UN ENV PROGR WOR; Bruhl C., 1988, CLIM DYNAM, V2, P173, DOI 10.1007/BF01053474; BRUNE WH, 1992, SCIENCE, V256, P1154, DOI 10.1126/science.256.5060.1154; BUTLER JH, 1991, J GEOPHYS RES-ATMOS, V96, P22347, DOI 10.1029/91JD02126; CHAMEIDES WL, 1982, J GEOPHYS RES-OCEANS, V87, P4863, DOI 10.1029/JC087iC07p04863; CHAMEIDES WL, 1977, J GEOPHYS RES-OC ATM, V82, P1795, DOI 10.1029/JC082i012p01795; CHANG JS, 1987, J GEOPHYS RES-ATMOS, V92, P14681, DOI 10.1029/JD092iD12p14681; CHATFIELD RB, 1984, J GEOPHYS RES-ATMOS, V89, P7111, DOI 10.1029/JD089iD05p07111; CRAIG H, 1982, GEOPHYS RES LETT, V9, P1221, DOI 10.1029/GL009i011p01221; CRUTZEN P, 1973, PURE APPL GEOPHYS, V106, P1385, DOI 10.1007/BF00881092; CRUTZEN PJ, 1979, NATURE, V282, P253, DOI 10.1038/282253a0; CRUTZEN PJ, 1983, J GEOPHYS RES-OCEANS, V88, P6641, DOI 10.1029/JC088iC11p06641; CRUTZEN PJ, 1991, TELLUS A, V43, P136, DOI 10.1034/j.1600-0870.1991.00012.x; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; CUNNOID DM, 1992, J GEOPHYS RES, V96, P17392; DEMORE WB, 1990, NASA JPL PUBL, V901; DERWENT RG, 1982, ATMOS ENVIRON, V16, P1997, DOI 10.1016/0004-6981(82)90470-X; DICKERSON RR, 1987, SCIENCE, V235, P460, DOI 10.1126/science.235.4787.460; DODGE MC, 1989, J GEOPHYS RES-ATMOS, V94, P5121, DOI 10.1029/JD094iD04p05121; DORN H-P, 1988, Tellus Series B Chemical and Physical Meteorology, V40, P437; EHHALT DH, 1988, CHANGING ATMOSPHERE, P25; Finlayson-Pitts B.J., 1986, ATMOSPHERIC CHEM FUN; FISHMAN J, 1990, J GEOPHYS RES-ATMOS, V95, P3599, DOI 10.1029/JD095iD04p03599; FISHMAN J, 1991, SCIENCE, V252, P1693, DOI 10.1126/science.252.5013.1693; FISHMAN J, COMMUNICATION; GERY MW, 1989, J GEOPHYS RES-ATMOS, V94, P12925, DOI 10.1029/JD094iD10p12925; GERY MW, 1991, ENV EFFECTS OZONE DE; GERY MW, 1986, J GEOPHYS RES, V91, P10905; Graedel T. E., 1978, CHEM COMPOUNDS ATMOS; GRAEDEL TE, 1981, REV GEOPHYS, V19, P505, DOI 10.1029/RG019i004p00505; GUNZ DW, 1990, ATMOS ENVIRON A-GEN, V24, P1601, DOI 10.1016/0960-1686(90)90496-A; Guthrie PD, 1989, GLOBAL BIOGEOCHEM CY, V3, P287, DOI 10.1029/GB003i004p00287; HAMEED S, 1979, J GEOPHYS RES-OCEANS, V84, P763, DOI 10.1029/JC084iC02p00763; HOFZUMAHAUS A, 1991, ATMOS ENVIRON A-GEN, V25, P2017, DOI 10.1016/0960-1686(91)90281-B; HOGAN KB, 1991, NATURE, V354, P181, DOI 10.1038/354181a0; HOUGH AM, 1990, NATURE, V344, P645, DOI 10.1038/344645a0; HOUGH AM, 1988, J GEOPHYS RES-ATMOS, V93, P3789, DOI 10.1029/JD093iD04p03789; ISAKSEN I S A, 1987, Tellus Series B Chemical and Physical Meteorology, V39, P271, DOI 10.1111/j.1600-0889.1987.tb00099.x; Isaksen I. S. A., 1988, CHANGING ATMOSPHERE, P141; ISAKSEN ISA, 1992, SCI ASSESSMENT OZONE, pCH5; ISAKSEN ISA, 1989, OZONE ATMOSPHERE, P576; Jackman C., 1989, NASA C PUBLICATION, V3042; JOHNSON C, 1992, NATURE, V355, P69, DOI 10.1038/355069a0; KANAKIDOU M, 1991, J GEOPHYS RES-ATMOS, V96, P15395, DOI 10.1029/91JD01345; KANAKIDOU M, IN PRESS CHEMOSPHERE; KHALIL MAK, 1985, ATMOS ENVIRON, V19, P397, DOI 10.1016/0004-6981(85)90161-1; KLEY D, 1989, GLOBAL REGIONAL ENV, P9; LACIS AA, 1990, J GEOPHYS RES-ATMOS, V95, P9971, DOI 10.1029/JD095iD07p09971; LASHOF DA, 1990, USEPA21P20031 REP; LAW KS, 1991, ATMOS ENVIRON A-GEN, V25, P1863, DOI 10.1016/0960-1686(91)90269-D; LEIFER IS, 1991, EOS, V72, P99; LELIEVELD J, 1990, NATURE, V343, P227, DOI 10.1038/343227a0; LEONE JA, 1985, ATMOS ENVIRON, V19, P437, DOI 10.1016/0004-6981(85)90166-0; LEVINE JS, 1985, NATURE, V318, P254, DOI 10.1038/318254a0; LEVY H, 1972, PLANET SPACE SCI, V20, P919, DOI 10.1016/0032-0633(72)90177-8; LIN X, 1988, J GEOPHYS RES-ATMOS, V93, P15879, DOI 10.1029/JD093iD12p15879; LIU SC, 1988, J ATMOS CHEM, V6, P221, DOI 10.1007/BF00053857; LIU SC, 1980, J GEOPHYS RES-OCEANS, V85, P7546, DOI 10.1029/JC085iC12p07546; LIU SC, 1987, J GEOPHYS RES-ATMOS, V92, P4191, DOI 10.1029/JD092iD04p04191; LOGAN JA, 1985, J GEOPHYS RES-ATMOS, V90, P10463, DOI 10.1029/JD090iD06p10463; LOGAN JA, 1988, TROPOSPHERIC OZONE, P327; LU Y, 1991, CHEMOSPHERE, V23, P397, DOI 10.1016/0045-6535(91)90194-I; Lu Y.R., UNPUB; LUBIN D, 1989, J GEOPHYS RES-ATMOS, V94, P8491, DOI 10.1029/JD094iD06p08491; MADRONICH S, 1987, J GEOPHYS RES-ATMOS, V92, P9740, DOI 10.1029/JD092iD08p09740; MADRONICH S, 1992, GEOPHYS RES LETT, V19, P465, DOI 10.1029/92GL00378; MADRONICH S, 1992, GEOPHYS RES LETT, V19, P37, DOI 10.1029/91GL02954; MCELROY MB, 1989, PHYS CH EAR, V8, P363; MOUNT GH, 1992, J GEOPHYS RES-ATMOS, V97, P2427, DOI 10.1029/91JD02971; MOUNT GH, 1992, SCIENCE, V256, P1187, DOI 10.1126/science.256.5060.1187; NEFTEL A, 1984, NATURE, V311, P43, DOI 10.1038/311043a0; OLTMANS SJ, 1986, J GEOPHYS RES-ATMOS, V91, P5229, DOI 10.1029/JD091iD04p05229; PENKETT SA, 1979, ATMOS ENVIRON, V13, P123, DOI 10.1016/0004-6981(79)90251-8; PENKETT SA, 1986, NATURE, V319, P655, DOI 10.1038/319655a0; PICKERING KE, 1990, J GEOPHYS RES-ATMOS, V95, P14049, DOI 10.1029/JD095iD09p14049; PINTO JP, 1991, TELLUS B, V43, P347, DOI 10.1034/j.1600-0889.1991.t01-2-00001.x; PRATHER M, 1990, J GEOPHYS RES-ATMOS, V95, P18723, DOI 10.1029/JD095iD11p18723; PRATHER MJ, 1989, NASA C PUBL, V3023; PRINN R, 1987, SCIENCE, V238, P945, DOI 10.1126/science.238.4829.945; PRINN R, 1992, J GEOPHYS RES-ATMOS, V97, P2445, DOI 10.1029/91JD02755; RASMUSSEN RA, 1981, J GEOPHYS RES-OCEANS, V86, P9826, DOI 10.1029/JC086iC10p09826; RASMUSSEN RA, 1984, J GEOPHYS RES-ATMOS, V89, P1599, DOI 10.1029/JD089iD07p11599; RAYNAUD D, 1988, NATURE, V333, P655, DOI 10.1038/333655a0; RIND D, 1990, J ATMOS SCI, V47, P475, DOI 10.1175/1520-0469(1990)047<0475:CCATMA>2.0.CO;2; SANDRONI S, 1992, J GEOPHYS RES-ATMOS, V97, P2535, DOI 10.1029/91JD02660; SCHNELL RC, 1991, NATURE, V351, P726, DOI 10.1038/351726a0; SIGG A, 1991, NATURE, V351, P557, DOI 10.1038/351557a0; SIGG A, 1992, J ATMOS CHEM, V14, P223, DOI 10.1007/BF00115235; Sigg A., 1988, ANN GLACIOL, V10, P157; SOLBERG S, 1989, OZONE ATMOSPHERE, P548; SPIVAKOVSKY CM, 1991, J GEOPHYS RES-ATMOS, V96, P17395, DOI 10.1029/91JD01669; STAUFFER B, 1985, SCIENCE, V229, P1386, DOI 10.1126/science.229.4720.1386; STAUFFER B, 1988, NATURE, V332, P812, DOI 10.1038/332812a0; STOCKWELL WR, 1986, ATMOS ENVIRON, V20, P1615, DOI 10.1016/0004-6981(86)90251-9; STOCKWELL WR, 1990, J GEOPHYS RES-ATMOS, V95, P16343, DOI 10.1029/JD095iD10p16343; STOLARSKI RS, 1991, GEOPHYS RES LETT, V18, P1015, DOI 10.1029/91GL01302; SZE N D, 1977, Science (Washington D C), V195, P673, DOI 10.1126/science.195.4279.673; Thompson AD, UNPUB; THOMPSON AM, 1986, J GEOPHYS RES-ATMOS, V91, P853, DOI 10.1029/JD091iD10p10853; THOMPSON AM, 1990, J GEOPHYS RES-ATMOS, V95, P9829, DOI 10.1029/JD095iD07p09829; THOMPSON AM, 1989, ATMOS ENVIRON, V23, P519, DOI 10.1016/0004-6981(89)90001-2; THOMPSON AM, 1991, ATMOS ENVIRON A-GEN, V25, P1837, DOI 10.1016/0960-1686(91)90267-B; THOMPSON AM, 1991, J GEOPHYS RES-ATMOS, V96, P13089, DOI 10.1029/91JD01056; THOMPSON AM, 1984, J GEOPHYS RES-ATMOS, V89, P1341, DOI 10.1029/JD089iD01p01341; THOMPSON AM, 1991, NATURE, V352, P282, DOI 10.1038/352282a0; THOMPSON AM, IN PRESS ATMOS ENV; VALENTIN KM, 1990, THESIS JOHANNESGUTEN; VOLZ A, 1988, NATURE, V332, P240, DOI 10.1038/332240a0; WANG WC, 1980, J ATMOS SCI, V37, P333, DOI 10.1175/1520-0469(1980)037<0333:CEDTHC>2.0.CO;2; WATSON RT, 1990, CLIMATE CHANGE IPCC, pCH1; WUEBBLES DJ, 1989, JAPCA J AIR WASTE MA, V39, P22, DOI 10.1080/08940630.1989.10466502; WUEBBLES DJ, 1989, 1988 SENS URB REG CH; WUEBBLES DJ, 1987, UCRL21178 LAWR LIV N; ZIMMERMANN PH, 1988, AIR POLLUTION MODELI, V6, P593; 1990, NOAACMDL18 SUMM REP, P40	121	612	643	14	216	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1992	256	5060					1157	1165		10.1126/science.256.5060.1157	http://dx.doi.org/10.1126/science.256.5060.1157			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1317061				2022-12-28	WOS:A1992HV19200024
J	SURETTE, MG; CHACONAS, G				SURETTE, MG; CHACONAS, G			THE MU-TRANSPOSITIONAL ENHANCER CAN FUNCTION IN TRANS - REQUIREMENT OF THE ENHANCER FOR SYNAPSIS BUT NOT STRAND CLEAVAGE	CELL			English	Article							INTEGRATION HOST FACTOR; SITE-SPECIFIC RECOMBINATION; BACTERIOPHAGE-MU; INVITRO TRANSPOSITION; MICROSCOPIC ANALYSIS; PHAGE-MU; DNA; PROTEIN; MECHANISM; TRANSPOSOSOMES	The phage Mu transpositional enhancer has been previously shown to stimulate the initial rate of the Mu DNA strand transfer reaction by a factor of 100. We now show that the Mu enhancer can function in trans on an unlinked DNA molecule. This activity is greatly facilitated by the presence of a free DNA end proximal to the enhancer element. Function of the enhancer in trans does not alter either the requirement for donor DNA supercoiling or for the two Mu ends to be in their proper orientation on the donor plasmid. An important consequence of these findings is that we have been able to evaluate directly the step in the transposition reaction for which the enhancer is required. We show that the role of the enhancer is limited to promoting productive synapsis; efficient strand cleavage can occur in the absence of the enhancer.			SURETTE, MG (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.							ARTHUR A, 1979, MOL GEN GENET, V175, P267, DOI 10.1007/BF00397226; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BOOCOCK MR, 1985, BIOCHEM SOC T, V14, P214; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; GELLERT M, 1987, NATURE, V325, P401, DOI 10.1038/325401a0; GLASGOW AC, 1989, MOBILE DNA, P637; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HAFFTER P, 1988, EMBO J, V7, P3991, DOI 10.1002/j.1460-2075.1988.tb03287.x; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; JOHNSON RC, 1987, NATURE, V329, P462, DOI 10.1038/329462a0; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Pato ML, 1989, MOBILE DNA, P23; Sambrook J, 1989, MOL CLONING LABORATO; SCHUMM JW, 1981, VIROLOGY, V114, P429, DOI 10.1016/0042-6822(81)90224-5; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; Sherratt D. J., 1987, DNA REPLICATION RECO, P703; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; SURETTE MG, 1990, THESIS U W ONTARIO L	37	65	65	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1101	1108		10.1016/0092-8674(92)90081-M	http://dx.doi.org/10.1016/0092-8674(92)90081-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1312394				2022-12-28	WOS:A1992HK67400013
J	MOERTEL, CG; LEFKOPOULO, M; LIPSITZ, S; HAHN, RG; KLAASSEN, D				MOERTEL, CG; LEFKOPOULO, M; LIPSITZ, S; HAHN, RG; KLAASSEN, D			STREPTOZOCIN DOXORUBICIN, STREPTOZOCIN FLUOROURACIL, OR CHLOROZOTOCIN IN THE TREATMENT OF ADVANCED ISLET-CELL CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-I; THERAPY; TABLES	Background. The combination of streptozocin and fluorouracil has become the standard therapy for advanced islet-cell carcinoma. However, doxorubicin has also been shown to be active against this type of tumor, as has chlorozotocin, a drug that is structurally similar to streptozocin but less frequently causes vomiting. Methods. In this multicenter trial, we randomly assigned 105 patients with advanced islet-cell carcinoma to receive one of three treatment regimens: streptozocin plus fluorouracil, streptozocin plus doxorubicin, or chlorozotocin alone. The 31 patients in whom the disease did not respond to treatment were crossed over to chlorozotocin alone or to one of the combination regimens. Results. Streptozocin plus doxorubicin was superior to streptozocin plus fluorouracil in terms of the rate of tumor regression, measured objectively (69 percent vs. 45 percent, P = 0.05), and the length of time to tumor progression (median, 20 vs. 6.9 months; P = 0.001). Streptozocin plus doxorubicin also had a significant advantage in terms of survival (median, 2.2 vs. 1.4 years; P = 0.004) that was accentuated when we considered long-term survival (> 2 years). Chlorozotocin alone produced a 30 percent regression rate, with the length of time to tumor progression and the survival time equivalent to those observed with streptozocin plus fluorouracil. Crossover therapy after the failure of either chlorozotocin alone or one of the combination regimens produced an overall response rate of only 17 percent, and the responses were transient. Toxic reactions to all regimens included vomiting, which was least severe with chlorozotocin; hematologic depression; and, with long-term therapy, renal insufficiency. Conclusions. The combination of streptozocin and doxorubicin is superior to the current standard regimen of streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. Chlorozotocin alone is similar in efficacy to streptozocin plus fluorouracil, but it produces fewer gastrointestinal side effects than the regimens containing streptozocin. It therefore merits study as a constituent of combination drug regimens.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; CANC CONTROL AGCY,VANCOUVER V5Z 3J3,BC,CANADA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	MOERTEL, CG (corresponding author), MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905, USA.				NATIONAL CANCER INSTITUTE [U10CA023318, U10CA013650] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13650, CA 15947, CA 23318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRESTI A, 1977, PSYCHOMETRIKA, V44, P75; BRODER LE, 1973, ANN INTERN MED, V79, P108, DOI 10.7326/0003-4819-79-1-108; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1970, ANAL BINARY DATA; ERICKSON B, 1986, LANCET, V2, P1307; HOTH D, 1978, CLIN PHARMACOL THER, V23, P712; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KESSINGER A, 1983, CANCER, V51, P790, DOI 10.1002/1097-0142(19830301)51:5<790::AID-CNCR2820510507>3.0.CO;2-3; KOVACH JS, 1979, CANCER, V43, P2189, DOI 10.1002/1097-0142(197906)43:6<2189::AID-CNCR2820430605>3.0.CO;2-#; MANTEL N, 1959, J NATL CANCER I, V22, P719; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; MOERTEL CG, 1982, CANCER TREAT REP, V66, P1567; MOERTEL CG, 1980, NEW ENGL J MED, V303, P1189, DOI 10.1056/NEJM198011203032101; MOERTEL CG, 1987, J CLIN ONCOL, V10, P1502	15	672	680	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					519	523		10.1056/NEJM199202203260804	http://dx.doi.org/10.1056/NEJM199202203260804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD658	1310159				2022-12-28	WOS:A1992HD65800004
J	GOODWIN, FK				GOODWIN, FK			HICKORY DICKORY DOCK - WHOS INHERITED MOUSIES CLOCK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					480	480		10.1001/jama.267.4.480	http://dx.doi.org/10.1001/jama.267.4.480			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1309583				2022-12-28	WOS:A1992GZ43900005
J	LEVERETTE, RD; ANDREWS, MT; MAXWELL, ES				LEVERETTE, RD; ANDREWS, MT; MAXWELL, ES			MOUSE U14 SNRNA IS A PROCESSED INTRON OF THE COGNATE HSC70 HEAT-SHOCK PREMESSENGER RNA	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; PROTEIN; GENE; NUCLEAR; CELLS; U3; EXPRESSION; SEQUENCE	U14 snRNA is a small nucleolar RNA species essential for eukaryotic pre-rRNA processing. We have previously shown that the mouse U14 snRNA genes are positioned within introns 5, 6, and 8 on the coding strand of the constitutively expressed cognate hsc70 heat shock gene. This genomic organization suggested the possibility that U14 snRNAs are transcribed as part of the hsc70 pre-mRNA and then excised from the intron to yield mature U14 snRNA species. To test this hypothesis directly, we have microinjected Xenopus oocytes with hsc70 pre-mRNA transcripts possessing intron 5 and the encoded U14 snRNA sequence. Processing results demonstrate that, in addition to the splicing of upstream and downstream exons, a mature 87 nt U14 snRNA is excised from the intron. Accurate excision of U14 snRNA from hsc70 intron 5 can occur in the absence of splicing. These results demonstrate a biosynthetic pathway for an snRNA species and provide a novel example of a eukaryotic pre-mRNA intron that is processed to produce a stable, biologically functional RNA species.	N CAROLINA STATE UNIV,DEPT GENET,RALEIGH,NC 27695	University of North Carolina; North Carolina State University	LEVERETTE, RD (corresponding author), N CAROLINA STATE UNIV,DEPT BIOCHEM,RALEIGH,NC 27695, USA.				NICHD NIH HHS [HD-24673] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD024673] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; JARMOLOWSKI A, 1990, EMBO J, V9, P4503, DOI 10.1002/j.1460-2075.1990.tb07901.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIU J, 1990, NUCLEIC ACIDS RES, V18, P6565, DOI 10.1093/nar/18.22.6565; MAXWELL ES, 1986, P NATL ACAD SCI USA, V83, P7261, DOI 10.1073/pnas.83.19.7261; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; Sambrook J, 1989, MOL CLONING LABORATO; SHANAB GM, 1991, NUCLEIC ACIDS RES, V19, P4891, DOI 10.1093/nar/19.18.4891; SHANAB GM, 1992, EUR J BIOCHEM, V206, P391, DOI 10.1111/j.1432-1033.1992.tb16939.x; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; TRINHROHLIK Q, 1988, NUCLEIC ACIDS RES, V16, P521; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; ZAGORSKI J, 1988, MOL CELL BIOL, V8, P3282, DOI 10.1128/MCB.8.8.3282	25	94	96	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1215	1221		10.1016/S0092-8674(05)80069-8	http://dx.doi.org/10.1016/S0092-8674(05)80069-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1282084				2022-12-28	WOS:A1992KE60400015
J	TAYTON, K				TAYTON, K			AN UNUSUAL CASE OF NEUROPATHIC ULCERATION	BRITISH MEDICAL JOURNAL			English	Article											TAYTON, K (corresponding author), ROYAL GWENT HOSP,NEWPORT NP9 2UB,GWENT,WALES.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1577	1577		10.1136/bmj.305.6868.1577	http://dx.doi.org/10.1136/bmj.305.6868.1577			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286397	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KD77100034
J	RUDENSKY, AY; PRESTONHURLBURT, P; ALRAMADI, BK; ROTHBARD, J; JANEWAY, CA				RUDENSKY, AY; PRESTONHURLBURT, P; ALRAMADI, BK; ROTHBARD, J; JANEWAY, CA			TRUNCATION VARIANTS OF PEPTIDES ISOLATED FROM MHC CLASS-II MOLECULES SUGGEST SEQUENCE MOTIFS	NATURE			English	Article							B-CELL INTERACTION; IA MOLECULE; IDENTIFICATION; ANTIGEN; SELF; IMMUNOGLOBULIN; PROTEIN; RECOGNITION; EPITOPE; CLONES	T CELLS recognize foreign protein antigens in the form of peptide fragments bound tightly to the outer aspect of molecules encoded by the major histocompatibility complex (MHC). Most of the amino-acid differences that distinguish MHC allelic variants line the peptide-binding cleft, and different allelic forms of MHC molecules bind distinct peptides1,2. It has been demonstrated that peptide-binding to MHC class I involves anchor residues in certain positions and that antigenic peptides associated with MHC class I exhibit allele-specific structural motifs3. We have previously reported an analysis of MHC class II-associated peptide sequences4. Here we extend this analysis and show that certain amino-acid residues occur at particular positions in the sequence of peptides binding to a given MHC class II molecule. These sequence motifs require the amino terminus to be shifted one or two positions to obtain alignment; such shifts occur naturally for a single peptide sequence without qualitatively altering CD4 T-cell recognition.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University	RUDENSKY, AY (corresponding author), IMMULOG PHARMACEUT CORP,PALO ALTO,CA 94304, USA.							BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CHEN JS, 1991, J IMMUNOL, V147, P3672; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINNEGAN A, 1986, J EXP MED, V164, P897, DOI 10.1084/jem.164.3.897; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HEBERKATZ E, 1983, J MOL CELL IMMUNOL, V1, P3; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KABAT EA, 1991, NIH913242 US DEP HLT; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; MARGULIES D H, 1992, Current Biology, V2, P211, DOI 10.1016/0960-9822(92)90542-I; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MURRAY JS, 1992, EUR J IMMUNOL, V22, P559, DOI 10.1002/eji.1830220239; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; R/tzschke O., 1990, NATURE, V348, P253; RATH S, IN PRESS EUR J IMMUN; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; RUDENSKY AY, 1989, EUR J IMMUNOL, V19, P1677, DOI 10.1002/eji.1830190923; SAKAI K, 1988, J NEUROIMMUNOL, V19, P21, DOI 10.1016/0165-5728(88)90032-X; SHASTRI N, 1986, J EXP MED, V164, P882, DOI 10.1084/jem.164.3.882; SHUMACHER TNM, 1991, NATURE, V350, P703; TUOHY VK, 1989, J IMMUNOL, V142, P1523; VANBLEEK GM, 1990, NATURE, V348, P213; WEISS S, 1989, P NATL ACAD SCI USA, V86, P282, DOI 10.1073/pnas.86.1.282; YURIN VL, 1989, EUR J IMMUNOL, V19, P1685, DOI 10.1002/eji.1830190924	29	247	255	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					429	431		10.1038/359429a0	http://dx.doi.org/10.1038/359429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1328884				2022-12-28	WOS:A1992JQ62400061
J	BROUN, ER; NICHOLS, CR; KNEEBONE, P; WILLIAMS, SD; LOEHRER, PJ; EINHORN, LH; TRICOT, GJK				BROUN, ER; NICHOLS, CR; KNEEBONE, P; WILLIAMS, SD; LOEHRER, PJ; EINHORN, LH; TRICOT, GJK			LONG-TERM OUTCOME OF PATIENTS WITH RELAPSED AND REFRACTORY GERM-CELL TUMORS TREATED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW RESCUE	ANNALS OF INTERNAL MEDICINE			English	Article						BONE MARROW TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; GERM CELL NEOPLASMS; CARBOPLATIN; ETOPOSIDE	PHASE-I; TRANSPLANTATION; CARBOPLATIN; VP-16-213; CANCER	Objective: To review the long-term outcome of patients with recurrent and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Design: Cohort study. Setting: A university hospital. Patients: Forty consecutive patients with recurrent or refractory germ cell tumors treated at Indiana University between September 1986 and June 1989. Interventions: Patients were treated with high-dose carboplatin (900 to 2000 mg/m2 body surface area) and etoposide (1200 mg/m2). Three patients also received ifosfamide (10g/m2). All patients had autologous bone marrow rescue. Of the 40 study patients, 26 received two full courses of therapy. Measurements: Patient charts were reviewed to determine the rate and duration of complete and partial remission and the number of long-term, disease-free survivors. The influence of cisplatin-refractory disease and the site of the primary tumor on the incidence of remission and survival were also investigated. Results: Of the 40 study patients, 26 (65%) responded to treatment; 12 (30%) achieved a complete response, and 14 (35%) achieved a partial response. Of the 12 complete responders, 5 relapsed, and 1 died of treatment-related acute leukemia 27.5 months after treatment without evidence of germ cell cancer. Six (15%) of the original 40 patients, of whom 3 were refractory to cisplatin, remained in complete remission after at least 24 months of follow-up. Eight of 40 patients had primary mediastinal germ cell tumors with no complete remissions and a median survival of 2 months (range, 0.5 to 9.0 months). Conclusions: Treatment with high-dose carboplatin and etoposide in conjunction with autologous bone marrow rescue in patients with relapsed or refractory germ cell tumors is a potentially curative therapeutic option, even for heavily pretreated or cisplatin-refractory patients. Some degree of disease resistance to cisplatin can be overcome with dose escalation of platinum compounds. Patients with multiple recurrences of relapsed or refractory primary mediastinal germ cell tumors were not helped by this approach.			BROUN, ER (corresponding author), INDIANA UNIV HOSP, 926 W MICHIGAN, ROOM 1730, INDIANAPOLIS, IN 46202 USA.		Nichols, Craig/ABE-1107-2020		NATIONAL CANCER INSTITUTE [R23CA038844] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 38844-07] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTAL M, 1991, J CLIN ONCOL, V9, P865, DOI 10.1200/JCO.1991.9.5.865; BAUME D, 1990, B CANCER, V77, P169; BROUN ER, 1991, CANCER, V68, P1513, DOI 10.1002/1097-0142(19911001)68:7<1513::AID-CNCR2820680708>3.0.CO;2-8; BROUN ER, 1991, BONE MARROW TRANSPL, V7, P53; DEPAUW BE, 1990, BONE MARROW TRANSPL, V5, P179; EINHORN LH, 1981, CANCER RES, V41, P3275; ENGLISH D, 1989, TRANSFUSION, V29, P12, DOI 10.1046/j.1537-2995.1989.29189101156.x; HAINSWORTH JD, 1983, AM J MED, V75, P817, DOI 10.1016/0002-9343(83)90413-8; HARTSTRICK A, 1991, J CLIN ONCOL, V9, P1549; HEIMDAHL A, 1989, ORAL SURG ORAL MED O, V68, P711, DOI 10.1016/0030-4220(89)90160-6; HORWITZ LJ, 1989, AUTOLOGOUS BONE MARR, P67; LINKESCH W, 1990, P AN M AM SOC CLIN, V9, P141; MOTZER RJ, 1990, CANCER, V66, P2476, DOI 10.1002/1097-0142(19901215)66:12<2476::AID-CNCR2820661206>3.0.CO;2-D; MULDER POM, 1988, EUR J CANCER CLIN ON, V24, P675, DOI 10.1016/0277-5379(88)90298-2; MUNSHI NC, 1990, P AN M AM SOC CLIN, V9, P134; NICHOLS CR, 1992, J CLIN ONCOL, V10, P558, DOI 10.1200/JCO.1992.10.4.558; NICHOLS CR, 1989, J CLIN ONCOL, V7, P932, DOI 10.1200/JCO.1989.7.7.932; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PIZZOCARO G, 1990, P ASCO, V9, P131; SHEA TC, 1989, J CLIN ONCOL, V7, P651, DOI 10.1200/JCO.1989.7.5.651; SPINOLO JA, 1990, CANCER, V66, P619, DOI 10.1002/1097-0142(19900815)66:4<619::AID-CNCR2820660403>3.0.CO;2-Z; VALTEAU D, 1990, Bone Marrow Transplantation, V5, P133; VILLABLANCA JG, 1990, BONE MARROW TRANSPL, V5, P387; WADE JC, 1982, ANN INTERN MED, V97, P503, DOI 10.7326/0003-4819-97-4-503; WOLFF SN, 1983, J CLIN ONCOL, V1, P701, DOI 10.1200/JCO.1983.1.11.701	25	146	147	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					124	128		10.7326/0003-4819-117-2-124	http://dx.doi.org/10.7326/0003-4819-117-2-124			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1318648				2022-12-28	WOS:A1992JD12300005
J	DAVIS, RL; WEINTRAUB, H				DAVIS, RL; WEINTRAUB, H			ACQUISITION OF MYOGENIC SPECIFICITY BY REPLACEMENT OF 3 AMINO-ACID-RESIDUES FROM MYOD INTO E12	SCIENCE			English	Article							DISTINCT TRANSCRIPTION FACTORS; ENHANCER MU-E5/KE2 MOTIF; DNA-BINDING DOMAIN; DROSOPHILA-MELANOGASTER; MYC HOMOLOGY; MUSCLE; FIBROBLASTS; EXPRESSION; MYOBLASTS; PROTEIN	The basic helix-loop-helix (bHLH) protein MyoD is a transcription factor that is important for the induction of the myogenic phenotype. The DNA binding basic region (13 amino acids) is necessary for recognition of the consensus MyoD binding site, for transcriptional activation, and for conversion of fibroblasts to muscle. In contrast, the non-tissue-specific bHLH protein E12 can bind to the MyoD binding site but does not induce myogenesis. Here, it is shown that only two amino acids in the MyoD basic region and a single amino acid from the junction, which separates the basic region and helix 1, are sufficient for myogenic specificity when substituted into the corresponding region of E12. These findings suggest that the recognition of particular determinants in the basic region is required for conversion of fibroblasts to muscle.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST LAB,SEATTLE,WA 98104	Fred Hutchinson Cancer Center								BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; GARCIABELLIDO A, 1979, GENETICS, V91, P491; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JOHNSON JP, IN PRESS P NATL ACAD; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MULLER HJ, 1955, BROOKHAVEN SYM BIOL, V8, P126; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242	31	135	135	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					1027	1030		10.1126/science.1317057	http://dx.doi.org/10.1126/science.1317057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1317057				2022-12-28	WOS:A1992HU22400041
J	BENTLEY, CR; DAVIES, G; ACLIMANDOS, WA				BENTLEY, CR; DAVIES, G; ACLIMANDOS, WA			LESSON OF THE WEEK - TAMOXIFEN RETINOPATHY - A RARE BUT SERIOUS COMPLICATION	BRITISH MEDICAL JOURNAL			English	Article							LOW DOSAGE		UNIV LONDON KINGS COLL HOSP,DEPT OPHTHALMOL,LONDON SE5 9RS,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London								de Jong-Busnac M, 1989, Ned Tijdschr Geneeskd, V133, P514; GERNER EW, 1989, ANN OPHTHALMOL, V21, P420; GRIFFITHS MFP, 1987, AM J OPHTHALMOL, V104, P185, DOI 10.1016/0002-9394(87)90014-6; HEEL RC, 1978, DRUGS, V16, P1, DOI 10.2165/00003495-197816010-00001; INSLER V, 1986, INFERTILITY MALE FEM, P436; KAISERKUPFER MI, 1978, CANCER TREAT REP, V62, P315; KAISERKUPFER MI, 1981, OPHTHALMOLOGY, V88, P89; MCKEOWN CA, 1981, BRIT J OPHTHALMOL, V65, P177, DOI 10.1136/bjo.65.3.177; VINDING T, 1983, ACTA OPHTHALMOL, V61, P45; 1987, LANCET, V2, P171; 1985, LANCET, V1, P836	11	37	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					495	496		10.1136/bmj.304.6825.495	http://dx.doi.org/10.1136/bmj.304.6825.495			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1312376	Bronze, Green Published			2022-12-28	WOS:A1992HF55500030
J	GOODWIN, FK				GOODWIN, FK			BEHAVIORAL STRESS REACTIVITY RELATED TO ARTHRITIS SUSCEPTIBILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							STERNBERG EM, 1992, BRAIN RES, V570, P54, DOI 10.1016/0006-8993(92)90563-O	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					910	910						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1310338				2022-12-28	WOS:A1992HD15500004
J	SCHLAGHECKE, R; KORNELY, E; SANTEN, RT; RIDDERSKAMP, P				SCHLAGHECKE, R; KORNELY, E; SANTEN, RT; RIDDERSKAMP, P			THE EFFECT OF LONG-TERM GLUCOCORTICOID THERAPY ON PITUITARY-ADRENAL RESPONSES TO EXOGENOUS CORTICOTROPIN-RELEASING HORMONE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA ADRENOCORTICOTROPIN; CORTISOL RESPONSE; DOSE-RESPONSE; DEXAMETHASONE; SECRETION; RECOVERY; AXIS; ACTH; RAT	Background. Suppression of pituitary-adrenal function is a well-known consequence of glucocorticoid therapy, manifested principally by decreased corticotropin secretion. To determine the degree of suppression of pituitary-adrenal function in patients treated with different doses of synthetic glucocorticoid medication for different periods, we measured the pituitary-adrenal response to the administration of exogenous human corticotropin-releasing hormone (CRH). Methods. We studied 279 patients who were receiving daily therapy with 5 to 30 mg of prednisone or its equivalent to treat various chronic diseases, principally collagen vascular disorders, and 50 normal subjects. Therapy ranged in duration from 1 week to 15 years. Stimulation tests using 100-mu-g of CRH as a bolus injection were performed in the morning, 24 hours after the most recent dose of glucocorticoids. In 61 patients an insulin hypoglycemia test, thought by many to be the reference standard, was also performed to assess the reliability of the CRH results. Results. After the administration of CRH, 43 patients had no increase in plasma concentrations of corticotropin and cortisol. The response was blunted in 133 patients and normal in 103. There was poor correlation between the plasma cortisol response after the administration of CRH and the dose or duration of therapy or the basal plasma cortisol concentration. Although plasma cortisol concentrations after stimulation with CRH were generally lower than those after insulin administration, there was a significant correlation between the plasma cortisol responses to the two stimuli (r = 0.82). Conclusions. Pituitary-adrenal function in patients treated with synthetic glucocorticoids cannot be reliably estimated from the dose of glucocorticoid, the duration of therapy, or the basal plasma cortisol concentration. In such patients, testing with CRH is nearly as useful as insulin hypoglycemia testing in the assessment of pituitary-adrenal function.			SCHLAGHECKE, R (corresponding author), UNIV DUSSELDORF,DEPT ENDOCRINOL & RHEUMATOL,MOORENSTR 5,W-4000 DUSSELDORF 1,GERMANY.							BECKER KL, 1990, PRINCIPLES PRACTICE, P1740; BOLT HM, 1980, THERAPIEWOCHE, V30, P6257; BORST GC, 1982, NEW ENGL J MED, V306, P1462, DOI 10.1056/NEJM198206173062405; CARNES M, 1987, NEUROENDOCRINOLOGY, V45, P160, DOI 10.1159/000124718; CHRISTY NP, 1971, HUMAN ADRENAL CORTEX, P395; CUNNINGHAM SK, 1983, ARCH INTERN MED, V143, P2276, DOI 10.1001/archinte.143.12.2276; EBERWINE JH, 1984, J BIOL CHEM, V259, P2166; HAGG E, 1987, CLIN ENDOCRINOL, V26, P221, DOI 10.1111/j.1365-2265.1987.tb00780.x; HARRISON BDW, 1982, CLIN ENDOCRINOL, V17, P109, DOI 10.1111/j.1365-2265.1982.tb01570.x; HASHIMOTO K, 1988, J CLIN INVEST, V82, P13, DOI 10.1172/JCI113561; JINGAMI H, 1985, ENDOCRINOLOGY, V117, P1314, DOI 10.1210/endo-117-4-1314; KELLERWOOD ME, 1984, ENDOCR REV, V51, P1; LIVANOU T, 1967, LANCET, V2, P856; MCEVEN BS, 1986, PHYSIOL REV, V66, P1121; MELBY JC, 1974, ANN INTERN MED, V81, P505, DOI 10.7326/0003-4819-81-4-505; MULLER OA, 1986, PSYCHONEUROENDOCRINO, V11, P49, DOI 10.1016/0306-4530(86)90031-4; NINK M, 1991, KLIN WOCHENSCHR, V69, P185, DOI 10.1007/BF01646939; ORTH DN, 1983, J CLIN INVEST, V71, P587, DOI 10.1172/JCI110804; SCHURMEYER TH, 1985, J CLIN ENDOCR METAB, V61, P22, DOI 10.1210/jcem-61-1-22; SCHURMEYER TH, 1984, J CLIN ENDOCR METAB, V59, P1103, DOI 10.1210/jcem-59-6-1103; STEWART PM, 1988, LANCET, V1, P1208; STRECK WF, 1979, AM J MED, V66, P910, DOI 10.1016/0002-9343(79)90444-3; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; TAYLOR AL, 1988, NEW ENGL J MED, V319, P213, DOI 10.1056/NEJM198807283190405; VALE W, 1983, ENDOCRINOLOGY, V113, P1121, DOI 10.1210/endo-113-3-1121; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VOIGT KH, 1981, THERAPIEWOCHE, V31, P6230; WAND GS, 1985, CLIN ENDOCRINOL META, V14, P33, DOI 10.1016/S0300-595X(85)80064-5; WATSON AC, 1988, CLIN ENDOCRINOL, V28, P471, DOI 10.1111/j.1365-2265.1988.tb03681.x	29	293	298	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					226	230		10.1056/NEJM199201233260403	http://dx.doi.org/10.1056/NEJM199201233260403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1309389				2022-12-28	WOS:A1992HA43100003
J	DEVOTO, SH; MUDRYJ, M; PINES, J; HUNTER, T; NEVINS, JR				DEVOTO, SH; MUDRYJ, M; PINES, J; HUNTER, T; NEVINS, JR			A CYCLIN-A-PROTEIN KINASE COMPLEX POSSESSES SEQUENCE-SPECIFIC DNA-BINDING ACTIVITY - P33CDK2 IS A COMPONENT OF THE E2F-CYCLIN-A COMPLEX	CELL			English	Article							ADENOVIRUS E1A PROTEINS; MATURATION-PROMOTING FACTOR; E2F TRANSCRIPTION FACTOR; CELL-DIVISION CYCLE; LARGE-T-ANTIGEN; SV40 LARGE-T; FISSION YEAST; M-PHASE; CONTROL GENE; SACCHAROMYCES-CEREVISIAE	The E2F transcription factor has been found in association with the cyclin A protein, and this complex accumulates during the S phase of the cell cycle, suggesting that E2F may play a role in cell cycle control. In independent studies, cyclin A has been shown to be associated with two other proteins, the Rb-related p107 protein and the cdc2-related p33 cdk2 protein kinase. Through an analysis of the E2F-cyclin A complex, we now find that both the p107 protein and the cdc2-related p33cdk2 kinase are components of the previously described complex. Moreover, the complex possesses H1 kinase activity. These results thus define a cyclin A-cdk2 kinase complex that possesses sequence-specific DNA binding activity. This suggests that the cdk2 kinase may phosphorylate other DNA-bound substrates, and that one role of the E2F factor may be to localize this protein kinase to the DNA.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Salk Institute	DEVOTO, SH (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,GENET SECT,DURHAM,NC 27710, USA.			Devoto, Stephen/0000-0001-9513-3962; Pines, Jonathon/0000-0002-5227-6004				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1986, EMBO J, V5, P369, DOI 10.1002/j.1460-2075.1986.tb04221.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN M, 1991, IN PRESS SCIENCE; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1991, IN PRESS SCIENCE; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEYERSON M, 1991, IN PRESS COLD SPRING, V58; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PINES J, 1991, IN PRESS COLD SPRING, V58; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	81	367	383	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					167	176		10.1016/0092-8674(92)90215-X	http://dx.doi.org/10.1016/0092-8674(92)90215-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1310073				2022-12-28	WOS:A1992GZ58300018
J	ARMSTRONG, R				ARMSTRONG, R			THE WARD ROUND	BRITISH MEDICAL JOURNAL			English	Editorial Material											ARMSTRONG, R (corresponding author), WESTMINSTER MED SCH & HOSP,LONDON SW1P 2NS,ENGLAND.			Armstrong, Rachel/0000-0002-3516-6815					0	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1543	1544		10.1136/bmj.305.6868.1543	http://dx.doi.org/10.1136/bmj.305.6868.1543			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286378	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KD77100015
J	BREWSTER, NT; HOWIE, CR				BREWSTER, NT; HOWIE, CR			THAT SINKING FEELING	BRITISH MEDICAL JOURNAL			English	Article											BREWSTER, NT (corresponding author), RAIGMORE HOSP,DEPT ORTHOPAED,INVERNESS IV2 3UJ,SCOTLAND.			Howie, Colin/0000-0001-6656-2821					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1579	1580		10.1136/bmj.305.6868.1579	http://dx.doi.org/10.1136/bmj.305.6868.1579			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286399	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992KD77100037
J	EYNONLEWIS, NJ; FERRY, D; PEARSE, MF				EYNONLEWIS, NJ; FERRY, D; PEARSE, MF			GLUCK,THEMISTOCLES - AN UNRECOGNIZED GENIUS	BRITISH MEDICAL JOURNAL			English	Item About an Individual									MT GOULD HOSP,PLYMOUTH,ENGLAND; QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham	PEARSE, MF (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP,DEPT ORTHOPAED,LEVEL 3,BRISTOL BS2 8HW,AVON,ENGLAND.							GLUCK T, PUBLICATION LIST; LANGE F, 1933, THEMISTOCLES GLUCK Z; Muster D, 1990, Bull Hist Dent, V38, P3; WESSINGHAGE D, 1991, Z ORTHOP GRENZGEB, V129, P383, DOI 10.1055/s-2008-1040261; Zipple J, 1975, Z Orthop Ihre Grenzgeb, V113, P134	5	24	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1534	1536		10.1136/bmj.305.6868.1534	http://dx.doi.org/10.1136/bmj.305.6868.1534			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286374	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100011
J	ETZIONI, A; FRYDMAN, M; POLLACK, S; AVIDOR, I; PHILLIPS, ML; PAULSON, JC; GERSHONIBARUCH, R				ETZIONI, A; FRYDMAN, M; POLLACK, S; AVIDOR, I; PHILLIPS, ML; PAULSON, JC; GERSHONIBARUCH, R			RECURRENT SEVERE INFECTIONS CAUSED BY A NOVEL LEUKOCYTE ADHESION DEFICIENCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CELL-ADHESION; CARBOHYDRATE LIGAND; ELAM-1; NEUTROPHIL; INTEGRINS; SELECTIN; INVIVO; LEWIS; SERUM		TEL AVIV UNIV, SACKLER FAC MED, IL-69978 TEL AVIV, ISRAEL; CYTEL CORP, SAN DIEGO, CA USA; SCRIPPS RES INST, LA JOLLA, CA USA; HASHARON HOSP, DEPT PEDIAT, PETAH TIQWA, ISRAEL; RAMBAM MED CTR, DEPT CLIN IMMUNOL, HAIFA, ISRAEL; TECHNION ISRAEL INST TECHNOL, BRUCE RAPPAPORT FAC MED, HAIFA, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Scripps Research Institute; Rabin Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	ETZIONI, A (corresponding author), RAMBAM MED CTR, DEPT PEDIAT, POB 9602, IL-31096 HAIFA, ISRAEL.		Paulson, James/AAG-3565-2019					ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDERSON DC, 1989, METABOLIC BASIS INHE, V2, P2751; BERG EL, 1991, J BIOL CHEM, V266, P14869; BOWEN TJ, 1982, J PEDIATR-US, V101, P932, DOI 10.1016/S0022-3476(82)80013-9; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; ETZIONI A, 1987, J PEDIATR-US, V110, P549, DOI 10.1016/S0022-3476(87)80546-2; ETZIONI A, 1990, ACTA PAEDIATR SCAND, V79, P156, DOI 10.1111/j.1651-2227.1990.tb11432.x; FERNSTEN PD, 1986, CANCER RES, V46, P2970; FRYDMAN M, IN PRESS AM J MED GE; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LAU YL, 1991, CLIN EXP IMMUNOL, V85, P202; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEPENDU J, 1985, AM J HUM GENET, V37, P749; LEY K, 1991, BLOOD, V77, P2553; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; PAULSON JC, 1992, ADHESION ITS ROLE IN, P19; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WEXLER DE, 1983, INFECT IMMUN, V39, P239, DOI 10.1128/IAI.39.1.239-246.1983	25	430	439	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1992	327	25					1789	1792		10.1056/NEJM199212173272505	http://dx.doi.org/10.1056/NEJM199212173272505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB975	1279426				2022-12-28	WOS:A1992KB97500005
J	GOGOS, JA; HSU, T; BOLTON, J; KAFATOS, FC				GOGOS, JA; HSU, T; BOLTON, J; KAFATOS, FC			SEQUENCE DISCRIMINATION BY ALTERNATIVELY SPLICED ISOFORMS OF A DNA-BINDING ZINC FINGER DOMAIN	SCIENCE			English	Article							SITE SELECTION ANALYSIS; OLIGONUCLEOTIDE MIXTURES; PROTEIN; RECOGNITION; DROSOPHILA; COMPLEX; MYOD; FORM	Two major developmentally regulated isoforms of the Drosophila chorion transcription factor CF2 differ by an extra zinc finger within the DNA binding domain. The preferred DNA binding sites were determined and are distinguished by an internal duplication of TAT in the site recognized by the isoform with the extra finger. The results are consistent with modular interactions between zinc fingers and trinucleotides and also suggest rules for recognition of AT-rich DNA sites by zinc finger proteins. The results show how modular finger interactions with trinucleotides can be used, in conjunction with alternative splicing, to alter the binding specificity and increase the spectrum of sites recognized by a DNA binding domain. Thus, CF2 may potentially regulate distinct sets of target genes during development.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138; UNIV CRETE,FORTH,INST MOLEC BIOL & BIOTECHNOL,GR-71110 IRAKLION,GREECE; UNIV CRETE,DEPT BIOL,GR-71110 IRAKLION,GREECE	Harvard University; Foundation for Research & Technology - Hellas (FORTH); University of Crete; University of Crete								BALDWIN AS, 1987, CURRENT PROTOCOLS MO; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GOGOS JA, 1991, NUCLEIC ACIDS RES, V19, P1449, DOI 10.1093/nar/19.7.1449; GOGOS JA, UNPUB; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIU AL, 1981, J BIOL CHEM, V256, P13200; MAINA CV, 1988, GENE, V74, P355; MARSTON FA, 1987, DNA CLONING PRACTICA, P65; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; UEDA H, 1991, NUCLEIC ACIDS RES, V19, P3689, DOI 10.1093/nar/19.13.3689; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332	27	91	98	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1951	1955		10.1126/science.1290524	http://dx.doi.org/10.1126/science.1290524			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1290524				2022-12-28	WOS:A1992JP59400033
J	MACKOWIAK, PA; WASSERMAN, SS; LEVINE, MM				MACKOWIAK, PA; WASSERMAN, SS; LEVINE, MM			A CRITICAL-APPRAISAL OF 98.6-DEGREES-F, THE UPPER LIMIT OF THE NORMAL BODY-TEMPERATURE, AND OTHER LEGACIES OF WUNDERLICH,CARL,REINHOLD,AUGUST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To evaluate critically Carl Wundedich's axioms on clinical thermometry. Design.-Descriptive analysis of baseline oral temperature data from volunteers participating in Shigella vaccine trials conducted at the University of Maryland Center for Vaccine Development, Baltimore. Setting.-Inpatient clinical research unit. Participants.-One hundred forty-eight healthy men and women aged 18 through 40 years. Main Measurements.-Oral temperatures were measured one to four times daily for 3 consecutive days using an electronic digital thermometer. Results.-Our findings conflicted with Wunderlich's in that 36.8-degrees-C (98.2-degrees-F) rather than 37.0-degrees-C (98.6-degrees-F) was the mean oral temperature of our subjects; 37.7-degrees-C (99.9-degrees-F) rather than 38.0-degrees-C (100.4-degrees-F) was the upper limit of the normal temperature range; maximum temperatures, like mean temperatures, varied with time of day; and men and women exhibited comparable thermal variability. Our data corroborated Wunderlich's in that mean temperature varied diurnally, with a 6 AM nadir, a 4 to 6 PM zenith, and a mean amplitude of variability of 0.5-degrees-C (0.9-degrees-F); women had slightly higher normal temperatures than men; and there was a trend toward higher temperatures among black than among white subjects. Conclusions.-Thirty-seven degrees centigrade (98.6-degrees-F) should be abandoned as a concept relevant to clinical thermometry; 37.2-degrees-C (98.9-degrees-F) in the early morning and 37.7-degrees-C (99.9-degrees-F) overall should be regarded as the upper limit of the normal oral temperature range in healthy adults aged 40 years or younger, and several of Wundedich's other cherished dictums should be revised.	UNIV MARYLAND,SCH MED,CTR VACCINE DEV,BALTIMORE,MD 21218; UNIV MARYLAND,SCH MED,DEPT MED,BALTIMORE,MD 21218	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	MACKOWIAK, PA (corresponding author), UNIV MARYLAND,VET AFFAIRS MED CTR,SCH MED,MED SERV 111,3900 LOCH RAVEN BLVD,BALTIMORE,MD 21218, USA.							[Anonymous], 1871, MED THERMOMETRY HUMA; Beutler B, 1992, CECIL TXB MED, P1568; BRENGELMANN GL, 1989, TXB PHYSL, P1584; DINARELLO CA, 1978, NEW ENGL J MED, V298, P607, DOI 10.1056/NEJM197803162981107; DINARELLO CA, 1990, PRINCIPLES PRACTICE, P462; Dominguez E, 1991, FEVER BASIC MECH MAN, P71; GARRISON FH, 1929, INTRO HIST MED, P757; GUYTON AC, 1991, TXB MED PHYSL, P6; HENSYL WR, 1990, STEDMANS MED DICT, P574; HORVATH STEVEN M., 1950, JOUR AMER MED ASSOC, V144, P1562; IVY AC, 1944, B NW U MED SCH, V18, P22; Linder F.E., 1935, HUM BIOL, V7, P24; PETERSDORF RG, 1991, HARRISONS PRINCIPLES, P2194; TANNER JM, 1951, J PHYSIOL-LONDON, V115, P391, DOI 10.1113/jphysiol.1951.sp004677; TAUBER MG, 1990, INTERNAL MED, P1240; THOMAS CL, 1989, TABERS CYCLOPEDIC ME, P665; Whiting MH, 1915, BIOMETRIKA, V11, P1; Wunderlich C.A., 1869, AM J MED SCI, V57, P425, DOI DOI 10.1097/00000441-186904000-00021; WUNDERLICH CA, 1871, TEMPERATURE DISEASES, P71; Wunderlich CA, 1868, VERHALTEN EIAENWARME; 1982, HLTH DEVICES, V12, P3	21	328	333	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1578	1580		10.1001/jama.268.12.1578	http://dx.doi.org/10.1001/jama.268.12.1578			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1302471				2022-12-28	WOS:A1992JN25600029
J	MOUNTJOY, KG; ROBBINS, LS; MORTRUD, MT; CONE, RD				MOUNTJOY, KG; ROBBINS, LS; MORTRUD, MT; CONE, RD			THE CLONING OF A FAMILY OF GENES THAT ENCODE THE MELANOCORTIN RECEPTORS	SCIENCE			English	Article							MELANOCYTE STIMULATING HORMONE; POTENT ALPHA-MELANOTROPIN; FUNCTIONAL EXPRESSION; CANNABINOID RECEPTOR; CELLS; CDNA; SEQUENCE; PROTEIN; BINDING; DNA	Melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) regulate pigmentation and adrenal cortical function, respectively. These peptides also have a variety of biological activities in other areas, including the brain, the pituitary, and the immune system. A complete understanding of the biological activities of these hormones requires the isolation and characterization of their corresponding receptors. The murine and human MSH receptors (MSH-Rs) and a human ACTH receptor (ACTH-R) were cloned. These receptors define a subfamily of receptors coupled to guanine nucleotide-binding proteins that may include the cannabinoid receptor.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University			Mountjoy, Kathy/L-4473-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043859] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43859-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BUCKLEY DI, 1981, P NATL ACAD SCI-BIOL, V78, P7431, DOI 10.1073/pnas.78.12.7431; CANNON JG, 1986, J IMMUNOL, V137, P2232; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5924; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWIED D, 1982, PHYSIOL REV, V62, P977; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; ELLERKMANN E, 1992, ENDOCRINOLOGY, V130, P133, DOI 10.1210/en.130.1.133; GERARD C, 1990, NUCLEIC ACIDS RES, V18, P7142, DOI 10.1093/nar/18.23.7142; GERST JE, 1988, ENDOCRINOLOGY, V123, P1792, DOI 10.1210/endo-123-4-1792; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GRAHAMES.DG, 1967, J BIOL CHEM, V242, P5535; HANNEMAN E, 1989, PEPTIDE HORMONES PRO, P53; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MERTZ LM, 1991, P NATL ACAD SCI USA, V88, P8525, DOI 10.1073/pnas.88.19.8525; MOUNTJOY KG, UNPUB; MURPHY MT, 1983, SCIENCE, V221, P192, DOI 10.1126/science.6602381; PAWELEK J, 1976, J INVEST DERMATOL, V66, P210; PAWELEK JM, 1985, YALE J BIOL MED, V58, P571; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER TK, 1980, P NATL ACAD SCI-BIOL, V77, P5754, DOI 10.1073/pnas.77.10.5754; SLOMINSKI A, 1992, LIFE SCI, V50, P1103, DOI 10.1016/0024-3205(92)90347-R; SOLCA F, 1989, J BIOL CHEM, V264, P14277; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; TATRO JB, 1990, J CLIN INVEST, V85, P1825, DOI 10.1172/JCI114642; TATRO JB, 1990, BRAIN RES, V536, P124, DOI 10.1016/0006-8993(90)90016-5; TATRO JB, 1990, CANCER RES, V50, P1237; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	37	1401	1474	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1248	1251		10.1126/science.1325670	http://dx.doi.org/10.1126/science.1325670			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1325670				2022-12-28	WOS:A1992JL05000024
J	PITCHER, JA; INGLESE, J; HIGGINS, JB; ARRIZA, JL; CASEY, PJ; KIM, C; BENOVIC, JL; KWATRA, MM; CARON, MG; LEFKOWITZ, RJ				PITCHER, JA; INGLESE, J; HIGGINS, JB; ARRIZA, JL; CASEY, PJ; KIM, C; BENOVIC, JL; KWATRA, MM; CARON, MG; LEFKOWITZ, RJ			ROLE OF BETA-GAMMA-SUBUNITS OF G-PROTEINS IN TARGETING THE BETA-ADRENERGIC-RECEPTOR KINASE TO MEMBRANE-BOUND RECEPTORS	SCIENCE			English	Article							MAMMALIAN BETA-2-ADRENERGIC RECEPTOR; AGONIST-DEPENDENT PHOSPHORYLATION; NUCLEOTIDE-BINDING-PROTEIN; ROD OUTER SEGMENTS; ADENYLYL CYCLASE; RHODOPSIN KINASE; GTP-BINDING; TRANSDUCIN; INHIBITION; PURIFICATION	The rate and extent of the agonist-dependent phosphorylation of beta-2-adrenergic receptors and rhodopsin by beta-adrenergic receptor kinase (beta-ARK) are markedly enhanced on addition of G protein beta-gamma subunits. With a model peptide substrate it was demonstrated that direct activation of the kinase could not account for this effect. G protein beta-gamma subunits were shown to interact directly with the COOH-terminal region of beta-ARK, and formation of this beta-ARK-beta-gamma complex resulted in receptor-facilitated membrane localization of the enzyme. The beta-gamma subunits of transducin were less effective at both enhancing the rate of receptor phosphorylation and binding to the COOH-terminus of beta-ARK, suggesting that the enzyme preferentially binds specific beta-gamma complexes. The beta-gamma-mediated membrane localization of beta-ARK serves to intimately link receptor activation to beta-ARK-mediated desensitization.	DUKE UNIV,MED CTR,HOWARD HUGHES MED RES INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED RES INST,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED RES INST,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Duke University; Duke University; Duke University; Duke University; Jefferson University			Pitcher, Julie/ABH-2078-2020; Kwatra, Madan/ABD-2008-2020; Lefkowitz, Robert/AAW-2649-2021	Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [4R37-HL16039] Funding Source: Medline; NIGMS NIH HHS [GM 44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENOVIC JL, 1986, NATURE, V322, P869; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, IN PRESS NATURE; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PITCHER JA, UNPUB; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	42	626	631	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1264	1267		10.1126/science.1325672	http://dx.doi.org/10.1126/science.1325672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1325672				2022-12-28	WOS:A1992JL05000029
J	HILES, ID; OTSU, M; VOLINIA, S; FRY, MJ; GOUT, I; DHAND, R; PANAYOTOU, G; RUIZLARREA, F; THOMPSON, A; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD				HILES, ID; OTSU, M; VOLINIA, S; FRY, MJ; GOUT, I; DHAND, R; PANAYOTOU, G; RUIZLARREA, F; THOMPSON, A; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD			PHOSPHATIDYLINOSITOL 3-KINASE - STRUCTURE AND EXPRESSION OF THE 110KD CATALYTIC SUBUNIT	CELL			English	Article							RECEPTOR TYROSINE KINASES; DEPENDENT PROTEIN-KINASE; FACTOR-I RECEPTOR; MIDDLE T-ANTIGEN; PDGF RECEPTOR; BOVINE BRAIN; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; ACTIVATED NEUTROPHILS; PHOSPHOLIPASE-C	Purified bovine brain phosphatidylinositol 3-kinase (Pl3-kinase) is composed of 85 kd and 110 kd subunits. The 85 kd subunit (p85-alpha) lacks Pl3-kinase activity and acts as an adaptor, coupling the 110 kd subunit (p110) to activated protein tyrosine kinases. Here the characterization of the p110 subunit is presented. cDNA cloning reveals p110 to be a 1068 aa protein related to Vps34p, a S. cerevisiae protein involved in the sorting of proteins to the vacuole. p110 expressed in insect cells possesses Pl3-kinase activity and associates with p85-alpha into an active p85-alpha-p110 complex that binds the activated colony-stimulating factor 1 receptor. p110 expressed in COS-1 cells is catalytically active only when complexed with p85-alpha.	UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND; EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	University of London; University College London; European Molecular Biology Laboratory (EMBL); Cancer Research UK	HILES, ID (corresponding author), LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND.		Volinia, Stefano/AAA-9264-2019; Parker, Peter j/D-5192-2013; Hsuan, Justin/C-8825-2009; Volinia, Stefano/A-3029-2010	Volinia, Stefano/0000-0003-0910-3893; Hsuan, Justin/0000-0001-6083-7564; Volinia, Stefano/0000-0003-0910-3893; Ruiz Larrea, Fernanda/0000-0001-5610-7745; parker, peter/0000-0002-6218-2933; Fry, Michael/0000-0001-8518-1370				ASHMUN RA, 1989, BLOOD, V73, P827; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P294; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARVEY RJ, 1991, NUCLEIC ACIDS RES, V19, P4002, DOI 10.1093/nar/19.14.4002; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; Maniatis T., 1982, MOL CLONING; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAGE MJ, 1989, NUCLEIC ACIDS RES, V17, P454, DOI 10.1093/nar/17.1.454; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TOTTY NF, 1992, IN PRESS PROTEIN SCI, V1; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITLEY GSJ, 1987, MOL CELL ENDOCRINOL, V52, P279, DOI 10.1016/0303-7207(87)90056-6; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	63	644	815	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					419	429		10.1016/0092-8674(92)90166-A	http://dx.doi.org/10.1016/0092-8674(92)90166-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322797	Bronze			2022-12-28	WOS:A1992JH12400007
J	INDORF, AS; PEGRAM, PS				INDORF, AS; PEGRAM, PS			ESOPHAGEAL ULCERATION RELATED TO ZALCITABINE (DDC)	ANNALS OF INTERNAL MEDICINE			English	Note						DIDEOXYCYTIDINE; HUMAN IMMUNODEFICIENCY VIRUS; ESOPHAGEAL DISEASES; ZIDOVUDINE; ACQUIRED IMMUNODEFICIENCY SYNDROME		Zalcitabine (dideoxycytidine, ddC) is an antiretroviral agent currently being evaluated for thc management of human immunodeficiency virus (HIV) infection. We report a case of recurrent esophageal ulceration in a patient taking zalcitabine while enrolled in a randomized, double blind study of zalcitabine compared with zidovudine. The patient had recurrent episodes of esophageal symptoms that were temporally related to the ingestion of zalcitabine. Serial esophagrams and endoscopy revealed midesophageal ulcerations; cultures were negative, and a biopsy was consistent with nonspecific inflammation. Symptoms resolved completely after the withdrawal of zalcitabine. The exclusion of other possible causes and the recurring temporal relationship between zalcitabine ingestion and esophageal symptoms imply a probable causal relationship in this patient. The potential role of zalcitabine in the management of HIV infection makes it important to understand its adverse effects in this patient population.	BOWMAN GRAY SCH MED, INFECT DIS SECT, MED CTR BLVD, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center								BACH MC, 1990, ANN INTERN MED, V112, P465, DOI 10.7326/0003-4819-76-3-112-6-465; EDWARDS P, 1990, ANN INTERN MED, V112, P65, DOI 10.7326/0003-4819-112-1-65; KIKENDALL JW, 1983, DIGEST DIS SCI, V28, P174, DOI 10.1007/BF01315148	3	28	28	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					133	134		10.7326/0003-4819-117-2-133	http://dx.doi.org/10.7326/0003-4819-117-2-133			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1318649				2022-12-28	WOS:A1992JD12300007
J	PRYCIAK, PM; VARMUS, HE				PRYCIAK, PM; VARMUS, HE			NUCLEOSOMES, DNA-BINDING PROTEINS, AND DNA-SEQUENCE MODULATE RETROVIRAL INTEGRATION TARGET SITE SELECTION	CELL			English	Article							I-HYPERSENSITIVE SITES; CHROMATIN STRUCTURE; PREFERRED TARGETS; CORE PARTICLE; INVITRO; REGIONS; MAP; PROMOTER; OPERATOR; COMPLEX	Integration of retroviral DNA can serve as a paradigm for cellular functions that are affected by the packaging of DNA into chromatin. We have used a novel polymerase chain reaction-based assay to survey DNA and chromatin for the precise distribution of many integration sites. Integration into naked DNA targets is non-uniform, implying a nucleotide sequence bias. In chromatin, integration occurs preferentially at positions where the major groove is on the exposed face of the nucleosomal DNA helix, generating a 10 bp periodic spacing of preferred sites. Chromatin assembly enhances the reactivity of many sites, so that integration occurs most frequently at sites in nucleosomal, rather than nucleosome-free, regions of minichromosomes. In contrast, integration is prevented in a region occupied by a site-specific DNA-binding protein. Comparisons of integration events mediated by viral nucleoprotein complexes or by two different retroviral integrases show that the integration machinery also affects target site selection.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	PRYCIAK, PM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.		Pryciak, Peter/P-7205-2019	Pryciak, Peter/0000-0001-9142-1369				BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; DREW HR, 1990, DNA TOPOLOGY ITS BIO, P1; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KING W, 1985, SCIENCE, V228, P554, DOI 10.1126/science.3838595; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; MOOSLEHNER K, 1990, J VIROL, V64, P3056, DOI 10.1128/JVI.64.6.3056-3058.1990; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THOMA F, 1985, NATURE, V315, P250, DOI 10.1038/315250a0; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; VARMUS H, 1989, MOBILE DNA, P53; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; WOLFFE A P, 1991, Current Biology, V1, P366, DOI 10.1016/0960-9822(91)90195-3	44	240	247	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					769	780		10.1016/0092-8674(92)90289-O	http://dx.doi.org/10.1016/0092-8674(92)90289-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1317268				2022-12-28	WOS:A1992HW83800008
J	GORLICH, D; HARTMANN, E; PREHN, S; RAPOPORT, TA				GORLICH, D; HARTMANN, E; PREHN, S; RAPOPORT, TA			A PROTEIN OF THE ENDOPLASMIC-RETICULUM INVOLVED EARLY IN POLYPEPTIDE TRANSLOCATION	NATURE			English	Article							SIGNAL RECOGNITION PARTICLE; OUTER-MEMBRANE PROTEIN; NASCENT PREPROLACTIN; SECRETORY PROTEIN; SEQUENCE RECEPTOR; IMPORT; SRP; PHOTOCROSSLINKING; IDENTIFICATION; COMPONENT	To identify components of the mammalian endoplasmic reticulum involved in the translocation of secretory proteins, crosslinking and reconstitution methods were combined. A multispanning abundant membrane glycoprotein was found which is in proximity to nascent chains early in translocation. In reconstituted proteoliposomes, this protein is stimulatory or required for the translocation of secretory proteins.	MAX DELBRUCK CTR MOLEC MED, ROBERT ROSSLE STR 10, O-1115 BERLIN, GERMANY; HUMBOLDT UNIV, INST BIOCHEM, O-1040 BERLIN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin			Hartmann, Enno/C-5687-2013; Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; MEYER DI, 1982, NATURE, V297, P503; MUSCH A, IN PRESS CELL; NICCHITTA C, 1991, METHOD CELL BIOL, V34, P263; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; ROTHBLATT JA, 1989, J CELL BIOL, V72, P61; SANDERS S, IN PRESS CELL; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	31	258	263	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 7	1992	357	6373					47	52		10.1038/357047a0	http://dx.doi.org/10.1038/357047a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1315422				2022-12-28	WOS:A1992HT22900052
J	KOELLE, DM; BENEDETTI, J; LANGENBERG, A; COREY, L				KOELLE, DM; BENEDETTI, J; LANGENBERG, A; COREY, L			ASYMPTOMATIC REACTIVATION OF HERPES-SIMPLEX VIRUS IN WOMEN AFTER THE 1ST EPISODE OF GENITAL HERPES	ANNALS OF INTERNAL MEDICINE			English	Article						PATIENT EDUCATION; HERPES GENITALIS; SEXUALLY TRANSMITTED DISEASES; PREGNANCY COMPLICATIONS, INFECTIOUS; CONTRACEPTIVE DEVICES, MALE	ORAL ACYCLOVIR; INTRAVENOUS ACYCLOVIR; CONTROLLED TRIAL; INFECTION; TRANSMISSION; ACQUISITION; RECURRENCES; ANTIBODIES; FREQUENCY; PARTNER	Objective: To determine frequency, anatomic site, and host factors associated with asymptomatic shedding of herpes simplex virus after initial episodes of genital herpes. Design: Cohort study with follow-up for a median of 63 weeks. Setting: Referral clinic. Patients: Women (306) with first episode of herpes; 43 had primary herpes simplex virus type 1, and 227 and 36 had primary and nonprimary herpes simplex virus type 2, respectively. Measurements: Cultures were obtained for herpes simplex virus every 4 to 6 weeks at times in which genital lesions and symptoms were not present. Main Results: Asymptomatic shedding was detected among 11.9%, 18.3%, and 22.9% of women with primary herpes simplex virus type 1, primary HSV type 2, and nonprimary HSV type 2, respectively. Among patients with type 2 infection, previous type 1 antibody was associated with a lower rate of asymptomatic vulvar shedding. Asymptomatic cervical shedding was 3 times more frequent during the first three months after resolution of primary type 2 disease than during later time periods. In contrast, the rate of symptomatic recurrent herpes did not change over time. Conclusions: Asymptomatic genital herpes simplex type 2 is more common than type 1. Asymptomatic genital shedding occurs more often during the first 3 months after acquisition of primary type 2 disease than during later periods. Patients with HSV type 2 should be advised of this high early rate of asymptomatic shedding and of potential transmission to sexual partners.	UNIV WASHINGTON, DIV VIROL, 1200 12TH AVE S, ROOM 9301, SEATTLE, WA 98144 USA; CHILDRENS HOSP & MED CTR, SEATTLE, WA USA	University of Washington; University of Washington Seattle; Seattle Children's Hospital			Corey, Lawrence/AAE-1796-2020; Koelle, David/Q-6529-2016	Corey, Lawrence/0000-0002-2179-2436; Koelle, David/0000-0003-1255-9023	NATIONAL CANCER INSTITUTE [R44CA094611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381, P01AI030731] Funding Source: NIH RePORTER; NCI NIH HHS [R44 CA094611] Funding Source: Medline; NIAID NIH HHS [P01 AI030731, AI-30731, AI-20381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM E, 1979, OBSTET GYNECOL, V54, P171; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARTON SE, 1986, GENITOURIN MED, V62, P181; BARTON SE, 1987, GENITOURIN MED, V63, P102; BROCK BV, 1990, JAMA-J AM MED ASSOC, V263, P418, DOI 10.1001/jama.263.3.418; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BRYSON YJ, 1983, NEW ENGL J MED, V308, P916, DOI 10.1056/NEJM198304213081602; BUCHMAN TG, 1978, J INFECT DIS, V138, P488, DOI 10.1093/infdis/138.4.488; COREY L, 1985, SEX TRANSM DIS, V12, P215, DOI 10.1097/00007435-198510000-00009; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P914, DOI 10.7326/0003-4819-98-6-914; GUINAN ME, 1981, NEW ENGL J MED, V304, P759, DOI 10.1056/NEJM198103263041305; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; MCCAUGHTRY ML, 1982, J MED VIROL, V10, P283, DOI 10.1002/jmv.1890100408; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1984, JAMA-J AM MED ASSOC, V252, P1147, DOI 10.1001/jama.252.9.1147; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; MINDEL A, 1986, GENITOURIN MED, V62, P28; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; REEVES WC, 1981, NEW ENGL J MED, V305, P315, DOI 10.1056/NEJM198108063050604; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STENZELPOORE MP, 1987, SEX TRANSM DIS, V14, P17, DOI 10.1097/00007435-198701000-00004; STONE KM, 1990, REV INFECT DIS, V12, pS610; STONE KM, 1989, SEX TRANSM DIS, V16, P152, DOI 10.1097/00007435-198907000-00007; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; 1991, EGRET REFERENCE MANU	28	172	173	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					433	437		10.7326/0003-4819-116-6-433	http://dx.doi.org/10.7326/0003-4819-116-6-433			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1310837	Green Accepted			2022-12-28	WOS:A1992HJ59800001
J	MINTZ, IM; VENEMA, VJ; SWIDEREK, KM; LEE, TD; BEAN, BP; ADAMS, ME				MINTZ, IM; VENEMA, VJ; SWIDEREK, KM; LEE, TD; BEAN, BP; ADAMS, ME			P-TYPE CALCIUM CHANNELS BLOCKED BY THE SPIDER TOXIN OMEGA-AGA-IVA	NATURE			English	Article							FUNNEL-WEB SPIDER; CHICK SENSORY NEURONS; BRAIN MESSENGER-RNA; AGELENOPSIS-APERTA; CONOTOXIN GVIA; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; XENOPUS OOCYTES; VENOM; CURRENTS	VOLTAGE-DEPENDENT calcium channels mediate calcium entry into neurons, which is crucial for many processes in the brain including synaptic transmission, dendritic spiking, gene expression and cell death 1-5. Many types of calcium channels exist in mammalian brains 6-19, but high-affinity blockers are available for only two types, L-type channels (targeted by nimodipine and other dihydropyridine channel blockers 20-22) and N-type channels (targeted by omega-conotoxin 22-26). In a search for new channel blockers, we have identified a peptide toxin from funnel web spider venom, omega-Aga-IVA, which is a potent inhibitor of both calcium entry into rat brain synaptosomes and of 'P-type' calcium channels 8 in rat Purkinje neurons. omega-Aga-IVA will facilitate characterization of brain calcium channels resistant to existing channel blockers and may assist in the design of neuroprotective drugs.	UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010	University of California System; University of California Riverside; Harvard University; Harvard Medical School; City of Hope; Beckman Research Institute of City of Hope			Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113				ADAMS ME, 1989, J COMP PHYSIOL A, V164, P333, DOI 10.1007/BF00612993; ADAMS ME, 1990, J BIOL CHEM, V265, P861; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; BINDOKAS VP, 1989, J NEUROBIOL, V20, P171, DOI 10.1002/neu.480200402; BINDOKAS VP, 1991, J NEUROPHYSIOL, V66, P590, DOI 10.1152/jn.1991.66.2.590; BOSSU JL, 1989, PFLUG ARCH EUR J PHY, V414, P92, DOI 10.1007/BF00585632; DUTAR P, 1989, EUR J PHARMACOL, V174, P261, DOI 10.1016/0014-2999(89)90318-X; FEIGENBAUM P, 1988, BIOCHEM BIOPH RES CO, V154, P298, DOI 10.1016/0006-291X(88)90684-5; FISHER RE, 1990, J NEUROPHYSIOL, V64, P91, DOI 10.1152/jn.1990.64.1.91; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; FOX AP, 1987, J PHYSIOL-LONDON, V394, P173, DOI 10.1113/jphysiol.1987.sp016865; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLMAN D, 1991, P NATL ACAD SCI USA, V88, P7076, DOI 10.1073/pnas.88.16.7076; HYUI A, 1991, NEURON, V7, P35; JASYS VJ, 1990, J AM CHEM SOC, V112, P6696, DOI 10.1021/ja00174a037; KUAN YF, 1986, EUR J PHARMACOL, V130, P273, DOI 10.1016/0014-2999(86)90278-5; LEONARD JP, 1987, J NEUROSCI, V7, P875; LIN JW, 1990, P NATL ACAD SCI USA, V87, P4538, DOI 10.1073/pnas.87.12.4538; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P569, DOI 10.1113/jphysiol.1981.sp013764; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LUNDY PM, 1991, EUR J PHARM-MOLEC PH, V206, P61, DOI 10.1016/0922-4106(91)90147-A; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MINTZ M, 1991, P NATL ACAD SCI USA, V88, P6628; MOGUL DJ, 1991, J PHYSIOL-LONDON, V433, P259, DOI 10.1113/jphysiol.1991.sp018425; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; ODELL TJ, 1991, J PHYSIOL-LONDON, V436, P739, DOI 10.1113/jphysiol.1991.sp018577; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; QUISTAD GB, 1990, BIOCHEM BIOPH RES CO, V169, P51, DOI 10.1016/0006-291X(90)91431-Q; REGAN LJ, 1991, J NEUROSCI, V11, P2259; REGAN LJ, 1991, NEURON, V6, P259; REYNOLDS IJ, 1986, P NATL ACAD SCI USA, V83, P8804, DOI 10.1073/pnas.83.22.8804; SCOTT RH, 1990, MOL PHARMACOL, V38, P711; SCROGGS RS, 1991, J NEUROSCI, V11, P1334; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; SUSZKIW JB, 1989, J NEUROCHEM, V52, P1260, DOI 10.1111/j.1471-4159.1989.tb01874.x; SUSZKIW JB, 1986, J NEUROSCI, V6, P1349; TAKAHASHI K, 1989, NEUROSCI LETT, V104, P229, DOI 10.1016/0304-3940(89)90359-5; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WEISS JH, 1990, SCIENCE, V247, P1474, DOI 10.1126/science.2157282; YAARI Y, 1987, SCIENCE, V235, P680, DOI 10.1126/science.2433765	47	842	853	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					827	829		10.1038/355827a0	http://dx.doi.org/10.1038/355827a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1311418				2022-12-28	WOS:A1992HF63600056
J	GINZBERG, E				GINZBERG, E			PHYSICIAN SUPPLY POLICIES AND HEALTH REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GINZBERG, E (corresponding author), COLUMBIA UNIV,EISENHOWER CTR CONSERVAT HUMAN RESOURCES,NEW YORK,NY 10027, USA.							CAMPION FD, 1984, AMA US HLTH POLICY 1, P233; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; EBERT RH, 1992, FEB C SPONS J MAC F; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P2559, DOI 10.1001/jama.265.19.2559; LEVIT KR, 1991, HLTH CARE FINANC REV, V13, P49; PETERSDORF RG, 1990, OCT ANN M ASS AM MED; THOMPSON JS, 1992, ANN INTERN MED, V116, P1084, DOI 10.7326/0003-4819-116-12-1084; 1992, PHYSICIAN CHARACTERI	8	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1992	268	21					3115	3118		10.1001/jama.268.21.3115	http://dx.doi.org/10.1001/jama.268.21.3115			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA002	1304737				2022-12-28	WOS:A1992KA00200036
J	PELISKA, JA; BENKOVIC, SJ				PELISKA, JA; BENKOVIC, SJ			MECHANISM OF DNA STRAND TRANSFER-REACTIONS CATALYZED BY HIV-1 REVERSE-TRANSCRIPTASE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ROUS-SARCOMA VIRUS; RETROVIRAL RECOMBINATION; GENETIC-RECOMBINATION; RNASE-H; POLYMERASE; REPLICATION; SUBSTITUTIONS; MUTAGENESIS; HYDROLYSIS	Two DNA strand transfer reactions occur during retroviral reverse transcription. The mechanism of the first, minus strand strong-stop DNA, transfer has been studied in vitro with human immunodeficiency virus 1 reverse transcriptase (HIV-1 RT) and a model template-primer system derived from the HIV-1 genome. The results reveal that HIV-1 RT alone can catalyze DNA strand transfer reactions. Two kinetically distinct ribonuclease (RNase) H activities associated with HIV-1 RT are required for removal of RNA fragments annealed to the nascent DNA strand. Examination of the binding of DNA . RNA duplex and single-stranded RNA to HIV-1 RT during strand transfer supports a model where the enzyme accommodates both the acceptor RNA template and the nascent DNA strand before the transfer event is completed. The polymerase activity incorporated additional bases beyond the 5' end of the RNA template, resulting in a base misincorporation upon DNA strand transfer. Such a process occurring in vivo during retroviral homologous recombination could contribute to the hypermutability of the HIV-1 genome.			PELISKA, JA (corresponding author), PENN STATE UNIV, DEPT CHEM, University Pk, PA 16802 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008275] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08275] Funding Source: Medline; NIGMS NIH HHS [GM13306] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; CHENG N, 1991, BIOCHEM BIOPH RES CO, V174, P785, DOI 10.1016/0006-291X(91)91486-V; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; COLLETT MS, 1978, NATURE, V272, P181, DOI 10.1038/272181a0; DARLIX JL, 1977, J VIROL, V23, P659, DOI 10.1128/JVI.23.3.659-668.1977; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GARCES J, 1991, P ROY SOC B-BIOL SCI, V243, P235, DOI 10.1098/rspb.1991.0037; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GOPALAKRISHNAN V, IN PRESS P NATL ACAD; GUISER RG, 1991, J BIOL CHEM, V266, P13103; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; HUBER HE, 1989, J BIOL CHEM, V264, P4669; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sambrook J, 1989, MOL CLONING; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; STUHLMANN H, 1992, J VIROL, V66, P2378, DOI 10.1128/JVI.66.4.2378-2388.1992; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Varmus H. E., 1982, RNA TUMOR VIRUSES, P369; WEBER J, 1989, NUCLEIC ACIDS RES, V17, P1379, DOI 10.1093/nar/17.4.1379; YU H, 1992, J BIOL CHEM, V267, P10888	49	306	312	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1992	258	5085					1112	1118		10.1126/science.1279806	http://dx.doi.org/10.1126/science.1279806			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1279806				2022-12-28	WOS:A1992JX85200020
J	NIGHTINGALE, SL				NIGHTINGALE, SL			1ST DRUG AVAILABLE UNDER PARALLEL TRACK POLICY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1328699				2022-12-28	WOS:A1992JW61600005
J	DURAND, B; SAUNDERS, M; LEROY, P; LEID, M; CHAMBON, P				DURAND, B; SAUNDERS, M; LEROY, P; LEID, M; CHAMBON, P			ALL-TRANS AND 9-CIS RETINOIC ACID INDUCTION OF CRABPII TRANSCRIPTION IS MEDIATED BY RAR-RXR HETERODIMERS BOUND TO DR1 AND DR2 REPEATED MOTIFS	CELL			English	Article							BINDING-PROTEIN GENE; HORMONE RECEPTOR SUPERFAMILY; RESPONSE ELEMENT; MOLECULAR-CLONING; NUCLEAR RECEPTORS; TERATOCARCINOMA CELLS; DIFFERENTIAL PATTERN; NEGATIVE REGULATION; THYROID-HORMONE; MESSENGER-RNA	Two cooperating retinoic acid response elements (RAREs) in the cellular retinoic acid-binding protein II (CRABPII) gene mediate differential transcriptional transactivation by retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in P19 embryonal carcinoma cells. RARE1 and RARE2 are direct repeats (DR) of two motifs separated by 2 bp (DR2) and 1 bp (DR1), respectively, and bind RAR-RXR heterodimers more efficiently than homodimers. Using all-trans and 9-cis RA, which differentially activate RARs and RXRs, and RAR and RXR dominant-negative mutants, RAR-RXR heterodimers bound to RARE1 and RARE2 are shown to be responsible for CRABPII promoter transactivation, arguing against a unique DR spacing specifying recognition by RARs. Within heterodimers, RAR and RXR independently and differentially transactivate, depending on the specific RARE. Consistent with these results, 9-cis RA increases CRABPII mRNA levels more efficiently than all-trans RA. In contrast, all-trans and 9-cis RA have identical effects on induction of RARbeta2 transcripts.			DURAND, B (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,INSERM,GENET MOLEC EUCARYOTES LAB, CNRS, UNITE 184, F-67085 STRASBOURG, FRANCE.		DURAND, Beatrice C/J-6387-2015	DURAND, Beatrice C/0000-0002-0047-288X				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASTROM A, 1991, J BIOL CHEM, V266, P17662; BAILEY JS, 1988, J BIOL CHEM, V263, P9326; BALLING R, 1991, TRENDS GENET, V7, P35; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BOCQUEL MT, IN PRESS; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BREITMAN TR, 1981, BLOOD, V57, P1000; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHYTIL F, 1991, RETINOIDS : 10 YEARS ON, P38; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DE LUCA LM, 1991, FASEB J, V5, P2924; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIDIERJEAN L, 1991, BIOCHEM BIOPH RES CO, V180, P204, DOI 10.1016/S0006-291X(05)81277-X; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; ELDER JT, 1992, J INVEST DERMATOL, V98, P673, DOI 10.1111/1523-1747.ep12499896; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KASTNER P, 1992, DEV PATTERNING VERTE, P75; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEROY P, 1992, RETINOIDS NORMAL DEV, P7; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIBBY PR, 1982, CARCINOGENESIS, V3, P481, DOI 10.1093/carcin/3.5.481; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MADEN M, 1989, DEVELOPMENT, V107, P109; Maden M., 1991, SEMIN DEV BIOL, V2, P161; MADER S, 1992, IN PRESS J BIOL CHEM, V267; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MENDELSOHN C, 1992, DEV BIOL, V152, P50, DOI 10.1016/0012-1606(92)90155-A; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1992, IN PRESS CELL, V70; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTSON M, 1987, NATURE, V330, P420, DOI 10.1038/330420a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROSENBERGER M, 1992, IN PRESS P NATL ACAD, V89; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; ROWE A, 1991, DEVELOPMENT, V111, P771; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Ruberte E., 1991, SEMIN DEV BIOL, V2, P153; RUBERTE E, 1992, IN PRESS DEVELOPMENT; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAURAT JH, 1990, RETINOIDS 10 YEARS; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SIEGENTHALER G, 1990, RETINOIDS 10 YEARS, P56; SMITH SM, 1989, DEVELOPMENT, V107, P121; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STONER CM, 1989, CANCER RES, V49, P1497; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; WEI LN, 1990, DNA CELL BIOL, V9, P471, DOI 10.1089/dna.1990.9.471; WEI LN, 1991, DEVELOPMENT, V112, P847; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	91	409	417	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					73	85		10.1016/0092-8674(92)90267-G	http://dx.doi.org/10.1016/0092-8674(92)90267-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1327537	Green Published			2022-12-28	WOS:A1992JQ62300008
J	WIEBEL, FF; KUNAU, WH				WIEBEL, FF; KUNAU, WH			THE PAS2 PROTEIN ESSENTIAL FOR PEROXISOME BIOGENESIS IS RELATED TO UBIQUITIN-CONJUGATING ENZYMES	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; ENCODES; GENE; DEGRADATION; MEMBER; FIBROBLASTS; FAMILY; SYSTEM	IN the yeast Saccharomyces cerevisiae, PAS genes are essential for the biogenesis and proliferation of peroxisomes1,2. Recently, the first two genes, PAS1 (ref. 3) and PAS3 (ref. 4), have been characterized. Here we report the cloning and sequencing of the PAS2 gene. It encodes a new member of the ubiquitin-conjugating (UBC) protein family5-7 and is the first member associated with peroxisomes. The proposed function of the Pas2 protein as a UBC enzyme (UBC10) is supported by the fact that site-directed mutagenesis of a strictly conserved and functionally essential cysteine residue of UBC proteins leads to mutant Pas2 proteins unable to complement pas2 mutant strains. Ubiquitination of proteins is known to play an important part in DNA repair, sporulation, cell cycle control and degradation of abnormal proteins5-8. We provide evidence for a crucial role of the ubiquitin-conjugation pathway in organelle formation.			WIEBEL, FF (corresponding author), RUHR UNIV BOCHUM,INST PHYSIOL CHEM,ZELLBIOCHEM ABT,W-4630 BOCHUM 1,GERMANY.							DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; ERDMANN R, IN PRESS CELL BIOCH; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; HOHFELD J, IN PRESS NEW COMPREH; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; QIN S, 1991, J BIOL CHEM, V266, P15549; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; Rose MD., 1990, METHODS YEAST GENETI; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; ZHUANG ZP, 1992, J BIOL CHEM, V267, P591	23	170	175	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					73	76		10.1038/359073a0	http://dx.doi.org/10.1038/359073a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1326082				2022-12-28	WOS:A1992JL66200057
J	YOSHIKAWA, K; AIZAWA, T; HAYASHI, Y				YOSHIKAWA, K; AIZAWA, T; HAYASHI, Y			DEGENERATION INVITRO OF POSTMITOTIC NEURONS OVEREXPRESSING THE ALZHEIMER AMYLOID PROTEIN-PRECURSOR	NATURE			English	Article							CARCINOMA CELL-LINE; SENILE PLAQUES; DOWNS-SYNDROME; MESSENGER-RNA; DISEASE; DIFFERENTIATION; EXPRESSION; LOCALIZATION; MICROGLIA; PEPTIDE	A PATHOLOGICAL hallmark of Alzheimer's disease is the deposition of amyloid fibrils in the brain. The principal component of amyloid fibrils is beta/A4 amyloid protein1,2, which can be generated by the aberrant processing of a large membrane-bound glycoprotein, the beta/A4 amyloid protein precursor (App)3. To test whether overexpression of APP generates abnormally processed derivatives that affect the viability of neurons, we stably transfected full-length human APP complementary DNA into murine embryonal carcinoma P19 cells. These cells differentiate into post-mitotic neurons and astrocytes after exposure to retinoic acid4-6. When differentiation of the APP cDNA-transfected P19 cells was induced, all neurons showed severe degenerative changes and disappeared within a few days. The degenerating neurons contained large amounts of APP derivatives that were truncated at the amino terminus and encompassed the entire beta/A4 domain. These results suggest that post-mitotic neurons are vulnerable to overexpressed APP, which undergoes aberrant processing to generate potentially amyloidogenic fragments.	TOKYO INST PSYCHIAT, DEPT MOLEC BIOL, SETAGAYA KU, TOKYO 153, JAPAN; MORINAGA MILK IND CO LTD, BIOCHEM RES LAB, KANAGAWA 228, JAPAN	Tokyo Institute of Psychiatry; Morinaga Milk Industry Company, Ltd								AIZAWA T, 1991, DEV BRAIN RES, V59, P89, DOI 10.1016/0165-3806(91)90033-F; ALLSOP D, 1989, NEUROPATH APPL NEURO, V15, P531, DOI 10.1111/j.1365-2990.1989.tb01252.x; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FUKUCHI K, 1992, BIOCHEM BIOPH RES CO, V182, P165, DOI 10.1016/S0006-291X(05)80126-3; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1991, J NEUROSCI, V11, P3783; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; NUKADA T, 1987, FEBS LETT, V211, P5, DOI 10.1016/0014-5793(87)81263-2; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PROBST A, 1991, ACTA NEUROPATHOL, V83, P21, DOI 10.1007/BF00294426; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YAMADA T, 1989, BIOCHEM BIOPH RES CO, V158, P906, DOI 10.1016/0006-291X(89)92808-8; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YOSHIKAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P204, DOI 10.1016/0006-291X(90)91377-5	28	182	185	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					64	67		10.1038/359064a0	http://dx.doi.org/10.1038/359064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1301020				2022-12-28	WOS:A1992JL66200054
J	HARRIS, JR; LIPPMAN, ME; VERONESI, U; WILLETT, W				HARRIS, JR; LIPPMAN, ME; VERONESI, U; WILLETT, W			MEDICAL PROGRESS .2. BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DUCTAL CARCINOMA INSITU; INTRADUCTAL CARCINOMA; LOBULAR CARCINOMA; CONSERVING SURGERY; RADIATION-THERAPY; RANDOMIZED TRIAL; FOLLOW-UP; CONSERVATIVE MANAGEMENT; DEFINITIVE IRRADIATION; PRIMARY CHEMOTHERAPY		HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT RADIAT ONCOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; IST NAZL STUDIO & CURA TUMORI,I-20133 MILAN,ITALY; GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Georgetown University; Fondazione IRCCS Istituto Nazionale Tumori Milan; Georgetown University; Georgetown University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	HARRIS, JR (corresponding author), HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,DEPT RADIAT ONCOL,50 BINNEY ST,BOSTON,MA 02115, USA.							ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3; Andersen J, 1985, Verh Dtsch Ges Pathol, V69, P88; ANDERSEN JA, 1974, ACTA PATH MICRO IM A, VA 82, P519; ANGELL M, 1992, NEW ENGL J MED, V326, P1695, DOI 10.1056/NEJM199206183262510; BADWE RA, 1991, LANCET, V337, P1261, DOI 10.1016/0140-6736(91)92927-T; BARTKOVA J, 1990, HUM PATHOL, V21, P1164, DOI 10.1016/0046-8177(90)90154-W; BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; Blichert-Toft M, 1992, J Natl Cancer Inst Monogr, P19; BONADONNA G, 1990, J NATL CANCER I, V82, P1539, DOI 10.1093/jnci/82.19.1539; BOYAGES J, 1990, RADIOTHER ONCOL, V19, P29, DOI 10.1016/0167-8140(90)90163-Q; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; CARTER D, 1986, HUM PATHOL, V17, P330, DOI 10.1016/S0046-8177(86)80455-5; CLARK RM, 1987, AM J CLIN ONCOL-CANC, V10, P461, DOI 10.1097/00000421-198712000-00001; DEWYS WD, 1972, CANCER RES, V32, P374; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FISHER B, 1983, CANCER RES, V43, P1488; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FISHER ER, 1990, BREAST CANCER RES TR, V16, P215, DOI 10.1007/BF01806330; FISHER ER, 1991, J SURG ONCOL, V47, P139, DOI 10.1002/jso.2930470302; FISHER ER, 1986, CANCER-AM CANCER SOC, V57, P197, DOI 10.1002/1097-0142(19860115)57:2<197::AID-CNCR2820570203>3.0.CO;2-N; FISHER JC, 1992, NEW ENGL J MED, V326, P1696, DOI 10.1056/NEJM199206183262511; FOURQUET A, 1989, INT J RADIAT ONCOL, V17, P719, DOI 10.1016/0360-3016(89)90057-6; FRYKBERG ER, 1987, SURG GYNECOL OBSTET, V164, P285; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; GOLDWYN RM, 1987, NEW ENGL J MED, V317, P1711, DOI 10.1056/NEJM198712313172706; GRAHAM MD, 1991, EUR J SURG ONCOL, V17, P258; HAAGENSEN CD, 1978, CANCER, V42, P737, DOI 10.1002/1097-0142(197808)42:2<737::AID-CNCR2820420247>3.0.CO;2-T; HAMMOND S, 1987, ACTA CYTOL, V31, P276; HARRIS M, 1984, BRIT J CANCER, V50, P23, DOI 10.1038/bjc.1984.135; HAYWARD J, 1987, ARCH SURG-CHICAGO, V122, P1244; HOLLAND R, 1990, LANCET, V335, P519, DOI 10.1016/0140-6736(90)90747-S; HOLLAND R, 1990, J CLIN ONCOL, V8, P113, DOI 10.1200/JCO.1990.8.1.113; HOLLAND R, 1985, CANCER, V56, P979, DOI 10.1002/1097-0142(19850901)56:5<979::AID-CNCR2820560502>3.0.CO;2-N; HRUSHESKY WJM, 1989, LANCET, V2, P949; JACQUILLAT C, 1990, CANCER, V66, P119, DOI 10.1002/1097-0142(19900701)66:1<119::AID-CNCR2820660122>3.0.CO;2-3; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; KINNE DW, 1989, ARCH SURG-CHICAGO, V124, P33; LAGIOS MD, 1982, CANCER-AM CANCER SOC, V50, P1309, DOI 10.1002/1097-0142(19821001)50:7<1309::AID-CNCR2820500716>3.0.CO;2-#; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; LEMANNE D, 1991, P AN M AM SOC CLIN, V10, P45; LODATO RF, 1990, MODERN PATHOL, V3, P449; MAURIAC L, 1991, ANN ONCOL, V2, P347, DOI 10.1093/oxfordjournals.annonc.a057953; MCGUIRE WL, 1991, ANN INTERN MED, V115, P401, DOI 10.7326/0003-4819-115-5-401; MEYER JS, 1986, BREAST CANCER RES TR, V7, P171, DOI 10.1007/BF01806247; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; PAGE DL, 1991, HUM PATHOL, V22, P1232, DOI 10.1016/0046-8177(91)90105-X; PATCHEFSKY AS, 1989, CANCER, V63, P731, DOI 10.1002/1097-0142(19890215)63:4<731::AID-CNCR2820630422>3.0.CO;2-#; PRICE P, 1990, BRIT J CANCER, V61, P869, DOI 10.1038/bjc.1990.194; RADOVAN C, 1982, PLAST RECONSTR SURG, V69, P15; RATAJCZAK HV, 1988, J EXP MED, V168, P73, DOI 10.1084/jem.168.1.73; ROBBINS GF, 1964, CANCER-AM CANCER SOC, V17, P1501, DOI 10.1002/1097-0142(196412)17:12<1501::AID-CNCR2820171202>3.0.CO;2-P; ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001; ROSEN PP, 1978, AM J SURG PATHOL, V2, P225, DOI 10.1097/00000478-197809000-00001; ROSEN PP, 1980, CANCER, V46, P919, DOI 10.1002/1097-0142(19800815)46:4+<919::AID-CNCR2820461311>3.0.CO;2-Z; SARRAZIN D, 1989, RADIOTHER ONCOL, V14, P177, DOI 10.1016/0167-8140(89)90165-5; SCHAIN WS, 1984, CLIN PLAST SURG, V11, P237; SCHWARTZ GF, 1984, CANCER, V53, P1379, DOI 10.1002/1097-0142(19840315)53:6<1379::AID-CNCR2820530627>3.0.CO;2-R; SENIE RT, 1991, ANN INTERN MED, V115, P337, DOI 10.7326/0003-4819-115-5-337; SILVERSTEIN MJ, 1991, ARCH SURG-CHICAGO, V126, P424; SOLIN LJ, 1991, CANCER-AM CANCER SOC, V68, P2337, DOI 10.1002/1097-0142(19911201)68:11<2337::AID-CNCR2820681102>3.0.CO;2-R; SOLIN LJ, 1991, INT J RADIAT ONCOL, V21, P279, DOI 10.1016/0360-3016(91)90772-V; SPITALIER JM, 1986, WORLD J SURG, V10, P1014, DOI 10.1007/BF01658662; STOMPER PC, 1989, RADIOLOGY, V172, P235, DOI 10.1148/radiology.172.1.2544922; Straus K, 1992, J Natl Cancer Inst Monogr, P27; VERONESI U, 1990, EUR J CANCER, V26, P671, DOI 10.1016/0277-5379(90)90114-9; VERONESI U, 1990, EUR J CANCER, V26, P668, DOI 10.1016/0277-5379(90)90113-8; VICINI F, 1991, ANN SURG, V214, P200, DOI 10.1097/00000658-199109000-00002; Vicini F A, 1992, J Natl Cancer Inst Monogr, P33; VONDONGEN J, 1992, J NATL CANCER I MONO, V11, P15; WHEELER JE, 1974, CANCER-AM CANCER SOC, V34, P554, DOI 10.1002/1097-0142(197409)34:3<554::AID-CNCR2820340313>3.0.CO;2-7; 1991, JAMA-J AM MED ASSOC, V265, P391; [No title captured]; 1990, J NATL CANCER I, V82, P277; 1980, LANCET, V2, P55	76	182	189	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					390	398		10.1056/NEJM199208063270606	http://dx.doi.org/10.1056/NEJM199208063270606			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1320737				2022-12-28	WOS:A1992JG35600006
J	BAUER, PH; MULLER, S; PUZICHA, M; PIPPIG, S; OBERMAIER, B; HELMREICH, EJM; LOHSE, MJ				BAUER, PH; MULLER, S; PUZICHA, M; PIPPIG, S; OBERMAIER, B; HELMREICH, EJM; LOHSE, MJ			PHOSDUCIN IS A PROTEIN KINASE-A-REGULATED G-PROTEIN REGULATOR	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; PURIFICATION; BOVINE; DESENSITIZATION; PHOSPHOPROTEIN; TRANSDUCIN; COMPONENT; ARRESTIN; COMPLEX	SIGNAL transduction by G-protein-coupled receptors is regulated by various mechanisms acting at the receptor level; those studied most thoroughly are from the beta-adrenergic receptor/G(s)/adenylyl cyclase system 1-3. We report here a regulatory mechanism occurring at the level of the G proteins themselves. A protein with M(r) 33,000 that inhibits G(s)-GTPase activity was purified from bovine brain. This protein is very similar or identical to phosducin, a protein previously thought to be specific for retina and pineal gland 4-8. Recombinant phosducin inhibited the GTPase activity of several G proteins, and also inhibited G(s)-mediated adenylyl cyclase activation. Blockade of its inhibitory effects by protein kinase A suggests that phosducin may be part of a complex regulatory network controlling G-protein-mediated signalling.	UNIV WURZBURG,DEPT PHYSIOL CHEM,W-8700 WURZBURG,GERMANY	University of Wurzburg	BAUER, PH (corresponding author), UNIV MUNICH,MAX PLANCK INST BIOCHEM,MOLEC BIOL LAB,W-8033 MARTINSRIED,GERMANY.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				ABE T, 1990, GENE, V91, P209, DOI 10.1016/0378-1119(90)90090-E; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4519; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; KUO CH, 1989, BIOCHEM BIOPH RES CO, V162, P1063, DOI 10.1016/0006-291X(89)90781-X; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LOHSE MJ, 1986, MOL PHARMACOL, V30, P403; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3210; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOHSE MJ, 1992, SIGNAL TRANSMISSION, P160; REIG JA, 1990, J BIOL CHEM, V265, P5816; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	30	184	185	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					73	76		10.1038/358073a0	http://dx.doi.org/10.1038/358073a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1319556				2022-12-28	WOS:A1992JB34100057
J	CULVER, KW; RAM, Z; WALLBRIDGE, S; ISHII, H; OLDFIELD, EH; BLAESE, RM				CULVER, KW; RAM, Z; WALLBRIDGE, S; ISHII, H; OLDFIELD, EH; BLAESE, RM			INVIVO GENE-TRANSFER WITH RETROVIRAL VECTOR PRODUCER CELLS FOR TREATMENT OF EXPERIMENTAL BRAIN-TUMORS	SCIENCE			English	Article							THYMIDINE KINASE GENES; RAT-BRAIN; INTERLEUKIN-2; POTENT	Direct in situ introduction of exogenous genes into proliferating tumors could provide an effective therapeutic approach for treatment of localized tumors. Rats with a cerebral glioma were given an intratumoral stereotaxic injection of murine fibroblasts that were producing a retroviral vector in which the herpes simplex thymidine kinase (HS-tk) gene had been inserted. After 5 days during which the HS-tk retroviral vectors that were produced in situ transduced the neighboring proliferating glioma cells, the rats were treated with the anti-herpes drug ganciclovir. Gliomas in the ganciclovir- and vector-treated rats regressed completely both macroscopically and microscopically. This technique exploits what was previously considered to be a disadvantage of retroviral vectors-that is, their inability to transfer genes into nondividing cells. Instead, this feature of retroviruses is used to target gene delivery to dividing tumor cells and to spare nondividing neural tissue.	NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	CULVER, KW (corresponding author), NCI,METAB BRANCH,CELLULAR IMMUNOL SECT,BETHESDA,MD 20892, USA.							BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; CULVER KW, UNPUB; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GANSBACHER B, 1990, CANCER RES, V50, P7820; ISHII H, UNPUB; ITAYA T, 1987, CANCER RES, V47, P3136; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MOOLTEN FL, 1990, J NATL CANCER I, V82, P297, DOI 10.1093/jnci/82.4.297; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; SHORT MP, 1990, J NEUROSCI RES, V27, P427, DOI 10.1002/jnr.490270322; SPIESS PJ, 1987, JNCI-J NATL CANCER I, V79, P1067; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; WEIZSAECKER M, 1981, J NEUROL, V224, P183, DOI 10.1007/BF00313280; WIDNER H, 1988, BRAIN RES REV, V13, P287, DOI 10.1016/0165-0173(88)90010-0	17	1486	1680	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1550	1552		10.1126/science.1317968	http://dx.doi.org/10.1126/science.1317968			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317968				2022-12-28	WOS:A1992HY07500027
J	SCHWEIGHOFFER, F; BARLAT, I; CHEVALLIERMULTON, MC; TOCQUE, B				SCHWEIGHOFFER, F; BARLAT, I; CHEVALLIERMULTON, MC; TOCQUE, B			IMPLICATION OF GAP IN RAS-DEPENDENT TRANSACTIVATION OF A POLYOMA ENHANCER SEQUENCE	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; RAS-P21 GTPASE; INHIBITION; DOMAIN; CELLS; P21; TRANSFORMATION; ONCOGENES; MUTANT	Controversy exists as to whether the interaction of a guanosine triphosphatase activating protein (GAP) with Ras proteins functions both to initiate and to terminate Ras-dependent signaling events or only to terminate them. GAP-C, a carboxyl-terminal fragment of GAP that is sufficient to stimulate GTPase activity, inhibited the stimulation of transcription produced by some oncoproteins (v-Src, polyoma middle T, wild-type Ras, and oncogenic Ras) but not that produced by v-Mos. Wild-type GAP did not affect transcription induced by oncogenic Ras but reversed the inhibitory effect of GAP-C on transcription induced by oncogenic Ras. These results indicate that GAP is a negative regulator of wild-type Ras and elicits a downstream signal by interacting with Ras-GTP (guanosine triphosphate).			SCHWEIGHOFFER, F (corresponding author), RHONE POULENC RORER, CTR RECH VITRY ALFORTVILLE, 13 QUAI JULES GUESDE, BP 14, F-94403 Vitry Sur Seine, FRANCE.							BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATA Y, 1990, J BIOL CHEM, V265, P7104; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; REY I, 1991, ONCOGENE, V6, P347; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHWEIGHOFFER F, UNPUB; STACEY DW, 1988, COLD SPRING HARB SYM, V53, P871, DOI 10.1101/SQB.1988.053.01.100; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	32	57	57	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					825	827		10.1126/science.1317056	http://dx.doi.org/10.1126/science.1317056			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1317056				2022-12-28	WOS:A1992HT23500041
J	MCCARRON, JG; MCGEOWN, JG; REARDON, S; IKEBE, M; FAY, FS; WALSH, JV				MCCARRON, JG; MCGEOWN, JG; REARDON, S; IKEBE, M; FAY, FS; WALSH, JV			CALCIUM-DEPENDENT ENHANCEMENT OF CALCIUM CURRENT IN SMOOTH-MUSCLE BY CALMODULIN-DEPENDENT PROTEIN KINASE-II	NATURE			English	Article							LIGHT-CHAIN KINASE; INTRACELLULAR CALCIUM; CA-2+ CURRENT; CELLS; CHANNELS; PHOSPHORYLATION; BINDING; SITE; IDENTIFICATION; ACETYLCHOLINE	CALCIUM entry through voltage-activated Ca2+ channels is important in regulating many cellular functions. Activation of these channels in many cell types results in feedback regulation of channel activity 1. Mechanisms linking Ca2+ channel activity with its downregulation have been described 2,3, but little is known of the events responsible for the enhancement of Ca2+ current that in many cells follows Ca2+ channel activation and an increase in cytoplasmic Ca2+ concentration 4,5. Here we investigate how this positive feedback is achieved in single smooth muscle cells. We find that in these cells voltage-activated calcium current is persistently but reversibly enhanced after periods of activation. This persistent enhancement of the Ca2+ current is mediated by activation of calmodulin-dependent protein kinase II because it is blocked when either the rise in cytoplasmic Ca2+ is inhibited or activation of calmodulin-dependent protein kinase II is prevented by specific peptide inhibitors of calcium-calmodulin or calmodulin-dependent protein kinase II itself. This mechanism may be important in different forms of Ca2+ current potentiation, such as those that depend on prior Ca2+ channel activation or are a result of agonist-induced release of Ca2+ from internal stores.	UNIV MASSACHUSETTS,MED CTR,DEPT PHYSIOL,WORCESTER,MA 01655; CASE WESTERN RESERVE UNIV,COLL MED,DEPT PHYSIOL,CLEVELAND,OH 44106	University of Massachusetts System; University of Massachusetts Worcester; Case Western Reserve University	MCCARRON, JG (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,BIOMED IMAGING GRP,WORCESTER,MA 01655, USA.							ARMSTRONG D, 1988, J GEN PHYSIOL, V92, pA10; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; BENHAM CD, 1987, CIRC RES, V61, P10; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; CLAPP LH, 1987, P NATL ACAD SCI USA, V84, P2092, DOI 10.1073/pnas.84.7.2092; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; FAY FS, 1973, P NATL ACAD SCI USA, V70, P641, DOI 10.1073/pnas.70.3.641; FAY FS, 1982, METHOD ENZYMOL, V85, P284; GURNEY AM, 1989, NATURE, V341, P65, DOI 10.1038/341065a0; HIMPENS B, 1988, J PHYSIOL-LONDON, V395, P507, DOI 10.1113/jphysiol.1988.sp016932; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P11242, DOI 10.1021/bi00503a013; IKEBE M, 1990, BIOCHEM BIOPH RES CO, V168, P714, DOI 10.1016/0006-291X(90)92380-I; IKEBE M, 1991, ARCH BIOCHEM BIOPHYS, V288, P538, DOI 10.1016/0003-9861(91)90232-8; IKEBE M, 1990, J BIOL CHEM, V265, P17607; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KALMAN D, 1988, J GEN PHYSIOL, V92, P531, DOI 10.1085/jgp.92.4.531; LUCCHESI P, 1989, AM J PHYSIOL, V255, pC226; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MARBAN E, 1982, J PHYSIOL-LONDON, V329, P589, DOI 10.1113/jphysiol.1982.sp014321; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VIVAUDOU MB, 1991, PFLUG ARCH EUR J PHY, V418, P144, DOI 10.1007/BF00370463; VIVAUDOU MB, 1988, FASEB J, V2, P2497, DOI 10.1096/fasebj.2.9.2453389; WALSH JV, 1987, PFLUG ARCH EUR J PHY, V408, P83, DOI 10.1007/BF00581336; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; WILLIAMS DA, 1986, AM J PHYSIOL, V250, pC779, DOI 10.1152/ajpcell.1986.250.5.C779; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109	33	127	128	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					74	77		10.1038/357074a0	http://dx.doi.org/10.1038/357074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1315424				2022-12-28	WOS:A1992HT22900061
J	CEDERGRENZEPPEZAUER, ES; LARSSON, G; NYMAN, PO; DAUTER, Z; WILSON, KS				CEDERGRENZEPPEZAUER, ES; LARSSON, G; NYMAN, PO; DAUTER, Z; WILSON, KS			CRYSTAL-STRUCTURE OF A DUTPASE	NATURE			English	Article							DEOXYURIDINE TRIPHOSPHATE NUCLEOTIDOHYDROLASE; TUMOR NECROSIS FACTOR; ESCHERICHIA-COLI; RESOLUTION; PURIFICATION; SEQUENCE; PROTEIN; BINDING	THE enzyme dUTPase catalyses the hydrolysis of dUTP1 and maintains a low intracellular concentration of dUTP so that uracil cannot be incorporated into DNA 2. dUTPase from Escherichia coli is strictly specific for its dUTP substrate 3, the active site discriminating between nucleotides with respect to the sugar moiety as well as the pyrimidine base. Here we report the three-dimensional structure of E. coli dUTPase determined by X-ray crystallography at a resolution of 1.9 angstrom. The enzyme is a symmetrical trimer, and of the 152 amino acid residues in the subunit, the first 136 are visible in the crystal structure. The tertiary structure resembles a jelly-roll fold and does not show the 'classical' nucleotide-binding domain. In the quaternary structure there is a complex interaction between the subunits that may be important in catalysis. This possibility is supported by the location of conserved elements in the sequence.	UNIV LUND,CTR CHEM,DEPT BIOCHEM,S-22100 LUND,SWEDEN; DESY,EUROPEAN MOLEC BIOL LAB,W-2000 HAMBURG 52,GERMANY	Lund University; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	CEDERGRENZEPPEZAUER, ES (corresponding author), UNIV STOCKHOLM,WENNER GREN INST,DEPT ZOOL CELL BIOL,S-10691 STOCKHOLM,SWEDEN.			Wilson, Keith/0000-0002-3581-2194				BERTANI LE, 1963, J BIOL CHEM, V238, P3407; BRANDEN CI, 1991, INTRO PROTEIN STRUCT, P70; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CEDERGRENZEPPEZAUER ES, 1988, PROTEINS, V4, P71, DOI 10.1002/prot.340040110; ECK MJ, 1989, J BIOL CHEM, V264, P17595; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, V1, P43; HOFFMANN I, 1987, EUR J BIOCHEM, V164, P45, DOI 10.1111/j.1432-1033.1987.tb10990.x; HOFFMANN I, 1988, THESIS U SAARBRUCKEN; HOKARI S, 1987, ARCH BIOCHEM BIOPHYS, V253, P350, DOI 10.1016/0003-9861(87)90188-3; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kornberg A., 1991, DNA REPLICATION; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LUNDBERG LG, 1983, EMBO J, V2, P967, DOI 10.1002/j.1460-2075.1983.tb01529.x; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; WANG BC, 1985, METHOD ENZYMOL, V115, P90	19	140	144	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					740	743		10.1038/355740a0	http://dx.doi.org/10.1038/355740a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1311056				2022-12-28	WOS:A1992HE60400069
J	DUNN, JT				DUNN, JT			IODINE DEFICIENCY - THE NEXT TARGET FOR ELIMINATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											DUNN, JT (corresponding author), UNIV VIRGINIA,SCH MED,CHARLOTTESVILLE,VA 22908, USA.							DELANGE F, 1986, BIOL NEONATE, V49, P322, DOI 10.1159/000242547; Dunn JT, 1990, PRACTICAL GUIDE CORR; HETZEL BS, 1983, LANCET, V2, P1126; MARINE D, 1923, ATLANTIC MED J, V26, P437; MARKEL H, 1987, AM J PUBLIC HEALTH, V77, P219, DOI 10.2105/AJPH.77.2.219; PFANNENSTIEL P, 1989, IDD NEWSLETTER, V5, P7; TONGLET R, 1992, NEW ENGL J MED, V326, P236, DOI 10.1056/NEJM199201233260405; 1990, **NON-TRADITIONAL**	8	38	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					267	268		10.1056/NEJM199201233260411	http://dx.doi.org/10.1056/NEJM199201233260411			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1309392				2022-12-28	WOS:A1992HA43100011
J	ATTISANO, L; WRANA, JL; CHEIFETZ, S; MASSAGUE, J				ATTISANO, L; WRANA, JL; CHEIFETZ, S; MASSAGUE, J			NOVEL ACTIVIN RECEPTORS - DISTINCT GENES AND ALTERNATIVE MESSENGER-RNA SPLICING GENERATE A REPERTOIRE OF SERINE THREONINE KINASE RECEPTORS	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; ERYTHROID-DIFFERENTIATION FACTOR; OVARIAN FOLLICULAR-FLUID; FACTOR-BETA; TGF-BETA; MEMBRANE-RECEPTOR; CELL; INHIBIN; IDENTIFICATION; EXPRESSION	We have cloned ActR-IIB, which encodes four new activin receptor isoforms belonging to the protein serine/threonine kinase receptor family. Two of the ActR-IIB isoforms have higher affinity for activin A than the previously cloned activin receptor and differ from each other by the inclusion of an alternatively spliced segment in the cytoplasmic juxtamembrane region. A second alternative splicing event generates two additional receptor isoforms that lack a proline cluster in the external juxtamembrane region and have lower affinity for activin A. All isoforms bind inhibin A with low affinity. Thus, the repertoire of activin receptors includes species that differ in ligand binding affinity, cytoplasmic domain structure, or both. This receptor heterogeneity might underlie the sharply different responses that activin can elicit in a dose- or cell-specific manner.	MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	ATTISANO, L (corresponding author), MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA.		Wrana, Jeffrey/F-8857-2013	Massague, Joan/0000-0001-9324-8408				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FORAGE RG, 1986, P NATL ACAD SCI USA, V83, P3091, DOI 10.1073/pnas.83.10.3091; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GONZALEZMANCHON C, 1989, ENDOCRINOLOGY, V125, P1666, DOI 10.1210/endo-125-3-1666; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HEDGER MP, 1989, MOL CELL ENDOCRINOL, V61, P133, DOI 10.1016/0303-7207(89)90198-6; HINO M, 1989, J BIOL CHEM, V264, P10309; KOJIMA I, 1989, BIOCHEM BIOPH RES CO, V159, P1107, DOI 10.1016/0006-291X(89)92223-7; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAPOLT PS, 1989, MOL ENDOCRINOL, V3, P1666, DOI 10.1210/mend-3-10-1666; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P7059; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MEUNIER H, 1988, P NATL ACAD SCI USA, V85, P247, DOI 10.1073/pnas.85.1.247; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARALKAR VM, 1991, P NATL ACAD SCI USA, V88, P3397, DOI 10.1073/pnas.88.8.3397; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETRAGLIA F, 1989, P NATL ACAD SCI USA, V86, P5114, DOI 10.1073/pnas.86.13.5114; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SPORN MB, 1990, HDB EXPT PHARM, V95; SUGINO H, 1988, J BIOL CHEM, V263, P15249; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vale W., 1990, HDB EXPT PHARM, P211; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VOGELI G, 1987, METHOD ENZYMOL, V152, P407; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WRANA JL, 1991, BIOCHEM J, V273, P523, DOI 10.1042/bj2730523; YING SY, 1986, BIOCHEM BIOPH RES CO, V135, P950, DOI 10.1016/0006-291X(86)91020-X; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	58	506	542	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					97	108		10.1016/0092-8674(92)90209-U	http://dx.doi.org/10.1016/0092-8674(92)90209-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1310075				2022-12-28	WOS:A1992GZ58300012
J	MCBRIDE, D; GILL, F; PROOPS, D; HARRINGTON, M; GARDINER, K; ATTWELL, C				MCBRIDE, D; GILL, F; PROOPS, D; HARRINGTON, M; GARDINER, K; ATTWELL, C			NOISE AND THE CLASSICAL MUSICIAN	BRITISH MEDICAL JOURNAL			English	Article							HEARING	Objectives-To test the hypothesis that noise exposure may cause hearing loss in classical musicians. Design-Comparison of hearing levels between two risk groups identified during the study by measuring sound levels. Setting-Symphony orchestra and occupational health department in the west Midlands, Main outcome measures-Hearing level as measured by clinical pure tone audiometry. Results-Trumpet and piccolo players received a noise dose of 160% and 124%, respectively, over mean levels during part of the study. Comparison of the hearing levels of 18 woodwind and brass musicians with 18 string musicians matched for age and sex did not show a significant difference in hearing, the mean difference in the hearing levels at the high (2, 4, and 8 KHz) audiometric frequencies being 1.02 dB (95% confidence interval -2.39 to 4.43). Conclusions-This study showed that there is a potential for occupational hearing loss in classical orchestral musicians.	QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham	MCBRIDE, D (corresponding author), UNIV BIRMINGHAM,INST OCCUPAT HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		McBride, David I/F-9664-2010	McBride, David I/0000-0001-5531-7687				Axelsson A, 1981, Acta Otolaryngol Suppl, V377, P3; Burns W, 1973, J Soc Occup Med, V23, P86; RABINOWITZ J, 1982, MED HYG, V40, P1; ROYSTER JD, 1991, J ACOUST SOC AM, V89, P2793, DOI 10.1121/1.400719; SANTUCCI M, 1990, MED PROBL PERFORM AR, V5, P136; SATALOFF RT, 1991, AM J OTOL, V12, P122; 1989, NOISE WORK REGULATIO	7	44	49	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1561	1563		10.1136/bmj.305.6868.1561	http://dx.doi.org/10.1136/bmj.305.6868.1561			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	KD771	1286387	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992KD77100024
J	TAYLOR, S				TAYLOR, S			CONFESSIONS OF A BENEDICTINE DRINKER	BRITISH MEDICAL JOURNAL			English	Article											TAYLOR, S (corresponding author), ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND.							DEQUINCEY T, CONFESSIONS ENGLISH	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1585	1586		10.1136/bmj.305.6868.1585	http://dx.doi.org/10.1136/bmj.305.6868.1585			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286404	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100043
J	DOUGAN, S; DINARDO, S				DOUGAN, S; DINARDO, S			DROSOPHILA WINGLESS GENERATES CELL TYPE DIVERSITY AMONG ENGRAILED EXPRESSING CELLS	NATURE			English	Article							SEGMENT-POLARITY GENE; LARVAL EPIDERMIS; FUSHI-TARAZU; ZYGOTIC LOCI; MELANOGASTER; EMBRYOS; PATTERN; CUTICLE; CHROMOSOME; PROTEIN	DURING embryogenesis, body pattern is established in a stepwise process1. After specification of the body axis, the embryo is subdivided into smaller units. Within these units, a diverse array of cell types is then generated. The subdivisions of the Drosophila embryo, called parasegments2, are defined by the interface between cells expressing the homeoprotein Engrailed and cells expressing the secreted protein Wingless3-5. We have examined the generation of cell-type diversity within parasegments by focusing on the choice of cell fate made by the engrailed (en)-expressing cells. These cells differentiate as one of two alternative cell types6. We report here that this choice is mediated by wingless (wg), in a function distinct from its early role maintaining en expression7,8. Thus, en cells exhibit different responses to the wg signal at different developmental stages. Early wg input stabilizes the subdivision of the body axis by maintaining en expression, whereas later input generates cell-type diversity.			DOUGAN, S (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.		Dougan, Scott/B-8416-2008	Dougan, Scott/0000-0003-0214-4772; DiNardo, Stephen/0000-0003-4131-5511				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1985, NATURE, V313, P639; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HILLMAN R, 1970, J MORPHOL, V131, P383, DOI 10.1002/jmor.1051310403; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KASSIS JA, 1991, GENETICS, V128, P751; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	22	111	111	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					347	350		10.1038/360347a0	http://dx.doi.org/10.1038/360347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1280330				2022-12-28	WOS:A1992JZ63000052
J	GINZBERG, E				GINZBERG, E			HEALTH-CARE REFORM - WHERE ARE WE AND WHERE SHOULD WE BE GOING	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											GINZBERG, E (corresponding author), COLUMBIA UNIV,EISENHOWER CTR CONSERVAT HUMAN RESOURCES,NEW YORK,NY 10027, USA.							BOWSHER CA, 1991, GAOTHRD9116; GINZBERG E, 1992, NY TIMES        0220, pA24; MEYER J, 1990, CRITICAL CHOICES CON; ROPER WL, 1989, HEALTH AFFAIR, V8, P97, DOI 10.1377/hlthaff.8.4.97; SHORTELL SM, 1992, HEALTH AFFAIR, V11, P108, DOI 10.1377/hlthaff.11.1.108; 1992, IN PRESS SOURCE BOOK; 1992, JAN WASH BUS GROUP H; 1992, GHAAS NATIONAL DIREC; 1992, SOCIOECONOMIC CHARAC	9	20	20	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1310	1312		10.1056/NEJM199210293271812	http://dx.doi.org/10.1056/NEJM199210293271812			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV259	1306654				2022-12-28	WOS:A1992JV25900012
J	PLATE, KH; BREIER, G; WEICH, HA; RISAU, W				PLATE, KH; BREIER, G; WEICH, HA; RISAU, W			VASCULAR ENDOTHELIAL GROWTH-FACTOR IS A POTENTIAL TUMOR ANGIOGENESIS FACTOR IN HUMAN GLIOMAS INVIVO	NATURE			English	Article							METASTASIS; FEATURES; MITOGEN; FAMILY	CLINICAL and experimental studies suggest that angiogenesis is a prerequisite for solid tumour growth1,2. Several growth factors with mitogenic or chemotactic activity for endothelial cells in vitro have been described, but it is not known whether these mediate tumour vascularization in vivo3,4. Glioblastoma, the most common and most malignant brain tumour in humans, is distinguished from astrocytoma by the presence of necroses and vascular proliferations5,6. Here we show that expression of an endothelial cell-specific mitogen, vascular endothelial growth factor (VEGF), is induced in astrocytoma cells but is dramatically upregulated in two apparently different subsets of glioblastoma cells. The high-affinity tyrosine kinase receptor for VEGF, flt, although not expressed in normal brain endothelium, is upregulated in tumour endothelial cells in vivo. These observations strongly support the concept that tumour angiogenesis is regulated by paracrine mechanisms and identify VEGF as a potential tumour angiogenesis factor in vivo.	MAX PLANCK INST PSYCHIAT,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; UNIV FREIBURG,INST MOLEK ZELLBIOL,W-7800 FREIBURG,GERMANY; MAX PLANCK INST PHYSIOL & CLIN RES,W-6350 BAD NAUHEIM,GERMANY	Max Planck Society; University of Freiburg; Max Planck Society			Breier, Georg/E-3580-2016	Breier, Georg/0000-0002-9467-780X				BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; BREIER G, 1992, DEVELOPMENT, V114, P521; BREM SS, 1990, AM J PATHOL, V137, P1121; BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1991, BIOL THERAPY CANCER, P743; GERMANO IM, 1989, J NEUROSURG, V70, P701, DOI 10.3171/jns.1989.70.5.0701; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; JAIN RK, 1988, CANCER RES, V48, P2641; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLAGSBRUN M, 1990, HDB EXPT PHARM, V95, P549; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; PLATE KH, 1992, LAB INVEST, V67, P529; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; RISAU W, IN PRESS GROWTH FACT; Russell D., 1989, PATHOLOGY TUMORS NER; Scherer HJ, 1935, VIRCHOWS ARCH A, V294, P823, DOI 10.1007/BF01889141; SHIBUYA M, 1990, ONCOGENE, V5, P519; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4	31	2103	2215	3	87	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					845	848		10.1038/359845a0	http://dx.doi.org/10.1038/359845a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279432				2022-12-28	WOS:A1992JV77700069
J	NAGPAL, S; SAUNDERS, M; KASTNER, P; DURAND, B; NAKSHATRI, H; CHAMBON, P				NAGPAL, S; SAUNDERS, M; KASTNER, P; DURAND, B; NAKSHATRI, H; CHAMBON, P			PROMOTER CONTEXT-DEPENDENT AND RESPONSE ELEMENT-DEPENDENT SPECIFICITY OF THE TRANSCRIPTIONAL ACTIVATION AND MODULATING FUNCTIONS OF RETINOIC ACID RECEPTORS	CELL			English	Article							HUMAN ESTROGEN-RECEPTOR; HUMAN PROGESTERONE-RECEPTOR; DIFFERENTIAL PATTERN; NUCLEAR RECEPTORS; BINDING-PROTEINS; BETA-GENE; MOUSE; GAMMA; IDENTIFICATION; DOMAINS	Using several naturally occurring and synthetic retinoic acid (RA)-responsive reporter genes, we show that the patterns of transcriptional activation by various retinoic acid receptor (RAR) and retinoid X receptor (RXR) forms vary according to the nature of the RA response element and the context of the stimulated promoter. We demonstrate the presence of autonomous, ligand-inducible, and promoter context-dependent transactivation functions (AF-2s) located in the C-terminal region of all RARs and RXRs. In addition, promoter context-specific modulating transactivation functions are associated with the N-terminal A and B regions of RARs and RXRs. We also show that these transactivation and modulating functions exhibit response-element specificity. The modulating functions display a marked specificity in their cooperation with the AF-2 transactivation functions, cooperation that depends on the receptor origin of the modulating and transactivation functions and the promoter context of the RA-responsive gene, thus accounting for the specific transactivation properties of RAR and RXR types.			NAGPAL, S (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,INSERM,U184,UNITE BIOL MOLEC & GENIE GENET,CNRS,F-67085 STRASBOURG,FRANCE.		DURAND, Beatrice C/J-6387-2015; Nagpal, Sunil/A-8007-2009	DURAND, Beatrice C/0000-0002-0047-288X; Nakshatri, Harikrishna/0000-0001-8876-0052				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; EVANS RM, 1988, SCIENCE, V240, P89; GAUB MP, 1992, IN PRESS EXP CELL RE, V201; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MADER S, 1992, IN PRESS J BIOL CHEM, V267; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; MENDELSOHN C, 1992, DEV BIOL, V152, P50, DOI 10.1016/0012-1606(92)90155-A; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MEYER ME, 1992, J BIOL CHEM, V267, P10882; NAGATA T, 1992, P NATL ACAD SCI USA, V89, P937, DOI 10.1073/pnas.89.3.937; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROWE A, 1991, DEVELOPMENT, V111, P771; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Ruberte E., 1991, SEMIN DEV BIOL, V2, P153; SAURAT JH, 1990, RETINOIDS 10 YEARS O; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TURCOTTE B, 1991, J BIOL CHEM, V266, P2582; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE JH, 1988, COLD SPRING HARB SYM, V53, P819, DOI 10.1101/SQB.1988.053.01.093; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	71	336	342	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					1007	1019		10.1016/0092-8674(92)90250-G	http://dx.doi.org/10.1016/0092-8674(92)90250-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1326406	Green Published			2022-12-28	WOS:A1992JN78100015
J	KLIEWER, SA; UMESONO, K; NOONAN, DJ; HEYMAN, RA; EVANS, RM				KLIEWER, SA; UMESONO, K; NOONAN, DJ; HEYMAN, RA; EVANS, RM			CONVERGENCE OF 9-CIS RETINOIC ACID AND PEROXISOME PROLIFERATOR SIGNALING PATHWAYS THROUGH HETERODIMER FORMATION OF THEIR RECEPTORS	NATURE			English	Article							HORMONE; GENE; RAT	PEROXISOMES are cytoplasmic organelles which are important in mammals in modulation of lipid homeostasis, including the metabolism of long-chain fatty acids and conversion or cholesterol to bile salts (reviewed in refs 1 and 2). Amphipathic carboxylates such as clofibric acid have been used in man as hypolipidaemic agents and in rodents they stimulate the proliferation of peroxisomes. These agents, termed peroxisome proliferators, and all-trans retinoic acid activate genes involved in peroxisomal-mediated beta-oxidation of fatty acids1-4. Here we show that the receptor activated by peroxisome proliferators5 and the retinoid X receptor-alpha (ref. 6) form a heterodimer that activates acyl-CoA oxidase gene expression in response to either clofibric acid or the retinoid X receptor-alpha ligand, 9-cis retinoic acid, an all-trans retinoic acid metabolite7,8; simultaneous exposure to both activators results in a synergistic induction of gene expression. These data demonstrate the coupling of the peroxisome proliferator and retinoid signalling pathways and provide evidence for a physiological role for 9-cis retinoic acid in modulating lipid metabolism.	LIGAND PHARMACEUT,SAN DIEGO,CA 92121	Ligand Pharmaceuticals	KLIEWER, SA (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; HERTZ R, 1992, BIOCHEM J, V281, P41, DOI 10.1042/bj2810041; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIJKATA M, 1990, J BIOL CHEM, V265, P4600; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NEMALI MR, 1988, CANCER RES, V48, P5316; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vamecq J, 1989, Essays Biochem, V24, P115; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	20	1528	1603	3	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					771	774		10.1038/358771a0	http://dx.doi.org/10.1038/358771a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1324435	Green Accepted			2022-12-28	WOS:A1992JK69900058
J	FERGUSON, M; TORRI, AF; WARD, DC; ENGLUND, PT				FERGUSON, M; TORRI, AF; WARD, DC; ENGLUND, PT			INSITU HYBRIDIZATION TO THE CRITHIDIA-FASCICULATA KINETOPLAST REVEALS 2 ANTIPODAL SITES INVOLVED IN KINETOPLAST DNA-REPLICATION	CELL			English	Article							TRYPANOSOMA-BRUCEI; GUIDE RNAS; MINICIRCLES; MITOCHONDRIA; NETWORKS; LOCALIZATION; ORGANIZATION; TRANSCRIPT; PROTOZOA; CLONING	Kinetoplast DNA is a network of interlocked minicircles and maxicircles. In situ hybridization, using probes detected by digital fluorescence microscopy, has clarified the in vivo structure and replication mechanism of the network. The probe recognizes only nicked minicircles. Hybridization reveals prereplication kinetoplasts (with closed minicircles), donut-shaped replicating kinetoplasts (with nicked minicircles on the periphery and closed minicircles in the center), and postreplication kinetoplasts (with nicked minicircles). Replicating kinetoplasts are associated with two peripheral structures containing free minicircle replication intermediates and DNA polymerase. Replication may involve release of closed minicircles from the center of the kinetoplast and their migration to the peripheral structures, replication of the free minicircles therein, and then peripheral reattachment of the progeny minicircles to the kinetoplast.	YALE UNIV,DEPT BIOCHEM & GENE,NEW HAVEN,CT 06510; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Yale University; Johns Hopkins University	FERGUSON, M (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013604, R37GM027608, R01GM027608, R01GM040115] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-27608, GM-40115, GM13604-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON W, 1969, J CELL SCI, V4, P611; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BIRKENMEYER L, 1987, J BIOL CHEM, V262, P2384; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BOYLE AR, 1990, CURRENT PROTOCOLS S, V12; COSGROVE WB, 1970, J PROTOZOOL, V17, P172, DOI 10.1111/j.1550-7408.1970.tb02350.x; DELAIN E, 1969, CR ACAD SCI D NAT, V268, P1225; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; ENGLUND PT, 1979, J BIOL CHEM, V254, P4895; ENGLUND PT, 1982, MITOCHONDRIAL GENES, P423; ENGMAN DM, 1989, MOL CELL BIOL, V9, P5163, DOI 10.1128/MCB.9.11.5163; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; GONZALEZ A, 1990, MOL BIOCHEM PARASIT, V40, P233, DOI 10.1016/0166-6851(90)90045-N; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KUSEL JP, 1967, J PROTOZOOL, V14, P283, DOI 10.1111/j.1550-7408.1967.tb01999.x; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MARINI JC, 1980, J BIOL CHEM, V255, P4976; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; SHELINE C, 1989, MOL CELL BIOL, V9, P169, DOI 10.1128/MCB.9.1.169; SILVER LE, 1986, CELL, V47, P537, DOI 10.1016/0092-8674(86)90618-5; SIMPSON AM, 1976, J PROTOZOOL, V23, P583, DOI 10.1111/j.1550-7408.1976.tb03846.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SIMPSON L, 1974, BIOCHIM BIOPHYS ACTA, V349, P161, DOI 10.1016/0005-2787(74)90077-X; STUART K, 1983, MOL BIOCHEM PARASIT, V9, P93, DOI 10.1016/0166-6851(83)90103-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; SUGISAKI H, 1987, MOL BIOCHEM PARASIT, V23, P253, DOI 10.1016/0166-6851(87)90032-6; TORRI AF, 1992, J BIOL CHEM, V267, P4786	33	115	115	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					621	629		10.1016/0092-8674(92)90431-B	http://dx.doi.org/10.1016/0092-8674(92)90431-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1324122				2022-12-28	WOS:A1992JJ88600011
J	MAGID, D; SCHWARTZ, B; CRAFT, J; SCHWARTZ, JS				MAGID, D; SCHWARTZ, B; CRAFT, J; SCHWARTZ, JS			PREVENTION OF LYME-DISEASE AFTER TICK BITES - A COST-EFFECTIVENESS ANALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED IMMUNOSORBENT-ASSAY; WHITE-TAILED DEER; BORRELIA-BURGDORFERI; ENDEMIC AREA; MANIFESTATIONS; SPIROCHETE; ABNORMALITIES; CEFTRIAXONE; PREVALENCE; DIAGNOSIS	Background. In areas of endemic disease, the probability of Lyme disease after a tick bite ranges from about 0.012 to 0.05. Early treatment with oral antibiotics prevents most complications of Lyme disease, but antibiotics are generally not prescribed until rash or other symptoms develop. Methods. We used decision analysis to evaluate the outcomes, costs, and cost effectiveness of three alternative strategies to treat patients bitten by ixodes ticks in areas of endemic Lyme disease: empirically treat all patients with two weeks of doxycycline, treat only patients in whom erythema migrans develops, and treat only patients with erythema migrans or a positive serologic test for Lyme disease one month after exposure. Results. Empirical treatment is the least expensive strategy and results in the fewest cases of Lyme disease and the fewest complications when the probability of Borrelia burgdorferi infection after a tick bite is 0.036 or higher. For probabilities of infection below 0.036, empirical therapy prevents most major complications, sequelae, and adverse events, but it incurs additional minor complications, especially as the probability of infection falls below 0.01. Conclusions. Empirical treatment of patients with tick bites is indicated when the probability of B. burgdorferi infection after a bite is 0.036 or higher, and this treatment may be preferred when the probability of infection ranges from 0.01 to 0.035. When the probability of infection after a tick bite is less than 0.01, empirical therapy is not warranted.	UNIV PENN, LEONARD DAVIS INST HLTH ECON, 3641 LOCUST WALK, PHILADELPHIA, PA 19104 USA; DENVER GEN HOSP, EMERGENCY MED SERV, DENVER, CO 80204 USA; UNIV COLORADO, HLTH SCI CTR, EMERGENCY MED RES CTR, DENVER, CO 80262 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, DIV OCCUPAT HLTH, BALTIMORE, MD 21218 USA; YALE UNIV, SCH MED, DEPT MED, RHEUMATOL SECT, NEW HAVEN, CT 06510 USA; UNIV PENN, SCH MED, DIV GEN INTERNAL MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, CLIN EPIDEMIOL UNIT, PHILADELPHIA, PA 19104 USA; UNIV PENN, WHARTON SCH, DEPT HLTH CARE SYST, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Johns Hopkins University; Yale University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026853] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 26853] Funding Source: Medline; NIAMS NIH HHS [AR 4007] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRE F, 1991, AM J DIS CHILD, V145, P391; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; BOSLER EM, 1984, YALE J BIOL MED, V57, P651; BOWEN GS, 1984, YALE J BIOL MED, V57, P661; BURGDORFER W, 1985, AM J TROP MED HYG, V34, P925, DOI 10.4269/ajtmh.1985.34.925; BURGDORFER W, 1989, RHEUM DIS CLIN N AM, V15, P775; Centers for Disease Control (CDC), 1988, MMWR Suppl, V37, P1; CLARK JR, 1985, LARYNGOSCOPE, V95, P1341; COCKBURN J, 1987, BRIT MED J, V295, P814, DOI 10.1136/bmj.295.6602.814; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; DATTWYLER RJ, 1988, LANCET, V1, P1191; FALCO RC, 1988, ANN NY ACAD SCI, V539, P456, DOI 10.1111/j.1749-6632.1988.tb31905.x; GELMAN CR, 1992, DOXYCYCLINE DRUG EVA, V72; GELMAN CR, 1992, CEFTRIAXONE DRUG EVA, V72; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; LACOMBE E, 1992, 5TH INT C LYM BORR W, pA49; LANE RS, 1988, ANN NY ACAD SCI, V539, P192, DOI 10.1111/j.1749-6632.1988.tb31853.x; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LEVINE JF, 1985, AM J TROP MED HYG, V34, P355, DOI 10.4269/ajtmh.1985.34.355; LIU N Y, 1989, Arthritis and Rheumatism, V32, pS46; MAGNARELLI LA, 1988, J CLIN MICROBIOL, V26, P1482, DOI 10.1128/JCM.26.8.1482-1486.1988; MAGNARELLI LA, 1984, J WILDLIFE DIS, V20, P21, DOI 10.7589/0090-3558-20.1.21; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MAGNARELLI LA, 1988, ANN NY ACAD SCI, V539, P154, DOI 10.1111/j.1749-6632.1988.tb31848.x; MALAWISTA SE, 1986, ADV INTERNAL MED, V31, P147; MATHER TN, 1992, 5TH INT C LYM BORR W, pA49; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; MOSKOVITZ BL, 1984, AM J MED, V77, P84; NADELMAN RB, 1992, 5TH INT C LYM BORR W, pA80; NEU HC, 1988, ANN NY ACAD SCI, V539, P314, DOI 10.1111/j.1749-6632.1988.tb31865.x; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SCHEIFE RT, 1976, DRUG EFFECTS HOSPITA, P263; Schoen R T, 1989, Conn Med, V53, P335; SHAPIRO ED, 1992, 5TH P INT C LYM BORR, pA47; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1979, ANN INTERN MED, V91, P730, DOI 10.7326/0003-4819-91-5-730; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; 1989, MED LETT DRUGS THER, V31, P57; 1991, LYME DISEASE SURVEIL, V2, P1	51	137	139	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					534	541		10.1056/NEJM199208203270806	http://dx.doi.org/10.1056/NEJM199208203270806			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1298217	Bronze			2022-12-28	WOS:A1992JJ45700006
J	KHAN, AA; STEINER, JP; KLEIN, MG; SCHNEIDER, MF; SNYDER, SH				KHAN, AA; STEINER, JP; KLEIN, MG; SCHNEIDER, MF; SNYDER, SH			IP3 RECEPTOR - LOCALIZATION TO PLASMA-MEMBRANE OF T-CELLS AND COCAPPING WITH THE T-CELL RECEPTOR	SCIENCE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CEREBELLAR PURKINJE-CELLS; LYMPHOCYTES-T; RAT-LIVER; ENDOPLASMIC-RETICULUM; INSP3 RECEPTOR; ACINAR-CELLS; K+ CHANNELS; PATCH CLAMP; ACTIVATION	Immune responses in lymphocytes require cellular accumulation of large amounts of calcium (Ca2+) from extracellular sources. In the T cell tumor line Jurkat, receptors for the Ca2+-releasing messenger inositol 1,4,5-trisphosphate (IP3) were localized to the plasma membrane (PM). Capping of the T cell receptor-CD3 complex, which is associated with signal transduction, was accompanied by capping of IP3 receptors. The IP3 receptor on T cells appears to be responsible for the entry of Ca2+ that initiates proliferative responses.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore					NHLBI NIH HHS [P01-HL27867] Funding Source: Medline; NIDA NIH HHS [DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGARD DA, 1984, ANNU REV BIOPHYS BIO, V13, P191; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BOURGUIGNON LYW, 1988, SIGNAL TRANSDUCTION, P111; Castleman KR., 1979, DIGITAL IMAGE PROCES; CUNNINGHAM A, UNPUB; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DARGEMONT C, 1988, BIOCHEM J, V256, P117, DOI 10.1042/bj2560117; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; GARDNER P, 1989, J BIOL CHEM, V264, P1068; GARDNER P, 1990, ANNU REV IMMUNOL, V8, P231, DOI 10.1146/annurev.iy.08.040190.001311; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KHAN AT, UNPUB; KIMBALL PM, 1988, CELL IMMUNOL, V113, P107, DOI 10.1016/0008-8749(88)90010-X; KLEIN DP, 1990, J IMMUNOL, V145, P2967; KUNO M, 1986, NATURE, V323, P269, DOI 10.1038/323269a0; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MONCK JR, 1992, J CELL BIOL, V116, P745, DOI 10.1083/jcb.116.3.745; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SHARP AH, 1992, J BIOL CHEM, V267, P7444; SHARP AH, 1991, BIOPHYS J, V59, P525; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169	49	204	205	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					815	818		10.1126/science.1323146	http://dx.doi.org/10.1126/science.1323146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323146				2022-12-28	WOS:A1992JG85100041
J	LIMPER, AH; CARPENTER, PC; SCHEITHAUER, B; STAATS, BA				LIMPER, AH; CARPENTER, PC; SCHEITHAUER, B; STAATS, BA			THE CUSHING SYNDROME INDUCED BY BRONCHIAL CARCINOID-TUMORS	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA; NORFLOXACIN; CAMPYLOBACTER INFECTIONS; SALMONELLA INFECTIONS; DYSENTERY	ECTOPIC ACTH SYNDROME; CORTICOTROPIN; DIAGNOSIS; SECRETION; ADENOMA; LUNG	Objectives: To define the clinical spectrum of bronchial carcinoid tumors in patients presenting with the Cushing syndrome, to evaluate the role of chest radiographs and computed tomography in their diagnosis, to review the characteristic histologic features, and to determine patient outcome. Design: Retrospective analysis of consecutive patients. Setting. A referral-based medical center. Patients: Fifteen consecutive patients with the Cushing syndrome evaluated at the Mayo Clinic with histologically proven bronchial carcinoid tumors. Measurements: Clinical, radiographic, and histologic features. Results: The Cushing syndrome was the initial clinical presentation, and bronchial carcinoid tumors were found later in all 15 patients. The diagnosis of carcinoid tumor was proved histologically in all cases. Ten biopsies showed typical carcinoid tumors, three were histologically atypical, and three were metastatic. Corticotropin was detected by immunostaining in seven of these tumors. Biochemical analysis showed marked elevations of circulating corticotropin with a mean serum value of 156 +/- 58 pmol/L (normal, 4 to 22 pmol/L). Additional clinical features included hypokalemia in six patients and glucocorticoid response to either high-dose dexamethasone or metyrapone in 6 of 13. These hormonally active carcinoid tumors were frequently radiographically occult, with 10 of 15 patients initially having normal chest radiographs. Computed tomography was successful in locating carcinoid tumors in five patients with negative chest radiographs evaluated after 1980. All five remaining patients with normal chest radiographs evaluated before 1980 eventually developed nodular lesions on standard chest radiography from 1 to 10 years later. Ten patients achieved complete remission and two patients, partial remission of the Cushing syndrome after surgical resection. Three patients continued to have symptomatic glucocorticoid excess due to metastatic disease. Conclusions: Although uncommon, the Cushing syndrome may be the initial clinical manifestation of an otherwise indolent bronchial carcinoid tumor. Radiographic imaging of occult lesions can be successfully accomplished with computed tomography. Surgical resection is curative in most patients with this disorder.	MAYO CLIN & MAYO FDN, DIV ENDOCRINOL & INTERNAL MED, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PATHOL & LAB MED, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic	LIMPER, AH (corresponding author), MAYO CLIN & MAYO FDN, DIV THORAC DIS & INTERNAL MED, E-18B, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ALTMAN RL, 1973, THORAX, V28, P433, DOI 10.1136/thx.28.4.433; ARRIGONI MG, 1972, J THORAC CARDIOV SUR, V64, P413; AZZOPARDI JG, 1968, CANCER-AM CANCER SOC, V22, P274, DOI 10.1002/1097-0142(196808)22:2<274::AID-CNCR2820220204>3.0.CO;2-W; CARPENTER PC, 1988, ENDOCRIN METAB CLIN, V17, P445, DOI 10.1016/S0889-8529(18)30412-2; DELGAUDIO A, 1988, INT SURG, V73, P44; DESTEPHANO DB, 1984, HUM PATHOL, V15, P890, DOI 10.1016/S0046-8177(84)80151-3; DOPPMAN JL, 1989, RADIOLOGY, V172, P115, DOI 10.1148/radiology.172.1.2544919; FINDLING JW, 1986, ARCH INTERN MED, V146, P929, DOI 10.1001/archinte.146.5.929; HOWLETT TA, 1986, CLIN ENDOCRINOL, V24, P699, DOI 10.1111/j.1365-2265.1986.tb01667.x; JEX RK, 1985, AM J SURG, V149, P276; KAO PC, 1979, CLIN CHEM, V25, P1267; KAYE TB, 1990, ANN INTERN MED, V112, P434, DOI 10.7326/0003-4819-76-3-112-6-434; LAWSON RM, 1976, THORAX, V31, P245, DOI 10.1136/thx.31.3.245; LEINUNG MC, 1990, MAYO CLIN PROC, V65, P1314, DOI 10.1016/S0025-6196(12)62142-9; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; MALCHOFF CD, 1988, AM J MED, V84, P760, DOI 10.1016/0002-9343(88)90116-7; MASON A M S, 1972, Clinical Endocrinology, V1, P3, DOI 10.1111/j.1365-2265.1972.tb00374.x; MCDANIEL HG, 1980, SOUTHERN MED J, V73, P1194, DOI 10.1097/00007611-198009000-00008; MURRAY RJ, 1988, CHEST, V93, P1249, DOI 10.1378/chest.93.6.1249; OKIKE N, 1976, ANN THORAC SURG, V22, P270, DOI 10.1016/S0003-4975(10)64915-6; OLURIN EO, 1973, CANCER, V31, P1514, DOI 10.1002/1097-0142(197306)31:6<1514::AID-CNCR2820310631>3.0.CO;2-C; RAFF H, 1989, CLIN CHEM, V35, P596; Roberts L, 1985, WILLIAMS TXB ENDOCRI, P1363; ROZENMAN J, 1987, CHEST, V92, P145, DOI 10.1378/chest.92.1.145; SCHTEINGART DE, 1986, J CLIN ENDOCR METAB, V63, P770, DOI 10.1210/jcem-63-3-770; SKRABANEK P, 1978, CANCER, V42, P1263, DOI 10.1002/1097-0142(197809)42:3<1263::AID-CNCR2820420335>3.0.CO;2-O; STROTT CA, 1968, AM J MED, V44, P97, DOI 10.1016/0002-9343(68)90240-4; WHITE FE, 1982, BRIT MED J, V284, P771, DOI 10.1136/bmj.284.6318.771; ZARATE A, 1986, CLIN ENDOCRINOL, V24, P523, DOI 10.1111/j.1365-2265.1986.tb03281.x; 1981, NEW ENGL J MED, V305, P1637	30	110	113	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					209	214		10.7326/0003-4819-117-3-209	http://dx.doi.org/10.7326/0003-4819-117-3-209			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1319693				2022-12-28	WOS:A1992JF30400006
J	GRAF, T; MCNAGNY, K; BRADY, G; FRAMPTON, J				GRAF, T; MCNAGNY, K; BRADY, G; FRAMPTON, J			CHICKEN ERYTHROID-CELLS TRANSFORMED BY THE GAG-MYB-ETS-ENCODING E26 LEUKEMIA-VIRUS ARE MULTIPOTENT	CELL			English	Article							MYELOMONOCYTIC GROWTH-FACTOR; HEMATOPOIETIC STEM-CELLS; MYELOID CELLS; PHILADELPHIA-CHROMOSOME; MONOCLONAL-ANTIBODY; AUTOCRINE GROWTH; VULVAR INDUCTION; GENE-EXPRESSION; TARGET-CELLS; DIFFERENTIATION	The E26 avian leukemia virus encodes a transcriptional activator-type oncoprotein consisting of Gag, Myb, and Ets domains, and transforms early erythroid cells as well as myeloblasts. Surprisingly, we have found that "early erythroid" transformants obtained in culture are multipotent, since they can be induced to differentiate into myeloblasts and eosinophils after superinfection with retroviruses containing kinase-type or ras oncogenes. In addition, TPA is an efficient inducer that generates predominantly eosinophils at low concentrations and myeloblasts at high concentrations. The determination process involves the complete extinction of erythroid/thrombocytic markers and the subsequent activation of myelomonocytic/eosinophilic properties, including the acquisition of specific growth factor requirements. "Erythroleukemic" cells from virus-infected animals were likewise found to be multipotent, making this a unique system to study the genesis of stem cell leukemias and the molecular basis of lineage commitment during hematopoiesis.			GRAF, T (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY.		Graf, Thomas/B-4252-2015; McNagny, Kelly/P-5239-2014	Graf, Thomas/0000-0003-2774-4117; McNagny, Kelly/0000-0003-4737-3499				ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ANDERSSON LC, 1979, INT J CANCER, V23, P143, DOI 10.1002/ijc.2910230202; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; BROWN G, 1986, LEUKEMIA, V1, P150; BRUNE K, 1973, J INFECT DIS, V127, P84, DOI 10.1093/infdis/127.1.84; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dieterlen-Lievre F., 1988, P257; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EWERT DL, 1984, J IMMUNOL, V132, P2524; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1988, LEUKEMIA, V2, P127; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GREENBERG SM, 1988, BLOOD, V72, P1968; GREENBERGER JS, 1983, J NATL CANCER I, V70, P323; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KAPLOW LS, 1965, BLOOD-J HEMATOL, V26, P215, DOI 10.1182/blood.V26.2.215.215; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KLINKEN SP, 1991, CANCER CELL-MON REV, V3, P373; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lucas AM, 1961, AGR MONOGRAPH, V25; MANDI Y, 1987, IMMUNOBIOLOGY, V174, P292, DOI 10.1016/S0171-2985(87)80004-9; Maniatis T., 1982, MOL CLONING; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCNAGNY K, 1992, IN PRESS LEUKEMIA; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NAVARRO S, 1991, EXP HEMATOL, V19, P11; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGAWA M, 1983, BLOOD, V61, P823; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAPAYANNOPOULOU T, 1988, BLOOD, V72, P1029; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; PIERCE JH, 1989, BIOCHIM BIOPHYS ACTA, V989, P179, DOI 10.1016/0304-419X(89)90042-5; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; POOLE AR, 1977, LYSOSOMES LABORATORY; QUEVA C, 1992, DEVELOPMENT, V114, P125; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SEIGNEURIN D, 1987, EXP HEMATOL, V15, P822; SOTIROV N, 1981, J NATL CANCER I, V66, P1143, DOI 10.1093/jnci/66.6.1143; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; YU G, 1989, J BIOL CHEM, V264, P10276	65	138	138	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					201	213		10.1016/0092-8674(92)90096-U	http://dx.doi.org/10.1016/0092-8674(92)90096-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1322247				2022-12-28	WOS:A1992JE75700005
J	JOHNSON, EM				JOHNSON, EM			METHADONE AND AZT TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, EM (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							FRIEDLAND, J ACQUIRED IMMUNODEF	1	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					447	447						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1320132				2022-12-28	WOS:A1992JD47200003
J	BODE, W; GOMISRUTH, FX; HUBER, R; ZWILLING, R; STOCKER, W				BODE, W; GOMISRUTH, FX; HUBER, R; ZWILLING, R; STOCKER, W			STRUCTURE OF ASTACIN AND IMPLICATIONS FOR ACTIVATION OF ASTACINS AND ZINC-LIGATION OF COLLAGENASES	NATURE			English	Article							AMINO-ACID SEQUENCE; HUMAN FIBROBLAST COLLAGENASE; THERMOLYSIN; PROTEASE; PROTEINS	ASTACIN, a digestive zinc-endopeptidase from the crayfish Astacus astacus L. 1,2, is the prototype for the 'astacin family' 3-5, which includes mammalian metallo-endopeptidases 5 and developmentally regulated proteins of man 6, fruitfly 7, frog 8 and sea urchin 9,10. Here we report the X-ray crystal structure of astacin, which reveals a deep active-site cleft, with the zinc at its bottom ligated by three histidines, a water molecule and a more remote tyrosine. The third histidine (His 102) forms part of a consensus sequence, shared not only by the members of the astacin family, but also by otherwise sequentially unrelated proteinases, such as vertebrate collagenases 11. It may therefore represent the elusive 'third' zinc ligand in these enzymes. The amino terminus of astacin is buried forming an internal salt-bridge with Glu 103, adjacent to His 102. Astacin pro-forms extended at the N terminus, as observed for some 'latent' mammalian astacin homologues, did not exhibit this 'active' conformation, indicating an activation mechanism reminiscent of trypsin-like serine proteinases.	UNIV HEIDELBERG,INST ZOOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	BODE, W (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.		Stöcker, Walter/AAB-9704-2019	Stöcker, Walter/0000-0002-1515-6994; Gomis-Ruth, F. Xavier/0000-0002-6848-6874				BARRETT AJ, 1991, BIOCHEM SOC T, V19, P707, DOI 10.1042/bst0190707; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1990, XPLOR MANUAL VERSION; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JONES TA, 1978, ACTA CRYSTALLOGR A, V34, P931; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17530; LEPAGE T, 1992, DEVELOPMENT, V114, P147; Lipscomb W N, 1968, Brookhaven Symp Biol, V21, P24; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; PAUPTIT RA, 1988, J MOL BIOL, V199, P525, DOI 10.1016/0022-2836(88)90623-7; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STOCKER W, 1990, BIOCHEMISTRY-US, V29, P10418; STOCKER W, 1988, BIOCHEMISTRY-US, V27, P5026; STOCKER W, 1991, BIOL CHEM H-S, V372, P385, DOI 10.1515/bchm3.1991.372.1.385; THAYER MM, 1991, J BIOL CHEM, V266, P2864; TITANI K, 1987, BIOCHEMISTRY-US, V26, P222, DOI 10.1021/bi00375a029; TITANI K, 1972, NATURE-NEW BIOL, V238, P35, DOI 10.1038/newbio238035a0; TURK D, 1992, THESIS TU MUNCHEN; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	30	297	306	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					164	167		10.1038/358164a0	http://dx.doi.org/10.1038/358164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1319561				2022-12-28	WOS:A1992JC58300057
J	TILZEY, AJ; PALMER, SJ; BARROW, S; PERRY, KR; TYRRELL, H; SAFARY, A; BANATVALA, JE				TILZEY, AJ; PALMER, SJ; BARROW, S; PERRY, KR; TYRRELL, H; SAFARY, A; BANATVALA, JE			CLINICAL-TRIAL WITH INACTIVATED HEPATITIS-A VACCINE AND RECOMMENDATIONS FOR ITS USE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VIRAL-HEPATITIS; VIRUS; IMMUNOGENICITY; VOLUNTEERS	Objective-To compare the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine in two different immunisation schedules. Design - Randomised trial. Setting-One London teaching hospital. Subjects-104 healthy adult volunteers (71 men, 33 women aged 19-60). Interventions-Hepatitis A vaccine to group 1 (54 volunteers) at 0, 1, and 2 months and to group 2 (50) at 0, 1, and 6 months. Main outcome measures-Symptoms at and after each dose; liver function, hepatitis A virus specific serum immune response; and responses in saliva and parotid fluid in immunised volunteers and subjects with natural immunity. Results-The vaccine was well tolerated; 97% (96/99) and 100% of those immunised developed serum antibody after one and two doses of vaccine respectively. Geometric mean titres increased progressively after each dose and were significantly higher in men but not women in group 2 after the third dose (ratio between geometric mean titres 0.265, 95% confidence interval 0.18 to 0.39; p < 0.0001). At one year this group-sex interaction was absent; geometric mean titres for both sexes were significantly higher in group 2 (ratio 0.330, 0.227 to 0.478; p < 0.0001). Antibody responses were not significantly different between the groups at two years. Compared with naturally infected subjects immunised volunteers developed poor or undetectable virus specific IgG and IgA responses in saliva and parotid fluid. Conclusions-The vaccine was safe and highly immunogenic, and the differences in the immune responses in saliva and parotid fluid are unlikely to affect its efficacy.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT VIROL, ST THOMAS CAMPUS, LONDON SE1 7EH, ENGLAND; SMITHKLINE BEECHAM PHARMACEUT, WELWYN GARDEN CITY, ENGLAND; CENT PUBL HLTH LAB, VIRUS REFERENCE LAB, COLINDALE, ENGLAND; SMITHKLINE BEECHAM BIOL, RIXENSART, BELGIUM	University of London; King's College London; GlaxoSmithKline; GlaxoSmithKline								ANDRE FE, 1990, PROG MED VIROL, V37, P72; ANDRE FE, 1990, 1990 P INT S VIR HEP, P85; CHIN KP, 1991, J MED VIROL, V34, P191, DOI 10.1002/jmv.1890340312; ELLIS RW, 1989, RECENT DEV PROPHYLAC, P181; FAGAN EA, 1990, BRIT MED BULL, V46, P462, DOI 10.1093/oxfordjournals.bmb.a072410; FLEHMIG B, 1989, LANCET, V1, P1039; GRUER LD, 1982, LANCET, V2, P163; JACOBSON IM, 1985, J MED VIROL, V16, P163, DOI 10.1002/jmv.1890160208; KANI J, 1991, BRIT MED J, V302, P1399, DOI 10.1136/bmj.302.6789.1399-a; KARPINSKI KF, 1987, J IMMUNOL METHODS, V103, P189, DOI 10.1016/0022-1759(87)90289-4; LIM WL, 1992, LANCET, V339, P304, DOI 10.1016/0140-6736(92)91372-F; MAO JS, 1990, VACCINE, V8, P523, DOI 10.1016/0264-410X(90)90001-3; OGRA PL, 1968, NEW ENGL J MED, V279, P893, DOI 10.1056/NEJM196810242791701; PARRY JV, 1989, J MED VIROL, V28, P255, DOI 10.1002/jmv.1890280410; POLLOCK TM, 1969, LANCET, V1, P281; PROVOST PJ, 1979, P SOC EXP BIOL MED, V160, P213, DOI 10.3181/00379727-160-40422; PROVOST PJ, 1978, P SOC EXP BIOL MED, V159, P201, DOI 10.3181/00379727-159-40314; STAPLETON JT, 1985, GASTROENTEROLOGY, V89, P637, DOI 10.1016/0016-5085(85)90462-7; TILZEY AJ, 1991, BMJ-BRIT MED J, V302, P1552, DOI 10.1136/bmj.302.6792.1552; VENTO S, 1991, LANCET, V337, P1183, DOI 10.1016/0140-6736(91)92858-Y; WIEDERMANN G, 1990, VACCINE, V8, P581, DOI 10.1016/0264-410X(90)90013-C; 1990, 8946 COMM DIS REP; 1991, COMMUNICABLE DISEASE, V1, P2; 1988, MMWR, V37, P297	24	52	52	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	1992	304	6837					1272	1276		10.1136/bmj.304.6837.1272	http://dx.doi.org/10.1136/bmj.304.6837.1272			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1318765	Green Published, Bronze			2022-12-28	WOS:A1992HV08600018
J	BABCOCK, GT; WIKSTROM, M				BABCOCK, GT; WIKSTROM, M			OXYGEN ACTIVATION AND THE CONSERVATION OF ENERGY IN CELL RESPIRATION	NATURE			English	Review							CYTOCHROME-C-OXIDASE; ELECTRON-PARAMAGNETIC-RESONANCE; STRETCHING RAMAN BAND; PROTON PUMP; ESCHERICHIA-COLI; PARACOCCUS-DENITRIFICANS; AMBIENT-TEMPERATURE; HYDROGEN-PEROXIDE; DIOXYGEN REACTION; BINUCLEAR CENTER	Many of the membrane-associated oxidases that catalyse respiratory reduction of O2 to water simultaneously couple this exergonic reaction to the translocation of protons across the inner mitochondrial membrane, or the cell membrane in prokaryotes, a process by which metabolic energy is conserved for subsequent synthesis of ATP. The molecular mechanism of O2 reduction and its linkage to H+ translocation are now emerging. The bimetallic haem iron-copper reaction centre in this family of enzymes is the critical structure for catalysis of both these processes.	UNIV HELSINKI, DEPT MED CHEM, SF-00170 HELSINKI 17, FINLAND	University of Helsinki	BABCOCK, GT (corresponding author), MICHIGAN STATE UNIV, DEPT CHEM, E LANSING, MI 48824 USA.		Wikstrom, Marten KF/A-4403-2008					AHMAD S, 1988, INORG CHEM, V27, P2230, DOI 10.1021/ic00286a006; ALBEN JO, 1981, P NATL ACAD SCI-BIOL, V78, P234, DOI 10.1073/pnas.78.1.234; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; ANTALIS TM, 1982, J BIOL CHEM, V257, P6194; BABCOCK GT, 1984, J AM CHEM SOC, V106, P8305, DOI 10.1021/ja00338a056; BABCOCK GT, 1989, BIOCHEMISTRY-US, V28, P9557, DOI 10.1021/bi00451a001; BABCOCK GT, 1988, BIOL APPLICATIONS RE, V3, P294; BEINERT H, 1988, CHEM SCRIPTA, V28A, P35; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; BLAIR DF, 1986, BIOPHYS J, V50, P713, DOI 10.1016/S0006-3495(86)83511-1; BLAIR DF, 1985, J AM CHEM SOC, V107, P7389, DOI 10.1021/ja00311a029; BOUGESBOCQUET B, 1980, BIOCHIM BIOPHYS ACTA, V594, P85, DOI 10.1016/0304-4173(80)90006-3; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CHANCE B, 1975, J BIOL CHEM, V250, P9226; CHANG CK, 1976, P NATL ACAD SCI USA, V73, P3338, DOI 10.1073/pnas.73.10.3338; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CLORE GM, 1980, BIOCHEM J, V185, P139, DOI 10.1042/bj1850139; FINDSEN EW, 1987, J AM CHEM SOC, V109, P5367, DOI 10.1021/ja00252a011; GEORGE P, 1965, OXIDASES RELATED RED, V1, P3; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; HALTIA T, 1991, EMBO J, V10, P2015, DOI 10.1002/j.1460-2075.1991.tb07731.x; HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x; HALTIA T, IN PRESS MOL MECHANI; HAN S, 1990, P NATL ACAD SCI USA, V87, P8408, DOI 10.1073/pnas.87.21.8408; HAN S, 1990, P NATL ACAD SCI USA, V87, P2491, DOI 10.1073/pnas.87.7.2491; HAN SH, 1990, BIOCHEMISTRY-US, V29, P1380, DOI 10.1021/bi00458a006; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HANSSON O, 1982, EMBO J, V1, P1295, DOI 10.1002/j.1460-2075.1982.tb01313.x; HILL BC, 1991, J BIOL CHEM, V266, P2219; HILL BC, 1986, BIOCHIM BIOPHYS ACTA, V853, P91, DOI 10.1016/0304-4173(86)90006-6; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; KOBAYASHI K, 1989, J BIOL CHEM, V264, P7976; KRAB K, 1987, BIOCHIM BIOPHYS ACTA, V895, P25, DOI 10.1016/S0304-4173(87)80015-0; KRONECK PMH, 1988, FEBS LETT, V242, P70, DOI 10.1016/0014-5793(88)80987-6; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; LEMIEUX LJ, IN PRESS J BIOL CHEM; LINDSAY JG, 1975, ARCH BIOCHEM BIOPHYS, V169, P492, DOI 10.1016/0003-9861(75)90192-7; LUBBEN M, 1992, EMBO J, V11, P805, DOI 10.1002/j.1460-2075.1992.tb05117.x; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; MALATESTA F, 1990, P NATL ACAD SCI USA, V87, P7410, DOI 10.1073/pnas.87.19.7410; MALMSTROM BG, 1982, ANNU REV BIOCHEM, V51, P21, DOI 10.1146/annurev.bi.51.070182.000321; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MALMSTROM BG, 1989, FEBS LETT, V250, P9, DOI 10.1016/0014-5793(89)80675-1; MARTIN CT, 1988, J BIOL CHEM, V263, P8420; MIMS MP, 1983, J BIOL CHEM, V258, P4219; MINAGAWA J, IN PRESS J BIOL CHEM; MITCHELL P, 1988, ANN NY ACAD SCI, V550, P185, DOI 10.1111/j.1749-6632.1988.tb35335.x; MITCHELL P, 1979, EUR J BIOCHEM, V95, P1, DOI 10.1111/j.1432-1033.1979.tb12934.x; MITCHELL P, 1981, OXYGEN FUELS LIVIN 1, P1; MORGAN JE, 1991, BIOCHEMISTRY-US, V30, P948, DOI 10.1021/bi00218a010; NAQUI A, 1986, ANNU REV BIOCHEM, V55, P137, DOI 10.1146/annurev.biochem.55.1.137; NICHOLLS P, 1988, ANN NY ACAD SCI, V550, P59, DOI 10.1111/j.1749-6632.1988.tb35323.x; OERTLING WA, 1990, INORG CHEM, V29, P2633, DOI 10.1021/ic00339a021; OGURA T, 1990, J AM CHEM SOC, V112, P5630, DOI 10.1021/ja00170a032; OGURA T, 1990, J BIOL CHEM, V265, P14721; OGURA T, IN PRESS B CHEM SOC; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P436, DOI 10.1021/bi00216a019; ORII Y, 1984, J BIOL CHEM, V259, P7187; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; PRONIEWICZ LM, 1991, J AM CHEM SOC, V113, P3294, DOI 10.1021/ja00009a012; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; RODGERS MA, 1981, OXYGEN OXYRADICALS C; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SANTANA M, IN PRESS J BIOL CHEM; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCOTT RA, 1989, ANNU REV BIOPHYS BIO, V18, P137, DOI 10.1146/annurev.bb.18.060189.001033; SHAPLEIGH J, IN PRESS P NATN ACAD; SOLIOZ M, 1982, J BIOL CHEM, V257, P1579; SONE N, 1982, J BIOL CHEM, V257, P2600; STEFFENS GJ, 1979, H-S Z PHYSIOL CHEM, V360, P613; TABUSHI I, 1988, COORDIN CHEM REV, V86, P1, DOI 10.1016/0010-8545(88)85011-2; TRAYLOR TG, 1991, PURE APPL CHEM, V63, P265, DOI 10.1351/pac199163020265; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; VAROTSIS C, 1989, J AM CHEM SOC, V111, P6439, DOI 10.1021/ja00198a075; VAROTSIS C, 1990, J AM CHEM SOC, V112, P1297, DOI 10.1021/ja00159a091; VAROTSIS C, 1990, J BIOL CHEM, V265, P11131; VAROTSIS C, UNPUB P NATN ACAD SC; VYGODINA T, 1989, BIOCHIM BIOPHYS ACTA, V973, P390, DOI 10.1016/S0005-2728(89)80380-9; VYGODINA TV, IN PRESS BIOL MEMBR; WIKSTROM M, 1987, CHEM SCRIPTA, V27B, P53; WIKSTROM M, 1981, P NATL ACAD SCI-BIOL, V78, P4051, DOI 10.1073/pnas.78.7.4051; WIKSTROM M, 1988, CHEM SCRIPTA, V28A, P71; WIKSTROM M, 1988, FEBS LETT, V231, P247, DOI 10.1016/0014-5793(88)80741-5; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM M, 1979, BIOCHIM BIOPHYS ACTA, V549, P177, DOI 10.1016/0304-4173(79)90014-4; WIKSTROM M, 1978, ENERGY CONSERVATION, P128; Wikstrom M., 1981, CYTOCHROME OXIDASE S; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; WILLIAMS RJP, 1987, FEBS LETT, V226, P1, DOI 10.1016/0014-5793(87)80539-2; WILLIAMS RJP, 1961, J THEOR BIOL, V1, P1, DOI 10.1016/0022-5193(61)90023-6; WILSON MT, 1982, BIOCHEM J, V203, P483, DOI 10.1042/bj2030483; WOODRUFF WH, 1991, P NATL ACAD SCI USA, V88, P2588, DOI 10.1073/pnas.88.6.2588; WRIGGLESWORTH JM, 1984, BIOCHEM J, V217, P715, DOI 10.1042/bj2170715; WU W, 1992, J AM CHEM SOC, V114, P1182, DOI 10.1021/ja00030a009; YOSHIKAWA S, 1990, J BIOL CHEM, V265, P7945; ZIMMERMANN BH, 1988, P NATL ACAD SCI USA, V85, P5779, DOI 10.1073/pnas.85.16.5779	101	1091	1100	4	171	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 26	1992	356	6367					301	309		10.1038/356301a0	http://dx.doi.org/10.1038/356301a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1312679				2022-12-28	WOS:A1992HK79400052
J	WIENANDS, J; RETH, M				WIENANDS, J; RETH, M			GLYCOSYL-PHOSPHATIDYLINOSITOL LINKAGE AS A MECHANISM FOR CELL-SURFACE EXPRESSION OF IMMUNOGLOBULIN-D	NATURE			English	Article							NATURAL-KILLER CELLS; ANTIGEN RECEPTOR COMPLEX; LINKED MEMBRANE-PROTEIN; B-CELLS; MOLECULAR-COMPONENTS; IGM; GENE; GLYCOPROTEIN; DIFFER; LFA-3	THE B-cell antigen receptor of the IgM and IgD class is a multimeric complex consisting of the membrane-bound form of the immunoglobulin molecule and two other proteins, Ig-alpha and Ig-beta 1-8. The Ig-alpha and Ig-beta proteins form a disulphide-linked alpha/beta heterodimer and are encoded by the mb-1 (refs 9, 10) and B29 genes 11,12, respectively 13,14. Surface expression of the membrane-bound IgM molecule requires assembly with the alpha/beta heterodimer 1,3,4,8. The IgD molecule, however, can be expressed on the cell surface in an alpha/beta-dependent and -independent forms 8,15. We show here that in the alpha/beta-independent form the IgD molecule is anchored in the plasma membrane through a glycosyl-phosphatidylinositol linker. In the presence of the alpha/beta heterodimer, most of the otherwise glycosyl-phosphatidylinositol-linked IgD molecule is expressed on the cell surface as transmembrane proteins.			WIENANDS, J (corresponding author), MAX PLANCK INST IMMUNBIOL,STUBEWEG 51,W-7800 FREIBURG,GERMANY.							BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CHEN JZ, 1990, EMBO J, V9, P2117, DOI 10.1002/j.1460-2075.1990.tb07380.x; DHAR A, 1991, BIOCHIM BIOPHYS ACTA, V1091, P15, DOI 10.1016/0167-4889(91)90215-J; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HOMBACH J, 1988, J EXP MED, V167, P652, DOI 10.1084/jem.167.2.652; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; PARKHOUSE RME, 1990, IMMUNOLOGY, V69, P298; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; VANNOESEL CJM, 1990, EUR J IMMUNOL, V20, P2789, DOI 10.1002/eji.1830201238; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WALLNER BP, 1987, J EXP MED, V166, P923, DOI 10.1084/jem.166.4.923; WIENANDS J, 1991, EUR J IMMUNOL, V21, P2373, DOI 10.1002/eji.1830211012; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x	29	63	63	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					246	248		10.1038/356246a0	http://dx.doi.org/10.1038/356246a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1313152				2022-12-28	WOS:A1992HJ94400060
J	LIN, HY; WANG, XF; NGEATON, E; WEINBERG, RA; LODISH, HF				LIN, HY; WANG, XF; NGEATON, E; WEINBERG, RA; LODISH, HF			EXPRESSION CLONING OF THE TGF-BETA TYPE-II RECEPTOR, A FUNCTIONAL TRANSMEMBRANE SERINE THREONINE KINASE	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; OVARIAN FOLLICULAR-FLUID; PROTEIN-KINASE; MYOGENIC DIFFERENTIATION; SIGNAL TRANSDUCTION; CELL PROLIFERATION; MOLECULAR-CLONING; MEMBRANE-RECEPTOR; SEQUENCE-ANALYSIS; EPITHELIAL-CELLS	A cDNA encoding the TGF-beta type II receptor protein has been isolated by an expression cloning strategy. The cloned cDNA, when transfected into COS cells, leads to overexpression of an approximately 80 kd protein that specifically binds radioiodinated TGF-beta-1. Excess TGF-beta-1 competes for binding of radioiodinated TGF-beta-1 in a dose-dependent manner and is more effective than TGF-beta-2. The predicted receptor structure includes a cysteine-rich extracellular domain, a single hydrophobic transmembrane domain, and a predicted cytoplasmic serine/threonine kinase domain. A chimeric protein containing the intracellular domain of the type II receptor and expressed in E. coli can phosphorylate itself on serine and threonine residues in vitro, indicating that the cytoplasmic domain of the type II receptor is a functional kinase. This result implicates serine/threonine phosphorylation as an important mechanism of TGF-beta receptor-mediated signaling.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	LIN, HY (corresponding author), WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.				NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007287] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA39826] Funding Source: Medline; NHLBI NIH HHS [HL-41484] Funding Source: Medline; NIGMS NIH HHS [T 32 GM07287-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARTEAGA CL, 1988, CANCER RES, V48, P3898; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CENTRELLA M, 1988, FASEB J, V2, P3066, DOI 10.1096/fasebj.2.15.2903838; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P3083, DOI 10.1021/bi00359a003; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; FORAGE RG, 1986, P NATL ACAD SCI USA, V83, P3091, DOI 10.1073/pnas.83.10.3091; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GEISER AG, 1992, IN PRESS J BIOL CHEM; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLDRING SR, 1978, BIOCHEM BIOPH RES CO, V83, P434, DOI 10.1016/0006-291X(78)91009-4; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOSES HL, 1985, CANCER CELL, V3, P65; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	71	1058	1147	0	26	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					775	785		10.1016/0092-8674(92)90152-3	http://dx.doi.org/10.1016/0092-8674(92)90152-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1310899				2022-12-28	WOS:A1992HF44000017
J	MAKI, H; SEKIGUCHI, M				MAKI, H; SEKIGUCHI, M			MUTT PROTEIN SPECIFICALLY HYDROLYZES A POTENT MUTAGENIC SUBSTRATE FOR DNA-SYNTHESIS	NATURE			English	Article							ESCHERICHIA-COLI; POLYMERASE SUBUNIT; MOLECULAR-CLONING; FIDELITY; MUTATOR; PURIFICATION; REPLICATION; SITE	ERRORS in the replication of DNA are a major source of spontaneous mutations, and a number of cellular functions are involved in correction of these errors to keep the frequency of spontaneous mutations very low 1. We report here a novel mechanism which prevents replicational errors by degrading a potent mutagenic substrate for DNA synthesis. This error-avoiding process is catalysed by a protein encoded by the mutT gene of Escherichia coli, mutations of which increase the occurrence of A . T --> C . G transversions 100 to 10,000 times the level of the wild type 2. Spontaneous oxidation of dGTP forms 8-oxo-7,8-dihydro-2'-dGTP (8-oxodGTP), which is inserted opposite dA and dC residues of template DNA with almost equal efficiency, and the MutT protein specifically degrades 8-oxodGTP to the monophosphate. This indicates that elimination from the nucleotide pool of the oxidized form of guanine nucleotide is important for the high fidelity of DNA synthesis.			MAKI, H (corresponding author), KYUSHU UNIV,FAC MED,DEPT BIOCHEM,FUKUOKA 812,JAPAN.							AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; FERSHT A, 1977, ENZYME STRUCTURE MEC, P91; HORIUCHI T, 1989, B I PASTEUR, V87, P309; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; KASAI H, 1984, JPN J CANCER RES, V75, P1037; MAKI H, 1985, J BIOL CHEM, V260, P2987; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	19	814	834	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					273	275		10.1038/355273a0	http://dx.doi.org/10.1038/355273a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1309939				2022-12-28	WOS:A1992GZ69400075
J	HEALY, B				HEALY, B			RELATIVE TOXICITY OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS EVALUATED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, ARTHRITIS RHEUM, V34, P1353	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					209	209						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1309267				2022-12-28	WOS:A1992GY04600004
J	YAN, Q; ELLIOTT, J; SNIDER, WD				YAN, Q; ELLIOTT, J; SNIDER, WD			BRAIN-DERIVED NEUROTROPHIC FACTOR RESCUES SPINAL MOTOR NEURONS FROM AXOTOMY-INDUCED CELL-DEATH	NATURE			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; RETROGRADE TRANSPORT; CORD MOTONEURONS; DEVELOPING RATS; FACTOR FAMILY; TRKB; NGF; EXPRESSION; MEMBER	CURRENT ideas about the dependence of neurons on target-derived growth factors were formulated on the basis of experiments involving neurons with projections to the periphery1,2. Nerve growth factor (NGF) and recently identified members of the NGF family of neuronal growth factors, known as neurotrophins, are thought to regulate survival of sympathetic and certain populations of sensory ganglion cells during development3-8. Far less is known about factors that regulate the survival of spinal and cranial motor neurons, which also project to peripheral targets. NGF has not been shown to influence motor neuron survival9,10, and whether the newly identified neurotrophins promote motor neuron survival is unknown. We show here that brain-derived neurotrophic factor (BDNF) is retrogradely transported by motor neurons in neonatal rats and that local application of BDNF to transected sciatic nerve prevents the massive death of motor neurons that normally follows axotomy in the neonatal period. These results show that BDNF has survival-promoting effects on motor neurons in vivo and suggest that BDNF may influence motor neuron survival during development.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROL SURG NEUROL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	YAN, Q (corresponding author), AMGEN INC,AMGEN CTR,NEUROBIOL PROGRAM,THOUSAND OAKS,CA 91320, USA.							ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; KASHIHARA Y, 1987, J PHYSIOL-LONDON, V386, P135, DOI 10.1113/jphysiol.1987.sp016526; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P229; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1982, J COMP NEUROL, V210, P174, DOI 10.1002/cne.902100208; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHMALBRUCH H, 1984, J COMP NEUROL, V224, P252, DOI 10.1002/cne.902240206; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; WAYNE DB, 1988, DEV BIOL, V127, P220, DOI 10.1016/0012-1606(88)90203-5; YAN Q, 1988, NEURON, V1, P335; YAN Q, 1988, J NEUROSCI, V8, P3481; YAN Q, 1991, Society for Neuroscience Abstracts, V17, P1119	31	633	680	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					753	755		10.1038/360753a0	http://dx.doi.org/10.1038/360753a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1281520				2022-12-28	WOS:A1992KE47200037
J	STAMLER, JS; SINGEL, DJ; LOSCALZO, J				STAMLER, JS; SINGEL, DJ; LOSCALZO, J			BIOCHEMISTRY OF NITRIC-OXIDE AND ITS REDOX-ACTIVATED FORMS	SCIENCE			English	Article							AQUEOUS NITROSYLIRON(II) CHEMISTRY; SOLUBLE GUANYLATE-CYCLASE; RELAXING FACTOR; HEME-PROTEINS; DENITRIFYING BACTERIA; NITROSONIUM CATION; ELECTRON-TRANSFER; REDUCTION; OXIDATION; SUPEROXIDE	Nitric oxide (NO.), a potentially toxic molecule, has been implicated in a wide range of biological functions. Details of its biochemistry, however, remain poorly understood. The broader chemistry of nitrogen monoxide (NO) involves a redox array of species with distinctive properties and reactivities: NO+ (nitrosonium), NO., and NO- (nitroxyl anion). The integration of this chemistry with current perspectives of NO biology illuminates many aspects of NO biochemistry, including the enzymatic mechanism of synthesis, the mode of transport and targeting in biological systems, the means by which its toxicity is mitigated, and the function-regulating interaction with target proteins.	HARVARD UNIV,BROCKTON W ROXBURY VET ADM MED CTR,SCH MED,CARDIOL SECT,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02142; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard University; Brigham & Women's Hospital	STAMLER, JS (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV RESP,BOSTON,MA 02115, USA.		Loscalzo, Joseph/ABD-8980-2021	Stamler, Jonathan/0000-0002-6866-1572	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043344, R01HL040411] Funding Source: NIH RePORTER; NCRR NIH HHS [RRO4870] Funding Source: Medline; NHLBI NIH HHS [HL40411, HL43344] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bates JN, 1990, BIOCHEM PHARMACOL, V42, P157, DOI DOI 10.1016/0006-2952(91)90406-U; BAZYLINSKI DA, 1985, INORG CHEM, V24, P4285, DOI 10.1021/ic00219a017; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BLOUGH NV, 1985, INORG CHEM, V24, P3502, DOI 10.1021/ic00216a003; BONNER FT, 1982, INORG CHEM, V21, P1973, DOI 10.1021/ic00135a053; BOTTOMLEY F, 1973, J CHEM SOC CHEM COMM, P919, DOI 10.1039/c39730000919; BOTTOMLEY F, 1978, ACCOUNTS CHEM RES, V11, P158, DOI 10.1021/ar50124a006; BRAUGHLER JM, 1983, BIOCHEM PHARMACOL, V32, P811, DOI 10.1016/0006-2952(83)90581-6; BRAUGHLER JM, 1982, BIOCHEM PHARMACOL, V31, P3847, DOI 10.1016/0006-2952(82)90301-X; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUNTON CA, 1957, RECENT ASPECTS INORG, P113; Challis B.C., 1987, IARC SCI PUBL, V84, P308; CHALLIS BC, 1980, IARC SCI PUBL, V31, P127; DEMASTER EG, 1984, BIOCHEM BIOPH RES CO, V122, P358, DOI 10.1016/0006-291X(84)90483-2; DOYLE MP, 1988, J AM CHEM SOC, V110, P593, DOI 10.1021/ja00210a047; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; DOYLE MP, 1984, J BIOL CHEM, V259, P80; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; EBERSON L, 1984, ACTA CHEM SCAND B, V38, P861, DOI 10.3891/acta.chem.scand.38b-0861; ENEMARK JH, 1972, P NATL ACAD SCI USA, V69, P3534, DOI 10.1073/pnas.69.12.3534; FUKUTO JM, 1992, BIOCHEM PHARMACOL, V43, P607, DOI 10.1016/0006-2952(92)90584-6; FUKUTO JM, IN PRESS J PHARM EXP; GORETSKI J, 1988, J BIOL CHEM, V263, P2316; GORETSKI J, 1991, BIOCHEM BIOPH RES CO, V175, P901, DOI 10.1016/0006-291X(91)91650-2; GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P1003; GWOST D, 1973, INORG CHEM, V12, P2095, DOI 10.1021/ic50127a030; HENRY Y, 1990, EUR BIOPHYS J, V20, P1; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KIM CH, 1984, J BIOL CHEM, V259, P2092; KIM EK, 1991, J AM CHEM SOC, V113, P4962, DOI 10.1021/ja00013a036; KOSAKA H, 1989, CARCINOGENESIS, V10, P563, DOI 10.1093/carcin/10.3.563; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAPETINA EG, 1984, IN PRESS J BIOL CHEM, V259, P13590; LEE KY, 1990, INORG CHEM, V29, P4196, DOI 10.1021/ic00346a008; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; MARICQ MM, 1989, J CHEM PHYS, V90, P3136, DOI 10.1063/1.455915; MARLETTA M A, 1990, Biofactors, V2, P219; MASON J, 1969, J CHEM SOC A, P1587; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCCLEVERTY JA, 1979, CHEM REV, V79, P53, DOI 10.1021/cr60317a005; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MIRVISH SS, 1975, TOXICOL APPL PHARM, V31, P325, DOI 10.1016/0041-008X(75)90255-0; MIWA M, 1987, CARCINOGENESIS, V8, P995; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORIGUCHI M, 1992, BIOCHEM BIOPH RES CO, V183, P598, DOI 10.1016/0006-291X(92)90524-O; MORRIS SL, 1984, J BIOL CHEM, V259, P3590; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NIROOMAND F, 1989, BIOCHEM BIOPH RES CO, V161, P75, DOI 10.1016/0006-291X(89)91562-3; OAE S, 1983, ORG PREP PROCED INT, V15, P165, DOI 10.1080/00304948309355444; OH SMNYF, 1991, J CHEM SOC PERK T 2, P685, DOI 10.1039/p29910000685; OLSON JS, 1981, METHOD ENZYMOL, V76, P361; ONEILL IK, 1987, IARC SCI PUBL, V84, P322; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEARSALL KA, 1982, INORG CHEM, V21, P1978, DOI 10.1021/ic00135a054; PORTER TD, 1991, J BIOL CHEM, V266, P13469; PRYOR WA, 1981, SCIENCE, V214, P435, DOI 10.1126/science.214.4519.435; RADI R, 1991, J BIOL CHEM, V266, P4244; RIDD JH, 1978, ADV PHYS ORG CHEM, V16, P1; RINDEN E, 1989, J AM CHEM SOC, V111, P1203, DOI 10.1021/ja00186a006; SARAN M, 1990, FREE RADICAL RES COM, V10, P221, DOI 10.3109/10715769009149890; SCHMIDT HHHW, 1992, FEBS LETT, V307, P102, DOI 10.1016/0014-5793(92)80910-9; SCHULZ U, 1969, CAN J CHEMISTRY, V47, P2021, DOI 10.1139/v69-326; SEN NP, 1975, IARC SCI PUBL, V9, P103; SHARMA VS, 1983, BIOCHEMISTRY-US, V22, P3897, DOI 10.1021/bi00285a026; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STAMLER J, UNPUB; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1992, INT M BIOL NITRIC OX, P20; Stuehr DJ, 2006, ADV ENZYMOL RELAT AR, V65, P287, DOI DOI 10.1002/9780470123119.CH8; SWINEHART J. H., 1967, COORDIN CHEM REV, V2, P385; Tannenbaum S R, 1987, IARC Sci Publ, P292; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TURK T, 1992, BIOCHEM BIOPH RES CO, V183, P983, DOI 10.1016/S0006-291X(05)80287-6; VANIN A. F., 1967, BIOKHIMIYA, V32, P277; VANIN AF, 1991, FEBS LETT, V289, P1, DOI 10.1016/0014-5793(91)80894-9; VEDERNIKOV YP, 1992, EUR J PHARMACOL, V211, P313, DOI 10.1016/0014-2999(92)90386-I; WADE RS, 1990, CHEM RES TOXICOL, V3, P289, DOI 10.1021/tx00016a002; WATARU E, 1989, KAGAKU KOGAKU RONBUN, V15, P1115; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Williams D.C., 1988, NITROSATION, P1; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3; WU XB, 1992, ARCH BIOCHEM BIOPHYS, V294, P75, DOI 10.1016/0003-9861(92)90139-N; YE RW, 1991, J BIOL CHEM, V266, P12848; [No title captured]	99	2363	2443	3	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1898	1902		10.1126/science.1281928	http://dx.doi.org/10.1126/science.1281928			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1281928				2022-12-28	WOS:A1992KD08800021
J	PEANO, GM; FENOGLIO, LM; MENARDI, G; BALBO, R; MARENCHINO, D; FENOGLIO, S				PEANO, GM; FENOGLIO, LM; MENARDI, G; BALBO, R; MARENCHINO, D; FENOGLIO, S			HETEROSEXUAL TRANSMISSION OF HEPATITIS-C VIRUS IN FAMILY GROUPS WITHOUT RISK-FACTORS	BRITISH MEDICAL JOURNAL			English	Article							NON-B-HEPATITIS; SEXUAL TRANSMISSION; NON-A		OSPED S CROCE,SERV IMMUNOEMATOL & TRASFUSIONALE,USL 58,BLOOD BANK UNIT,MED STAFF,CUNEO,ITALY; UNIV TURIN,MED CLIN B,DIV MED GEN 1,I-10124 TURIN,ITALY	University of Turin	PEANO, GM (corresponding author), VIA Q SELLA 22,I-12100 CUNEO,ITALY.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; KIYOSAWA K, 1991, J MED VIROL, V33, P114, DOI 10.1002/jmv.1890330209; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; TEDDER RS, 1991, BRIT MED J, V302, P1299, DOI 10.1136/bmj.302.6788.1299	5	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1473	1474		10.1136/bmj.305.6867.1473	http://dx.doi.org/10.1136/bmj.305.6867.1473			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1283543	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KC91800023
J	KITAJIMA, I; SHINOHARA, T; BILAKOVICS, J; BROWN, DA; XU, X; NERENBERG, M				KITAJIMA, I; SHINOHARA, T; BILAKOVICS, J; BROWN, DA; XU, X; NERENBERG, M			ABLATION OF TRANSPLANTED HTLV-I TAX-TRANSFORMED TUMORS IN MICE BY ANTISENSE INHIBITION OF NF-KAPPA-B	SCIENCE			English	Article							T-CELL LEUKEMIA; HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION FACTOR; TRANSGENIC MICE; RETROVIRUS; EXPRESSION; LYMPHOMA; PROTEIN; GENE; OLIGODEOXYNUCLEOTIDES	Mice transgenic for the human T cell leukemia virus (HTLV-1) Tax gene develop fibroblastic tumors that express NF-kappaB-inducible early genes. In vitro inhibition of NF-kappaB expression by antisense oligodeoxynucleotides (ODNs) inhibited growth of these culture-adapted Tax-transformed fibroblasts as well as an HTLV-I-transformed human lymphocyte line. In contrast, antisense inhibition of Tax itself had no apparent effect on cell growth. Mice treated with antisense to NF-kappaB ODNs showed rapid regression of transplanted fibrosarcomas. This suggests that NF-kappaB expression may be necessary for the maintenance of the malignant phenotype and provides a therapeutic approach for HTLV-I-associated disease.	Scripps Res Inst, DEPT NEUROPHARMACOL, CVN 10, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NCI NIH HHS [CA50234] Funding Source: Medline; NIMH NIH HHS [MH47680] Funding Source: Medline; NINDS NIH HHS [NS01330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH047680] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V63, P1072; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; FELGNER PL, 1988, P NATL ACAD SCI USA, V85, P7413; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; IVERSEN P, 1991, ANTI-CANCER DRUG DES, V6, P531; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KITAJIMA I, UNPUB; KITAJIMA I, IN PRESS J BIOL CHEM; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MACGREGOR GR, 1989, METHODS MOL BIOL; MILLER PS, 1980, J BIOL CHEM, V255, P9659; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1989, AM J PATHOL, V135, P1025; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	27	270	295	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1792	1795		10.1126/science.1299224	http://dx.doi.org/10.1126/science.1299224			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1299224				2022-12-28	WOS:A1992KB96400038
J	LUIRINK, J; HIGH, S; WOOD, H; GINER, A; TOLLERVEY, D; DOBBERSTEIN, B				LUIRINK, J; HIGH, S; WOOD, H; GINER, A; TOLLERVEY, D; DOBBERSTEIN, B			SIGNAL-SEQUENCE RECOGNITION BY AN ESCHERICHIA-COLI RIBONUCLEOPROTEIN COMPLEX	NATURE			English	Article							4.5S RNA; NASCENT PREPROLACTIN; PARTICLE; PROTEINS; MEMBRANE; TRANSLOCATION; POLYPEPTIDE; INSERTION; DOMAIN; ER	HYDROPHOBIC signal-sequences direct the transfer of secretory proteins across the inner membrane of prokaryotes and the endoplasmic reticulum membranes of eukaryotes1. In mammalian cells, signal-sequences are recognized by the 54K protein (M(r) 54,000) of the signal recognition particle (SRP)2,3 which is believed to hold the nascent chain in a translocation-competent conformation until it contacts the endoplasmic reticulum membrane4. The SRP consists of a 7S RNA and six different polypeptides. The 7S RNA and the 54K signal-sequence-binding protein (SRP54) of mammalian SRP exhibit strong sequence similarity to the 4.5S RNA and P48 protein (Ffh) of Escherichia coli5-7 which form a ribonucleoprotein particle. Depletion of 4.5S RNA or overproduction of P48 causes the accumulation of the beta-lactamase precursor, although not of other secretory proteins8,9. Whether 4.5S RNA and P48 are part of an SRP-like complex with a role in protein export is controversial. Here we show that the P48/4.5S RNA ribonucleoprotein complex interacts specifically with the signal sequence of a nascent secretory protein and therefore is a signal recognition particle.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Luirink, Joen/AAB-8658-2021; Tollervey, David/AAR-6662-2020	Tollervey, David/0000-0003-2894-2772; High, Stephen/0000-0002-4532-8152				BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BROWN S, 1991, NEW BIOL, V3, P430; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201	19	158	161	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					741	743		10.1038/359741a0	http://dx.doi.org/10.1038/359741a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1279430	Green Submitted			2022-12-28	WOS:A1992JU65000060
J	CERAMI, C; FREVERT, U; SINNIS, P; TAKACS, B; CLAVIJO, P; SANTOS, MJ; NUSSENZWEIG, V				CERAMI, C; FREVERT, U; SINNIS, P; TAKACS, B; CLAVIJO, P; SANTOS, MJ; NUSSENZWEIG, V			THE BASOLATERAL DOMAIN OF THE HEPATOCYTE PLASMA-MEMBRANE BEARS RECEPTORS FOR THE CIRCUMSPOROZOITE PROTEIN OF PLASMODIUM-FALCIPARUM SPOROZOITES	CELL			English	Article							HUMAN MALARIA PARASITES; VACCINE DEVELOPMENT; SYNTHETIC PEPTIDES; SURFACE-ANTIGEN; MONOCLONAL-ANTIBODIES; SULFATED GLYCOLIPIDS; VONWILLEBRAND-FACTOR; PROTECTIVE ANTIGEN; SEQUENCE HOMOLOGY; CELL EPITOPES	Minutes after injection into the circulation, malaria sporozoites enter hepatocytes. The speed and specificity of the invasion process suggest that it is receptor mediated. We show here that recombinant Plasmodium falciparum circumsporozoite protein (CS) binds specifically to regions of the plasma membrane of hepatocytes exposed to circulating blood in the Disse space. No binding has been detected in other organs, or even in other regions of the hepatocyte membrane. The interaction of CS with hepatocytes, as well as sporozoite invasion of HepG2 cells, is inhibited by synthetic peptides representing the evolutionarily conserved region II of CS. We conclude that region II is a sporozoite ligand for hepatocyte receptors localized to the basolateral domain of the plasma membrane. Our findings provide a rational explanation for the target cell specificity of malaria sporozoites.	NYU MED CTR, DEPT MED & MOLEC PARASITOL, NEW YORK, NY 10016 USA; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES NEW TECHNOL, CH-4002 BASEL, SWITZERLAND; CATHOLIC UNIV CHILE, SANTIAGO, CHILE	New York University; Roche Holding; Pontificia Universidad Catolica de Chile	CERAMI, C (corresponding author), NYU MED CTR, KAPLAN CANC CTR, DEPT PATHOL, MICHAEL HEIDELBERGER DIV IMMUNOL, NEW YORK, NY 10016 USA.			Frevert, Ute/0000-0001-9556-7330; Cerami, Carla/0000-0002-7634-0955	NCI NIH HHS [5T32CA9161-16] Funding Source: Medline; NIGMS NIH HHS [5T32GM07308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKAWA M, 1981, J IMMUNOL, V126, P2494; ALEY SB, 1986, J EXP MED, V164, P1915, DOI 10.1084/jem.164.6.1915; BALLOU WR, 1985, SCIENCE, V228, P996, DOI 10.1126/science.2988126; BEIER JC, 1991, MED VET ENTOMOL, V5, P71, DOI 10.1111/j.1365-2915.1991.tb00523.x; BURKOT TR, 1991, PARASITE IMMUNOL, V13, P161, DOI 10.1111/j.1365-3024.1991.tb00272.x; CERAMI C, 1992, MOL BIOCHEM PARASIT, V54, P1, DOI 10.1016/0166-6851(92)90089-3; CLARKE LE, 1990, MOL BIOCHEM PARASIT, V41, P269, DOI 10.1016/0166-6851(90)90190-W; COCHRANE AH, 1976, J IMMUNOL, V116, P859; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELACRUZ VF, 1987, J BIOL CHEM, V262, P11935; DOOLAN DL, 1992, INFECT IMMUN, V60, P675, DOI 10.1128/IAI.60.2.675-682.1992; DUKOR P, 1970, P NATL ACAD SCI USA, V67, P991, DOI 10.1073/pnas.67.2.991; EICHINGER DJ, 1986, MOL CELL BIOL, V6, P3965, DOI 10.1128/MCB.6.11.3965; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; FREVERT U, 1992, IN PRESS INFECT IMMU; GALINSKI MR, 1987, CELL, V48, P311, DOI 10.1016/0092-8674(87)90434-X; GODSON GN, 1983, NATURE, V305, P29, DOI 10.1038/305029a0; GOOD MF, 1988, ANNU REV IMMUNOL, V6, P663, DOI 10.1146/annurev.iy.06.040188.003311; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HARLOW E, 1988, ANTIBODIES LABORATOR; HEDSTROM RC, 1990, WHO B OMS S, V68, P152; HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709; HOLLINGDALE MR, 1981, SCIENCE, V213, P1021, DOI 10.1126/science.7022652; HOLT GD, 1989, J BIOL CHEM, V264, P12138; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LAL AA, 1987, J BIOL CHEM, V262, P2937; LAL AA, 1988, J BIOL CHEM, V263, P5495; LAL AA, 1988, MOL BIOCHEM PARASIT, V30, P291, DOI 10.1016/0166-6851(88)90099-0; LAMBERT JM, 1978, BIOCHEMISTRY-US, V17, P5406, DOI 10.1021/bi00618a014; LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X; MCCUTCHAN TF, 1985, SCIENCE, V230, P1381, DOI 10.1126/science.2416057; MEIS JFGM, 1983, PARASITOLOGY, V86, P231, DOI 10.1017/S003118200005040X; MOROOSE R, 1986, ANNU REV MED, V37, P157; NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; RIVIER J, 1984, J CHROMATOGR, V288, P303, DOI 10.1016/S0021-9673(01)93709-4; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1986, J BIOL CHEM, V261, P6872; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; RUSSELL DG, 1983, PARASITOLOGY, V87, P199, DOI 10.1017/S0031182000052562; SANTORO F, 1983, J BIOL CHEM, V258, P3341; SHIN SCJ, 1982, J PROTOZOOL, V29, P448, DOI 10.1111/j.1550-7408.1982.tb05431.x; Sinden R. E., 1981, Parasitological topics -- a presentation volume to P.C.C. Garnham, F.R.S. on the occasion of his 80th birthday, 1981., P242; SINDEN RE, 1990, WHO B S, V68, P115; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; STEWART MJ, 1986, INFECT IMMUN, V51, P859, DOI 10.1128/IAI.51.3.859-864.1986; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; TAKACS BJ, 1991, J IMMUNOL METHODS, V143, P231, DOI 10.1016/0022-1759(91)90048-K; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUSZYNSKI GP, 1989, EXP CELL RES, V182, P473, DOI 10.1016/0014-4827(89)90251-6; VANDERBERG J, 1969, MIL MED, V134, P1183; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; YOSHIDA N, 1981, J EXP MED, V154, P1225, DOI 10.1084/jem.154.4.1225; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	65	306	315	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					1021	1033		10.1016/0092-8674(92)90251-7	http://dx.doi.org/10.1016/0092-8674(92)90251-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1326407				2022-12-28	WOS:A1992JN78100016
J	FRANCIS, DP				FRANCIS, DP			TOWARD A COMPREHENSIVE HIV PREVENTION PROGRAM FOR THE CDC AND THE NATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERVENTION				FRANCIS, DP (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,REG AIDS DIV,ATLANTA,GA 30333, USA.							[Anonymous], 1978, Bull World Health Organ, V56, P247; FRANCIS DP, 1989, JAMA-J AM MED ASSOC, V262, P2572, DOI 10.1001/jama.262.18.2572; KELLY JA, 1991, AM J PUBLIC HEALTH, V81, P168, DOI 10.2105/AJPH.81.2.168; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCITOVSKY AA, 1987, PUBLIC HLTH REPORTS, V102, P1; Shilts R., 1987, BAND PLAYED ON, P273; STALL R, 1989, EPIDEMIOLOGY AIDS EX, P266; WEINSTEIN I, 1947, AM J PUBLIC HEALTH, V37, P1376; ZWEIGHAFT RM, 1977, NEW ENGL J MED, V297, P803, DOI 10.1056/NEJM197710132971504; 1986, CONFRONTING AIDS DIR, P10; 1981, STATISTICAL ABSTRACT; 1990, MMWR, V39, P110	12	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1444	1447		10.1001/jama.268.11.1444	http://dx.doi.org/10.1001/jama.268.11.1444			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JM849	1324996				2022-12-28	WOS:A1992JM84900028
J	DAN, Y; POO, MM				DAN, Y; POO, MM			HEBBIAN DEPRESSION OF ISOLATED NEUROMUSCULAR SYNAPSES INVITRO	SCIENCE			English	Article							LONG-TERM POTENTIATION; SYNAPTIC TRANSMISSION; EMBRYONIC NEURON; EVOKED RELEASE; HIPPOCAMPUS; ACETYLCHOLINE; MECHANISM; TRANSMITTER; ENHANCEMENT; INDUCTION	Modulation of synaptic efficacy may depend on the temporal correlation between pre- and postsynaptic activities. At isolated neuromuscular synapses in culture, repetitive postsynaptic application of acetylcholine pulses alone or in the presence of asynchronous presynaptic activity resulted in immediate and persistent synaptic depression, whereas synchronous pre- and postsynaptic coactivation had no effect. This synaptic depression was a result of a reduction of evoked transmitter release, but induction of the depression requires a rise in postsynaptic cytosolic calcium concentration. Thus, Hebbian modulation operates at isolated peripheral synapses in vitro, and transsynaptic retrograde interaction appears to be an underlying mechanism.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				Dan, Yang/0000-0002-3818-877X	NINDS NIH HHS [NS 22764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER EM, 1991, J NEUROSCI, V11, P1496; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BETZ WJ, 1989, J PHYSIOL-LONDON, V418, P25, DOI 10.1113/jphysiol.1989.sp017827; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DAN Y, UNPUB; DECKER ER, 1990, J NEUROSCI, V10, P3413; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; GIOVANELLI A, 1991, P NATL ACAD SCI USA, V88, P10069, DOI 10.1073/pnas.88.22.10069; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEBB DO, 1949, ORG BEHAVIOR; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POO MM, 1982, NATURE, V295, P332, DOI 10.1038/295332a0; POPOV S, 1992, J NEUROSCI, V12, P77; PURVES D, 1985, PRINCIPLES NEURAL DE; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SEJNOWSKI T J, 1991, Current Biology, V1, P38, DOI 10.1016/0960-9822(91)90122-D; Sejnowski T.J., 1989, NEURAL MODELS PLASTI, P94; SKREDE KK, 1981, BRAIN RES, V208, P436, DOI 10.1016/0006-8993(81)90573-4; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; SUN YA, 1987, P NATL ACAD SCI USA, V84, P2540, DOI 10.1073/pnas.84.8.2540; Tabti N., 1991, CULTURING NERVE CELL, P137; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0	33	107	107	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1570	1573		10.1126/science.1317971	http://dx.doi.org/10.1126/science.1317971			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317971				2022-12-28	WOS:A1992HY07500033
J	BELICH, MP; MADRIGAL, JA; HILDEBRAND, WH; ZEMMOUR, J; WILLIAMS, RC; LUZ, R; PETZLERLER, ML; PARHAM, P				BELICH, MP; MADRIGAL, JA; HILDEBRAND, WH; ZEMMOUR, J; WILLIAMS, RC; LUZ, R; PETZLERLER, ML; PARHAM, P			UNUSUAL HLA-B ALLELES IN 2 TRIBES OF BRAZILIAN INDIANS	NATURE			English	Article							SELECTION	THE Kaingang and Guarani are culturally and linguistically distinct tribes of southern Brazil 1,2. Like all Amerindian groups 3,4 they show limited HLA polymorphism, which probably reflects the small founder populations that colonized America by overland migration from Asia 11,000-40,000 years ago, 5,6. We find the nucleotide sequences of HLA-B alleles from the Kaingang and Guarani to be distinct from those characterized in caucasian, oriental and other populations 7. By comparison, the HLA-A and C alleles are familiar. These results and those reported in the accompanying paper 8 on the Waorani of Ecuador reveal that a marked evolution of HLA-B has occurred since humans first entered South America. New alleles have been formed through recombination between pre-existing alleles, not by point mutation, giving rise to distinctive diversification of HLA-B in different South American Indian tribes.	FED UNIV PARANA,DEPT GENET,BR-81531 CURITIBA,PARANA,BRAZIL; BLOOD SYST INC,HISTOCOMPATIBIL LAB,SCOTTSDALE,AZ 85257; STANFORD UNIV,DEPT MICROBIOL,STANFORD,CA 94305; STANFORD UNIV,DEPT IMMUNOL,STANFORD,CA 94305	Universidade Federal do Parana; Vitalant; Stanford University; Stanford University	BELICH, MP (corresponding author), STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305, USA.		Petzl-Erler, Maria Luiza/H-8221-2012	Petzl-Erler, Maria Luiza/0000-0002-0345-5276				BLACK FL, 1984, AM J HUM GENET, V36, P1318; BODMER JG, IN PRESS TISSUE ANTI; CASTANO AR, 1991, IMMUNOGENETICS, V34, P281, DOI 10.1007/BF00211991; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; DUPOINT B, 1989, IMMUNOBIOLOGY HLA1; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; Fagan Brian M, 1987, GREAT JOURNEY PEOPLI; HEDRICK PW, 1991, P NATL ACAD SCI USA, V88, P5897, DOI 10.1073/pnas.88.13.5897; HEDRICK PW, 1983, GENETICS, V104, P449; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; KLEIN J, 1986, NATURAL HIST MAJOR H, P627; KOSTYU DD, 1981, TISSUE ANTIGENS, V16, P111; NEEL JV, 1978, AM J HUM GENET, V30, P465; NEVES WA, 1985, AM J PHYS ANTHROPOL, V67, P13, DOI 10.1002/ajpa.1330670104; PARHAM P, 1989, J IMMUNOL, V142, P3937; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SALZANO FM, 1980, AM J PHYS ANTHROPOL, V53, P513, DOI 10.1002/ajpa.1330530408; WATKINS DI, 1992, NATURE, V357, P329, DOI 10.1038/357329a0; WILLIAMS RC, 1992, HUM IMMUNOL, V33, P39, DOI 10.1016/0198-8859(92)90050-W; WILLS C, 1991, IMMUNOL REV, V124, P165, DOI 10.1111/j.1600-065X.1991.tb00621.x; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941; ZEMMOUR J, 1991, IMMUNOGENETICS, V33, P310, DOI 10.1007/BF00216690; ZEMMOUR J, IN PRESS TISSUE ANTI	24	268	279	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					326	329		10.1038/357326a0	http://dx.doi.org/10.1038/357326a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1317015				2022-12-28	WOS:A1992HW13200047
J	BLUMENTHAL, D; EPSTEIN, AM				BLUMENTHAL, D; EPSTEIN, AM			PHYSICIAN-PAYMENT REFORM - UNFINISHED BUSINESS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,GEN MED UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,HLTH POLICY RES & DEV UNIT,BOSTON,MA 02114; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital								ALMY TP, 1981, NEW ENGL J MED, V304, P225, DOI 10.1056/NEJM198101223040408; BLUMENTHAL D, 1991, MED CARE, V29, P502, DOI 10.1097/00005650-199106000-00010; BLUMENTHAL D, 1986, INQUIRY-J HEALTH CAR, V23, P268; BLUMENTHAL D, 1988, RENEWING PROMISE MED, P3; EPSTEIN AM, 1986, NEW ENGL J MED, V314, P1089, DOI 10.1056/NEJM198604243141706; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; FRUEN MA, 1980, HEALTH POLICY EDUC, V1, P143, DOI 10.1016/S0165-2281(80)80019-1; HSIAO WC, 1988, JAMA-J AM MED ASSOC, V260, P2429, DOI 10.1001/jama.260.16.2429; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; Schroeder S A, 1978, Internist, V19, P8; 1991, FED REGISTER, V56, P59502; 1990, OVERVIEW ENTITLEMENT; 1991, FED REGISTER, V56, P59568	13	18	18	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1992	326	20					1330	1334		10.1056/NEJM199205143262005	http://dx.doi.org/10.1056/NEJM199205143262005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT803	1304717				2022-12-28	WOS:A1992HT80300005
J	WEBER, S; TRAUNECKER, A; OLIVERI, F; GERHARD, W; KARJALAINEN, K				WEBER, S; TRAUNECKER, A; OLIVERI, F; GERHARD, W; KARJALAINEN, K			SPECIFIC LOW-AFFINITY RECOGNITION OF MAJOR HISTOCOMPATIBILITY COMPLEX PLUS PEPTIDE BY SOLUBLE T-CELL RECEPTOR	NATURE			English	Article							ANTIGEN; HEMAGGLUTININ; DETERMINANT; ANTIBODIES; LINES; SITE	THE T-cell receptor is necessary and sufficient for recognition of peptides presented by major histocompatibility complex molecules 1,2. Other adhesion molecules, like CD4 or CD8, play an auxiliary role in antigen recognition by T cells 3,4. Here we analyse T-cell receptor (TCR) binding using a soluble rather than a cell-bound receptor molecule. A TCR-immunoglobulin chimaera is constructed with the variable and the first constant regions of both the TCR alpha- and beta-chains linked to the immunoglobulin light-chain constant regions. This soluble TCR is expressed, assembled and secreted as an alpha-beta-heterodimer by a myeloma cell line transfected with the recombinant genes. Furthermore, the soluble TCR is biologically active: it specifically inhibits antigen-dependent activation of the relevant T-cell clones and thus discriminates between proper and irrelevant peptides presented by major histocompatibility complex molecules.	WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute	WEBER, S (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		Karjalainen, Klaus/A-2206-2011					BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; DAVIS MM, 1989, COLD SPRING HARB SYM, V54, P119; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; HABERMAN AM, 1990, J IMMUNOL, V145, P3087; HACKETT CJ, 1983, J EXP MED, V158, P294, DOI 10.1084/jem.158.2.294; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; KAPPLER JW, 1984, REGULATION IMMUNE SY, P377; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; OZATO K, 1980, J IMMUNOL, V124, P533; RUBERTI G, 1992, J EXP MED, V175, P157, DOI 10.1084/jem.175.1.157; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; STAERZ U, 1985, MOL BIOL IMMUNE SYST, P61; TAYLOR AH, 1990, J EXP MED, V172, P1643, DOI 10.1084/jem.172.6.1643; TRAUNECKER A, 1989, IMMUNOL TODAY, V10, P29, DOI 10.1016/0167-5699(89)90062-5; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; TRAUNECKER A, 1986, EUR J IMMUNOL, V16, P851, DOI 10.1002/eji.1830160722; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WALKER E, 1982, J IMMUNOL, V128, P2164; YAGUE J, 1985, CELL, V42, P81, DOI 10.1016/S0092-8674(85)80103-3	23	221	235	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					793	796		10.1038/356793a0	http://dx.doi.org/10.1038/356793a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1315417				2022-12-28	WOS:A1992HR18600050
J	GOLDHAMER, DJ; FAERMAN, A; SHANI, M; EMERSON, CP				GOLDHAMER, DJ; FAERMAN, A; SHANI, M; EMERSON, CP			REGULATORY ELEMENTS THAT CONTROL THE LINEAGE-SPECIFIC EXPRESSION OF MYOD	SCIENCE			English	Article							GENE FAMILY; MYOGENESIS; MEMBER; DIFFERENTIATION; FIBROBLASTS; MUSCULATURE; HOMOLOGY; EMBRYOS; VECTORS; ORIGIN	The molecular basis of skeletal muscle lineage determination was investigated by analyzing DNA control elements that regulate the myogenic determination gene myoD. A distal enhancer was identified that positively regulates expression of the human myoD gene. The myoD enhancer and promoter were active in myogenic and several nonmyogenic cell lines. In transgenic mouse embryos, however, the myoD enhancer and promoter together directed expression of a lacZ transgene specifically to the skeletal muscle lineage. These data suggest that during development myoD is regulated by mechanisms that restrict accessibility of myoD control elements to positive trans-acting factors.	FOX CHASE CANC INST, INST CANC RES, PHILADELPHIA, PA 19111 USA; VOLCANI CTR, INST ANIM SCI, IL-50250 BET DAGAN, ISRAEL	Fox Chase Cancer Center; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD007796] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD007796] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NICHD NIH HHS [HD-07796] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; FAERMAN A, UNPUB; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GOLDHAMER DJ, UNPUB; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOGAN B, 1986, MANIPULATING MOUSE E; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PEDEN K, 1982, CELL, V31, P71, DOI 10.1016/0092-8674(82)90406-8; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUGH R, 1990, MOUSE ITS REPRODUCTI; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHANI M, 1986, MOL CELL BIOL, V6, P2624, DOI 10.1128/MCB.6.7.2624; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	38	136	138	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1992	256	5056					538	542		10.1126/science.1315077	http://dx.doi.org/10.1126/science.1315077			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1315077				2022-12-28	WOS:A1992HQ18700069
J	FITZGERALD, F; HOLCROFT, JW				FITZGERALD, F; HOLCROFT, JW			COLD LEGS AND FEET	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FITZGERALD, F (corresponding author), UNIV CALIF DAVIS,MED CTR,DAVIS,CA 95616, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2249	2249		10.1001/jama.267.16.2249	http://dx.doi.org/10.1001/jama.267.16.2249			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1313511				2022-12-28	WOS:A1992HN84100041
J	COFFIN, JM				COFFIN, JM			SUPERANTIGENS AND ENDOGENOUS RETROVIRUSES - A CONFLUENCE OF PUZZLES	SCIENCE			English	Editorial Material							MAMMARY-TUMOR VIRUS; LONG TERMINAL REPEAT; T-CELL LYMPHOMAS; LEUKEMIA-CELLS; B RETROVIRUS; ACTIVATION; PROVIRUSES; GENOMES; REGION; GENE				COFFIN, JM (corresponding author), TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02111, USA.				NCI NIH HHS [R35 CA 44385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BACCALA R, 1991, P NATL ACAD SCI USA, V88, P2908, DOI 10.1073/pnas.88.7.2908; BALL JK, 1985, VIROLOGY, V140, P159, DOI 10.1016/0042-6822(85)90455-6; BALL JK, 1988, J VIROL, V62, P2985, DOI 10.1128/JVI.62.8.2985-2993.1988; BEUTNER U, UNPUB; BRANDTCARLSON C, 1991, J VIROL, V65, P6051, DOI 10.1128/JVI.65.11.6051-6060.1991; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; COFFIN JM, 1981, J VIROL, V40, P953, DOI 10.1128/JVI.40.3.953-957.1981; COFFIN JM, 1985, RNA TUMOR VIRUSES, P1109; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DORNER AJ, 1985, J VIROL, V53, P32, DOI 10.1128/JVI.53.1.32-39.1985; DUDLEY J, 1984, J VIROL, V49, P92, DOI 10.1128/JVI.49.1.92-101.1984; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FRANKEL WN, UNPUB; GASCOIGNE NRJ, 1991, P NATL ACAD SCI USA, V88, P613, DOI 10.1073/pnas.88.2.613; GRAY DA, 1986, VIROLOGY, V154, P271, DOI 10.1016/0042-6822(86)90453-8; HSU CLL, 1988, J VIROL, V62, P4644, DOI 10.1128/JVI.62.12.4644-4652.1988; HUANG M, 1990, J VIROL, V64, P5764, DOI 10.1128/JVI.64.12.5764-5772.1990; HUGIN AW, 1991, SCIENCE, V252, P424, DOI 10.1126/science.1850169; IMBERTI L, 1991, SCIENCE, V254, P850; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; JANEWAY CA, 1990, CELL, V63, P659, DOI 10.1016/0092-8674(90)90130-7; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MICHALIDES R, 1985, MOL CELL BIOL, V5, P823, DOI 10.1128/MCB.5.4.823; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; NUSSE R, 1986, TRENDS GENET, V2, P244, DOI 10.1016/0168-9525(86)90247-7; RACEVSKIS J, 1986, J VIROL, V58, P441, DOI 10.1128/JVI.58.2.441-449.1986; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SIRACUSA LD, 1991, GENETICS, V127, P169; SONIGO P, 1986, CELL, V45, P375, DOI 10.1016/0092-8674(86)90323-5; STOYE J, 1985, RNA TUMOR VIRUSES, P357; STOYE JP, 1987, J VIROL, V61, P2659, DOI 10.1128/JVI.61.9.2659-2669.1987; THOMSON BJ, 1991, NATURE, V351, P530, DOI 10.1038/351530a0; TSUBURA A, 1988, CANCER RES, V48, P6555; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEISS R, 1984, RNA TUMOR VIRUSES; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; YANAGAWA SI, 1990, J VIROL, V64, P2474, DOI 10.1128/JVI.64.6.2474-2483.1990	46	49	51	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					411	413		10.1126/science.1310360	http://dx.doi.org/10.1126/science.1310360			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1310360				2022-12-28	WOS:A1992HA59000027
J	CLEMONS, MJ; CLEMONS, KR; SKINNER, R				CLEMONS, MJ; CLEMONS, KR; SKINNER, R			MEDICINE - THE HEARING PROFESSION	BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV BRISTOL,BRISTOL BS8 1TH,ENGLAND	Newcastle University - UK; University of Bristol	SKINNER, R (corresponding author), ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							WALTERS S, 1988, BRIT MED J, V297, P1665	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1568	1569		10.1136/bmj.305.6868.1568	http://dx.doi.org/10.1136/bmj.305.6868.1568			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286390	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992KD77100027
J	PETER, G				PETER, G			CURRENT CONCEPTS - CHILDHOOD IMMUNIZATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MUMPS-RUBELLA VACCINE; UNITED-STATES; CHANGING EPIDEMIOLOGY; CONJUGATE VACCINE; B POLYSACCHARIDE; HEPATITIS-B; MEASLES; EFFICACY; CHILDREN; POPULATION		BROWN UNIV,SCH MED,PROVIDENCE,RI 02912	Brown University	PETER, G (corresponding author), RHODE ISL HOSP,DIV PEDIAT INFECT DIS,593 EDDY ST,PROVIDENCE,RI 02903, USA.							ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; COCHI SL, 1988, AM J DIS CHILD, V142, P499, DOI 10.1001/archpedi.1988.02150050037025; COHENABBO A, 1992, SEMIN PEDITR INFECT, V3, P6; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; DEFOREST A, 1988, PEDIATRICS, V81, P237; DEQUADROS CA, 1992, ANNU REV PUBL HEALTH, V13, P239, DOI 10.1146/annurev.publhealth.13.1.239; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; FARIZO KM, 1992, CLIN INFECT DIS, V14, P708, DOI 10.1093/clinids/14.3.708; FARIZO KM, 1992, PEDIATRICS, V89, P589; FRANKS AL, 1989, NEW ENGL J MED, V321, P1301, DOI 10.1056/NEJM198911093211905; HADLER SC, 1992, CURRENT CLIN TOPICS, V12; HERSH BS, 1991, J PEDIATR-US, V119, P187, DOI 10.1016/S0022-3476(05)80726-7; Hinman A R, 1985, Dev Biol Stand, V61, P429; HINMAN AR, 1988, VACCINES, P587; HOWSON CP, 1992, PEDIATRICS, V89, P318; HURIE MB, 1992, PEDIATRICS, V89, P269; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; KROBER MS, 1991, JAMA-J AM MED ASSOC, V265, P2095, DOI 10.1001/jama.265.16.2095; LEE SH, 1992, JAMA-J AM MED ASSOC, V267, P2616, DOI 10.1001/jama.267.19.2616; MARGOLIS HS, 1990, VACCINE, V8, pS81, DOI 10.1016/0264-410X(90)90224-A; MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202; MCCONNOCHIE KM, 1992, PEDIATRICS, V89, P1019; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; ORENSTEIN WA, 1990, AM J DIS CHILD, V144, P517, DOI 10.1001/archpedi.1990.02150290011002; ORENSTEIN WA, 1992, IN PRESS 26TH P NAT; PETER G, 1991, JAMA-J AM MED ASSOC, V265, P2111, DOI 10.1001/jama.265.16.2111; PETER G, 1991, PEDIATRIC AIDS, P651; Peter G., 1991, 1991 RED BOOK REPORT, P7; Plotkin SA, 1988, VACCINES-BASEL; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SCHLENKER TL, 1992, JAMA-J AM MED ASSOC, V267, P823, DOI 10.1001/jama.267.6.823; SOSIN DM, 1989, PEDIATRICS, V84, P779; STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; WEST DJ, 1992, PEDIATR INFECT DIS J, V11, P866, DOI 10.1097/00006454-199210000-00012; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; 1991, MMWR MORB MORTAL WKL, V40, P1; 1990, PEDIATRICS, V85, P714; 1989, MMWR MORB MORTAL WKL, V38, P219; 1989, PEDIATRICS, V84, P1110; 1992, PEDIATRICS, V89, P795; 1989, MMWR MORB MORTAL WKL, V38, P205; 1991, PEDIATRICS, V88, P169; 1991, ANN NEUROL, V29, P458; IN PRESS JAMA; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1992, MMWR MORB MORTAL WKL, V40, P888; 1991, PEDIATRICS, V88, P397; 1989, MMWR MORB MORTAL WKL, V38, P1; 1992, MMWR MORB MORTAL WKL, V41, P326; 1992, PEDIATRICS, V90, P121	53	54	54	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1992	327	25					1794	1800						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB975	1306662				2022-12-28	WOS:A1992KB97500007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSAL TO PROVIDE MORE PEDIATRIC USE INFORMATION IN DRUG LABELING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1902, FED REG         1016, V57, P47427	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1328699				2022-12-28	WOS:A1992JW61600004
J	HEMMATIBRIVANLOU, A; MELTON, DA				HEMMATIBRIVANLOU, A; MELTON, DA			A TRUNCATED ACTIVIN RECEPTOR INHIBITS MESODERM INDUCTION AND FORMATION OF AXIAL STRUCTURES IN XENOPUS EMBRYOS	NATURE			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; MESSENGER-RNA; BODY AXIS; NEURAL INDUCTION; EARLY RESPONSE; EXPRESSION; ANTERIOR; HOMOLOG; LAEVIS; CELLS	Activins can induce mesoderm in embryonic explants and have been proposed as the natural inducer in Xenopus. A mutant activin receptor that inhibits activin signalling is used to show that activin is required for the induction of mesoderm in vivo and the patterning of the embryonic body plan. Blocking the activin signal transduction pathway also reveals autonomous induction of a neural marker and unmasks a relationship between activin and fibroblast growth factor.			HEMMATIBRIVANLOU, A (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALTABA ARI, 1990, TRENDS GENET, V6, P57; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1990, NATURWISSENSCHAFTEN, V77, P389, DOI 10.1007/BF01135742; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; BOLCE M, IN PRESS; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CONDIE BG, 1987, DEVELOPMENT, V101, P93; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1991, METHODS CELL BIOL; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; Harland RM, 1991, METHODS CELL BIOL; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLO.A, IN PRESS; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JONAS EA, 1989, DEVELOPMENT, V106, P399; JONES CM, 1992, DEVELOPMENT, V115, P639; KELLER R, 1988, DEVELOPMENT, V103, P193; KELLER R, 1991, METHODS CELL BIOL; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SYMES K, 1987, DEVELOPMENT, V101, P185; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VIZE PD, 1991, XENOPUS LAEVIS PRACT, P361; WILSON PA, 1989, DEVELOPMENT, V105, P155	56	500	530	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					609	614		10.1038/359609a0	http://dx.doi.org/10.1038/359609a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1328888				2022-12-28	WOS:A1992JT82400047
J	YAO, TP; SEGRAVES, WA; ORO, AE; MCKEOWN, M; EVANS, RM				YAO, TP; SEGRAVES, WA; ORO, AE; MCKEOWN, M; EVANS, RM			DROSOPHILA ULTRASPIRACLE MODULATES ECDYSONE RECEPTOR FUNCTION VIA HETERODIMER FORMATION	CELL			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; RESPONSE ELEMENT; ESTROGEN-RECEPTOR; TRANS-ACTIVATION; BETA-GENE; SUPERFAMILY; IDENTIFICATION; BINDING; MEMBER	The vertebrate retinoid X receptor (RXR) has been implicated in the regulation of multiple hormonal signaling pathways through the formation of heteromeric receptor complexes that bind DNA with high affinity. We now demonstrate that ultraspiracle (usp), a Drosophila RXR homolog, can substitute for RXR in stimulating the DNA binding of receptors for retinoic acid, T3, vitamin D, and peroxisome proliferator activators. These observations led to the search and ultimate identification of the ecdysone receptor (EcR) as a Drosophila partner of usp. Together, usp and EcR bind DNA in a highly cooperative fashion. Cotransfection of both EcR and usp expression vectors is required to render cultured mammalian cells ecdysone responsive. These results implicate usp as an integral component of the functional EcR. By demonstrating that receptor heterodimer formation precedes the divergence of vertebrate and invertebrate lineages, these data underscore a central role for RXR and its homolog usp in the evolution and control of the nuclear receptor-based endocrine system.	UNIV CALIF SAN DIEGO, DEPT BIOL, GRAD PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	YAO, TP (corresponding author), SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				ANDRES AJ, 1992, TRENDS GENET, V8, P132, DOI 10.1016/0168-9525(92)90079-J; ASHBURNER M, 1990, CELL, V61, P1, DOI 10.1016/0092-8674(90)90205-S; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1992, IN PRESS TRANSCRIPTI; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1992, DEVELOPMENT, V115, P449; ORO AE, 1991, THESIS U CALIFORNIA; Oro AE, 1992, CURR OPIN GENET DEV, V2, P269, DOI 10.1016/S0959-437X(05)80284-9; PICARD D, 1988, CELL, V54, P170; Ragsdale CW, 1991, CURR OPIN CELL BIOL, V3, P928, DOI 10.1016/0955-0674(91)90109-C; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; RIDDIFORD LM, 1985, COMPREHENSIVE INSECT, V8, P38; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SLITER TJ, 1992, GENETICS, V130, P555; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STEEL CGH, 1985, COMPREHENSIVE INSECT, V8, P1; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	61	615	686	4	23	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					63	72		10.1016/0092-8674(92)90266-F	http://dx.doi.org/10.1016/0092-8674(92)90266-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1327536				2022-12-28	WOS:A1992JQ62300007
J	STOUTLAND, PO; DYER, RB; WOODRUFF, WH				STOUTLAND, PO; DYER, RB; WOODRUFF, WH			ULTRAFAST INFRARED-SPECTROSCOPY	SCIENCE			English	Article							VIBRATIONAL-ENERGY TRANSFER; TUNABLE PICOSECOND PULSES; NON-RRKM DECOMPOSITION; CYTOCHROME-C-OXIDASE; OPTICAL PULSES; TRANSIENT ABSORPTION; NAKED CR(CO)5; TIME; RELAXATION; DYNAMICS	Recent advances in ultrafast infrared spectroscopy are described, including experimental details and fundamental limitations. The utility of this technique is illustrated with two recent examples.	LOS ALAMOS NATL LAB,DIV ISOTOPE & NUCL CHEM,LOS ALAMOS,NM 87545	United States Department of Energy (DOE); Los Alamos National Laboratory	STOUTLAND, PO (corresponding author), LOS ALAMOS NATL LAB,DIV CHEM & LASER SCI,LOS ALAMOS,NM 87545, USA.		Woodruff, William/AAH-6890-2021	Dyer, Richard/0000-0002-0090-7580	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036263] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36263] Funding Source: Medline; NIGMS NIH HHS [GM48509] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINRUD PA, 1990, J PHYS CHEM-US, V94, P1180, DOI 10.1021/j100366a033; ANFINRUD PA, 1991, J PHYS CHEM-US, V95, P574, DOI 10.1021/j100155a017; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; BECKERLE JD, 1992, CHEM PHYS, V160, P487, DOI 10.1016/0301-0104(92)80015-N; BERKERLE JD, 1991, J CHEM PHYS, V95, P5403; CHOY MM, 1976, PHYS REV B, V14, P1693, DOI 10.1103/PhysRevB.14.1693; DOORN SK, 1992, J AM CHEM SOC, V114, P3133, DOI 10.1021/ja00034a067; DULING IN, 1985, J OPT SOC AM B, V2, P616, DOI 10.1364/JOSAB.2.000616; DURAND D, 1989, PHYS REV B, V39, P6096, DOI 10.1103/PhysRevB.39.6096; DYER RB, 1989, J AM CHEM SOC, V111, P7657, DOI 10.1021/ja00201a080; DYER RB, 1991, J AM CHEM SOC, V113, P6276, DOI 10.1021/ja00016a057; ELSAESSER T, 1985, OPT COMMUN, V52, P355, DOI 10.1016/0030-4018(85)90201-9; FENDT A, 1978, OPT COMMUN, V28, P142; FLEMING GR, 1990, DYE LASER PRINCIPLES; GLOWNIA JH, 1987, OPT LETT, V12, P19, DOI 10.1364/OL.12.000019; GRAENER H, 1989, J CHEM PHYS, V90, P3413, DOI 10.1063/1.455849; GRAENER H, 1990, CHEM PHYS LETT, V172, P435, DOI 10.1016/0009-2614(90)80134-Y; HAIM A, 1985, INORG CHEM, V14, P113; HEILWEIL EJ, 1989, OPT LETT, V14, P551, DOI 10.1364/OL.14.000551; HEILWEIL EJ, 1989, ANNU REV PHYS CHEM, V40, P143; HEILWEIL EJ, 1987, CHEM PHYS LETT, V134, P181, DOI 10.1016/0009-2614(87)87118-X; HUBNER HJ, 1991, CHEM PHYS LETT, V182, P315, DOI 10.1016/0009-2614(91)80221-I; JEDJU TM, 1988, OPT LETT, V13, P961, DOI 10.1364/OL.13.000961; JEDJU TM, 1988, APPL OPTICS, V27, P615, DOI 10.1364/AO.27.000615; JEDJU TM, 1992, APPL OPTICS, V31, P2684, DOI 10.1364/AO.31.002684; JOFFRE M, 1988, OPT LETT, V13, P276, DOI 10.1364/OL.13.000276; JOFFRE M, 1988, J MOD OPTIC, V35, P1951, DOI 10.1080/713822327; JORTNER J, 1988, J CHEM PHYS, V88, P167, DOI 10.1063/1.454632; KAHLOW MA, 1988, REV SCI INSTRUM, V59, P1098, DOI 10.1063/1.1139734; LAENEN R, 1990, OPT LETT, V15, P971, DOI 10.1364/OL.15.000971; LAENEN R, 1990, P SPIE INT SOC OPT E, V1268, P73; LAUBEREAU A, 1974, APPL PHYS LETT, V25, P87, DOI 10.1063/1.1655292; MA ZL, 1991, J CHEM PHYS, V94, P8608, DOI 10.1063/1.460044; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MIGUS A, 1982, IEEE J QUANTUM ELECT, V18, P101, DOI 10.1109/JQE.1982.1071384; MIGUS A, 1985, J OPT SOC AM B, V2, P584, DOI 10.1364/JOSAB.2.000584; MIGUS A, 1982, SPRINGER SERIES CHEM, V23, P6; MOORE JN, 1987, CHEM PHYS LETT, V138, P110, DOI 10.1016/0009-2614(87)80351-2; MOORE JN, 1988, P NATL ACAD SCI USA, V85, P5062, DOI 10.1073/pnas.85.14.5062; NAKAMOTO K, 1986, INFRARED RAMAN SPECT, P273; OOWRUTSKY JC, 1991, CHEM PHYS LETT, V184, P368; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1989, CHEM PHYS, V131, P31, DOI 10.1016/0301-0104(89)87079-X; ROBINSON JM, 1990, J CHEM PHYS, V93, P3207, DOI 10.1063/1.458853; ROGERS P, 1982, CHEM PHYS LETT, V89, P9, DOI 10.1016/0009-2614(82)83331-9; ROGERS PJ, 1983, CHEM PHYS LETT, V97, P313, DOI 10.1016/0009-2614(83)80014-1; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; SEILMEIER A, 1978, OPT COMMUN, V24, P237, DOI 10.1016/0030-4018(78)90001-9; SEYMOUR RJ, 1976, APPL PHYS LETT, V29, P705, DOI 10.1063/1.88933; SHANK CV, 1986, SCIENCE, V233, P1276, DOI 10.1126/science.233.4770.1276; SPEARS KG, 1988, OPT COMMUN, V66, P167, DOI 10.1016/0030-4018(88)90055-7; STOUTLAND PO, 1991, J PHYS CHEM-US, V95, P6406, DOI 10.1021/j100170a004; WANG L, 1989, J PHYS CHEM-US, V93, P2, DOI 10.1021/j100338a001; WANG L, 1988, J AM CHEM SOC, V110, P8695, DOI 10.1021/ja00234a020; WOODRUFF WH, 1991, P NATL ACAD SCI USA, V88, P2588, DOI 10.1073/pnas.88.6.2588; XU XB, 1991, J CHEM PHYS, V95, P2445, DOI 10.1063/1.460949; YEN R, 1983, MATER RES SOC S P, V13, P13; ZEWAIL AH, 1988, SCIENCE, V242, P1645, DOI 10.1126/science.242.4886.1645; [No title captured]	59	63	63	6	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1913	1917		10.1126/science.1329200	http://dx.doi.org/10.1126/science.1329200			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1329200				2022-12-28	WOS:A1992JP59400024
J	BAILEY, TC; TRULOCK, EP; STORCH, GA; POWDERLY, WG				BAILEY, TC; TRULOCK, EP; STORCH, GA; POWDERLY, WG			GANCICLOVIR FOR CYTOMEGALOVIRUS AFTER HEART-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							RECIPIENTS; INFECTION				BAILEY, TC (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63108, USA.			Powderly, William/0000-0001-7808-3086				BAILEY TC, 1992, J INFECT DIS, V165, P548, DOI 10.1093/infdis/165.3.548; DUMMER JS, 1985, J INFECT DIS, V152, P1182, DOI 10.1093/infdis/152.6.1182; MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703	5	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					891	891						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1324431				2022-12-28	WOS:A1992JN12000021
J	WHITLEY, RJ; GNANN, JW				WHITLEY, RJ; GNANN, JW			ACYCLOVIR - A DECADE LATER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HERPES-SIMPLEX-VIRUS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RECURRENT GENITAL HERPES; VARICELLA-ZOSTER VIRUS; MARROW TRANSPLANT PATIENTS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND TRIAL; RECEIVING MULTIPLE COURSES; ORAL ACYCLOVIR; INTRAVENOUS ACYCLOVIR		UNIV ALABAMA, DEPT PEDIAT, BIRMINGHAM, AL USA; UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL USA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [5-PO1-AI-24009, N01-AI-15113] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024009, N01AI015113] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER GJM, 1987, J MED VIROL, V21, P81, DOI 10.1002/jmv.1890210111; ANDREWS EB, 1988, AM J MED, V85, P123; BALFOUR HH, 1990, J PEDIATR-US, V116, P633, DOI 10.1016/S0022-3476(05)81618-X; BALFOUR HH, 1983, NEW ENGL J MED, V308, P1448, DOI 10.1056/NEJM198306163082404; BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; BALFOUR HH, 1992, J PEDIATR-US, V120, P627, DOI 10.1016/S0022-3476(05)82495-3; BEAN B, 1982, LANCET, V2, P118; BIANCHETTI MG, 1991, PEDIATR NEPHROL, V5, P238, DOI 10.1007/BF01095963; BIRON KK, 1980, ANTIMICROB AGENTS CH, V18, P443, DOI 10.1128/AAC.18.3.443; BRIGDEN D, 1982, AM J MED, V73, P182, DOI 10.1016/0002-9343(82)90087-0; BRIGDEN D, 1985, SCAND J INFECT DIS, P33; BRYSON YJ, 1983, NEW ENGL J MED, V308, P916, DOI 10.1056/NEJM198304213081602; BURNS WH, 1982, LANCET, V1, P421; COBO LM, 1986, OPHTHALMOLOGY, V93, P763; COHEN JI, 1991, MEDICINE, V70, P137, DOI 10.1097/00005792-199103000-00005; COHEN SMZ, 1984, ANN INTERN MED, V100, P920, DOI 10.7326/0003-4819-100-6-920_1; COLLINS P, 1979, J ANTIMICROB CHEMOTH, V5, P431, DOI 10.1093/jac/5.4.431; COREY L, 1983, J ANTIMICROB CHEMOTH, V12, P79, DOI 10.1093/jac/12.suppl_B.79; COREY L, 1983, ANN INTERN MED, V98, P914, DOI 10.7326/0003-4819-98-6-914; COREY L, 1982, NEW ENGL J MED, V306, P1313, DOI 10.1056/NEJM198206033062201; CRUMPACKER CS, 1979, ANTIMICROB AGENTS CH, V15, P642, DOI 10.1128/AAC.15.5.642; CRUMPACKER CS, 1982, NEW ENGL J MED, V306, P343, DOI 10.1056/NEJM198202113060606; DATTA AK, 1980, P NATL ACAD SCI-BIOL, V77, P5163, DOI 10.1073/pnas.77.9.5163; DEMIRANDA P, 1983, J ANTIMICROB CHEMOTH, V12, P29, DOI 10.1093/jac/12.suppl_B.29; DERSE D, 1981, J BIOL CHEM, V256, P1447; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; ENGLUND JA, 1990, ANN INTERN MED, V112, P416, DOI 10.7326/0003-4819-76-3-112-6-416; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; ERLICH KS, 1989, ANN INTERN MED, V110, P710, DOI 10.7326/0003-4819-110-9-710; FEDER HM, 1990, ARCH INTERN MED, V150, P2061, DOI 10.1001/archinte.150.10.2061; FIDDIAN AP, 1983, BMJ-BRIT MED J, V286, P1699, DOI 10.1136/bmj.286.6379.1699; FRENKEL LM, 1991, AM J OBSTET GYNECOL, V164, P569, DOI 10.1016/S0002-9378(11)80023-2; FURMAN PA, 1979, J VIROL, V32, P72, DOI 10.1128/JVI.32.1.72-77.1979; FURMAN PA, 1984, J BIOL CHEM, V259, P9575; FYFE JA, 1978, J BIOL CHEM, V253, P8721; GATELEY A, 1990, J INFECT DIS, V161, P711, DOI 10.1093/infdis/161.4.711; GUTMAN LT, 1986, J INFECT DIS, V154, P415, DOI 10.1093/infdis/154.3.415; HAAKE DA, 1990, REV INFECT DIS, V12, P788; HOLLANDER H, 1989, AM J MED, V87, P628, DOI 10.1016/S0002-9343(89)80394-8; HOLMES GP, 1990, ANN INTERN MED, V112, P833, DOI 10.7326/0003-4819-112-11-833; HOVDING G, 1989, ACTA OPHTHALMOL, V67, P51; HUFF JC, 1988, AM J MED, V85, P84; JACOBSON MA, 1990, ANN INTERN MED, V112, P187, DOI 10.7326/0003-4819-112-3-187; KAPLOWITZ LG, 1991, JAMA-J AM MED ASSOC, V265, P747, DOI 10.1001/jama.265.6.747; LASKIN OL, 1984, ARCH INTERN MED, V144, P1241, DOI 10.1001/archinte.144.6.1241; LJUNGMAN P, 1990, J INFECT DIS, V162, P244, DOI 10.1093/infdis/162.1.244; LUBY JP, 1984, J INFECT DIS, V150, P1, DOI 10.1093/infdis/150.1.1; MARKS GL, 1989, REV INFECT DIS, V11, P474; MCGILL J, 1983, J INFECTION, V6, P157, DOI 10.1016/S0163-4453(83)92787-1; MCKENDRICK MW, 1989, BRIT MED J, V298, P431, DOI 10.1136/bmj.298.6671.431; MERTZ GJ, 1984, JAMA-J AM MED ASSOC, V252, P1147, DOI 10.1001/jama.252.9.1147; MERTZ GJ, 1988, JAMA-J AM MED ASSOC, V260, P201, DOI 10.1001/jama.260.2.201; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MEYERS JD, 1982, AM J MED, V73, P229, DOI 10.1016/0002-9343(82)90097-3; MORTON P, 1989, NEW ZEAL MED J, V102, P93; NILSEN AE, 1982, LANCET, V2, P571; NUSINOFFLEHRMAN S, 1986, ANN INTERN MED, V104, P786; NYERGES G, 1988, J INFECT DIS, V157, P309, DOI 10.1093/infdis/157.2.309; PAHWA S, 1988, JAMA-J AM MED ASSOC, V260, P2879, DOI 10.1001/jama.260.19.2879; PEACOCK JE, 1988, AM J MED, V85, P301, DOI 10.1016/0002-9343(88)90578-5; PETERSLUND NA, 1981, LANCET, V2, P827; PROBER CG, 1982, J PEDIATR-US, V101, P622, DOI 10.1016/S0022-3476(82)80725-7; RABORN GW, 1987, J AM DENT ASSOC, V115, P38, DOI 10.14219/jada.archive.1987.0211; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; REICHMAN RC, 1983, J INFECT DIS, V147, P336, DOI 10.1093/infdis/147.2.336; RESNICK L, 1988, JAMA-J AM MED ASSOC, V259, P384, DOI 10.1001/jama.259.3.384; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; SAFRIN S, 1991, ANN INTERN MED, V115, P19, DOI 10.7326/0003-4819-115-1-19; SARAL R, 1981, NEW ENGL J MED, V305, P63, DOI 10.1056/NEJM198107093050202; SCHAEFFER HJ, 1978, NATURE, V272, P583, DOI 10.1038/272583a0; SCHOOLEY RT, 1986, ANN INTERN MED, V104, P636, DOI 10.7326/0003-4819-104-5-636; SHAW M, 1985, BMJ-BRIT MED J, V291, P7, DOI 10.1136/bmj.291.6487.7; SHEPP DH, 1986, NEW ENGL J MED, V314, P208, DOI 10.1056/NEJM198601233140404; SHEPP DH, 1985, ANN INTERN MED, V102, P783, DOI 10.7326/0003-4819-102-6-783; SHEPP DH, 1987, TRANSPLANTATION, V43, P654, DOI 10.1097/00007890-198705000-00010; SKOLDENBERG B, 1984, LANCET, V2, P707; SPIEGAL DM, 1986, JAMA-J AM MED ASSOC, V255, P1882, DOI 10.1001/jama.1986.03370140080027; SPRUANCE SL, 1982, J INFECT DIS, V146, P85, DOI 10.1093/infdis/146.1.85; SPRUANCE SL, 1988, JAMA-J AM MED ASSOC, V260, P1597, DOI 10.1001/jama.260.11.1597; SPRUANCE SL, 1990, J INFECT DIS, V161, P185, DOI 10.1093/infdis/161.2.185; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107; STRAUS SE, 1988, NEW ENGL J MED, V319, P1692, DOI 10.1056/NEJM198812293192602; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; STRAUS SE, 1988, JAMA-J AM MED ASSOC, V260, P2227, DOI 10.1001/jama.260.15.2227; VANDERHORST C, 1991, J INFECT DIS, V164, P788, DOI 10.1093/infdis/164.4.788; WADE JC, 1983, J INFECT DIS, V148, P1077, DOI 10.1093/infdis/148.6.1077; WADE JC, 1982, ANN INTERN MED, V96, P265, DOI 10.7326/0003-4819-96-3-265; WADE JC, 1984, ANN INTERN MED, V100, P823, DOI 10.7326/0003-4819-100-6-823; WADE JC, 1983, ANN INTERN MED, V98, P921, DOI 10.7326/0003-4819-98-6-921; WADE JC, 1983, J INFECT DIS, V148, P557, DOI 10.1093/infdis/148.3.557; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; WHITLEY RJ, 1982, NEW ENGL J MED, V307, P971, DOI 10.1056/NEJM198210143071602; WHITLEY RJ, 1992, J INFECT DIS, V165, P450, DOI 10.1093/infdis/165.3.450; WHITLEY RJ, 1986, NEW ENGL J MED, V314, P144, DOI 10.1056/NEJM198601163140303; WHITLEY RJ, 1982, AM J MED, V73, P165, DOI 10.1016/0002-9343(82)90084-5; WOOD MJ, 1988, AM J MED, V85, P79	99	265	285	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					782	789						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1288525				2022-12-28	WOS:A1992JL66100008
J	PATERSON, CR; BEAL, RJ; DENT, JA				PATERSON, CR; BEAL, RJ; DENT, JA			LESSON OF THE WEEK - OSTEOGENESIS IMPERFECTA - FRACTURES OF THE FEMUR WHEN TESTING FOR CONGENITAL DISLOCATION OF THE HIP	BRITISH MEDICAL JOURNAL			English	Article									ROYAL INFIRM,DEPT ORTHOPAED & TRAUMA,DUNDEE DD1 9ND,SCOTLAND	Royal Infirmary of Edinburgh	PATERSON, CR (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT BIOCHEM MED,DUNDEE DD1 9SY,SCOTLAND.							BARLOW TG, 1962, J BONE JOINT SURG BR, V44, P292, DOI 10.1302/0301-620X.44B2.292; BLUMENTHAL I, 1980, ARCH DIS CHILD, V134, P1155; du Toit S N, 1969, Bull Hosp Joint Dis, V30, P164; MOSS GD, 1991, BRIT MED J, V302, P878, DOI 10.1136/bmj.302.6781.878; NOVICK GS, 1988, RADIOL CLIN N AM, V26, P29; Ortolani M., 1937, PEDIATRIA, V45, P129; PATERSON CR, 1989, BMJ-BRIT MED J, V299, P1451, DOI 10.1136/bmj.299.6713.1451; SILLENCE DO, 1989, CLIN ORTHOP RELAT R, V159, P11; Smith R., 1983, BRITTLE BONE SYNDROM; VONROSEN S, 1962, J BONE JOINT SURG BR, V44, P284, DOI 10.1302/0301-620X.44B2.284	10	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					464	466		10.1136/bmj.305.6851.464	http://dx.doi.org/10.1136/bmj.305.6851.464			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1294087	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JK68000029
J	WERZBERGER, A; MENSCH, B; KUTER, B; BROWN, L; LEWIS, J; SITRIN, R; MILLER, W; SHOUVAL, D; WIENS, B; CALANDRA, G; RYAN, J; PROVOST, P; NALIN, D				WERZBERGER, A; MENSCH, B; KUTER, B; BROWN, L; LEWIS, J; SITRIN, R; MILLER, W; SHOUVAL, D; WIENS, B; CALANDRA, G; RYAN, J; PROVOST, P; NALIN, D			A CONTROLLED TRIAL OF A FORMALIN-INACTIVATED HEPATITIS-A VACCINE IN HEALTHY-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATTENUATED HEPATITIS; VIRUS-VACCINE; LIVE	Background. Although inactivated hepatitis A vaccine is known to be well tolerated and immunogenic in healthy children and adults, its efficacy has yet to be established. Methods. To evaluate the efficacy of the hepatitis A vaccine in protecting against clinically apparent disease, we conducted a double-blind, placebo-controlled trial in a Hasidic Jewish community in upstate New York that has had recurrent outbreaks of hepatitis A. At the beginning of a summer outbreak, 1037 healthy seronegative children 2 to 16 years of age were randomly assigned to receive one intramuscular injection of a highly purified, formalin-inactivated hepatitis A vaccine or placebo. A case was defined by the presence of typical signs and symptoms, a diagnostic increase in IgM antibody to hepatitis A, and a serum concentration of alanine aminotransferase at least twice the upper limit of normal. Cases occurring greater-than-or-equal-to 50 days after the injection were included in the evaluation of efficacy. The children were followed for a mean of 103 days. Results. A total of 519 children received vaccine, and 518 received placebo. The vaccine was well tolerated, with no serious adverse reactions. From day 50 after the injection, 25 cases of clinically apparent hepatitis A occurred in the placebo group and none in the vaccine group (P<0.001), confirming that the vaccine had 100 percent protective efficacy. Before day 21, seven cases occurred in the vaccine group and three cases in the placebo group. After that time, there were no cases among vaccine recipients and 34 cases among placebo recipients. Conclusions. The inactivated purified hepatitis A vaccine that we tested is well tolerated, and a single dose is highly protective against clinically apparent hepatitis A.	HADASSAH UNIV HOSP,LIVER UNIT,IL-91120 JERUSALEM,ISRAEL; MERCK SHARP & DOHME LTD,W POINT,PA 19486	Hebrew University of Jerusalem; Merck & Company	WERZBERGER, A (corresponding author), KIRYAS JOEL INST MED,36 SATMAR DR,POB 682,MONROE,NY 10950, USA.		Shouval, Daniel/U-2779-2017	Shouval, Daniel/0000-0002-0512-6513; Wiens, Brian/0000-0003-2321-8259				BLOCK S, 1991, 31ST INT C ANT AG CH, P314; CONRAD ME, 1987, J INFECT DIS, V156, P56, DOI 10.1093/infdis/156.1.56; ELLERBECK E, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P91; HADLER SC, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P14; KRAH DL, 1991, J INFECT DIS, V163, P634, DOI 10.1093/infdis/163.3.634; KUTER B, 1991, 31ST INT C ANT AG CH, P282; LEMON SM, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P20; LEWIS JA, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P94; MIDTHUN K, 1991, J INFECT DIS, V163, P735, DOI 10.1093/infdis/163.4.735; NALIN D R, 1991, American Journal of Tropical Medicine and Hygiene, V45, P218; PROVOST PJ, 1983, P SOC EXP BIOL MED, V172, P357, DOI 10.3181/00379727-172-41570; PROVOST PJ, 1979, P SOC EXP BIOL MED, V160, P213, DOI 10.3181/00379727-160-40422; PROVOST PJ, 1986, J MED VIROL, V19, P23, DOI 10.1002/jmv.1890190105; PROVOST PJ, 1986, J MED VIROL, V20, P165, DOI 10.1002/jmv.1890200208; PROVOST PJ, 1978, P SOC EXP BIOL MED, V159, P201, DOI 10.3181/00379727-159-40314; PURCELL RH, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P41; ROBERTSON BH, 1991, J INFECT DIS, V163, P286, DOI 10.1093/infdis/163.2.286; SHOUVAL D, 1991, 5TH EUR C CLIN MICR; SMITH PF, 1986, 35TH EP INT SERV ANN; VILLAREJOS VM, 1982, AM J EPIDEMIOL, V115, P577, DOI 10.1093/oxfordjournals.aje.a113339; WARD R, 1958, NEW ENGL J MED, V258, P407, DOI 10.1056/NEJM195802272580901	21	419	435	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					453	457		10.1056/NEJM199208133270702	http://dx.doi.org/10.1056/NEJM199208133270702			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1320740	Bronze			2022-12-28	WOS:A1992JH34000002
J	LOWENSTEIN, EJ; DALY, RJ; BATZER, AG; LI, W; MARGOLIS, B; LAMMERS, R; ULLRICH, A; SKOLNIK, EY; BARSAGI, D; SCHLESSINGER, J				LOWENSTEIN, EJ; DALY, RJ; BATZER, AG; LI, W; MARGOLIS, B; LAMMERS, R; ULLRICH, A; SKOLNIK, EY; BARSAGI, D; SCHLESSINGER, J			THE SH2 AND SH3 DOMAIN CONTAINING PROTEIN GRB2 LINKS RECEPTOR TYROSINE KINASES TO RAS SIGNALING	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; BINDING-SITE; PHOSPHATIDYLINOSITOL-3 KINASE; SUBSTRATE-SPECIFICITY; CYTOPLASMIC PROTEIN; SYNTHETIC PEPTIDES; ESCHERICHIA-COLI; PDGF RECEPTOR	A cDNA clone encoding a novel, widely expressed protein (called growth factor receptor-bound protein 2 or GRB2) containing one src homology 2 (SH2) domain and two SH3 domains was isolated. Immunoblotting experiments indicate that GRB2 associates with tyrosine-phosphorylated epidermal growth factor receptors (EGFRs) and platelet-derived growth factor receptors (PDGFRs) via its SH2 domain. Interestingly, GRB2 exhibits striking structural and functional homology to the C. elegans protein sem-5. It has been shown that sem-5 and two other genes called let-23 (EGFR like) and let-60 (ras like) lie along the same signal transduction pathway controlling C. elegans vulval induction. To examine whether GRB2 is also a component of ras signaling in mammalian cells, microinjection studies were performed. While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis. These results suggest that GRB2/sem-5 plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Max Planck Society; Cold Spring Harbor Laboratory	LOWENSTEIN, EJ (corresponding author), NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.		Daly, Roger J/C-8179-2009	Bar-Sagi, Dafna/0000-0003-2597-8948; Daly, Roger/0000-0002-5739-8027	NATIONAL CANCER INSTITUTE [R37CA055360, P01CA046370, R01CA055360] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55360, CA 46370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1991, J BIOL CHEM, V266, P6808; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, IN PRESS NATURE; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROTIN D, 1992, J BIOL CHEM, V267, P9676; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY MG, 1988, SCIENCE, V242, P1696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG K, 1982, METHOD ENZYMOL, V85, P514; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	56	1512	1566	2	103	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					431	442		10.1016/0092-8674(92)90167-B	http://dx.doi.org/10.1016/0092-8674(92)90167-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322798	hybrid			2022-12-28	WOS:A1992JH12400008
J	ARSHAVSKY, VY; BOWNDS, MD				ARSHAVSKY, VY; BOWNDS, MD			REGULATION OF DEACTIVATION OF PHOTORECEPTOR G-PROTEIN BY ITS TARGET ENZYME AND CGMP	NATURE			English	Article							ROD OUTER SEGMENTS; CYCLIC-GMP PHOSPHODIESTERASE; MOLECULAR MECHANISM; VISUAL EXCITATION; TRANSDUCIN GTPASE; CASCADE; ACTIVATION; MEMBRANES; TURNOVER; SUBUNIT	THE photoreceptor G protein, transducin, is One of the class of heterotrimeric G proteins that mediates between membrane receptors and intracellular enzymes or ion channels. Light-activated rhodopsin catalyses the exchange of GDP for GTP on multiple transducin molecules. Activated transducin then stimulates cyclic GMP phosphodiesterase by releasing an inhibitory action of the phosphodiesterase gamma-subunits. This leads to a decrease in cGMP levels in the rod, and closure of plasma membrane cationic channels gated by cGMP 1-4. In this and other systems, turn-off of the response requires the GTP bound to G protein to be hydrolysed by an intrinsic GTPase activity 5-7. Here we report that the interaction of transducin with cGMP phosphodiesterase, specifically with its gamma-subunits, accelerates GTPase activity by several fold. Thus the gamma-subunits of the phosphodiesterase serve a function analogous to the GTPase-activating proteins that regulate the class of small GTP-binding proteins. The acceleration can be partially suppressed by cGMP, most probably through the non-catalytic cGMP-binding sites of phosphodiesterase alpha and beta-subunits. This cGMP regulation may function in light-adaptation of the photoresponse as a negative feedback that decreases the lifetime of activated cGMP phosphodiesterase as light causes decreases in cytoplasmic cGMP.	UNIV WISCONSIN,DEPT ZOOL,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	ARSHAVSKY, VY (corresponding author), UNIV WISCONSIN,DEPT ZOOL,MOLEC BIOL LAB,MADISON,WI 53706, USA.							ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; FAIN GL, 1976, J PHYSIOL-LONDON, V261, P71, DOI 10.1113/jphysiol.1976.sp011549; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; IYENGAR R, 1990, G PROTEINS; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; ROBINSON PR, 1980, J GEN PHYSIOL, V76, P631, DOI 10.1085/jgp.76.5.631; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAYLOR CW, 1990, BIOCHEM J, V272, P1; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WAGNER R, 1988, FEBS LETT, V234, P44, DOI 10.1016/0014-5793(88)81299-7; WITT PL, 1984, J GEN PHYSIOL, V84, P251, DOI 10.1085/jgp.84.2.251; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619	30	239	241	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					416	417		10.1038/357416a0	http://dx.doi.org/10.1038/357416a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1317509	Bronze, Green Published			2022-12-28	WOS:A1992HX17200067
J	JOHNSON, E				JOHNSON, E			ANIMAL-MODEL FOR AIDS DEMENTIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1992, SCIENCE, V255, P1246	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2293	2293						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1314314				2022-12-28	WOS:A1992HR01500005
J	CAGAN, RL; KRAMER, H; HART, AC; ZIPURSKY, SL				CAGAN, RL; KRAMER, H; HART, AC; ZIPURSKY, SL			THE BRIDE OF SEVENLESS AND SEVENLESS INTERACTION - INTERNALIZATION OF A TRANSMEMBRANE LIGAND	CELL			English	Article							GROWTH-FACTOR RECEPTOR; CELL FATE; DROSOPHILA RETINA; KINASE-ACTIVITY; PROTEIN; EYE; DOMAIN	During Drosophila retinal development, the R8 photo-receptor neuron induces a neighboring cell to assume an R7 cell fate through cell contact. This is mediated by the transmembrane protein bride of sevenless (boss) on the surface of the R8 cell, which binds the sevenless tyrosine kinase receptor (sev) on the surface of the R7 precursor cell. The boss protein, which contains a large extracellular domain, seven transmembrane segments, and a C-terminal cytoplasmic domain, has an exceptional structure for a ligand of a receptor tyrosine kinase. Using a panel of antibodies directed to various cytoplasmic and extracellular epitopes, we demonstrate that the entire boss protein from its extreme N-terminus to its extreme C-terminus is internalized by sev-expressing tissue culture cells and by the R7 precursor cell in the developing eye imaginal disc. The receptor-mediated transfer of a transmembrane ligand represents a novel mechanism for protein transfer between developing cells.			CAGAN, RL (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL CHEM,INST MOLEC BIOL,LOS ANGELES,CA 90024, USA.		Cagan, Ross Leigh/AAV-9528-2021	Cagan, Ross/0000-0001-5297-450X; Kramer, Helmut/0000-0002-1167-2676; Zipursky, Stephen/0000-0001-5630-7181	NIGMS NIH HHS [GM-07104] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBURNER M, 1989, DROSPHILA LABORATORY; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HARLOW E, 1988, ANTIBODIES LABORATOR; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; Holtzman E, 1989, LYSOSOMES; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAZARIDES E, 1979, SCI AM, V240, P100, DOI 10.1038/scientificamerican0579-100; MATSUMOTO B, 1987, PROC R SOC SER B-BIO, V230, P339, DOI 10.1098/rspb.1987.0023; MULLINS MC, 1991, P NATL ACAD SCI USA, V88, P9387, DOI 10.1073/pnas.88.21.9387; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	27	153	153	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					393	399		10.1016/0092-8674(92)90442-F	http://dx.doi.org/10.1016/0092-8674(92)90442-F			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1316239				2022-12-28	WOS:A1992HT07800003
J	PEPPELENBOSCH, MP; TERTOOLEN, LGJ; DENHERTOG, J; DELAAT, SW				PEPPELENBOSCH, MP; TERTOOLEN, LGJ; DENHERTOG, J; DELAAT, SW			EPIDERMAL GROWTH-FACTOR ACTIVATES CALCIUM CHANNELS BY PHOSPHOLIPASE-A2/5-LIPOXYGENASE-MEDIATED LEUKOTRIENE-C4 PRODUCTION	CELL			English	Article							C-FOS GENE; SIGNAL TRANSDUCTION; ARACHIDONIC-ACID; A431 CELLS; INOSITOL PHOSPHATES; PROTO-ONCOGENE; K+-CHANNEL; 3T3 CELLS; RECEPTOR; PHOSPHOLIPASE-A2	Epidermal growth factor (EGF) induces a Ca2+ influx in many cell types, but the underlying mechanisms are so far unresolved. We report that: EGF-induced Ca2+ channel activity is eliminated by lipoxygenase inhibition and is mimicked by artificial induction of lipoxygenase activity; addition of leukotriene C4 can fully mimic EGF in its ability to activate Ca2+ channels; and EGF induces a rapid accumulation of intracellular leukotriene C4. In addition, we show that EGF-induced, Ca2+-dependent membrane hyperpolarization and junB proto-oncogene expression are dependent on lipoxygenase activity, whereas EGF-induced cytoplasmic alkalinization is not. We conclude that PLA2/5-lipoxygenase-mediated leukotriene C4 production constitutes a novel and specific signal transduction pathway in growth factor action.			PEPPELENBOSCH, MP (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.			Peppelenbosch, Maikel/0000-0001-9112-6028				BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; DENHERTOG J, 1991, CELL GROWTH DIFFER, V2, P155; DENHERTOG J, 1991, EXP CELL RES, V196, P226, DOI 10.1016/0014-4827(91)90255-S; DOROSHENKO P, 1991, J PHYSIOL-LONDON, V436, P725, DOI 10.1113/jphysiol.1991.sp018576; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONZALEZ FA, 1988, J CELL PHYSIOL, V135, P269, DOI 10.1002/jcp.1041350214; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HACK M, 1991, BIOCHEM J, V275, P263; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HUANG N, 1991, J CELL PHYSL, V146, P473; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; MACARA IG, 1986, J BIOL CHEM, V261, P9321; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MAHOUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; Maniatis T., 1982, MOL CLONING; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; TILLY BC, 1988, BIOCHEM J, V252, P857, DOI 10.1042/bj2520857; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	41	193	193	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					295	303		10.1016/0092-8674(92)90410-E	http://dx.doi.org/10.1016/0092-8674(92)90410-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1314702				2022-12-28	WOS:A1992HQ18300009
J	BOLKER, M; URBAN, M; KAHMANN, R				BOLKER, M; URBAN, M; KAHMANN, R			THE A MATING TYPE LOCUS OF U-MAYDIS SPECIFIES CELL SIGNALING COMPONENTS	CELL			English	Article							YEAST RHODOSPORIDIUM-TORULOIDES; CONJUGATION TUBE FORMATION; USTILAGO-MAYDIS; SACCHAROMYCES-CEREVISIAE; TREMELLA-MESENTERICA; RHODOTORUCINE-A; SEXUAL-DIFFERENTIATION; NEUROSPORA-CRASSA; FISSION YEAST; B-LOCUS	The a mating type locus of the phytopathogenic fungus U. maydis controls fusion of haploid cells and filamentous growth of the dikaryotic mycelium. The a locus exists in two alleles, termed a1 and a2, which are defined by nonhomologous DNA regions comprising 4.5 kb for a1 and 8 kb for a2, flanked by identical sequences. Based on functional assays, mutants, and sequencing, we demonstrate that the mating type in each allele is determined by a set of two genes. One encodes a precursor for a lipopeptide mating factor, and the other specifies the receptor for the pheromone secreted by cells of opposite mating type. Thus, U. maydis employs a novel strategy to determine its mating type by providing the primary determinants of cell-cell recognition directly from the mating type locus.			BOLKER, M (corresponding author), INST GENBIOL FORSCH BERLIN GMBH, IHNESTR 63, W-1000 BERLIN 33, GERMANY.		; Urban, Martin/G-6004-2010	Bolker, Michael/0000-0002-7366-3855; Urban, Martin/0000-0003-2440-4352				ABE K, 1975, J BACTERIOL, V122, P710, DOI 10.1128/JB.122.2.710-718.1975; AKADA R, 1989, ARCH MICROBIOL, V152, P484, DOI 10.1007/BF00446934; AKADA R, 1989, MOL CELL BIOL, V9, P3491, DOI 10.1128/MCB.9.8.3491; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BETZ R, 1987, J BIOL CHEM, V262, P546; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHRISTENSEN JJ, 1963, AM PHYTOPATHOL SOC M, V2; DAY PR, 1971, P NATL ACAD SCI USA, V68, P533, DOI 10.1073/pnas.68.3.533; DAY PR, 1971, NATURE-NEW BIOL, V231, P19, DOI 10.1038/newbio231019a0; EGEL R, 1990, TRENDS GENET, V6, P369, DOI 10.1016/0168-9525(90)90279-F; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROELIGER EH, 1991, GENE, V100, P113, DOI 10.1016/0378-1119(91)90356-G; FUJINO M, 1980, NATURWISSENSCHAFTEN, V67, P406, DOI 10.1007/BF00405487; Gething M, 1985, PROTEIN TRANSPORT SE, P103; GILLISSEN B, 1992, IN PRESS CELL, V68; GLASS NL, 1990, P NATL ACAD SCI USA, V87, P4912, DOI 10.1073/pnas.87.13.4912; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLLIDAY R, 1961, GENET RES, V2, P231, DOI 10.1017/S0016672300000720; Holliday R., 1974, HDB GENETICS, P575, DOI 10.1007/978-1-4899-1710-2_31; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIBASHI Y, 1984, BIOCHEMISTRY-US, V23, P1399, DOI 10.1021/bi00302a010; KAMIYA Y, 1978, BIOCHEM BIOPH RES CO, V83, P1077, DOI 10.1016/0006-291X(78)91505-X; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KOHLER K, 1991, METHOD ENZYMOL, V194, P393; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; KRONSTAD JW, 1990, GENE DEV, V4, P1384, DOI 10.1101/gad.4.8.1384; KRONSTAD JW, 1989, P NATL ACAD SCI USA, V86, P978, DOI 10.1073/pnas.86.3.978; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; NAG DK, 1988, GENE, V64, P135, DOI 10.1016/0378-1119(88)90487-8; NAKAYAMA N, 1987, EMBO J, V6, P249, DOI 10.1002/j.1460-2075.1987.tb04746.x; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; PUHALLA JE, 1970, GENET RES, V16, P229, DOI 10.1017/S0016672300002457; PUHALLA JE, 1968, GENETICS, V60, P461; PUHALLA JE, 1969, PHYTOPATHOLOGY, V59, P1771; ROWELL JB, 1955, PHYTOPATHOLOGY, V45, P370; ROWELL JB, 1954, PHYTOPATHOLOGY, V44, P356; SAKAGAMI Y, 1979, AGR BIOL CHEM TOKYO, V43, P2643, DOI 10.1080/00021369.1979.10863880; SAKAGAMI Y, 1981, SCIENCE, V212, P1525, DOI 10.1126/science.212.4502.1525; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; TSUKUDA T, 1988, MOL CELL BIOL, V8, P3703, DOI 10.1128/MCB.8.9.3703; WANG J, 1988, P NATL ACAD SCI USA, V85, P865, DOI 10.1073/pnas.85.3.865; [No title captured]	50	310	317	5	26	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					441	450		10.1016/0092-8674(92)90182-C	http://dx.doi.org/10.1016/0092-8674(92)90182-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1310895	hybrid			2022-12-28	WOS:A1992HD39800006
J	HUANG, S; TERSTAPPEN, LWMM				HUANG, S; TERSTAPPEN, LWMM			FORMATION OF HEMATOPOIETIC MICROENVIRONMENT AND HEMATOPOIETIC STEM-CELLS FROM SINGLE HUMAN BONE-MARROW STEM-CELLS	NATURE			English	Article							HEMATOPOIETIC PROGENITORS; MONOCLONAL-ANTIBODY; PRECURSORS; EXPRESSION	HAEMATOPOIETIC stem cells are a population of cells capable both of self renewal and of differentiation into a variety of haematopoietic lineages1-4. Enrichment techniques of human haematopoietic stem cells have used the expression of CD34, present on bone marrow progenitor cells5-7. But most CD34+ bone marrow cells are committed to their lineage, and more recent efforts have focused on the precise characterization of the pluripotent subset of CD34+ cells8-17. Here we report the characterization of two distinct subsets of pluripotent stem cells from human fetal bone marrow, a CD34+, HLA-DR+, CD38- subset that can differentiate into all haematopoietic lineages, and a distinct more primitive subset, that is CD34+, HLA-DR-, CD38-, that can differentiate into haematopoietic precursors and stromal cells capable of supporting the differentiation of these precursors. These data represent, to our knowledge, the first identification of a single cell capable of reconstituting the haematopoietic cells and their associated bone marrow microenvironment.	BECTON DICKINSON IMMUNOCYTOMETRY SYST, 2350 QUME DR, SAN JOSE, CA 95131 USA	Becton Dickinson	TERSTAPPEN, LWMM (corresponding author), BECTON DICKINSON IMMUNOCYTOMETRY SYST, 2350 QUME DR, SAN JOSE, CA 95131 USA.		terstappen, leon/O-4923-2018	terstappen, leon/0000-0001-5944-3787				ANDREWS RG, 1989, J EXP MED, V169, P1721, DOI 10.1084/jem.169.5.1721; CIVIN CI, 1984, J IMMUNOL, V133, P157; EAVES CJ, 1991, SEMIN HEMATOL, V28, P126; LANDSORP PM, 1990, J EXP MED, V172, P363; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LEARY AG, 1987, BLOOD, V69, P953; MAYANI H, 1989, INT J CELL CLONING, V7, P30, DOI 10.1002/stem.5530070105; SAELAND S, 1988, BLOOD, V72, P1580; SIMMONS PJ, 1991, BLOOD, V78, P55; SIMMONS PJ, 1991, BLOOD, V78, P2848; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SROUR EF, 1992, BLOOD, V79, P1404; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; VERFAILLIE C, 1990, J EXP MED, V172, P509, DOI 10.1084/jem.172.2.509; VISSER JWM, 1984, J EXP MED, V159, P1576, DOI 10.1084/jem.159.6.1576; WOLPERT L, 1988, J CELL SCI, P1	17	220	254	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 24	1992	360	6406					745	749		10.1038/360745a0	http://dx.doi.org/10.1038/360745a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1281519				2022-12-28	WOS:A1992KE47200035
J	CRISP, AJ				CRISP, AJ			A FATHERS WORST NIGHTMARE	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1581	1582		10.1136/bmj.305.6868.1581	http://dx.doi.org/10.1136/bmj.305.6868.1581			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286401	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992KD77100040
J	NEWENS, AJ; JARVIS, SN; GEORGE, R				NEWENS, AJ; JARVIS, SN; GEORGE, R			HOW TO GAIN WEIGHT BY LOOKING UP	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND; GATESHEAD HLTH AUTHOR,GATESHEAD NE8 3EP,ENGLAND	Newcastle University - UK	JARVIS, SN (corresponding author), UNIV NEWCASTLE UPON TYNE,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.							BARELL V, 1988, AM J EPIDEMIOL, V128, P218, DOI 10.1093/oxfordjournals.aje.a114944; Townsend PP., 1988, HLTH DEPRIVATION INE; 1977, MANUAL INT STATISTIC, V1	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1576	1577		10.1136/bmj.305.6868.1576	http://dx.doi.org/10.1136/bmj.305.6868.1576			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286396	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KD77100033
J	KANAI, Y; HEDIGER, MA				KANAI, Y; HEDIGER, MA			PRIMARY STRUCTURE AND FUNCTIONAL-CHARACTERIZATION OF A HIGH-AFFINITY GLUTAMATE TRANSPORTER	NATURE			English	Article							EXCITATORY AMINO-ACIDS; GLIAL-CELLS; RAT-BRAIN; SEROTONIN TRANSPORTER; EXPRESSION CLONING; RECEPTORS; CARRIER; IDENTIFICATION; METABOLISM; ASPARTATE	GLUTAMATE transport across plasma membranes of neurons, glial cells and epithelial cells of the small intestine and kidney proceeds by high- and low-affinity transport systems1-5. High-affinity (K(m) 2-50 muM) transport systems have been described1,6,7 that are dependent on Na+ but not Cl- ions and have a preference for L-glutamate and D- and L-aspartate. In neurons high-affinity glutamate transporters are essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft6,7. We have isolated a complementary DNA encoding an electrogenic Na+- but not Cl--dependent high-affinity glutamate transporter (named EAAC1) from rabbit small intestine by expression in Xenopus oocytes. We find EAAC1 transcripts in specific neuronal structures in the central nervous system as well as in the small intestine, kidney, liver and heart. The function and pharmacology of the expressed protein are characteristic of the high-affinity glutamate transporter already identified in neuronal tissues. The abnormal glutamate transport that is associated with certain neurodegenerative diseases8 and which occurs during ischaemia and anoxia7 Could be due to abnormalities in the function of this protein.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Hediger, Matthias/0000-0003-1946-027X				BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; COX DWG, 1977, J NEUROCHEM, V29, P579, DOI 10.1111/j.1471-4159.1977.tb10707.x; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EIEN A, 1992, CAN J NEUROL SCI, V19, P117; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELKE T, 1989, J BACTERIOL, V171, P5551, DOI 10.1128/jb.171.10.5551-5560.1989; FERKANY J, 1986, J NEUROSCI RES, V16, P491, DOI 10.1002/jnr.490160305; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1986, ANAL BIOCHEM, V159, P280, DOI 10.1016/0003-2697(86)90344-1; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; KANAI Y, IN PRESS AM J PHYSL; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KILTY J, 1991, SCIENCE, V254, P78; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; ROMANO PM, 1989, AM J PHYSIOL, V257, pR180, DOI 10.1152/ajpregu.1989.257.1.R180; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; Schousboe A, 1981, Int Rev Neurobiol, V22, P1, DOI 10.1016/S0074-7742(08)60289-5; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SIESJO BK, 1990, NEWS PHYSIOL SCI, V5, P120; SILBERNAGL S, 1979, KLIN WOCHENSCHR, V57, P1009, DOI 10.1007/BF01479986; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; WANG CD, 1991, MOL PHARMACOL, V40, P168; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WINGROVE TG, 1988, AM J PHYSIOL, V255, pC737, DOI 10.1152/ajpcell.1988.255.6.C737	43	1205	1233	0	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					467	471		10.1038/360467a0	http://dx.doi.org/10.1038/360467a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1280334				2022-12-28	WOS:A1992KA79700061
J	SHWEIKI, D; ITIN, A; SOFFER, D; KESHET, E				SHWEIKI, D; ITIN, A; SOFFER, D; KESHET, E			VASCULAR ENDOTHELIAL GROWTH-FACTOR INDUCED BY HYPOXIA MAY MEDIATE HYPOXIA-INITIATED ANGIOGENESIS	NATURE			English	Article							PERMEABILITY FACTOR; CELL MITOGEN; GLIOBLASTOMA-MULTIFORME; MESSENGER-RNA; EXPRESSION; GENE; SECRETE; PROTEIN; TUMORS; LINE	INEFFICIENT vascular supply and the resultant reduction in tissue oxygen tension often lead to neovascularization in order to satisfy the needs of the tissue1. Examples include the compensatory development of collateral blood vessels in ischaemic tissues that are otherwise quiescent for angiogenesis and angiogenesis associated with the healing of hypoxic wounds2. But the presumptive hypoxia-induced angiogenic factors that mediate this feedback response have not been identified. Here we show that vascular endothelial growth factor (VEGF; also known as vascular permeability factor) probably functions as a hypoxia-inducible angiogenic factor. VEGF messenger RNA levels are dramatically increased within a few hours of exposing different cell cultures to hypoxia and return to background when normal oxygen supply is resumed. In situ analysis of tumour specimens undergoing neovascularization show that the production of VEGF is specifically induced in a subset of glioblastoma cells distinguished by their immediate proximity to necrotic foci (presumably hypoxic regions) and the clustering of capillaries alongside VEGF-producing cells.	HADASSAH HEBREW UNIV HOSP,MED CTR,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL; HADASSAH HEBREW UNIV HOSP,MED CTR,DEPT PATHOL,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	SHWEIKI, D (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL.		Keshet, Eli/GQR-0445-2022					ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HIRANO A, 1975, HUM PATHOL, V6, P611, DOI 10.1016/S0046-8177(75)80045-1; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JELLINGER K, 1978, ACTA NEUROCHIR, V42, P5, DOI 10.1007/BF01406628; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KINASEWITZ GT, 1986, J APPL PHYSIOL, V61, P554, DOI 10.1152/jappl.1986.61.2.554; KNIGHTON D, 1987, CURRENT COMMUNICATIO, P150; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; OLSEN SP, 1986, BRAIN RES, V368, P24; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x	30	3726	3915	7	286	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					843	845		10.1038/359843a0	http://dx.doi.org/10.1038/359843a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279431				2022-12-28	WOS:A1992JV77700068
J	CAMBIEN, F; POIRIER, O; LECERF, L; EVANS, A; CAMBOU, JP; ARVEILER, D; LUC, G; BARD, JM; BARA, L; RICARD, S; TIRET, L; AMOUYEL, P; ALHENCGELAS, F; SOUBRIER, F				CAMBIEN, F; POIRIER, O; LECERF, L; EVANS, A; CAMBOU, JP; ARVEILER, D; LUC, G; BARD, JM; BARA, L; RICARD, S; TIRET, L; AMOUYEL, P; ALHENCGELAS, F; SOUBRIER, F			DELETION POLYMORPHISM IN THE GENE FOR ANGIOTENSIN-CONVERTING ENZYME IS A POTENT RISK FACTOR FOR MYOCARDIAL-INFARCTION	NATURE			English	Article							SMOOTH-MUSCLE CELLS; HYPERTENSION; INHIBITORS; BRADYKININ; RENIN	FACTORS involved in the pathogenesis of atherosclerosis, thrombosis and vasoconstriction1,2 contribute to the development of coronary heart disease. In a study comparing patients after myocardial infarction with controls, we have explored a possible association between coronary heart disease and a variation found in the gene encoding angiotensin-converting enzyme (ACE). The polymorphism ACE/ID is strongly associated with the level of circulating enzyme3. This enzyme plays a key role in the production of angiotensin II and in the catabolism of bradykinin, two peptides involved in the modulation of vascular tone and in the proliferation of smooth muscle cells. Here we report that the DD genotype, which is associated with higher levels of circulating ACE than the ID and II genotypes, is significantly more frequent in patients with myocardial infarction (n = 610) than in controls (n = 733) (P = 0.007), especially among subjects with low body-mass index and low plasma levels of ApoB (P < 0.0001). The ACE.ID polymorphism seems to be a potent risk factor of coronary heart disease in subjects formerly considered to be at low risk according to common criteria.	HOP BROUSSAIS,INSERM,U258,F-75674 PARIS 14,FRANCE; MONICA PROJECT,F-67085 STRASBOURG,FRANCE; CHU PURPAN,INSERM,U326,MONICA PROJECT,F-31059 TOULOUSE,FRANCE; ECOLE MED PARIS,THROMBOSE EXPTL LAB,F-75005 PARIS,FRANCE; INSERM,U36,F-75005 PARIS,FRANCE; QUEENS UNIV BELFAST,MONICA PROJECT,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND; INST PASTEUR,MONICA PROJECT,F-59019 LILLE,FRANCE; INST PASTEUR,INSERM,U325,SERLIA,F-59019 LILLE,FRANCE; INSERM,U367,F-75005 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Queens University Belfast; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	CAMBIEN, F (corresponding author), INSERM,SC7,17 RUE FER A MOULIN,F-75005 PARIS,FRANCE.		Bard, Jean-Marie/AFT-1583-2022; Alhenc-Gelas, Francois/F-9511-2017; Cambien, Francois/AAP-9751-2020	Bard, Jean-Marie/0000-0002-9123-8123; LECERF, LAURE/0000-0001-8342-5298; Amouyel, Philippe/0000-0001-9088-234X				ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; ALHENCGELAS F, 1991, J LAB CLIN MED, V117, P33; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; CAMBIEN F, 1988, AM J HUM GENET, V43, P774; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; FARHY RD, 1992, BIOCHEM BIOPH RES CO, V182, P283, DOI 10.1016/S0006-291X(05)80142-1; FUSTER V, 1992, NEW ENGL J MED, V326, P310; JEUNEMAITRE K, 1992, NATURE GENET, V1, P72; KATO H, 1991, J HYPERTENS, V9, P17; MAGRINI F, 1987, CIRCULATION, V75, P168; MASERI A, 1978, NEW ENGL J MED, V299, P1271, DOI 10.1056/NEJM197812072992303; MCMURRAY J, 1991, J HYPERTENS, V9, P393, DOI 10.1097/00004872-199105000-00002; PARRA HJ, 1992, ARTERIOSCLER THROMB, V12, P701, DOI 10.1161/01.ATV.12.6.701; PELC LR, 1991, CIRCULATION, V83, P2048, DOI 10.1161/01.CIR.83.6.2048; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; TIRET L, 1992, AM J HUM GENET, V51, P197; WIEMER G, 1991, HYPERTENSION, V18, P558, DOI 10.1161/01.HYP.18.4.558; 1988, J CLIN EPIDEMIOL, V41, P105	23	1834	1899	2	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					641	644		10.1038/359641a0	http://dx.doi.org/10.1038/359641a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1328889				2022-12-28	WOS:A1992JT82400059
J	FUKAMI, K; FURUHASHI, K; INAGAKI, M; ENDO, T; HATANO, S; TAKENAWA, T				FUKAMI, K; FURUHASHI, K; INAGAKI, M; ENDO, T; HATANO, S; TAKENAWA, T			REQUIREMENT OF PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE FOR ALPHA-ACTININ FUNCTION	NATURE			English	Article							CAPPING PROTEIN; SMOOTH-MUSCLE; POLYPHOSPHOINOSITIDE; COMPLEXES; GELSOLIN	INOSITOL phospholipid turnover is enhanced during mitogenic stimulation of cells by growth factors1 and the breakdown of phosphatidylinositol 4,5-bisphosphate (PtdInsP2) may be important in triggering cell proliferation. PtdInsP2 also binds actin-binding proteins to regulate their activity2-7, but it is not yet understood how this control is achieved. The protein alpha-actinin from striated muscle contains large amounts of endogenous PtdInsP2, whereas that from smooth muscle has only a little but will bind exogenously added PtdInsP2. In vitro alpha-actinin binds to F-actin and will crosslink actin filaments, increasing the viscosity of F-actin solutions8,9. We report here that alpha-actinin from striated muscle is an endogenous PtdInsP2-bound protein and that the specific interaction between alpha-actinin and PtdInsP2 regulates the F-actin-gelating activity of alpha-actinin. Although the F-actin-gelating activity of alpha-actinin from smooth muscle is much reduced compared with that from striated muscle, exogenous PtdInsP2 can enhance the activity of smooth muscle alpha-actinin to the level seen in striated muscles. These results show that PtdInsP2 is present in striated muscle alpha-actinin and that it is necessary for alpha-actinin to realize its maximum gelating activity.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,SAKAE CHO,ITABASHI KU,TOKYO 173,JAPAN; CHIBA UNIV,DEPT BIOL,YAYOI,CHIBA 260,JAPAN; AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Chiba University; Aichi Cancer Center; Nagoya University			Inagaki, Masaki/B-9920-2016					ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BENNETT JP, 1984, BIOCHEMISTRY-US, V23, P5081, DOI 10.1021/bi00316a039; BURN P, 1985, NATURE, V314, P469, DOI 10.1038/314469a0; EBASHI S, 1964, NATURE, V203, P645, DOI 10.1038/203645a0; ENDO T, 1982, BIOCHEM BIOPH RES CO, V107, P1467, DOI 10.1016/S0006-291X(82)80164-2; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FURUHASHI K, 1992, BIOCHEM BIOPH RES CO, V184, P121; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KOBAYASHI R, 1984, EUR J BIOCHEM, V143, P125, DOI 10.1111/j.1432-1033.1984.tb08351.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MARUYAMA K, 1965, J BIOCH, V58, P7; MASAKI T, 1967, J BIOCHEM-TOKYO, V62, P630, DOI 10.1093/oxfordjournals.jbchem.a128717; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MEYER RK, 1982, P NATL ACAD SCI-BIOL, V79, P4280, DOI 10.1073/pnas.79.14.4280; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	23	310	316	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					150	152		10.1038/359150a0	http://dx.doi.org/10.1038/359150a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1326084				2022-12-28	WOS:A1992JM49400053
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WARNINGS ISSUED ON NONSEDATING ANTIHISTAMINES TERFENADINE AND ASTEMIZOLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	46	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					705	705		10.1001/jama.268.6.705	http://dx.doi.org/10.1001/jama.268.6.705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1322467				2022-12-28	WOS:A1992JG66600004
J	HEDRICK, SM				HEDRICK, SM			DAWN OF THE HUNT FOR NONCLASSICAL MHC FUNCTION	CELL			English	Review							CLASS-I MOLECULES; HISTOCOMPATIBILITY COMPLEX; IMMUNOGENIC PEPTIDES; ANTIGEN; PROTEIN; MOUSE		UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093	University of California System; University of California San Diego	HEDRICK, SM (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Hedrick, Stephen M/E-9171-2010	Hedrick, Stephen/0000-0002-6345-8751				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BLUESTONE JA, 1991, IMMUNOL REV, V120, P5, DOI 10.1111/j.1600-065X.1991.tb00585.x; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FLAHERTY L, 1990, CRIT REV IMMUNOL, V10, P131; FLAVELL RA, 1986, SCIENCE, V233, P437, DOI 10.1126/science.3726537; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KLEIN J, 1990, IMMUNOGENETICS, V32, P147, DOI 10.1007/BF02114967; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PAMER EG, 1992, CELL, V70, P215, DOI 10.1016/0092-8674(92)90097-V; Rodgers J R, 1986, Adv Immunol, V38, P313, DOI 10.1016/S0065-2776(08)60010-3; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7; WILLS C, 1991, IMMUNOL REV, V124, P165, DOI 10.1111/j.1600-065X.1991.tb00621.x	19	33	33	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					177	180		10.1016/0092-8674(92)90092-Q	http://dx.doi.org/10.1016/0092-8674(92)90092-Q			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1322246				2022-12-28	WOS:A1992JE75700001
J	BIRREN, SJ; VERDI, JM; ANDERSON, DJ				BIRREN, SJ; VERDI, JM; ANDERSON, DJ			MEMBRANE DEPOLARIZATION INDUCES P140(TRK) AND NGF RESPONSIVENESS, BUT NOT P75(LNGFR), IN MAH CELLS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; SUPERIOR CERVICAL-GANGLION; NEURONAL DIFFERENTIATION; SYMPATHETIC NEURONS; CHROMAFFIN CELLS; RECEPTOR; GLUCOCORTICOIDS; EXPRESSION; DEPENDENCE; DEATH	Nerve growth factor (NGF) is required for the maturation and survival of sympathetic neurons, but the mechanisms controlling expression of the NGF receptor in developing neuroblasts have not been defined. MAH cells, an immortalized sympathoadrenal progenitor cell line, did not respond to NGF and expressed neither low-affinity NGF receptor (p75) nor p140trk messenger RNAs. Depolarizing concentrations of potassium chloride, but none of a variety of growth factors, induced expression of p140trk but not p75 messenger RNA. A functional response to NGF was acquired by MAH cells under these conditions, suggesting that expression of p75 is not essential for this response. Depolarization also permitted a relatively high proportion of MAH cells to develop and survive as neurons in fibroblast growth factor and NGF. These data establish a relation between electrical activity and neurotrophic factor responsiveness in developing neurons, which may operate in the functioning of the mature nervous system as well.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute					NINDS NIH HHS [NS23476] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023476] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BIRREN SJ, UNPUB; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COUGHLIN MD, 1985, DEV BIOL, V110, P392, DOI 10.1016/0012-1606(85)90098-3; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; ERNSBERGER U, 1989, DEV BIOL, V135, P250, DOI 10.1016/0012-1606(89)90177-2; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KORSCHING S, 1988, DEV BIOL, V126, P40, DOI 10.1016/0012-1606(88)90236-9; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; MADERDRUT JL, 1988, BRAIN RES, V444, P189, DOI 10.1016/0006-8993(88)90928-6; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1991, DEVELOPMENT, V112, P813; RUBIN E, 1985, J NEUROSCI, V5, P673; RUBIN E, 1985, J NEUROSCI, V5, P697; RUBIN E, 1985, J NEUROSCI, V5, P685; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; UNSICKER K, 1989, INT J DEV NEUROSCI, V7, P413, DOI 10.1016/0736-5748(89)90002-6; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A	29	128	129	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					395	397		10.1126/science.1321502	http://dx.doi.org/10.1126/science.1321502			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1321502				2022-12-28	WOS:A1992JD67400036
J	BREO, DL				BREO, DL			JFK DEATH - THE PLAIN TRUTH FROM THE MDS WHO DID THE AUTOPSY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	23	23	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2794	2803		10.1001/jama.267.20.2794	http://dx.doi.org/10.1001/jama.267.20.2794			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1307683				2022-12-28	WOS:A1992HV26500031
J	KEREM, E; REISMAN, J; COREY, M; CANNY, GJ; LEVISON, H				KEREM, E; REISMAN, J; COREY, M; CANNY, GJ; LEVISON, H			PREDICTION OF MORTALITY IN PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-LUNG TRANSPLANTATION; PROGNOSTIC FACTORS; SURVIVAL; SEX; AGE	Background. The majority of patients with cystic fibrosis die in early adulthood of lung disease. Lung transplantation is a treatment option for patients with advanced pulmonary disease, although the waiting period for organs may be as long as two years. Our purpose was to determine whether the risk of death due to respiratory failure could be predicted one or two years in advance on the basis of pulmonary function, blood gas levels, and nutritional status. Methods. The study cohort consisted of 673 patients followed between 1977 and 1989. In each patient, pulmonary function, blood gas levels, nutritional status, and vital status were assessed between 1977 and 1987. Cox proportional-hazards regression analysis was used to compute the relative risk of death within one or two years after particular measurements. The effects of age and sex on mortality were also included in the analysis. Results. One hundred ninety patients (28 percent) died during the study period. Overall, patients with a forced expiratory volume in one second (FEV1) less than 30 percent of the predicted value, a partial pressure of arterial oxygen below 55 mm Hg, or a partial pressure of arterial carbon dioxide above 50 mm Hg had two-year mortality rates above 56 percent. Among the laboratory measurements, the FEV1 was the most significant predictor of mortality, but age and sex were also significant in predicting risk. After adjustment for age and sex, the relative risk of death within two years was 2.0 (95 percent confidence interval, 1.9 to 2.2) for each decrement in the FEV1 of 10 percent below the predicted value. Among patients with the same FEV1, the relative risk of death was 2.0 (95 percent confidence interval, 1.5 to 2.6) in patients 10 years younger than other patients, and 2.2 (1.6 to 3.1) in female patients as compared with male patients. Conclusions. Patients with cystic fibrosis should be considered candidates for lung transplantation when the FEV1 falls below 30 percent of the predicted value. Female patients and younger patients may need to be considered for transplantation at an earlier stage.	HOSP SICK CHILDREN,DEPT PEDIAT,DIV PULM,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BRITTON JR, 1989, BRIT MED J, V298, P483, DOI 10.1136/bmj.298.6672.483; CANNY GJ, 1986, PEDIATR PULM, V2, P313; COREY M, 1988, J CLIN EPIDEMIOL, V41, P583, DOI 10.1016/0895-4356(88)90063-7; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; HUANG NN, 1987, AM J MED, V82, P871, DOI 10.1016/0002-9343(87)90147-1; HUDSON I, 1987, PEDIATR PULM, V3, P288, DOI 10.1002/ppul.1950030503; HUTTER JA, 1988, AM J MED, V85, P4, DOI 10.1016/0002-9343(88)90496-2; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; MACLUSKY I, 1990, DISORDERS RESP TRACT, P692; MOORE DJ, 1985, NUTR RES, V5, P797, DOI 10.1016/S0271-5317(85)80167-6; ORENSTEIN DM, 1991, CHEST, V100, P1016, DOI 10.1378/chest.100.4.1016; PHELAN P, 1984, ARCH DIS CHILD, V59, P71, DOI 10.1136/adc.59.1.71; SCOTT J, 1988, LANCET, V2, P192; SITAL A, 1991, NEW ENGL J MED, V325, P1243; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; VEATCH RM, 1991, NEW ENGL J MED, V325, P1246, DOI 10.1056/NEJM199110243251711; WAGENER JS, 1980, PERSPECTIVES CYSTIC, P236; WHITEHEAD B, 1991, ARCH DIS CHILD, V66, P1018, DOI 10.1136/adc.66.9.1018; WHITEHEAD B, 1991, ARCH DIS CHILD, V66, P1022, DOI 10.1136/adc.66.9.1022; WOOD RE, 1984, CYSTIC FIBROSIS, P434; 1989, 1989 CAN CYST FIBR F; [No title captured]; 1988, BMJ, V297, P1599	23	735	751	0	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1187	1191		10.1056/NEJM199204303261804	http://dx.doi.org/10.1056/NEJM199204303261804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1285737				2022-12-28	WOS:A1992HR00800004
J	WILSON, TE; PAULSEN, RE; PADGETT, KA; MILBRANDT, J				WILSON, TE; PAULSEN, RE; PADGETT, KA; MILBRANDT, J			PARTICIPATION OF NON-ZINC FINGER RESIDUES IN DNA-BINDING BY 2 NUCLEAR ORPHAN RECEPTORS	SCIENCE			English	Article							HORMONE RECEPTOR; THYROID-HORMONE; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; RESPONSE ELEMENT; AMINO-ACIDS; GENE; SUPERFAMILY; MEMBER; PROTEIN	Steroid-thyroid hormone receptors typically bind as dimers to DNA sequences that contain repeated elements termed half-sites. NGFI-B, an early response protein and orphan member of this receptor superfamily, binds to a DNA sequence that contains only one half-site (5'-AAAGGTCA-3'). A domain separate from the NGFI-B zinc fingers, termed the A box, was identified and is required for recognition of the two adenine-thymidine (A-T) base Pairs at the 5' end of the NGFI-B DNA binding element. In addition, a domain downstream of the zinc fingers of the orphan receptor H-2 region II binding protein, termed the T box, determined binding to tandem repeats of the estrogen receptor half-site (5'-AGGTCA-3').	WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)				Milbrandt, Jeffrey/0000-0002-5477-7689; Paulsen, Ragnhild Elisabeth/0000-0003-0154-8775	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001018] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49712] Funding Source: Medline; NINDS NIH HHS [NS01018] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DAY ML, 1990, J BIOL CHEM, V265, P15253; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILLIAMS DC, 1982, SCIENCE, V215, P687, DOI 10.1126/science.7036343; WILSON T, UNPUB; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WILSON TE, IN PRESS J BIOL CHEM	36	314	318	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					107	110		10.1126/science.1314418	http://dx.doi.org/10.1126/science.1314418			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1314418				2022-12-28	WOS:A1992HL82200039
J	ASHER, J				ASHER, J			COCAINE TOXICITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ASHER, J (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, BRAIN RES, V542, P1	1	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1584	1584		10.1001/jama.267.12.1584	http://dx.doi.org/10.1001/jama.267.12.1584			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1311777				2022-12-28	WOS:A1992HJ59700007
J	FARAG, SS; GREEN, MD; MORSTYN, G; SHERIDAN, WP; FOX, RM				FARAG, SS; GREEN, MD; MORSTYN, G; SHERIDAN, WP; FOX, RM			DELAY BY INTERNISTS IN OBTAINING DIAGNOSTIC BIOPSIES IN PATIENTS WITH SUSPECTED CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						BIOPSY; LYMPHOMA; GASTROINTESTINAL NEOPLASMS; LUNG NEOPLASMS; COST CONTROL	UNKNOWN PRIMARY; METASTATIC CANCER; PRIMARY SITE; ORIGIN; ADENOCARCINOMA; CARCINOMA	Objective: To investigate the degree and type of delays in performing diagnostic biopsies in medical patients with suspected malignancy. Design: Retrospective survey of clinical histories of patients referred between January 1985 and March 1989. Setting: Inner city teaching hospital internal medicine (nononcologic) services. Patients: Patients with gastrointestinal and lung cancers, adenocarcinoma of unknown primary site, and lymphomas were referred as inpatients by internists. Two hundred fifty-five patients were eligible, and 177 were evaluable. Main Outcome Measures: The number, type, and results of tests done before and after biopsy were analyzed. Results: In 67% of patients the biopsied lesion was detected by the second day of evaluation; however, there was an 8- to 10-day delay before a biopsy was done. This delay was consistent across the four malignancy groups studied. Although logistic and other unavoidable delays occurred in 40% of the cases, in 60% delays could only be attributed to continued, frequently low yield, noninvasive tests. An average of 3.3 tests were made per patient, with only 24% leading to a definitive biopsy. Conclusion: Because of the performance of many other tests, a substantial delay exists in proceeding to biopsy during the diagnosis of cancer by internists.	ROYAL MELBOURNE HOSP, DEPT MED ONCOL, PARKVILLE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital				Sheridan, William/0000-0001-8320-1323				GRECO FA, 1986, ANN INTERN MED, V104, P547, DOI 10.7326/0003-4819-104-4-547; GREENBERG BR, 1988, MED CLIN N AM, V72, P1055, DOI 10.1016/S0025-7125(16)30729-5; KIRSTEN F, 1987, OJ MED, V238, P143; LEVINE MN, 1985, CAN MED ASSOC J, V133, P977; MOERTEL CG, 1972, CANCER-AM CANCER SOC, V30, P1469, DOI 10.1002/1097-0142(197212)30:6<1469::AID-CNCR2820300609>3.0.CO;2-T; NYSTROM JS, 1979, JAMA-J AM MED ASSOC, V241, P381, DOI 10.1001/jama.241.4.381; NYSTROM JS, 1977, SEMIN ONCOL, V4, P53; SIMPSON GT, 1980, OTOLARYNG CLIN N AM, V13, P489; STEWART JF, 1979, BRIT MED J, V1, P1530, DOI 10.1136/bmj.1.6177.1530; ULTMANN JE, 1980, HARRISONS PRINCIPLES, P1583; ULTMANN JE, 1987, CANCER PRINCIPLES PR, P1843	11	21	21	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					473	478		10.7326/0003-4819-116-6-473	http://dx.doi.org/10.7326/0003-4819-116-6-473			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1310838				2022-12-28	WOS:A1992HJ59800007
J	ETTEHADIEH, E; SANGHERA, JS; PELECH, SL; HESSBIENZ, D; WATTS, J; SHASTRI, N; AEBERSOLD, R				ETTEHADIEH, E; SANGHERA, JS; PELECH, SL; HESSBIENZ, D; WATTS, J; SHASTRI, N; AEBERSOLD, R			TYROSYL PHOSPHORYLATION AND ACTIVATION OF MAP KINASES BY P56LCK	SCIENCE			English	Article							SERINE-THREONINE KINASE; CELL-CYCLE CONTROL; PROTEIN-KINASE; LYMPHOCYTES-T; CD4 RECEPTOR; CYTOPLASMIC DOMAINS; INSULIN; STIMULATION; MATURATION; COMPLEXES	T cell signaling via the CD4 surface antigen is mediated by the associated tyrosyl protein kinase p56lck. The 42-kilodalton mitogen-activated protein (MAP) kinase (p42mapk) was tyrosyl-phosphorylated and activated after treatment of the murine T lymphoma cell line 171CD4+, which expresses CD4, with antibody to CD3. Treatment of the CD4-deficient cell line 171 with the same antibody did not result in phosphorylation or activation of p42mapk. Purified p56lck both tyrosyl-phosphorylated and stimulated the seryl-threonyl phosphotransferase activity of purified p44mpk, a MAP kinase isoform from sea star oocytes. A synthetic peptide modeled after the putative regulatory phosphorylation site in murine p42mapk (Tyr185) was phosphorylated by p56lck with a similar V(max), but a fivefold lower Michaelis constant (K(m)) than a peptide containing the Tyr394 autophosphorylation site from p56lck. MAP kinases may participate in protein kinase cascades that link Src family protein-tyrosyl kinases to seryl-threonyl kinases such as those encoded by rsk and raf, which are putative substrates of MAP kinases.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia; University of California System; University of California Berkeley; University of British Columbia; University of British Columbia					PHS HHS [R126604] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHN NG, 1991, J BIOL CHEM, V256, P11487; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSON P, 1988, J IMMUNOL, V140, P1732; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAREST D, IN PRESS; CHUCK RS, 1990, P NATL ACAD SCI USA, V87, P5021, DOI 10.1073/pnas.87.13.5021; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTH Y, 1991, EMBO J, V10, P2661; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HOSHI M, 1988, J BIOL CHEM, V263, P5396; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; NEL AE, 1991, J IMMUNOL, V147, P1933; NEL AE, 1990, J IMMUNOL, V145, P971; NEL AE, 1990, J IMMUNOL, V144, P2683; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROBEY E, 1990, CELL, V60, P697, DOI 10.1016/0092-8674(90)90082-P; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; SANGHERA J, UNPUB; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WATTS JD, 1992, IN PRESS J BIOL CHEM	48	138	141	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1992	255	5046					853	855		10.1126/science.1311128	http://dx.doi.org/10.1126/science.1311128			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD548	1311128				2022-12-28	WOS:A1992HD54800039
J	MERTZ, GJ; BENEDETTI, J; ASHLEY, R; SELKE, SA; COREY, L				MERTZ, GJ; BENEDETTI, J; ASHLEY, R; SELKE, SA; COREY, L			RISK-FACTORS FOR THE SEXUAL TRANSMISSION OF GENITAL HERPES	ANNALS OF INTERNAL MEDICINE			English	Article						HERPES GENITALIS; HERPESVIRUS-HOMINIS; SEXUALLY TRANSMITTED DISEASES, VIRAL; ANTIBODIES, VIRAL; PREGNANCY COMPLICATIONS, INFECTIOUS	SIMPLEX VIRUS-INFECTIONS; DOUBLE-BLIND; ORAL ACYCLOVIR; TYPE-2; ACQUISITION; SUPPRESSION; ANTIBODIES; GONORRHEA; PARTNER; TRIAL	Objective: To determine the risk of sexual transmission of genital herpes simplex virus (HSV) in heterosexual couples. Design: Prospective study of couples who were participants in a clinical trial. Each source partner had symptomatic, recurrent genital HSV, and each susceptible partner was without serologic or clinical evidence of genital herpes. Couples were followed for a median of 334 days. Setting: Two university-based research clinics. Patients: One hundred forty-four heterosexual couples were studied out of an initial enrollment of 214 couples. Main Outcome Measures: Development of culture-proven HSV infection or type-specific antibodies in the susceptible partner. Main Results: Transmission occurred in 14 (9.7%) couples, including 11 (16.9%) of 65 couples with male and 3 (3.8%) of 79 with female source partners (P = 0.05). The annual rate of acquisition was higher (31.8%) in susceptible, female partners who lacked antibodies to either HSV type 1 or 2 at entry compared with females with HSV type 1 antibodies at entry (9.1%). Couples avoiding transmission of HSV reported fewer days with genital lesions in source partners. Detailed histories were available at the time of transmission in 13 couples. In nine couples, transmission occurred when the source partner was reported to be asymptomatic and in four, it resulted from sexual contact at the time of prodrome (1 case) or within hours before lesions were first noticed by the source partner (3 cases). Conclusions: Despite clear recognition of genital herpes in source partners, there was substantial risk for transmission; in 70% of patients, transmission appeared to result from sexual contact during periods of asymptomatic viral shedding. The risk for acquisition of HSV was higher in women than men, and previous HSV type 1 infection appeared to reduce the risk for acquisition of HSV type 2 infection among women.	UNIV NEW MEXICO, DEPT MED, ALBUQUERQUE, NM 87131 USA; UNIV WASHINGTON, PACIFIC MED CTR,DEPT LAB MED,ROOM 9301, 1200 12TH AVE S, SEATTLE, WA 98144 USA	University of New Mexico; University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731, R01AI020381] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30731, AI-20381] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1987, J VIROL, V61, P264, DOI 10.1128/JVI.61.2.264-268.1987; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BERNSTEIN DI, 1985, J MED VIROL, V15, P251, DOI 10.1002/jmv.1890150306; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; Handsfield H.H., 1990, PRINCIPLES PRACTICE, P1613; HOLMES KK, 1970, AM J EPIDEMIOL, V91, P170, DOI 10.1093/oxfordjournals.aje.a121125; HOOPER RR, 1978, AM J EPIDEMIOL, V108, P136, DOI 10.1093/oxfordjournals.aje.a112597; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1988, JAMA-J AM MED ASSOC, V260, P201, DOI 10.1001/jama.260.2.201; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107; THIN RNT, 1971, BRIT J VENER DIS, V47, P27; WENTWORTH BB, 1973, HEALTH LAB SCI, V10, P75; WHITLEY R, 1991, NEW ENGL J MED, V324, P450, DOI 10.1056/NEJM199102143240704; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; YEAGER AS, 1984, PEDIATRICS, V73, P188	22	385	395	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					197	202		10.7326/0003-4819-116-3-197	http://dx.doi.org/10.7326/0003-4819-116-3-197			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1309413				2022-12-28	WOS:A1992HB35600004
J	RAJFER, J; ARONSON, WJ; BUSH, PA; DOREY, FJ; IGNARRO, LJ				RAJFER, J; ARONSON, WJ; BUSH, PA; DOREY, FJ; IGNARRO, LJ			NITRIC-OXIDE AS A MEDIATOR OF RELAXATION OF THE CORPUS CAVERNOSUM IN RESPONSE TO NONADRENERGIC, NONCHOLINERGIC NEUROTRANSMISSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; SMOOTH-MUSCLE RELAXATION; INDUCED PENILE ERECTION; RELAXING FACTOR; ENDOTHELIAL-CELLS; IMPOTENT MEN; CYCLIC-GMP; L-ARGININE; ARTERY; HEMODYNAMICS	Background. Nitric oxide has been identified as an endothelium-derived relaxing factor in blood vessels. We tried to determine whether it is involved in the relaxation of the corpus cavernosum that allows penile erection. The relaxation of this smooth muscle is known to occur in response to stimulation by nonadrenergic, noncholinergic neurons. Methods. We studied strips of corpus cavernosum tissue obtained from 21 men in whom penile prostheses were inserted because of impotence. The mounted smooth-muscle specimens were pretreated with guanethidine and atropine and submaximally contracted with phenylephrine. We then studied the smooth-muscle relaxant responses to stimulation by an electrical field and to nitric oxide. Results. Electrical-field stimulation caused a marked, transient, frequency-dependent relaxation of the corpus cavernosum that was inhibited in the presence of N-nitro-L-arginine and N-amino-L-arginine, which selectively inhibit the biosynthesis of nitric oxide from L-arginine. The addition of excess L-arginine, but not D-arginine, largely reversed these inhibitory effects. The specific liberation of nitric oxide (by S-nitroso-N-acetylpenicillamine) caused rapid, complete, and concentration-dependent relaxation of the corpus cavernosum. The relaxation caused by either electrical stimulation or nitric oxide was enhanced by a selective inhibitor of cyclic guanosine monophosphate (GMP) phosphodiesterase (M&B 22,948). Relaxation was inhibited by methylene blue, which inhibits cyclic GMP synthesis. Conclusions. Our findings support the hypothesis that nitric oxide is involved in the nonadrenergic, noncholinergic neurotransmission that leads to the smooth-muscle relaxation in the corpus cavernosum that permits penile erection. Defects in this pathway may cause some forms of impotence.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,DIV UROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,TORRANCE,CA 90509	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center				Bush, Margaret/0000-0003-1937-2640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040922, R01HL035014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35014, HL40922] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON PO, 1984, J PHYSIOL-LONDON, V350, P209, DOI 10.1113/jphysiol.1984.sp015197; BARNES CD, 1965, DRUG DOSAGE LABORATO, P261; BUGA GM, 1991, HYPERTENSION, V17, P187, DOI 10.1161/01.HYP.17.2.187; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; DETEJADA IS, 1988, AM J PHYSIOL, V254, pH459, DOI 10.1152/ajpheart.1988.254.3.H459; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; FOURNIER GR, 1987, J UROLOGY, V137, P163, DOI 10.1016/S0022-5347(17)43911-5; FUCHS AM, 1989, J UROLOGY, V141, P1353, DOI 10.1016/S0022-5347(17)41305-X; FUKUTO JM, 1990, BIOCHEM BIOPH RES CO, V168, P458, DOI 10.1016/0006-291X(90)92343-X; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1990, NATURE, V347, P131, DOI 10.1038/347131b0; IGNARRO LJ, 1987, CIRC RES, V60, P82, DOI 10.1161/01.RES.60.1.82; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JUENEMANN KP, 1986, J UROLOGY, V136, P158, DOI 10.1016/S0022-5347(17)44763-X; JUENEMANN KP, 1987, J UROLOGY, V138, P871, DOI 10.1016/S0022-5347(17)43406-9; KLINGE E, 1977, ACTA PHYSIOL SCAND, V100, P354, DOI 10.1111/j.1748-1716.1977.tb05961.x; KUKOVETZ WR, 1979, N-S ARCH PHARMACOL, V310, P129, DOI 10.1007/BF00500277; LUE TF, 1986, J UROLOGY, V135, P479, DOI 10.1016/S0022-5347(17)45697-7; LUE TF, 1983, J UROLOGY, V130, P1237, DOI 10.1016/S0022-5347(17)51768-1; OTTESEN B, 1984, BRIT MED J, V288, P9, DOI 10.1136/bmj.288.6410.9; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SHABSIGH R, 1988, UROLOGY, V32, P83, DOI 10.1016/0090-4295(88)90303-2; STACKL W, 1988, J UROLOGY, V140, P66, DOI 10.1016/S0022-5347(17)41488-1; WOOD KS, 1990, BIOCHEM BIOPH RES CO, V170, P80, DOI 10.1016/0006-291X(90)91243-L; 1989, DHHS871751 NAT CTR H; 1988, VITAL HLTH STATIS 13, V93	33	776	819	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1992	326	2					90	94		10.1056/NEJM199201093260203	http://dx.doi.org/10.1056/NEJM199201093260203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY045	1309211				2022-12-28	WOS:A1992GY04500003
J	SMITH, GD; CARROLL, D; RANKIN, S; ROWAN, D				SMITH, GD; CARROLL, D; RANKIN, S; ROWAN, D			SOCIOECONOMIC DIFFERENTIALS IN MORTALITY - EVIDENCE FROM GLASGOW GRAVEYARDS	BRITISH MEDICAL JOURNAL			English	Article							INEQUALITIES		GLASGOW POLYTECH,DEPT PSYCHOL,GLASGOW G4 0BA,SCOTLAND	Glasgow Caledonian University	SMITH, GD (corresponding author), UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8RZ,SCOTLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				ANTONOVSKY A, 1967, MILBANK FUND Q, V45, P31, DOI 10.2307/3348839; BLANE D, 1990, BRIT MED J, V301, P429, DOI 10.1136/bmj.301.6749.429; BOOTH C, 1969, C BOOTHS LONDON PORT; Chadwick Edwin, 1965, REPORT SANITARY COND; Chapin CV, 1924, AM J PUBLIC HEALTH, V14, P647, DOI 10.2105/AJPH.14.8.647-a; CHECKLAND O, 1982, HLTH CARE SOCIAL HIS; FOX J, 1982, LONGITUDINAL STUDY S; GOLDBLATT P, 1990, LONGITUDINAL STUDY M, P163; HART JT, 1972, LANCET, V1, P192; JANNERFELDT E, 1986, BMJ, V296, P678; Logan WPD, 1954, BRIT J PREV SOC MED, V8, P128; MORRIS JN, 1979, LANCET, V1, P87; Morris JN, 1957, USES OF EPIDEMIOLOGY; MORRISON AS, 1977, AM J EPIDEMIOL, V106, P487, DOI 10.1093/oxfordjournals.aje.a112496; Moser K., 1990, LONGITUDINAL STUDY M, P145; PAMUK ER, 1985, POP STUD-J DEMOG, V39, P17, DOI 10.1080/0032472031000141256; SMITH GD, 1992, AM J PUBLIC HEALTH, V82, P1079, DOI 10.2105/AJPH.82.8.1079; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; Stevenson THC, 1923, BIOMETRIKA, V15, P382; Stevenson THC, 1928, J R STAT SOC, V91, P207, DOI 10.2307/2341530; Stocks P, 1938, J R STAT SOC, V101, P669, DOI 10.2307/2980497; Titmuss Richard, 1943, BIRTH POVERTY WEALTH; WILLING JA, 1986, BURIAL GROUNDS GLASG; [No title captured]; 1990, SPONS ARCHITECTS BUI; 1892, 36TH REG GEN BIRTHS; 1905, INTERDEPARTMENTAL CO	28	55	55	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1554	1557		10.1136/bmj.305.6868.1554	http://dx.doi.org/10.1136/bmj.305.6868.1554			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286385	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KD77100022
J	FOOR, F; PARENT, SA; MORIN, N; DAHL, AM; RAMADAN, N; CHREBET, G; BOSTIAN, KA; NIELSEN, JB				FOOR, F; PARENT, SA; MORIN, N; DAHL, AM; RAMADAN, N; CHREBET, G; BOSTIAN, KA; NIELSEN, JB			CALCINEURIN MEDIATES INHIBITION BY FK506 AND CYCLOSPORINE OF RECOVERY FROM ALPHA-FACTOR ARREST IN YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CYCLOPHILIN; GENE; PROTEIN; CDNA	THE structurally unrelated immunosuppressants FK506 and cyclosporin A (CsA) act similarly, inhibiting a Ca2+-dependent signal required for interleukin-2 transcription and T-cell activation1. Each drug binds to its cytosolic receptor, FKBP-12 and cyclophilin, respectively, and the drug-receptor complexes inhibit the Ca2+/calmodulin-dependent protein phosphatase, calcineurin2-4. In yeast, calcineurin has been implicated in recovery from alpha-mating factor arrest5,6. Here we show that FK506 bound to yeast FKBP-12 appears to form a complex with yeast calcineurin. Moreover, recovery from mating factor arrest is highly sensitive to FK506 or CsA, and this sensitivity requires the presence of FKBP-12 or cyclophilin, respectively. These results define a key physiological target of an FK506- and CsA-sensitive signal pathway in yeast, suggest a high degree of mechanistic conservation with mammalian cells, and indicate that further examination of the yeast system should provide insight into the same process in T cells.	MERCK RES LABS,POB 2000,BLDG R80Y-2A97,RAHWAY,NJ 07065	Merck & Company								BARNES DA, 1986, MOL CELL BIOL, V6, P2828, DOI 10.1128/MCB.6.8.2828; BRIZUELA L, 1991, MOL CELL BIOL, V11, P4616, DOI 10.1128/MCB.11.9.4616; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; NIELSEN JB, 1992, P NATL ACAD SCI USA, V89, P7471, DOI 10.1073/pnas.89.16.7471; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0	14	200	206	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					682	684						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1281518				2022-12-28	WOS:A1992KD08200059
J	MANN, MC; VOTTO, J; KAMBE, J; MCNAMEE, MJ				MANN, MC; VOTTO, J; KAMBE, J; MCNAMEE, MJ			MANAGEMENT OF THE SEVERELY ANEMIC PATIENT WHO REFUSES TRANSFUSION - LESSONS LEARNED DURING THE CARE OF A JEHOVAH WITNESS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						JEHOVAH WITNESSES; ANEMIA; BLOOD TRANSFUSION; ETHICS, MEDICAL; TREATMENT REFUSAL	RECOMBINANT-HUMAN-ERYTHROPOIETIN; PROLONGED NEUROMUSCULAR BLOCKADE; CRITICALLY ILL PATIENTS; FLUOSOL-DA; BLOOD CONSERVATION; SURGERY; FLUID; HEMODILUTION; DESMOPRESSIN; SUBSTITUTES	Objective: To present the case of a Jehovah's Witness with severe anemia and to review the religious philosophy of such patients, the ethical and medicolegal aspects of their care, and the therapeutic options available to clinicians. Data Sources: A MEDLINE literature search (1980 to 1992) identified most studies. Other studies were selected from the bibliographies of identified articles. Study Selection: Selection of articles was limited to the history, philosophy, medicolegal and ethical issues, and clinical management of anemic Jehovah's Witnesses; a recent article on recommendations for red cell transfusion was also reviewed. Conclusions: A clear understanding of the philosophy of the Jehovah's Witnesses regarding blood transfusion and of the medicolegal and ethical aspects of their care is essential to clinicians who care for such patients. One must also be aware of the many alternative therapeutic options that can maximize oxygen delivery and minimize oxygen consumption. The insights gained from this review are applicable to any severely anemic patient who refuses blood transfusion.	NEW BRITAIN GEN HOSP, NEW BRITAIN, CT 06050 USA; UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06032 USA; NEW BRITAIN MEM HOSP, DIV PULM, 2150 CORBIN AVE, NEW BRITAIN, CT 06053 USA	University of Connecticut								ALSOP KS, 1987, LAB MED, V18, P444, DOI 10.1093/labmed/18.7.444; ANAGNOSTOU A, 1977, BLOOD, V50, P1093; AUERBACH M, 1988, J LAB CLIN MED, V111, P566; Boerema I, 1960, J CARDIOVASC SURG TO, V1, P133; BOSHKOV LK, 1991, AM J HEMATOL, V37, P53, DOI 10.1002/ajh.2830370113; CHERNOW B, 1991, CRIT CARE MED, V19, P313; CHERVENAK FA, HASTINGS CTR REP; COOPER JR, 1990, INT ANESTHESIOL CLIN, V28, P210, DOI 10.1097/00004311-199002840-00006; DAVIS NJ, 1974, CLIN ORTHOP RELAT R, V101, P93; DECOUL AAWO, 1985, CLIN NEUROL NEUROSUR, V87, P17, DOI 10.1016/0303-8467(85)90060-5; DUDRICK SJ, 1985, ARCH SURG-CHICAGO, V120, P721; EDWARDS JD, 1989, CRIT CARE MED, V17, P996, DOI 10.1097/00003246-198910000-00006; ENDERBY GE, 1961, BRIT J ANAESTH, V33, P109, DOI 10.1093/bja/33.2.109; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; Gonzalez E R, 1980, JAMA, V243, P724, DOI 10.1001/jama.243.8.720; GOOCH JL, 1991, CRIT CARE MED, V19, P1125, DOI 10.1097/00003246-199109000-00006; GOULD SA, 1986, NEW ENGL J MED, V314, P1653, DOI 10.1056/NEJM198606263142601; GREEN D, 1990, ANN INTERN MED, V113, P720, DOI 10.7326/0003-4819-113-9-720_2; HAMPTON HJ, 1953, ARCH SURG-CHICAGO, V67, P549; Jim R T, 1990, Hawaii Med J, V49, P209; JOHNSON PWM, 1991, BRIT J CANCER, V63, P476, DOI 10.1038/bjc.1991.111; Jonsen A R, 1986, Crit Care Clin, V2, P91; KHINE HH, 1978, ANESTH ANALG, V57, P279; KOESTNER JA, 1990, J TRAUMA, V30, P1406, DOI 10.1097/00005373-199011000-00016; KUPFER Y, 1987, CRIT CARE MED, V15, P795, DOI 10.1097/00003246-198708000-00019; LARSON AG, 1964, ANESTHESIOLOGY, V25, P682, DOI 10.1097/00000542-196409000-00018; LAW EJ, 1991, BURNS, V17, P75, DOI 10.1016/0305-4179(91)90020-H; LEWIS CTP, 1991, ANN THORAC SURG, V51, P448, DOI 10.1016/0003-4975(91)90862-K; LICHTENSTEIN A, 1988, ANESTHESIOLOGY, V69, P119, DOI 10.1097/00000542-198807000-00022; LICHTIGER B, 1982, ANESTH ANALG, V61, P618; LOCKWOOD DNJ, 1988, ANAESTHESIA, V43, P391, DOI 10.1111/j.1365-2044.1988.tb09021.x; LONGMUIR IS, 1962, LIFE SCI, P297, DOI 10.1016/0024-3205(62)90121-2; MARGOLIS BD, 1991, CHEST, V100, P877, DOI 10.1378/chest.100.3.877; MARTENS PR, 1989, LANCET, V1, P1322; MESSMER K, 1975, SURG CLIN N AM, V55, P659; MICHENFELDER JD, 1965, BRIT J ANAESTH, V37, P738; MISHLER JM, 1984, CLIN HAEMATOL, V13, P75; MOFFAT AS, 1991, SCIENCE, V253, P32, DOI 10.1126/science.2063203; NEARMAN HS, 1983, CRIT CARE MED, V11, P142, DOI 10.1097/00003246-198302000-00018; NELSON CL, 1986, J BONE JOINT SURG AM, V68A, P350, DOI 10.2106/00004623-198668030-00006; OHYANAGI H, 1984, ARTIF ORGANS, V8, P10, DOI 10.1111/j.1525-1594.1984.tb04238.x; OLSEN JB, 1990, SCAND J THORAC CARD, V24, P165, DOI 10.3109/14017439009098063; ONESON R, 1985, TRANSFUSION, V25, P179, DOI 10.1046/j.1537-2995.1985.25285169218.x; PARTRIDGE BL, 1990, CRIT CARE MED, V18, P1177, DOI 10.1097/00003246-199010000-00025; POOL R, 1990, SCIENCE, V250, P1655, DOI 10.1126/science.2270476; SALZMAN EW, 1986, NEW ENGL J MED, V314, P1402, DOI 10.1056/NEJM198605293142202; SEGREDO V, 1990, ANESTHESIOLOGY, V72, P566, DOI 10.1097/00000542-199003000-00030; SMOLLER BR, 1986, NEW ENGL J MED, V314, P1233, DOI 10.1056/NEJM198605083141906; SPENCE RK, 1990, CRIT CARE MED, V18, P1227, DOI 10.1097/00003246-199011000-00008; STONE DJ, 1988, ANESTHESIOLOGY, V69, P1028, DOI 10.1097/00000542-198812000-00056; STONE WJ, 1988, AM J MED SCI, V296, P171, DOI 10.1097/00000441-198809000-00005; THOMPSON R, 1977, J ELECTROCARDIOL, V10, P67, DOI 10.1016/S0022-0736(77)80034-4; TREMPER KK, 1980, CRIT CARE MED, V8, P738, DOI 10.1097/00003246-198012000-00009; TREMPER KK, 1982, NEW ENGL J MED, V307, P277, DOI 10.1056/NEJM198207293070503; TROUWBORST A, 1990, BRIT J ANAESTH, V64, P646, DOI 10.1093/bja/64.5.646; VINCENT JL, 1991, EUR J ANAESTH, V8, P297; WAXMAN K, 1984, ARCH SURG-CHICAGO, V119, P721; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393; Whipple GH, 1940, J EXP MED, V71, P569, DOI 10.1084/jem.71.4.569; 1977, JEHOVAHS WITNESSES Q; 1945, WATCHTOWER, V66, P195	62	64	64	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					1042	1048		10.7326/0003-4819-117-12-1042	http://dx.doi.org/10.7326/0003-4819-117-12-1042			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1307705				2022-12-28	WOS:A1992KB98000010
J	NAHASS, GT; GOLDSTEIN, BA; ZHU, WY; SERFLING, U; PENNEYS, NS; LEONARDI, CL				NAHASS, GT; GOLDSTEIN, BA; ZHU, WY; SERFLING, U; PENNEYS, NS; LEONARDI, CL			COMPARISON OF TZANCK SMEAR, VIRAL CULTURE, AND DNA DIAGNOSTIC METHODS IN DETECTION OF HERPES-SIMPLEX AND VARICELLA-ZOSTER INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; VIRUS-INFECTIONS	Objective.-To compare Tzanck smears, viral cultures, and DNA diagnostic methods using the polymerase chain reaction (PCR) in detection of herpes simplex virus (HSV) or varicella-zoster virus (VZV) infection in clinically suspected cases. Design.-A 12-month trial comparing PCR with viral cultures and Tzanck smears in patients with clinically suspected HSV or VZV infection. Setting.-Both ambulatory and hospitalized patients were recruited from a tertiary referral center and the Miami (Fla) Veterans Affairs Medical Center. Patients.-Convenience samples of patients clinically suspected to have HSV (n=48) or VZV (n=35). To be included in the final analysis patients needed to have a positive Tzanck smear, viral culture, or PCR result. Patients who were clinically suspected to have HSV but had VZV by viral culture or PCR were analyzed in the VZV group. Similarly, patients who were clinically suspected to have VZV, but had HSV by viral culture or PCR were analyzed in the HSV group. Seventy-seven patients were available for final analysis: HSV (n=30), VZV (n=32), and 15 control cases who did not have evidence of viral infection. Results.-For HSV, PCR detected HSV DNA sequences in 73% of stained smears and 83% of unstained smears. For VZV infection, VZV DNA sequences were detected in 88% of stained smears and 97% of unstained smears. Viral DNA sequences were not detected in the 15 control cases. Viral cultures were positive in 83% and 44% of HSV and VZV cases, respectively. The Tzanck smear was positive in 60% and 75% of HSV and VZV cases, respectively. Conclusions.-PCR is a reliable method for detecting HSV and VZV DNA sequences from single stained and unstained Tzanck smears. It is clearly superior to viral culture in identifying VZV infection and is equivalent to conventional culture techniques in identifying cases of HSV.	UNIV MIAMI,SCH MED,DEPT DERMATOL & CUTANEOUS SURG,MIAMI,FL 33152; UNIV MIAMI,SCH MED,VET AFFAIRS MED CTR,MIAMI,FL 33152	University of Miami; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA)	NAHASS, GT (corresponding author), ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,DIV DERMATOL,1402 S GRAND BLVD,ST LOUIS,MO 63104, USA.							BLANK H, 1951, JAMA-J AM MED ASSOC, V146, P1410, DOI 10.1001/jama.1951.63670150005012b; DLUGOSCH D, 1991, J MED VIROL, V35, P136, DOI 10.1002/jmv.1890350212; FREY HM, 1981, J INFECT DIS, V143, P274, DOI 10.1093/infdis/143.2.274; KIDO S, 1991, J CLIN MICROBIOL, V29, P76, DOI 10.1128/JCM.29.1.76-79.1991; KIMURA H, 1990, MED MICROBIOL IMMUN, V179, P177, DOI 10.1007/BF00195248; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LIESEGANG TJ, 1984, J AM ACAD DERMATOL, V11, P165, DOI 10.1016/S0190-9622(84)70148-4; OBRIEN JJ, 1989, DRUGS, V37, P233, DOI 10.2165/00003495-198937030-00002; PENNEYS NS, 1991, J CUTAN PATHOL, V18, P3, DOI 10.1111/j.1600-0560.1991.tb00594.x; PENNEYS NS, 1991, J AM ACAD DERMATOL, V24, P689, DOI 10.1016/0190-9622(91)70103-9; SADICK NS, 1987, J AM ACAD DERMATOL, V17, P64, DOI 10.1016/S0190-9622(87)70172-8; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SERFLING U, 1991, Journal of Cutaneous Pathology, V18, P389; SOLOMON AR, 1984, JAMA-J AM MED ASSOC, V251, P633, DOI 10.1001/jama.251.5.633; SOLOMON AR, 1988, J AM ACAD DERMATOL, V18, P218, DOI 10.1016/S0190-9622(88)70032-8; SOLOMON AR, 1986, ARCH DERMATOL, V122, P282, DOI 10.1001/archderm.122.3.282; TZANCK A, 1954, MODERN TRENDS DERMAT, P87	17	107	112	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2541	2544		10.1001/jama.268.18.2541	http://dx.doi.org/10.1001/jama.268.18.2541			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1328700				2022-12-28	WOS:A1992JW61600026
J	BEERS, MH; OUSLANDER, JG; FINGOLD, SF; MORGENSTERN, H; REUBEN, DB; ROGERS, W; ZEFFREN, MJ; BECK, JC				BEERS, MH; OUSLANDER, JG; FINGOLD, SF; MORGENSTERN, H; REUBEN, DB; ROGERS, W; ZEFFREN, MJ; BECK, JC			INAPPROPRIATE MEDICATION PRESCRIBING IN SKILLED-NURSING FACILITIES	ANNALS OF INTERNAL MEDICINE			English	Article						NURSING HOMES; PRESCRIPTIONS, DRUG; DOSE-RESPONSE RELATIONSHIP, DRUG; ACTIVITIES OF DAILY LIVING; QUALITY OF LIFE	CARE; POPULATION; RESIDENTS; HOMES; RISK	Objective: To quantity the appropriateness of medication prescriptions in nursing home residents. Design: Prospective, cohort study. Setting: Twelve nursing homes in the greater Los Angeles area. Participants: A total of 1106 nursing home residents. Main Outcome Measures: The appropriateness of medication prescriptions was evaluated using explicit criteria developed through consensus by 13 experts from the United States and Canada. These experts identified 19 drugs that should generally be avoided and 11 doses, frequencies, or durations of use of specific drugs that generally should not be exceeded. Results: Based on the consensus criteria, 40% of residents received at least one inappropriate medication order, and 10% received two or more inappropriate medication orders concurrently; 7% of all prescriptions were inappropriate. Physicians prescribed a greater number of inappropriate medications for female residents. Regression analysis, corrected for clustering effects within facilities, showed that a greater number of inappropriate medication prescriptions were ordered in larger nursing homes. Inappropriate prescriptions were not related to the proportion of Medicaid (Medi-Cal) residents or the number of physicians practicing in the homes. Conclusions: Inappropriate medication prescribing in nursing homes is common. Female residents and residents of large nursing homes are at the greatest risk for receiving an inappropriate prescription.	UNIV CALIF LOS ANGELES, SCH MED, CTR HLTH SCI, MULTICAMPUS DIV GERIATR & GERONTOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA 90024 USA; RAND CORP, SANTA MONICA, CA 90403 USA; PATIENT CARE PHARM, LOS ANGELES, CA 90045 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; RAND Corporation								ABRAMS W B, 1985, Rational Drug Therapy, V19, P1; ALBRICH JM, 1988, AMBULATORY MED LETT, P1; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; BEERS MH, 1989, DRUGS, V37, P105, DOI 10.2165/00003495-198937010-00008; BEERS MH, 1985, DRUGS, V19, P1; BROOK RH, 1990, HEALTH POLICY, V14, P225, DOI 10.1016/0168-8510(90)90037-E; CROSBY WH, 1986, ARCH INTERN MED, V146, P779, DOI 10.1001/archinte.146.4.779; DALKEY NC, 1967, P3704 RAND RAND CORP; DAVIES DM, 1985, TXB ADVERSE DRUG REA, P241; GRAUBARD BI, 1989, BIOMETRICS, V45, P1053, DOI 10.2307/2531760; HOHMANN AA, 1989, MED CARE, V27, P478, DOI 10.1097/00005650-198905000-00004; MONANE M, 1991, J AM GERIATR SOC, V39, pA42; NOLAN L, 1989, AGE AGEING, V18, P52, DOI 10.1093/ageing/18.1.52; OSTROM JR, 1985, MED CARE, V23, P157, DOI 10.1097/00005650-198502000-00006; PRENTICE RL, 1988, BIOMETRICS, V44, P1033, DOI 10.2307/2531733; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; SOLDO BJ, 1982, GERIATRIC MED, P17; [No title captured]; 1976, US DHEW OS7650050 PU	22	217	221	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					684	689		10.7326/0003-4819-117-8-684	http://dx.doi.org/10.7326/0003-4819-117-8-684			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1308759				2022-12-28	WOS:A1992JR86100010
J	MUIR, KW; RODGER, JC; DEBONO, JS; MCDONALD, H; IRVING, JB				MUIR, KW; RODGER, JC; DEBONO, JS; MCDONALD, H; IRVING, JB			DRUGS AND THE EXERCISE TEST	BRITISH MEDICAL JOURNAL			English	Article									MONKLANDS DIST GEN HOSP,AIRDRIE ML6 0JS,LANARK,SCOTLAND; ST JOHNS HOSP,LIVINGSTON,W LOTHIAN,SCOTLAND				Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X; de Bono, Johann S/0000-0002-2034-595X				AKHRAS F, 1991, LANCET, V338, P1036, DOI 10.1016/0140-6736(91)91900-F; CURTIS JL, 1991, AM HEART J, V121, P1655, DOI 10.1016/0002-8703(91)90009-7; Lollgen H, 1988, Eur Heart J, V9 Suppl K, P3; SCHLANT RC, 1986, CIRCULATION, V74, P653; 1990, ANN INTERN MED, V113, P703	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					808	809		10.1136/bmj.305.6857.808-a	http://dx.doi.org/10.1136/bmj.305.6857.808-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1301028	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JT25600023
J	BENFENATI, F; VALTORTA, F; RUBENSTEIN, JL; GORELICK, FS; GREENGARD, P; CZERNIK, AJ				BENFENATI, F; VALTORTA, F; RUBENSTEIN, JL; GORELICK, FS; GREENGARD, P; CZERNIK, AJ			SYNAPTIC VESICLE-ASSOCIATED CA2+/CALMODULIN-DEPENDENT PROTEIN KINASE-II IS A BINDING-PROTEIN FOR SYNAPSIN-I	NATURE			English	Article							POSTSYNAPTIC DENSITY PROTEIN; BRAIN; FRAGMENTS; CLEAVAGE; RELEASE; ASSAY	SYNAPSIN I is a synaptic vesicle-associated phosphoprotein that is involved in the modulation of neurotransmitter release1. Ca2+ calmodulin-dependent protein kinase II, which phosphorylates two sites in the carboxy-terminal region of synapsin I, causes synapsin I to dissociate from synaptic vesicles2 and increases nerotransmitter release3,4. Conversely, the dephosphorylated form of synapsin I, but not the form phosphorylated by Ca2+/calmodulin-dependent protein kinase II, inhibits neurotransmitter release4-6. The amino-terminal region of synapsin I interacts with membrane phospholipids, whereas the C-terminal region binds to a protein component of synaptic vesicles7,8. Here we demonstrate that the binding of the C-terminal region of synapsin I involves the regulatory domain of a synaptic vesicle-associated form of Ca2+/calmodulin-dependent protein kinase II. Our results indicate that this form of the kinase functions both as a binding protein for synapsin I, and as an enzyme that phosphorylates synapsin I and promotes its dissociation from the vesicles.	UNIV MILAN,CNR,CTR CYTOPHARMACOL,BRUNO CECCARELLI CTR,S RAFFAELE SCI INST,I-20122 MILAN,ITALY; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Rockefeller University	BENFENATI, F (corresponding author), UNIV MODENA,INST HUMAN PHYSIOL,VIA CAMPI 287,I-41100 MODENA,ITALY.		Flavia, Valtorta/F-3450-2012	Flavia, Valtorta/0000-0001-9556-4746; Gorelick, Fred/0000-0001-8293-6803	Telethon [112] Funding Source: Medline	Telethon(Fondazione Telethon)		BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1989, J CELL BIOL, V108, P1851, DOI 10.1083/jcb.108.5.1851; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; GOELZ SE, 1981, P NATL ACAD SCI-BIOL, V78, P2130, DOI 10.1073/pnas.78.4.2130; HACKETT JT, 1990, J NEUROPHYSIOL, V63, P701, DOI 10.1152/jn.1990.63.4.701; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IMADA M, 1980, BIOCHIM BIOPHYS ACTA, V625, P179, DOI 10.1016/0005-2795(80)90282-2; JAHN R, 1984, P NATL ACAD SCI-BIOL, V81, P1684, DOI 10.1073/pnas.81.6.1684; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MCGUINNESS TL, 1983, FEBS LETT, V163, P329, DOI 10.1016/0014-5793(83)80846-1; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NICHOLS RA, 1992, J NEUROCHEM, V58, P783, DOI 10.1111/j.1471-4159.1992.tb09788.x; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; WU K, 1992, P NATL ACAD SCI USA, V89, P3015, DOI 10.1073/pnas.89.7.3015	26	242	246	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					417	420		10.1038/359417a0	http://dx.doi.org/10.1038/359417a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1328883				2022-12-28	WOS:A1992JQ62400057
J	HARRIS, PL				HARRIS, PL			REDUCING THE MORTALITY FROM ABDOMINAL AORTIC-ANEURYSMS - NEED FOR A NATIONAL SCREENING-PROGRAM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURGICAL-TREATMENT; POPULATION				HARRIS, PL (corresponding author), BROADGREEN HOSP, LIVERPOOL L14 3LB, MERSEYSIDE, ENGLAND.							ARMOUR RH, 1977, BRIT MED J, V2, P1055, DOI 10.1136/bmj.2.6094.1055; BARODOI JC, 1991, ANN VASC SURG, V5, P491; BENGTSSON H, 1989, BRIT J SURG, V76, P589, DOI 10.1002/bjs.1800760620; Bengtsson H, 1989, Eur J Vasc Surg, V3, P497, DOI 10.1016/S0950-821X(89)80123-9; BERGQVIST D, 1992, ANN CHIR GYNAECOL FE, V81, P205; BLAMEY RW, 1986, RECENT ADV SURGERY, V12, P29; COLLIN J, 1989, SURG GYNECOL OBSTET, V169, P527; COLLIN J, 1988, LANCET, V2, P613; COLLIN J, 1990, CAUSE MANAGEMENT ANE; COLLIN J, 1989, BMJ-BRIT MED J, V299, P49; ELLIS M, 1991, BRIT J SURG, V78, P614, DOI 10.1002/bjs.1800780529; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; INGOLDBY CJH, 1986, BRIT J SURG, V73, P551, DOI 10.1002/bjs.1800730711; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; MCGREGOR JC, 1975, SCOT MED J, V20, P133, DOI 10.1177/003693307502000313; MELTON LJ, 1984, AM J EPIDEMIOL, V120, P379, DOI 10.1093/oxfordjournals.aje.a113902; OKELLY TJ, 1989, BRIT J SURG, V76, P479, DOI 10.1002/bjs.1800760517; POWELL JT, 1990, CLIN SCI, V78, P13, DOI 10.1042/cs0780013; SCOTT RAP, 1986, BRIT J SURG, V73, P318; SCOTT RAP, 1988, BRIT MED J, V296, P1709, DOI 10.1136/bmj.296.6638.1709-a; SMITH FCT, 1992, BRIT J SURG, V79, P358; SZILAGYI DE, 1972, ARCH SURG-CHICAGO, V104, P600; TURK KAD, 1965, P ROY SOC MED, V58, P869, DOI 10.1177/003591576505811P109; 1984, MORTALITY STATISTICS; 1992, HLTH NATION STRATEGY; 1986, ENGLAND WALES MORTAL	26	55	55	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1992	305	6855					697	699		10.1136/bmj.305.6855.697	http://dx.doi.org/10.1136/bmj.305.6855.697			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1296605	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JP51100029
J	ROTH, D; FERNANDEZ, JA; BABISCHKIN, S; DEMATTOS, A; BUCK, BE; QUAN, S; OLSON, L; BURKE, GW; NERY, JR; ESQUENAZI, V; SCHIFF, ER; MILLER, J				ROTH, D; FERNANDEZ, JA; BABISCHKIN, S; DEMATTOS, A; BUCK, BE; QUAN, S; OLSON, L; BURKE, GW; NERY, JR; ESQUENAZI, V; SCHIFF, ER; MILLER, J			DETECTION OF HEPATITIS-C VIRUS-INFECTION AMONG CADAVER ORGAN DONORS - EVIDENCE FOR LOW TRANSMISSION OF DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C; ORGAN TRANSPLANTATION; CADAVER	NON-B-HEPATITIS; NON-A; LIVER-DISEASE; TRANSPLANT RECIPIENTS; BLOOD-DONORS; ANTIBODIES; ASSAY; RNA	Objective: To determine the prevalence of antibodies to hepatitis C virus (anti-HCV) and HCV RNA among cadaver organ donors and to correlate these results with donor liver histologic abnormalities and evidence for transmission of disease through organ transplantation. Design: Retrospective testing of stored serum samples from cadaver organ donors for anti-HCV and HCV RNA. Setting: Transplantation service of the University of Miami/Jackson Memorial Medical Center and other cooperative medical centers furnishing follow-up data. Subjects: Of 1096 cadaver organ donors harvested between 1 January 1979 and 28 February 1991, 484 had stored serum samples available for analysis. Recipients of organs from recombinant immunoblot assay (RIBA)-positive donors for whom adequate follow-up was available were also included in the analysis. Measurements: Samples were tested for anti-HCV by enzyme-linked immunosorbent assay (ELISA). Confirmatory testing was done using a second-generation RIBA. Hepatitis C viral RNA was detected in serum using the polymerase chain reaction. Liver biopsies were obtained from the organ donor and interpreted blindly by a pathologist unaware of the clinical data. Liver chemistry profiles and serum sample analysis for HCV RNA were done for transplant recipients. Results: From the 484 cadaver organ donors, 89 samples (18%; 95% CI, 15% to 21%) were reactive by ELISA. Of these, 33 (6.8%; CI, 4.6% to 9%) were RIBA seropositive. Hepatitis C viral RNA sequences were detected in 50% of the RIBA-positive serum samples tested. Liver tissue was available from 24 of the 33 RIBA-positive donors and showed chronic active hepatitis in 16, chronic persistent hepatitis in 2, and no abnormality in 6. Among the 46 recipients of a kidney from a RIBA-positive donor, 13 (28%; CI, 15% to 41%) developed post-transplant liver disease, of which only 4 cases were highly suggestive of viral transmission from the donor. Little morbidity and no mortality could be attributed to liver disease in this cohort of recipients. Conclusions: These data suggest that HCV transmission by organ transplantation is low and that the consequences of infection are small. If the medical condition of the potential recipient is so serious that other options no longer exist, the use of an organ from an anti-HCV-seropositive donor should be considered.							NIDDK NIH HHS [R01DK25243] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025243] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTI A, 1991, ANN INTERN MED, V114, P1010, DOI 10.7326/0003-4819-114-12-1010; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CHA TA, 1991, J CLIN MICROBIOL, V29, P2528, DOI 10.1128/JCM.29.11.2528-2534.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CZAFA AJ, 1990, MAYO CLIN P, V65, P1303; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; ESTEBAN JI, 1989, LANCET, V2, P294; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MADDREY WC, 1990, HEPATOLOGY TXB LIVER, P1025; MILGROM M, 1989, TRANSPLANT P, V21, P3934; PEREIRA BJG, 1991, NEW ENGL J MED, V325, P454, DOI 10.1056/NEJM199108153250702; PONZ E, 1991, KIDNEY INT, V40, P748, DOI 10.1038/ki.1991.270; QUAN S, 1990, 2ND P INT S HEP C VI; ROTH D, 1991, TRANSPLANTATION, V51, P396, DOI 10.1097/00007890-199102000-00024; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; 1989, 1ST P INT S HEP C VI, P25	23	93	94	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					470	475		10.7326/0003-4819-117-6-470	http://dx.doi.org/10.7326/0003-4819-117-6-470			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1323944				2022-12-28	WOS:A1992JN25700005
J	DONAHUE, JG; MUNOZ, A; NESS, PM; BROWN, DE; YAWN, DH; MCALLISTER, HA; REITZ, BA; NELSON, KE				DONAHUE, JG; MUNOZ, A; NESS, PM; BROWN, DE; YAWN, DH; MCALLISTER, HA; REITZ, BA; NELSON, KE			THE DECLINING RISK OF POSTTRANSFUSION HEPATITIS-C VIRUS-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; POSTTRANSFUSION HEPATITIS; TRANSMITTED VIRUSES; CARDIAC-SURGERY; BLOOD-DONORS; ANTIBODY; RECIPIENTS; TRANSMISSION; ANTIGEN	Background. The most common serious complication of blood transfusion is post-transfusion hepatitis from the hepatitis C virus (HCV). Blood banks now screen blood donors for surrogate markers of non-A, non-B hepatitis and antibodies to HCV, but the current risk of post-transfusion hepatitis C is unknown. Methods. From 1985 through 1991, blood samples and medical information were obtained prospectively from patients before and at least six months after cardiac surgery. The stored serum samples were tested for antibodies to HCV by enzyme immunoassay, and by recombinant immunoblotting if positive. Results. Of the 912 patients who received transfusions before donors were screened for surrogate markers, 35 seroconverted to HCV, for a risk of 3.84 percent per patient (0.45 percent per unit transfused). For the 976 patients who received transfusions after October 1986 with blood screened for surrogate markers, the risk of seroconversion was 1.54 percent per patient (0.19 percent per unit). For the 522 patients receiving transfusions since the addition in May 1990 of screening for antibodies to HCV, the risk was 0.57 percent per patient (0.03 percent per unit). The trend toward decreasing risk with increasingly stringent screening of donors was statistically significant (P<0.001). After we controlled for the method of donor screening, the risk of seroconversion was strongly associated (P<0.001) with the volume of blood transfused, but not with the use of particular blood components. Conclusions. The incidence of post-transfusion hepatitis C has decreased markedly since the implementation of donor screening for surrogate markers and antibodies to HCV. The current risk of post-transfusion hepatitis is about 3 per 10,000 units transfused.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY,RM 763,BALTIMORE,MD 21205; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; ST LUKES EPISCOPAL HOSP,DEPT CARDIAC PATHOL,HOUSTON,TX 77030; JOHNS HOPKINS UNIV HOSP,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT CARDIAC SURG,BALTIMORE,MD 21205; METHODIST HOSP,HOUSTON,TX 77030	Johns Hopkins University; Baylor College of Medicine; Saint Lukes Episcopal Hospital; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; The Methodist Hospital System; The Methodist Hospital - Houston					NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NHLBI NIH HHS [N01-HB-86-7025, R01-HL-45333-01A2] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045333] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; Aach RD, 1978, VIRAL HEPATITIS, P383; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P396; BOVE JR, 1987, NEW ENGL J MED, V317, P242, DOI 10.1056/NEJM198707233170411; BRADLEY DW, 1986, SEMIN LIVER DIS, V6, P56, DOI 10.1055/s-2008-1040794; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COHEN ND, 1989, NEW ENGL J MED, V320, P1172, DOI 10.1056/NEJM198905043201803; Cox DR., 1989, ANAL BINARY DATA; DIENSTAG JL, 1986, SEMIN LIVER DIS, V6, P67, DOI 10.1055/s-2008-1040795; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P743; ESTEBAN JI, 1989, LANCET, V2, P294; ESTEBAN JI, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P431; HANSON MR, 1987, TRANSFUSION, V27, P107, DOI 10.1046/j.1537-2995.1987.27187121451.x; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LARSEN J, 1990, TRANSFUSION, V30, P431, DOI 10.1046/j.1537-2995.1990.30590296376.x; LEE SD, 1991, J INFECT DIS, V163, P1354, DOI 10.1093/infdis/163.6.1354; NAGACHINTA T, 1987, J INFECT DIS, V156, P967, DOI 10.1093/infdis/156.6.967; SHIBATA M, 1991, BLOOD, V77, P1157; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; WILLIAMS AE, 1990, ANN CLIN LAB SCI, V20, P192; 1982, MMWR, V31, P652; 1991, LANCET, V338, P1040	27	628	631	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					369	373		10.1056/NEJM199208063270601	http://dx.doi.org/10.1056/NEJM199208063270601			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1320736				2022-12-28	WOS:A1992JG35600001
J	BRAZIER, JE; HARPER, R; JONES, NMB; OCATHAIN, A; THOMAS, KJ; USHERWOOD, T; WESTLAKE, L				BRAZIER, JE; HARPER, R; JONES, NMB; OCATHAIN, A; THOMAS, KJ; USHERWOOD, T; WESTLAKE, L			VALIDATING THE SF-36 HEALTH SURVEY QUESTIONNAIRE - NEW OUTCOME MEASURE FOR PRIMARY CARE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROFILE	Objectives-To test the acceptability, validity and reliability of the short form 36 health survey questionnaire (SF-36) and to compare it with th Nottingham health profile. Design-Postal survey using a questionnaire booklet together with a letter from the genera practitioner. Non-respondents received two reminders at two week intervals. The SF-36 questionnaire was retested on a subsample of respondents two weeks after the first mailing. Setting-Two general practices in Sheffield. Patients-1980 patients aged 16-74 years randomly selected from the two practice lists. Main outcome measures-Scores for each health dimension on the SF-36 questionnaire and the Nottingham health profile. Response to questions on recent use of health services and sociodemographic characteristics. Results-The response rate for the SF-36 questionnaire was high (83%) and the rate of completion for each dimension was over 95%. Considerable evidence was found for the reliability of the SF-36 (Cronbach's-alpha >0.85, reliability coefficient >0.75 for all dimensions except social functioning) and for construct validity in terms of distinguishing between groups with expected health differences. The SF-36 was able to detect low levels of ill health in patients who had scored 0 (good health) on the Nottingham health profile. Conclusions-The SF-36 is a promising new instrument for measuring health perception in a general population. It is easy to use, acceptable to patients, and fulfils stringent criteria of reliability and validity. Its use in other contexts and with different disease groups requires further research.	UNIV SHEFFIELD, SCH MED, DEPT GEN PRACTICE, SHEFFIELD S10 2RX, S YORKSHIRE, ENGLAND	University of Sheffield	BRAZIER, JE (corresponding author), UNIV SHEFFIELD, SCH MED, MED CARE RES UNIT, SHEFFIELD S10 2RX, S YORKSHIRE, ENGLAND.		brazier, john e/B-1936-2008	Brazier, John/0000-0001-8645-4780				ANDERSON JS, 1990, FAM PRACT, V7, P205, DOI 10.1093/fampra/7.3.205; BAUM FE, 1989, MED J AUSTRALIA, V150, P581, DOI 10.5694/j.1326-5377.1989.tb136696.x; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bowling A., 1991, MEASURING HLTH REV Q; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CARRHILL RA, 1991, BRIT MED J, V303, P699, DOI 10.1136/bmj.303.6804.699; DELAME PA, 1989, ACTA CARDIOL, V44, P289; HUNT SM, 1989, NOTTINGHAM HLTH PROF; JENKINSON C, 1988, SOC SCI MED, V27, P1411, DOI 10.1016/0277-9536(88)90207-9; KERLINGER FN, 1973, F BEHAVIORAL RES; KIND P, 1987, SOC SCI MED, V25, P905, DOI 10.1016/0277-9536(87)90260-7; MAY N, 1990, INT J TECHNOL ASSESS, V6, P631; McDowell I, 1987, MEASURING HLTH GUIDE; MILNER DC, 1989, J LITHOTRIPSY STONE, V1, P122; OBRIEN BJ, 1988, J EPIDEMIOL COMMUN H, V42, P232, DOI 10.1136/jech.42.3.232; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Streiner DL., 2001, HLTH MEASUREMENT SCA, V2nd; WARE JE, IN PRESS MED CARE; Ware Jr J, 1980, R19871HEW RAND CORP; Wiklund I, 1988, Int Disabil Stud, V10, P159; WILKIN D, 1992, MEASURES NEED OUTCOM; 1991, FINAL REPORT CASPE F	22	3065	3125	1	103	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 18	1992	305	6846					160	164		10.1136/bmj.305.6846.160	http://dx.doi.org/10.1136/bmj.305.6846.160			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1285753	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JF06300028
J	HUGGINS, GR; WENTZ, AC				HUGGINS, GR; WENTZ, AC			OBSTETRICS AND GYNECOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CERVICAL INTRAEPITHELIAL NEOPLASIA; TRANSFORMATION ZONE LLETZ; LARGE LOOP EXCISION; LASER		NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611	Northwestern University	HUGGINS, GR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.							GANELLI DM, 1992, AM MED NEWS, V35, P45; GUNASEKERA PC, 1990, BRIT J OBSTET GYNAEC, V97, P995, DOI 10.1111/j.1471-0528.1990.tb02470.x; LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; PEARSON SE, 1989, BRIT J OBSTET GYNAEC, V96, P486, DOI 10.1111/j.1471-0528.1989.tb02429.x; PRENDIVILLE W, 1989, BRIT J OBSTET GYNAEC, V96, P1054, DOI 10.1111/j.1471-0528.1989.tb03380.x; VISSCHER RD, 1992, ARCH PATHOL LAB MED, V116, P318; WHITELEY PF, 1990, AM J OBSTET GYNECOL, V162, P1272, DOI 10.1016/0002-9378(90)90035-6; 1990, FERTIL STERIL S, V53, pS1; 1991, FERTIL STERIL, V56, P194	9	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					384	385						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1296594				2022-12-28	WOS:A1992JC35200041
J	ROSCH, T; LIGHTDALE, CJ; BOTET, JF; BOYCE, GA; SIVAK, MV; YASUDA, K; HEYDER, N; PALAZZO, L; DANCYGIER, H; SCHUSDZIARRA, V; CLASSEN, M				ROSCH, T; LIGHTDALE, CJ; BOTET, JF; BOYCE, GA; SIVAK, MV; YASUDA, K; HEYDER, N; PALAZZO, L; DANCYGIER, H; SCHUSDZIARRA, V; CLASSEN, M			LOCALIZATION OF PANCREATIC ENDOCRINE TUMORS BY ENDOSCOPIC ULTRASONOGRAPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISLET-CELL TUMORS; ZOLLINGER-ELLISON SYNDROME; INTRAOPERATIVE ULTRASONOGRAPHY; LOCALIZING INSULINOMAS; VEIN CATHETERIZATION; PORTAL-VEIN; GASTRINOMAS; MANAGEMENT; CT; ARTERIOGRAPHY	Background. After a pancreatic endocrine tumor has been diagnosed on the basis of clinical signs and the results of laboratory tests, localization of the tumor by the usual imaging procedures fails in as many as 40 to 60 percent of patients. Endoscopic ultrasonography, a sensitive test for small carcinomas of the pancreas, might also be useful in patients with endocrine tumors of the pancreas that cannot be localized by conventional methods. Methods. We studied 37 patients later shown to have 39 endocrine tumors of the pancreas who had negative results on transabdominal ultrasonography and CT. All the patients underwent endoscopic ultrasonography, and 22 also underwent selective angiography. All the tumors were confirmed by surgical excision and immunohistologic examination; they consisted of 31 insulinomas, 7 gastrinomas, and 1 glucagonoma, 0.5 to 2.5 cm (mean, 1.4 cm) in diameter. All but one of the patients were cured of their disease, as ascertained by at least six months of clinical and laboratory follow-up. Results. Using endoscopic ultrasonography, we were able to localize 32 of the 39 tumors (sensitivity, 82 percent); no tumor was incorrectly localized. The size of the tumors was very similar (within 2 mm) to that predicted by endoscopic ultrasonography. Among the 22 patients who underwent both angiography and endoscopic ultrasonography, ultrasonography was significantly more sensitive than angiography for tumor localization (sensitivity, 82 percent vs. 27 percent). Among 19 control patients without pancreatic endocrine tumors, endoscopic ultrasonography was negative in 18 (specificity, 95 percent). Conclusions. Endoscopic ultrasonography is a highly sensitive and specific procedure for the localization of pancreatic endocrine tumors. It should be considered for the preoperative localization of such tumors once the clinical and laboratory diagnosis has been established.	TECH UNIV MUNICH, DEPT INTERNAL MED 2, W-8000 MUNICH 2, GERMANY; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; UNIV S FLORIDA, COLL MED, DIV DIGEST DIS & NUTR, TAMPA, FL 33620 USA; CLEVELAND CLIN, DEPT GASTROENTEROL, CLEVELAND, OH 44106 USA; KYOTO 2ND RED CROSS HOSP, DEPT GASTROENTEROL, KYOTO, JAPAN; UNIV HOSP ERLANGEN, DEPT INTERNAL MED 1, ERLANGEN, GERMANY; UNIV PARIS 05, CONCHON GASTROENTEROL HOSP, F-75270 PARIS 06, FRANCE; MUNICIPAL HOSP, DEPT INTERNAL MED 2, OFFENBACH, GERMANY	Technical University of Munich; Memorial Sloan Kettering Cancer Center; State University System of Florida; University of South Florida; Cleveland Clinic Foundation; University of Erlangen Nuremberg; UDICE-French Research Universities; Universite Paris Cite; Sana Klinikum Offenbach								BOLONDI L, 1990, J CLIN GASTROENTEROL, V12, P218; BOTTGER TC, 1990, WORLD J SURG, V14, P107; BROUGHAN TA, 1986, SURGERY, V99, P671; CHO KJ, 1982, AM J ROENTGENOL, V139, P237, DOI 10.2214/ajr.139.2.237; DELVALLE J, 1989, GASTROINTESTINAL DIS, P1884; DUNNICK NR, 1980, AM J ROENTGENOL, V135, P747, DOI 10.2214/ajr.135.4.747; ELLISON EH, 1964, ANN SURG, V160, P512, DOI 10.1097/00000658-196409000-00013; FRUCHT H, 1990, GASTROENTEROLOGY, V99, P1622, DOI 10.1016/0016-5085(90)90466-E; GALIBER AK, 1988, RADIOLOGY, V166, P405, DOI 10.1148/radiology.166.2.2827232; GIERCKSKY KE, 1980, SCAND J GASTROENTERO, V15, P129, DOI 10.3109/00365528009181444; GORMAN B, 1986, AM J ROENTGENOL, V147, P929, DOI 10.2214/ajr.147.5.929; GRANT CS, 1988, ARCH SURG-CHICAGO, V123, P843; GUNTHER RW, 1983, RADIOLOGY, V148, P485; HANCKE S, 1979, SCAND J GASTROENTERO, V14, P115; HEMMINGSSON A, 1981, ACTA RADIOL DIAGN, V22, P657, DOI 10.1177/028418518102200606; HEYDER N, 1985, NEW ENGL J MED, V312, P860; HOEVELS J, 1980, ACTA RADIOL DIAGN, V21, P593, DOI 10.1177/028418518002100505; HOFMANN JW, 1973, ARCH SURG-CHICAGO, V107, P334; KATZ LB, 1986, SURG GYNECOL OBSTET, V163, P509; KRUDY AG, 1984, AM J ROENTGENOL, V143, P585, DOI 10.2214/ajr.143.3.585; LIGHTDALE CJ, 1991, CANCER, V68, P1815, DOI 10.1002/1097-0142(19911015)68:8<1815::AID-CNCR2820680828>3.0.CO;2-B; MATON PN, 1987, GASTROENTEROLOGY, V92, P913, DOI 10.1016/0016-5085(87)90964-4; NORTON JA, 1986, ANN SURG, V204, P468, DOI 10.1097/00000658-198610000-00015; NORTON JA, 1988, ANN SURG, V207, P160, DOI 10.1097/00000658-198802000-00008; PALVANSALO M, 1989, EUR J RADIOL, V9, P173; PROYE C, 1987, ACTA CHIR SCAND, V153, P481; ROCHE A, 1982, RADIOLOGY, V145, P621, DOI 10.1148/radiology.145.3.6292994; ROSCH T, 1991, GASTROINTEST ENDOSC, V37, P347, DOI 10.1016/S0016-5107(91)70729-3; ROSCH T, 1992, GASTROENTEROLOGY, V102, P188; ROSCH T, IN PRESS ADV GASTROI, V2; RUSZNIEWSKI P, 1991, Gastroenterology, V100, pA297; STARK DD, 1984, RADIOLOGY, V150, P491, DOI 10.1148/radiology.150.2.6318260; STEFANINI P, 1974, SURGERY, V75, P597; VANHEERDEN JA, 1979, ANN SURG, V189, P677, DOI 10.1097/00000658-197906000-00002; VIAMONTE M, 1975, RADIOLOGY, V114, P457, DOI 10.1148/114.2.457; VINIK AI, 1990, SURGERY, V107, P246; WANK SA, 1987, GASTROENTEROLOGY, V92, P905, DOI 10.1016/0016-5085(87)90963-2; WOLFE MM, 1982, NEW ENGL J MED, V306, P1533, DOI 10.1056/NEJM198206243062506; YASUDA K, 1988, GASTROINTEST ENDOSC, V34, P1, DOI 10.1016/S0016-5107(88)71220-1	39	535	552	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1992	326	26					1721	1726		10.1056/NEJM199206253262601	http://dx.doi.org/10.1056/NEJM199206253262601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ894	1317506				2022-12-28	WOS:A1992HZ89400001
J	MULLER, T; MOLLER, T; BERGER, T; SCHNITZER, J; KETTENMANN, H				MULLER, T; MOLLER, T; BERGER, T; SCHNITZER, J; KETTENMANN, H			CALCIUM ENTRY THROUGH KAINATE RECEPTORS AND RESULTING POTASSIUM-CHANNEL BLOCKADE IN BERGMANN GLIAL-CELLS	SCIENCE			English	Article							BRAIN	Glutamate receptors, the most abundant excitatory transmitter receptors in the brain, are not restricted to neurons; they have also been detected on glial cells. Bergmann glial cells in mouse cerebellar slices revealed a kainate-type glutamate receptor with a sigmoid current-to-voltage relation, as demonstrated with the patch-clamp technique. Calcium was imaged with fura-2, and a kainate-induced increase in intracellular calcium concentration was observed, which was blocked by the non-N-methyl-D-aspartate (NMDA) glutamate receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and by low concentrations of external calcium, indicating that there was an influx of calcium through the kainate receptor itself. The entry of calcium led to a marked reduction in the resting (passive) potassium conductance of the cell. Purkinje cells, which have glutamatergic synapses, are closely associated with Bergmann glial cells and therefore may provide a functionally important stimulus.	UNIV HEIDELBERG,DEPT NEUROBIOL,NEUENHEIMER FELD 345,W-6900 HEIDELBERG,GERMANY; MAX PLANCK INST BRAIN RES,W-6000 FRANKFURT,GERMANY	Ruprecht Karls University Heidelberg; Max Planck Society			Möller, Thomas/W-8974-2019; Kettenmann, Helmut/AAJ-5142-2021	Kettenmann, Helmut/0000-0001-8208-0291				BLANKENFELD G, 1992, MOL NEUROBIOL, V5, P31; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FINDLAY I, 1987, PFLUG ARCH EUR J PHY, V410, P313, DOI 10.1007/BF00580282; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Ito M, 1984, CEREBELLUM NEURAL CO; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829	14	312	316	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1563	1566		10.1126/science.1317969	http://dx.doi.org/10.1126/science.1317969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317969				2022-12-28	WOS:A1992HY07500031
J	KULLMANN, DM; NICOLL, RA				KULLMANN, DM; NICOLL, RA			LONG-TERM POTENTIATION IS ASSOCIATED WITH INCREASES IN QUANTAL CONTENT AND QUANTAL AMPLITUDE	NATURE			English	Article							PRESYNAPTIC MECHANISM; HIPPOCAMPAL SLICES; PERFORANT PATH; NEURONS; INDUCTION; ALGORITHM; RELEASE	LONG-TERM potentiation (LTP) of synaptic transmission in CA1 neurons of the hippocampus, elicited by the conjunction of presynaptic firing and postsynaptic depolarization, is an important model of plasticity, which may underlie memory storage 1-3. Although induction of LTP takes place in the postsynaptic cell 4-7, it is not clear whether it is expressed through an enhancement of transmitter release 8-12 or through an increased postsynaptic response to the same amount of transmitter 13-16. Analysis of the trial-to-trial amplitude fluctuations of synaptic signals, that is quantal analysis, gives an important insight into the probabilistic mechanisms of transmission, although attempts to apply it to the mode of expression of LTP have so far yielded inconsistent results 9-12,15, at least in part because they have relied on models of transmitter release that have not been confirmed experimentally 17-19. Here we report clear evidence for quantal fluctuation in a subset of cells. Induction of LTP in these cells causes abrupt increases in either quantal content or quantal amplitude, or both. This shows that two different mechanisms can underlie the maintenance of LTP.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Kullmann, Dimitri M/A-3162-2009	Kullmann, Dimitri M/0000-0001-6696-3545				BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T V P, 1988, P3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; CLEMENTS J, 1991, NATURE, V353, P396, DOI 10.1038/353396a0; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GULL SF, 1978, NATURE, V272, P686, DOI 10.1038/272686a0; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1989, J NEUROSCI METH, V30, P231, DOI 10.1016/0165-0270(89)90134-9; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALINOW R, 1991, NATURE, V252, P722; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; VORONIN LL, 1990, NEUROPHYSIOLOGY+, V22, P341; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; ZUCKER RS, 1973, J PHYSIOL-LONDON, V229, P787, DOI 10.1113/jphysiol.1973.sp010167	31	232	234	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					240	244		10.1038/357240a0	http://dx.doi.org/10.1038/357240a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1317014				2022-12-28	WOS:A1992HV19500054
J	MOODIE, PCE; MARSHALL, T				MOODIE, PCE; MARSHALL, T			GUIDELINES FOR LOCAL RESEARCH ETHICS COMMITTEES	BRITISH MEDICAL JOURNAL			English	Article									UNIV BIRMINGHAM,FAC LAW,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								KENNEDY I, 1989, MED LAW TEXT MATERIA, P872; MOODIE P, 1992, BRIT MED J, V304, P1129, DOI 10.1136/bmj.304.6835.1129; Neuberger J, 1992, ETHICS HLTH CARE ROL; NICHOLSON RH, 1991, BRIT MED J, V303, P995, DOI 10.1136/bmj.303.6808.995-b; ROBINSON K, 1991, J ROY COLL PHYS LOND, V25, P43; SMITH J, 1991, BRIT MED J, V303, P488; 1991, HSG915 DEP HLTH; 1975, HSCIS153 DEP HLTH SO; 1964, CMND2382; 1967, REPORT COMMITTEE SUP; 1989, LOCAL RES ETHICS COM	11	16	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1293	1295		10.1136/bmj.304.6837.1293	http://dx.doi.org/10.1136/bmj.304.6837.1293			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1295490	Bronze, Green Published			2022-12-28	WOS:A1992HV08600028
J	WANG, JF; CECH, TR				WANG, JF; CECH, TR			TERTIARY STRUCTURE AROUND THE GUANOSINE-BINDING SITE OF THE TETRAHYMENA RIBOZYME	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; SEQUENCE-SPECIFIC CLEAVAGE; SELF-SPLICING RNA; ENDORIBONUCLEASE ACTIVITY; DNA; SUBSTRATE; CATALYSIS; RESOLUTION; INTRONS; ACID	A cleavage reagent directed to the active site of the Tetrahymena catalytic RNA was synthesized by derivatization of the guanosine substrate with a metal chelator. When complexed with iron(II), this reagent cleaved the RNA in five regions. Cleavage at adenosine 207, which is far from the guanosine-binding site in the primary and secondary structure, provides a constraint for the higher order folding of the RNA. This cleavage site constitutes physical evidence for a key feature of the Michel-Westhof model. Targeting a reactive entity to a specific site should be generally useful for determining proximity within folded RNA molecules or ribonucleoprotein complexes.	UNIV COLORADO, DEPT CHEM & BIOCHEM, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BEEN MD, 1987, COLD SPRING HARB SYM, V52, P147, DOI 10.1101/SQB.1987.052.01.019; BRUCE AG, 1982, BIOCHEMISTRY-US, V21, P855, DOI 10.1021/bi00534a007; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, UNPUB; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHU BCF, 1985, P NATL ACAD SCI USA, V82, P963, DOI 10.1073/pnas.82.4.963; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HEUER TS, 1991, P NATL ACAD SCI USA, V88, P11105, DOI 10.1073/pnas.88.24.11105; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HNATOWICH DJ, 1982, INT J APPL RADIAT IS, V33, P327, DOI 10.1016/0020-708X(82)90144-2; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; IVANOVSKAYA MG, 1987, NUCLEOS NUCLEOT, V6, P913, DOI 10.1080/15257778708073437; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LOHMAN TM, 1990, BIOCHEMISTRY-US, V29, P5220; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOORE MJ, IN PRESS SCIENCE; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; TAYLOR JS, 1984, TETRAHEDRON, V40, P457, DOI 10.1016/0040-4020(84)85050-4; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; WANG JC, UNPUB; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	38	85	88	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1992	256	5056					526	529		10.1126/science.1315076	http://dx.doi.org/10.1126/science.1315076			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1315076				2022-12-28	WOS:A1992HQ18700065
J	WEGNER, M; CAO, ZD; ROSENFELD, MG				WEGNER, M; CAO, ZD; ROSENFELD, MG			CALCIUM-REGULATED PHOSPHORYLATION WITHIN THE LEUCINE ZIPPER OF C/EBP-BETA	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; ENHANCER-BINDING-PROTEIN; MOLECULAR-CLONING; RAT-BRAIN; TRANSCRIPTION FACTOR; JUN ENCODES; CALMODULIN; GENE; EXPRESSION; FAMILY	Alterations in intracellular calcium levels activate several signal transduction pathways resulting in distinct patterns of gene expression. Here, a pathway for calcium-mediated signals is demonstrated that involves C/EBP-beta, a member of the bZip family of transcription factors. In pituitary cells C/EBP-beta was phosphorylated in response to increased intracellular calcium concentrations as a consequence of the activation of a calcium-calmodulin-dependent protein kinase. Phosphorylation of serine at position 276 within the leucine zipper of C/EBP-beta appeared to confer calcium-regulated transcriptional stimulation of a promoter that contained binding sites for C/EBP-beta.	UNIV CALIF SAN DIEGO,EUKARYOT REGULATORY BIOL PROGRAM,CELLULAR & MOLEC MED BLDG,LA JOLLA,CA 92093; CARNEGIE INST WASHINGTON,DEPT EMBRYOL,HOWARD HUGHES RES LABS,BALTIMORE,MD 21210; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of California System; University of California San Diego; Carnegie Institution for Science; HRL Laboratories; Howard Hughes Medical Institute; University of California System; University of California San Diego				Wegner, Michael/0000-0002-4586-3294				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FUKUNAGA K, 1986, BIOMED RES-TOKYO, V7, P405; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENGARD P, 1978, SCIENCE, V199, P146, DOI 10.1126/science.22932; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HATADA Y, 1983, J NEUROCHEM, V40, P1082, DOI 10.1111/j.1471-4159.1983.tb08096.x; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KELLY PT, 1985, DEV BRAIN RES, V18, P211, DOI 10.1016/0165-3806(85)90265-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, COMMUNICATION; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WEGNER M, UNPUB; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	44	353	356	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					370	373		10.1126/science.256.5055.370	http://dx.doi.org/10.1126/science.256.5055.370			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1314426				2022-12-28	WOS:A1992HP03200034
J	STENSON, WF; CORT, D; RODGERS, J; BURAKOFF, R; DESCHRYVERKECSKEMETI, K; GRAMLICH, TL; BEEKEN, W				STENSON, WF; CORT, D; RODGERS, J; BURAKOFF, R; DESCHRYVERKECSKEMETI, K; GRAMLICH, TL; BEEKEN, W			DIETARY SUPPLEMENTATION WITH FISH OIL IN ULCERATIVE-COLITIS	ANNALS OF INTERNAL MEDICINE			English	Article						COLITIS, ULCERATIVE; FISH OILS; LEUKOTRIENE-B; PREDNISONE; SALICYLAZOSULFAPYRIDINE	INFLAMMATORY BOWEL-DISEASE; N-3 FATTY-ACIDS; RHEUMATOID-ARTHRITIS; LEUKOTRIENE-B4; TRIAL; PROSTAGLANDINS; BIOSYNTHESIS; NEUTROPHILS; CROSSOVER	Objective: To determine the efficacy of fish oil supplementation in patients with active ulcerative colitis. Design: Multicenter, randomized, double-blind, placebo-controlled, crossover trial with 4-month treatment periods (fish oil and placebo) separated by a 1-month washout. Setting: Four gastroenterology divisions. Patients: Twenty-four patients with active ulcerative colitis entered the study. Five dropped out, and one was noncompliant. Eighteen patients completed the study. All patients had active disease as manifested by diarrhea and rectal inflammation. Interventions: Treatment with prednisone and sulfasalazine was continued. Fish oil supplementation consisted of 18 Max-EPA (eicosapentaenoic acid) capsules daily (eicosapentaenoic acid, 3.24 g; and docosahexaenoic acid, 2.16 g). Placebo supplementation consisted of 18 identical capsules containing isocaloric amounts of vegetable oil. Measurements: Patients were evaluated at study entry and after each diet period. Evaluations included a review of symptoms, flexible sigmoidoscopy, rectal biopsy, and rectal dialysis to measure prostaglandin E2 and leukotriene B4 levels. Results: Fish oil supplementation resulted in a significant decrease in rectal dialysate levels of leukotriene B4 from 71.0 to 27.7 pg/mL (average change, - 43.3 pg/mL; 95% Cl, - 83 to - 3.6). Significant improvements were seen in acute histology index (average change, - 8.5 units from a baseline of 10.5 units; Cl, - 12.9 to - 4.2) and total histology index (average change,- 8.5 units from a baseline of 14.80; Cl, - 13.2 to - 3.8) as well as significant weight gain (average weight gain, 1.74 kg, Cl, 0.94 to 2.54). No significant changes occurred in any variable during the placebo period. Seven patients received concurrent treatment with prednisone. During the fish oil supplementation period, the mean prednisone dose decreased from 12.9 mg/d to 6.1 mg/d and rose from 10.4 mg/d to 12.9 mg/d during the placebo diet period (P > 0.20). Conclusions: Four months of diet supplementation with fish oil in patients with inflammatory bowel disease resulted in reductions in rectal dialysate leukotriene B4 levels, improvements in histologic findings, and weight gain.	UNION UNIV, ALBANY, NY 12208 USA; WINTHROP UNIV HOSP, MINEOLA, NY USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; UNIV VERMONT, BURLINGTON, VT 05405 USA	Union College; Winthrop University Hospital; Case Western Reserve University; University of Vermont	STENSON, WF (corresponding author), JEWISH HOSP ST LOUIS, DEPT MED, 216 S KINGSHIGHWAY, ST LOUIS, MO 63110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033165, R37DK033165] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00036, RR109] Funding Source: Medline; NIDDK NIH HHS [DK33165] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJORNEBOE A, 1988, BRIT J DERMATOL, V118, P77, DOI 10.1111/j.1365-2133.1988.tb01753.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DAVIES P, 1984, ANNU REV IMMUNOL, V2, P335, DOI 10.1146/annurev.immunol.2.1.335; DICK AP, 1966, GUT, V7, P355, DOI 10.1136/gut.7.4.355; FORDHUTCHINSON AW, 1984, NATURE, V266, P264; KORELITZ BI, 1975, AM J GASTROENTEROL, V64, P365; KREMER JM, 1987, ANN INTERN MED, V106, P497, DOI 10.7326/0003-4819-106-4-497; KREMER JM, 1990, ARTHRITIS RHEUM, V33, P810, DOI 10.1002/art.1780330607; LAURITSEN K, 1986, GASTROENTEROLOGY, V91, P837, DOI 10.1016/0016-5085(86)90684-0; LAURITSEN K, 1990, Gastroenterology, V98, pA185; LEE TH, 1986, ADV IMMUNOL, V39, P145; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; LEE TH, 1984, J BIOL CHEM, V259, P2383; LOBOS EA, 1987, DIGEST DIS SCI, V32, P1380, DOI 10.1007/BF01296664; LORENZ R, 1989, J INTERN MED, V225, P225, DOI 10.1111/j.1365-2796.1989.tb01461.x; NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944; PRESCOTT SM, 1984, J BIOL CHEM, V259, P7615; ROSENBERG JL, 1975, GASTROENTEROLOGY, V69, P96; SALOMON P, 1990, J CLIN GASTROENTEROL, V12, P157, DOI 10.1097/00004836-199004000-00009; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; STENSON WF, 1984, J BIOL CHEM, V259, P1784; TERANO T, 1984, PROSTAGLANDINS, V27, P217, DOI 10.1016/0090-6980(84)90075-3; ZIFRONI A, 1983, GUT, V24, P659, DOI 10.1136/gut.24.7.659	24	305	313	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					609	614		10.7326/0003-4819-116-8-609	http://dx.doi.org/10.7326/0003-4819-116-8-609			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1312317				2022-12-28	WOS:A1992HN84400001
J	BAILEY, WJ; SLIGHTOM, JL; GOODMAN, M				BAILEY, WJ; SLIGHTOM, JL; GOODMAN, M			REJECTION OF THE FLYING PRIMATE HYPOTHESIS BY PHYLOGENETIC EVIDENCE FROM THE E-GLOBIN GENE	SCIENCE			English	Article							AMINO-ACID SEQUENCES; NUCLEOTIDE-SEQUENCE; EPSILON-GLOBIN; EVOLUTION; MEGABATS; FAMILY	Whether the bat suborder Megachiroptera (megabats) is most closely related to the other suborder of bats, Microchiroptera (microbats), or whether Megachiroptera is the sister group of order Primates has been an issue of much debate. Should all bats be classified into a monophyletic order (Chiroptera) or do bats have diphyletic origins, and are the megabats actually "flying primates"? These questions were addressed by phylogenetic analysis of epsilon-globin gene sequences from a number of primates and other eutherian mammals. Results of parsimony analysis not only support bat monophyly, but the strength of Chiroptera grouping is comparable to that supporting the monophyly of the prosimian primate suborder Strepsirhini (galago and lemur). Furthermore, 39 derived nucleotide sequence changes are uniquely shared by the megabat (Cynopterus sphinx) and microbat (Megaderma lyra) versus three commonly shared by the megabat, primates, and Dermoptera or flying lemur (Cynocephalus variegatus), and only two shared by either megabat and primates, or by megabat and flying lemur.	UPJOHN CO,MOLEC BIOL UNIT 7242,KALAMAZOO,MI 49007; WAYNE STATE UNIV,SCH MED,DEPT ANAT & CELL BIOL,DETROIT,MI 48201	Pfizer; Wayne State University	BAILEY, WJ (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,DETROIT,MI 48201, USA.							ADKINS RM, 1991, P NATL ACAD SCI USA, V88, P10317, DOI 10.1073/pnas.88.22.10317; BAKER RJ, 1991, SYST ZOOL, V40, P216, DOI 10.2307/2992259; BAKER RJ, 1991, B AM MUS NAT HIST, V206, P42; BEARD KC, 1991, ORIGINES BIPEDIE CHE, P91; COLLINS FS, 1984, PROG NUCLEIC ACID RE, V31, P315, DOI 10.1016/S0079-6603(08)60382-7; CZELUSNIAK J, 1990, CURRENT MAMMALOGY, V2, pCH12; CZELUSNIAK J, 1990, METHODS ENZYMOLOGY, V183, pCH37; GOODMAN M, 1984, J MOL BIOL, V180, P803, DOI 10.1016/0022-2836(84)90258-4; HARDISON RC, 1983, J BIOL CHEM, V258, P8739; HARRIS S, 1986, MOL BIOL EVOL, V3, P465; JUKES T H, 1969, P21; KOOP BF, 1986, J MOL EVOL, V24, P94, DOI 10.1007/BF02099956; KOOP BF, 1989, MOL BIOL EVOL, V6, P580; LINNAEUS C, 1757, SYSTEMA NATURAE REGN, P18; MINDELL DP, 1991, P NATL ACAD SCI USA, V88, P10322, DOI 10.1073/pnas.88.22.10322; NOVACEK MJ, 1990, CURRENT MAMMALOGY, V2, pCH11; PETTIGREW JD, 1989, PHILOS T ROY SOC B, V325, P489, DOI 10.1098/rstb.1989.0102; PETTIGREW JD, 1986, SCIENCE, V231, P1304, DOI 10.1126/science.3945827; PETTIGREW JD, 1991, SYST ZOOL, V40, P199, DOI 10.2307/2992258; PRAGER EM, 1988, J MOL EVOL, V27, P326, DOI 10.1007/BF02101195; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHAPIRO SG, 1983, J MOL BIOL, V169, P31, DOI 10.1016/S0022-2836(83)80174-0; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; SWOFFORD DL, 1990, MOL SYSTEMATICS, P489; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; [No title captured]; [No title captured]	28	91	98	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					86	89		10.1126/science.1301735	http://dx.doi.org/10.1126/science.1301735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1301735				2022-12-28	WOS:A1992HL82200031
J	ASHER, J				ASHER, J			NEWSCASTER NEURONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ASHER, J (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							DESIMONE R, 1991, SCIENCE, V254, P1377; 1991, BRAIN RES, V542, P1	2	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1584	1584		10.1001/jama.267.12.1584	http://dx.doi.org/10.1001/jama.267.12.1584			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1311777				2022-12-28	WOS:A1992HJ59700006
J	GOODWIN, FK				GOODWIN, FK			NEED TO LOSE WEIGHT AGAIN - OH RATS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							FRASER C, 1991, J BIOL CHEM, V266, P24053	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					910	910						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1310338				2022-12-28	WOS:A1992HD15500003
J	GRIFFITH, JP; GRIFFITH, DL; RAYMENT, I; MURAKAMI, WT; CASPAR, DLD				GRIFFITH, JP; GRIFFITH, DL; RAYMENT, I; MURAKAMI, WT; CASPAR, DLD			INSIDE POLYOMAVIRUS AT 25-A RESOLUTION	NATURE			English	Article							SIMIAN VIRUS-40; MINICHROMOSOMES; INVITRO; VP1	EMPTY capsids and complete virions of polyomavirus crystallize isomorphously 1. Here we use difference Fourier analysis of X-ray diffraction data at 25-angstrom resolution from these crystals to obtain an electron-density map of the inside of the virion. The polyomavirus capsid is built from 72 pentamers of VP1 that form three different types of connections in the T = 7d icosahedral surface lattice 2. Self-assembly of purified recombinant VP1 into capsid-like aggregates 3,4 has shown that switching of the bonding specificity to form the unanticipated 5 non-equivalent connections is an inherent property of the VP1 pentamers. Our map of the inside of the virion displays 72 prongs of electron density extending from the core into the axial cavities of the VP1 pentamers. We identify these prongs with the VP2 and VP3 molecules, which may function to guide the assembly of the highly ordered capsid on the nucleohistone core. The atomic structure of the closely related simian virus-40 capsid has been determined from the high-resolution diffraction data 6. Our polyomavirus map, calculated using all the low-resolution diffraction data, shows no indication of regular order inside the spherical core.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Brandeis University			rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835				ADOLPH KW, 1979, SCIENCE, V203, P1117, DOI 10.1126/science.218286; AMBROSE C, 1987, NUCLEIC ACIDS RES, V15, P3703, DOI 10.1093/nar/15.9.3703; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CLEVER J, 1991, VIROLOGY, V181, P78, DOI 10.1016/0042-6822(91)90472-N; COLE CN, 1977, J VIROL, V24, P277, DOI 10.1128/JVI.24.1.277-294.1977; DUBOCHET J, 1986, EMBO J, V5, P519, DOI 10.1002/j.1460-2075.1986.tb04241.x; GHARAKHANIAN E, 1988, P NATL ACAD SCI USA, V85, P6607, DOI 10.1073/pnas.85.18.6607; KRAUZEWICZ N, 1990, J VIROL, V64, P4414, DOI 10.1128/JVI.64.9.4414-4420.1990; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LIN W, 1984, J VIROL, V50, P363, DOI 10.1128/JVI.50.2.363-371.1984; MONTROSS L, 1991, J VIROL, V65, P4991, DOI 10.1128/JVI.65.9.4991-4998.1991; RAYMENT I, 1983, ACTA CRYSTALLOGR B, V39, P505, DOI 10.1107/S0108768183002785; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; Tooze J., 1981, COLD SPRING HARB MON, Vsecond	18	89	93	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					652	654		10.1038/355652a0	http://dx.doi.org/10.1038/355652a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1311415				2022-12-28	WOS:A1992HD54700061
J	LJUNGQVIST, A; SIMPSON, JL				LJUNGQVIST, A; SIMPSON, JL			MEDICAL-EXAMINATION FOR HEALTH OF ALL ATHLETES REPLACING THE NEED FOR GENDER VERIFICATION IN INTERNATIONAL SPORTS - THE INTERNATIONAL-AMATEUR-ATHLETIC-FEDERATION PLAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									UNIV TENNESSEE CTR HLTH SCI,DEPT OBSTET & GYNECOL,800 MADISON AVE,MEMPHIS,TN 38163; KAROLINSKA HOSP,DEPT PATHOL,S-10401 STOCKHOLM 60,SWEDEN	University of Tennessee System; University of Tennessee Health Science Center; Karolinska Institutet; Karolinska University Hospital								BASSIS LM, 1987, JAMA-J AM MED ASSOC, V257, P1896, DOI 10.1001/jama.257.14.1896; CARLSON A, 1991, WOMENS SPORT FIT MAR, P24; DELACHAPELLE A, 1986, JAMA-J AM MED ASSOC, V256, P1920, DOI 10.1001/jama.256.14.1920; DELACHAPELLE A, 1986, NEW STUD ATHLETICS, V2, P49; EHRHARDT AA, 1981, SCIENCE, V211, P1312, DOI 10.1126/science.7209510; Ferguson-Smith M A, 1991, Br J Sports Med, V25, P17; JORGENSEN G, 1972, INTERSEXUALITAT SPOR; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KRAWCZYNSKI M, 1978, WIAD LEK, V3, P189; RYAN AJ, 1976, PHYSICIAN SPORTSMED, V4, P39; SAKAMOTO H, 1988, INT J SPORTS MED, V9, P193, DOI 10.1055/s-2007-1025003; SIMPSON JL, 1986, JAMA-J AM MED ASSOC, V256, P1938; Tachezy R, 1969, J Sports Med Phys Fitness, V9, P119	13	34	35	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1992	267	6					850	852		10.1001/jama.267.6.850	http://dx.doi.org/10.1001/jama.267.6.850			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC484	1298204				2022-12-28	WOS:A1992HC48400033
J	JESSUS, C; BEACH, D				JESSUS, C; BEACH, D			OSCILLATION OF MPF IS ACCOMPANIED BY PERIODIC ASSOCIATION BETWEEN CDC25 AND CDC2-CYCLIN-B	CELL			English	Article							MATURATION-PROMOTING FACTOR; CELL-DIVISION CYCLE; FISSION YEAST CDC25; HISTONE H-1 KINASE; CONTROL GENE CDC2+; SEA-URCHIN EGGS; PROTEIN-KINASE; MEIOTIC MATURATION; SCHIZOSACCHAROMYCES-POMBE; CYTOPLASMIC FACTOR	Activation of maturation-promoting factor at the onset of mitosis requires the tyrosine dephosphorylation of one of its components, the cdc2 protein kinase. cdc25 is the specific tyrosine phosphatase that activates cdc2. We find that Xenopus oocytes contain a relative of cdc25, p72. In Xenopus embryos the abundance of p72 does not oscillate during the cell cycle. However, p72 directly associates with cdc2-cyclin B in a cell cycle-dependent manner, reaching a peak at M phase. The M phase kinase that associates with p72 is catalytically active. These results suggest that the mechanism by which cdc25 triggers cdc2 activation involves a periodic physical association between cdc25 and the cyclin B-cdc2 complex and also that mitotic control can be affected by mechanisms other than transcriptional regulation of the cdc25 gene.			JESSUS, C (corresponding author), COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069620] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM69620] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLAKHA RC, 1988, J CELL BIOL, V106, P1445, DOI 10.1083/jcb.106.5.1445; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1988, CELL, V54, P739; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAGAN I, 1988, J CELL SCI, V91, P587; HASHIMOTO N, 1988, DEV BIOL, V126, P242, DOI 10.1016/0012-1606(88)90135-2; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; JESSUS C, 1987, J CELL SCI, V87, P705; JESSUS C, 1991, DEVELOPMENT, V111, P813; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KISHIMOTO T, 1982, EXP CELL RES, V137, P121, DOI 10.1016/0014-4827(82)90014-3; KISHIMOTO T, 1976, NATURE, V260, P321, DOI 10.1038/260321a0; KOBAYASHI AH, 1991, J CELL BIOL, V114, P755; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LABBE JC, 1988, DEV BIOL, V127, P157, DOI 10.1016/0012-1606(88)90197-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WEINTRAUB H, 1982, CR ACAD SCI III-VIE, V295, P787; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	64	101	104	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					323	332		10.1016/0092-8674(92)90473-P	http://dx.doi.org/10.1016/0092-8674(92)90473-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310257				2022-12-28	WOS:A1992HB35300011
J	WANG, WD; CAREY, M; GRALLA, JD				WANG, WD; CAREY, M; GRALLA, JD			POLYMERASE-II PROMOTER ACTIVATION - CLOSED COMPLEX-FORMATION AND ATP-DRIVEN START SITE OPENING	SCIENCE			English	Article							RNA-POLYMERASE; TRANSCRIPTION INITIATION; MECHANISM INVIVO; GAL4 DERIVATIVES; DNA; REQUIREMENT; INVITRO; GENE	Studies on bacterial RNA polymerases have divided the initiation pathway into three steps, namely (i) promoter binding to form the closed complex; (ii) DNA melting to form an open complex, and (iii) messenger RNA initiation. Potassium permanganate was used to detect DNA melting by mammalian RNA polymerase II in vitro. Closed complexes formed in a rate-limiting step that was stimulated by the activator GAL4-VP16. Adenosine triphosphate was then hydrolyzed to rapidly melt the DNA within the closed complex to form an open complex. Addition of nucleoside triphosphates resulted in the melted bubble moving away from the start site, completing initiation.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928; Carey, Michael/0000-0003-3899-6280	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046424, R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46424, GM35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER CC, 1981, J MOL BIOL, V149, P189, DOI 10.1016/0022-2836(81)90298-9; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; Carey M, 1991, CURR OPIN CELL BIOL, V3, P452, DOI 10.1016/0955-0674(91)90073-8; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; FIRE A, 1984, J BIOL CHEM, V259, P2509; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAWLEY DK, 1985, J BIOL CHEM, V260, P8618; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LI Z, 1989, GENE DEV, V3, P1814, DOI 10.1101/gad.3.11.1814; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WALTER G, 1967, EUR J BIOCHEM, V3, P194, DOI 10.1111/j.1432-1033.1967.tb19515.x; Wang W., UNPUB; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	34	198	199	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 24	1992	255	5043					450	453		10.1126/science.1310361	http://dx.doi.org/10.1126/science.1310361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1310361				2022-12-28	WOS:A1992HA59000036
J	HIRSCH, MS				HIRSCH, MS			THE TREATMENT OF CYTOMEGALOVIRUS IN AIDS - MORE THAN MEETS THE EYE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IMMUNODEFICIENCY VIRUS TYPE-1; REPLICATION INVITRO; FOSCARNET; PHOSPHONOFORMATE				HIRSCH, MS (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA 02114, USA.							ERIKSSON BFH, 1989, ANTIMICROB AGENTS CH, V33, P663, DOI 10.1128/AAC.33.5.663; JACOBSON MA, 1989, ANTIMICROB AGENTS CH, V33, P736, DOI 10.1128/AAC.33.5.736; JACOBSON MA, 1991, J INFECT DIS, V163, P1219, DOI 10.1093/infdis/163.6.1219; JOHNSON VA, 1989, ANTIVIRAL CHEMOTHERA, V2, P275; MANISCHEWITZ JF, 1990, ANTIMICROB AGENTS CH, V34, P373, DOI 10.1128/AAC.34.2.373; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; SANDSTROM EG, 1985, LANCET, V1, P1480; SKOLNIK PR, 1988, J INFECT DIS, V157, P508, DOI 10.1093/infdis/157.3.508; 1992, NEW ENGL J MED, V326, P213	10	16	16	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					264	266		10.1056/NEJM199201233260409	http://dx.doi.org/10.1056/NEJM199201233260409			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1309391				2022-12-28	WOS:A1992HA43100009
J	THOMAS, G				THOMAS, G			MAP KINASE BY ANY OTHER NAME SMELLS JUST AS SWEET	CELL			English	Review							PROTEIN-KINASE; INSULIN; IDENTIFICATION; MUSCLE				THOMAS, G (corresponding author), FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND.							AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HALL FL, 1991, J BIOL CHEM, V266, P17430; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; MELOCHE S, 1991, IN PRESS MOL BIOL CE; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1991, IN PRESS SCIENCE; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; WU T, 1991, KP NATL ACAD SCI US, V88, P9508	34	333	336	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					3	6		10.1016/0092-8674(92)90199-M	http://dx.doi.org/10.1016/0092-8674(92)90199-M			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1310074				2022-12-28	WOS:A1992GZ58300002
J	JOHNSON, DE; MILLER, LC; IVERSON, S; THOMAS, W; FRANCHINO, B; DOLE, K; KIERNAN, MT; GEORGIEFF, MK; HOSTETTER, MK				JOHNSON, DE; MILLER, LC; IVERSON, S; THOMAS, W; FRANCHINO, B; DOLE, K; KIERNAN, MT; GEORGIEFF, MK; HOSTETTER, MK			THE HEALTH OF CHILDREN ADOPTED FROM ROMANIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPATITIS-B; ABUSE-DWARFISM; TRANSMISSION; GROWTH; INFECTION; RESCUE; HIV-1	Objective.-To determine the medical condition of Romanian adoptees and the effects of the Romanian orphanage system on their health. Design.-Case series. Setting.-The international adoption clinics at the University of Minnesota, Minneapolis, and the New England Medical Center, Tufts University, Boston, Mass. Participants.-Sixty-five Romanian adoptees who were brought to the United States during a 12-month period beginning in October 1990. Main Outcome Measures.-Incidence of hepatitis B, intestinal parasites, tuberculosis, syphilis, human immunodeficiency virus type 1, growth failure, and developmental delay. Results.-Although the adopted children were presumably chosen from the most vital and attractive adoptees, only 15% were judged to be physically healthy and developmentally normal. Fifty-three percent had serological evidence of past or present hepatitis B infection, and 20% of screened children tested positive for hepatitis B surface antigen. In children aged 7 months or older, the overall prevalence of chronic hepatitis B was 23%. Intestinal parasites were found in 33% of subjects, and 45% of infected children had two or more pathogens identified. All the children tested for human immunodeficiency virus type 1 were negative. Two patterns of growth failure were observed that resembled the two subtypes of psychosocial short stature that occur in association with prolonged psychological harassment or emotional deprivation. Infants' length, weight, head circumference, and weight-for-height were adversely affected by institutionalization. Older children's height was reduced. Only 10% of children older than 12 months were developmentally normal. Conclusion.-Romanian adoptees are an extraordinarily high-risk pediatric group as a consequence of decades of government-sanctioned child neglect and abuse.	UNIV MINNESOTA,DEPT PEDIAT,INT ADOPT CLIN,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH PUBL HLTH,DIV BIOSTAT,MINNEAPOLIS,MN 55455; TUFTS UNIV,NEW ENGLAND MED CTR,DEPT PEDIAT,INT ADOPT CLIN,BOSTON,MA 02111	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Tufts Medical Center; Tufts University	JOHNSON, DE (corresponding author), BOX 211 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.							AACH RD, 1987, TXB PEDIATRIC INFECT, P718; BABES VT, 1980, VIROLOGIE, V31, P283; BABSON SG, 1976, J PEDIATR-US, V89, P814, DOI 10.1016/S0022-3476(76)80815-3; BARTIATA M, 1991, WASHINGTON POST 0107, pA20; BATTIATA M, 1990, WASHINGTON POST 1005; BATTIATA M, 1990, WASHINGTON POST 0607, pA31; Blizzard RM, 1990, PEDIAT ENDOCRINOLOGY, P77; BLUMENTHAL R, 1989, NY TIMES        1226, pA18; BYME C, 1991, MINNEAPOLIS TAR 0728; BYRNE C, 1991, MINNEAPOLIS STA 0728, pA17; FISHBEIN MM, 1992, AAP NEWS, V8, P13; FISHBEIN MM, 1992, AAP NEWS, V8, P12; FRIEDE A, 1988, AM J PUBLIC HEALTH, V78, P26, DOI 10.2105/AJPH.78.1.26; GYORKOS TW, 1992, NEW ENGL J MED, V326, P410; HERSHOW RC, 1987, PEDIATR INFECT DIS J, V6, P431, DOI 10.1097/00006454-198705000-00002; HOSTETTER M, 1989, AM J DIS CHILD, V143, P325, DOI 10.1001/archpedi.1989.02150150079022; HOSTETTER MK, 1991, NEW ENGL J MED, V325, P479, DOI 10.1056/NEJM199108153250706; HUNT K, 1991, NY TIMES MAGAZI 0324, V140, P24; INDREDAVIK M S, 1991, Tidsskrift for den Norske Laegeforening, V111, P2109; ION-NEDELCU N, 1989, Revista de Igiena Bacteriologie Virusologie Parazitologie Epidemiologie Pneumoftiziologie Seria Bacteriologia Virusologia Parazitologia Epidemiologia, V34, P155; Jamieson F, 1991, Nurs Times, V87, P39; JARRIEL T, 1990, NEW YORK ABC NE 1005; JENISTA JA, 1992, JAMA-J AM MED ASSOC, V268, P601, DOI 10.1001/jama.1992.03490050049013; KASZA L, 1974, LANCET, V1, P675; KIFNER J, 1989, NY TIMES        1226, pA16; KILTON B, 1990, SAN FRANCISCO E 0211; KURTZ J, 1991, BRIT MED J, V302, P1399, DOI 10.1136/bmj.302.6789.1399; LYNCH M, 1991, AAP NEWS, V12, P16; Manu-Koch S, 1970, Monatsschr Kinderheilkd, V118, P347; MONEY J, 1983, J CLIN CHILD PSYCHOL, V12, P279, DOI 10.1207/s15374424jccp1203_8; MONEY J, 1983, PSYCHONEUROENDOCRINO, V8, P309, DOI 10.1016/0306-4530(83)90005-7; NACHTWEY J, 1990, NY TIMES MAGAZI 0624, V139, P28; NELLHAUS G, 1968, PEDIATRICS, V41, P106; NORDENFELT E, 1978, SCAND J INFECT DIS, V10, P161, DOI 10.3109/inf.1978.10.issue-3.01; OATES RK, 1971, MED J AUSTRALIA, V2, P199, DOI 10.5694/j.1326-5377.1971.tb50499.x; OLSZEWSKI L, 1990, SAN FRANCISCO C 1210; Panoiu L, 1979, Virologie, V30, P193; PATRASCU IV, 1990, LANCET, V335, P672, DOI 10.1016/0140-6736(90)90466-I; POWELL GF, 1990, PEDIATRIC ENDOCRINOL, P133; ROTHMAN DJ, 1990, NEW YORK REV BOOKS, V37, P5; RUDIN C, 1990, LANCET, V336, P1592, DOI 10.1016/0140-6736(90)93380-8; Sabau M, 1983, Virologie, V34, P197; SHIRKS M, 1991, ST LOUIS POST D 0520; TURNER T, 1991, NURS TIMES, V87, P1617; VERNON TM, 1976, JAMA-J AM MED ASSOC, V235, P2829, DOI 10.1001/jama.235.26.2829; VITA MC, 1990, ATLANTA J CONST 0701; WAPOLE RE, 1982, INTRO STATISTICS, P40; WILLIAMS C, 1990, LOS ANGELES TIM 1210, pA17; ZAKNUN D, 1991, Paediatrie und Paedologie, V26, P65; 1983, MEASURING CHANGE NUT, P63; 1992, OURS MAGAZINE, V25, P8; 1991, OURS MAGAZINE, V24, P9; 1990, MMWR, V39, P1	53	153	154	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3446	3451		10.1001/jama.268.24.3446	http://dx.doi.org/10.1001/jama.268.24.3446			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1281241				2022-12-28	WOS:A1992KC83900032
J	GREAVES, I; PORTER, KM				GREAVES, I; PORTER, KM			HOLY SPIRIT - AN UNUSUAL CAUSE OF PSEUDOMONAL INFECTION IN A MULTIPLY INJURED PATIENT	BRITISH MEDICAL JOURNAL			English	Article											GREAVES, I (corresponding author), BIRMINGHAM ACCID HOSP,BIRMINGHAM B15 1NA,W MIDLANDS,ENGLAND.								0	10	10	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1578	1578		10.1136/bmj.305.6868.1578	http://dx.doi.org/10.1136/bmj.305.6868.1578			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286398	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100035
J	KUMAR, KT				KUMAR, KT			TO CHILDREN WITH LOVE	BRITISH MEDICAL JOURNAL			English	Editorial Material											KUMAR, KT (corresponding author), BHUWANESHWARI MAHILA ASHRAM,PAURI 246001,UTTAR PRADESH,INDIA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1582	1583		10.1136/bmj.305.6868.1582	http://dx.doi.org/10.1136/bmj.305.6868.1582			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286402	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992KD77100041
J	BENNETT, HJ				BENNETT, HJ			CALLING DR-DOCTOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		DEPAOLIS M, 1992, POSTGRAD MED, V91, P47	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1992	268	21					3060	3060		10.1001/jama.268.21.3060	http://dx.doi.org/10.1001/jama.268.21.3060			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA002	1306061				2022-12-28	WOS:A1992KA00200010
J	PARKER, L; CRAFT, AW; DALE, G; BELL, S; COLE, M; MCGILL, AC; SEVIOUR, JA; SMITH, J				PARKER, L; CRAFT, AW; DALE, G; BELL, S; COLE, M; MCGILL, AC; SEVIOUR, JA; SMITH, J			SCREENING FOR NEUROBLASTOMA IN THE NORTH OF ENGLAND	BRITISH MEDICAL JOURNAL			English	Article							NEURO-BLASTOMA; CHILDHOOD NEUROBLASTOMA; SAPPORO CITY; JAPAN	Objective-To determine the feasibility of establishing a system of screening for neuroblastoma. Design-Prospective study of mass screening in four clearly defined geographical areas. Setting-Four health districts of the Northern region of England. Subjects-20 829 babies aged 6 months, 92% of target population. Interventions-Collection of urine on filter paper for analysis of content of homovanillic and vanillylmandelic acid in relation to urinary creatinine concentrations. Main outcome measures-Derivation of reference range. Identification of babies with homovanillic or vanillylmandelic acid >3 SD above the mean (positive cases). Investigation of positive cases for evidence of neuroblastoma. Results-The upper limit of normal (3 SD above the mean) for vanillylmandelic acid was 15 mumol/mmol creatinine and for homovanillic acid 24 mumol/mmol creatinine. Of the 20 829 babies screened, 2537 (12.2%) required a second sample to be taken because the first sample was inadequate. Of these, 527 (2.5%) provided a liquid urine specimen and 10 (0.04%) had positive results for neuroblastoma. Two of them had neuroblastoma (true positives) and eight did not (false positives). A further three children from the cohort were subsequently found to have neuroblastoma; they had raised homovanillic acid or vanillylmandelic acid values, or both, but screened negative at 6 months. Conclusions-Screening for neuroblastoma is possible in the health care system of the United Kingdom. Evaluation of the efficacy of screening in reducing the mortality from neuroblastoma requires a controlled trial.	NEWCASTLE GEN HOSP,DEPT CLIN BIOCHEM,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital	PARKER, L (corresponding author), MED SCH NEWCASTLE UPON TYNE,DEPT CHILD HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.			PARKER, LOUISE/0000-0002-5188-8113				BRODEUR GM, 1987, CANCER RES, V47, P4248; COLE M, 1992, MED PEDIATR ONCOL, V20, P84, DOI 10.1002/mpo.2950200119; COLE M, IN PRESS ARCH DIS CH; CRAFT AW, 1987, BRIT J CANCER, V56, P853, DOI 10.1038/bjc.1987.305; DALE G, 1988, ANN CLIN BIOCHEM, V25, P233, DOI 10.1177/000456328802500306; EVANS AE, 1987, CANCER, V59, P1853, DOI 10.1002/1097-0142(19870601)59:11<1853::AID-CNCR2820591102>3.0.CO;2-F; HANAWA Y, 1990, MED PEDIATR ONCOL, V18, P472, DOI 10.1002/mpo.2950180607; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MIZUTA M, 1988, JPN J PUBLIC HLTH, V35, P179; NISHI M, 1990, J PEDIATR SURG, V25, P545, DOI 10.1016/0022-3468(90)90570-Y; NISHI M, 1987, CANCER, V60, P433, DOI 10.1002/1097-0142(19870801)60:3<433::AID-CNCR2820600326>3.0.CO;2-H; NISHI M, 1989, PEDIATR RES, V26, P603, DOI 10.1203/00006450-198912000-00018; PARKER L, 1991, CANCER SCREENING, P337; RUTHVEN CRJ, 1979, CHEM DIAGNOSIS DISEA, P1239; SAWADA T, 1984, LANCET, V2, P271; SAWADA T, 1991, CANCER SCREENING, P337; SEVIOUR JA, 1988, J CHROMATOGR-BIOMED, V432, P273, DOI 10.1016/S0378-4347(00)80652-0; SHAFFORD EA, 1984, J CLIN ONCOL, V2, P742, DOI 10.1200/JCO.1984.2.7.742; TUCHMAN M, 1990, PEDIATRICS, V86, P765; TUCHMAN M, 1987, PEDIATRICS, V79, P203	20	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1260	1263		10.1136/bmj.305.6864.1260	http://dx.doi.org/10.1136/bmj.305.6864.1260			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1303649	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JZ52100023
J	MERLANO, M; VITALE, V; ROSSO, R; BENASSO, M; CORVO, R; CAVALLARI, M; SANGUINETI, G; BACIGALUPO, A; BADELLINO, F; MARGARINO, G; BREMA, F; PASTORINO, G; MARZIANO, C; GRIMALDI, A; SCASSO, F; SPERATI, G; PALLESTRINI, E; GARAVENTA, G; ACCOMANDO, E; CORDONE, G; COMELLA, G; DAPONTE, A; RUBAGOTTI, A; BRUZZI, P; SANTI, L				MERLANO, M; VITALE, V; ROSSO, R; BENASSO, M; CORVO, R; CAVALLARI, M; SANGUINETI, G; BACIGALUPO, A; BADELLINO, F; MARGARINO, G; BREMA, F; PASTORINO, G; MARZIANO, C; GRIMALDI, A; SCASSO, F; SPERATI, G; PALLESTRINI, E; GARAVENTA, G; ACCOMANDO, E; CORDONE, G; COMELLA, G; DAPONTE, A; RUBAGOTTI, A; BRUZZI, P; SANTI, L			TREATMENT OF ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK WITH ALTERNATING CHEMOTHERAPY AND RADIOTHERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMBINED MODALITY TREATMENT; RADIATION-THERAPY; 5-FLUOROURACIL INFUSION; RANDOMIZED TRIAL; CANCER-TREATMENT; II TRIAL; PHASE-I; BLEOMYCIN; CISPLATIN; RECURRENT	Background. For patients with advanced, unresectable squamous-cell carcinoma of the head and neck, radiotherapy is the standard treatment but has poor results. We therefore designed a randomized trial to determine whether alternating chemotherapy with radiotherapy would improve the survival of such patients. Methods. Patients in the trial had biopsy-confirmed unresectable, previously untreated Stage III or IV, squamous-cell carcinoma of the oral cavity, pharynx, or larynx. They were randomly assigned to chemotherapy consisting of four cycles of intravenous cisplatin (20 mg per square meter of body-surface area per day for five consecutive days) and fluorouracil (200 mg per square meter per day for five consecutive days) alternating with radiotherapy in three two-week courses (20 Gy per course; 2 Gy per day, five days per week), or to radiotherapy alone (up to 70 Gy; 2 Gy per day, five days per week). Results. The 80 patients given chemotherapy alternating with radiotherapy and the 77 given radiotherapy alone were comparable in terms of age, sex, performance status, disease stage, and site of the primary tumor. Complete responses were obtained in 42 percent of the patients in the combined-therapy group and 22 percent of those in the radiotherapy group (P = 0.037). The median survival was 16.5 months in the combined-therapy group and 11.7 months in the radiotherapy group (P<0.05); the 3-year survival was 41 percent and 23 percent, respectively. Severe mucositis occurred in 19 percent of the patients in the combined-therapy group and 18 percent of those in the radiotherapy group. Conclusions. In patients with advanced unresectable squamous-cell carcinoma of the head and neck, chemotherapy alternating with radiotherapy increases the median survival and doubles the probability of survival for three years as compared with radiotherapy alone. However, since local disease cannot be controlled in over halt the patients who receive the combined treatment and since almost two thirds die within three years, further improvements in management are necessary.	NATL INST CANC RES, DEPT SURG ONCOL, GENOA, ITALY; S PAOLO HOSP, DEPT RADIAT ONCOL, SAVONA, ITALY; GALLIERA HOSP, DEPT RADIAT ONCOL, GENOA, ITALY; CELESIA HOSP, DEPT HEAD & NECK SURG, GENOA, ITALY; SAN MARTINO HOSP, DEPT HEAD & NECK SURG, GENOA, ITALY; PASCALE INST, DEPT MED ONCOL, NAPLES, ITALY; NATL INST CANC RES, OFF DIRECTOR, GENOA, ITALY; NATL INST CANC RES, DEPT CLIN EPIDEMIOL & TRIALS, GENOA, ITALY; NATL INST CANC RES, DEPT RADIAT ONCOL, I-16132 GENOA, ITALY; UNIV GENOA, DEPT HEAD & NECK SURG, I-16126 GENOA, ITALY	University of Genoa; IRCCS AOU San Martino IST; Ente Ospedaliero Ospedali Galliera; University of Genoa; IRCCS AOU San Martino IST; IRCCS Fondazione Pascale; University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; University of Genoa	MERLANO, M (corresponding author), NATL INST CANC RES, DEPT MED ONCOL, V BENEDETTO XVN 10, I-16132 GENOA, ITALY.		Bruzzi, Paolo/AAU-3363-2021; Corvò, Renzo G/K-4993-2012; Bacigalupo, Almalina/AAB-1916-2020	Bacigalupo, Almalina/0000-0001-6875-5803; CORVO, RENZO/0000-0002-5001-4844; RUBAGOTTI, Alessandra/0000-0002-4009-8829				ALSARRAF M, 1988, SEMIN ONCOL, V15, P70; BYFIELD JE, 1984, J CLIN ONCOL, V2, P406, DOI 10.1200/JCO.1984.2.5.406; CLIFFORD P, 1976, J LARYNGOL OTOL, V90, P221, DOI 10.1017/S0022215100082013; Eschwege F, 1988, NCI Monogr, P275; FU KK, 1987, J CLIN ONCOL, V5, P1410, DOI 10.1200/JCO.1987.5.9.1410; GLICK JH, 1981, INT J RADIAT ONCOL, V7, P229, DOI 10.1016/0360-3016(81)90442-9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEANE TJ, 1985, RADIOTHER ONCOL, V4, P205, DOI 10.1016/S0167-8140(85)80085-2; KISH JA, 1984, CANCER, V53, P1819, DOI 10.1002/1097-0142(19840501)53:9<1819::AID-CNCR2820530903>3.0.CO;2-R; LO TCM, 1976, AM J ROENTGENOL, V126, P229, DOI 10.2214/ajr.126.2.229; LOONEY WB, 1985, CANCER TREAT REP, V69, P769; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MERLANO M, 1985, CANCER TREAT REP, V69, P961; MERLANO M, 1991, CANCER-AM CANCER SOC, V67, P915, DOI 10.1002/1097-0142(19910215)67:4<915::AID-CNCR2820670410>3.0.CO;2-8; MERLANO M, 1988, AM J CLIN ONCOL-CANC, V11, P538, DOI 10.1097/00000421-198810000-00006; MERLANO M, 1987, CANCER TREAT REP, V71, P485; MERLANO M, 1990, AM J CLIN ONCOL-CANC, V13, P1; MERLANO M, 1992, J INFUSION CHEMOTHER, V2, P1620; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MILLION RR, 1985, CANCER PRINCIPLES PR, V1, P407; MOERTEL CG, 1981, CANCER, V48, P1705, DOI 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4; SEIFERT P, 1975, CANCER-AM CANCER SOC, V36, P123, DOI 10.1002/1097-0142(197507)36:1<123::AID-CNCR2820360108>3.0.CO;2-C; SHANTA V, 1980, CLIN RADIOL, V31, P617, DOI 10.1016/S0009-9260(80)80069-9; STEFANI S, 1971, RADIOLOGY, V101, P391, DOI 10.1148/101.2.391; STELL PM, 1983, CLIN RADIOL, V34, P463, DOI 10.1016/S0009-9260(83)80247-5; TANNOCK IF, 1989, RADIOTHER ONCOL, V16, P83, DOI 10.1016/0167-8140(89)90025-X; TAYLOR SG, 1985, CANCER TREAT REP, V69, P933; TUBIANA M, 1989, INT J RADIAT ONCOL, V16, P763, DOI 10.1016/0360-3016(89)90496-3; VERMUND H, 1985, INT J RADIAT ONCOL, V11, P1877, DOI 10.1016/0360-3016(85)90267-6; VOKES, 1990, J CLIN ONCOL, V8, P1447, DOI 10.1200/JCO.1990.8.8.1447; VOKES EE, 1990, J CLIN ONCOL, V8, P911, DOI 10.1200/JCO.1990.8.5.911	31	243	246	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1115	1121		10.1056/NEJM199210153271602	http://dx.doi.org/10.1056/NEJM199210153271602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT153	1302472				2022-12-28	WOS:A1992JT15300002
J	JOHNSON, S; HOMANN, SR; BETTIN, KM; QUICK, JN; CLABOTS, CR; PETERSON, LR; GERDING, DN				JOHNSON, S; HOMANN, SR; BETTIN, KM; QUICK, JN; CLABOTS, CR; PETERSON, LR; GERDING, DN			TREATMENT OF ASYMPTOMATIC CLOSTRIDIUM-DIFFICILE CARRIERS (FECAL EXCRETORS) WITH VANCOMYCIN OR METRONIDAZOLE - A RANDOMIZED, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						CLOSTRIDIUM-DIFFICILE; VANCOMYCIN; METRONIDAZOLE; DIARRHEA; DISEASE OUTBREAKS	COLITIS; DIARRHEA; INFECTION; COLONIZATION; METABOLITES; CLINDAMYCIN	Objective: To compare the efficacy of vancomycin and metronidazole for eradication of asymptomatic Clostridium difficile fecal excretion as a means of controlling nosocomial outbreaks of C. difficile diarrhea. Design: Randomized, placebo-controlled, nonblinded trial, Setting: Six hundred-bed regional referral Veterans Affairs Medical Center. Patients: Thirty patients excreting C. difficile without diarrhea or abdominal symptoms. Interventions: All patients were randomized to receive 10 days of oral vancomycin, 125 mg four times daily; metronidazole, 500 mg twice daily; or placebo, three times daily. Measurements: Stool cultures were obtained during treatment and for 2 months after treatment. All C. difficile isolates were typed by restriction endonuclease analysis (REA). Results: Clostridium difficile organisms were not detected during and immediately after treatment in 9 of 10 patients treated with vancomycin compared with 3 of 10 patients treated with metronidazole (P = 0.02) and 2 of 10 patients in the placebo group (P = 0.005). The fecal vancomycin concentration was 1406 +/- 1164-mu-g/g feces, but metronidazole was not detectable in 9 of 10 patients. Eight of the nine evaluable patients who had negative stool cultures after treatment with vancomycin began to excrete C. difficile again 20 +/- 8 days after completing treatment. Three of these patients received additional antibiotics before C. difficile excretion recurred, and five acquired new C. difficile REA strains. Four of six patients who received only vancomycin before C. difficile excretion recurred were culture-positive at the end of the study compared with one of nine patients who received only placebo (P = 0.047). Conclusions: Asymptomatic fecal excretion of C. difficile is transient in most patients, and treatment with metronidazole is not effective. Although treatment with vancomycin is temporarily effective, it is associated with a significantly higher rate of C. difficile carriage 2 months after treatment and is not recommended.	UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	JOHNSON, S (corresponding author), VET AFFAIRS MED CTR, DEPT MED, INFECT DIS SECT 111F, 1 VET DR, MINNEAPOLIS, MN 55417 USA.			Johnson, Stuart/0000-0001-9548-229X				ARABI Y, 1979, J ANTIMICROB CHEMOTH, V5, P531, DOI 10.1093/jac/5.5.531; ARONSSON B, 1987, EUR J CLIN MICROBIOL, V6, P352, DOI 10.1007/BF02017639; ASERKOFF B, 1969, NEW ENGL J MED, V281, P636, DOI 10.1056/NEJM196909182811202; BANNATYNE R, 1987, EUR J CLIN MICROBIOL, V6, P505, DOI 10.1007/BF02013130; BENDER BS, 1986, LANCET, V2, P11, DOI 10.1016/S0140-6736(86)92559-6; BOLTON RP, 1986, GUT, V27, P1169, DOI 10.1136/gut.27.10.1169; CLABOTS CR, 1989, J CLIN MICROBIOL, V27, P2386, DOI 10.1128/JCM.27.10.2386-2387.1989; DELMEE M, 1987, EUR J CLIN MICROBIOL, V6, P623, DOI 10.1007/BF02013056; GEORGE WL, 1979, J CLIN MICROBIOL, V9, P214; GERDING DN, 1990, AM J SURG, V159, P212, DOI 10.1016/S0002-9610(05)80264-8; GERDING DN, 1990, 3RD P INT C NOS INF; HORN SD, 1983, MED CARE, V21, P14, DOI 10.1097/00005650-198301000-00002; HOVERSTAD T, 1986, SCAND J GASTROENTERO, V21, P621, DOI 10.3109/00365528609003109; INGS RMJ, 1975, XENOBIOTICA, V5, P223, DOI 10.3109/00498257509052069; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; JOHNSON S, 1989, J INFECT DIS, V159, P340, DOI 10.1093/infdis/159.2.340; KERR RB, 1990, AM J INFECT CONTROL, V18, P332, DOI 10.1016/0196-6553(90)90233-I; MARQUES RA, 1978, J CHROMATOGR, V146, P163, DOI 10.1016/S0378-4347(00)81303-1; MCFARLAND LV, 1987, J CLIN MICROBIOL, V25, P2241, DOI 10.1128/JCM.25.11.2241-2242.1987; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MCKINNEY WP, 1989, JAMA-J AM MED ASSOC, V261, P3430, DOI 10.1001/jama.261.23.3430; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P240; RYBOLT AH, 1989, LANCET, V1, P1353; SCHWENZER KS, 1983, THER DRUG MONIT, V5, P341, DOI 10.1097/00007691-198309000-00017; SHANHOLTZER CJ, 1983, J CLIN MICROBIOL, V17, P906, DOI 10.1128/JCM.17.5.906-908.1983; TEASLEY DG, 1983, LANCET, V2, P1043; TEDESCO F, 1978, LANCET, V2, P226	27	263	272	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					297	302		10.7326/0003-4819-117-4-297	http://dx.doi.org/10.7326/0003-4819-117-4-297			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1322075				2022-12-28	WOS:A1992JH46400005
J	DOVER, JS; ARNDT, KA				DOVER, JS; ARNDT, KA			DERMATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; T-CELL LYMPHOMA; EXTRACORPOREAL PHOTOCHEMOTHERAPY		HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	DOVER, JS (corresponding author), NEW ENGLAND DEACONESS HOSP, BOSTON, MA 02215 USA.							ALLOUB MI, 1989, BMJ-BRIT MED J, V298, P153, DOI 10.1136/bmj.298.6667.153; ASHINOFF R, 1991, ARCH DERMATOL, V127, P1813, DOI 10.1001/archderm.127.12.1813; BARNHILL RL, 1991, CANCER-AM CANCER SOC, V67, P3157, DOI 10.1002/1097-0142(19910615)67:12<3157::AID-CNCR2820671237>3.0.CO;2-6; CLEMENTE C, 1991, HUM PATHOL, V22, P313, DOI 10.1016/0046-8177(91)90078-4; COBB MW, 1990, J AM ACAD DERMATOL, V22, P547, DOI 10.1016/0190-9622(90)70073-Q; EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603; GISSMANN L, 1986, PAPILLOMAVIRUSES, P190; HALPERN AC, 1991, ARCH DERMATOL, V127, P995, DOI 10.1001/archderm.127.7.995; HEALD PW, 1989, YALE J BIOL MED, V62, P629; KAWASHIMA M, 1990, J INVEST DERMATOL, V95, P537, DOI 10.1111/1523-1747.ep12504887; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; MELSKI JW, 1992, JAMA-J AM MED ASSOC, V267, P1516; MOY RL, 1989, JAMA-J AM MED ASSOC, V261, P2669, DOI 10.1001/jama.261.18.2669; PIERCEALL WE, 1991, J INVEST DERMATOL, V97, P880, DOI 10.1111/1523-1747.ep12491612; ROCK B, 1992, ARCH DERMATOL, V128, P495, DOI 10.1001/archderm.128.4.495; ROOK AH, 1990, ANN INTERN MED, V112, P303, DOI 10.7326/0003-4819-112-4-303; ROOK AH, 1992, ARCH DERMATOL, V128, P337, DOI 10.1001/archderm.128.3.337; TRENTHAM DE, 1992, ARCH DERMATOL, V128, P389, DOI 10.1001/archderm.128.3.389	18	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					342	344		10.1001/jama.268.3.342	http://dx.doi.org/10.1001/jama.268.3.342			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1319509				2022-12-28	WOS:A1992JC35200024
J	BACKX, PH; YUE, DT; LAWRENCE, JH; MARBAN, E; TOMASELLI, GF				BACKX, PH; YUE, DT; LAWRENCE, JH; MARBAN, E; TOMASELLI, GF			MOLECULAR LOCALIZATION OF AN ION-BINDING SITE WITHIN THE PORE OF MAMMALIAN SODIUM-CHANNELS	SCIENCE			English	Article							VOLTAGE-DEPENDENT ACTION; CALF PURKINJE-FIBERS; POTASSIUM CHANNELS; NA CHANNELS; TETRODOTOXIN; BLOCK; SAXITOXIN; MYOCYTES; MUSCLE; MODEL	Sodium channels are the major proteins that underlie excitability in nerve, heart, and skeletal muscle. Chemical reaction rate theory was used to analyze the blockage of single wild-type and mutant sodium channels by cadmium ions. The affinity of cadmium for the native tetrodotoxin (TTX)-resistant cardiac channel was much higher than its affinity for the TTX-sensitive skeletal muscle isoform of the channel (mu-l). Mutation of Tyr401 to Cys, the corresponding residue in the cardiac sequence, rendered mu-l highly susceptible to cadmium blockage but resistant to TTX. The binding site was localized approximately 20% of the distance down the electrical field, thus defining the position of a critical residue within the sodium channel pore.	JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT BIOMED ENGN,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University			Marban, Eduardo/GWC-8514-2022		NHLBI NIH HHS [K08 HL2421, K11 HL02639, R01 HL36957] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002421, R01HL036957, K11HL002639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKX PH, 1990, BIOPHYS J, V57, pA298; BAER M, 1976, NATURE, V263, P344, DOI 10.1038/263344a0; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BOWERS CW, 1985, BRAIN RES, V340, P143, DOI 10.1016/0006-8993(85)90783-8; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; COHEN CJ, 1981, J GEN PHYSIOL, V78, P383, DOI 10.1085/jgp.78.4.383; DIFRANCESCO D, 1985, PROC R SOC SER B-BIO, V223, P475, DOI 10.1098/rspb.1985.0013; FRELIN C, 1986, EUR J PHARMACOL, V122, P245, DOI 10.1016/0014-2999(86)90109-3; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HALLOWAY SF, 1989, PFLUEGERS ARCH, V414, P613; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HILLE B, 1975, J GEN PHYSIOL, V66, P535, DOI 10.1085/jgp.66.5.535; HILLE B, 1975, BIOPHYS J, V15, P615, DOI 10.1016/S0006-3495(75)85842-5; Hille B., 1992, IONIC CHANNELS EXCIT; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MARTELL AE, 1989, CRITICAL STABILITY C, V1, P47; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; PUSCH M, 1991, EUR BIOPHYS J, V20, P127, DOI 10.1007/BF01561134; RAVINDRAN A, 1991, J GEN PHYSIOL, V97, P89, DOI 10.1085/jgp.97.1.89; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHILD L, 1991, J GEN PHYSIOL, V97, P117, DOI 10.1085/jgp.97.1.117; SCHILD L, 1991, BIOPHYS J, V59, P523, DOI 10.1016/S0006-3495(91)82269-X; SHEETS MF, IN PRESS J PHYSL; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; VASSILEV PM, 1986, AM J PHYSIOL, V251, pH475, DOI 10.1152/ajpheart.1986.251.2.H475; VISENTIN S, 1990, PFLUG ARCH EUR J PHY, V417, P213, DOI 10.1007/BF00370702; YAMAMOTO D, 1984, BIOPHYS J, V45, P337, DOI 10.1016/S0006-3495(84)84159-4; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; YUE DT, 1990, J GEN PHYSIOL, V95, P911, DOI 10.1085/jgp.95.5.911	41	248	251	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					248	251		10.1126/science.1321496	http://dx.doi.org/10.1126/science.1321496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321496				2022-12-28	WOS:A1992JC58500041
J	BORGULYA, P; KISHI, H; UEMATSU, Y; VONBOEHMER, H				BORGULYA, P; KISHI, H; UEMATSU, Y; VONBOEHMER, H			EXCLUSION AND INCLUSION OF ALPHA-T-CELL AND BETA-T-CELL RECEPTOR ALLELES	CELL			English	Article							IMMUNOGLOBULIN GENE REARRANGEMENT; TRANSGENIC MICE; ANTIGEN RECEPTOR; CHAIN GENES; B-CELLS; EXPRESSION; DIFFERENTIATION; THYMOCYTES; DELETION; IDENTIFICATION	Exclusion and inclusion of T cell receptor (TCR) genes were analyzed in alpha-beta-TCR transgenic mice. Both transgenes are expressed unusually early on the surface of CD4-8-, HSA+, IL-2R- thymocytes. These progenitor cells give rise to progeny, which at the single-cell level contains endogenous-alpha but not beta-TCR-RNA as well as protein, in addition to products encoded by the transgenes. Thus, the surface expression of an alpha-beta-TCR does not prevent further alpha-TCR rearrangement in immature thymocytes that still transcribe RAG-1 and RAG-2 genes. Reduced levels of RAG-1 and RAG-2 RNA are detectable only in CD4+8+ TCR(high) cells, which result from positive selection in the thymus. The results suggest that a developing T cell may try different alpha-beta-TCRs for binding to thymic MHC ligands, and that recombination at the alpha-locus ceases only after positive selection.			BORGULYA, P (corresponding author), BASEL INST IMMUNOL,487 GRENZACHERSTR,CH-4005 BASEL,SWITZERLAND.							ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLECLOUGH C, 1981, NATURE, V290, P372, DOI 10.1038/290372a0; COUEZ D, 1991, INT IMMUNOL, V3, P719, DOI 10.1093/intimm/3.7.719; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P545, DOI 10.1007/BF01572589; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; HUGHES EN, 1981, J BIOL CHEM, V256, P7023; IMAI K, 1986, P NATL ACAD SCI USA, V83, P8708, DOI 10.1073/pnas.83.22.8708; KISIELOW P, 1984, J IMMUNOL, V133, P1117; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MAKI R, 1980, SCIENCE, V209, P1366, DOI 10.1126/science.6774416; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MAROLLEAU JP, 1988, CELL, V55, P291, DOI 10.1016/0092-8674(88)90052-9; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; RITCHIE KA, 1984, NATURE, V312, P517, DOI 10.1038/312517a0; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WABL M, 1982, P NATL ACAD SCI-BIOL, V79, P6976, DOI 10.1073/pnas.79.22.6976; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; WILSON A, 1988, J IMMUNOL, V140, P1461; WILSON A, 1988, J IMMUNOL, V140, P1470; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	44	335	338	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					529	537		10.1016/0092-8674(92)90453-J	http://dx.doi.org/10.1016/0092-8674(92)90453-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1316241				2022-12-28	WOS:A1992HT07800014
J	LI, QX; YOUNG, LS; NIEDOBITEK, G; DAWSON, CW; BIRKENBACH, M; WANG, F; RICKINSON, AB				LI, QX; YOUNG, LS; NIEDOBITEK, G; DAWSON, CW; BIRKENBACH, M; WANG, F; RICKINSON, AB			EPSTEIN-BARR-VIRUS INFECTION AND REPLICATION IN A HUMAN EPITHELIAL-CELL SYSTEM	NATURE			English	Article							HUMAN LYMPHOCYTES-B; LATENT MEMBRANE-PROTEIN; CROSS-LINKED ENVELOPE; HUMAN EPIDERMAL-CELLS; NASOPHARYNGEAL CARCINOMA; MONOCLONAL-ANTIBODIES; INSITU HYBRIDIZATION; HUMAN KERATINOCYTES; EBV/C3D RECEPTOR; BURKITT-LYMPHOMA	EPSTEIN-BARR virus, a human herpesvirus with oncogenic potential, infects two target tissues in vivo: B lymphocytes, where the infection is largely non-productive 1, and stratified squamous epithelium in which virus replication occurs 2,3. The interaction with B cells, initiated through virus binding to the B-cell surface molecule CR2 (ref. 4), has been studied in vitro and the virus 'latent' genes associated with B-cell growth transformation defined 5. By comparison, viral infection of epithelium remains poorly understood, reflecting the lack of an appropriate cell-culture model. Here we describe the development of such a model using as targets CR2-expressing transfected cells of two independent human epithelial lines. A high proportion of these cells bind virus and become actively infected, expressing the small EBER RNAs (small non-polyadenylated virus-coded RNAs) and the Epstein-Barr nuclear antigen 1 but not other latent proteins; thereafter, under conditions favouring epithelial differentiation, up to 30% of the cells can be induced to enter virus productive cycle with some progressing to full virus replication. We find significant differences between laboratory virus strains in their ability to infect epithelium that do not correlate with their B-cell growth-transforming activity.	UNIV BIRMINGHAM,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	University of Birmingham; Harvard University; Brigham & Women's Hospital			Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298				AHEARN JM, 1988, P NATL ACAD SCI USA, V85, P9307, DOI 10.1073/pnas.85.23.9307; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; CANTALOUBE JF, 1990, EUR J IMMUNOL, V20, P409, DOI 10.1002/eji.1830200226; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; KIEFF E, 1990, VIROLOGY, P1889; LERNER MR, 1981, P NATL ACAD SCI-BIOL, V78, P805, DOI 10.1073/pnas.78.2.805; LIN JC, 1984, J VIROL, V50, P50, DOI 10.1128/JVI.50.1.50-55.1984; MILANI S, 1989, HEPATOLOGY, V10, P84, DOI 10.1002/hep.1840100117; MILLER G, 1981, SCIENCE, V212, P452, DOI 10.1126/science.6259735; MOORE MD, 1987, P NATL ACAD SCI USA, V84, P9194, DOI 10.1073/pnas.84.24.9194; NIEDOBITEK G, 1989, HUM PATHOL, V20, P796, DOI 10.1016/0046-8177(89)90075-0; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; PARKINSON EK, 1984, CARCINOGENESIS, V5, P1071, DOI 10.1093/carcin/5.8.1071; PEARSON GR, 1983, J VIROL, V47, P193, DOI 10.1128/JVI.47.1.193-201.1983; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; RUBIN AL, 1986, CANCER RES, V46, P2356; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; SHAPIRO IM, 1983, SCIENCE, V215, P1225; SIXBEY JW, 1983, NATURE, V306, P480, DOI 10.1038/306480a0; SIXBEY JW, 1987, J GEN VIROL, V68, P805, DOI 10.1099/0022-1317-68-3-805; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; VROMAN B, 1985, J VIROL, V53, P107, DOI 10.1128/JVI.53.1.107-113.1985; WEIS JJ, 1988, J EXP MED, V167, P1047, DOI 10.1084/jem.167.3.1047; WEIS JJ, 1986, P NATL ACAD SCI USA, V83, P5639, DOI 10.1073/pnas.83.15.5639; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991	39	172	188	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					347	350		10.1038/356347a0	http://dx.doi.org/10.1038/356347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1312681				2022-12-28	WOS:A1992HK79400067
J	MOLLA, A; JANG, SK; PAUL, AV; REUER, Q; WIMMER, E				MOLLA, A; JANG, SK; PAUL, AV; REUER, Q; WIMMER, E			CARDIOVIRAL INTERNAL RIBOSOMAL ENTRY SITE IS FUNCTIONAL IN A GENETICALLY ENGINEERED DICISTRONIC POLIOVIRUS	NATURE			English	Article							ENCEPHALOMYOCARDITIS VIRUS-RNA; 5'-UNTRANSLATED REGION; SECONDARY STRUCTURE; GENE ORGANIZATION; INITIATION SITE; TRANSLATION; NEUROVIRULENCE; PROTEINASES; EXPRESSION; ELEMENTS	HIGH mutation rates have driven RNA viruses to shorten their genomes to the minimum possible size 1. Mammalian (+)-strand RNA viruses and retroviruses have responded by reducing the number of cis-acting regulatory elements, a constraint that has led to the emergence of the polyprotein 2. Poliovirus is a (+)-stranded picornavirus whose polyprotein, encoded by an open reading frame spanning most of the viral RNA 3, is processed by virus-encoded proteinases 4,5. Despite their genetic austerity, picornaviruses have retained long 5' untranslated regions 6-8, which harbour cis-acting elements that promote initiation of translation independently of the uncapped 5' end of the viral messenger RNA 9-12. These elements are termed 'internal ribosomal entry sites' 10 and are formed from highly structured RNA segments 13-15 of at least 400 nucleotides 16. How these elements function-is not known, but special RNA-binding proteins may be involved 17. The ribosome or its 40S subunit probably binds at or near a Y(n)X(m)AUG motif (where Y is a pyrimidine and X is a purine) at the 3' border of the internal ribosomal entry site 17, which either provides the initiating codon 16,18 or enables the ribosome to translocate to one downstream (E.W. et al., submitted). Initiation from most eukaryotic messenger RNAs usually occurs by ribosomal recognition of the 5' and subsequent scanning to the AUG codon 19. Here we describe a genetic strategy for the dissection of polyproteins which proves that an internal ribosomal entry site element can initiate translation independently of the 5' end.			MOLLA, A (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA.		Jang, Sung K/P-1230-2017					ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251; DAVIS BD, 1980, MICROBIOLOGY, P874; DORNER AJ, 1982, J VIROL, V42, P1017, DOI 10.1128/JVI.42.3.1017-1028.1982; Harris KS, 1990, SEMINARS VIROLOGY, V1, P323; HELLEN CUT, 1991, J VIROL, V65, P4226, DOI 10.1128/JVI.65.8.4226-4231.1991; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; NICKLIN MJH, 1987, P NATL ACAD SCI USA, V84, P4002, DOI 10.1073/pnas.84.12.4002; PALMENBERG AC, 1987, UCLA S CELLULAR BIOL, V54, P25; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1989, J VIROL, V63, P441, DOI 10.1128/JVI.63.1.441-444.1989; PILIPENKO EV, 1989, VIROLOGY, V168, P201, DOI 10.1016/0042-6822(89)90259-6; PILIPENKO EV, 1989, NUCLEIC ACIDS RES, V17, P5701, DOI 10.1093/nar/17.14.5701; PINCUS SE, 1986, J VIROL, V57, P638, DOI 10.1128/JVI.57.2.638-646.1986; REANNEY DC, 1984, S SOC GEN MICROBIOL, V35, P175; RUECKERT RR, 1990, VIROLOGY, P507; SKINNER MA, 1989, J MOL BIOL, V207, P379, DOI 10.1016/0022-2836(89)90261-1; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330	29	105	118	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1992	356	6366					255	257		10.1038/356255a0	http://dx.doi.org/10.1038/356255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1313153				2022-12-28	WOS:A1992HJ94400063
J	PAGANO, M; DRAETTA, G; JANSENDURR, P				PAGANO, M; DRAETTA, G; JANSENDURR, P			ASSOCIATION OF CDK2 KINASE WITH THE TRANSCRIPTION FACTOR-E2F DURING S-PHASE	SCIENCE			English	Article							ADENOVIRUS E1A PROTEINS; FACTOR E2F; CYCLIN-A; ACTIVATION; CELLS; GENE; PHOSPHORYLATION; IDENTIFICATION; COMPLEXES; BINDING	The transcription factor E2F controls the expression of several proliferation-related genes and is a target of the adenovirus E1A oncogene. In human cells, both cyclin A and the cdk2 protein kinase were found in complexes with E2F. Although the total amounts of cdk2 were constant in the cell cycle, binding to E2F was detected only when cells entered S phase, a time when the cdk2 kinase is activated. These data suggest that the interaction between cdk2 and E2F requires an active kinase that has cyclin A as a targeting component.	GERMAN CANC RES CTR,W-6900 HEIDELBERG 1,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)	PAGANO, M (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY.		Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; pagano, michele/0000-0003-3210-2442				BAEUERLE P, 1989, GENE DEV, V3, P1681; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BALDIN V, UNPUB; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOEUF H, 1990, P NATL ACAD SCI USA, V87, P1782, DOI 10.1073/pnas.87.5.1782; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HARLOW E, 1988, ANTIBODIES LABORATOR; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JANSENDURR P, 1989, EMBO J, V8, P3365, DOI 10.1002/j.1460-2075.1989.tb08499.x; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KUMAR V, 1988, CELL, V55, P507; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; PAGANO M, IN PRESS PROG GROWTH; PAGANO M, IN PRESS EMBO J; PAGANO M, UNPUB; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; THALMEIER K, 1989, GENE DEV, V3, P327; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	39	250	255	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1144	1147		10.1126/science.1312258	http://dx.doi.org/10.1126/science.1312258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1312258				2022-12-28	WOS:A1992HF63200047
J	SAYERS, MH; ANDERSON, KC; GOODNOUGH, LT; KURTZ, SR; LANE, TA; PISCIOTTO, P; SILBERSTEIN, LE				SAYERS, MH; ANDERSON, KC; GOODNOUGH, LT; KURTZ, SR; LANE, TA; PISCIOTTO, P; SILBERSTEIN, LE			REDUCING THE RISK FOR TRANSFUSION-TRANSMITTED CYTOMEGALOVIRUS-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Review							BONE-MARROW TRANSPLANTATION; RED-BLOOD-CELLS; VIRUS CMV INFECTION; RENAL-TRANSPLANTATION; IMMUNE GLOBULIN; NEWBORN-INFANTS; ACUTE-LEUKEMIA; PREVENTION; DISEASE; DONORS	Objective: To define the groups of patients at risk for transfusion-transmitted cytomegalovirus infection and to define the methods to reduce this risk. Data Sources: English-language publications on transfusion medicine. Study Selection and Data Extraction: Studies were selected that described cytomegalovirus infection in transfusion-dependent patients. Special attention was paid to reports that included observations about the prevalence and clinical manifestations of cytomegalovirus infection and recommendations for the prevention of infection. Data Synthesis. Some patients with impaired immune responses who have never been exposed to cytomegalovirus are at risk for transfusion-transmitted cytomegalovirus infection. This infection, which is associated with substantial morbidity and mortality, can be avoided by additional screening of blood donors or by special processing of components for transfusion. Conclusions. Transfusion products that are unlikely to transmit cytomegalovirus infection can be prepared by filtration to remove leukocytes or can be obtained by selecting donors who are seronegative for antibodies to cytomegalovirus. These products are indicated for certain groups of immunosuppressed patients, including pregnant women who are cytomegalovirus seronegative, premature infants of low birth weight who are born to cytomegalovirus-seronegative mothers, cytomegalovirus-seronegative recipients of allogeneic bone marrow transplants from cytomegalovirus-seronegative donors, and cytomegalovirus-seronegative patients with the acquired immunodeficiency syndrome (AIDS).	UNIV WASHINGTON, SEATTLE, WA 98195 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV HOSP CLEVELAND, CLEVELAND, OH 44106 USA; IRELAND CANC CTR, CLEVELAND, OH USA; LAHEY CLIN FDN, MED CTR, BURLINGTON, MA USA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06032 USA; UNIV PENN, BLOOD BANK, PHILADELPHIA, PA 19104 USA	University of Washington; University of Washington Seattle; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University Hospitals of Cleveland; Lahey Hospital & Medical Center; University of California System; University of California San Diego; University of Connecticut; University of Pennsylvania	SAYERS, MH (corresponding author), PUGET SOUND BLOOD CTR, 921 TERRY AVE, SEATTLE, WA 98104 USA.							Adler S P, 1988, Transfus Med Rev, V2, P235, DOI 10.1016/S0887-7963(88)70051-6; ADLER SP, 1984, TRANSFUSION, V24, P333, DOI 10.1046/j.1537-2995.1984.24484275576.x; ADLER SP, 1983, PEDIATR INFECT DIS J, V2, P114, DOI 10.1097/00006454-198303000-00009; ADLER SP, 1983, REV INFECT DIS, V5, P977; ADLER SP, 1986, CRIT REV CL LAB SCI, V23, P1; ADLER SP, 1984, VOX SANG, V46, P387, DOI 10.1111/j.1423-0410.1984.tb00103.x; APPELBAUM FR, 1982, TRANSPLANTATION, V33, P265; ARMSTRONG JA, 1976, YALE J BIOL MED, V49, P83; BAUMGARTNER JD, 1982, LANCET, V2, P63; BENEKE JS, 1984, J INFECT DIS, V150, P883, DOI 10.1093/infdis/150.6.883; BETTS RF, 1979, J MED VIROL, V4, P89, DOI 10.1002/jmv.1890040203; Bowden R.A., 1989, TRANSFUSION S, V29, P57; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; BOWDEN RA, 1990, SEMIN HEMATOL, V27, P17; BOWDEN RA, 1987, TRANSFUSION, V27, P478, DOI 10.1046/j.1537-2995.1987.27688071699.x; BOWDEN RA, 1990, MODERN TRANSFUSION T, V2, P269; BRADY MT, 1984, J INFECT DIS, V150, P334, DOI 10.1093/infdis/150.3.334; CHOU SW, 1986, NEW ENGL J MED, V314, P1418, DOI 10.1056/NEJM198605293142205; DEGRAANHENTZEN YCE, 1987, BRIT J HAEMATOL, V66, P421; DEMMLER GJ, 1986, J PEDIATR-US, V108, P762, DOI 10.1016/S0022-3476(86)81062-9; DIOSI P, 1969, BRIT MED J, V4, P660, DOI 10.1136/bmj.4.5684.660; DREW WL, 1982, JAMA-J AM MED ASSOC, V247, P2389, DOI 10.1001/jama.247.17.2389; FRYD DS, 1980, TRANSPLANTATION, V30, P436, DOI 10.1097/00007890-198012000-00010; GILBERT GL, 1989, LANCET, V1, P1228, DOI 10.1016/S0140-6736(89)92330-1; GLENN J, 1981, REV INFECT DIS, V3, P1151; HO M, 1982, CYTOMEGALOVIRUS BIOL, P171; JACKSON JB, 1988, TRANSFUSION, V28, P187, DOI 10.1046/j.1537-2995.1988.28288179029.x; KAARIAINEN L, 1966, BMJ-BRIT MED J, V1, P1270, DOI 10.1136/bmj.1.5498.1270; KRECH U, 1973, B WORLD HEALTH ORGAN, V49, P103; KREEL I, 1960, SURG GYNECOL OBSTET, V111, P317; KUMAR ML, 1984, J PEDIATR-US, V104, P674, DOI 10.1016/S0022-3476(84)80942-7; KURTZ JB, 1984, Q J MED, V53, P341; LAMBERSON HV, 1988, J INFECT DIS, V157, P820, DOI 10.1093/infdis/157.4.820; LANG DJ, 1977, TRANSFUSION, V17, P391, DOI 10.1046/j.1537-2995.1977.17477216868.x; LUBAN NLC, 1987, AM J DIS CHILD, V141, P416, DOI 10.1001/archpedi.1987.04460040074018; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MEYERS JD, 1983, ANN INTERN MED, V98, P442, DOI 10.7326/0003-4819-98-4-442; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; MEYERS JD, 1985, CURRENT CLIN TOPICS, P261; MURPHY MF, 1986, BRIT J HAEMATOL, V62, P529, DOI 10.1111/j.1365-2141.1986.tb02965.x; MURPHY MF, 1988, BRIT J HAEMATOL, V70, P253, DOI 10.1111/j.1365-2141.1988.tb02473.x; ONORATO IM, 1985, REV INFECT DIS, V7, P479; PREIKSAITIS JK, 1983, J INFECT DIS, V147, P974, DOI 10.1093/infdis/147.6.974; PREIKSAITIS JK, 1985, J MED VIROL, V15, P283, DOI 10.1002/jmv.1890150309; PREIKSAITIS JK, 1988, TRANSFUSION, V28, P205, DOI 10.1046/j.1537-2995.1988.28388219143.x; PRINCE AM, 1971, NEW ENGL J MED, V284, P1125, DOI 10.1056/NEJM197105202842004; RAKELA J, 1987, TRANSPL P, V19, P2399; RAND KH, 1977, NEW ENGL J MED, V296, P1372, DOI 10.1056/NEJM197706162962402; REUSSER P, 1990, BLOOD, V75, P1888; RINGDEN O, 1987, BONE MARROW TRANSPL, V2, P299; RUBIN RH, 1985, TRANSPLANTATION, V40, P243, DOI 10.1097/00007890-198509000-00004; SANTOS GW, 1985, IMMUNOL REV, V88, P169, DOI 10.1111/j.1600-065X.1985.tb01158.x; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; STAGNO S, 1983, SEMIN PERINATOL, V7, P31; TAYLOR BJ, 1986, PEDIATR INFECT DIS J, V5, P188, DOI 10.1097/00006454-198603000-00005; TEGTMEIER GE, 1986, SEMIN LIVER DIS, V6, P82, DOI 10.1055/s-2008-1040796; TEGTMEIER GE, 1986, VOX SANG, V51, P22, DOI 10.1111/j.1423-0410.1986.tb01990.x; TEGTMEIER GE, 1987, TRANSFUSION TRANSMIT, P87; TOLKOFFRUBIN NE, 1978, ANN INTERN MED, V89, P625, DOI 10.7326/0003-4819-89-5-625; VERDONCK LF, 1987, BONE MARROW TRANSPL, V2, P73; WALLINGTON TB, 1987, PROGR TRANSFUSION ME, V2, P26; WILHELM JA, 1986, J INFECT DIS, V154, P169, DOI 10.1093/infdis/154.1.169; WINGARD JR, 1988, BLOOD, V71, P1432; WINSTON DJ, 1982, ANN INTERN MED, V97, P11, DOI 10.7326/0003-4819-97-1-11; YEAGER AS, 1981, J PEDIATR-US, V98, P281, DOI 10.1016/S0022-3476(81)80662-2; YEAGER AS, 1974, AM J DIS CHILD, V128, P478, DOI 10.1001/archpedi.1974.02110290048008; YEAGER AS, 1983, J PEDIATR-US, V102, P918, DOI 10.1016/S0022-3476(83)80025-0; 1989, LANCET, V2, P160	68	84	86	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					55	62		10.7326/0003-4819-116-1-55	http://dx.doi.org/10.7326/0003-4819-116-1-55			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1309201	Bronze			2022-12-28	WOS:A1992GX15700010
J	JONES, EY; DAVIS, SJ; WILLIAMS, AF; HARLOS, K; STUART, DI				JONES, EY; DAVIS, SJ; WILLIAMS, AF; HARLOS, K; STUART, DI			CRYSTAL-STRUCTURE AT 2.8-ANGSTROM RESOLUTION OF A SOLUBLE FORM OF THE CELL-ADHESION MOLECULE CD2	NATURE			English	Article							ERYTHROCYTE RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; ANTIGEN; PROTEIN; BINDING; RECOGNITION; EXPRESSION; FRAGMENT	The crystal structure of a soluble form of the T lymphocyte antigen CD2 provides the first complete view of the extracellular region of a cell adhesion molecule. The topology of the molecule, which comprises two immunoglobulin-like domains, is the same as that of the first two domains of CD4 but the relative domain orientation is altered by a fairly flexible linker region. The putative ligand-binding beta-sheet forms a flat surface towards the top of the molecule. Crystal contacts between these surfaces suggest a plausible model for the adhesive interaction.	UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, MRC, CELLULAR IMMUNOL UNIT, OXFORD OX1 3RE, ENGLAND	University of Oxford	JONES, EY (corresponding author), LAB MOLEC BIOPHYS, REX RICHARDS BLDG, S PARKS RD, OXFORD OX1 3QU, ENGLAND.		Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210				BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CLARK SJ, 1988, J EXP MED, V167, P1861, DOI 10.1084/jem.167.6.1861; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; DAVIS SJ, IN PRESS PROTEIN ENG; DECKERT M, 1991, FASEB J, V5, pA614; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; HARLOS K, 1992, J APPL CRYSTALLOGR, V25, P536, DOI 10.1107/S0021889892002656; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; HUNIG T, 1985, J EXP MED, V162, P890, DOI 10.1084/jem.162.3.890; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES EY, 1991, ACTA CRYSTALLOGR A, V47, P753, DOI 10.1107/S0108767391006839; JONES EY, 1991, ISOMORPHOUS REPLACEM, P39; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; McPherson A, 1982, PREPARATION ANAL PRO; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RECNY MA, 1990, J BIOL CHEM, V265, P8542; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAUL FA, 1978, J BIOL CHEM, V253, P585; SAYRE PH, 1989, J EXP MED, V169, P995, DOI 10.1084/jem.169.3.995; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SPRINGER TA, 1991, NATURE, V353, P704, DOI 10.1038/353704a0; SPRUYT LL, 1991, J EXP MED, V174, P1407, DOI 10.1084/jem.174.6.1407; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STAUNTON DE, 1989, J EXP MED, V169, P1087, DOI 10.1084/jem.169.3.1087; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; YAGITA H, IN PRESS J EXP MED	49	307	315	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1992	360	6401					232	239		10.1038/360232a0	http://dx.doi.org/10.1038/360232a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1279440				2022-12-28	WOS:A1992JY96000042
J	SCHULTE, RJ; CAMPBELL, MA; FISCHER, WH; SEFTON, BM				SCHULTE, RJ; CAMPBELL, MA; FISCHER, WH; SEFTON, BM			TYROSINE PHOSPHORYLATION OF CD22 DURING B-CELL ACTIVATION	SCIENCE			English	Article							ANTIGEN RECEPTOR COMPLEX; LYMPHOCYTES-B; CROSS-LINKING; MEMBRANE IMMUNOGLOBULIN; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; PHOSPHOLIPASE-C; KINASE; PHOSPHOTYROSINE; STIMULATION	Ligation of the antigen receptor on B cells induces the rapid phosphorylation of tyrosine on a number of cellular proteins. A monoclonal antibody that recognized a tyrosine-phosphorylated cell surface protein that was present in activated B cells was generated. Amino acid sequence analysis showed that this 140-kilodalton protein was CD22, a B cell-specific cell surface glycoprotein and putative extracellular ligand of the protein tyrosine phosphatase CD45. Tyrosine phosphorylation of CD22 may be important in B cell signal transduction, possibly through regulation of the adhesiveness of activated B cells.	SALK INST,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92186; SALK INST,PEPTIDE BIOL LAB,SAN DIEGO,CA 92186	Salk Institute; Salk Institute					NATIONAL CANCER INSTITUTE [R01CA017289, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14195, CA17289] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESMARTINEZ JE, 1992, EUR J IMMUNOL, V22, P845, DOI 10.1002/eji.1830220332; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CARTER RH, 1991, J IMMUNOL, V147, P3663; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; COGGESHALL KM, 1984, J IMMUNOL, V133, P3382; DIMINNO G, 1983, BLOOD, V61, P140; DORKEN B, 1986, J IMMUNOL, V136, P4470; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LANE PJL, 1990, J IMMUNOL, V144, P3684; LANE PJL, 1991, J IMMUNOL, V146, P715; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PEZZUTTO A, 1987, J IMMUNOL, V138, P98; PEZZUTTO A, 1987, LEUKOCYTE TYPING, V3, P361; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; SCHULTE RJ, UNPUB; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1992, CELL, V68, P1003, DOI 10.1016/0092-8674(92)90071-J; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEINANDS J, 1990, EMBO J, V9, P449; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	51	139	140	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					1001	1004		10.1126/science.1279802	http://dx.doi.org/10.1126/science.1279802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1279802				2022-12-28	WOS:A1992JW79600037
J	PALABRICA, T; LOBB, R; FURIE, BC; ARONOVITZ, M; BENJAMIN, C; HSU, YM; SAJER, SA; FURIE, B				PALABRICA, T; LOBB, R; FURIE, BC; ARONOVITZ, M; BENJAMIN, C; HSU, YM; SAJER, SA; FURIE, B			LEUKOCYTE ACCUMULATION PROMOTING FIBRIN DEPOSITION IS MEDIATED INVIVO BY P-SELECTIN ON ADHERENT PLATELETS	NATURE			English	Article							GRANULE MEMBRANE-PROTEIN; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; MONOCLONAL-ANTIBODY; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; GMP-140; NEUTROPHILS; RECEPTOR	THE glycoprotein P-selectin is a cell adhesion molecule of stimulated platelets and endothelial cells, which mediates the interaction of these cells with neutrophils and monocytes1,2. It is a membrane component of cell storage granules3-6, and is a member of the selectin family which includes E-selectin and L-selectin7,8. P-selectin recognizes both lineage-specific carbohydrate ligands on monocytes and neutrophils, including the Lewis x antigen, sialic acid, and a protein component9-12. In inflammation and thrombosis, P-selectin may mediate the interaction of leukocytes with platelets bound in the region of tissue injury and with stimulated endothelium1,2. To evaluate the role of P-selectin in platelet-leukocyte adhesion in vivo, the accumulation of leukocytes within an experimental thrombus was explored in an arteriovenous shunt model in baboons13. A Dacron graft implanted within an arteriovenous shunt is thrombogenic, accumulating platelets and fibrin within its lumen. These bound platelets express P-selectin14. Here we show that antibody inhibition of leukocyte binding to P-selectin expressed on platelets immobilized on the graft blocks leukocyte accumulation and inhibits the deposition of fibrin within the thrombus. These results indicate that P-selectin is an important adhesion molecule on platelets, mediating platelet-leukocyte binding in vivo, that the presence of leukocytes in thrombi is mediated by P-selectin, and that these leukocytes promote fibrin deposition.	NEW ENGLAND MED CTR,DIV CARDIOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; BIOGEN INC,CAMBRIDGE,MA 02142; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Biogen; Tufts University	PALABRICA, T (corresponding author), NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111, USA.							BAUMAN J M, 1986, Journal of Nuclear Medicine Technology, V14, P15; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; KUDRYK B, 1984, MOL IMMUNOL, V21, P89, DOI 10.1016/0161-5890(84)90093-2; LAMOYI E, 1986, METHOD ENZYMOL, V121, P652; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LERNER EA, 1981, YALE J BIOL MED, V54, P377; LOBB RR, 1991, J IMMUNOL, V147, P124; MACKEY WC, 1984, J SURG RES, V37, P112, DOI 10.1016/0022-4804(84)90170-7; MCAFEE JG, 1976, J NUCL MED, V17, P408; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; NIEMETZ J, 1972, J CLIN INVEST, V51, P307, DOI 10.1172/JCI106815; PALABRICA TM, 1989, P NATL ACAD SCI USA, V86, P1036, DOI 10.1073/pnas.86.3.1036; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; ROSEBROUGH SF, 1988, J NUCL MED, V29, P1212; SAUVAGE LR, 1976, HEALING ARTERIAL PRO; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; THAKAU ML, 1977, J NUCL MED, V518, P1022; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	26	702	736	2	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					848	851		10.1038/359848a0	http://dx.doi.org/10.1038/359848a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279433				2022-12-28	WOS:A1992JV77700070
J	DRUMMOND, IA; MADDEN, SL; ROHWERNUTTER, P; BELL, GI; SUKHATME, VP; RAUSCHER, FJ				DRUMMOND, IA; MADDEN, SL; ROHWERNUTTER, P; BELL, GI; SUKHATME, VP; RAUSCHER, FJ			REPRESSION OF THE INSULIN-LIKE GROWTH FACTOR-II GENE BY THE WILMS-TUMOR SUPPRESSOR WT1	SCIENCE			English	Article							FETAL KIDNEY; EGR FAMILY; EXPRESSION; TRANSCRIPTION; PROMOTER; PRODUCT; IDENTIFICATION; DELETION; SEQUENCE; CANCER	The Wilms tumor suppressor gene wt1 encodes a zinc finger DNA binding protein, WT1, that functions as a transcriptional repressor. The fetal mitogen insulin-like growth factor II (IGF-II) is overexpressed in Wilms tumors and may have autocrine effects in tumor progression. The major fetal IGF-II promoter was defined in transient transfection assays as a region spanning from nucleotides -295 to +135, relative to the transcription start site. WT1 bound to multiple sites in this region and functioned as a potent repressor of IGF-II transcription in vivo. Maximal repression was dependent on the presence of WT1 binding sites on each side of the transcriptional initiation site. These findings provide a molecular basis for overexpression of IGF-II in Wilms tumors and suggest that WT1 negatively regulates blastemal cell proliferation by limiting the production of a fetal growth factor in the developing vertebrate kidney.	UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; WISTAR INST, PHILADELPHIA, PA 19104 USA; UNIV CHICAGO, DEPT BIOCHEM, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC BIOL & MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC GENET, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; The Wistar Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago			Sukhatme, Vikas/W-2776-2019		NCI NIH HHS [CA 52009, CA 10817, CA 47983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047983, P01CA052009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRUMMOND IT, UNPUB; GANSLER T, 1988, AM J PATHOL, V130, P431; GANSLER T, 1989, AM J PATHOL, V135, P961; GARVIN AJ, 1987, AM J PATHOL, V129, P353; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAY A, 1987, DNA-J MOLEC CELL BIO, V6, P283, DOI 10.1089/dna.1987.6.283; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRVONEN H, 1989, J CELL BIOL, V108, P1093, DOI 10.1083/jcb.108.3.1093; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; PAIK S, 1989, LAB INVEST, V61, P522; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; Sambrook J, 1989, MOL CLONING LABORATO; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6	37	524	537	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1992	257	5070					674	678		10.1126/science.1323141	http://dx.doi.org/10.1126/science.1323141			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1323141				2022-12-28	WOS:A1992JF85200038
J	HIRSCHOWITZ, L; RAFFLE, AE; MACKENZIE, EFD; HUGHES, AO				HIRSCHOWITZ, L; RAFFLE, AE; MACKENZIE, EFD; HUGHES, AO			LONG-TERM FOLLOW-UP OF WOMEN WITH BORDERLINE CERVICAL SMEAR TEST-RESULTS - EFFECTS OF AGE AND VIRAL-INFECTION ON PROGRESSION TO HIGH-GRADE DYSKARYOSIS	BRITISH MEDICAL JOURNAL			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; GYNECOLOGICAL CYTO-PATHOLOGY; CANCER; TERMINOLOGY; COLPOSCOPY; MANAGEMENT; ATYPIA; RISK	Objective - To follow up and assess the significance of borderline change in cervical smears. Design - Retrospective study of women undergoing routine cervical cytological screening in 1981. Setting - Avon Cervical Screening Programme, covering 250 000 women in Bristol and Weston super Mare. Subjects - 437 women showing borderline cervical changes in 1981 and 437 age matched controls with normal results in 1981. Main outcome measures - Cytological progression to high grade dyskaryosis (cervical intraepithelial neoplasia grade III or invasive carcinoma). Results - During follow up ranging from 13 to 106 months 98 of the 437 women (22.4%) with borderline cytological changes on routine cervical cytology screening had a subsequent smear test showing high grade dyskaryosis compared with three of the 437 women (0.9%) in the control group. The risk of progression was greater in women aged 20 to 39 than in those aged 40 and over. Human papillomavirus infection had initially been diagnosed cytologically in 101 of the 437 (23%) women with borderline results. Significantly fewer of these women developed high grade dyskaryosis (13/98 (13%) v 88/339 (26%), p < 0.05). Conclusions - Women with borderline smear test results are at increased risk of developing high grade dyskaryosis, particularly if the borderline changes occur without cytological features of human papillomavirus infection. Progression occurs within three years in 50% of cases, although a linearly increasing risk was sustained over the nine years of follow up and was greatest in women aged 20 to 39. Careful follow up of these women is indicated.	BRISTOL ROYAL INFIRM & GEN HOSP,DEPT HISTOPATHOL,BRISTOL BS2 8HW,AVON,ENGLAND; SOUTHMEAD GEN HOSP,DEPT PUBL HLTH MED,BRISTOL BS10 5NB,AVON,ENGLAND; SOUTHMEAD GEN HOSP,DEPT CYTOL,BRISTOL BS10 5NB,AVON,ENGLAND; BRISTOL MED SCH,DEPT EPIDEMIOL,BRISTOL B58 2PR,ENGLAND	Bristol Royal Infirmary; Southmead Hospital; Southmead Hospital; University of Bristol								CAMPION MJ, 1986, LANCET, V2, P237; DAVIS RM, 1972, OBSTET GYNECOL, V40, P23; EVANS DMD, 1987, J CLIN PATHOL, V40, P530, DOI 10.1136/jcp.40.5.530; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; GILES JA, 1989, BRIT J OBSTET GYNAEC, V96, P1967; HULKA BS, 1968, AM J OBSTET GYNECOL, V101, P190, DOI 10.1016/0002-9378(68)90187-7; JENKINS D, 1987, LANCET, V1, P748; KINLEN LJ, 1978, LANCET, V2, P463; KIRKUP W, 1982, BRIT J OBSTET GYNAEC, V89, P571, DOI 10.1111/j.1471-0528.1982.tb03662.x; KITCHENER HC, 1988, BRIT J OBSTET GYNAEC, V95, P182, DOI 10.1111/j.1471-0528.1988.tb06849.x; KITCHENER HC, 1988, BRIT J OBSTET GYNAEC, V95, P1089, DOI 10.1111/j.1471-0528.1988.tb06783.x; KRISTENSEN GB, 1991, ACTA CYTOL, V35, P47; MITCHELL H, 1986, LANCET, V1, P573; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NUOVO GJ, 1988, AM J SURG PATHOL, V12, P198, DOI 10.1097/00000478-198803000-00005; NYIRJESY I, 1972, J AMER MED ASSOC, V222, P691; PAIRWUTI S, 1991, ACTA CYTOL, V35, P40; RAFFLE AE, 1990, BMJ-BRIT MED J, V301, P907, DOI 10.1136/bmj.301.6757.907; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SINGER A, 1991, BRIT MED J, V302, P251, DOI 10.1136/bmj.302.6771.251; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; TIDY JA, 1989, LANCET, V1, P434; 1989, LANCET, V2, P1051	24	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1209	1212		10.1136/bmj.304.6836.1209	http://dx.doi.org/10.1136/bmj.304.6836.1209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1325232	Bronze, Green Published			2022-12-28	WOS:A1992HT96400018
J	HOLICK, MF; SHAO, Q; LIU, WW; CHEN, TC				HOLICK, MF; SHAO, Q; LIU, WW; CHEN, TC			THE VITAMIN-D CONTENT OF FORTIFIED MILK AND INFANT FORMULA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The fortification of milk and infant formula with vitamin D has had an important role in eliminating rickets in children and osteomalacia in adults. A recent outbreak of vitamin D intoxication caused by drinking milk fortified with excess vitamin D has led to questions about the level of vitamin D in milk from other producers. Methods. We used high-performance liquid chromatography to measure vitamin D in samples of 13 brands of milk with various fat contents and 5 brands of infant formula purchased at random from local supermarkets in five Eastern states. Results. Only 12 (29 percent) of the 42 samples of the 13 brands of milk and none of the 10 samples of the 5 brands of infant formula contained 80 to 120 percent of the amount of vitamin D stated on the label. Twenty-six of the 42 milk samples (62 percent) contained less than 80 percent of the amount claimed on the label. No vitamin D was detected in 3 of the 14 samples of skim milk tested (lower limit of assay, 4.7 IU per quart [5.0 IU per liter]). One milk sample labeled as containing vitamin D2 (ergocalciferol) contained vitamin D3 (cholecalciferol). Seven of the 10 samples of infant formula contained more than 200 percent of the amount stated on the label; the sample with the highest concentration contained 419 percent of the stated amount. None of the samples of infant formula contained less than the amount stated. Conclusions. Milk and infant-formula preparations rarely contain the amount of vitamin D stated on the label and may be either underfortified or overfortified. Since both underfortification and overfortification are hazardous, better monitoring of the fortification process is needed.	BOSTON UNIV,SCH MED,VITAMIN D SKIN & BONE RES LAB,BOSTON,MA 02118	Boston University	HOLICK, MF (corresponding author), BOSTON CITY HOSP,80 E CONCORD ST,M-1013,BOSTON,MA 02118, USA.			Holick, Michael/0000-0001-6023-9062; Chen, Tai/0000-0002-5704-5694	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004390] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36963] Funding Source: Medline; NIA NIH HHS [AG-04390] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHEN TC, 1990, J NUTR BIOCHEM, V1, P272, DOI 10.1016/0955-2863(90)90078-Y; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; Hess AF, 1921, J AMER MED ASSOC, V77, P39; Hess AF, 1924, J BIOL CHEM, V62, P301; Holick M. F., 1990, BONE MINERAL RES ANN, P313; HOLICK MF, 1990, J NUTR, V120, P1464, DOI 10.1093/jn/120.suppl_11.1464; HOLICK MF, 1989, LANCET, V2, P1104; HOLLIS BW, 1983, ANAL BIOCHEM, V131, P211, DOI 10.1016/0003-2697(83)90157-4; Huldschinsky K, 1919, DEUT MED WOCHENSCHR, V45, P712, DOI 10.1055/s-0028-1137830; JACOBUS CH, 1992, NEW ENGL J MED, V326, P1173, DOI 10.1056/NEJM199204303261801; Jeans PC, 1938, J PEDIATR-US, V13, P730, DOI 10.1016/S0022-3476(38)80162-1; KAVOOKJIAN H, 1990, ORTHOPED T, V14, P580; REYNODS SL, 1984, ANALYST, V19, P489; SHELDON W, 1943, ARCH DIS CHILD, V18, P58; SOKOLOFF L, 1978, AM J SURG PATHOL, V2, P21, DOI 10.1097/00000478-197803000-00003; STEENBOCK H, 1924, J BIOL CHEM, V61, P45; TANNER JT, 1988, J ASSOC OFF ANA CHEM, V71, P607; [No title captured]	18	147	149	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1178	1181		10.1056/NEJM199204303261802	http://dx.doi.org/10.1056/NEJM199204303261802			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1313548	Bronze			2022-12-28	WOS:A1992HR00800002
J	DANIELS, N				DANIELS, N			HIV-INFECTED PROFESSIONALS, PATIENT RIGHTS, AND THE SWITCHING DILEMMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The ethical issues surrounding the Centers for Disease Control and American Medical Association guidelines for health professionals infected with the human immunodeficiency virus are examined and discussed. Although human immunodeficiency virus transmission risks during surgery are lower than many risks we routinely face, it is not irrational for a patient to want to switch from an infected professional to an uninfected one. The American Medical Association claim that physicians have a duty to avoid imposing any identifiable risks is implausible. Knowing the Centers for Disease Control estimate of risks gives us no way to decide whether the rights of patients or those of handicapped (infected) workers should be given priority. Granting priority to patient rights, either by giving patients the opportunity to know the risks they face and to switch to another provider, or by removing infected providers (compulsory switching), makes us all worse off. This gives us reason to reject these guidelines and emphasize other infection control measures.			DANIELS, N (corresponding author), TUFTS UNIV,DEPT PHILOSOPHY,MEDFORD,MA 02168, USA.				NATIONAL LIBRARY OF MEDICINE [R01LM005005] Funding Source: NIH RePORTER; NLM NIH HHS [1 R01LM05005] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Barnes M, 1990, Law Med Health Care, V18, P311; GROSS J, 1991, NY TIMES        0818, V140, P1; LANDESMAN SH, 1991, ARCH INTERN MED, V151, P655, DOI 10.1001/archinte.151.4.655; LEARY W, 1975, NY TIMES        1215, V140, P38; LOWENFELS AB, 1991, NEW ENGL J MED, V325, P888, DOI 10.1056/NEJM199109193251212; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; Parmet W E, 1990, Law Med Health Care, V18, P331; Taylor M., 1987, POSSIBILITY COOPERAT; WILSON R, 1979, TECHNOL REV, V81, P41; WOLFF C, 1991, NY TIMES        0727, V140, pA1; WOLFF C, 1991, NY TIMES        0729, V140, pB1; 1990, PUB L, V101, P104; 1991, MMWR, V40, P1; 1991, ESTIMATES RISK ENDEM; 1991, UNPUB RECOMMENDATION; 1991, AMA STATEMENT HIV IN	16	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1368	1371		10.1001/jama.267.10.1368	http://dx.doi.org/10.1001/jama.267.10.1368			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1311045				2022-12-28	WOS:A1992HG67800031
J	LO, B; STEINBROOK, R				LO, B; STEINBROOK, R			HEALTH-CARE WORKERS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS - THE NEXT STEPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS; RISK; UNCERTAINTY; PERCEPTION; PREVENTION	The tragedy of five patients who contracted human immunodeficiency virus (HIV) infection from a seropositive dentist has alarmed the public. The Centers for Disease Control (CDC) recently revised its recommendations for preventing the transmission of HIV infection to patients during invasive procedures. The CDC abandoned a previous plan to list exposure-prone invasive procedures that HIV-infected health care workers should not perform. The CDC said "expert review panels" should decide on a case-by-case basis whether seropositive health care workers may perform invasive procedures. As of February 1992, the revised recommendations were under review by the US Department of Health and Human Services. Many issues remain to be clarified, such as how these panels will operate and whether decisions will be consistent in similar cases. Disregarding the CDC guidelines or infection-control precautions may further erode public trust and lead to draconian restrictions on HIV-infected health care workers. Physicians and dentists should respond more effectively to public fears about HIV transmission. The challenge is to protect patients while respecting the privacy and livelihood of health care workers.	UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459-06] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; ANNAS GJ, 1990, AM HLTH LAW, P437; AOUN H, 1989, NEW ENGL J MED, V321, P693, DOI 10.1056/NEJM198909073211020; APPELBAUM P, 1987, INFORMED CONSENT LEG; Barnes M, 1990, Law Med Health Care, V18, P311; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; BENENSON AS, 1989, JAMA-J AM MED ASSOC, V262, P3435; Bobbitt P., 1978, TRAGIC CHOICES; BRENNAN TA, 1987, ANN INTERN MED, V107, P581, DOI 10.7326/0003-4819-107-4-581; BRENNAN TA, 1991, NEW ENGL J MED, V324, P1504, DOI 10.1056/NEJM199105233242112; CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; CLARKE OW, 1991, JAMA-J AM MED ASSOC, V266, P2876, DOI 10.1001/jama.266.20.2876; COLOMBOTOS J, 1991, 910024 AG HLTH CAR P; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; FOX DM, 1988, HASTINGS CENT REP, V18, P5; FRADZEL S, 1991, AIDS PATIENT CARE, V5, P129; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; Gostin L, 1990, Law Med Health Care, V18, P303; GUTHEIL TG, 1984, NEW ENGL J MED, V311, P49, DOI 10.1056/NEJM198407053110110; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; LO B, 1989, ANN INTERN MED, V110, P727; MANDELBROT DA, 1990, SURG GYNECOL OBSTET, V171, P99; MANGIONE CM, 1991, AM J MED, V90, P85, DOI 10.1016/0002-9343(91)90510-5; MISHKIN B, 1988, JAMA-J AM MED ASSOC, V260, P1932; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; NELKIN D, 1989, ANNU REV PUBL HEALTH, V10, P95, DOI 10.1146/annurev.pu.10.050189.000523; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P1134, DOI 10.1001/jama.266.8.1134; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; QUILL TE, 1989, ANN INTERN MED, V111, P51, DOI 10.7326/0003-4819-111-1-51; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; WRIGHT JG, 1991, JAMA-J AM MED ASSOC, V266, P1668, DOI 10.1001/jama.266.12.1668; 1991, NY TIMES        0818, pA1; 1987, AIDS ALERT, V2, P153; 1991, NY TIMES        0622, pA5; 1991, NY TIMES        0402, pA1; 1991, NY TIMES        0415, pA8; 1987, AM MED NEWS     1002, P1; 1991, HLTH WEEK       1118, P1; 1991, MMWR, V40, P1; 1991, NY TIMES        1204, pA1; 1991, NY TIMES        0209, pA1; 1991, NY TIMES        0802, pB1; 1991, MICHIGAN RECOMMENDAT; 1989, IMPROVING RISK COMMU, P14; 1991, LOS ANGELES TIM 0826, pA1; 1990, NY TIMES        1208, pA1; 1991, WASHINGTON POST 0816, pC1; 1991, P HOUSE DELEGATES AM, P140; 1989, IMPROVING RISK COMMU, P30; 1991, C RECORD, V137; 1991, NY TIMES        0730, pB6; 1991, NEWSWEEK        0701, P48; 1987, NY TIMES        0711, pA1; 1991, NY TIMES        0820, pB5; 1991, 1991 STUDENT AFFAIRS; 1989, IMPROVING RISK COMMU, P94; 1991, ANN EMERG MED, V20, P1036; 1991, NY TIMES        0830, pA1; 1991, MMWR, V40, P21	61	34	34	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1100	1105		10.1001/jama.267.8.1100	http://dx.doi.org/10.1001/jama.267.8.1100			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HE391	1310512				2022-12-28	WOS:A1992HE39100026
J	NICHOLAS, J; CAMERON, KR; HONESS, RW				NICHOLAS, J; CAMERON, KR; HONESS, RW			HERPESVIRUS SAIMIRI ENCODES HOMOLOGS OF G-PROTEIN-COUPLED RECEPTORS AND CYCLINS	NATURE			English	Article							EPSTEIN-BARR VIRUS; CELL-CYCLE; SEQUENCE-ANALYSIS; BOVINE RHODOPSIN; GENE; EXPRESSION; TRANSFORMATION; GENOME; KINASE	HERPESVIRUS saimiri (HVS) is a T-lymphotropic gammaherpesvirus which establishes asymptomatic infections in its natural host the squirrel monkey (Saimiri sciureus), but which causes fatal lymphoproliferative diseases in other New World primates 1. Sequencing studies show HVS is closely related to the human B-lymphotropic gammaherpesvirus Epstein-Barr virus (EBV) 2-4. However, despite the general collinearity between the genomes of HVS and EBV, HVS contains genes not found in EBV or in the genomes of any of the other sequenced herpesviruses 5-8. We have identified two genes, occurring in a region of divergence between HVS and EBV, that have cellular homologues. One of these, ECRF3, is homologous to the genes encoding the human cytomegalovirus (HCMV) and cellular G protein-coupled receptor family of proteins 9. The other HVS gene, ECLF2, is homologous to the genes encoding cellular cyclins and to our knowledge is the first reported example of a viral cyclin. The presence of G protein-coupled receptor and cyclin homologues in HVS suggests that these genes may be important in the regulation of viral and cellular processes during productive and/or latent infection of host cells, and in particular may be of relevance in the transformation and rapid proliferation of T cells during HVS infections of hosts susceptible to HVS-induced lymphoproliferative diseases.			NICHOLAS, J (corresponding author), NATL INST MED RES, DIV VIROL, MILL HILL, LONDON NW7 1AA, ENGLAND.							BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANKIER AT, 1983, TECHNIQUES LIFE SCI, P1; CAMERON KR, 1987, J VIROL, V61, P2063, DOI 10.1128/JVI.61.7.2063-2070.1987; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P253; FLIESLER SJ, 1985, P NATL ACAD SCI USA, V82, P1116, DOI 10.1073/pnas.82.4.1116; GOMPELS UA, 1988, J VIROL, V62, P757, DOI 10.1128/JVI.62.3.757-767.1988; HONESS RW, 1986, P NATL ACAD SCI USA, V83, P3604, DOI 10.1073/pnas.83.11.3604; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NICHOLAS J, 1991, J VIROL, V65, P2457, DOI 10.1128/JVI.65.5.2457-2466.1991; NICHOLAS J, 1990, VIROLOGY, V179, P189, DOI 10.1016/0042-6822(90)90288-3; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TRIMBLE JJ, 1988, SCIENCE, V239, P1145, DOI 10.1126/science.2830673; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	36	164	172	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1992	355	6358					362	365		10.1038/355362a0	http://dx.doi.org/10.1038/355362a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1309943				2022-12-28	WOS:A1992HA59100072
J	MERRILL, JM				MERRILL, JM			ESTROGEN REPLACEMENT THERAPY AFTER BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RISK				MERRILL, JM (corresponding author), NORTHWESTERN UNIV,CTR CANC,CHICAGO,IL 60611, USA.							BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; CARBONE PP, 1989, JAMA-J AM MED ASSOC, V261, P3616; ESKIN BA, 1991, JAMA-J AM MED ASSOC, V266, P1146; HAYES DF, 1990, JAMA-J AM MED ASSOC, V263, P1145; HULKA BS, 1990, CA-CANCER J CLIN, V40, P289, DOI 10.3322/canjclin.40.5.289; KELSEY JL, 1988, CANCER RES, V48, P5616	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					568	568						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1309584				2022-12-28	WOS:A1992GZ43900037
J	POSADA, J; COOPER, JA				POSADA, J; COOPER, JA			REQUIREMENTS FOR PHOSPHORYLATION OF MAP KINASE DURING MEIOSIS IN XENOPUS OOCYTES	SCIENCE			English	Article							NERVE GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; STIMULATED PROTEIN; PHOSPHOTYROSYL PROTEIN; PC12 CELLS; TYROSINE; ACTIVATION; IDENTIFICATION; PURIFICATION; PHOSPHATASES	Mitogen-activated protein (MAP) kinases are activated in response to a variety of extracellular stimuli by phosphorylation on tyrosine and threonine residues. Xp42 is a Xenopus laevis MAP kinase that is activated during oocyte maturation. Modified forms of Xp42 that lacked enzymatic activity or either of the phosphorylation sites were expressed in Xenopus oocytes. When meiotic maturation was induced with progesterone, each mutant Xp42 was phosphorylated, indicating that at least one kinase was activated that can phosphorylate Xp42 on tyrosine and threonine. Phosphorylation of one residue is not strictly dependent on phosphorylation of the other.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center				Posada, James/0000-0003-3582-9612	NATIONAL CANCER INSTITUTE [F32CA008860, P01CA028151] Funding Source: NIH RePORTER; NCI NIH HHS [CA-28151, CA-08860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, UNPUB; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STRATTON KR, 1991, J NEUROCHEM, V56, P147, DOI 10.1111/j.1471-4159.1991.tb02574.x; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSAO H, 1990, J BIOL CHEM, V265, P15471; TUNG HYL, 1984, EUR J BIOCHEM, V145, P57, DOI 10.1111/j.1432-1033.1984.tb08521.x; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	45	290	297	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1992	255	5041					212	215		10.1126/science.1313186	http://dx.doi.org/10.1126/science.1313186			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY704	1313186				2022-12-28	WOS:A1992GY70400041
J	KIMMANCE, KJ; WATERS, WE				KIMMANCE, KJ; WATERS, WE			INFANT-MORTALITY AND ARMY FAMILIES - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article									SALISBURY HLTH AUTHOR,SALISBURY,ENGLAND; UNIV SOUTHAMPTON,DEPT COMMUNITY MED,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	University of Southampton								ATALLA MA, 1986, J R ARMY MED CORPS, V132, P173; FEDRICK J, 1974, BRIT J PREV SOC MED, V28, P93; Fleiss JL, 1981, STAT METHODS RATES P; Powell J, 1983, J R Nav Med Serv, V69, P141; RAO M, 1988, BRIT MED J, V297, P662, DOI 10.1136/bmj.297.6649.662	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1197	1197		10.1136/bmj.305.6863.1197	http://dx.doi.org/10.1136/bmj.305.6863.1197			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1302478	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JY77700022
J	MOMBURG, F; ORTIZNAVARRETE, V; NEEFJES, J; GOULMY, E; VANDEWAL, Y; SPITS, H; POWIS, SJ; BUTCHER, GW; HOWARD, JC; WALDEN, P; HAMMERLING, GJ				MOMBURG, F; ORTIZNAVARRETE, V; NEEFJES, J; GOULMY, E; VANDEWAL, Y; SPITS, H; POWIS, SJ; BUTCHER, GW; HOWARD, JC; WALDEN, P; HAMMERLING, GJ			PROTEASOME SUBUNITS ENCODED BY THE MAJOR HISTOCOMPATIBILITY COMPLEX ARE NOT ESSENTIAL FOR ANTIGEN PRESENTATION	NATURE			English	Article							CLASS-II REGION; MULTICATALYTIC PROTEINASE; LINKED LMP; HUMAN MHC; GENE; MOLECULES; ANTIBODY; TRANSPORTERS; INVITRO	MAJOR histocompatibility complex (MHC) class I molecules bind and deliver peptides derived from endogenously synthesized proteins to the cell surface for survey by cytotoxic T lymphocytes. It is believed that endogenous antigens are generally degraded in the cytosol, the resulting peptides being translocated into the endoplasmic reticulum where they bind to MHC class I molecules. Transporters containing an ATP-binding cassette encoded by the MHC class II region seem to be responsible for this transport1-8. Genes coding for two subunits of the '20S' proteasome (a multicatalytic proteinase) have been found in the vicinity of the two transporter genes in the MHC class II region, indicating that the proteasome could be the unknown proteolytic entity in the cytosol involved in the generation of MHC class I-binding peptides9-13. By introducing rat genes encoding the MHC-linked transporters into a human cell line lacking both transporter and proteasome subunit genes, we show here that the MHC-encoded proteasome subunits are not essential for stable MHC class I surface expression, or for processing and presentation of antigenic peptides from influenza virus and an intracellular protein.	UNIV HOSP LEIDEN,DEPT IMMUNOHAEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV HOSP LEIDEN,BLOOD BANK,2300 RC LEIDEN,NETHERLANDS; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; AFRC,INST ANIM PHYSIOL & GENET RES,DEPT IMMUNOL,CAMBRIDGE CB2 4AT,ENGLAND; MAX PLANCK INST BIOL,W-7400 TUBINGEN,GERMANY	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Max Planck Society	MOMBURG, F (corresponding author), GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.		Neefjes, Jacques J.C./H-8780-2017; Ortiz-Navarrete, Vianney/H-1932-2016	Neefjes, Jacques J.C./0000-0001-6763-2211; Powis, Simon/0000-0003-4218-2984; Howard, Jonathan/0000-0003-2756-5143; Ortiz-Navarrete, Vianney/0000-0001-6546-9713				ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HORAI S, 1992, IMMUNOGENETICS, V16, P135; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MULLER C, 1983, HUM IMMUNOL, V6, P189, DOI 10.1016/0198-8859(83)90092-7; MULLER C, 1985, HUM IMMUNOL, V14, P333, DOI 10.1016/0198-8859(85)90241-1; MULLER C, 1981, HUM IMMUNOL, V5, P269; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0	32	267	274	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					174	177		10.1038/360174a0	http://dx.doi.org/10.1038/360174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1299222	Green Submitted			2022-12-28	WOS:A1992JX75200065
J	BOOKER, GW; BREEZE, AL; DOWNING, AK; PANAYOTOU, G; GOUT, I; WATERFIELD, MD; CAMPBELL, ID				BOOKER, GW; BREEZE, AL; DOWNING, AK; PANAYOTOU, G; GOUT, I; WATERFIELD, MD; CAMPBELL, ID			STRUCTURE OF AN SH2 DOMAIN OF THE P85-ALPHA SUBUNIT OF PHOSPHATIDYLINOSITOL-3-OH KINASE	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL STRUCTURES; SIGNAL TRANSDUCTION; PROTEIN STRUCTURES; DISTANCE DATA; PROGRAM; CONFORMATIONS; DYNAMICS	RECEPTOR protein-tyrosine kinases, through phosphorylation of specific tyrosine residues, generate high-affinity binding sites which direct assembly of multienzyme signalling complexes1,2. Many of these signalling proteins, including phospholipase C-gamma, GTPase-activating protein and phosphatidylinositol-3-OH kinase, contain src-homology 2 (SH2) domains, which bind with high affinity and specificity to tyrosine-phosphorylated sequences3,4. The critical role played by SH2 domains in signalling has been highlighted by recent studies showing that mutation of specific phosphorylation sites on the platelet-derived growth factor receptor impair its association with phosphatidylinositol-3-OH kinase, preventing growth factor-induced mitogenesis5,6. Here we report the solution structure of an isolated SH2 domain from the 85K regulatory subunit of phosphatidylinositol-3-OH kinase, determined using multidimensional nuclear magnetic resonance spectroscopy. The structure is characterized by a central region of beta-sheet flanked by two alpha-helices, with a highly flexible loop close to functionally important residues previously identified by site-directed mutagenesis7,8.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; ICI PLC,PHARMACEUT,PROT STRUCT FUNCT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	University of Oxford; Ludwig Institute for Cancer Research				Breeze, Alexander/0000-0001-9723-3350				BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1987, PROTEIN ENG, V1, P399, DOI 10.1093/protein/1.5.399; BRUNGER AT, 1988, XPLOR MANUAL; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DOWNING AK, 1992, J MOL BIOL, V225, P821, DOI 10.1016/0022-2836(92)90403-7; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HILES I, IN PRESS CELL; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Maniatis T., 1982, MOL CLONING; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; WUTHRICH K, 1991, FEBS LETT, V285, P327	28	169	171	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					684	687		10.1038/358684a0	http://dx.doi.org/10.1038/358684a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1323062				2022-12-28	WOS:A1992JJ88200059
J	KELLERMANN, AL; RIVARA, FP; SOMES, G; REAY, DT; FRANCISCO, J; BANTON, JG; PRODZINSKI, J; FLIGNER, C; HACKMAN, BB				KELLERMANN, AL; RIVARA, FP; SOMES, G; REAY, DT; FRANCISCO, J; BANTON, JG; PRODZINSKI, J; FLIGNER, C; HACKMAN, BB			SUICIDE IN THE HOME IN RELATION TO GUN OWNERSHIP	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADOLESCENT SUICIDE; PREVENTION PROGRAMS; FIREARM REGULATIONS; LEGISLATION; CONSUMPTION; HANDGUNS; SMOKING; RATES	Background. It has been suggested that limiting access to firearms could prevent many suicides, but this belief is controversial. To assess the strength of the association between the availability of firearms and suicide, we studied all suicides that took place in the homes of victims in Shelby County, Tennessee, and King County, Washington, over a 32-month period. Methods. For each suicide victim (case subject), we obtained data from police or the medical examiner and interviewed a proxy. Their answers were compared with those of control subjects from the same neighborhood, matched with the victim according to sex, race, and age range. Crude and adjusted odds ratios were calculated with matched-pairs methods. Results. During the study period, 803 suicides occurred in the two counties, 565 of which (70 percent) took place in the home of the victim. Fifty-eight percent (326) of these suicides were committed with a firearm. After excluding 11 case subjects for various reasons, we were able to interview 80 percent (442) of the proxies for the case subjects. Matching controls were identified for 99 percent of these subjects, producing 438 matched pairs. Univariate analyses revealed that the case subjects were more likely than the controls to have lived alone, taken prescribed psychotropic medication, been arrested, abused drugs or alcohol, or not graduated from high school. After we controlled for these characteristics through conditional logistic regression, the presence of one or more guns in the home was found to be associated with an increased risk of suicide (adjusted odds ratio, 4.8; 95 percent confidence interval, 2.7 to 8.5). Conclusions. Ready availability of firearms is associated with an increased risk of suicide in the home. Owners of firearms should weigh their reasons for keeping a gun in the home against the possibility that it might someday be used in a suicide.	HARBORVIEW INJURY PREVENT & RES CTR,SEATTLE,WA; UNIV TENNESSEE CTR HLTH SCI,DEPT MED,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT PREVENT MED,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT PATHOL,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT BIOSTAT & EPIDEMIOL,MEMPHIS,TN 38163; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					PHS HHS [CCR402424] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BLACKMAN PH, 1990, NEW ENGL J MED, V323, P136; BLACKMAN PH, 1990, CRIMINOLOGYS ASTROLO; BOYD JH, 1983, NEW ENGL J MED, V308, P872, DOI 10.1056/NEJM198304143081504; BRENT DA, 1988, ARCH GEN PSYCHIAT, V45, P581, DOI 10.1001/archpsyc.1988.01800300079011; BRENT DA, 1991, JAMA-J AM MED ASSOC, V266, P2989, DOI 10.1001/jama.266.21.2989; Cook PJ., 1979, POLICY STUDIES REV A, V3, P743; EDDY DM, 1987, MED CARE, V25, pS57, DOI 10.1097/00005650-198712001-00003; EILERS R, 1992, NEW ENGL J MED, V326, P1158; FORD AB, 1979, AM J PUBLIC HEALTH, V69, P459, DOI 10.2105/AJPH.69.5.459; GARLAND A, 1989, J AM ACAD CHILD PSY, V28, P931, DOI 10.1097/00004583-198911000-00019; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KELLERMANN AL, 1990, AM J EPIDEMIOL, V131, P1080, DOI 10.1093/oxfordjournals.aje.a115600; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; MACK TM, 1986, JNCI-J NATL CANCER I, V76, P49; MARKUSH RE, 1984, AM J PUBLIC HEALTH, V74, P123, DOI 10.2105/AJPH.74.2.123; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; RICH CL, 1990, AM J PSYCHIAT, V147, P342; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P124; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SHAFFER D, 1990, JAMA-J AM MED ASSOC, V264, P3151, DOI 10.1001/jama.264.24.3151; SLOAN JH, 1990, NEW ENGL J MED, V322, P369, DOI 10.1056/NEJM199002083220605; WESTERMEYER J, 1984, AM J PUBLIC HEALTH, V74, P108, DOI 10.2105/AJPH.74.2.108; WRIGHT J, 1981, WEAPONS CRIME VIOLEN, P145; YU MC, 1983, CANCER RES, V43, P6077; 1988, MMWR MORB MORTAL SS6, V37; 1989, AM J PREV MED S, V5, P252; 1978, ATTITUDES AM ELECTOR; 1991, MED LETT DRUGS THER, V33, P43; 1990, MONTHLY VITAL STAT S, V39; 1958, SOCIAL CLASS MENTAL, P387; 1983, 1980 CENSUS POPULATI, V1; 1985, SUICIDE SURVEILLANCE	35	581	584	4	56	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					467	472		10.1056/NEJM199208133270705	http://dx.doi.org/10.1056/NEJM199208133270705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JH340	1308093				2022-12-28	WOS:A1992JH34000005
J	LENSCHOW, DJ; ZENG, YJ; THISTLETHWAITE, JR; MONTAG, A; BRADY, W; GIBSON, MG; LINSLEY, PS; BLUESTONE, JA				LENSCHOW, DJ; ZENG, YJ; THISTLETHWAITE, JR; MONTAG, A; BRADY, W; GIBSON, MG; LINSLEY, PS; BLUESTONE, JA			LONG-TERM SURVIVAL OF XENOGENEIC PANCREATIC-ISLET GRAFTS INDUCED BY CTLA4IG	SCIENCE			English	Article							ANTIGEN-PRESENTING CELLS; T-CELL; REJECTION; CTLA-4; TRANSPLANTATION; ACTIVATION; RECEPTOR; MOUSE	Antigen-specific T cell activation depends on T cell receptor-ligand interaction and co-stimulatory signals generated when accessory molecules bind to their ligands, such as CD28 to the B7 (also called BB1) molecule. A soluble fusion protein of human CTLA-4 (a protein homologous to CD28) and the immunoglobulin (Ig) G1 Fc region (CTLA4Ig) binds to human and murine B7 with high avidity and blocks T cell activation in vitro. CTLA4Ig therapy blocked human pancreatic islet rejection in mice by directly affecting T cell recognition of B7+ antigen-presenting cells. In addition, CTLA4Ig induced long-term, donor-specific tolerance, which may have applications to human organic transplantation.	UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637; UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT SURG,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Bristol-Myers Squibb					NIAID NIH HHS [AI29531] Funding Source: Medline; NIDDK NIH HHS [R29 DK40092] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI029531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; DAMLE NK, 1992, J IMMUNOL, V148, P1985; FAUSTMAN D, 1991, SCIENCE, V252, P1700, DOI 10.1126/science.1710828; GILL RG, 1989, J IMMUNOL, V143, P2176; HAO L, 1987, J IMMUNOL, V139, P4022; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARPER K, 1991, J IMMUNOL, V147, P1037; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LENSCHOW DJ, UNPUB; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LUCAS PJ, 1990, J IMMUNOL, V144, P4548; MOSES RD, 1992, TRANSPLANTATION, V53, P203, DOI 10.1097/00007890-199201000-00039; MOSES RD, 1990, J EXP MED, V172, P567, DOI 10.1084/jem.172.2.567; REISER H, 1992, P NATL ACAD SCI USA, V89, P271, DOI 10.1073/pnas.89.1.271; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; RICORDI C, 1991, TRANSPLANTATION, V52, P519, DOI 10.1097/00007890-199109000-00026; TAN PH, UNPUB; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; YOKOCHI T, 1982, J IMMUNOL, V128, P823; ZENG YJ, 1992, TRANSPLANTATION, V53, P277, DOI 10.1097/00007890-199202010-00005	24	1157	1269	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					789	792		10.1126/science.1323143	http://dx.doi.org/10.1126/science.1323143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323143				2022-12-28	WOS:A1992JG85100032
J	MOSS, SJ; SMART, TG; BLACKSTONE, CD; HUGANIR, RL				MOSS, SJ; SMART, TG; BLACKSTONE, CD; HUGANIR, RL			FUNCTIONAL MODULATION OF GABA(A) RECEPTORS BY CAMP-DEPENDENT PROTEIN-PHOSPHORYLATION	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; A RECEPTOR; SUBUNIT COMPOSITION; MOLECULAR-BIOLOGY; KINASE-C; GAMMA-2-SUBUNIT; DESENSITIZATION; PHARMACOLOGY; POTENTIATION; EXPRESSION	Gamma-aminobutyric acid(A) (GABA(A)) receptors are ligand-gated ion channels that mediate inhibitory synaptic transmission in the central nervous system. The role of protein phosphorylation in the modulation of GABA(A) receptor function was examined with cells transiently transfected with GABA(A) receptor subunits. GABA(A) receptors consisting of the alpha-1 and beta-1 or the alpha-1, beta-1, and gamma-2, subunits were directly phosphorylated on the beta-1 subunit by adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase (PKA). The phosphorylation decreased the amplitude of the GABA response of both receptor types and the extent of rapid desensitization of the GABA(A) receptor that consisted of the alpha-1 and beta-1 subunits. Site-specific mutagenesis of the serine residue phosphorylated by PKA completely eliminated the PKA phosphorylation and modulation of the GABA(A) receptor. In primary embryonic rat neuronal cell cultures, a similar regulation of GABA(A) receptors by PKA was observed. These results demonstrate that the GABA(A) receptor is directly modulated by protein phosphorylation and suggest that neurotransmitters or neuropeptides that regulate intracellular cAMP levels may modulate the responses of neurons to GABA and consequently have profound effects on synaptic excitability.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205; UNIV LONDON,DEPT PHARMACOL,LONDON WC1N 1AX,ENGLAND	Howard Hughes Medical Institute; Johns Hopkins University; University of London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; LEIDENHEIMER NJ, 1991, J NEUROCHEM, V57, P722, DOI 10.1111/j.1471-4159.1991.tb03806.x; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1991, NEUROSCI LETT, V123, P265, DOI 10.1016/0304-3940(91)90947-R; MOSS SJ, UNPUB; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SESSLER FM, 1989, BRAIN RES, V499, P27, DOI 10.1016/0006-8993(89)91132-3; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SMART TG, 1991, BRIT J PHARMACOL, V103, P1837, DOI 10.1111/j.1476-5381.1991.tb12337.x; SMART TG, 1992, J PHYSIOL-LONDON, V447, P587, DOI 10.1113/jphysiol.1992.sp019020; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TICKU MK, 1990, MOL PHARMACOL, V38, P719; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WANG JB, IN PRESS J MOL NEURO	29	267	270	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					661	665		10.1126/science.1323140	http://dx.doi.org/10.1126/science.1323140			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1323140				2022-12-28	WOS:A1992JF85200034
J	ATTREE, O; OLIVOS, IM; OKABE, I; BAILEY, LC; NELSON, DL; LEWIS, RA; MCINNES, RR; NUSSBAUM, RL				ATTREE, O; OLIVOS, IM; OKABE, I; BAILEY, LC; NELSON, DL; LEWIS, RA; MCINNES, RR; NUSSBAUM, RL			THE LOWE OCULOCEREBRORENAL SYNDROME GENE ENCODES A PROTEIN HIGHLY HOMOLOGOUS TO INOSITOL POLYPHOSPHATE-5-PHOSPHATASE	NATURE			English	Article							XQ24-Q26; MARKERS; BRAIN	LOWE'S oculocerebrorenal syndrome1-3 (OCRL) is a human X-linked developmental disorder of unknown pathogenesis4-8 and has a pleiotropic phenotype affecting the lens, brain and kidneys. The OCRL locus has been mapped to Xq25-q26 by linkage9-11 and by finding de novo X; autosome translocations at Xq25-q26 in two unrelated females with OCRL12,13 . Here we use yeast artificial chromosomes with inserts that span the X chromosomal breakpoint from a female OCRL patient in order to isolate complementary DNAs for a gene that is interrupted by the translocation. We show that the transcript is absent in both female OCRL patients with X ;autosome translocations and that it is absent or abnormally sized in 9 of 13 unrelated male OCRL patients with no detectable genomic rearrangement. The open reading frame encodes a new protein with 71% similarity to human inositol polyphosphate-5-phosphatase. Our results suggest that OCRL may be an inborn error of inositol phosphate metabolism.	UNIV PENN,SCH MED,DEPT HUMAN GENET,422 CURIE BLVD,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; HOSP SICK CHILDREN,TORONTO M5G 1X8,ONTARIO,CANADA; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT OPHTHALMOL,HOUSTON,TX 77030	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Baylor College of Medicine; Baylor College of Medicine								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CAMMARATA PR, 1990, CURR EYE RES, V9, P561, DOI 10.3109/02713689008999596; CAMMARATA PR, 1991, DIABETES, V40, P731, DOI 10.2337/diabetes.40.6.731; CHARNAS LR, 1991, NEW ENGL J MED, V324, P1318, DOI 10.1056/NEJM199105093241904; Clements R S Jr, 1979, Adv Exp Med Biol, V124, P105; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HARPER GS, 1987, J BIOL CHEM, V262, P5637; HODGSON SV, 1986, AM J MED GENET, V23, P837, DOI 10.1002/ajmg.1320230311; HORIE K, 1988, CLIN CHIM ACTA, V177, P41, DOI 10.1016/0009-8981(88)90305-1; KIERAS FJ, 1984, BIOCHEM MED METAB B, V31, P201, DOI 10.1016/0006-2944(84)90024-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOWE CU, 1952, AMA AM J DIS CHILD, V83, P164, DOI 10.1001/archpedi.1952.02040060030004; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MCKUSICK VA, 1989, MENDELIAN INHERITANC, P1335; MUELLER OT, 1991, AM J HUM GENET, V49, P804; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; NUSSBAUM RL, 1986, AM J MED GENET, V23, P457, DOI 10.1002/ajmg.1320230137; OKABE I, IN PRESS J INHER MET; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; REILLY DS, 1988, AM J HUM GENET, V42, P748; REILLY DS, 1990, GENOMICS, V8, P62, DOI 10.1016/0888-7543(90)90226-K; ROSS TS, 1991, J BIOL CHEM, V266, P20283; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT AF, 1979, P NATL ACAD SCI USA, V76, P4563, DOI 10.1073/pnas.76.9.4563; SILVER DN, 1987, J CLIN INVEST, V79, P282, DOI 10.1172/JCI112795; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; YAMASHINA I, 1983, MOL CELL BIOCHEM, V52, P107; YOSHIDA H, 1982, BIOCHEM BIOPH RES CO, V107, P1144, DOI 10.1016/0006-291X(82)90641-6	32	381	397	2	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					239	242		10.1038/358239a0	http://dx.doi.org/10.1038/358239a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1321346				2022-12-28	WOS:A1992JD58700055
J	MEYER, T; HANSON, PI; STRYER, L; SCHULMAN, H				MEYER, T; HANSON, PI; STRYER, L; SCHULMAN, H			CALMODULIN TRAPPING BY CALCIUM-CALMODULIN DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							AUTOPHOSPHORYLATION SITES; CA-2+-INDEPENDENT ACTIVITY; PHOSPHORYLATION; IDENTIFICATION; THREONINE-286; GENERATION; EXPRESSION; BRAIN	Multifunctional calcium-calmodulin-dependent protein kinase (CaM kinase) transduces transient elevations in intracellular calcium into changes in the phosphorylation state and activity of target proteins. By fluorescence emission anisotropy, the affinity of CaM kinase for dansylated calmodulin was measured and found to increase 1000 times after autophosphorylation of the threonine at position 286 of the protein. Autophosphorylation markedly slowed the release of bound calcium-calmodulin; the release time increased from less than a second to several hundred seconds. In essence, calmodulin is trapped by autophosphorylation. The shift in affinity does not occur in a site-directed mutant in which threonine at position 286 has been replaced by a non-phosphorylatable amino acid. These experiments demonstrate the existence of a new state in which calmodulin is bound to CaM kinase even though the concentration of calcium is basal. Calmodulin trapping provides for molecular potentiation of calcium transients and may enable detection of their frequency.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University; Stanford University			Hanson, Phyllis/E-9420-2012	Meyer, Tobias/0000-0003-4339-3804	NIGMS NIH HHS [GM24032, GM 40600] Funding Source: Medline; NIMH NIH HHS [MH45324] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600, R01GM024032, R37GM024032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045324] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Cohen P, 1988, CALMODULIN; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Estep R P, 1990, Curr Top Cell Regul, V31, P161; FONG YL, 1989, J BIOL CHEM, V264, P16759; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; KENNEDY MB, 1990, COLD SH Q B, V55, P101; KINCAID RL, 1988, METHOD ENZYMOL, V159, P605; LAI Y, 1987, P NATL ACAD SCI USA, V84, P5710, DOI 10.1073/pnas.84.16.5710; LOU LL, 1989, J NEUROSCI, V9, P2020; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MINTA A, 1989, J BIOL CHEM, V264, P8171; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; ROSENBERG GB, 1987, METHOD ENZYMOL, V139, P776; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; Schulman H, 1991, Curr Opin Neurobiol, V1, P43, DOI 10.1016/0959-4388(91)90009-V; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; Skene J H, 1990, Neurosci Res Suppl, V13, pS112, DOI 10.1016/0921-8696(90)90040-A; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; YAMAUCHI T, 1989, J BIOL CHEM, V264, P19108	23	513	518	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1199	1202		10.1126/science.256.5060.1199	http://dx.doi.org/10.1126/science.256.5060.1199			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1317063				2022-12-28	WOS:A1992HV19200035
J	IBANEZ, CF; EBENDAL, T; BARBANY, G; MURRAYRUST, J; BLUNDELL, TL; PERSSON, H				IBANEZ, CF; EBENDAL, T; BARBANY, G; MURRAYRUST, J; BLUNDELL, TL; PERSSON, H			DISRUPTION OF THE LOW AFFINITY RECEPTOR-BINDING SITE IN NGF ALLOWS NEURONAL SURVIVAL AND DIFFERENTIATION BY BINDING TO THE TRK GENE-PRODUCT	CELL			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; MESSENGER-RNA; PHEOCHROMOCYTOMA CELLS; BIOLOGICAL-ACTIVITY; CLONAL LINE; PC12 CELLS; C-FOS; EXPRESSION	Nerve growth factor (NGF), like many other growth factors and hormones, binds to two different receptor molecules on responsive cells. The product of the proto-oncogene trk, p140trk, is a tyrosine kinase receptor that has been identified as a signal-transducing receptor for NGF, while the role of the low affinity NGF receptor, p75NGFR, in signal transduction is less clear. The crystal structure of NGF has recently been determined, although structures involved in receptor binding and biological activity are unknown. Here we show that Lys-32, Lys-34, and Lys-95 form a positively charged interface involved in binding to p75NGFR. Simultaneous modification of Lys-32 with either of the two other lysines resulted in loss of binding to p75NGFR. Despite the lack of binding to p75NGFR, these mutants retained binding to p140trk and biological activity, demonstrating a functional dissociation between the two NGF receptors.	UNIV UPPSALA,CTR BIOMED,DEPT DEV BIOL,S-75123 UPPSALA,SWEDEN; BIRBECK COLL,IMPERIAL CANC RES FUND,STRUCT MOLEC BIOL UNIT,LONDON WC1,ENGLAND; BIRBECK COLL,DEPT CRYSTALLOG,MOLEC BIOL LAB,LONDON WC1,ENGLAND	Uppsala University	IBANEZ, CF (corresponding author), KAROLINSKA INST,DEPT MED CHEM,MOLEC NEUROBIOL LAB,S-10401 STOCKHOLM 60,SWEDEN.				NIA NIH HHS [AG04418] Funding Source: Medline; NINDS NIH HHS [NS09199] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS009199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004418] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGELETT.RH, 1971, P NATL ACAD SCI USA, V68, P2417, DOI 10.1073/pnas.68.10.2417; ANGELETT.RH, 1973, BIOCHEMISTRY-US, V12, P100, DOI 10.1021/bi00725a018; BANERJEE SP, 1973, P NATL ACAD SCI USA, V70, P2519, DOI 10.1073/pnas.70.9.2519; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BUXSER SE, 1983, J BIOL CHEM, V258, P3370; CARRIERO F, 1991, MOL REPROD DEV, V29, P313, DOI 10.1002/mrd.1080290402; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CURRAN T, 1987, ONCOGENE, V2, P79; EBENDAL T, 1989, J NEUROSCI RES, V22, P223, DOI 10.1002/jnr.490220302; EBENDAL T, 1986, EMBO J, V5, P1483, DOI 10.1002/j.1460-2075.1986.tb04386.x; EBENDAL T, 1989, NERVE GROWTH FACTORS, P81; EBENDAL T, 1984, ORGANIZING PRINCIPLE, P93; EDWARDS RH, 1988, J BIOL CHEM, V263, P6810; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HALLBOOK F, 1990, DEVELOPMENT, V108, P693; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HERRUP K, 1973, P NATL ACAD SCI USA, V70, P3884, DOI 10.1073/pnas.70.12.3884; HERRUP K, 1979, EXP CELL RES, V121, P71, DOI 10.1016/0014-4827(79)90445-2; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1991, J NEUROCHEM, V57, P1033, DOI 10.1111/j.1471-4159.1991.tb08254.x; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; IP NY, 1992, IN PRESS P NATL ACAD; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LONGO FM, 1990, CELL REGUL, V1, P189, DOI 10.1091/mbc.1.2.189; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEIER R, 1986, EMBO J, V5, P1489, DOI 10.1002/j.1460-2075.1986.tb04387.x; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RICHARDSON PM, 1986, J NEUROSCI, V6, P2312; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUVE K, 1991, P NATL ACAD SCI USA, V88, P4636, DOI 10.1073/pnas.88.11.4636; SCHWARZ MA, 1989, J NEUROCHEM, V52, P1203, DOI 10.1111/j.1471-4159.1989.tb01867.x; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SELBY MJ, 1987, J NEUROSCI RES, V18, P293, DOI 10.1002/jnr.490180205; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; SUTTER A, 1979, J BIOL CHEM, V254, P5972; THOENEN H, 1987, REV PHYSIOL BIOCH P, V109, P145, DOI 10.1007/BFb0031026; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; ULLRICH A, 1983, NATURE, V303, P821, DOI 10.1038/303821a0; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; YAN Q, 1988, J NEUROSCI, V8, P3481; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	70	321	334	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					329	341		10.1016/0092-8674(92)90413-7	http://dx.doi.org/10.1016/0092-8674(92)90413-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1314703				2022-12-28	WOS:A1992HQ18300012
J	HANN, BC; STIRLING, CJ; WALTER, P				HANN, BC; STIRLING, CJ; WALTER, P			SEC65 GENE-PRODUCT IS A SUBUNIT OF THE YEAST SIGNAL RECOGNITION PARTICLE REQUIRED FOR ITS INTEGRITY	NATURE			English	Article							PROTEIN	PROTEIN targeting to the endoplasmic reticulum (ER) in mammalian cells is catalysed by the signal recognition particle (SRP), which consists of six protein subunits and an RNA subunit 1,2. Saccharomyces cerevisiae SRP is a 16S particle, of which only two subunits have been identified: a protein subunit, SRP54p, which is homologous to the mammalian SRP54 subunit, and an RNA subunit, scR1 (ref. 3). The sec65-1 mutant yeast cells 4 are temperature-sensitive for growth and defective in the translocation of several secreted and membrane-bound proteins. The DNA sequence of the SEC65 gene suggests that its product is related to mammalian SRP19 subunit and may have a similar functions 5. Here we show that SEC65p is a subunit of the S. cervisiae SRP and that it is required for the stable association of another subunit, SRP54p, with SRP. Overexpression of SRP54p suppresses both growth and protein translocation defects in sec65-1 mutant cells.	UNIV MANCHESTER,DEPT BIOCHEM & MOLEC BIOL,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester	HANN, BC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, IN PRESS MOL BIOL CE; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	9	56	59	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					532	533		10.1038/356532a0	http://dx.doi.org/10.1038/356532a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1313947				2022-12-28	WOS:A1992HN23100062
J	SIXBEY, JW; YAO, QY				SIXBEY, JW; YAO, QY			IMMUNOGLOBULIN-A-INDUCED SHIFT OF EPSTEIN-BARR-VIRUS TISSUE TROPISM	SCIENCE			English	Article							TRANS-EPITHELIAL TRANSPORT; INTESTINAL M-CELLS; NASOPHARYNGEAL CARCINOMA; SECRETORY COMPONENT; MEMBRANE ANTIGEN; NPC PATIENTS; B-CELLS; IGA; RECEPTOR; ANTIBODY	Increased immunoglobulin A (IgA) antibodies to the Epstein-Barr virus (EBV) appear months to years before the clinical onset of nasopharyngeal carcinoma and define populations at high risk for this EBV-associated epithelial cancer common in south China. In the human HT-29 epithelial cell line, polymeric IgA (pIgA) specific for EBV promoted infection of the otherwise refractory epithelial cells. When bound to pIgA, EBV entered epithelial cells through secretory component-mediated IgA transport but no longer infected B lymphocytes. Such an immune-induced shift in EBV tissue tropism provides a paradigm for endogenous spread of EBV in the immune host that predicts infectious sequelae of epithelium.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOLEC BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	SIXBEY, JW (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT INFECT DIS, 332 N LAUDERDALE, MEMPHIS, TN 38101 USA.				NATIONAL CANCER INSTITUTE [R01CA038877, R23CA038877, P30CA021765, R01CA052258] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA52258, CA38877] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI MY, 1967, UICC UNION INT CONTR, V1, P138; BISWAS R, 1985, BIOCHEMISTRY-US, V24, P3795, DOI 10.1021/bi00335a056; BRANDTZAEG P, 1981, CLIN EXP IMMUNOL, V44, P221; BROWN WR, 1977, GASTROENTEROLOGY, V73, P1333; CHINTALACHARUVU KR, 1991, J CELL PHYSIOL, V148, P35, DOI 10.1002/jcp.1041480105; CRAGO SS, 1978, J EXP MED, V147, P1832, DOI 10.1084/jem.147.6.1832; DAVID EM, 1988, J IMMUNOL METHODS, V108, P231, DOI 10.1016/0022-1759(88)90424-3; DELACROIX DL, 1983, J CLIN INVEST, V71, P358, DOI 10.1172/JCI110777; DESGRANGES C, 1977, INT J CANCER, V19, P627, DOI 10.1002/ijc.2910190506; DESGRANGES C, 1977, INT J CANCER, V20, P881, DOI 10.1002/ijc.2910200610; EPSTEIN MA, 1985, NATURE, V318, P287, DOI 10.1038/318287a0; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HASHIDO M, 1989, J CLIN MICROBIOL, V27, P2609, DOI 10.1128/JCM.27.11.2609-2611.1989; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HEREMANS JF, 1974, ANTIGENS, V2, P365; HOFFMAN GJ, 1980, P NATL ACAD SCI-BIOL, V77, P2979, DOI 10.1073/pnas.77.5.2979; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; INOUYE S, 1978, J CLIN MICROBIOL, V8, P1; KAETZEL CS, 1991, P NATL ACAD SCI USA, V88, P8796, DOI 10.1073/pnas.88.19.8796; MARSH M, 1984, BIOCHEM J, V218, P1; MILLER G, 1990, VIROLOGY, P1921; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; NOMORI H, 1985, JPN J CLIN ONCOL, V15, P95; PONZI AN, 1985, J CLIN MICROBIOL, V22, P505, DOI 10.1128/JCM.22.4.505-509.1985; RAO CK, 1987, RECENT ADV MUCOSAL B, P1071; RICKINSON AB, 1985, BRIT MED BULL, V41, P75, DOI 10.1093/oxfordjournals.bmb.a072030; ROQUEBARREIRA MC, 1985, J IMMUNOL, V134, P1740; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; SIXBEY JW, 1987, J GEN VIROL, V68, P805, DOI 10.1099/0022-1317-68-3-805; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SIXBEY JW, 1991, J INFECT DIS, V163, P1008, DOI 10.1093/infdis/163.5.1008; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; THORLEYLAWSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P5307, DOI 10.1073/pnas.77.9.5307; TOMASI TB, 1965, J EXP MED, V121, P101, DOI 10.1084/jem.121.1.101; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737; WRIGHT DH, 1985, BURKITTS LYMPHOMA HU, P37; YAO Q, UNPUB; YAO QY, 1991, INT J CANCER, V48, P45; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; ZENG Y, 1985, ADV CANCER RES, V44, P121, DOI 10.1016/S0065-230X(08)60027-5	45	179	192	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1992	255	5051					1578	1580		10.1126/science.1312750	http://dx.doi.org/10.1126/science.1312750			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1312750				2022-12-28	WOS:A1992HJ80900043
J	FEDERMAN, AD; CONKLIN, BR; SCHRADER, KA; REED, RR; BOURNE, HR				FEDERMAN, AD; CONKLIN, BR; SCHRADER, KA; REED, RR; BOURNE, HR			HORMONAL-STIMULATION OF ADENYLYL CYCLASE THROUGH GI-PROTEIN BETA-GAMMA-SUBUNITS	NATURE			English	Article							MUSCARINIC K+-CHANNEL; AMINO-ACID SEQUENCE; ALPHA-SUBUNIT; RAT-BRAIN; RECEPTOR; PATHWAYS; PHOSPHOLIPASE-A2; TRANSDUCIN; ACTIVATE; CLONING	AGONIST-BOUND receptors activate heterotrimeric (alpha-beta-gamma) G proteins by catalysing replacement by GTP of GDP bound to the alpha-subunit, resulting in dissociation of alpha-GTP from the beta-gamma-subunits. In most cases, alpha-GTP carries the signal to effectors, as in hormonal stimulation 1-4 and inhibition 5,6 of adenylyl cyclase by alpha(s) and alpha(i) respectively. By contrast, genetic evidence in yeast 7 and studies in mammalian cells 8-10 suggest that beta-gamma-subunits of G proteins may also regulate effector pathways. Indeed, of the four recombinant mammalian adenylyl cyclases available for study 11-14, two, adenylyl cyclases II and IV, are stimulated by beta-gamma. This effect of beta-gamma requires costimulation by alpha(s)-GTP 14,15. This conditional pattern of effector responsiveness led to the prediction 15 that receptors coupled to many G proteins will mediate elevation of cellular cyclic AMP, provided that G(s) is also active. We now confirm this prediction. Coexpression of mutationally active alpha(s) with adenylyl cyclase II converted agonists that act through 'inhibitory' receptors (coupled to G(i)) into stimulators of cAMP synthesis. Experiments using pertussis toxin and a putative scavenger of beta-gamma, the alpha-subunit of transducin, suggest that beta-gamma-subunits of the G(i) proteins mediated this stimulation. These findings assign a new signalling function to beta-gamma-subunits of G(i) proteins, the conditional stimulation of cAMP synthesis by adenylyl cyclase II.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Johns Hopkins University			Reed, Russell/HGU-0528-2022; Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061				BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BIRNBAUMER LA, 1990, REV PHARM TOX, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FRASER CM, 1989, J BIOL CHEM, V264, P11754; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GUYER CA, 1990, J BIOL CHEM, V265; HILL DR, 1985, BRIT J PHARMACOL, V84, P249; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KARBON EW, 1985, MOL PHARMACOL, V27, P53; KAZIRO Y, 1991, REV BIOCH, V60, P349; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SATTIN A, 1975, J PHARMACOL EXP THER, V192, P22; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WHITEWAY M, 1988, COLD SPRING HARB SYM, V53, P585, DOI 10.1101/SQB.1988.053.01.067; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	28	567	571	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					159	161		10.1038/356159a0	http://dx.doi.org/10.1038/356159a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1312225				2022-12-28	WOS:A1992HH73100062
J	ELLERBY, LM; NISHIDA, CR; NISHIDA, F; YAMANAKA, SA; DUNN, B; VALENTINE, JS; ZINK, JI				ELLERBY, LM; NISHIDA, CR; NISHIDA, F; YAMANAKA, SA; DUNN, B; VALENTINE, JS; ZINK, JI			ENCAPSULATION OF PROTEINS IN TRANSPARENT POROUS SILICATE-GLASSES PREPARED BY THE SOL-GEL METHOD	SCIENCE			English	Article							SUPEROXIDE-DISMUTASE	Novel sol-gel synthetic techniques were used to immobilize copper-zinc superoxide dismutase (CuZnSOD), cytochrome c, and myoglobin (Mb) by encapsulation in stable, optically transparent, porous silica glass matrices under mild conditions such that the biomolecules retained their characteristic reactivities and spectroscopic properties. The resulting glasses allowed transport of small molecules into and out of the glasses at reasonable rates but nevertheless retained the protein molecules within their pores. Chemical reactions of the immobilized proteins could be monitored by means of changes in their visible absorption spectra. Silica glasses containing the immobilized proteins were observed to have similar reactivities and spectroscopic properties to those found for the proteins in solution. For example, encapsulated CuZnSOD was demetallated and remetallated, encapsulated ferricytochrome c was reduced and then reoxidized, and encapsulated met Mb was reduced to deoxy Mb and then reacted either with dioxygen to make oxy Mb or with carbon monoxide to make carbonyl Mb.	UNIV CALIF LOS ANGELES,DEPT MAT SCI & ENGN,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	ELLERBY, LM (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.		Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIGMS NIH HHS [GM28222, T32 GM08375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222, T32GM008375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUN S, 1990, MATER LETT, V10, P1, DOI 10.1016/0167-577X(90)90002-4; BRINKER CJ, 1990, SOL GEL SCI PHYSICS; ELLERBY LM, UNPUB; ESQUIVIAS L, 1988, 3RD P INT C ULTR PRO, P255; FEE JA, 1972, J BIOL CHEM, V247, P60; HARRISON PM, 1985, METALLOPROTEINS 2; HARRISON PM, 1985, METALLOPROTEINS 1; HENCH LL, 1990, CHEM REV, V90, P33, DOI 10.1021/cr00099a003; KLEIN LC, 1985, ANNU REV MATER SCI, V15, P227; MCKIERNAN J, 1989, J PHYS CHEM-US, V93, P2129, DOI 10.1021/j100342a081; MCKIERNAN JM, 1990, J PHYS CHEM-US, V94, P5652, DOI 10.1021/j100378a007; MOSBACH K, 1987, IMMOBOLIZED ENZYMES, V1335; POUXVIEL JC, 1989, J PHYS CHEM-US, V93, P2134, DOI 10.1021/j100342a082; Valentine J.S., 1981, COPPER PROTEINS, P291; VALENTINE JS, 1985, J CHEM EDUC, V62, P990, DOI 10.1021/ed062p990; YAMANAKA SA, UNPUB	16	679	694	3	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1113	1115		10.1126/science.1312257	http://dx.doi.org/10.1126/science.1312257			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1312257				2022-12-28	WOS:A1992HF63200036
J	FORTINI, ME; SIMON, MA; RUBIN, GM				FORTINI, ME; SIMON, MA; RUBIN, GM			SIGNALING BY THE SEVENLESS PROTEIN TYROSINE KINASE IS MIMICKED BY RAS1 ACTIVATION	NATURE			English	Article							DEVELOPING DROSOPHILA EYE; ELEGANS VULVAR INDUCTION; CELL FATE; GENE; MELANOGASTER; RECEPTOR; EXPRESSION; ENCODES; SEQUENCE; DOMAIN	CELL-FATE specification of R7 photoreceptors in the developing Drosophila eye depends on an inductive signal from neighbouring R8 cells. Mutations in three genes, sevenless (sev), bride-of-sevenless (boss) and seven-in-absentia (sina) cause the R7 precursor to become a non-neural cone cell 1-3. The sev gene encodes a receptor protein tyrosine kinase (Sev) localized on the R7 surface, activated by a boss-encoded ligand presented by R8 (refs 4-6). The sina gene encodes a nuclear factor required in R7 (ref. 3). Reduction in the dosage of the Ras1 gene impairs Sev-mediated signalling, suggesting that activation of Ras1 may be an important consequence of Sev activation 7. We report here that Ras1 activation may account for all of the signalling action of Sev; an activated Ras1Val12 protein rescues the normal R7 precursor from transformation into a cone cell in sev and boss null mutants and induces the formation of supernumerary R7 cells. Similar activation of the Drosophila Ras2 protein does not produce these effects, demonstrating Ras protein specificity.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley				Rubin, Gerald/0000-0001-8762-8703				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BOWTELL DDL, 1991, P NATL ACAD SCI USA, V88, P6853, DOI 10.1073/pnas.88.15.6853; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BROCK HW, 1987, GENE, V51, P129, DOI 10.1016/0378-1119(87)90301-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; Dietrich W, 1909, Z WISS ZOOL ABT A, V92, P465; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Maniatis T., 1982, MOL CLONING; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	285	286	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					559	561		10.1038/355559a0	http://dx.doi.org/10.1038/355559a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1311054				2022-12-28	WOS:A1992HC52600063
J	HEYMAN, RA; MANGELSDORF, DJ; DYCK, JA; STEIN, RB; EICHELE, G; EVANS, RM; THALLER, C				HEYMAN, RA; MANGELSDORF, DJ; DYCK, JA; STEIN, RB; EICHELE, G; EVANS, RM; THALLER, C			9-CIS RETINOIC ACID IS A HIGH-AFFINITY LIGAND FOR THE RETINOID-X RECEPTOR	CELL			English	Article							INTESTINAL RECEPTOR; VITAMIN-A; IDENTIFICATION; GENE; EXPRESSION; ELEMENT; GAMMA	All-trans retinoic acid (RA) has previously been shown to modulate the transcriptional properties of the retinoic acid receptor (RAR) and retinoid X receptor (RXR). The inability of all-trans RA to bind to RXR suggests that it may be metabolized to a more active high affinity ligand. We report here an experimental approach that has identified 9-cis RA as an RXR ligand. It is up to 40-fold more potent than all-trans RA in transfection assays and binds with high affinity. The production of 9-cis RA in cultured cells and the identification of this molecule in liver and kidney demonstrates the existence of this molecule in living organisms. The discovery of this novel hormone points to the key role retinoid metabolism may have in generating new signaling pathways.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037; HOWARD HUGHES MED INST,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT BIOMED SCI,LA JOLLA,CA 92093; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Salk Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego; Baylor College of Medicine	HEYMAN, RA (corresponding author), LIGAN PHARMACEUT INC,SAN DIEGO,CA 92121, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Mangelsdorf, David/0000-0002-4355-0796				Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALLEGRETTO EA, 1987, J BIOL CHEM, V262, P1312; BERGER TS, 1992, IN PRESS J STEROID B; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; BROWN PS, 1959, NATURE, V184, P1377, DOI 10.1038/1841377a0; COREY EJ, 1968, J AM CHEM SOC, V90, P5616, DOI 10.1021/ja01022a059; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KLIEWER SA, 1992, IN PRESS P NATL ACAD; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1992, RETINOIDS NORMAL DEV; MATSUI M., 1958, JOUR VITAMINOL, V4, P178; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIKE JW, 1983, J BIOL CHEM, V258, P1289; PIKE JW, 1979, P NATL ACAD SCI USA, V76, P5485, DOI 10.1073/pnas.76.11.5485; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; SUMMERS MD, 1987, TEXAS AGR EXP STAT B, V155; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WECKSLER WR, 1979, ANAL BIOCHEM, V92, P314, DOI 10.1016/0003-2697(79)90664-X; WEDDEN S, 1990, METHOD ENZYMOL, V190, P201; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	30	1698	1796	7	81	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					397	406		10.1016/0092-8674(92)90479-V	http://dx.doi.org/10.1016/0092-8674(92)90479-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310260				2022-12-28	WOS:A1992HB35300017
J	GOODWIN, FK				GOODWIN, FK			ALCOHOLICS KIN DONT LIKE DIAZEPAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1992	267	4					480	480		10.1001/jama.267.4.480	http://dx.doi.org/10.1001/jama.267.4.480			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ439	1309583				2022-12-28	WOS:A1992GZ43900006
J	COSNETT, JE				COSNETT, JE			DICKENS AND DOCTORS - VIGNETTES OF VICTORIAN MEDICINE	BRITISH MEDICAL JOURNAL			English	Editorial Material											COSNETT, JE (corresponding author), 268 MANNING RD,DURBAN 4001,SOUTH AFRICA.							DICKENS C, PICKWICK PAPERS; DICKENS C, BLEAK HOUSE; DICKENS C, MARTIN CHUZZLEWIT; DICKENS C, LITTLE DORRIT; DICKENS C, OLD CURIOSITY SHOP	5	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1540	1542		10.1136/bmj.305.6868.1540	http://dx.doi.org/10.1136/bmj.305.6868.1540			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286377	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992KD77100014
J	RINTALA, M; MUSTAJOKI, P				RINTALA, M; MUSTAJOKI, P			COULD MANNEQUINS MENSTRUATE	BRITISH MEDICAL JOURNAL			English	Article							MENARCHE		UNIV HELSINKI,CENT HOSP,DEPT MED 3,SF-00290 HELSINKI 29,FINLAND	University of Helsinki; Helsinki University Central Hospital	MUSTAJOKI, P (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT MED 3,SF-00290 HELSINKI 29,FINLAND.							FRISCH RE, 1985, PERSPECT BIOL MED, V28, P611; PATTON GC, 1990, PSYCHOL MED, V20, P383, DOI 10.1017/S0033291700017700; SCOTT EC, 1982, J ADOLESCENT HEALTH, V2, P249, DOI 10.1016/S0197-0070(82)80059-4; SMITH DP, 1977, AM J CLIN NUTR, V30, P560, DOI 10.1093/ajcn/30.4.560; STEINKAMP RC, 1965, J CHRON DIS, V18, P1291, DOI 10.1016/0021-9681(65)90162-1	5	14	14	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1575	1576		10.1136/bmj.305.6868.1575	http://dx.doi.org/10.1136/bmj.305.6868.1575			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286395	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KD77100032
J	STRONGE, JM				STRONGE, JM			SITTING FOR YOUR PORTRAIT	BRITISH MEDICAL JOURNAL			English	Editorial Material											STRONGE, JM (corresponding author), NATL MATERN HOSP,DUBLIN 2,IRELAND.							SHEERAN I, 1989, BRIT MED J, V299, P37, DOI 10.1136/bmj.299.6690.37; Turner M, 1991, FET MED REV, V3, P67, DOI 10.1017/S0965539500000449	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1539	1540		10.1136/bmj.305.6868.1539	http://dx.doi.org/10.1136/bmj.305.6868.1539			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286376	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992KD77100013
J	TREVETT, AJ; LALLOO, DG; KEVAU, IH				TREVETT, AJ; LALLOO, DG; KEVAU, IH			A PISCATORIAL EPISTLE	BRITISH MEDICAL JOURNAL			English	Article							FISH		UNIV PAPUA NEW GUINEA,DEPT CLIN SCI,PORT MORESBY,PAPUA N GUINEA	University of Papua New Guinea	TREVETT, AJ (corresponding author), POB 2193,BOROKO,PAPUA N GUINEA.			Lalloo, David/0000-0001-7680-2200				BARSS P, 1984, MED J AUSTRALIA, V141, P854, DOI 10.5694/j.1326-5377.1984.tb132970.x; BARSS P, 1985, PAPUA NEW GUINEA MED, V28, P131; BARSS PG, 1985, MED J AUSTRALIA, V143, P617, DOI 10.5694/j.1326-5377.1985.tb119973.x; CAMPBELL CH, 1959, PAPUA NEW GUINEA MED, V3, P55; CAMPBELL CH, 1960, PAPUA NEW GUINEA MED, V4, P71; SCHUURKAMP GJ, 1987, PAPUA NEW GUINEA MED, V30, P203	6	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1578	1579		10.1136/bmj.305.6868.1578-a	http://dx.doi.org/10.1136/bmj.305.6868.1578-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1304747	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992KD77100036
J	ROOTENBERG, JD				ROOTENBERG, JD			INFORMATION TECHNOLOGIES IN UNITED-STATES-MEDICAL-SCHOOLS - CLINICAL PRACTICES OUTPACE ACADEMIC APPLICATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											ROOTENBERG, JD (corresponding author), INST MED INFORMAT & TECHNOL,707 14TH AVE,SAN FRANCISCO,CA 94118, USA.							BLOOM SW, 1989, MED EDUC, V23, P228, DOI 10.1111/j.1365-2923.1989.tb01538.x; Field MJ, 1990, CLIN PRACTICE GUIDEL; Flexner A., 1910, FLEXNER REPORT; Gardner E, 1992, Mod Healthc, V22, P32; GASTEL B, 1989, CLIN ED DOCTOR TOMOR; KRITCHEVSKY SB, 1991, JAMA-J AM MED ASSOC, V266, P1817, DOI 10.1001/jama.266.13.1817; MARSTON RQ, 1992, MED ED TRANSITION; ONEILL PN, 1990, ACAD MED, V65, P624, DOI 10.1097/00001888-199010000-00004; Shugars DA, 1991, HLTH AM PRACTITIONER; STEVENS RH, 1991, M D COMPUT, V8, P13; STEVENS RH, 1992, ACAD MED S, V67, P10; 1984, PHYSICIANS 21ST CENT	12	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1992	268	21					3106	3107		10.1001/jama.268.21.3106	http://dx.doi.org/10.1001/jama.268.21.3106			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA002	1306661				2022-12-28	WOS:A1992KA00200034
J	REZNIK, Y; ALLALIZERAH, V; CHAYVIALLE, JA; LEROYER, R; LEYMARIE, P; TRAVERT, G; LEBRETHON, MC; BUDI, I; BALLIERE, AM; MAHOUDEAU, J				REZNIK, Y; ALLALIZERAH, V; CHAYVIALLE, JA; LEROYER, R; LEYMARIE, P; TRAVERT, G; LEBRETHON, MC; BUDI, I; BALLIERE, AM; MAHOUDEAU, J			FOOD-DEPENDENT CUSHINGS-SYNDROME MEDIATED BY ABERRANT ADRENAL SENSITIVITY TO GASTRIC-INHIBITORY POLYPEPTIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADRENOCORTICAL DYSPLASIA; SOMATOSTATIN ANALOG; CORTISOL; SECRETION; DISEASE; HORMONE; STIMULATION	Background. Some patients with Cushing's syndrome have nodular adrenal hyperplasia. In most the disease is corticotropin-dependent, but in others it is corticotropin-independent. The cause of the adrenal hyperplasia in the latter patients is not known. Methods. We studied a 49-year-old woman with Cushing's syndrome and nodular adrenal hyperplasia in whom food stimulated cortisol secretion. Plasma cortisol concentrations were measured in response to the ingestion of mixed meals, glucose, protein, and fat and after the administration of various gastrointestinal and other types of hormones. We also studied the ability of the long-acting somatostatin analogue octreotide to prevent the food-induced increase in plasma cortisol concentrations and to ameliorate the clinical manifestations of Cushing's syndrome in this patient. Results. The patient's fasting plasma cortisol concentrations were subnormal, ranging from 3.0 to 7.5 mug per deciliter (83 to 207 nmol per liter), and they increased to as high as 16.5 mug per deciliter (455 nmol per liter) after a mixed meal. Her urinary cortisol excretion ranged from 164 to 250 mug per day (453 to 690 nmol per day) and could not be suppressed by a large dose of dexamethasone. Plasma corticotropin concentrations were virtually undetectable at all times. The ingestion of glucose, protein, and fat increased plasma cortisol concentrations to 3.6, 2.2, and 4 times the base-line value, respectively; the meal-induced and glucose-induced increases were inhibited by octreotide. The infusion of gastric inhibitory polypeptide (GIP) increased the patient's plasma cortisol concentration to 3.7 times the base-line value, but had no effect in normal subjects. The patient's fasting plasma GIP concentrations were normal both before and after a meal, and there was a close correlation between her plasma cortisol and GIP concentrations. Treatment with octreotide decreased urinary cortisol excretion and ameliorated the clinical manifestations of Cushing's syndrome. Conclusions. The development of aberrant adrenal sensitivity to GIP can result in food-dependent adrenal hyperplasia and therefore in Cushing's syndrome.	INSERM,U45,F-69008 LYON,FRANCE; INSERM,U307,F-69008 LYON,FRANCE; CHU CAEN,DEPT ENDOCRINOL,F-14033 CAEN,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Caen NORMANDIE; Universite de Caen Normandie				Travert, Georges/0000-0002-8288-2849				ALDAMLUJI S, 1987, CLIN ENDOCRINOL, V26, P629, DOI 10.1111/j.1365-2265.1987.tb00819.x; AMBROSI B, 1987, ACTA ENDOCRINOL-COP, V116, P216, DOI 10.1530/acta.0.1160216; BRANDENBERGER G, 1973, J PHYSIOLOGY PARIS, V66, P271; CARNEY JA, 1985, MEDICINE, V64, P270, DOI 10.1097/00005792-198507000-00007; CATALAND S, 1974, J CLIN ENDOCR METAB, V39, P223, DOI 10.1210/jcem-39-2-223; de Lacerda L, 1973, J Clin Endocrinol Metab, V36, P227; DUPRE J, 1973, J CLIN ENDOCR METAB, V37, P826, DOI 10.1210/jcem-37-5-826; FOLLENIUS M, 1982, J CLIN ENDOCR METAB, V55, P757, DOI 10.1210/jcem-55-4-757; HAMET P, 1987, CLIN INVEST MED, V10, P530; HODGE BO, 1988, ARCH INTERN MED, V148, P1133, DOI 10.1001/archinte.148.5.1133; ISHIZUKA B, 1983, J CLIN ENDOCR METAB, V57, P1111, DOI 10.1210/jcem-57-6-1111; JAFFE BM, 1979, ENDOCRINOLOGY, V3, P1669; KATZ MS, 1985, J CLIN ENDOCR METAB, V60, P900, DOI 10.1210/jcem-60-5-900; KNIGGE U, 1987, J CLIN ENDOCR METAB, V65, P1291, DOI 10.1210/jcem-65-6-1291; KRIEGER DT, 1983, ENDOCR REV, V4, P22, DOI 10.1210/edrv-4-1-22; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; LACROIX A, 1991, 73RD ANN M END SOC W, P91; LAROCHELLE P, 1983, CLIN PHARMACOL THER, V33, P343, DOI 10.1038/clpt.1983.43; LARSEN JL, 1986, AM J MED, V80, P976, DOI 10.1016/0002-9343(86)90648-0; MIAZZA B, 1985, GASTROENTEROLOGY, V88, P1215, DOI 10.1016/S0016-5085(85)80082-2; ODONNELL LJD, 1989, GUT, V30, P1165, DOI 10.1136/gut.30.9.1165; PENHOAT A, 1991, J CLIN ENDOCR METAB, V72, P23, DOI 10.1210/jcem-72-1-23; QUIGLEY ME, 1979, J CLIN ENDOCR METAB, V49, P945, DOI 10.1210/jcem-49-6-945; REES LH, 1976, SCI F ONCOLOGY, P112; SCHORR I, 1971, J BIOL CHEM, V246, P5806; VAGNUCCI AH, 1974, J CLIN ENDOCR METAB, V38, P761, DOI 10.1210/jcem-38-5-761; VANBERKHOUT FT, 1989, CLIN ENDOCRINOL, V31, P185; WEITZMAN ED, 1971, J CLIN ENDOCR METAB, V33, P14, DOI 10.1210/jcem-33-1-14; WOLTERING EA, 1988, SURG GYNECOL OBSTET, V167, P453; WULFFRAAT NM, 1988, J CLIN ENDOCR METAB, V66, P301, DOI 10.1210/jcem-66-2-301; YOUNG WF, 1989, NEW ENGL J MED, V321, P1659, DOI 10.1056/NEJM198912143212407	31	212	218	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					981	986		10.1056/NEJM199210013271403	http://dx.doi.org/10.1056/NEJM199210013271403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1325609				2022-12-28	WOS:A1992JQ22500003
J	WINSTON, DJ				WINSTON, DJ			GANCICLOVIR FOR CYTOMEGALOVIRUS AFTER HEART-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							BONE-MARROW TRANSPLANTATION; INFECTION; DISEASE				WINSTON, DJ (corresponding author), UNIV CALIF LOS ANGELES,MED CTR,LOS ANGELES,CA 90024, USA.							GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; WINSTON DJ, 1990, REV INFECT DIS, V12, pS776; WINSTON DJ, 1991, BONE MARROW TRANSPL, V8, P7	5	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					891	892						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1324432				2022-12-28	WOS:A1992JN12000022
J	MEYERS, C; FRATTINI, MG; HUDSON, JB; LAIMINS, LA				MEYERS, C; FRATTINI, MG; HUDSON, JB; LAIMINS, LA			BIOSYNTHESIS OF HUMAN PAPILLOMAVIRUS FROM A CONTINUOUS CELL-LINE UPON EPITHELIAL DIFFERENTIATION	SCIENCE			English	Article							VIRUS-INFECTION; TERMINAL DIFFERENTIATION; MOLECULAR MARKERS; UTERINE CERVIX; EXPRESSION; PROTEINS; INVITRO; KERATINOCYTE; REPLICATION; FILAGGRIN	The study of the human pathogen papillomaviruses (HPVs) has been hampered by the inability to propagate the virus in tissue culture. The addition of 12-O-tetradecanoyl phorbol-13-acetate to the media of organotypic (raft) cultures increased expression of physiological markers of keratinocyte differentiation and concomitantly induced production of virions. Capsid production was detected in differentiated suprabasal cells. Virions approximately 54 nanometers in size were observed by electron microscopy in raft tissue cross sections in the suprabasal layers. Virions purified through isopycnic gradients were found to contain type 31b DNA and exhibited an icosahedral shape similar to that of papillomaviruses found in clinical samples.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago; University of Chicago								ASSELINEAU D, 1986, J INVEST DERMATOL, V86, P181, DOI 10.1111/1523-1747.ep12284237; BALL RD, 1978, J BIOL CHEM, V253, P5861; BEDELL MA, 1991, J VIROL, V65, P2254, DOI 10.1128/JVI.65.5.2254-2260.1991; CRAWFORD DH, 1986, IMMUNOLOGY, V59, P405; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALE BA, 1987, J INVEST DERMATOL, V88, P306, DOI 10.1111/1523-1747.ep12466185; DALE BA, 1985, ANN NY ACAD SCI, V455, P330, DOI 10.1111/j.1749-6632.1985.tb50420.x; DAVIES AH, 1991, J VIROL, V65, P6838, DOI 10.1128/JVI.65.12.6838-6844.1991; DUNN AEG, 1968, J ULTRA MOL STRUCT R, V22, P282, DOI 10.1016/S0022-5320(68)90021-X; FAVRE M, 1975, J VIROL, V15, P1239, DOI 10.1128/JVI.15.5.1239-1247.1975; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KREIDER JW, 1990, VIROLOGY, V177, P415, DOI 10.1016/0042-6822(90)90503-J; KREIDER JW, 1987, J VIROL, V61, P590, DOI 10.1128/JVI.61.2.590-593.1987; LAURENCE J, 1990, BLOOD, V75, P696; LAVERTY CR, 1978, ACTA CYTOL, V22, P195; LEWIS RM, 1989, REV INFECT DIS, V11, P736; LI QX, 1992, NATURE, V356, P347, DOI 10.1038/356347a0; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MEYERS C, 1992, PAPILLOMAVIRUS RES, V3, P1; MEYERS CLF, UNPUB; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORIN C, 1980, ACTA CYTOL, V24, P82; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PFISTER H, 1987, PAPILLOMAVIRUSES HUM, P1; PILOTTI S, 1981, J CLIN PATHOL, V34, P532, DOI 10.1136/jcp.34.5.532; POLYAK SJ, 1991, J VIROL, V65, P3575, DOI 10.1128/JVI.65.7.3575-3582.1991; RADER JS, 1990, ONCOGENE, V5, P571; SALZMAN NP, 1987, PAPOVAVIRIDAE, V2; STERLING J, 1990, J VIROL, V64, P6305, DOI 10.1128/JVI.64.12.6305-6307.1990; SYRJANEN K, 1987, PAPILLOMAVIRUSES HUM; Taichman L.B., 1987, PAPOVAVIRIDEA, P109; VIAC J, 1978, J INVEST DERMATOL, V70, P263, DOI 10.1111/1523-1747.ep12541415; WEINSHENKER BG, 1988, J IMMUNOL, V140, P1626; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5	35	375	390	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					971	973		10.1126/science.1323879	http://dx.doi.org/10.1126/science.1323879			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1323879				2022-12-28	WOS:A1992JH82700037
J	KLEUSS, C; SCHERUBL, H; HESCHELER, J; SCHULTZ, G; WITTIG, B				KLEUSS, C; SCHERUBL, H; HESCHELER, J; SCHULTZ, G; WITTIG, B			DIFFERENT BETA-SUBUNITS DETERMINE G-PROTEIN INTERACTION WITH TRANSMEMBRANE RECEPTORS	NATURE			English	Article							GTP-BINDING PROTEINS; MUSCARINIC K+-CHANNEL; GAMMA-SUBUNITS; ADENYLATE-CYCLASE; INHIBITION; TRANSDUCIN; PHOSPHOLIPASE-A2; DIVERSITY; RHODOPSIN; ACTIVATE	REGULATORY GTP-binding proteins (G proteins) are membrane-attached heterotrimers (alpha, beta, gamma) that mediate cellular responses to a wide variety of extracellular stimuli1,2. They undergo a cycle of guanine-nucleotide exchange and GTP hydrolysis, during which they dissociate into alpha-subunit and beta-gamma-complex1. The roles of G-protein alpha-subunits in these processes and for the specificity of signal transduction are largely established; the beta- and gamma-subunits are essential for receptor-induced G-protein activation and seem to be less diverse and less specific. Although the complementary DNAs for several beta-subunits have been cloned2,5-8, isolated subunits have only been studied as beta-gamma-complexes3,9-12. Functional differences have been ascribed to the gamma-subunit on the basis of extensive sequence similarity among beta-subunits and apparent heterogeneity in gamma-subunit sequences13,14. Beta-gamma-complexes can inter act directly or indirectly with different effectors10,11,15-20. They seem to be interchangeable in their interaction with pertussis toxin-sensitive alpha-subunits3, so we tested this by microinjecting antisense oligonucleotides into nuclei of a rat pituitary cell line to suppress the synthesis of individual beta-subunits selectively. Here we show that two out of four subtypes of beta-subunits tested (beta-1 and beta-3) are selectively involved in the signal transduction cascades from muscarinic M4 (ref. 4) and somatostatin receptors, respectively, to voltage-dependent Ca2+ channels.	FREE UNIV BERLIN,INST PHARMAKOL,W-1000 BERLIN 33,GERMANY	Free University of Berlin	KLEUSS, C (corresponding author), FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,ARNIMALLEE 22,W-1000 BERLIN 33,GERMANY.							BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOYER JL, 1989, J BIOL CHEM, V264, P13917; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KATADA T, 1987, J BIOL CHEM, V262, P11897; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; OKABE K, 1990, J BIOL CHEM, V265, P12854; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F	23	373	376	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					424	426		10.1038/358424a0	http://dx.doi.org/10.1038/358424a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1322501				2022-12-28	WOS:A1992JF85300059
J	GUINAN, ME				GUINAN, ME			HIV, HETEROSEXUAL TRANSMISSION, AND WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GUINAN, ME (corresponding author), CTR DIS CONTROL, OFF DEPUTY DIRECTOR HIV, MAILSTOP D-21, EXECUT PK 26, ATLANTA, GA 30333 USA.							BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; GUINAN ME, 1987, JAMA-J AM MED ASSOC, V257, P2039; KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477; LISKIN L, 1990, POPUL REP H, P1; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; 1992, HIV AIDS SURVEILLANC, P1	7	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					520	521						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1320134				2022-12-28	WOS:A1992JD47200028
J	JOCE, R; WOOD, D; BROWN, D; BEGG, N				JOCE, R; WOOD, D; BROWN, D; BEGG, N			PARALYTIC POLIOMYELITIS IN ENGLAND AND WALES, 1985-91	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To ascertain all cases of paralytic poliomyelitis in England and Wales during 1985-91 and to determine the source of infection in each case. Design-Descriptive study of cases reported between 1985 and 1991. Setting-All health districts in England and Wales. Subjects-Patients normally resident in England and Wales whose clinical features were consistent with paralytic poliomyelitis or with laboratory evidence of recent poliovirus infection and compatible symptoms. Main outcome measures-Clinical, epidemiological, and laboratory features in identified cases. Results-Of 54 suspected cases of poliomyelitis, 33 were excluded, leaving 21 cases, of which 13 were vaccine associated (nine recipient and four contact) cases, five were imported cases, and three were cases whose source of infection was unknown. No cases due to indigenous wild polioviruses were identified; two were imported cases due to wild viruses. One patient died during the acute phase of the illness, and two children with previously unrecognised severe congenital immune deficiency died between one and two months after the onset of paralysis after the first or second dose of oral polio vaccine. The estimated risk of vaccine associated paralysis is 1.46 per million for the first dose, 0.49 for the second, zero for the third and fourth doses, and 0.33 for the fifth. Conclusions-Indigenous wild poliovirus seems to have been eradicated, although wild virus may be imported; improved surveillance of suspected cases including immediate notification and characterisation of the virus to ensure that eradication is maintained is essential.	PUBL HLTH LAB SERV,COMMUNICABLE SURVEILLANCE CTR,LONDON NW9 5EQ,ENGLAND; E & N HERTFORDSHIRE HLTH AUTHOR,WELWYN GARDEN CIT AL8 6RD,HERTS,ENGLAND; NATL INST BIOL STAND & CONTROLS,POTTERS BAR EN6 3QG,HERTS,ENGLAND; PUBL HLTH LAB SERV,VIRUS REFERENCE LAB,LONDON NW9 5EQ,ENGLAND	Public Health England; National Institute for Biological Standards & Control; Public Health England								BEGG NT, 1987, EPIDEMIOL INFECT, V99, P97, DOI 10.1017/S0950268800066905; COLLINGHAM KE, 1978, LANCET, V1, P976; EVANS DMA, 1985, NATURE, V314, P548, DOI 10.1038/314548a0; Hall S M, 1988, Arch Dis Child, V63, P344; HOVI T, 1986, J INFECT DIS, V153, P998, DOI 10.1093/infdis/153.5.998; KUBLI D, 1987, BRIT MED J, V295, P169, DOI 10.1136/bmj.295.6591.169; VANWEZEL AL, 1978, INTERVIROLOGY, V11, P2; WHITE PMB, 1986, BRIT MED J, V293, P1153, DOI 10.1136/bmj.293.6555.1153; 1988, EVALUATION POLIOMYEL; 1982, B WORLD HEALTH ORGAN, V69, P231; 1988, WHO WEEKLY EPIDEMIOL, V63, P161; 1990, MANUAL VIROLOGICAL I; 1990, IMMUNISATION INFECTI; 1989, WHO WEEKLY EPIDEMIOL, V64, P273	14	61	63	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1992	305	6845					79	82		10.1136/bmj.305.6845.79	http://dx.doi.org/10.1136/bmj.305.6845.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1322218	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JD85000019
J	MOSS, WT				MOSS, WT			CONSERVATIVE SURGERY AND RADIATION FOR INTRADUCTAL BREAST-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MOSS, WT (corresponding author), OREGON HLTH SCI UNIV,PORTLAND,OR 97201, USA.							SILVERSTEIN MJ, 1990, CANCER, V66, P102, DOI 10.1002/1097-0142(19900701)66:1<102::AID-CNCR2820660119>3.0.CO;2-5	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					266	266						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1318979				2022-12-28	WOS:A1992JB27900036
J	HUNT, DF; MICHEL, H; DICKINSON, TA; SHABANOWITZ, J; COX, AL; SAKAGUCHI, K; APPELLA, E; GREY, HM; SETTE, A				HUNT, DF; MICHEL, H; DICKINSON, TA; SHABANOWITZ, J; COX, AL; SAKAGUCHI, K; APPELLA, E; GREY, HM; SETTE, A			PEPTIDES PRESENTED TO THE IMMUNE-SYSTEM BY THE MURINE CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE-I-A(D)	SCIENCE			English	Article							MHC CLASS; PROTEIN ANTIGENS; BINDING PEPTIDES; SEQUENCE	Between 650 and 2000 different peptides are associated with the major histocompatibility complex class II molecule I-A(d). Sequences for nine of these were obtained by a combination of automated Edman degradation and tandem mass spectrometry. All of the peptides are derived from secretory or integral membrane proteins that are synthesized by the antigen-presenting cell itself. Peptides were 16 to 18 residues long, had ragged NH2- and COOH-termini, and contained a six-residue binding motif that was variably placed within the peptide chain. Binding data on truncated peptides suggest that the peptide binding groove on class II molecules can be open at both ends.	NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA; CYTEL CORP, SAN DIEGO, CA 92121 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HUNT, DF (corresponding author), UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA.		Hunt, Donald F/I-6936-2012; Sette, Alessandro/AFO-8916-2022	Hunt, Donald F/0000-0003-2815-6368; Cox, Andrea/0000-0002-9331-2462; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018634] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18634] Funding Source: Medline; NIGMS NIH HHS [GM37357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; ESNARD F, 1990, BIOL CHEM H-S, V371, P161; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; HYLDIGNIELSEN JJ, 1983, NUCLEIC ACIDS RES, V11, P5055, DOI 10.1093/nar/11.15.5055; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LI Z, 1989, NUCLEIC ACIDS RES, V17, P447, DOI 10.1093/nar/17.1.447; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; RAJAVASHISTH TB, 1985, P NATL ACAD SCI USA, V82, P8085, DOI 10.1073/pnas.82.23.8085; ROBERTS KP, 1990, MOL ENDOCRINOL, V4, P531, DOI 10.1210/mend-4-4-531; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296; SETTE A, 1988, J IMMUNOL, V141, P45; SETTE A, 1989, J IMMUNOL, V142, P35; SETTE A, 1992, J IMMUNOL, V148, P844; SETTE A, 1990, J IMMUNOL, V145, P1809; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANBLEEK GM, 1990, NATURE, V348, P213	28	664	691	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1992	256	5065					1817	1820		10.1126/science.1319610	http://dx.doi.org/10.1126/science.1319610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1319610				2022-12-28	WOS:A1992JA43400036
J	FARLEY, MM; STEPHENS, DS; BRACHMAN, PS; HARVEY, RC; SMITH, JD; WENGER, JD				FARLEY, MM; STEPHENS, DS; BRACHMAN, PS; HARVEY, RC; SMITH, JD; WENGER, JD			INVASIVE HAEMOPHILUS-INFLUENZAE DISEASE IN ADULTS - A PROSPECTIVE, POPULATION-BASED SURVEILLANCE	ANNALS OF INTERNAL MEDICINE			English	Article						HAEMOPHILUS-INFLUENZAE; PNEUMONIA; LUNG DISEASES; PREGNANCY; DRUG RESISTANCE, MICROBIAL; AMPICILLIN	NONTYPABLE HEMOPHILUS-INFLUENZAE; GENITOURINARY TRACT INFECTIONS; ANTIMICROBIAL RESISTANCE; OLIGOSACCHARIDE PORTION; PNEUMONIA; AMPICILLIN; SPECTRUM; LIPOOLIGOSACCHARIDE; EPIGLOTTITIS; MENINGITIS	Objective: To define the incidence of and possible risk factors for invasive Haemophilus influenzae disease in adults. Design: Prospective, population-based surveillance of hospital and referral bacteriology laboratories. Setting: Metropolitan Atlanta, Georgia community. Patients: All patients with H. influenzae isolated from normally sterile sites (blood, cerebrospinal fluid, joint, pleura) from 1 December 1988 through 31 May 1990. Measurements: Isolates of H. influenzae were analyzed for serotype and biotype status, outer membrane proteins, lipooligosaccharide phenotypes, ribotyping patterns and 13-lactamase production. Results: A total of 194 cases of invasive H. influenzae occurred (annual incidence of 5.6 cases/100 000 population), of which 47 (24%) were in adults 18 years old or older (annual incidence 1.7 cases/100 000 adults). Adults with invasive H. influenzae ranged from 18 to 96 years; 79% were women. Bacteremic pneumonia accounted for 70% of the adult cases. Other sources for invasive H. influenzae in adults were obstetric infections, epiglottitis, and tracheobronchitis; one patient had meningitis. Underlying conditions were noted in 92% of the patients. Chronic lung disease was the most common risk factor, but pregnancy (annual incidence, 4.9/100 000 pregnant women), HIV infection (annual incidence, 41/100 000 known HIV-infected adults), and malignancy were also important. Overall mortality was 28% in adults, and over half of pregnancy-related infections resulted in fetal death. Fifty percent of the 40 isolates available for testing were serotype b; 47.5%, nontypable; and 2.5%, serotype f. Sixteen of the 45 isolates (36%) were ampicillin-resistant. Based on biotypes, outer membrane protein profiles, lipooligosaccharide phenotypes, and ribotyping patterns, the type b isolates showed less heterogeneity than the nontypable isolates but were distinguishable from one another. Conclusions: Adult cases currently represent one quarter of all cases of invasive H. influenzae disease. Half of the reported adult cases were caused by type b H. influenzae, and the rate of ampicillin resistance in H. influenzae isolates from adults was higher than previously reported. Haemophilus influenzae is an important cause of bacteremia in compromised adults.	OFF EPIDEMIOL, DEPT HUMAN RESOURCES, ATLANTA, GA 30309 USA; CTR DIS CONTROL, CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, MENINGITIS & SPECIAL PATHOGENS BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	FARLEY, MM (corresponding author), ATLANTA DEPT VET AFFAIRS MED CTR, RES SERV 151, 1670 CLAIRMONT RD, DECATUR, GA 30033 USA.		Stephens, David S/A-8788-2012					ALBRITTON WL, 1978, ARCH INTERN MED, V138, P1819, DOI 10.1001/archinte.138.12.1819; BARENKAMP SJ, 1981, J INFECT DIS, V143, P668, DOI 10.1093/infdis/143.5.668; BERCZY J, 1973, LANCET, V1, P1197; BERK SL, 1982, ARCH INTERN MED, V142, P537, DOI 10.1001/archinte.142.3.537; BRUNHAM RC, 1988, J INFECT DIS, V158, P510, DOI 10.1093/infdis/158.3.510; CROWE HM, 1987, ARCH INTERN MED, V147, P241, DOI 10.1001/archinte.147.2.241; DOERN GV, 1986, DIAGN MICR INFEC DIS, V4, P95, DOI 10.1016/0732-8893(86)90143-4; DOERN GV, 1988, ANTIMICROB AGENTS CH, V32, P180, DOI 10.1128/AAC.32.2.180; GLODE MP, 1984, PEDIATR INFECT DIS J, V3, P548, DOI 10.1097/00006454-198411000-00013; GULIG PA, 1987, INFECT IMMUN, V55, P513, DOI 10.1128/IAI.55.3.513-520.1987; HALL GD, 1983, DIAGN MICR INFEC DIS, V1, P65, DOI 10.1016/0732-8893(83)90034-2; HIRSCHMANN JV, 1979, MEDICINE, V58, P80, DOI 10.1097/00005792-197901000-00005; JAKACKI R, 1990, ANN INTERN MED, V112, P143, DOI 10.7326/0003-4819-112-2-143; JANOFF EN, 1990, 30TH INT C ANT AG CH; KHAN W, 1974, JAMA-J AM MED ASSOC, V229, P298, DOI 10.1001/jama.229.3.298; KILIAN M, 1976, J GEN MICROBIOL, V93, P9, DOI 10.1099/00221287-93-1-9; KRISTENSEN K, 1989, SCAND J INFECT DIS, V21, P651, DOI 10.3109/00365548909021693; LEVIN DC, 1977, AM J MED, V62, P219, DOI 10.1016/0002-9343(77)90317-5; MAYOSMITH MF, 1986, NEW ENGL J MED, V314, P1133, DOI 10.1056/NEJM198605013141801; MENDELMAN PM, 1984, ANTIMICROB AGENTS CH, V26, P235, DOI 10.1128/AAC.26.2.235; MOXON ER, 1990, PRINCIPLES PRACTICE, P1722; MURPHY TF, 1983, J INFECT DIS, V147, P838, DOI 10.1093/infdis/147.5.838; MUSHER DM, 1983, ANN INTERN MED, V99, P444, DOI 10.7326/0003-4819-99-4-444; NORDEN CW, 1978, MED CLIN N AM, V62, P1037, DOI 10.1016/S0025-7125(16)31753-9; PATRICK CC, 1987, INFECT IMMUN, V55, P2902, DOI 10.1128/IAI.55.12.2902-2911.1987; QUENTIN R, 1989, J CLIN MICROBIOL, V27, P2286, DOI 10.1128/JCM.27.10.2286-2294.1989; Quinones C A, 1989, Semin Respir Infect, V4, P12; QUINTILIANI R, 1971, AM J MED, V50, P781, DOI 10.1016/0002-9343(71)90186-0; SCHLAMM HT, 1989, AM J MED, V86, P11, DOI 10.1016/0002-9343(89)90222-2; SIMON HB, 1980, AM J MED, V69, P219, DOI 10.1016/0002-9343(80)90381-2; SPAGNUOLO PJ, 1982, MEDICINE, V61, P74, DOI 10.1097/00005792-198203000-00002; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; STULL TL, 1988, J INFECT DIS, V157, P280, DOI 10.1093/infdis/157.2.280; TAKALA AK, 1990, ARCH INTERN MED, V150, P2573, DOI 10.1001/archinte.150.12.2573; TOMEH MO, 1974, JAMA-J AM MED ASSOC, V229, P295; TROLLFORS B, 1984, EUR J CLIN MICROBIOL, V3, P180, DOI 10.1007/BF02014874; WALLACE RJ, 1983, REV INFECT DIS, V5, P123; WALLACE RJ, 1981, J INFECT DIS, V144, P101, DOI 10.1093/infdis/144.2.101; WALLACE RJ, 1978, AM J MED, V64, P87, DOI 10.1016/0002-9343(78)90182-1; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WILLIAMS JD, 1986, REV INFECT DIS, V8, pS555; 1988, NCCLS M7T2 NAT COMM	42	125	127	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					806	812		10.7326/0003-4819-116-10-806	http://dx.doi.org/10.7326/0003-4819-116-10-806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1314530				2022-12-28	WOS:A1992HT80200004
J	GOLOVKINA, TV; CHERVONSKY, A; DUDLEY, JP; ROSS, SR				GOLOVKINA, TV; CHERVONSKY, A; DUDLEY, JP; ROSS, SR			TRANSGENIC MOUSE MAMMARY-TUMOR VIRUS SUPERANTIGEN EXPRESSION PREVENTS VIRAL-INFECTION	CELL			English	Article							T-CELLS; DNA; TOLERANCE; TRANSMISSION; SEQUENCES; RECEPTOR; GLAND; GENES; MICE; RNA	Endogenous mouse mammary tumor virus (MMTV) proviruses have recently been shown to cosegregate genetically with the minor lymphocyte-stimulating loci, also termed self-superantigens. The antigenic activity has been localized to the open reading frame (ORF) protein encoded in the long terminal repeat of MMTV. We show here that unlike their nontransgenic littermates, transgenic mice expressing high levels of an ORF protein derived from the C3H exogenous MMTV specifically delete their V-beta-14+ T cells and do not become infected with this virus when it is present in their mother's milk. Thus, it appears that MMTV utilizes cells of the immune system in its infection pathway, and mice that retain endogenous MMTVs should be immune to infection by exogenous virus. These results offer possible new approaches to anti-viral therapy or immunization.	UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Chicago; University of Texas System; University of Texas Austin	GOLOVKINA, TV (corresponding author), UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612, USA.			Chervonsky, Alexander/0000-0001-7547-871X; Ross, Susan R/0000-0002-3094-3769	NCI NIH HHS [R01 CA45954, R01 CA34780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034780, R01CA045954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI YW, 1987, J VIROL, V61, P3013, DOI 10.1128/JVI.61.10.3013-3019.1987; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FRITSCH EF, 1977, J VIROL, V24, P461, DOI 10.1128/JVI.24.2.461-469.1977; GUDKOV AV, 1989, INT J CANCER, V44, P1052, DOI 10.1002/ijc.2910440619; HAREL J, 1981, VIROLOGY, V110, P202, DOI 10.1016/0042-6822(81)90022-2; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HESTON WE, 1945, J NATL CANCER I, V5, P289; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; HUGIN AW, 1991, SCIENCE, V252, P424, DOI 10.1126/science.1850169; ICHIMARU M, 1991, CANCER DETECT PREV, V15, P177; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANEWAY CA, 1990, CELL, V63, P659, DOI 10.1016/0092-8674(90)90130-7; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Moore D H, 1979, Adv Cancer Res, V29, P347, DOI 10.1016/S0065-230X(08)60850-7; NANDI S, 1973, ADV CANCER RES, V17, P353; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PULLEN AM, 1992, J EXP MED, V175, P41, DOI 10.1084/jem.175.1.41; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; SAJI F, 1990, CANCER, V66, P1933, DOI 10.1002/1097-0142(19901101)66:9<1933::AID-CNCR2820660914>3.0.CO;2-5; SALMONS B, 1987, VIRUS RES, V8, P81, DOI 10.1016/0168-1702(87)90022-0; SELTZER V, 1990, OBSTET GYNECOL, V75, P713; SPRENT J, 1990, SCIENCE, V248, P1357, DOI 10.1126/science.1694041; SQUARTINI F, 1970, CANCER RES, V30, P2069; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TSUBURA A, 1988, CANCER RES, V48, P6555; VARMUS HE, 1973, J MOL BIOL, V79, P663, DOI 10.1016/0022-2836(73)90070-3; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WOODLAND DL, 1992, IN PRESS J EXP MED; ZIEGLER JB, 1985, LANCET, V1, P896	43	226	229	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					637	645		10.1016/0092-8674(92)90227-4	http://dx.doi.org/10.1016/0092-8674(92)90227-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1316806				2022-12-28	WOS:A1992HV08900008
J	LEE, WM; GALBRAITH, RM				LEE, WM; GALBRAITH, RM			MECHANISMS OF DISEASE - THE EXTRACELLULAR ACTIN-SCAVENGER SYSTEM AND ACTIN TOXICITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							D-BINDING-PROTEIN; GROUP-SPECIFIC COMPONENT; FULMINANT HEPATIC-NECROSIS; GEL-SOL TRANSFORMATION; VITAMIN-D; PLASMA GELSOLIN; GC-GLOBULIN; HUMAN-SERUM; ALPHA-FETOPROTEIN; F-ACTIN		MED UNIV S CAROLINA,DEPT MED,DIV GASTROENTEROL,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT MICROBIOL & IMMUNOL,CHARLESTON,SC 29425	Medical University of South Carolina; Medical University of South Carolina	LEE, WM (corresponding author), UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT INTERNAL MED,LIVER UNIT,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033082] Funding Source: NIH RePORTER; NIDDK NIH HHS [R0-1 DK33082] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCINNI L, 1983, CONNECT TISSUE RES, V11, P69, DOI 10.3109/03008208309015012; BARRAGRY JM, 1978, CLIN CHIM ACTA, V87, P359, DOI 10.1016/0009-8981(78)90179-1; BOUILLON R, 1984, J CLIN ENDOCR METAB, V59, P86, DOI 10.1210/jcem-59-1-86; BOUILLON R, 1980, ENDOCRINOLOGY, V107, P160, DOI 10.1210/endo-107-1-160; BOUTIN B, 1989, J STEROID BIOCHEM, V32, P59, DOI 10.1016/0022-4731(89)90014-9; CALVO M, 1989, BIOCHEM BIOPH RES CO, V163, P14, DOI 10.1016/0006-291X(89)92091-3; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; CHAPONNIER C, 1979, EXPERIENTIA, V35, P1039, DOI 10.1007/BF01949928; COHEN I, 1976, THROMB RES, V8, P383, DOI 10.1016/0049-3848(76)90031-1; CONSTANS J, 1978, HUM GENET, V41, P53; COOKE NE, 1986, HUM GENET, V73, P225, DOI 10.1007/BF00401232; COOKE NE, 1985, J CLIN INVEST, V76, P2420, DOI 10.1172/JCI112256; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DAIGER SP, 1975, P NATL ACAD SCI USA, V72, P2076, DOI 10.1073/pnas.72.6.2076; DESCHEERDER I, 1985, AM J CARDIOL, V56, P631, DOI 10.1016/0002-9149(85)91024-0; DUELAND S, 1991, BIOCHEM J, V274, P237, DOI 10.1042/bj2740237; EMERSON DL, 1983, AM J REPROD IMMUNOL, V4, P185, DOI 10.1111/j.1600-0897.1983.tb00276.x; ENA JM, 1989, BIOCHEM INT, V19, P1; GABBIANI G, 1973, AM J PATHOL, V72, P473; GOLDSCHMIDTCLERMONT PJ, 1985, CLIN CHIM ACTA, V148, P173, DOI 10.1016/0009-8981(85)90144-5; GOLDSCHMIDTCLERMONT PJ, 1986, BIOCHEMISTRY-US, V25, P6467, DOI 10.1021/bi00369a019; GOLDSCHMIDTCLERMONT PJ, 1988, GASTROENTEROLOGY, V94, P1454, DOI 10.1016/0016-5085(88)90686-5; GOLDSCHMIDTCLERMONT PJ, 1985, BIOCHEM J, V228, P471, DOI 10.1042/bj2280471; GOLDSCHMIDTCLERMONT PJ, 1985, ELECTROPHORESIS, V6, P155, DOI 10.1002/elps.1150060403; GOLDSCHMIDTCLERMONT PJ, 1987, BIOCHEM BIOPH RES CO, V146, P611, DOI 10.1016/0006-291X(87)90572-9; GOLDSCHMIDTCLERMONT PJ, 1988, J CLIN INVEST, V81, P1519, DOI 10.1172/JCI113484; GUOTH M, 1990, ENDOCRINOLOGY, V127, P2313, DOI 10.1210/endo-127-5-2313; HADDAD J, 1979, CLIN ORTHOP RELAT R, V142, P249; HADDAD JG, 1990, P NATL ACAD SCI USA, V87, P1381, DOI 10.1073/pnas.87.4.1381; HADDAD JG, 1984, BIOCHEM J, V218, P805, DOI 10.1042/bj2180805; HADDAD JG, 1982, ARCH BIOCHEM BIOPHYS, V213, P538, DOI 10.1016/0003-9861(82)90581-1; HARPER KD, 1987, J CLIN INVEST, V79, P1365, DOI 10.1172/JCI112963; HARRIS DA, 1981, P NATL ACAD SCI-BIOL, V78, P6798, DOI 10.1073/pnas.78.11.6798; HARRIS HE, 1981, FEBS LETT, V123, P49, DOI 10.1016/0014-5793(81)80017-8; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; JANMEY PA, 1986, BIOCHEM BIOPH RES CO, V136, P72, DOI 10.1016/0006-291X(86)90878-8; JANMEY PA, 1985, BIOCHIM BIOPHYS ACTA, V841, P151, DOI 10.1016/0304-4165(85)90016-9; JANMEY PA, 1987, BLOOD, V70, P524; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P8239; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAKI K, 1974, BIOCHIM BIOPHYS ACTA, V371, P519, DOI 10.1016/0005-2795(74)90048-8; LEE WM, 1989, CIRC SHOCK, V28, P249; LEE WM, 1985, HEPATOLOGY, V5, P271, DOI 10.1002/hep.1840050220; LEE WM, 1987, HEPATOLOGY, V7, P825, DOI 10.1002/hep.1840070506; LEES A, 1984, BIOCHEMISTRY-US, V23, P3038, DOI 10.1021/bi00308a030; LEVY E, 1990, J EXP MED, V172, P1865, DOI 10.1084/jem.172.6.1865; LIND SE, 1986, J CLIN INVEST, V78, P736, DOI 10.1172/JCI112634; LIND SE, 1988, AM REV RESPIR DIS, V138, P429, DOI 10.1164/ajrccm/138.2.429; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; LIND SE, 1991, J BIOL CHEM, V266, P5273; LIND SE, 1991, J BIOL CHEM, V266, P17673; MAURY CPJ, 1991, J CLIN INVEST, V87, P1195, DOI 10.1172/JCI115118; MCCOMBS JL, 1986, CYTOGENET CELL GENET, V42, P62, DOI 10.1159/000132252; MCLEOD JF, 1989, J BIOL CHEM, V264, P21760; MCLEOD JF, 1986, ENDOCRINOLOGY, V119, P77, DOI 10.1210/endo-119-1-77; MCLEOD JF, 1989, J BIOL CHEM, V264, P1260; NORBERG R, 1979, EUR J BIOCHEM, V100, P575, DOI 10.1111/j.1432-1033.1979.tb04204.x; PETRINI M, 1985, J BIOL CHEM, V260, P1804; PETRINI M, 1983, NATURE, V306, P73, DOI 10.1038/306073a0; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; ROSTENBERG I, 1979, J NATL CANCER I, V62, P299; SAFER D, 1991, J BIOL CHEM, V266, P4029; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SCARBOROUGH VD, 1981, BIOCHEM BIOPH RES CO, V100, P1314, DOI 10.1016/0006-291X(81)91967-7; SCHMIDTGAYK H, 1977, LANCET, V2, P105; SCHOENTGEN F, 1985, FEBS LETT, V185, P47, DOI 10.1016/0014-5793(85)80738-9; SMITH DB, 1988, BLOOD, V72, P214; SMITH DB, 1988, AM J PATHOL, V130, P261; SMITH DB, 1987, J LAB CLIN MED, V110, P189; SMITHIES O, 1955, BIOCHEM J, V61, P629, DOI 10.1042/bj0610629; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; VANBAELEN H, 1980, J BIOL CHEM, V255, P2270; WATT GH, 1989, CIRC SHOCK, V28, P279; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WILLIAMS MH, 1988, BIOCHEM BIOPH RES CO, V153, P1019, DOI 10.1016/S0006-291X(88)81330-5; YANG F, 1985, P NATL ACAD SCI USA, V82, P7994, DOI 10.1073/pnas.82.23.7994; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1980, J BIOL CHEM, V255, P9494; YIN HL, 1981, J CELL BIOL, V91, P901, DOI 10.1083/jcb.91.3.901; YIN HL, 1984, J BIOL CHEM, V259, P5271; YIN HL, 1988, J CELL BIOL, V106, P803; YOUNG WO, 1987, J LAB CLIN MED, V110, P83	87	311	331	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1992	326	20					1335	1341						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT803	1314333				2022-12-28	WOS:A1992HT80300006
J	DREYER, C; KREY, G; KELLER, H; GIVEL, F; HELFTENBEIN, G; WAHLI, W				DREYER, C; KREY, G; KELLER, H; GIVEL, F; HELFTENBEIN, G; WAHLI, W			CONTROL OF THE PEROXISOMAL BETA-OXIDATION PATHWAY BY A NOVEL FAMILY OF NUCLEAR HORMONE RECEPTORS	CELL			English	Article							THYROID-HORMONE; XENOPUS-LAEVIS; ESTROGEN-RECEPTOR; GENE; EXPRESSION; SEQUENCE; PROLIFERATION; SUPERFAMILY; RAT; IDENTIFICATION	Three novel members of the Xenopus nuclear hormone receptor superfamily have been cloned. They are related to each other and similar to the group of receptors that includes those for thyroid hormones, retinoids, and vitamin D3. Their transcriptional activity is regulated by agents causing peroxisome proliferation and carcinogenesis in rodent liver. All three Xenopus receptors activate the promoter of the acyl coenzyme A oxidase gene, which encodes the key enzyme of peroxisomal fatty acid beta-oxidation, via a cognate response element that has been identified. Therefore, peroxisome proliferators may exert their hypolipidemic effects through these receptors, which stimulate the peroxisomal degradation of fatty acids. Finally, the multiplicity of these receptors suggests the existence of hitherto unknown cellular signaling pathways for xenobiotics and putative endogenous ligands.	UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND	University of Lausanne	DREYER, C (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,W-7400 TUBINGEN,GERMANY.		Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009	Wahli, Walter/0000-0002-5966-9089				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROOKS AR, 1989, NUCLEIC ACIDS RES, V17, P9395, DOI 10.1093/nar/17.22.9395; CIOLEK E, 1991, BIOL CELL, V71, P313, DOI 10.1016/0248-4900(91)90276-S; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ELLINGERZIEGELBAUER H, 1991, GENE DEV, V5, P94, DOI 10.1101/gad.5.1.94; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GIACOBINO JP, 1989, MOL CELL ENDOCRINOL, V61, P217, DOI 10.1016/0303-7207(89)90133-0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GOLDFISCHER S, 1984, INT REV EXP PATHOL, V26, P45; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LAZAROW PB, 1982, J LIPID RES, V23, P317; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MARTINEZ E, 1991, NUCLEAR HORMONE RECE, P125; MILLER M, 1989, GENE DEV, V3, P572, DOI 10.1101/gad.3.4.572; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MOSKAITIS JE, 1989, MOL ENDOCRINOL, V3, P464, DOI 10.1210/mend-3-3-464; NEMALI MR, 1989, TOXICOL APPL PHARM, V97, P72, DOI 10.1016/0041-008X(89)90056-2; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OMALLEY BW, 1989, ENDOCRINOLOGY, V125, P1119, DOI 10.1210/endo-125-3-1119; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; OSUMI T, 1987, J BIOL CHEM, V262, P8138; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; REDDY JK, 1986, ENVIRON HEALTH PERSP, V65, P317, DOI 10.2307/3430199; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vamecq J, 1989, Essays Biochem, V24, P115; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WEILER IJ, 1987, MOL ENDOCRINOL, V1, P355, DOI 10.1210/mend-1-5-355	38	1180	1230	0	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					879	887		10.1016/0092-8674(92)90031-7	http://dx.doi.org/10.1016/0092-8674(92)90031-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1312391				2022-12-28	WOS:A1992HH74800007
J	HASEGAWA, H; SKACH, W; BAKER, O; CALAYAG, MC; LINGAPPA, V; VERKMAN, AS				HASEGAWA, H; SKACH, W; BAKER, O; CALAYAG, MC; LINGAPPA, V; VERKMAN, AS			A MULTIFUNCTIONAL AQUEOUS CHANNEL FORMED BY CFTR	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; XENOPUS OOCYTES; CHLORIDE CHANNEL; MESSENGER-RNA; EXPRESSION; WATER; PERMEABILITY; CELLS	The cystic fibrosis gene product (CFTR) is a complex protein that functions as an adenosine 3,5-monophosphate (cAMP)-stimulated ion channel and possibly as a regulator of intracellular processes. In order to determine whether the CFTR molecule contains a functional aqueous pathway, anion, water, and urea transport were measured in Xenopus oocytes expressing CFTR. Cyclic AMP agonists induced a Cl- conductance of 94 microsiemens and an increase in water permeability of 4 x 10(-4) centimeter per second that was inhibited by a Cl- channel blocker and was dependent on anion composition. CFTR has a calculated single channel water conductance of 9 x 10(-13) cubic centimeter per second, suggesting a pore-like aqueous pathway. Oocytes expressing CFTR also showed cAMP-stimulated transport of urea but not the larger solute sucrose. Thus CFTR contains a cAMP-stimulated aqueous pore that can transport anions, water, and small solutes. The results also provide functional evidence for water movement through an ion channel.	UNIV CALIF SAN FRANCISCO,CYST FIBROSIS RES CTR,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CYST FIBROSIS RES CTR,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK043840, R01DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, pC783, DOI 10.1152/ajpcell.1992.262.3.C783; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FINKELSTEIN A, 1987, DISTINGUISHED LECTUR, V4, pCH2; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GREEN ME, 1992, BIOPHYS J, V62, P101, DOI 10.1016/S0006-3495(92)81792-7; ILLINGER D, 1989, CELL BIOPHYS, V14, P17, DOI 10.1007/BF02797388; LEUCHTAG HR, 1992, BIOPHYS J, V62, P22, DOI 10.1016/S0006-3495(92)81766-6; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P221, DOI 10.1016/0005-2728(92)90230-Y; SKACH W, UNPUB; TILLY BC, 1992, J BIOL CHEM, V267, P9470; TSAI ST, 1991, BIOCHEMISTRY-US, V30, P2087, DOI 10.1021/bi00222a013; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; WANGEMANN P, 1986, PFLUG ARCH        S2, V407, P128; ZHANG R, 1991, AM J PHYSIOL, V260, pC26, DOI 10.1152/ajpcell.1991.260.1.C26; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG R, 1991, J CLIN INVEST, V88, P1553, DOI 10.1172/JCI115466; ZHANG R, IN PRESS J CELL BIOL	30	134	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1477	1479		10.1126/science.1279809	http://dx.doi.org/10.1126/science.1279809			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279809				2022-12-28	WOS:A1992JZ62500026
J	HEGINBOTHAM, L; ABRAMSON, T; MACKINNON, R				HEGINBOTHAM, L; ABRAMSON, T; MACKINNON, R			A FUNCTIONAL CONNECTION BETWEEN THE PORES OF DISTANTLY RELATED ION CHANNELS AS REVEALED BY MUTANT K+ CHANNELS	SCIENCE			English	Article							POTASSIUM CHANNEL; SELECTIVE CONDUCTANCE; COMPLEMENTARY-DNA; ACTIVATED CHANNEL; CALCIUM CHANNELS; SODIUM-CHANNEL; DROSOPHILA-EAG; RETINAL RODS; TEA BLOCKADE; SHAKER	The overall sequence similarity between the voltage-activated K+ channels and cyclic nucleotide-gated ion channels from retinal and olfactory neurons suggests that they arose from a common ancestor. On the basis of sequence comparisons, mutations were introduced into the pore of a voltage-activated K+ channel. These mutations confer the essential features of ion conduction in the cyclic nucleotide-gated ion channels; the mutant K+ channels display little selectivity among monovalent cations and are blocked by divalent cations. The property of K+ selectivity is related to the presence of two amino acids that are absent from the pore-forming region of the cyclic nucleotide-gated channels. These data demonstrate that very small differences in the primary structure of an ion channel can account for extreme functional diversity, and they suggest a possible connection between the pore-forming regions of K+, Ca2+, and cyclic nucleotide-gated ion channels.			HEGINBOTHAM, L (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.				NIGMS NIH HHS [GM43949, GM47400] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400, R01GM043949] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; DELGADO R, 1991, P NATL ACAD SCI USA, V88, P557, DOI 10.1073/pnas.88.2.557; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hille B., 1991, IONIC CHANNELS EXCIT; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YAU KW, 1981, NATURE, V292, P502, DOI 10.1038/292502a0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZIMMERMAN AL, 1992, J PHYSIOL-LONDON, V449, P759, DOI 10.1113/jphysiol.1992.sp019112; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	42	372	380	2	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1152	1155		10.1126/science.1279807	http://dx.doi.org/10.1126/science.1279807			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1279807				2022-12-28	WOS:A1992JX85200033
J	LAINE, L; DRETLER, RH; CONTEAS, CN; TUAZON, C; KOSTER, FM; SATTLER, F; SQUIRES, K; ISLAM, MZ				LAINE, L; DRETLER, RH; CONTEAS, CN; TUAZON, C; KOSTER, FM; SATTLER, F; SQUIRES, K; ISLAM, MZ			FLUCONAZOLE COMPARED WITH KETOCONAZOLE FOR THE TREATMENT OF CANDIDA ESOPHAGITIS IN AIDS - A RANDOMIZED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						ACQUIRED IMMUNODEFICIENCY SYNDROME; FLUCONAZOLE; KETOCONAZOLE; CANDIDIASIS; ESOPHAGITIS	ACQUIRED IMMUNODEFICIENCY SYNDROME; INFECTION; SYMPTOMS	Objective: To determine the clinical and endoscopic response of candida esophagitis to antifungal therapy and to compare the two oral antifungal agents, fluconazole and ketoconazole. Design: Multicenter, randomized, double-blind trial. Setting: Fifteen U.S. centers including university, private practice, and county hospital settings. Patients: A total of 169 patients with the acquired immunodeficiency syndrome (AIDS); odynophagia, dysphagia, or retrosternal pain; white esophageal plaques at endoscopy; and pseudohyphae on esophageal brushings or biopsies. Intervention: Patients were randomly assigned to fluconazole (100 mg/d) or ketoconazole (200 mg/d). Doses were doubled at week 1 or 2 if no symptomatic improvement had occurred during the preceding week. Therapy was continued for 2 weeks after resolution of symptoms or for a maximum of 8 weeks. Measurements: Patients were clinically evaluated weekly, and laboratory tests were done every 2 weeks. Endoscopy was repeated within 5 days after the end of therapy. Results: A total of 143 patients were clinically evaluable (assessed within 7 days after therapy), and 129 patients were endoscopically evaluable (endoscopy repeated after therapy). Endoscopic cure occurred in 91% of patients treated with fluconazole and in 52% of those given ketoconazole for a difference of 39% (95% Cl, 24% to 52%; P < 0.001). Esophageal symptoms resolved in 85% of fluconazole-treated patients and in 65% of ketoconazole-treated patients for a difference of 20% (Cl, 6% to 34%; P = 0.006). Intention-to-treat analyses also yielded statistically significant differences for the comparisons listed above. Side effects were minimal and comparable in the two groups; only one patient in each group had therapy discontinued for adverse effects that were possibly related to the study medications. Conclusions: Fluconazole is associated with significantly greater rates of endoscopic and clinical cure than ketoconazole in patients with AIDS and candida esophagitis. Both drugs appear to be safe and well tolerated.										ALEXANDER JA, 1988, DIGEST DIS SCI, V33, P1121, DOI 10.1007/BF01535788; BLUM RA, 1991, ANN INTERN MED, V114, P755, DOI 10.7326/0003-4819-114-9-755; BONACINI M, 1991, ARCH INTERN MED, V151, P1567, DOI 10.1001/archinte.151.8.1567; CONNOLLY GM, 1989, GUT, V30, P1033, DOI 10.1136/gut.30.8.1033; DESCHAMPS MMH, 1988, AM J GASTROENTEROL, V83, P20; DISMUKES WE, 1988, ANN INTERN MED, V109, P177, DOI 10.7326/0003-4819-109-3-177; FAZIO RA, 1983, AM J GASTROENTEROL, V78, P261; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GELB A, 1986, AM J GASTROENTEROL, V81, P619; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; HENDEL L, 1988, SCAND J GASTROENTERO, V23, P1182, DOI 10.3109/00365528809090188; KANTROWITZ PA, 1969, GASTROENTEROLOGY, V57, P424; LAKEBAKAAR G, 1988, ANN INTERN MED, V109, P471, DOI 10.7326/0003-4819-109-6-471; LAKEBAKAAR G, 1988, ANN INTERN MED, V109, P502, DOI 10.7326/0003-4819-109-6-502; LALOR E, 1991, DIGEST DIS SCI, V36, P279, DOI 10.1007/BF01318196; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; MEDOFF G, 1972, ARCH INTERN MED, V130, P241, DOI 10.1001/archinte.130.2.241; SAAG MS, 1988, ANTIMICROB AGENTS CH, V32, P1, DOI 10.1128/AAC.32.1.1; SMITH DE, 1991, AIDS, V5, P1367, DOI 10.1097/00002030-199111000-00014; WALSH TJ, 1988, POSTGRAD MED, V84, P193; WHEELER RR, 1987, REV INFECT DIS, V9, P88	21	124	126	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					655	660		10.7326/0003-4819-117-8-655	http://dx.doi.org/10.7326/0003-4819-117-8-655			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1308663				2022-12-28	WOS:A1992JR86100005
J	LACROIX, A; BOLTE, E; TREMBLAY, J; DUPRE, J; POITRAS, P; FOURNIER, H; GARON, J; GARREL, D; BAYARD, F; TAILLEFER, R; FLANAGAN, RJ; HAMET, P				LACROIX, A; BOLTE, E; TREMBLAY, J; DUPRE, J; POITRAS, P; FOURNIER, H; GARON, J; GARREL, D; BAYARD, F; TAILLEFER, R; FLANAGAN, RJ; HAMET, P			GASTRIC-INHIBITORY POLYPEPTIDE DEPENDENT CORTISOL HYPERSECRETION - A NEW CAUSE OF CUSHINGS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MACRONODULAR ADRENAL-HYPERPLASIA; NODULAR ADRENOCORTICAL HYPERPLASIA; ENDOCRINE NEOPLASIA TYPE-2A; ADENYLATE-CYCLASE; GIP RECEPTORS; CELL-LINE; DISEASE; INSULIN; GLUCOSE; HYPERCORTISOLISM	Background. Corticotropin-independent nodular adrenal hyperplasia is a rare cause of Cushing's syndrome, and the factors responsible for the adrenal hyperplasia are not known. Methods. We studied a 48-year-old woman with Cushing's syndrome, nodular adrenal hyperplasia, and undetectable plasma corticotropin concentrations in whom food stimulated cortisol secretion. Results. Cortisol secretion had an inverse diurnal rhythm in this patient, with low-to-normal fasting plasma cortisol concentrations and elevated postprandial cortisol concentrations that could not be suppressed with dexamethasone. The cortisol concentrations increased in response to oral glucose (4-fold increase) and a lipid-rich meal (4.8-fold increase) or a protein-rich meal (2.6-fold increase), but not intravenous glucose. The infusion of somatostatin blunted the plasma cortisol response to oral glucose. Intravenous infusion of gastric inhibitory polypeptide (GIP) for one hour increased the plasma cortisol concentration in the patient but not in four normal subjects. Fasting plasma GIP concentrations in the patient were similar to those in the normal subjects; feeding the patient test meals induced increases in plasma GIP concentrations that paralleled those in plasma cortisol concentrations. Cell suspensions of adrenal tissue from the patient produced more cortisol when stimulated by GIP than when stimulated by corticotropin. In contrast, adrenal cells from normal adults and fetuses or patients with cortisol-producing or aldosterone-producing adenomas responded to corticotropin but not to GIP. Conclusions. Nodular adrenal hyperplasia and Cushing's syndrome may be food-dependent as a result of abnormal responsiveness of adrenal cells to physiologic secretion of GIP. "Illicit" (ectopic) expression of GIP receptors on adrenal cells presumably underlies this disorder.	HOP HOTEL DIEU,RES CTR,MOLEC PATHOPHYSIOL LAB,MONTREAL H2W 1T8,QUEBEC,CANADA; HOP HOTEL DIEU,DEPT NUCL MED,MONTREAL H2W 1T8,QUEBEC,CANADA; HOP ST LUC,DIV GASTROENTEROL,MONTREAL,QUEBEC,CANADA; MERCK FROSST CANADA INC,MONTREAL,QUEBEC,CANADA; CLIN RES INST MONTREAL,NUTR & CANC LAB,MONTREAL H2W 1R7,QUEBEC,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,DEPT RADIOL,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV WESTERN ONTARIO,UNIV HOSP,LONDON N6A 5A5,ONTARIO,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal; Merck & Company; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; Western University (University of Western Ontario)	LACROIX, A (corresponding author), HOP HOTEL DIEU,DIV ENDOCRINOL METAB & NUTR,3840 ST URBAIN ST,MONTREAL H2W 1T8,QUEBEC,CANADA.		Cossette, Suzanne/I-8008-2016; Lacroix, Andre/AAI-5645-2020					ABOUSAMRA AB, 1985, J CLIN ENDOCR METAB, V61, P116; AIBA M, 1991, AM J CLIN PATHOL, V96, P334, DOI 10.1093/ajcp/96.3.334; AMIRANOFF B, 1986, EUR J BIOCHEM, V159, P353, DOI 10.1111/j.1432-1033.1986.tb09875.x; AMIRANOFF B, 1984, BIOCHEM BIOPH RES CO, V123, P671, DOI 10.1016/0006-291X(84)90281-X; ARENDT J, 1982, CLIN ENDOCRINOL, V16, P89, DOI 10.1111/j.1365-2265.1982.tb03151.x; ARON DC, 1981, AM J MED, V71, P302, DOI 10.1016/0002-9343(81)90132-7; BROWN JC, 1982, MONOGRAPHS ENDOCRINO, V24, P1; CHEITLIN RA, 1988, HORM RES, V29, P162, DOI 10.1159/000180995; CUGINI P, 1989, ENDOCRINOL JAPON, V36, P101; DOPPMAN JL, 1988, RADIOLOGY, V166, P347, DOI 10.1148/radiology.166.2.2827231; DOPPMAN JL, 1991, J COMPUT ASSIST TOMO, V15, P773, DOI 10.1097/00004728-199109000-00009; EMAMI S, 1986, PEPTIDES, V7, P121, DOI 10.1016/0196-9781(86)90174-9; FINDLAY JC, 1991, 73RD ANN M END SOC W, P259; FISH HR, 1986, CLIN NEUROPHARMACOL, V9, P303, DOI 10.1097/00002826-198606000-00009; HAMET P, 1987, CLIN INVEST MED, V10, P530; HASHIMOTO K, 1986, ENDOCRINOL JAPON, V33, P479; HERMUS AR, 1988, NEW ENGL J MED, V318, P966, DOI 10.1056/NEJM198804143181506; JACKSON JA, 1989, J ENDOCRINOL INVEST, V12, P269, DOI 10.1007/BF03349984; JORDE R, 1981, SCAND J GASTROENTERO, V16, P113; KATZ MS, 1985, J CLIN ENDOCR METAB, V60, P900, DOI 10.1210/jcem-60-5-900; KRARUP T, 1985, AM J PHYSIOL, V249, pE195, DOI 10.1152/ajpendo.1985.249.2.E195; KRARUP T, 1983, J CLIN ENDOCR METAB, V56, P1306, DOI 10.1210/jcem-56-6-1306; LAMBERTS SWJ, 1984, J CLIN ENDOCR METAB, V58, P1106, DOI 10.1210/jcem-58-6-1106; LARDINOIS CK, 1988, J AM COLL NUTR, V7, P241, DOI 10.1080/07315724.1988.10720241; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LUCEY MR, 1984, CLIN ENDOCRINOL, V21, P209, DOI 10.1111/j.1365-2265.1984.tb03461.x; MAKINO S, 1989, ENDOCRINOL JAPON, V36, P655; MALCHOFF CD, 1989, J CLIN ENDOCR METAB, V68, P855, DOI 10.1210/jcem-68-4-855; MALETTI M, 1987, DIABETES, V36, P1336, DOI 10.2337/diabetes.36.11.1336; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MCGUIGAN JE, 1989, ENDOCRINOLOGY, V3, P2741; PAGE DL, 1986, TUMORS ADRENAL AFIP, P66; POITRAS P, 1980, GUT, V21, P299, DOI 10.1136/gut.21.4.299; REZNIK Y, 1992, NEW ENGL J MED, V327, P981, DOI 10.1056/NEJM199210013271403; SALERA M, 1982, DIGESTION, V24, P126, DOI 10.1159/000198787; SCHLESER S, 1986, METABOLISM, V35, P679, DOI 10.1016/0026-0495(86)90234-9; SCHORR I, 1972, J CLIN ENDOCR METAB, V34, P447, DOI 10.1210/jcem-34-3-447; SCHORR I, 1971, J BIOL CHEM, V246, P5806; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SMALS AGH, 1984, J CLIN ENDOCR METAB, V58, P25, DOI 10.1210/jcem-58-1-25; TAKEMURA T, 1983, ACTA PATHOL JAPON, V33, P159; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; YOUNG WF, 1989, NEW ENGL J MED, V321, P1659, DOI 10.1056/NEJM198912143212407	43	273	277	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					974	980		10.1056/NEJM199210013271402	http://dx.doi.org/10.1056/NEJM199210013271402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1325608	Bronze			2022-12-28	WOS:A1992JQ22500002
J	SMITH, GD; PHILLIPS, AN				SMITH, GD; PHILLIPS, AN			CONFOUNDING IN EPIDEMIOLOGIC STUDIES - WHY INDEPENDENT EFFECTS MAY NOT BE ALL THEY SEEM	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; MYOCARDIAL-INFARCTION; CERVICAL-CANCER; MEN; DISEASE; SMOKING; HEALTH		UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON W1N 8AA,ENGLAND	University of London; University College London	SMITH, GD (corresponding author), UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8RZ,SCOTLAND.		Phillips, Andrew N/B-4427-2008; Davey Smith, George/A-7407-2013	Phillips, Andrew N/0000-0003-2384-4807; Davey Smith, George/0000-0002-1407-8314				ANGELL M, 1990, NEW ENGL J MED, V323, P823, DOI 10.1056/NEJM199009203231209; BARKER DJP, 1989, LANCET, V2, P577; DOYLE LW, 1992, LANCET, V339, P744, DOI 10.1016/0140-6736(92)90643-H; FEINSTEIN AR, 1988, SCIENCE, V242, P1257, DOI 10.1126/science.3057627; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; HILL AB, 1953, NEW ENGL J MED, V248, P995, DOI 10.1056/NEJM195306112482401; HOPKINS PN, 1981, ATHEROSCLEROSIS, V40, P1, DOI 10.1016/0021-9150(81)90122-2; KANNEL WB, 1983, AM J MED, V75, P4, DOI 10.1016/0002-9343(83)90111-0; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MACDONALD NE, 1990, JAMA-J AM MED ASSOC, V263, P3155, DOI 10.1001/jama.263.23.3155; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; ORR DP, 1991, PEDIATRICS, V87, P141; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSENBERG L, 1988, AM J EPIDEMIOL, V128, P570, DOI 10.1093/oxfordjournals.aje.a115004; ROTKIN ID, 1967, AM J PUBLIC HEALTH N, V57, P815, DOI 10.2105/AJPH.57.5.815; SAVITZ DA, 1989, AM J EPIDEMIOL, V129, P1062, DOI 10.1093/oxfordjournals.aje.a115210; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; Shaw George Bernard, 1944, EVERYBODYS POLITICAL; SLATTERY ML, 1989, JAMA-J AM MED ASSOC, V261, P1593, DOI 10.1001/jama.261.11.1593; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; [No title captured]	27	118	120	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1992	305	6856					757	759		10.1136/bmj.305.6856.757	http://dx.doi.org/10.1136/bmj.305.6856.757			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1298234	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JQ52000026
J	LLOYD, DK; PILGRIM, AJ; SIMMONS, VE				LLOYD, DK; PILGRIM, AJ; SIMMONS, VE			CORONARY VASOSPASM AND SUMATRIPTAN	BRITISH MEDICAL JOURNAL			English	Letter											LLOYD, DK (corresponding author), GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND.							CASTLE WM, 1992, BRIT MED J, V305, P117, DOI 10.1136/bmj.305.6845.117-c; CHESTER AH, 1990, CARDIOVASC RES, V24, P932, DOI 10.1093/cvr/24.11.932; STRICKLER BHC, 1992, BMJ, V305, P1118; WILLETT F, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415	4	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					310	311		10.1136/bmj.305.6848.310-d	http://dx.doi.org/10.1136/bmj.305.6848.310-d			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1327366	Green Published			2022-12-28	WOS:A1992JG74000044
J	RIZZUTO, R; SIMPSON, AWM; BRINI, M; POZZAN, T				RIZZUTO, R; SIMPSON, AWM; BRINI, M; POZZAN, T			RAPID CHANGES OF MITOCHONDRIAL CA2+ REVEALED BY SPECIFICALLY TARGETED RECOMBINANT AEQUORIN	NATURE			English	Article							CALCIUM; CELLS; CA-2+; INVOLVEMENT; RECEPTOR; PROTEINS	INTRODUCTION of Ca2+ indicators (photoproteins, fluorescent dyes) that can be trapped in the cytosolic compartment of living cells has yielded major advances in our knowledge of Ca2+ homeostasis1,2. Ca2+ however regulates functions not only in the cytosol but also within various organelles3,4 where indicators have not yet been specifically targeted. Here we present a novel procedure by which the free Ca2+ concentration of mitochondria, [Ca2+]m, can be monitored continuously at rest and during stimulation. The complementary DNA for the Ca2+ sensitive photoprotein aequorin was fused in frame with that encoding a mitochondrial presequence. The hybrid cDNA was transfected into bovine endothelial cells and stable clones were obtained expressing variable amounts of mitochondrially targeted apoaequorin. The functional photoprotein could be reconstituted in intact cells by incubation with purified coelenterazine and [Ca2+]m could thus be monitored in situ. This allowed the unprecedented direct demonstration that agonist-stimulated elevations of cytosolic free Ca2+, [Ca2+]i, (measured in parallel with Fura-2) evoke rapid and transient increases of [Ca2+]m, which can be prevented by pretreatment with a mitochondrial uncoupler. The possibility of targeting aequorin to cellular organelles not only offers a new and powerful method for studying aspects of Ca2+ homeostasis that up to now could not be directly approached, but might also be used in the future as a tool to report in situ a variety of apparently unrelated phenomena of wide biological interest.	UNIV OXFORD, PHYSIOL LAB, OXFORD OX1 3PT, ENGLAND	University of Oxford	RIZZUTO, R (corresponding author), UNIV PADUA, DEPT BIOMED SCI, VIA TRIESTE 75, I-35121 PADUA, ITALY.		Brini, Marisa/K-5189-2016; Rizzuto, Rosario/B-6312-2008	Brini, Marisa/0000-0001-5141-0243; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [126] Funding Source: Medline	Telethon(Fondazione Telethon)		ALLEN DG, 1978, NATURE, V273, P509, DOI 10.1038/273509a0; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; Blinks J.R., 1978, Methods in Enzymology, V57, P292; CASADEI J, 1990, P NATL ACAD SCI USA, V87, P2047, DOI 10.1073/pnas.87.6.2047; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; DEPIERRE JW, 1974, J BIOL CHEM, V249, P7111; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KNIGHT MR, 1991, FEBS LETT, V282, P405, DOI 10.1016/0014-5793(91)80524-7; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; RIZZUTO R, 1989, J BIOL CHEM, V264, P10595; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; Sambrook J, 1989, MOL CLONING; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHIMOMURA O, 1991, CELL CALCIUM, V12, P635, DOI 10.1016/0143-4160(91)90060-R; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TANAHASHI H, 1990, GENE, V96, P249, DOI 10.1016/0378-1119(90)90260-X; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49	36	783	827	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1992	358	6384					325	327		10.1038/358325a0	http://dx.doi.org/10.1038/358325a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1322496				2022-12-28	WOS:A1992JE68400062
J	OROURKE, B; BACKX, PH; MARBAN, E				OROURKE, B; BACKX, PH; MARBAN, E			PHOSPHORYLATION-INDEPENDENT MODULATION OF L-TYPE CALCIUM CHANNELS BY MAGNESIUM-NUCLEOTIDE COMPLEXES	SCIENCE			English	Article							GUINEA-PIG HEART; SINGLE VENTRICULAR CELLS; ADENOSINE-TRIPHOSPHATE; INWARD RECTIFICATION; POTASSIUM CHANNELS; CARDIAC MYOCYTES; CYCLIC-AMP; INACTIVATION; CA-2+; BLOCK	Free magnesium ions and magnesium-nucleotide complexes can exert opposite effects on many fundamental cellular processes. Although increases in the intracellular concentration of magnesium ions inhibit the L-type calcium current in heart cells, magnesium-adenosine triphosphate complexes (MgATP) would be expected to increase the current by promoting channel phosphorylation. Rapid increases in the intracellular concentration of MgATP induced by flash photolysis of caged magnesium or caged ATP resulted in enhanced calcium current. The increase in calcium current was not prevented by blocking phosphorylation, revealing a previously unrecognized direct regulatory action of the magnesium-nucleotide complex.	JOHNS HOPKINS UNIV,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205	Johns Hopkins University			Marban, Eduardo/GWC-8514-2022	O'Rourke, Brian/0000-0002-5548-4853	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036957, R37HL036957, F32HL007227] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07227, HL 36957] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUS ZS, 1989, BELLJUU, V256, pC452; Aikawa J.K., 1981, MAGNESIUM ITS BIOL S; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARTALEJO CR, 1990, NATURE, V348; BACKX PH, 1991, AM J HYPERTENS, V4, P416; BELLES B, 1988, PFLUG ARCH EUR J PHY, V411, P353, DOI 10.1007/BF00587713; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; FABIATO A, 1975, J PHYSIOL-LONDON, V249, P497, DOI 10.1113/jphysiol.1975.sp011027; FINDLAY I, 1987, J PHYSIOL-LONDON, V391, P611, DOI 10.1113/jphysiol.1987.sp016759; GARNER PS, 1973, FEBS LETT, V34, P243, DOI 10.1016/0014-5793(73)80803-8; GOLDHABER JI, 1991, J PHYSIOL-LONDON, V443, P371, DOI 10.1113/jphysiol.1991.sp018838; GURNEY AM, 1989, NATURE, V341, P65, DOI 10.1038/341065a0; HARTZELL HC, 1989, J GEN PHYSIOL, V94, P745, DOI 10.1085/jgp.94.4.745; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUME JR, 1991, P NATL ACAD SCI USA, V88, P6946; IRISAWA H, 1983, J PHYSIOL-LONDON, V338, P321, DOI 10.1113/jphysiol.1983.sp014675; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KAMEYAMA M, 1985, PFLUG ARCH EUR J PHY, V405, P285, DOI 10.1007/BF00582573; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORAD M, 1988, SCIENCE, V241, P842, DOI 10.1126/science.2457253; RUBIN H, 1975, P NATL ACAD SCI USA, V72, P3551, DOI 10.1073/pnas.72.9.3551; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; TANIGUCHI J, 1983, CIRC RES, V53, P131, DOI 10.1161/01.RES.53.2.131; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; TUNG RT, 1991, J PHYSIOL-LONDON, V437, P239, DOI 10.1113/jphysiol.1991.sp018593; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745	35	113	113	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					245	248		10.1126/science.1321495	http://dx.doi.org/10.1126/science.1321495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321495				2022-12-28	WOS:A1992JC58500040
J	SULLIVAN, V; TALARICO, CL; STANAT, SC; DAVIS, M; COEN, DM; BIRON, KK				SULLIVAN, V; TALARICO, CL; STANAT, SC; DAVIS, M; COEN, DM; BIRON, KK			A PROTEIN-KINASE HOMOLOG CONTROLS PHOSPHORYLATION OF GANCICLOVIR IN HUMAN CYTOMEGALOVIRUS-INFECTED CELLS	NATURE			English	Article							HERPES-SIMPLEX VIRUS; VARICELLA-ZOSTER VIRUS; COMPLETE DNA-SEQUENCE; EPSTEIN-BARR VIRUS; GENOME; PHOSPHOTRANSFERASE; HERPESVIRUSES; EXPRESSION; ACYCLOVIR	HUMAN cytomegalovirus (HCMV) is a major pathogen in immunosuppressed individuals, including patients with acquired immune deficiency syndrome. The nucleoside analogue ganciclovir (9-(1,3-dihydroxy-2-propoxymethyl)-guanine) is one of the few drugs available to treat HCMV infections, but resistant virus is a growing problem in the clinic 1 and there is a critical need for new drugs. The study of ganciclovir-resistant mutants has indicated that the selective action of ganciclovir depends largely on virus-controlled phosphorylation in HCMV-infected cells 2-5. The enzyme(s) responsible have not been identified. Here we report that the HCMV gene UL97, whose predicted product shares regions of homology with protein kinases, guanylyl cyclase and bacterial phosphotransferases 6-8, controls phosphorylation of ganciclovir in HCMV-infected cells. A four-amino-acid deletion of UL97 in a conserved region, which in cyclic AMP-dependent protein kinase participates in substrate recognition 9, causes impaired ganciclovir phosphorylation. The implications of these results for antiviral drug development and drug resistance are discussed.	BURROUGHS WELLCOME CO, DIV VIROL, RES TRIANGLE PK, NC 27709 USA	Burroughs Wellcome Fund	SULLIVAN, V (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.							AGUT H, 1989, RES VIROLOGY, V140, P219, DOI 10.1016/S0923-2516(89)80099-8; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BIRON KK, 1986, P NATL ACAD SCI USA, V83, P8769, DOI 10.1073/pnas.83.22.8769; BIRON KK, 1985, P NATL ACAD SCI USA, V82, P2473, DOI 10.1073/pnas.82.8.2473; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BRITT WJ, 1986, J VIROL, V58, P185, DOI 10.1128/JVI.58.1.185-191.1986; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEE MS, 1989, J GEN VIROL, V70, P1151, DOI 10.1099/0022-1317-70-5-1151; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DILUCA D, 1990, VIROLOGY, V175, P199, DOI 10.1016/0042-6822(90)90200-B; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; FLECKENSTEIN B, 1982, GENE, V18, P39, DOI 10.1016/0378-1119(82)90054-3; FREITAS VR, 1985, ANTIMICROB AGENTS CH, V28, P240, DOI 10.1128/AAC.28.2.240; FYFE JA, 1983, MOL PHARMACOL, V24, P316; FYFE JA, 1978, J BIOL CHEM, V253, P8721; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; LITTLER E, 1992, NATURE, V358, P160, DOI 10.1038/358160a0; MAR EC, 1981, J GEN VIROL, V57, P149, DOI 10.1099/0022-1317-57-1-149; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MICHELSON S, 1984, VIROLOGY, V134, P259, DOI 10.1016/0042-6822(84)90295-2; ROBY C, 1986, J VIROL, V59, P714, DOI 10.1128/JVI.59.3.714-727.1986; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SMITH RF, 1989, J VIROL, V63, P450, DOI 10.1128/JVI.63.1.450-455.1989; SOMOGYI T, 1990, VIROLOGY, V174, P276, DOI 10.1016/0042-6822(90)90075-3; STANAT SC, 1991, ANTIMICROB AGENTS CH, V35, P2191, DOI 10.1128/AAC.35.11.2191	28	368	373	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					162	164		10.1038/358162a0	http://dx.doi.org/10.1038/358162a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1319560				2022-12-28	WOS:A1992JC58300056
J	GOLDBERG, AL; ROCK, KL				GOLDBERG, AL; ROCK, KL			PROTEOLYSIS, PROTEASOMES AND ANTIGEN PRESENTATION	NATURE			English	Review							MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR-WEIGHT PROTEASE; MULTICATALYTIC PROTEINASE COMPLEX; RAT-LIVER; SKELETAL-MUSCLE; DEPENDENT PROTEOLYSIS; RABBIT RETICULOCYTES; 26S COMPLEX; T-CELLS; UBIQUITIN	Proteins presented to the immune system must first be cleaved to small peptides by intracellular proteinases. Proteasomes are proteolytic complexes that degrade cytosolic and nuclear proteins. These particles have been implicated in ATP-ubiquitin-dependent proteolysis and in the processing of intracellular antigens for cytolytic immune responses.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	GOLDBERG, AL (corresponding author), HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA.							AHN JY, 1991, J BIOL CHEM, V266, P15746; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; ARMON T, 1990, J BIOL CHEM, V265, P20723; ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BOCHES F, 1982, SCIENCE, V215, P1027; BRODSKY FM, 1990, NATURE, V348, P581, DOI 10.1038/348581a0; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; DAVIES JD, 1991, J EXP MED, V173, P823, DOI 10.1084/jem.173.4.823; DEMARTINO GN, 1979, J BIOL CHEM, V254, P3712; DESA MFG, 1988, J CELL BIOL, V107, P1517, DOI 10.1083/jcb.107.4.1517; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DICE JF, 1990, SEMINARS CELL BIOL; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; ESTRELA J, IN PRESS J BIOL CHEM; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FAGAN JM, 1987, BIOCHEM J, V243, P335, DOI 10.1042/bj2430335; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALKENBURG PE, 1988, NATURE, V331, P190, DOI 10.1038/331190a0; FINLEY D, 1991, REV CELL BIOL, V7, P25; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; Goldberg A L, 1990, Semin Cell Biol, V1, P423; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; HAASS C, 1989, EMBO J, V8, P2373, DOI 10.1002/j.1460-2075.1989.tb08366.x; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HERSHKO A, 1988, J BIOL CHEM, V262, P8303; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HOUGH R, 1986, J BIOL CHEM, V261, P2391; Hough R. F., 1988, UBIQUITIN, P101, DOI 10.1007/978-1-4899-2049-2_5; IKAI A, 1991, FEBS LETT, V292, P21, DOI 10.1016/0014-5793(91)80824-M; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KETTELHUT IC, 1988, DIABETES METAB REV, V4, P751, DOI 10.1002/dmr.5610040805; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KLEINSCHMIDT JA, 1988, FEBS LETT, V239, P35, DOI 10.1016/0014-5793(88)80540-4; KNECHT E, 1991, J BIOCH SOC T, V19, P2935; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MENON AS, 1987, J BIOL CHEM, V262, P14929; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; MULLER M, 1980, EUR J BIOCHEM, V109, P405, DOI 10.1111/j.1432-1033.1980.tb04808.x; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; MYKLES DL, 1991, ARCH BIOCHEM BIOPHYS, V288, P543, DOI 10.1016/0003-9861(91)90233-9; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PAL JK, 1988, J CELL SCI, V90, P555; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; PETERS JM, 1991, EUR J CELL BIOL, V56, P422; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; PURI J, 1988, J IMMUNOL, V141, P3313; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; ROBERTSON M, 1991, NATURE, V353, P300, DOI 10.1038/353300a0; ROSE IA, 1979, J BIOL CHEM, V254, P8135; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SCHERRER K, 1990, MOL BIOL REP, V14, P1, DOI 10.1007/BF00422709; SHELTON E, 1970, J CELL BIOL, V45, P1, DOI 10.1083/jcb.45.1.1; SPEISER S, 1982, J BIOL CHEM, V257, P4122; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J MOL BIOL, V203, P985, DOI 10.1016/0022-2836(88)90123-4; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TANAKA K, 1990, BIOCHEMISTRY-US, V29, P3777, DOI 10.1021/bi00467a026; TANAKA K, 1989, J CELL PHYSIOL, V139, P34, DOI 10.1002/jcp.1041390107; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; VANBLEEK GM, 1990, NATURE, V348, P213; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; WAXMAN L, 1986, FASEB J, V45, P1599; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; ZWICKL P, 1991, WEBS LETT, V278, P217	90	564	601	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 4	1992	357	6377					375	379		10.1038/357375a0	http://dx.doi.org/10.1038/357375a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1317508				2022-12-28	WOS:A1992HX17200052
J	STEELE, FR; WASHBURN, T; RIEGER, R; OTOUSA, JE				STEELE, FR; WASHBURN, T; RIEGER, R; OTOUSA, JE			DROSOPHILA RETINAL-DEGENERATION-C (RDGC) ENCODES A NOVEL SERINE THREONINE PROTEIN PHOSPHATASE	CELL			English	Article							LIGHT-INDUCED PHOSPHORYLATION; CALCIUM-BINDING PROTEINS; CHROMOSOMAL LOCALIZATION; NERVOUS-SYSTEM; GENE; MELANOGASTER; RHODOPSIN; POLYPEPTIDES; SEQUENCE; KINASES	The Drosophila retinal degeneration C (rdgC) gene is required to prevent light-induced retinal degeneration. Molecular analysis shows that the rdgC transcription unit encodes a novel serine/threonine protein phosphatase. Amino acids 153-393 define a domain that has 30% identity with the catalytic domains of types 1, 2A, and 2B serine/threonine protein phosphatases. A putative regulatory domain is appended that contains multiple potential Ca2+-binding sites or "EF hand motifs." Thus, the analysis suggests that the rdgC protein is a novel type of serine/threonine protein phosphatase that is directly regulated by Ca2+. rdgC is expressed in the visual systems of the fly, as well as in the mushroom bodies of the central brain.	UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN 46556 USA	University of Notre Dame	STEELE, FR (corresponding author), NEI, IMMUNOL LAB, BETHESDA, MD 20892 USA.			O'Tousa, Joseph/0000-0001-9754-6816	NEI NIH HHS [EY06808] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALAWI AA, 1972, ADV EXPT MED BIOL, P1; AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; BLEST AD, 1991, VISUAL NEUROSCI, V7, P35, DOI 10.1017/S0952523800010920; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Catty D., 1988, ANTIBODIES, V1, P19; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHADER GJ, 1988, RETINAL DISEASES BIO, P80; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; COHEN PTW, 1988, FEBS LETT, V232, P17, DOI 10.1016/0014-5793(88)80378-8; COHEN PTW, 1991, METHOD ENZYMOL, V201, P398; COHEN S, 1991, TRENDS GENET, V7, P267; DOMBRADI V, 1989, EUR J BIOCHEM, V183, P603, DOI 10.1111/j.1432-1033.1989.tb21089.x; DOMBRADI V, 1989, FEBS LETT, V247, P391, DOI 10.1016/0014-5793(89)81377-8; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FEIN A, 1986, TRENDS NEUROSCI, V9, P110, DOI 10.1016/0166-2236(86)90037-8; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GUERINI D, 1991, ADV PROT PHOSPHATASE, V6, P391; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ITOH N, 1985, DROS INF SERVICE, V61, P89; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MATSUMOTO H, 1984, SCIENCE, V223, P184, DOI 10.1126/science.6419348; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; MISMER D, 1987, GENETICS, V116, P565; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; ORGAD S, 1987, EUR J BIOCHEM, V164, P31, DOI 10.1111/j.1432-1033.1987.tb10988.x; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHEIH BH, 1989, NATURE, V338, P67; SIEGFRIED E, 1990, TRENDS GENET, V6, P357, DOI 10.1016/0168-9525(90)90277-D; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P103; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; VIHTELIC TS, 1991, GENETICS, V127, P761; YANG SD, 1991, BIOCHEM BIOPH RES CO, V178, P1306, DOI 10.1016/0006-291X(91)91036-C; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	55	137	139	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					669	676		10.1016/0092-8674(92)90230-A	http://dx.doi.org/10.1016/0092-8674(92)90230-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1316807				2022-12-28	WOS:A1992HV08900011
J	MARGOLIS, PA; COOK, RL; EARP, JA; LANNON, CM; KEYES, LL; KLEIN, JD				MARGOLIS, PA; COOK, RL; EARP, JA; LANNON, CM; KEYES, LL; KLEIN, JD			FACTORS ASSOCIATED WITH PEDIATRICIANS PARTICIPATION IN MEDICAID IN NORTH-CAROLINA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - To describe the relative importance of factors influencing pediatricians' participation in Medicaid in North Carolina. Design. - Questionnaire survey. Setting and Participants. - Nonacademic primary care pediatricians in direct patient care at least 50% of the time; 332 (85%) of the 389 eligible pediatricians responded. Main Outcome Measures. - Proportion of pediatricians who restricted Medicaid patients' access to their practices. The association between restricting access and the following factors was assessed: Medicaid reimbursement, pediatricians' demographic characteristics, knowledge of the Medicaid program, attitudes toward Medicaid patients and the Medicaid program, and beliefs about whether other physicians were available to care for Medicaid patients. Results. - Twenty-nine percent of pediatricians restricted Medicaid patients' access to their practices. The proportion of pediatricians restricting access was 62% in cities, 13% in medium-sized towns, and 12% in small towns (P < .001), but the proportion of pediatricians in cities who restricted access varied from 87% to 22%. Pediatricians who received a higher proportion of their usual fee were less likely to restrict Medicaid patients' access. The relationship between Medicaid payment and restricted access was substantially weakened after controlling for the following factors: (1) the size of the community, (2) pediatricians' attitudes toward Medicaid payment, (3) their perceptions that they were too busy to care for Medicaid patients, and (4) whether there were other resources for the care of Medicaid patients. At comparable levels of payment, rural pediatricians were about six times less likely than urban pediatricians to restrict access. Pediatricians who knew less about Medicaid reimbursement also restricted access more often. Whether or not they restricted access to new Medicaid patients, pediatricians provided acute, preventive, hospital, and emergency care to the Medicaid patients who were already in their practices. Conclusions. - Existing resources for the care of Medicaid patients, pediatricians' economic dependence on Medicaid, and the local norms of practice may be important factors in pediatricians' decision to participate in Medicaid. Increasing reimbursement will have only modest effects on Medicaid participation. Strategies to improve participation should also address pediatricians' knowledge of the Medicaid program and enlist the support of community physicians.	UNIV N CAROLINA, SCH MED, DEPT PEDIAT, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, SCH PUBL HLTH, DEPT HLTH BEHAV & HLTH EDUC, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, FRANK PORTER GRAHAM CHILD DEV CTR, CHAPEL HILL, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Cook, Robert Lewis/ABI-4866-2020	Klein, Jonathan/0000-0003-4185-1998				Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DAVIDSON SM, 1983, PEDIATRICS, V72, P552; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; FOSSETT JW, 1989, MED CARE, V27, P386, DOI 10.1097/00005650-198904000-00006; HADLEY J, 1979, HEALTH SERV RES, V14, P266; Held P J, 1985, Health Care Financ Rev, V7, P49; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; MCMANUS M, 1991, PEDIATRICS, V87, P909; MILKO C, 1990, SURVEY HLTH DEP CHIL; MITCHELL JB, 1984, MED CARE, V22, P1026, DOI 10.1097/00005650-198411000-00005; MITCHELL JB, 1983, MED CARE, V21, P929, DOI 10.1097/00005650-198309000-00008; PERLOFF JD, 1987, J HEALTH POLIT POLIC, V12, P221, DOI 10.1215/03616878-12-2-221; PERLOFF JD, 1986, MED CARE, V24, P749, DOI 10.1097/00005650-198608000-00010; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; YUDKOWSKY BK, 1990, PEDIATRICS, V85, P567; 1983, NATIONAL HTLH SUR 13, V34; 1991, STATISTICAL REPORT M; 1990, N CAROLINA MUNICIPAL; 1991, 661 COMM CLEAR HOU 2; 1989, STATISTICAL REPORTS; 1990, N CAROLINA HLTH MANP	23	38	38	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1942	1946		10.1001/jama.267.14.1942	http://dx.doi.org/10.1001/jama.267.14.1942			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1296580				2022-12-28	WOS:A1992HL67700028
J	SCHAAKEKONING, C; VANDENBOGAERT, W; DALESIO, O; FESTEN, J; HOOGENHOUT, J; VANHOUTTE, P; KIRKPATRICK, A; KOOLEN, M; MAAT, B; NIJS, A; RENAUD, A; RODRIGUS, P; SCHUSTERUITTERHOEVE, L; SCULIER, JP; VANZANDWIJK, N; BARTELINK, H				SCHAAKEKONING, C; VANDENBOGAERT, W; DALESIO, O; FESTEN, J; HOOGENHOUT, J; VANHOUTTE, P; KIRKPATRICK, A; KOOLEN, M; MAAT, B; NIJS, A; RENAUD, A; RODRIGUS, P; SCHUSTERUITTERHOEVE, L; SCULIER, JP; VANZANDWIJK, N; BARTELINK, H			EFFECTS OF CONCOMITANT CISPLATIN AND RADIOTHERAPY ON INOPERABLE NON-SMALL-CELL LUNG-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPY ONCOLOGY GROUP; RADIATION-THERAPY; RANDOMIZED TRIAL; FRACTIONATED SCHEDULES; PROGNOSTIC FACTORS; TUMOR-CONTROL; CARCINOMA; IRRADIATION; SURVIVAL; MOUSE	Background and Methods. Cisplatin (cis-diamminedichloroplatinum) has been reported to enhance the cell-killing effect of radiation, an effect whose intensity varies with the schedule of administration. We randomly assigned 331 patients with nonmetastatic inoperable non-small-cell lung cancer to one of three treatments: radiotherapy for two weeks (3 Gy given 10 times, in five fractions a week), followed by a three-week rest period and then radiotherapy for two more weeks (2.5 Gy given 10 times, five fractions a week); radiotherapy on the same schedule, combined with 30 mg of cisplatin per square meter of body-surface area, given on the first day of each treatment week; or radiotherapy on the same schedule, combined with 6 mg of cisplatin per square meter, given daily before radiotherapy. Results. Survival was significantly improved in the radiotherapy-daily-cisplatin group as compared with the radiotherapy group (P = 0.009): survival in the radiotherapy-daily-cisplatin group was 54 percent at one year, 26 percent at two years, and 16 percent at three years, as compared with 46 percent, 13 percent, and 2 percent, respectively, in the radiotherapy group. Survival in the radiotherapy-weekly-cisplatin group was intermediate (44 percent, 19 percent, and 13 percent) and not significantly different from survival in either of the other two groups. The survival benefit of daily combined treatment was due to improved control of local disease (P = 0.003). Survival without local recurrence was 59 percent at one year and 31 percent at two years in the radiotherapy-daily-cisplatin group; 42 percent and 30 percent, respectively, in the radiotherapy-weekly-cisplatin group; and 41 percent and 19 percent, respectively, in the radiotherapy group. Cisplatin induced nausea and vomiting in 86 percent of the patients given it weekly and in 78 percent of those given it daily; these effects were severe in 26 percent and 28 percent, respectively. Conclusions. Cisplatin, given daily in combination with the radiotherapy described here to patients with nonmetastatic but inoperable non-small-cell lung cancer, improved rates of survival and control of local disease at the price of substantial side effects.	MIDDELHEIM ZIEKENHIUS,ANTWERP,BELGIUM; ST RADBOUD HOSP,NIJMEGEN,NETHERLANDS; INST JULES BORDET,B-1000 BRUSSELS,BELGIUM; EUROPEAN ORG RES TREATMENT CANC,CTR DATA,BRUSSELS,BELGIUM; EUROPEAN ORG RES TREATMENT CANC,RADIOTHERAPY GRP,BRUSSELS,BELGIUM; EUROPEAN ORG RES TREATMENT CANC,LUNG CANC COOPERAT GRP,BRUSSELS,BELGIUM; UNIV AMSTERDAM,ACAD MED CTR,1105 AZ AMSTERDAM,NETHERLANDS; DR BERNARD VERBEETEN INST,TILBURG,NETHERLANDS; CHU TIVOLI,LA LOUVIERE,BELGIUM	ZNA Middelheim Hospital; Radboud University Nijmegen; Institut Jules Bordet; European Organisation for Research & Treatment of Cancer; European Organisation for Research & Treatment of Cancer; European Organisation for Research & Treatment of Cancer; University of Amsterdam; Academic Medical Center Amsterdam; Instituut Verbeeten	SCHAAKEKONING, C (corresponding author), NETHERLANDS CANC INST,DEPT RADIOTHERAPY,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		koning, caro/A-5339-2008; van Zandwijk, Nico/E-4177-2012	van Zandwijk, Nico/0000-0002-8405-9688	NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER; NCI NIH HHS [5-U10-CA-11488-16, 5-U10-CA-11488-17, 5-U10-CA-11488-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1979, WHO HDB REPORTING RE; ARRIAGADA R, 1990, International Journal of Radiation Oncology, Biology, Physics, V19, P195, DOI 10.1016/0360-3016(90)90787-K; BARTELINK H, 1986, RADIOTHER ONCOL, V6, P61, DOI 10.1016/S0167-8140(86)80110-4; Bartelink H, 1988, RADIOBIOLOGY RADIOTH, P177; BEGG AC, 1989, RADIOTHER ONCOL, V15, P79, DOI 10.1016/0167-8140(89)90121-7; BEGG AC, 1989, ANTITUMOR DRUG RAD I, P154; COX JD, 1990, J CLIN ONCOL, V8, P1543, DOI 10.1200/JCO.1990.8.9.1543; COX JD, 1983, SEMIN ONCOL, V10, P81; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; DEWIT L, 1987, INT J RADIAT ONCOL, V13, P403, DOI 10.1016/0360-3016(87)90015-0; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; DOUPLE EB, 1988, NATL CANCER I MONOGR, V6, P315; FREISE G, 1978, THORAX, V33, P228, DOI 10.1136/thx.33.2.228; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; HARMER MH, 1978, TNM CLASSIFICATION M; HASELOW RE, 1990, HEAD NECK CANCER, V2, P279; HOLSTI LR, 1980, INT J RADIAT ONCOL, V6, P977, DOI 10.1016/0360-3016(80)90104-2; KEIZER H J, 1984, Radiotherapy and Oncology, V1, P227; KJAER M, 1982, CANCER TREAT REV, V9, P1, DOI 10.1016/S0305-7372(82)80002-9; LEE RE, 1976, AM J ROENTGENOL, V126, P116, DOI 10.2214/ajr.126.1.116; LELIEVELD P, 1985, INT J RADIAT ONCOL, V11, P111, DOI 10.1016/0360-3016(85)90369-4; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; PEREZ CA, 1982, CANCER-AM CANCER SOC, V50, P1091, DOI 10.1002/1097-0142(19820915)50:6<1091::AID-CNCR2820500612>3.0.CO;2-0; PEREZ CA, 1987, CANCER, V59, P1874, DOI 10.1002/1097-0142(19870601)59:11<1874::AID-CNCR2820591106>3.0.CO;2-Z; PETROVICH Z, 1981, CANCER, V48, P1335, DOI 10.1002/1097-0142(19810915)48:6<1335::AID-CNCR2820480614>3.0.CO;2-S; PINEDO HM, 1983, J CANCER RES CLIN, V105, P79, DOI 10.1007/BF00391836; SAUER R, 1990, INT J RADIAT ONCOL, V19, P687, DOI 10.1016/0360-3016(90)90497-8; SAUNDERS MI, 1984, INT J RADIAT ONCOL, V10, P499, DOI 10.1016/0360-3016(84)90029-4; SCHAAKEKONING C, 1986, INT J RADIAT ONCOL, V12, P379, DOI 10.1016/0360-3016(86)90354-8; SCHAAKEKONING C, 1990, INT J RADIAT ONCOL, V19, P967, DOI 10.1016/0360-3016(90)90020-K; SCHAAKEKONING C, 1991, EUR J CANCER, V27, P615, DOI 10.1016/0277-5379(91)90242-6; SCHAAKEKONING C, 1983, INT J RADIAT ONCOL, V9, P1023, DOI 10.1016/0360-3016(83)90392-9; SIMPSON JR, 1989, INT J RADIAT ONCOL, V16, P1483, DOI 10.1016/0360-3016(89)90953-X; STANLEY K, 1981, CANCER-AM CANCER SOC, V47, P2725, DOI 10.1002/1097-0142(19810601)47:11<2725::AID-CNCR2820471131>3.0.CO;2-Y; STANLEY KE, 1980, J NATL CANCER I, V65, P25; STEEL GG, 1988, RADIOTHER ONCOL, V11, P31, DOI 10.1016/0167-8140(88)90044-8; TANABE M, 1987, INT J RADIAT ONCOL, V13, P1523, DOI 10.1016/0360-3016(87)90320-8; THAMES HD, 1990, RADIOTHER ONCOL, V19, P219, DOI 10.1016/0167-8140(90)90149-Q; THOMPSON DT, 1967, J THORAC CARDIOV SUR, V53, P159, DOI 10.1016/S0022-5223(19)43216-9; VONDERMAASE H, 1986, RADIOTHER ONCOL, V5, P245, DOI 10.1016/S0167-8140(86)80054-8	40	1097	1124	2	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					524	530		10.1056/NEJM199202203260805	http://dx.doi.org/10.1056/NEJM199202203260805			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD658	1310160				2022-12-28	WOS:A1992HD65800005
J	HEALY, B				HEALY, B			EXERCISE RADIONUCLIDE ANGIOCARDIOGRAPHY PREDICTS CARDIAC DEATH IN PATIENTS WITH CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, CIRCULATION S1, V84, P52	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					209	209						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1309267				2022-12-28	WOS:A1992GY04600006
J	DOLL, R				DOLL, R			HILL,AUSTIN,BRADFORD AND THE PROGRESS OF MEDICAL SCIENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Biographical-Item									UNIV OXFORD, OXFORD, ENGLAND	University of Oxford	DOLL, R (corresponding author), RADCLIFFE INFIRM, ICRF, CANC STUDIES UNIT, OXFORD OX2 6BR, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1952, Br Med J, V2, P735; [Anonymous], 1992, Lancet, V339, P1; [Anonymous], 1948, BMJ, V2, P769; [Anonymous], J MINISTRY AGR; Armitage P, 1982, Stat Med, V1, P345, DOI 10.1002/sim.4780010412; Armitage P., 1960, SEQUENTIAL MED TRIAL; BERKSON J, 1959, P STAFF M MAYO CLIN, V34, P206; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Cox D., 1966, RES PAPERS STAT FEST, P55; COX DR, 1972, J R STAT SOC B, V34, P187; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; Fibiger J., 1898, HOSPITALSTIDENDE, V6, P337; Fibiger J, 1898, HOSPITALSTIDENDE, V6, P309; Fisher RA, 1935, DESIGN EXPT; GEHAN EA, 1974, NEW ENGL J MED, V290, P198, DOI 10.1056/NEJM197401242900405; HILL AP, PUBLICATION LIST; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PETO R, 1992, TOBACCO HLTH 1990 GL; Simpson RJS, 1904, BRIT MED J, V1904, P1243; SUSSER M, 1985, EPIDEMIOL REV, V7, P147, DOI 10.1093/oxfordjournals.epirev.a036280; Williams C, 1992, INTRO NEW TREATMENTS, P49; 1950, BMJ, V1, P1463; 1950, BMJ, V2, P425; 1937, LANCET, V1, P31; 1955, BMJ, V2, P695; 1979, SMOKING HLTH REPORT; 1964, 1962 3 MED RES COUNC, P21; 1955, BMJ, V1, P555; 1954, BMJ, V1, P1223	34	56	58	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 19	1992	305	6868					1521	1526		10.1136/bmj.305.6868.1521	http://dx.doi.org/10.1136/bmj.305.6868.1521			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286370	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100007
J	TRUOG, RD; BERDE, CB; MITCHELL, C; GRIER, HE				TRUOG, RD; BERDE, CB; MITCHELL, C; GRIER, HE			BARBITURATES IN THE CARE OF THE TERMINALLY ILL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; PAIN; ANALGESIA; PATIENT; CANCER; SODIUM				TRUOG, RD (corresponding author), CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA.							ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ANNAS GJ, 1991, HASTINGS CENT REP, V21, P33, DOI 10.2307/3562337; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P127; BEDAU HA, 1982, DEATH PENALTY AM, P17; BERDE CB, 1990, ANESTHESIOLOGY, V72, P1094, DOI 10.1097/00000542-199006000-00025; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; CARLON GC, 1978, CRIT CARE MED, V6, P311, DOI 10.1097/00003246-197809000-00002; CARTON RW, 1990, JAMA-J AM MED ASSOC, V263, P2221, DOI 10.1001/jama.263.16.2221; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; COHEN MH, 1992, CANCER INVEST, V10, P317, DOI 10.3109/07357909209032756; Coyle N, 1990, J Pain Symptom Manage, V5, P83; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Edwards B S, 1991, J Clin Ethics, V2, P118; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; FOSBURG MT, 1983, JAMA-J AM MED ASSOC, V250, P511, DOI 10.1001/jama.250.4.511; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; GREENE WR, 1991, SOUTHERN MED J, V84, P332, DOI 10.1097/00007611-199103000-00009; Humphry Derek, 1991, FINAL EXIT PRACTICAL; Kuhse Helga, 1992, Bioethics, V6, P233, DOI 10.1111/j.1467-8519.1992.tb00200.x; LOWENSTEIN DH, 1988, NEUROLOGY, V38, P395, DOI 10.1212/WNL.38.3.395; MERZ B, 1991, AM MED NEWS, V3, P35; Mount B, 1990, J Palliat Care, V6, P5; PINKNEY DS, 1992, AM MED NEWS     0420, P11; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; RALL T W, 1990, P345; RASHKIN MC, 1987, NEUROLOGY, V37, P500, DOI 10.1212/WNL.37.3.500; Roy D J, 1990, J Palliat Care, V6, P3; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; STAVER S, 1992, AM MED NEWS     0316, P4; STRAIN JD, 1986, RADIOLOGY, V161, P105, DOI 10.1148/radiology.161.1.3763851; Truog Robert D, 1991, J Clin Ethics, V2, P127; Ventafridda V, 1990, J Palliat Care, V6, P7; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WAY WL, 1986, ANESTHESIA, V2, P799; 1992, PRINCIPLES ANALGESIC	39	96	96	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1992	327	23					1678	1682		10.1056/NEJM199212033272311	http://dx.doi.org/10.1056/NEJM199212033272311			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA260	1279424				2022-12-28	WOS:A1992KA26000011
J	SIEGEL, D; GOLDEN, E; WASHINGTON, AE; MORSE, SA; FULLILOVE, MT; CATANIA, JA; MARIN, B; HULLEY, SB				SIEGEL, D; GOLDEN, E; WASHINGTON, AE; MORSE, SA; FULLILOVE, MT; CATANIA, JA; MARIN, B; HULLEY, SB			PREVALENCE AND CORRELATES OF HERPES-SIMPLEX INFECTIONS - THE POPULATION-BASED AIDS IN MULTIETHNIC NEIGHBORHOODS STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS TYPE-2 INFECTION; GENITAL HERPES; GLYCOPROTEIN-G; UNITED-STATES; ANTIBODIES; EPIDEMIOLOGY; RISK; IDENTIFICATION; CHILDREN; GENE	Objective.-To examine the extent and correlates of infection with herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in an inner-city community, we studied the prevalence of antibodies to these viruses and their association with risk behaviors in a representative sample of unmarried white, black, and Hispanic adults living in San Francisco, Calif. Design.-Cross-sectional, community-based, random household survey. Participants.-In 1988 and 1989, we surveyed 1770 unmarried men and women aged 20 to 44 years from three San Francisco neighborhoods of varying geographic and cultural characteristics. Main Outcome Measures.-HSV-1 and HSV-2 antibodies based on an immunodot assay using type-specific glycoproteins gG-1 and gG-2. Results.- blood samples from 1212 participants available for testing, 750 (62%) had HSV-1 antibodies and 400 (33%) had HSV-2 antibodies. After controlling for other variables, HSV-1 antibody was significantly correlated (P<.05) with older age (in heterosexual men, women, and homosexually active men), less education (in heterosexual men and women), and Hispanic (especially those not born in the United States) or black race. HSV-2 antibody was significantly correlated (P<.05) with female gender, number of lifetime sexual partners and older age (in heterosexual men and women), and low levels of education and black or Hispanic race (in women). Among those with antibody to HSV-2, only 28 (19%) of 149 men and 32 (13%) of 251 women reported a history of genital herpes. However, most men (62%) and women (84%) who reported a history of genital herpes had HSV-2 antibodies. We observed a similar pattern (low sensitivity and moderate specificity) for a history of facial herpes and the presence of HSV-1 antibodies. After controlling for other variables, HSV-2 antibodies were associated with a lower frequency of HSV-1 antibodies among homosexual men infected with the human immunodeficiency virus. Conclusions.-HSV-1 antibodies were found in nearly two thirds of single urban adults and were most common among Hispanics not born in the United States. HSV-2 antibodies were found in one third of this population and were associated with risk behaviors for sexually transmitted diseases. For both facial and genital herpes infections, self-reporting of infection was very insensitive and moderately specific.	NEW YORK STATE PSYCHIAT INST & HOSP,HIV CTR CLIN & BEHAV STUDIES,NEW YORK,NY 10032; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143; COLUMBIA UNIV,NEW YORK,NY 10027; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; CTR DIS CONTROL,DIV SEXUALLY TRANSMITTED DIS LAB RES,ATLANTA,GA 30333; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143	New York State Psychiatry Institute; University of California System; University of California San Francisco; Columbia University; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco			Fullilove, Mindy Thompson/AAI-4919-2020		NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACKERMANN M, 1986, VIROLOGY, V150, P207, DOI 10.1016/0042-6822(86)90280-1; ADLERSTORTHZ K, 1985, AM J OBSTET GYNECOL, V151, P582, DOI 10.1016/0002-9378(85)90143-7; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BECKER TM, 1985, JAMA-J AM MED ASSOC, V253, P1601, DOI 10.1001/jama.253.11.1601; BECKER TM, 1988, AM J EPIDEMIOL, V127, P1071, DOI 10.1093/oxfordjournals.aje.a114883; BLACK FL, 1970, AM J EPIDEMIOL, V91, P430, DOI 10.1093/oxfordjournals.aje.a121153; BLACK FL, 1975, SCIENCE, V187, P515, DOI 10.1126/science.163483; BLACK FL, 1974, AM J EPIDEMIOL, V100, P230, DOI 10.1093/oxfordjournals.aje.a112032; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; CATANIA JA, 1992, AM J PUBLIC HEALTH, V82, P284, DOI 10.2105/AJPH.82.2.284; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; FULLILOVE MT, 1992, WESTERN J MED, V157, P32; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; GALLO D, 1986, J CLIN MICROBIOL, V23, P1049, DOI 10.1128/JCM.23.6.1049-1051.1986; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; GUINAN ME, 1985, EPIDEMIOL REV, V7, P127, DOI 10.1093/oxfordjournals.epirev.a036279; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; ISAGER H, 1983, ACTA PATH MICRO IM B, V91, P339; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; JOSEY WE, 1972, OBSTET GYNECOL SURV, V27, P295; KIEFF E, 1972, J VIROL, V9, P738, DOI 10.1128/JVI.9.5.738-745.1972; KJAER SK, 1990, AM J EPIDEMIOL, V131, P669, DOI 10.1093/oxfordjournals.aje.a115551; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LEE FK, 1986, J VIROL METHODS, V14, P111, DOI 10.1016/0166-0934(86)90041-8; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; LOWHAGEN GB, 1990, ACTA DERM-VENEREOL, V70, P330; MARSDEN HS, 1984, J VIROL, V50, P547, DOI 10.1128/JVI.50.2.547-554.1984; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P781, DOI 10.1056/NEJM197310112891505; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P719, DOI 10.1056/NEJM197310042891404; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P667, DOI 10.1056/NEJM197309272891305; NAHMIAS AJ, 1970, AM J EPIDEMIOL, V91, P539, DOI 10.1093/oxfordjournals.aje.a121165; OBERLE MV, 1989, AM J TROP MED HYG, V4, P224; PASQUINI P, 1988, EUR J CLIN MICROBIOL, V7, P54, DOI 10.1007/BF01962174; RAWLS WE, 1971, AM J OBSTET GYNECOL, V110, P682, DOI 10.1016/0002-9378(71)90254-7; RAWLS WE, 1981, HUMAN HERPESVIRUSES, P137; RICHMAN DD, 1986, J VIROL, V57, P647, DOI 10.1128/JVI.57.2.647-655.1986; ROIZMAN B, 1984, VIROLOGY, V133, P242, DOI 10.1016/0042-6822(84)90447-1; SANCHEZMARTINEZ D, 1991, J INFECT DIS, V164, P1196, DOI 10.1093/infdis/164.6.1196; SETH P, 1981, INDIAN J MED RES, V73, P475; STAVRAKY KM, 1983, AM J EPIDEMIOL, V118, P109, DOI 10.1093/oxfordjournals.aje.a113612	42	121	123	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1702	1708		10.1001/jama.268.13.1702	http://dx.doi.org/10.1001/jama.268.13.1702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1326673				2022-12-28	WOS:A1992JQ37600032
J	MATTSON, RH; CRAMER, JA; COLLINS, JF				MATTSON, RH; CRAMER, JA; COLLINS, JF			A COMPARISON OF VALPROATE WITH CARBAMAZEPINE FOR THE TREATMENT OF COMPLEX PARTIAL SEIZURES AND SECONDARILY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SODIUM VALPROATE; ANTIEPILEPTIC DRUGS; PHENYTOIN; MONOTHERAPY; EFFICACY; EPILEPSIES	Background. Valproate is approved for use primarily in patients with absence seizures, but the drug has a broad spectrum of activity against seizures of all types. Partial or secondarily generalized tonic-clonic seizures are often difficult to control adequately with standard treatment, usually carbamazepine or phenytoin. Methods. We conducted a multicenter, double-blind trial that compared valproate with carbamazepine in the treatment of 480 adults with complex partial seizures (206 patients) or secondarily generalized tonic-clonic seizures (274 patients). The patients were randomly assigned to treatment with carbamazepine or divalproex sodium (valproate) at doses adjusted to achieve blood levels in the middle of the therapeutic range. Patients were followed for one to five years or until seizures became uncontrollable, treatment had unacceptable adverse effects, or both these events occurred. Results. For the control of secondarily generalized tonic-clonic seizures, carbamazepine and valproate were comparably effective (in 136 patients and 138 patients, respectively). For complex partial seizures, four of five outcome measures favored carbamazepine (100 patients) over valproate (106 patients): the total number of seizures (2.7 vs. 7.6, P = 0.05), the number of seizures per month (0.9 vs. 2.2, P = 0.01), the time to the first seizure (P<0.02), and the seizure-rating score (P = 0.04). Carbamazepine was also superior according to a composite score that combined scores for the control of seizures and for adverse effects (P<0.001). Valproate was associated more frequently than carbamazepine with a weight gain of more than 5.5 kg (12 lb) (20 percent vs. 8 percent, P<0.001), with hair loss or change in texture (12 percent vs. 6 percent, P = 0.02), and with tremor (45 percent vs. 22 percent, P<0.001). Rash was more often associated with carbamazepine (11 percent vs. 1 percent, P<0.001). Conclusions. Valproate is as effective as carbamazepine for the treatment of generalized tonic-clonic seizures, but carbamazepine provides better control of complex partial seizures and has fewer long-term adverse effects.	VET AFFAIRS COOPERAT STUDIES PROGRAM COORDINATING, PERRY POINT, MD USA; YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06510 USA	Yale University	MATTSON, RH (corresponding author), VET AFFAIRS MED CTR, NEUROL SERV, 950 CAMPBELL AVE, West Haven, CT 06516 USA.							[Anonymous], 1981, Epilepsia, V22, P489; BOURGEOIS B, 1987, EPILEPSIA, V28, pS8, DOI 10.1111/j.1528-1157.1987.tb05769.x; CALLAGHAN N, 1985, J NEUROL NEUROSUR PS, V48, P639, DOI 10.1136/jnnp.48.7.639; CALLAGHAN N, 1983, BR J CLIN PRACT S27, V37, P7; CHADWICK D, 1985, J NEUROL NEUROSUR PS, V48, P1073, DOI 10.1136/jnnp.48.11.1073; CHADWICK DW, 1987, EPILEPSIA, V28, pS12, DOI 10.1111/j.1528-1157.1987.tb05766.x; COVANIS A, 1982, EPILEPSIA, V23, P693, DOI 10.1111/j.1528-1157.1982.tb05085.x; CRAMER JA, 1983, NEUROLOGY, V33, P26, DOI 10.1212/WNL.33.3_Suppl_1.26; CUTLER SJ, 1958, J CHRON DIS, V8, P699; DEAN JC, 1988, EPILEPSIA, V29, P687; DINESEN H, 1984, ACTA NEUROL SCAND, V70, P65; Dreifuss F E, 1988, Am J Med, V84, P34, DOI 10.1016/0002-9343(88)90055-1; DREIFUSS FE, 1985, EPILEPSIA, V26, P268; FARIELLO R, 1989, ANTIEPILEPTIC DRUGS, P567; HASSAN MN, 1976, ACTA NEUROL SCAND, V54, P209, DOI 10.1111/j.1600-0404.1976.tb04797.x; Hauser W, 1990, EPILEPSY FREQUENCY C; HELLER A J, 1989, Epilepsia, V30, P648; HOSKING G, 1989, 4TH INT S SOD VALPR, P71; JEAVONS PM, 1974, BRIT MED J, V2, P584, DOI 10.1136/bmj.2.5919.584; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KENNEBACK G, 1991, AM HEART J, V121, P1421, DOI 10.1016/0002-8703(91)90148-B; LOISEAU P, 1981, EPILEPSIA, V22, P141, DOI 10.1111/j.1528-1157.1981.tb04094.x; LOISEAU P, 1984, REV NEUROL-FRANCE, V140, P434; Mattson R H, 1988, Am J Med, V84, P23, DOI 10.1016/0002-9343(88)90053-8; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MATTSON RH, 1983, NEUROLOGY, V33, P14, DOI 10.1212/WNL.33.3_Suppl_1.14; MATTSON RH, 1989, ANTIEPILEPTIC DRUGS, P103; Mattson RH, 1986, TOLERANCE BENEFICIAL, P149; PELLOCK JM, 1991, NEUROLOGY, V41, P961, DOI 10.1212/WNL.41.7.961; PRICE DJE, 1975, CLIN PHARM ASPECTS S, P44; SCHMIDT D, 1982, ADVERSE EFFECTS ANTI; TURNBULL DM, 1985, BRIT MED J, V290, P815, DOI 10.1136/bmj.290.6471.815; TURNBULL DM, 1982, J NEUROL NEUROSUR PS, V45, P55, DOI 10.1136/jnnp.45.1.55; WILDER BJ, 1983, NEUROLOGY, V33, P1474, DOI 10.1212/WNL.33.11.1474	34	593	597	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					765	771		10.1056/NEJM199209103271104	http://dx.doi.org/10.1056/NEJM199209103271104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1298221	Bronze			2022-12-28	WOS:A1992JL66100004
J	WALLACE, MR; BOWLER, WA; MURRAY, NB; BRODINE, SK; OLDFIELD, EC				WALLACE, MR; BOWLER, WA; MURRAY, NB; BRODINE, SK; OLDFIELD, EC			TREATMENT OF ADULT VARICELLA WITH ORAL ACYCLOVIR - A RANDOMIZED, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						CEREBROVASCULAR DISORDERS; HEPARINOID; ENOXAPARIN; HEPARIN; THROMBOEMBOLISM	ZOSTER VIRUS-INFECTION; IMMUNOCOMPROMISED PATIENTS; HEALTHY-ADULTS; CHILDREN; COMPLICATIONS; CHICKENPOX; PNEUMONIA; RESISTANT; THERAPY; POPULATION	Objective: To assess the efficacy of oral acyclovir in treating adults with varicella and to describe the natural history of adult varicella. Design: Double-blind, placebo-controlled randomized trial. Setting: A naval hospital. Patients: One hundred forty-eight of 206 consecutive adult active duty Navy and Marine Corps personnel who were hospitalized for isolation and inpatient therapy of varicella and who could be treated within 72 hours of rash onset completed the study. The diagnosis of varicella was confirmed by acute and convalescent serology in 143 of 144 patients with available paired sera. Intervention: Patients were randomly assigned to receive either acyclovir, 800 mg orally five times per day for 7 days, or an identical placebo. Separate randomization codes were used for patients presenting within 24 hours of rash onset and for those presenting 25 to 72 hours after rash onset. Measurements: Daily lesion counts, symptom scores, temperature measurements, and laboratory tests were used to monitor the course of the illness. Results: Early treatment (initiated within 24 hours of rash onset) reduced the total time to (100%) crusting from 7.4 to 5.6 days (P = 0.001) and reduced the maximum number of lesions by 46% (P = 0.04). Duration of fever and severity of symptoms were also reduced by early therapy. Late therapy (25 to 72 hours after rash onset) had no effect on the course of illness. Only four patients had pneumonia, and no encephalitis or mortality was noted. Conclusions: Early therapy with oral acyclovir decreases the time to cutaneous healing of adult varicella, decreases the duration of fever, and lessens symptoms. Initiation of therapy after the first day of illness is of no value in uncomplicated cases of adult varicella. The low frequency of serious complications of varicella (pneumonia, encephalitis, or death) precluded any evaluation of the possible effect of acyclovir on these outcomes.	USN HOSP, DEPT INTERNAL MED, DIV INFECT DIS, SAN DIEGO, CA 92134 USA	United States Department of Defense; United States Navy	WALLACE, MR (corresponding author), USN HOSP, DEPT CLIN INVEST, SAN DIEGO, CA 92134 USA.							ALNAKIB W, 1983, J INFECTION, V6, P49, DOI 10.1016/S0163-4453(83)94129-4; AMUNDSON DE, 5TH PAN AM C DIS CHE; ASANO Y, 1990, J INFECT DIS, V161, P1095, DOI 10.1093/infdis/161.6.1095; BALFOUR HH, 1990, J PEDIATR-US, V116, P633, DOI 10.1016/S0022-3476(05)81618-X; BALFOUR HH, 1983, NEW ENGL J MED, V308, P1448, DOI 10.1056/NEJM198306163082404; CHRISTIE AB, 1987, INFECT DIS EPIDEMIOL, P353; COLE NL, 1986, J INFECT DIS, V153, P605, DOI 10.1093/infdis/153.3.605; DORSKY DI, 1987, ANN INTERN MED, V107, P859, DOI 10.7326/0003-4819-107-6-859; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; FEDER HM, 1990, ARCH INTERN MED, V150, P2061, DOI 10.1001/archinte.150.10.2061; GERSHON AA, 1988, J INFECT DIS, V158, P132, DOI 10.1093/infdis/158.1.132; GRAY GC, 1990, PEDIATRICS, V86, P867; GUESS HA, 1986, PEDIATRICS, V78, P723; HAAKE DA, 1990, REV INFECT DIS, V12, P788; HOCKBERGER RS, 1986, ANN EMERG MED, V15, P931, DOI 10.1016/S0196-0644(86)80679-5; JACOBSON MA, 1990, ANN INTERN MED, V112, P187, DOI 10.7326/0003-4819-112-3-187; KRAUSE PR, 1990, HOSP PRACT, V25, P61; LONGFIELD JN, 1990, ARCH INTERN MED, V150, P970, DOI 10.1001/archinte.150.5.970; NYERGES G, 1988, J INFECT DIS, V157, P309, DOI 10.1093/infdis/157.2.309; PITEL PA, 1980, PEDIATRICS, V65, P631; PREBLUD SR, 1981, PEDIATRICS, V68, P14; SAFRIN S, 1991, ANN INTERN MED, V115, P19, DOI 10.7326/0003-4819-115-1-19; SARGENT EN, 1967, CALIF MED, V107, P141; SCHLOSSBERG D, 1988, ARCH INTERN MED, V148, P1630, DOI 10.1001/archinte.148.7.1630; SHEPP DH, 1986, NEW ENGL J MED, V314, P208, DOI 10.1056/NEJM198601233140404; SHULMAN ST, 1985, AM J DIS CHILD, V139, P137, DOI 10.1001/archpedi.1985.02140040035021; Straus S E, 1987, Infect Dis Clin North Am, V1, P367; STRAUS SE, 1988, ANN INTERN MED, V108, P221, DOI 10.7326/0003-4819-108-2-221; TRIEBWASSER JH, 1967, MEDICINE, V46, P409, DOI 10.1097/00005792-196709000-00003; WEBER DM, 1965, J AMER MED ASSOC, V192, P572, DOI 10.1001/jama.1965.03080190138035	30	140	142	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					358	363		10.7326/0003-4819-117-5-358	http://dx.doi.org/10.7326/0003-4819-117-5-358			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1323943				2022-12-28	WOS:A1992JK67800002
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ZALCITABINE APPROVED FOR USE IN COMBINATION WITH ZIDOVUDINE FOR HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1992, JAMA-J AM MED ASSOC, V267, P3262	1	46	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					705	705		10.1001/jama.268.6.705	http://dx.doi.org/10.1001/jama.268.6.705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1322467				2022-12-28	WOS:A1992JG66600005
J	FOREJT, J; GREGOROVA, S				FOREJT, J; GREGOROVA, S			GENETIC-ANALYSIS OF GENOMIC IMPRINTING - AN IMPRINTOR-1 GENE CONTROLS INACTIVATION OF THE PATERNAL COPY OF THE MOUSE TME LOCUS	CELL			English	Article								The T(hP) deletion on mouse chromosome 17 is lethal when inherited from the mother, because it deletes the T.associated maternal effect (Tme) locus, the paternal copy of which is inactivated by genomic imprinting. We have found a paternally nonimprinted Tme variant in crosses of T(hp) females with Mus m. musculus males. The data are consistent with the existence of a single Tme-unlinked gene, Imprintor-1 (Imp-1), with two alleles, one of which only causes imprinting at the Tme locus. Imp-1 is unlinked to the gene for cation-dependent Man-6-P receptor and acts prezygotically. Although Tme and Igf2r were thought to be identical, they show different patterns of imprinting in interspecies hybrids. The apparent nonequivalence of the Igf2r gene and Tme results in occurrence of viable mice lacking an active Igf2r gene. These mice are bigger at birth than their normal littermates, in accord with the proposed function of the IGF-II/Man-6-P receptor.			FOREJT, J (corresponding author), CZECHOSLOVAK ACAD SCI, INST MOLEC GENET, VIDENSKA 1083, CS-14220 PRAGUE 4, CZECH REPUBLIC.		Forejt, Jiri/G-7719-2012; Forejt, Jiri/AAF-5276-2019	Forejt, Jiri/0000-0002-2793-3623; Forejt, Jiri/0000-0002-2793-3623				AGULNIK AI, 1991, J HERED, V82, P351, DOI 10.1093/oxfordjournals.jhered.a111099; ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; ARTZT K, 1984, CELL, V39, P565, DOI 10.1016/0092-8674(84)90463-X; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CATTANACH BM, 1990, DEVELOPMENT, P63; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHANDRA HS, 1990, DEVELOPMENT, P47; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FERGUSONSMITH AC, 1990, CANCER SURV, V9, P487; FOREJT J, 1988, GENET RES, V51, P111, DOI 10.1017/S0016672300024125; FOREJT J, 1980, GENET RES, V35, P165, DOI 10.1017/S0016672300014026; FOREJT J, 1991, MAMM GENOME, V1, P84, DOI 10.1007/BF02443783; FOREJT J, 1981, CURRENT TRENDS HISTO, V1, P103; GOODFELLOW P N, 1991, Current Biology, V1, P11, DOI 10.1016/0960-9822(91)90111-9; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HAIG D, 1991, PHILOS T ROY SOC B, V333, P1, DOI 10.1098/rstb.1991.0057; HAIG D, 1991, CELL, V64, P1045; HARVEY MB, 1991, DEVELOPMENT, V111, P1057; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JOHNSON DR, 1974, GENETICS, V76, P795; JOHNSON DR, 1974, GENET RES, V24, P207, DOI 10.1017/S0016672300015226; KIESS W, 1987, J BIOL CHEM, V262, P12745; KRICKER MC, 1992, P NATL ACAD SCI USA, V89, P1075, DOI 10.1073/pnas.89.3.1075; Lewontin R. C., 1974, The genetic basis of evolutionary change.; MONK M, 1988, GENE DEV, V2, P921, DOI 10.1101/gad.2.8.921; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; MOTTOLA C, 1984, J BIOL CHEM, V259, P2705; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; PAVLJUKOVA H, 1981, MOUSE NEWS LETT, V65, P44; Peters JA, 1959, CLASSIC PAPERS GENET; PIRROTTA V, 1990, BIOESSAYS, V12, P409, DOI 10.1002/bies.950120903; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REIK W, 1990, DEVELOPMENT, P99; REIK W, 1989, TRENDS GENET, V5, P331, DOI 10.1016/0168-9525(89)90138-8; RIDLEY RM, 1991, J MED GENET, V28, P224, DOI 10.1136/jmg.28.4.224; ROTH RA, 1990, KAR INS NCS, P73; RUVINSKY AO, 1990, DEV GENET, V11, P263, DOI 10.1002/dvg.1020110404; Sambrook J, 1989, MOL CLONING LABORATO; SAPIENZA C, 1989, ANN NY ACAD SCI, V564, P24, DOI 10.1111/j.1749-6632.1989.tb25885.x; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SAPIENZA C, 1990, SCI AM, V263, P52, DOI 10.1038/scientificamerican1090-52; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SASAKI H, 1991, DEVELOPMENT, V111, P573; SCHIMENTI J, 1987, J MOL BIOL, V194, P583, DOI 10.1016/0022-2836(87)90235-X; SEARLE AG, 1978, CYTOGENET CELL GENET, V20, P282, DOI 10.1159/000130859; SEARLE AG, 1990, GENET RES, V56, P237, DOI 10.1017/S0016672300035333; SENIOR PV, 1990, DEVELOPMENT, V109, P67; SILVER LM, 1987, MOL BIOL EVOL, V4, P473; SOLTER D, 1988, ANNU REV GENET, V22, P127; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TSAI JY, 1991, GENETICS, V129, P1159; VONDEIMLING OH, 1988, LAB ANIM-UK, V22, P61, DOI 10.1258/002367788780746610; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WASHBURN LL, 1983, NATURE, V303, P338, DOI 10.1038/303338a0; WINKING H, 1984, GENETICS, V108, P1013	65	107	107	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					443	450		10.1016/0092-8674(92)90168-C	http://dx.doi.org/10.1016/0092-8674(92)90168-C			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322799	Bronze			2022-12-28	WOS:A1992JH12400009
J	KOMURO, H; RAKIC, P				KOMURO, H; RAKIC, P			SELECTIVE ROLE OF N-TYPE CALCIUM CHANNELS IN NEURONAL MIGRATION	SCIENCE			English	Article							CEREBELLAR GRANULE CELLS; VERTEBRATE CELLS; EXPLANT CULTURES; CA2+ CHANNELS; RECEPTOR; DIFFERENTIATION; ACTIVATION; CURRENTS; DEPOLARIZATION; ASTROTACTIN	Analysis of neuronal migration in mouse cerebellar slice preparations by a laser scanning confocal microscope revealed that postmitotic granule cells initiate their migration only after the expression of N-type calcium channels on their plasmalemmal surface. Furthermore, selective blockade of these channels by addition of omega-conotoxin to the incubation medium curtailed cell movement. In contrast, inhibitors of L- and T-type calcium channels, as well as those of sodium and potassium channels, had no effect on the rate of granule cell migration. These results suggest that N-type calcium channels, which have been predominantly associated with neurotransmitter release in adult brain, also play a transient but specific developmental role in directed migration of immature neurons before the establishment of their synaptic circuits.			KOMURO, H (corresponding author), YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA.							ANTONICEK H, 1988, J NEUROSCI, V8, P2961; ARTALEJO CR, 1992, NEURON, V8, P85, DOI 10.1016/0896-6273(92)90110-Y; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CHUONG CM, 1987, J CELL BIOL, V104, P331, DOI 10.1083/jcb.104.2.331; CHUONG CM, 1990, EXPERIENTIA, V46, P892, DOI 10.1007/BF01939381; CONNOR JA, 1987, J NEUROSCI, V7, P1384; COURTNEY MJ, 1990, J NEUROSCI, V10, P3873, DOI 10.1523/JNEUROSCI.10-12-03873.1990; CULLCANDY SG, 1989, J PHYSIOL-LONDON, V414, P179, DOI 10.1113/jphysiol.1989.sp017683; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; EDMONDSON JC, 1988, J CELL BIOL, V106, P505, DOI 10.1083/jcb.106.2.505; FISHELL G, 1991, DEVELOPMENT, V113, P755; FORSCHER P, 1989, TRENDS NEUROSCI, V12, P468, DOI 10.1016/0166-2236(89)90098-2; FUJITA S, 1967, J CELL BIOL, V32, P277, DOI 10.1083/jcb.32.2.277; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HOCKBERGER PE, 1987, J NEUROSCI, V7, P1370; HOLLIDAY J, 1990, DEV BIOL, V141, P13, DOI 10.1016/0012-1606(90)90098-4; HORNE WA, 1991, J BIOL CHEM, V266, P13719; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KATER SB, 1991, J NEUROSCI, V11, P891; LOTURCO JJ, 1991, J NEUROSCI, V11, P792; MARCHETTI C, 1991, NEUROSCIENCE, V43, P121, DOI 10.1016/0306-4522(91)90422-K; MARTINMOUTOT N, 1990, NEUROSCI LETT, V115, P300, DOI 10.1016/0304-3940(90)90472-L; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MORAN D, 1991, AM J ANAT, V192, P14, DOI 10.1002/aja.1001920103; NEWGREEN DF, 1985, CELL TISSUE RES, V239, P329; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; Rakic P, 1985, CELL CONTACT ADHESIO, P67; RAKIC P, 1988, PROG BRAIN RES, V73, P15; ROBSON SJ, 1989, NEUROSCI LETT, V104, P110, DOI 10.1016/0304-3940(89)90338-8; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SLESINGER PA, 1991, J PHYSIOL-LONDON, V435, P101, DOI 10.1113/jphysiol.1991.sp018500; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; VIGERS AJ, 1991, DEV BRAIN RES, V60, P197, DOI 10.1016/0165-3806(91)90048-N; WAGNER JA, 1988, J NEUROSCI, V8, P3354	38	320	326	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					806	809		10.1126/science.1323145	http://dx.doi.org/10.1126/science.1323145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323145				2022-12-28	WOS:A1992JG85100038
J	MARTELLI, AM; GILMOUR, RS; BERTAGNOLO, V; NERI, LM; MANZOLI, L; COCCO, L				MARTELLI, AM; GILMOUR, RS; BERTAGNOLO, V; NERI, LM; MANZOLI, L; COCCO, L			NUCLEAR-LOCALIZATION AND SIGNALING ACTIVITY OF PHOSPHOINOSITIDASE-C-BETA IN SWISS 3T3 CELLS	NATURE			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-C; GROWTH-FACTOR; POLYPHOSPHOINOSITIDES; DIFFERENTIATION; PHOSPHORYLATION; INSULIN	THE hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdInsP2) is a widespread receptor-coupled signalling system at the plasma membrane of most eukaryotic cells. The existence of an entirely separate nuclear phosphoinositide signalling system is suggested from evidence that purified nuclei synthesize PtdInsP2 and phosphatidylinositol 4-phosphate (PtdInsP) in vitro1 and that a transient decrease in the mass of these lipids occurs when Swiss 3T3 cells are cultured in the presence of insulin-like growth factor-1 (IGF-1)2-4. These IGF-1-dependent changes in inositol lipids coincide with an increase in nuclear diacylglycerol4 and precede translocation to the nucleus and activation of protein kinase C (refs 5, 6). Circumstantial evidence that links these changes with mitosis comes from the isolation of a 3T3 clone that expresses the type-1 IGF receptor and binds IGF-1 peptide but does not respond mitogenically or show transient mass changes in nuclear inositol lipids7. A key question is how IGF-1 initiates the rapid breakdown of PtdInsP and PtdInsP2 in the nucleus. Here we present evidence that nuclei of 3T3 cells contain the beta-isozyme of phosphoinositidase C, whereas the gamma-isozyme is confined to the cytoplasm and that IGF-1 treatment stimulates exclusively the activity of nuclear phosphoinositidase C.	UNIV BOLOGNA, INST HUMAN ANAT, V IRNERIO 48, I-40126 BOLOGNA, ITALY; UNIV FERRARA, INST HUMAN ANAT, I-44100 FERRARA, ITALY; UNIV CHIETI, INST HUMAN ANAT, CHIETI, ITALY; IST RIZZOLI, CNR, INST CYTOMORPHOL, I-40136 BOLOGNA, ITALY; AFRC, INST ANIM PHYSIOL & GENET RES, CAMBRIDGE CB2 4AT, ENGLAND	University of Bologna; University of Ferrara; G d'Annunzio University of Chieti-Pescara; Consiglio Nazionale delle Ricerche (CNR); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute			BERTAGNOLO, VALERIA/L-2864-2018; Neri, Luca Maria/AAU-1772-2021; Neri, Luca Maria/J-2462-2017; Cocco, Lucio/AAI-2206-2020	BERTAGNOLO, VALERIA/0000-0002-4742-2302; Neri, Luca Maria/0000-0002-7924-1477; Cocco, Lucio/0000-0002-9206-8277				BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; COCCO L, 1989, BIOCHEM BIOPH RES CO, V159, P720, DOI 10.1016/0006-291X(89)90054-5; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; GARLAND RC, 1972, BIOCHEMISTRY-US, V11, P4712, DOI 10.1021/bi00775a012; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; KIM UH, 1991, J BIOL CHEM, V266, P1359; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANZOLI FA, 1989, ADV ENZYME REGUL, V28, P25; MARTELLI AM, 1991, BIOCHEM BIOPH RES CO, V177, P480, DOI 10.1016/0006-291X(91)92009-9; MARTELLI AM, 1991, FEBS LETT, V283, P243, DOI 10.1016/0014-5793(91)80598-W; MARTELLI AM, 1989, EXP CELL RES, V185, P191, DOI 10.1016/0014-4827(89)90048-7; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MICHELL R H, 1992, Current Biology, V2, P200, DOI 10.1016/0960-9822(92)90533-G; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RUBINS JB, 1990, P NATL ACAD SCI USA, V87, P7080, DOI 10.1073/pnas.87.18.7080; RYU SH, 1990, J BIOL CHEM, V265, P17941; SEYDEL U, 1991, J BIOL CHEM, V266, P7602; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THORNETJOMSLAND G, 1991, BIOL CELL, V71, P33, DOI 10.1016/0248-4900(91)90049-S; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; WU DQ, 1992, J BIOL CHEM, V267, P1811	28	327	332	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 16	1992	358	6383					242	245		10.1038/358242a0	http://dx.doi.org/10.1038/358242a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1321347				2022-12-28	WOS:A1992JD58700056
J	HELLER, RA; SONG, K; FAN, N; CHANG, DJ				HELLER, RA; SONG, K; FAN, N; CHANG, DJ			THE P70 TUMOR-NECROSIS-FACTOR RECEPTOR MEDIATES CYTOTOXICITY	CELL			English	Article							FACTOR-ALPHA; MOLECULAR-CLONING; MONOCLONAL-ANTIBODIES; SUPEROXIDE-DISMUTASE; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; GENE-EXPRESSION; GROWTH-FACTORS; FACTOR-BETA; FACTOR TNF	Tumor necrosis factor a (TNF) selectively kills tumor cells, but this specificity is not clearly understood. Two distinctly different cell surface receptors (TNFRs), proteins of 55 kd (p55) and 70-80 kd (p70), mediate TNF action. Mouse TA1 cells are not killed by human (h) TNF, but are killed by mouse (m) TNF alone. Since the mouse p70 TNFR is recognized only by mTNF, these results implicate p70 receptor action in TA1 cell killing. Human HeLa cells have mainly the p55 receptor and are not killed by hTNF alone. When transfected with the human p70 TNFR, HeLa p70 die within 24 hr. HeLa p70 cells also show reduced c-fos and manganous superoxide dismutase induction by TNF. NIH 3T3 mouse fibroblasts are sensitive to only mTNF, but overexpression of the human p70 receptor causes cell death by hTNF and increased sensitivity to mTNF. These results provide a direct function for the p70 TNFR in TNF-induced cytotoxicity.			HELLER, RA (corresponding author), SYNTEX RES,INST CANC & DEV BIOL,3401 HILLVIEW AVE,PALO ALTO,CA 94303, USA.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BELIZARIO JE, 1991, CANCER RES, V51, P2379; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DANESCH U, 1992, IN PRESS J BIOL CHEM; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HELLER RA, 1990, J BIOL CHEM, V265, P5708; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KAUSHANSKY K, 1988, J IMMUNOL, V141, P3410; KOHASE M, 1986, CELL, V45, P659, DOI 10.1016/0092-8674(86)90780-4; KULL FC, 1981, CANCER RES, V41, P4885; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; KUNG AL, 1990, CANCER RES, V50, P7307; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MILATOVICH A, 1991, SOMAT CELL MOLEC GEN, V17, P519, DOI 10.1007/BF01233176; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; REID T, 1991, J BIOL CHEM, V266, P16580; REID TR, 1989, J BIOL CHEM, V264, P4583; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SHEPARD HM, 1988, J CLIN IMMUNOL, V8, P333, DOI 10.1007/BF00917148; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPIES T, 1986, P NATL ACAD SCI USA, V83, P8699, DOI 10.1073/pnas.83.22.8699; STREITER RM, 1989, SCIENCE, V243, P1467; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SUGARMAN BJ, 1987, CANCER RES, V47, P780; TAKEDA K, 1986, NATURE, V323, P338, DOI 10.1038/323338a0; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; URBAN JL, 1986, P NATL ACAD SCI USA, V83, P5233, DOI 10.1073/pnas.83.14.5233; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; YOSHIE O, 1986, J BIOCHEM-TOKYO, V100, P531, DOI 10.1093/oxfordjournals.jbchem.a121744	51	309	317	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					47	56						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1320461				2022-12-28	WOS:A1992JC95700007
J	VANTOL, HHM; WU, CM; GUAN, HC; OHARA, K; BUNZOW, JR; CIVELLI, O; KENNEDY, J; SEEMAN, P; NIZNIK, HB; JOVANOVIC, V				VANTOL, HHM; WU, CM; GUAN, HC; OHARA, K; BUNZOW, JR; CIVELLI, O; KENNEDY, J; SEEMAN, P; NIZNIK, HB; JOVANOVIC, V			MULTIPLE DOPAMINE-D4 RECEPTOR VARIANTS IN THE HUMAN-POPULATION	NATURE			English	Article							CLONING; CDNA; EXPRESSION; GENE	THE dopamine D4 receptor structurally and pharmacologically resembles the dopamine D2 and D3 receptors 1-5. Clozapine, an atypical antipsychotic that is relatively free of the adverse effects of drug-induced parkinsonism and tardive dyskinesia 6,7, binds to the D4 receptor with an affinity 10 times higher than to the D2 and D3 receptors 1. This may explain clozapine's atypical properties. Here we report the existence of at least three polymorphic variations in the coding sequence of the human D4 receptor. A 48-base-pair sequence in the putative third cytoplasmic loop of this receptor exists either as a direct-repeat sequence (D4.2), as a fourfold repeat (D4.4) or as a sevenfold repeat (D4.7). Two more variant alleles were detected in humans. Expression of the complementary DNA for,the three cloned receptor variants showed different properties for the long form (D4.7) and the shorter forms (D4-2, D4.4) with respect to clozapine and spiperone.binding. To our knowledge, this is the first report of a receptor in the catecholamine receptor family that displays polymorphic variation in the human population. Such variation among humans may underlie individual differences in susceptibility to neuropsychiatric disease and in responsiveness to antipsychotic medication.	OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; CLARKE INST PSYCHIAT,MOLEC GENET LAB,TORONTO M5T 1R8,ONTARIO,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT PSYCHIAT,TORONTO M5S 1A8,ONTARIO,CANADA	Oregon Health & Science University; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto	VANTOL, HHM (corresponding author), CLARKE INST PSYCHIAT,MOLEC NEUROBIOL LAB,250 COLL ST,TORONTO M5T 1R8,ONTARIO,CANADA.		Civelli, Olivier/A-8392-2012					BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUDOWLE B, IN PRESS APPL THEORE; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CASEY DE, 1989, PSYCHOPHARMACOLOGY, V99, P47; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; GELERNTER J, 1992, GENOMICS, V13, P208, DOI 10.1016/0888-7543(92)90222-E; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; KELSOE JR, 1989, NATURE, V342, P238, DOI 10.1038/342238a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P461; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Sambrook J., 1989, MOL CLONING; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0	21	831	858	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					149	152						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1319557				2022-12-28	WOS:A1992JC58300051
J	RARICK, HM; ARTEMYEV, NO; HAMM, HE				RARICK, HM; ARTEMYEV, NO; HAMM, HE			A SITE ON ROD G-PROTEIN ALPHA-SUBUNIT THAT MEDIATES EFFECTOR ACTIVATION	SCIENCE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; CGMP PHOSPHODIESTERASE; OUTER SEGMENTS; INHIBITORY SUBUNIT; TRANSDUCTION; CYCLASE; CASCADE; VISION; CHAIN	The heterotrimeric guanine nucleotide binding proteins (G proteins) are activated by sensory or hormone receptors. In turn, the G proteins activate effector proteins such as adenylyl cyclase, cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE), phospholipase C, and potassium and calcium ion channels by mechanisms that are poorly understood. A site on the alpha-subunit of the G protein transducin (alpha(t)) has been identified that interacts with and activates cGMP phosphodiesterase, the effector enzyme in rod photoreceptors. A 22-amino acid peptide, corresponding to residues 293 to 314 from the COOH-terminal region of alpha(t), fully mimicked alpha(t) and potently activated PDE. This region is adjacent to the receptor activation domain; thus, the alpha-subunit of this G protein has a site for interaction with both its effector and receptor that maps near the COOH-terminus.	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, BOX 6998, CHICAGO, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY006062] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007692] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06062] Funding Source: Medline; NHLBI NIH HHS [T32 HL 07692-02] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHEE WW, 1989, J BIOL CHEM, V264, P5687; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; ITOH H, 1991, J BIOL CHEM, V266, P16226; KROLL S, 1989, J BIOL CHEM, V264, P4490; LAURSEN RA, 1981, J BIOL CHEM, V256, P8102; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MAY DC, 1985, J BIOL CHEM, V260, P5829; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; RARICK HM, UNPUB; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SPIEGEL AM, 1988, VITAM HORM, V44, P47; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKEMOTO DJ, 1990, CELL SIGNAL, V2, P99, DOI 10.1016/0898-6568(90)90013-Z; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028	31	98	111	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1992	256	5059					1031	1033		10.1126/science.1317058	http://dx.doi.org/10.1126/science.1317058			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1317058				2022-12-28	WOS:A1992HU22400042
J	ROTH, DB; NAKAJIMA, PB; MENETSKI, JP; BOSMA, MJ; GELLERT, M				ROTH, DB; NAKAJIMA, PB; MENETSKI, JP; BOSMA, MJ; GELLERT, M			V(D)J RECOMBINATION IN MOUSE THYMOCYTES - DOUBLE-STRAND BREAKS NEAR T-CELL RECEPTOR DELTA REARRANGEMENT SIGNALS	CELL			English	Article							GAMMA-DELTA; SACCHAROMYCES-CEREVISIAE; IMMUNOGLOBULIN GENES; HOMOLOGOUS RECOMBINATION; SEQUENCE HOMOLOGIES; CODING SEGMENTS; MAMMALIAN-CELLS; DNA; GENERATION; MECHANISM	In the murine T cell receptor delta-locus, V(D)J recombination events frequently involve the D2 and J1 elements. Here we report the presence of double-strand breaks at recombination signals flanking D2 in approximately 2% of thymus DNA. An excised linear species containing the sequences between D2 and J1 and a circular product of the joining of D2 and J1 recombination signals were also found. Although broken molecules with signal ends were detected, no species with coding ends could be identified. Observation of these broken molecules in thymus, but not in liver or spleen, provides the first direct evidence for an association between specific cleavage of chromosomal DNA and recombination in mammalian cells, and supports a breakage-reunion model of V(D)J recombination.	FOX CHASE CANC INST, INST CANC RES, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center	ROTH, DB (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.				NCI NIH HHS [CA-04946] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NIAID NIH HHS [AI-13323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA004946, R01CA004946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CEREDIG R, 1983, J EXP MED, V158, P1654, DOI 10.1084/jem.158.5.1654; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; CHIEN YH, 1987, NATURE, V327, P677, DOI 10.1038/327677a0; CONNOLLY B, 1988, MOL CELL BIOL, V8, P2342, DOI 10.1128/MCB.8.6.2342; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DESIDERIO S, 1984, NATURE, V308, P860, DOI 10.1038/308860a0; ELLIOTT JF, 1988, NATURE, V331, P627; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HANIFORD DB, 1991, CELL, V64, P171; HENDRICKSON EA, 1988, GENE DEV, V2, P817, DOI 10.1101/gad.2.7.817; HENDRICKSON EA, 1991, MOL CELL BIOL, V11, P3155, DOI 10.1128/MCB.11.6.3155; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HOPE TJ, 1986, SCIENCE, V231, P1141, DOI 10.1126/science.3003919; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; KATAOKA T, 1984, NUCLEIC ACIDS RES, V12, P5995, DOI 10.1093/nar/12.15.5995; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEWIS S, 1985, SCIENCE, V228, P677, DOI 10.1126/science.3158075; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MARYON E, 1991, MOL CELL BIOL, V11, P3268, DOI 10.1128/MCB.11.6.3268; MARYON E, 1991, MOL CELL BIOL, V11, P3278, DOI 10.1128/MCB.11.6.3278; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; OKAZAKI K, 1987, CELL, V49, P477, DOI 10.1016/0092-8674(87)90450-8; RAVEH D, 1989, MOL GEN GENET, V220, P33; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1989, MOL CELL BIOL, V9, P3049, DOI 10.1128/MCB.9.7.3049; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TAKESHITA S, 1989, EMBO J, V8, P3261, DOI 10.1002/j.1460-2075.1989.tb08486.x; THOMPSON SD, 1991, EUR J IMMUNOL, V21, P1939, DOI 10.1002/eji.1830210824; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WAKE CT, 1985, MOL CELL BIOL, V5, P2080, DOI 10.1128/MCB.5.8.2080; WELLS FB, 1991, SCIENCE, V253, P903, DOI 10.1126/science.1831565; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WINOTO A, 1989, NATURE, V338, P430, DOI 10.1038/338430a0	64	173	173	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					41	53		10.1016/0092-8674(92)90117-U	http://dx.doi.org/10.1016/0092-8674(92)90117-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1313336				2022-12-28	WOS:A1992HM44500005
J	MADDEN, BP; HODSON, ME; YACOUB, MH; ALTON, EWFW; BARNES, PJ; DENISON, DM; KAY, AB; NEWMANTAYLOR, A; GEDDES, DM; CHUNG, KF				MADDEN, BP; HODSON, ME; YACOUB, MH; ALTON, EWFW; BARNES, PJ; DENISON, DM; KAY, AB; NEWMANTAYLOR, A; GEDDES, DM; CHUNG, KF			ROYAL-BROMPTON GRAND ROUNDS - HEART-LUNG TRANSPLANTATION FOR CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Discussion									ROYAL BROMPTON HOSP,CARDIOTHORAC SURG,LONDON SW3 6HP,ENGLAND; ROYAL BROMPTON HOSP,MED,LONDON SW3 6HP,ENGLAND; ROYAL BROMPTON HOSP,THORAC MED,LONDON SW3 6HP,ENGLAND; ROYAL BROMPTON HOSP,CLIN PHYSIOL,LONDON SW3 6HP,ENGLAND; ROYAL BROMPTON HOSP,ALLERGY & CLIN IMMUNOL,LONDON SW3 6HP,ENGLAND	Royal Brompton Hospital; Royal Brompton Hospital; Royal Brompton Hospital; Royal Brompton Hospital; Royal Brompton Hospital	MADDEN, BP (corresponding author), ROYAL BROMPTON NATL HEART & LUNG HOSP,RESP MED,LONDON SW3 6HP,ENGLAND.			Barnes, Peter/0000-0002-5122-4018				PENKETH ARL, 1987, THORAX, V42, P526, DOI 10.1136/thx.42.7.526; SCOTT J, 1988, LANCET, V2, P192; TSANG V, 1990, PEDIATR PULM S, V5, P256; YACOUB MH, 1990, J HEART TRANSPLANT, V9, P459; 1988, BMJ, V297, P1599	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					835	836		10.1136/bmj.304.6830.835	http://dx.doi.org/10.1136/bmj.304.6830.835			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1327362	Bronze, Green Published			2022-12-28	WOS:A1992HL82700032
J	DRESSLER, KA; MATHIAS, S; KOLESNICK, RN				DRESSLER, KA; MATHIAS, S; KOLESNICK, RN			TUMOR-NECROSIS-FACTOR-ALPHA ACTIVATES THE SPHINGOMYELIN SIGNAL TRANSDUCTION PATHWAY IN A CELL-FREE SYSTEM	SCIENCE			English	Article							PROTEIN-KINASE-C; LEUKEMIC HL-60 CELLS; GH3 PITUITARY-CELLS; LONG-CHAIN BASES; FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; CERAMIDE KINASE; PHORBOL ESTERS; INHIBITION	The mechanism of tumor necrosis factor (TNF)-alpha signaling is unknown. TNF-alpha-signaling may involve sphingomyelin hydrolysis to ceramide by a sphingomyelinase and stimulation of a ceramide-activated protein kinase. In a cell-free system, TNF-alpha-induced a rapid reduction in membrane sphingomyelin content and a quantitative elevation in ceramide concentrations. Ceramide-activated protein kinase activity also increased. Kinase activation was mimicked by addition of sphingomyelinase but not by phospholipases A2, C, or D. Reconstitution of this cascade in a cell-free system demonstrates tight coupling to the receptor, suggesting this is a signal transduction pathway for TNF-alpha.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA042385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014207] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1-CA-42385] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM14207-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P28; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1991, J BIOL CHEM, V266, P11522; ENGELMANN H, 1990, J BIOL CHEM, V265, P13397; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HALL FL, 1991, J BIOL CHEM, V266, P17430; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, UNPUB; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P1823; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAO BG, 1976, J LIPID RES, V17, P506; RYFFEL B, 1991, AM J PATHOL, V139, P7; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SLIFE CW, 1989, J BIOL CHEM, V264, P1; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WILSON E, 1986, J BIOL CHEM, V261, P2616	42	446	465	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1715	1718		10.1126/science.1313189	http://dx.doi.org/10.1126/science.1313189			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1313189				2022-12-28	WOS:A1992HK81200042
J	JOE, EH; ANGELIDES, K				JOE, EH; ANGELIDES, K			CLUSTERING OF VOLTAGE-DEPENDENT SODIUM-CHANNELS ON AXONS DEPENDS ON SCHWANN-CELL CONTACT	NATURE			English	Article							RAT SPINAL-CORD; FREEZE-FRACTURE; MYELIN FORMATION; BASAL LAMINA; PERIPHERAL-NERVE; MEMBRANE; RANVIER; DIFFERENTIATION; INVITRO; FIBERS	IN myelinated nerves, segregation of voltage-dependent sodium channels to nodes of Ranvier is crucial for saltatory conduction along axons 1-4. As sodium channels associate 5 and colocalize with ankyrin at nodes of Ranvier 6, one possibility is that sodium channels are recruited and immobilized at axonal sites which are specified by the subaxolemmal cytoskeleton, independent of glial cell contact 7-10. Alternatively, segregation of channels at distinct sites along the axon may depend on glial cell contact 11-14. To resolve this question, we have examined the distribution of sodium channels, ankyrin and spectrin in myelination-competent cocultures of sensory neurons and Schwann cells by immunofluorescence, using sodium channel-, ankyrin- and spectrin-specific antibodies. In the absence of Schwann cells, sodium channels, ankyrin and spectrin are homogeneously distributed on sensory axons. When Schwann cells are introduced into these cultures, the distribution of sodium channels dramatically changes so that channel clusters on axons are abundant, but ankyrin and spectrin remain homogeneously distributed. Addition of latex beads or Schwann cell membranes does not induce channel clustering. Our results suggest that segregation of sodium channels on axons is highly dependent on interactions with active Schwann cells and that continuing axon-glial interactions are necessary to organize and maintain channel distribution during differentiation of myelinated axons.	BAYLOR COLL MED,DEPT BIOPHYS,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	JOE, EH (corresponding author), BAYLOR COLL MED,DEPT MOLEC BIOPHYS,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.							ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; BIGBEE JW, 1989, BRAIN RES, V494, P182, DOI 10.1016/0006-8993(89)90161-3; BLACK JA, 1985, J NEUROCYTOL, V14, P79, DOI 10.1007/BF01150264; BLACK JA, 1990, TRENDS NEUROSCI, V13, P48, DOI 10.1016/0166-2236(90)90068-L; BLACK JA, 1986, J NEUROCYTOL, V15, P745, DOI 10.1007/BF01625192; BLACK JA, 1981, J NEUROCYTOL, V10, P981, DOI 10.1007/BF01258525; BLACK JA, 1985, J NEUROCYTOL, V14, P887, DOI 10.1007/BF01224803; BOSTOCK H, 1978, J PHYSIOL-LONDON, V280, P273, DOI 10.1113/jphysiol.1978.sp012384; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CLARK MB, 1989, DEV BIOL, V133, P393, DOI 10.1016/0012-1606(89)90043-2; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; ELLISMAN MH, 1979, J NEUROCYTOL, V8, P719, DOI 10.1007/BF01206672; ELMER LW, 1990, BRAIN RES, V532, P222, DOI 10.1016/0006-8993(90)91763-7; FOSTER RE, 1980, SCIENCE, V210, P661, DOI 10.1126/science.6159685; FROEHNER SC, 1991, J CELL BIOL, V113, P1133; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; LEBEAU JM, 1987, J NEUROCYTOL, V16, P347, DOI 10.1007/BF01611346; OWENS GC, 1989, GLIA, V2, P119, DOI 10.1002/glia.440020208; RANSCHT B, 1987, J NEUROSCI, V7, P2936; RASMINSKY M, 1972, J PHYSIOL-LONDON, V227, P323, DOI 10.1113/jphysiol.1972.sp010035; RATNER N, 1984, J CELL BIOL, V98, P1150, DOI 10.1083/jcb.98.3.1150; REIGER F, 1986, J CELL BIOL, V103, P379; ROSENBLUTH J, 1984, NEUROSCI LETT, V48, P171, DOI 10.1016/0304-3940(84)90015-6; ROSENBLUTH J, 1979, J NEUROCYTOL, V8, P655, DOI 10.1007/BF01208515; ROSENBLUTH J, 1988, INT J DEV NEUROSCI, V6, P3, DOI 10.1016/0736-5748(88)90025-1; SMITH KJ, 1982, J NEUROL SCI, V54, P3; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; WAXMAN SG, 1985, SCIENCE, V228, P1502, DOI 10.1126/science.2409596; WAXMAN SG, 1980, PROC R SOC SER B-BIO, V209, P441, DOI 10.1098/rspb.1980.0105; WILEY CA, 1980, J CELL BIOL, V84, P261, DOI 10.1083/jcb.84.2.261; WILEYLIVINGSTON CA, 1980, DEV BIOL, V79, P334, DOI 10.1016/0012-1606(80)90120-7; WOOD PM, 1990, J NEUROSCI, V10, P3635	33	66	66	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					333	335		10.1038/356333a0	http://dx.doi.org/10.1038/356333a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1312680				2022-12-28	WOS:A1992HK79400062
J	ANTHONYCAHILL, SJ; BENFIELD, PA; FAIRMAN, R; WASSERMAN, ZR; BRENNER, SL; STAFFORD, WF; ALTENBACH, C; HUBBELL, WL; DEGRADO, WF				ANTHONYCAHILL, SJ; BENFIELD, PA; FAIRMAN, R; WASSERMAN, ZR; BRENNER, SL; STAFFORD, WF; ALTENBACH, C; HUBBELL, WL; DEGRADO, WF			MOLECULAR CHARACTERIZATION OF HELIX-LOOP-HELIX PEPTIDES	SCIENCE			English	Article							DNA-BINDING; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATOR; COILED-COIL; PROTEIN; MOTIF; MYOD; RECOGNITION; ENHANCER; DIMERIZATION	A class of regulators of eukaryotic gene expression contains a conserved amino acid sequence responsible for protein oligomerization and binding to DNA. This structure consists of an arginine- and lysine-rich basic region followed by a helix-loop-helix motif, which together mediate specific binding to DNA. Peptides were prepared that span this motif in the MyoD protein; in solution, they formed alpha-helical dimers and tetramers. They bound to DNA as dimers and their alpha-helical content increased on binding. Parallel and antiparallel four-helix models of the DNA-bound dimer were constructed. Peptides containing disulfide bonds were engineered to test the correctness of the two models. A disulfide that is compatible with the parallel model promotes specific interaction with DNA, whereas a disulfide compatible with the antiparallel model abolishes specific binding. Electron paramagnetic resonance (EPR) measurements of nitroxide-labeled peptides provided intersubunit distance measurements that also supported the parallel model.	DUPONT MERCK PHARMACEUT CO, DEPT BIOTECHNOL, POB 80328, WILMINGTON, DE 19880 USA; BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA	DuPont; Boston Biomedical Research Institute; University of California System; University of California Los Angeles			Stafford, Walter/ABC-6553-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014321, F32GM013731] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM14321, GM13731] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BROWN BM, 1990, BIOCHEMISTRY-US, V29, P11189, DOI 10.1021/bi00503a006; BRUCCOLERI RE, 1986, BIOPHYS J, V49, P79, DOI 10.1016/S0006-3495(86)83601-3; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEGRADO WF, 1985, J AM CHEM SOC, V107, P7685; Eisenberg D., 1982, FARADAY S CHEM SOC, V17, P109, DOI DOI 10.1039/FS9821700109; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HODGES R S, 1990, Peptide Research, V3, P123; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STAROVASNIK MA, 1991, 5TH S PROT SOC BALT; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TUDOS E, 1990, INT J PEPT PROT RES, V36, P236; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438	38	154	155	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					979	983		10.1126/science.1312255	http://dx.doi.org/10.1126/science.1312255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1312255				2022-12-28	WOS:A1992HE60500039
J	LUCKHOFF, A; CLAPHAM, DE				LUCKHOFF, A; CLAPHAM, DE			INOSITOL 1,3,4,5-TETRAKISPHOSPHATE ACTIVATES AN ENDOTHELIAL CA2+-PERMEABLE CHANNEL	NATURE			English	Article							CALCIUM INFLUX; ADENINE-NUCLEOTIDES; CYTOSOLIC CALCIUM; IONIC CURRENTS; MAST-CELLS; 1,4,5-TRISPHOSPHATE; STIMULATION; RELEASE; CA-2+; ENTRY	RECEPTOR-MEDIATED increases in the cytosolic free calcium ion concentration in most mammalian cells result from mobilization of Ca2+ from intracellular stores as well as transmembrane Ca2+ influx. Inositol 1,4,5-trisphosphate (InsP3) releases calcium from intracellular stores 1 by opening a Ca2+-permeable channel in the endoplasmic reticulum 2-4. But the mechanism and regulation of Ca2+ entry into nonexcitable cells has remained elusive because the entry pathway has not been defined. Here we characterize a novel inositol 1,3,4,5-tetrakisphosphate (InsP4) and Ca2+-sensitive Ca2+-permeable channel in endothelial cells. We find that InsP4, which induces Ca2+ influx into acinar cells 5,6, enhances the activity of the Ca2+-permeable channel when exposed to the intracellular surface of endothelial cell inside-out patches. Our results suggest a molecular mechanism which is likely to be important for receptor-mediated Ca2+ entry.			LUCKHOFF, A (corresponding author), MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA.		Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; COLDENSTANFIELD M, 1987, CIRC RES, V61, P632, DOI 10.1161/01.RES.61.5.632; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HALLAM TJ, 1988, BIOCHEM J, V255, P179, DOI 10.1042/bj2550179; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LINDAU M, 1986, NATURE, V319, P150, DOI 10.1038/319150a0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; LUCKHOFF A, 1990, PFLUG ARCH EUR J PHY, V416, P305, DOI 10.1007/BF00392067; LUCKHOFF A, 1986, J CELL PHYSIOL, V126, P414, DOI 10.1002/jcp.1041260312; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NILIUS B, 1991, NEWS PHYSIOL SCI, V6, P110; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; SCHILLING WP, 1989, AM J PHYSIOL, V257, pH778, DOI 10.1152/ajpheart.1989.257.3.H778; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0	29	413	413	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1992	355	6358					356	358		10.1038/355356a0	http://dx.doi.org/10.1038/355356a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1309941				2022-12-28	WOS:A1992HA59100070
J	DAVIDS, PHP; GROEN, AK; RAUWS, EAJ; TYTGAT, GNJ; HUIBREGTSE, K				DAVIDS, PHP; GROEN, AK; RAUWS, EAJ; TYTGAT, GNJ; HUIBREGTSE, K			RANDOMIZED TRIAL OF SELF-EXPANDING METAL STENTS VERSUS POLYETHYLENE STENTS FOR DISTAL MALIGNANT BILIARY OBSTRUCTION	LANCET			English	Article							BILE-DUCT OBSTRUCTION; ENDOPROSTHESIS; MANAGEMENT; INSERTION; JAUNDICE; COMPLICATIONS; PALLIATION; STRICTURES; PANCREAS; CANCER	Self-expanding metal stents are claimed to prolong biliary-stent patency, although no formal comparative trial between plastic and expandable stents has been done. In a prospective randomised trial, we assigned 105 patients with irresectable distal bile-duct malignancy to receive either a metal stent (49) or a straight polyethylene stent (56). Median patency of the first stent was significantly prolonged in patients with a metal stent compared with those with a polyethylene stent (273 vs 126 days; p = 0.006). The major cause of stent dysfunction was tumour ingrowth in the metal-stent group and sludge deposition in the polyethylene-stent group. Treatment after any occlusion included placement of a polyethylene stent. In the metal-stent group none of 14 second stents occluded, whereas 11 of 23 (48%) second stents clogged in the polyethylene-stent group (p = 0.002). Overall median survival was 149 days and did not differ significantly between treatment groups. Incremental cost-effectiveness analysis showed that intial placement of a metal stent results in a 28% decrease of endoscopic procedures. Self-expanding metal stents have a longer patency than polyethylene stents and offer adequate palliation in patients with irresectable malignant distal bile-duct obstruction.			DAVIDS, PHP (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, DEPT GASTROENTEROL, MEIBERGDREEF 9, 1105 AZ AMSTERDAM, NETHERLANDS.							ADAM A, 1991, AM J ROENTGENOL, V156, P321, DOI 10.2214/ajr.156.2.1702574; ANDERSEN JR, 1989, GUT, V30, P1132, DOI 10.1136/gut.30.8.1132; [Anonymous], 1979, WHO HDB REPORTING RE; COENE PPLO, 1990, GUT, V31, P913, DOI 10.1136/gut.31.8.913; COONS HG, 1989, RADIOLOGY, V170, P979, DOI 10.1148/radiology.170.3.2916066; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; CREMER M, 1990, GASTROINTEST ENDOSC, V36, P451, DOI 10.1016/S0016-5107(90)71113-3; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DOOLEY JS, 1984, GASTROENTEROLOGY, V86, P905; GILLAMS A, 1990, RADIOLOGY, V174, P137, DOI 10.1148/radiology.174.1.2294541; GROEN AK, 1987, ENDOSCOPY, V19, P57, DOI 10.1055/s-2007-1018235; HERMANN RE, 1979, NEW ENGL J MED, V301, P482, DOI 10.1056/NEJM197908303010906; HUIBREGTSE K, 1986, GASTROINTEST ENDOSC, V32, P334, DOI 10.1016/S0016-5107(86)71878-6; HUIBREGTSE K, 1989, ENDOSCOPY, V21, P280, DOI 10.1055/s-2007-1012969; HUIBREGTSE K, 1986, GASTROINTEST ENDOSC, V32, P403, DOI 10.1016/S0016-5107(86)71921-4; HUIBREGTSE K, 1992, ENDOSCOPY, V24, P391, DOI 10.1055/s-2007-1010505; HUIBREGTSE K, 1988, ENDOSCOPIC BILIARY P; JACKSON JE, 1991, AM J ROENTGENOL, V157, P291, DOI 10.2214/ajr.157.2.1713017; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; MATSUDA Y, 1991, AM J GASTROENTEROL, V86, P843; NEUHAUS H, 1991, GASTROINTEST ENDOSC, V37, P31, DOI 10.1016/S0016-5107(91)70617-2; REY JF, 1985, ENDOSCOPY, V17, P145, DOI 10.1055/s-2007-1018485; SARR MG, 1984, WORLD J SURG, V8, P906, DOI 10.1007/BF01656032; SHEPHERD HA, 1988, BRIT J SURG, V75, P1166, DOI 10.1002/bjs.1800751207; SMIT JM, 1989, GASTROINTEST ENDOSC, V35, P485, DOI 10.1016/S0016-5107(89)72895-9; SMITH AC, 1989, GUT, V30, pA1513; SPEER AG, 1987, LANCET, V2, P57, DOI 10.1016/S0140-6736(87)92733-4; SPEER AG, 1988, ANN INTERN MED, V108, P546, DOI 10.7326/0003-4819-108-4-546; SPEER AG, 1988, GASTROINTEST ENDOSC, V34, P412, DOI 10.1016/S0016-5107(88)71407-8; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706	30	812	838	2	41	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 19	1992	340	8834-5					1488	1492		10.1016/0140-6736(92)92752-2	http://dx.doi.org/10.1016/0140-6736(92)92752-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1281903				2022-12-28	WOS:A1992KD06900002
J	GIBBS, D; EVANS, J				GIBBS, D; EVANS, J			PAINTINGS OF A 19TH-CENTURY OPERATING-THEATER	BRITISH MEDICAL JOURNAL			English	Article									ROYAL LONDON HOSP ARCHIVES & MUSEUM,LONDON E1 2AA,ENGLAND	University of London; Queen Mary University London	EVANS, J (corresponding author), ROYAL LONDON HOSP ARCHIVES & MUSEUM,LONDON E1 2AA,ENGLAND.							GIBBS DD, 1992, J ROY SOC MED, V85, P565; Grenfell Wilfred, 1920, LABRADOR DOCTOR AUTO; HUTCHINSON J, 1897, LONDON HOSPITAL GAZE, V2, P4; TREVES F, 1919, LONDON HOSPITAL GAZA, V22, P223; 1980, OPERATING THEATRE UN; SURGERY BEADLES RETU	6	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1549	1550		10.1136/bmj.305.6868.1549	http://dx.doi.org/10.1136/bmj.305.6868.1549			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	KD771	1286383	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KD77100020
J	SIMKIN, B				SIMKIN, B			MOZART SCATOLOGICAL DISORDER	BRITISH MEDICAL JOURNAL			English	Article											SIMKIN, B (corresponding author), CEDARS SINAI MED CTR,DEPT MED,DIV ENDOCRINOL,8700 BEVERLY BLVD,LOS ANGELES,CA 90048, USA.							Anderson Emily, 1985, LETT MOZART HIS FAMI; BRUUN RD, 1991, GUIDE DIAGNOSIS TREA; COMINGS DE, 1991, JAMA-J AM MED ASSOC, V266, P1793, DOI 10.1001/jama.266.13.1793; DAVIES P, 1989, MOZART PERSON HIS CH, P145; DEUTSCH OE, 1965, MOZART DOCUMENTARY B, P537; ELDRIDGE R, 1977, NEUROLOGY, V27, P115, DOI 10.1212/WNL.27.2.115; ERENBERG G, 1986, CLEV CLIN J MED, V53, P127, DOI 10.3949/ccjm.53.2.127; Gilles de la Tourette G., 1885, ARCH NEUROL-CHICAGO, V9, P158; Gilles de la Tourette G, 1885, ARCH NEUROL-CHICAGO, V9, P158; GOLDEN GS, 1987, CURRENT THERAPY NEUR; HAIBEL S, 1965, MOZART DOCUMENTARY B, P537; JAHN O, 1891, LIFE MOZART, V3, P277; JAHN O, 1891, LIFE MOZART, V2, P420; KELLY M, 1826, REMINISCENCES M KELL, V1, P255; Mahler MS, 1943, PSYCHIAT QUART, V17, P579, DOI 10.1007/BF01561841; MENKES JH, 1990, TXB CHILD NEUROLOGY, P150; MURRAY TJ, 1979, BMJ-BRIT MED J, V1, P1610, DOI 10.1136/bmj.1.6178.1610; NIEMETSCHEK FX, 1798, LEBEN KOK KAPELLMEIS; SACKS O, 1992, NEW YORKER      0316, P85; SACKS O, 1991, 2ND INT SCI S TOUR S; SHAPIRO AK, 1978, G DELATOURETTE SYNDR, P143; STENDAHL HB, 1972, HAYDN MOZART METASTA; STEPTOE A, 1990, MOZART COMPENDIUM, P104; von Nissen Georg Nikolaus, 1828, BIOGRAPHIE WA MOZART; WALTON J, 1985, BRAINS DISEASES NERV, P350; WEINGARTEN K, 1968, HDB CLIN NEUROLOGY, P787; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001	27	40	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1563	1567		10.1136/bmj.305.6868.1563	http://dx.doi.org/10.1136/bmj.305.6868.1563			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	KD771	1286388	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100025
J	PORCELLI, S; MORITA, CT; BRENNER, MB				PORCELLI, S; MORITA, CT; BRENNER, MB			CD1B RESTRICTS THE RESPONSE OF HUMAN CD4-8- LYMPHOCYTES-T TO A MICROBIAL ANTIGEN	NATURE			English	Article							GAMMA-DELTA CELLS; HLA CLASS-I; MONOCLONAL-ANTIBODIES; RECOGNITION; GENES; EXPRESSION; RECEPTOR; DIFFERENTIATION; THYMOCYTES; MOLECULES	MOLECULES encoded by the human CD1 locus on chromosome 1 (ref. 33) are recognized by selected CD4-8- T-cell clones expressing either alphabeta or gammadelta T-cell antigen receptors1,2. The known structural resemblance of CD1 molecules to antigen-presenting molecules encoded by major histocompatibility complex (MHC) genes on human chromosome 6 (refs 3, 4, 34, 35), suggested that CD1 may represent a family of antigen-presenting molecules separate from those encoded in the MHC1,5,6. Here we report that the proliferative and cytotoxic responses of human CD4-8-alphabetaTCR+ T cells specific for Mycobacterium tuberculosis can be restricted by CD1b, one of the four identified protein products of the CD1 locus. The responses of these T cells to M. tuberculosis seemed not to involve MHC encoded molecules, but were absolutely dependent on the expression of CD1b by the antigen-presenting cell and involved an antigen processing requirement similar to that seen in MHC class II-restricted antigen presentation. These results provide, to our knowledge, the first direct evidence for the proposed antigen-presenting function of CD1 molecules and suggest that the CD1 family plays a role in cell-mediated immunity to microbial pathogens.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	PORCELLI, S (corresponding author), BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115, USA.		Morita, Craig T/C-1365-2011	Morita, Craig T/0000-0001-8496-8294				ALBERTSON DG, 1988, EMBO J, V7, P2801, DOI 10.1002/j.1460-2075.1988.tb03135.x; ANEGON I, 1991, J IMMUNOL, V147, P3973; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BLUESTONE JA, 1989, J IMMUNOL, V142, P1785; BOUMSELL L, 1989, LEUCOCYTE TYPING, V4, P251; BRODSKY FM, 1982, J IMMUNOL, V128, P129; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CHESNUT RW, 1982, J IMMUNOL, V129, P2382; ERLICH H, 1986, HUM IMMUNOL, V16, P205, DOI 10.1016/0198-8859(86)90049-2; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; FAVALORO EJ, 1986, DIS MARKERS, V4, P261; GLIMCHER LH, 1982, J EXP MED, V156, P640, DOI 10.1084/jem.156.2.640; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; LANIER LL, 1987, LEUKOCYTE TYPING, V3, P175; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; MORITA CT, 1991, EUR J IMMUNOL, V21, P2999, DOI 10.1002/eji.1830211215; OLIVE D, 1984, IMMUNOGENETICS, V20, P253, DOI 10.1007/BF00364207; PANCHAMOORTHY G, 1991, J IMMUNOL, V147, P3360; PARHAM P, 1992, NATURE, V357, P193, DOI 10.1038/357193a0; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RONCAROLO MG, 1991, J IMMUNOL, V147, P781; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SHAW S, 1985, HUM IMMUNOL, V12, P191, DOI 10.1016/0198-8859(85)90336-2; SHIUE L, 1988, J EXP MED, V168, P1993, DOI 10.1084/jem.168.6.1993; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZENMOUR J, 1992, J IMMUNOL, V148, P1941; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	35	533	541	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					593	597		10.1038/360593a0	http://dx.doi.org/10.1038/360593a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1281285				2022-12-28	WOS:A1992KB95900088
J	CORRELL, CC; BATIE, CJ; BALLOU, DP; LUDWIG, ML				CORRELL, CC; BATIE, CJ; BALLOU, DP; LUDWIG, ML			PHTHALATE DIOXYGENASE REDUCTASE - A MODULAR STRUCTURE FOR ELECTRON-TRANSFER FROM PYRIDINE-NUCLEOTIDES TO [2FE-2S]	SCIENCE			English	Article							FERREDOXIN-NADP+ REDUCTASE; GLUTATHIONE-REDUCTASE; CRYSTALLOGRAPHIC REFINEMENT; 3-DIMENSIONAL STRUCTURE; PSEUDOMONAS-CEPACIA; 2-IRON FERREDOXINS; SPINACH FERREDOXIN; PROTEIN-STRUCTURE; ATOMIC-STRUCTURE; RESOLUTION	Phthalate dioxygenase reductase (PDR) is a prototypical iron-sulfur flavoprotein (36 kilodaltons) that utilizes flavin mononucleotide (FMN) to mediate electron transfer from the two-electron donor, reduced nicotinamide adenine nucleotide (NADH), to the one-electron acceptor, [2Fe-2S]. The crystal structure of oxidized PDR from Pseudomonas cepacia has been analyzed at 2.0 angstrom resolution resolution; reduced PDR and pyridine nucleotide complexes have been analyzed at 2.7 angstrom resolution. NADH, FMN, and the [2Fe-2S] cluster, bound to distinct domains, are brought together near a central cleft in the molecule, with only 4.9 angstroms separating the flavin 8-methyl and a cysteine sulfur ligated to iron. The domains that bind FMN and [2Fe-2S] are packed so that the flavin ring and the plane of the [2Fe-2S] core are approximately perpendicular. The [2Fe-2S] group is bound by four cysteines in a site resembling that in plant ferredoxins, but its redox potential (-174 millivolts at pH 7.0) is much higher than the potentials of plant ferredoxins. Structural and sequence similarities assign PDR to a distinct family of flavoprotein reductases, all related to ferredoxin NADP+-reductase.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DIV BIOPHYS RES, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dballou@umich.edu, David P/A-1298-2007		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020877, R01GM020877] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20877, GM 16429] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; AXUP AW, 1988, J AM CHEM SOC, V110, P435, DOI 10.1021/ja00210a020; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Batie C. J., 1991, CHEM BIOCH FLAVOENZY, V3, P543; BATIE CJ, 1987, J BIOL CHEM, V262, P1510; BATIE CJ, UNPUB; BATIE CJ, 1987, FLAVINS FLAVOPROTEIN, P377; BHATTACHARYYA AK, 1986, BIOCHEMISTRY-US, V25, P4655, DOI 10.1021/bi00364a030; BRICOGNE G, 1982, COMPUTATIONAL CRYSTA, P223; BRUNEL F, 1988, J BACTERIOL, V170, P4924, DOI 10.1128/jb.170.10.4924-4930.1988; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1990, XPLOR 2 1; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CAMMACK R, 1977, BIOCHEM J, V168, P205, DOI 10.1042/bj1680205; CAMMACK R, 1991, ADV INORG CHEM, V38, P1; CORRELL CC, 1985, J BIOL CHEM, V260, P4633; CORRELL CC, UNPUB; CORRELL CC, 1992, THESIS U MICHIGAN; COWAN JA, 1988, ANN NY ACAD SCI, V550, P68, DOI 10.1111/j.1749-6632.1988.tb35324.x; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; DUGAD LB, 1990, BIOCHEMISTRY-US, V29, P2263, DOI 10.1021/bi00461a009; DUNHAM WR, 1971, BIOCHIM BIOPHYS ACTA, V253, P373, DOI 10.1016/0005-2728(71)90041-7; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FRITZ J, 1973, HELV CHIM ACTA, V56, P2250, DOI 10.1002/hlca.19730560713; GASSNER G, UNPUB; GRAY HB, 1989, BIOCHEMISTRY-US, V28, P7499, DOI 10.1021/bi00445a001; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; HAHM S, 1992, BIOCHEMISTRY-US, V31, P3472, DOI 10.1021/bi00128a022; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; Hendrickson W. A., 1985, T AM CRYSTALLOGR ASS, V21, P11; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; IPPOLITO JA, 1990, J MOL BIOL, V215, P457, DOI 10.1016/S0022-2836(05)80364-X; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; LIM LW, 1986, J BIOL CHEM, V261, P5140; LIU R, 1992, 1992 ANN M AM SOC MI, P262; LIU R, COMMUNICATION; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; LUND J, 1985, EUR J BIOCHEM, V147, P297, DOI 10.1111/j.1432-1033.1985.tb08750.x; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Manstein D.J., 1987, FLAVINS FLAVOPROTEIN, P3; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; Massey V., 1983, BIOL OXIDATION, P114; MATHEWS FS, 1991, BIOCHEMISTRY-US, V30, P238, DOI 10.1021/bi00215a034; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; MCLENDON G, 1988, ACCOUNTS CHEM RES, V21, P160, DOI 10.1021/ar00148a005; MEADE TJ, 1989, J AM CHEM SOC, V111, P4353, DOI 10.1021/ja00194a030; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; MOSER CC, 1990, ADV CHEM SERIES, V226; NEIDLE EL, 1991, J BACTERIOL, V173, P5385, DOI 10.1128/jb.173.17.5385-5395.1991; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; POE M, 1970, P NATL ACAD SCI USA, V65, P797, DOI 10.1073/pnas.65.4.797; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; SALMEEN I, 1972, ARCH BIOCHEM BIOPHYS, V150, P767, DOI 10.1016/0003-9861(72)90096-3; SHIEH HS, 1981, BIOCHEMISTRY-US, V20, P4766, DOI 10.1021/bi00519a037; SIMON MJ, IN PRESS GENE; SKJELDAL L, 1991, BIOCHEMISTRY-US, V30, P7363, DOI 10.1021/bi00244a002; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TOLLIN G, 1986, BIOCHIM BIOPHYS ACTA, V853, P29, DOI 10.1016/0304-4173(86)90003-0; WALKER MC, 1990, ARCH BIOCHEM BIOPHYS, V281, P76, DOI 10.1016/0003-9861(90)90415-U; WALSH C, 1980, ACCOUNTS CHEM RES, V13, P148, DOI 10.1021/ar50149a004; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; YAMAGUCHI M, 1981, J BIOL CHEM, V256, P6783; ZIPPLIES MF, 1984, FLAVINS FLAVOPROTEIN, P21; [No title captured]	79	265	269	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1992	258	5088					1604	1610		10.1126/science.1280857	http://dx.doi.org/10.1126/science.1280857			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1280857				2022-12-28	WOS:A1992KA89600022
J	YU, HT; ROSEN, MK; SHIN, TB; SEIDELDUGAN, C; BRUGGE, JS; SCHREIBER, SL				YU, HT; ROSEN, MK; SHIN, TB; SEIDELDUGAN, C; BRUGGE, JS; SCHREIBER, SL			SOLUTION STRUCTURE OF THE SH3 DOMAIN OF SRC AND IDENTIFICATION OF ITS LIGAND-BINDING SITE	SCIENCE			English	Article							COHERENCE TRANSFER SPECTROSCOPY; 3-DIMENSIONAL NMR-SPECTROSCOPY; MULTIPLE-QUANTUM COHERENCE; PROTEINS; SPECTRA; SIMPLIFICATION; ASSIGNMENTS; RECEPTOR; SYSTEMS; YEAST	The Src homology 3 (SH3) region is a protein domain of 55 to 75 amino acids found in many cytoplasmic proteins, including those that participate in signal transduction pathways. The solution structure of the SH3 domain of the tyrosine kinase Src was determined by multidimensional nuclear magnetic resonance methods. The molecule is composed of two short three-stranded anti-parallel beta sheets packed together at approximately right angles. Studies of the SH3 domain bound to proline-rich peptide ligands revealed a hydrophobic binding site on the surface of the protein that is lined with the side chains of conserved aromatic amino acids.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139	Harvard University; Takeda Pharmaceutical Company Ltd; Takeda Oncology				Yu, Hongtao/0000-0002-8861-049X	NCI NIH HHS [CA27951] Funding Source: Medline; NCRR NIH HHS [1-S10-RR04870] Funding Source: Medline; NIGMS NIH HHS [GM44993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027951, R37CA027951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044993] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH CH, 1990, BIOCHEMISTRY-US, V29, P6332, DOI 10.1021/bi00479a002; BAX A, 1981, J MAGN RESON, V43, P478, DOI 10.1016/0022-2364(81)90060-3; BOLTON PH, 1982, CHEM PHYS LETT, V89, P139, DOI 10.1016/0009-2614(82)83390-3; BOLTON PH, 1982, J MAGN RESON, V48, P336, DOI 10.1016/0022-2364(82)90288-8; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, XPLOR MANUAL; BRUNGER AT, 1992, XPLOR MANUAL 5 3 0; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EICH G, 1982, J AM CHEM SOC, V104, P3731, DOI 10.1021/ja00377a036; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOYAMA S, UNPUB; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER B, COMMUNICATION; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MULLER N, 1986, J AM CHEM SOC, V108, P6482, DOI 10.1021/ja00281a006; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMUTH SP, 1989, MOL CELL BIOL, V9, P1109; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PATTERSON Y, 1990, SCIENCE, V249, P755; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Potts W M, 1988, Oncogene Res, V3, P343; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; WAGNER G, 1983, BIOCHEM BIOPH RES CO, V113, P854, DOI 10.1016/0006-291X(83)91077-X; WAGNER G, 1983, J MAGN RESON, V55, P151, DOI 10.1016/0022-2364(83)90284-6; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WENG ZY, UNPUB; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	43	306	317	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1665	1668		10.1126/science.1280858	http://dx.doi.org/10.1126/science.1280858			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1280858				2022-12-28	WOS:A1992KA89600042
J	AUVINEN, M; PAASINEN, A; ANDERSSON, LC; HOLTTA, E				AUVINEN, M; PAASINEN, A; ANDERSSON, LC; HOLTTA, E			ORNITHINE DECARBOXYLASE ACTIVITY IS CRITICAL FOR CELL-TRANSFORMATION	NATURE			English	Article							ROUS-SARCOMA VIRUS; POLYAMINE METABOLISM; GENE-EXPRESSION; TYROSINE; GROWTH; PHOSPHORYLATION; AMPLIFICATION; INDUCTION; KINASES; DNA	THE enzyme ornithine decarboxylase is the key regulator of the synthesis of polyamines1-3 which are essential for cell proliferation4,5. Expression of this enzyme is transiently increased upon stimulation by growth factors1-3, but becomes constitutively activated during cell transformation induced by carcinogens6,7, viruses8-10 or oncogenes11-14. To test whether ornithine decarboxylase could be a common mediator of transformation and oncogenic itself, we transfected NIH3T3 cells with expression vectors carrying the complementary DNA encoding human ornithine decarboxylase in sense and antisense orientations. The increased expression of the enzyme (50-100-times endogenous levels) induced not only cell transformation, but also anchorage-independent growth in soft agar and increased tyrosine phosphorylation of a protein of M(r) 130K. Expression of ornithine decarboxylase antisense RNA was associated with an epithelioid morphology and reduced cell proliferation. Moreover, blocking the endogenous enzyme using specific inhibitor or synthesizing antisense RNA prevented transformation of rat fibroblasts by temperature-sensitive v-src oncogene. Our results imply that the gene encoding ornithine decarboxylase is a proto-oncogene central for regulation of cell growth and transformation.	UNIV HELSINKI,DEPT PATHOL,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND	University of Helsinki								BALASUNDARAM D, 1991, P NATL ACAD SCI USA, V88, P5872, DOI 10.1073/pnas.88.13.5872; CHANG BK, 1988, BIOCHEM BIOPH RES CO, V157, P264, DOI 10.1016/S0006-291X(88)80042-1; DON S, 1975, CANCER RES, V35, P3618; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ERIKSON RL, 1980, J CELL BIOL, V87, P319, DOI 10.1083/jcb.87.2.319; GAZDAR AF, 1976, NATURE, V262, P696, DOI 10.1038/262696a0; GILMOUR SK, 1987, CANCER RES, V47, P1221; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HADDOX MK, 1980, CANCER RES, V40, P604; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Janne J, 1983, Spec Top Endocrinol Metab, V5, P227; JANNE OA, 1984, ANN NY ACAD SCI, V438, P72, DOI 10.1111/j.1749-6632.1984.tb38277.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KATZ A, 1989, EMBO J, V8, P1163, DOI 10.1002/j.1460-2075.1989.tb03487.x; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; POHJANPELTO P, 1981, NATURE, V293, P475, DOI 10.1038/293475a0; Sambrook J, 1989, MOL CLONING LABORATO; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SEILER N, 1990, CANCER RES, V50, P5077; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEGLICH C, 1985, SOMAT CELL MOLEC GEN, V11, P11, DOI 10.1007/BF01534730; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TONIN PN, 1989, ONCOGENE, V4, P1117; YUSPA SH, 1976, NATURE, V262, P402, DOI 10.1038/262402a0	34	640	657	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					355	358		10.1038/360355a0	http://dx.doi.org/10.1038/360355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1280331				2022-12-28	WOS:A1992JZ63000055
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			INTERPRETING HOOFBEATS - CAN BAYES HELP CLEAR THE HAZE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DECISION-ANALYSIS; PHEOCHROMOCYTOMA		TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GEN INTERNAL MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CLIN DECIS MAKING,BOSTON,MA 02111, USA.							BRAVO EL, 1979, NEW ENGL J MED, V301, P682, DOI 10.1056/NEJM197909273011302; BRAVO EL, 1991, KIDNEY INT, V40, P544, DOI 10.1038/ki.1991.244; FEINSTEIN AR, 1977, CLIN PHARMACOL THER, V21, P482; FELDMAN JM, 1989, HOSP PRACT, V24, P175; HENRY JB, 1984, CLIN DIAGNOSIS MANAG, P1439; INGELFINGER JA, 1983, BIOSTATISTICS CLIN M, P198; KAPLAN NM, 1990, CLIN HYPERTENSION, P350; KAPLAN NM, 1990, CLIN HYPERTENSION, P26; Kaplan S. L., 1990, CLIN PEDIAT ENDOCRIN, P1; LUSTED LB, 1968, INTRO MED DECISION M, P20; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; Politser P, 1982, Med Decis Making, V2, P47, DOI 10.1177/0272989X8200200108; SHAPIRO B, 1985, J NUCL MED, V26, P576; STEWART BH, 1978, NEW ENGL J MED, V299, P460, DOI 10.1056/NEJM197808312990907; WEINBERGER MH, 1992, TXB INTERNAL MED, P236; YOUNG MJ, 1989, J GEN INTERN MED, V4, P273, DOI 10.1007/BF02597394	16	28	29	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					1009	1013		10.1056/NEJM199210013271407	http://dx.doi.org/10.1056/NEJM199210013271407			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1298225				2022-12-28	WOS:A1992JQ22500007
J	TORNOS, MP; PERMANYERMIRALDA, G; OLONA, M; GIL, M; GALVE, E; ALMIRANTE, B; SOLERSOLER, J				TORNOS, MP; PERMANYERMIRALDA, G; OLONA, M; GIL, M; GALVE, E; ALMIRANTE, B; SOLERSOLER, J			LONG-TERM COMPLICATIONS OF NATIVE VALVE INFECTIVE ENDOCARDITIS IN NONADDICTS - A 15-YEAR FOLLOW-UP-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ENDOCARDITIS; HEART VALVE DISEASE; AORTIC VALVE; DEATH, SUDDEN, CARDIAC; HEART VALVE PROSTHESIS	DISEASE	Objective: To describe the incidence and clinical manifestations of long-term cardiac complications of endocarditis. Design: Cohort study. Setting: University-affiliated tertiary medical center. Patients: One hundred twelve consecutive patients, survivors from a series of 140 non-addicted patients with a first episode of infective endocarditis on native valves hospitalized from 1975 to 1990. Thirty-two patients had had valve replacement during the active phase of the infection, and the remaining 80 patients received medical treatment alone. Measurements: Relapse, recurrence, need for late cardiac surgery, and cardiac mortality. Results: Relapses occurred in three patients (2.7%) and recurrences in five patients (4.5%, incidence density at 15 years, 0.0030 per patient-year). Late cardiac surgery was needed by 47% of the patients treated medically during the active phase, and most had surgery in the first 2 years of follow-up (incidence density, 0.25 per patient-year at 2 years). Aortic valve involvement (relative risk, 2.66; 95% Cl, 1.15 to 6.17) and end-diastolic diameter greater than 60 mm (relative risk, 1.04; 95% Cl, 1.03 to 2.43) were associated with the need for late surgery in univariate analysis. Multiple logistic regression analysis showed aortic valve involvement to be an independent predictor of the need for late surgery (relative risk, 3.04; Cl, 1.23 to 7.54). Only 2 of the 32 patients who had surgery during the active infection needed a second operation during follow-up. At the end of follow-up, the number of patients who had surgery after the onset of the infection was 86 (60% of the whole series). Cardiac death occurred in 16 patients; most deaths were sudden or postoperative and occurred in the first 2 years of follow-up (incidence density, 0.047 per patient-year at 2 years). Independent predictors of death were not found. Survival was 90% at 2 years, 88% at 5 years, 81 % at 10 years, and 61 % at 15 years. Conclusions: Survival after infective endocarditis is fair (81% probability of survival at 10 years), and the most common types of cardiac death are sudden and postoperative. Aortic valve involvement is an independent predictor of the need for late cardiac surgery. The rate of recurrences is not negligible (incidence density at 15 years, 0.0030 per patient-year).			TORNOS, MP (corresponding author), UNIV BARCELONA, HOSP GEN VALL DHEBRON, P VALL DHEBRON SN, E-08035 BARCELONA, SPAIN.			Almirante, Benito/0000-0002-1189-2361				BADDOUR LM, 1988, REV INFECT DIS, V10, P1163; BAYLISS R, 1983, BRIT HEART J, V50, P513, DOI 10.1136/hrt.50.6.513; CALDERWOOD SB, 1986, J THORAC CARDIOV SUR, V92, P776; CHAMBERS HF, 1983, MEDICINE, V62, P170, DOI 10.1097/00005792-198305000-00004; DAVID TE, 1990, ANN THORAC SURG, V49, P701, DOI 10.1016/0003-4975(90)90006-R; DELAHAYE JP, 1989, ARCH MAL COEUR VAISS, V82, P543; DURACK DT, 1990, HEART, P1230; GERACI JE, 1982, MAYO CLIN PROC, V57, P145; IVERT TSA, 1984, CIRCULATION, V69, P223, DOI 10.1161/01.CIR.69.2.223; JAFFE WM, 1990, J AM COLL CARDIOL, V15, P1227, DOI 10.1016/S0735-1097(10)80005-1; KAYE D, 1991, HARRISONS PRINCIPLES, P508; KAYE D, 1976, INFECTIVE ENDOCARDIT, P201; Kleimbaum DG., 1982, EPIDEMIOLOGIC RES PR, P96; KOMSHIAN SV, 1990, REV INFECT DIS, V12, P693; MCANULTY JH, 1979, JAMA-J AM MED ASSOC, V242, P77, DOI 10.1001/jama.242.1.77; ORMISTON JA, 1981, AUST NZ J MED, V11, P620, DOI 10.1111/j.1445-5994.1981.tb03536.x; PRINGLE SD, 1989, INT J CARDIOL, V24, P179, DOI 10.1016/0167-5273(89)90302-1; RICE LB, 1991, REV INFECT DIS, V13, P1; SCHELD WM, 1990, PRINCIPLES PRACTICE, P670; STECKELBERG JM, 1991, ANN INTERN MED, V114, P635, DOI 10.7326/0003-4819-114-8-635; STECKELBERG JM, 1990, AM J MED, V88, P582, DOI 10.1016/0002-9343(90)90521-E; STEIN DS, 1987, REV INFECT DIS, V9, P908; TORNOSMAS MP, 1984, EUR HEART J, V5, P107, DOI 10.1093/eurheartj/5.suppl_C.107; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; WEINSTEIN L, 1988, HEART DISEASE TXB CA, P1093	25	123	124	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					567	572		10.7326/0003-4819-117-7-567	http://dx.doi.org/10.7326/0003-4819-117-7-567			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1306055				2022-12-28	WOS:A1992JQ22600004
J	LASKE, A; GALLINO, A; CARREL, T; TURINA, MI				LASKE, A; GALLINO, A; CARREL, T; TURINA, MI			GANCICLOVIR FOR CYTOMEGALOVIRUS AFTER HEART-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											LASKE, A (corresponding author), UNIV HOSP ZURICH,CH-8091 ZURICH,SWITZERLAND.							LASKE A, 1991, TRANSPLANT P, V23, P1170; McCarthy P M, 1989, Clin Transpl, P63; PRICE GD, 1992, J HEART LUNG TRANSPL, V11, P403	3	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					892	892						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1324433				2022-12-28	WOS:A1992JN12000023
J	CHEN, J; MARTIN, BL; BRAUTIGAN, DL				CHEN, J; MARTIN, BL; BRAUTIGAN, DL			REGULATION OF PROTEIN SERINE-THREONINE PHOSPHATASE TYPE-2A BY TYROSINE PHOSPHORYLATION	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; CATALYTIC SUBUNIT ISOTYPES; RABBIT SKELETAL-MUSCLE; AMINO-ACID SEQUENCE; SEA STAR OOCYTES; S6 KINASE; PHOSPHOPROTEIN PHOSPHATASE; TRANSFORMING GENE; RAT-LIVER; INSULIN	Extracellular signals that promote cell growth activate cascades of protein kinases. The kinases are dephosphorylated and deactivated by a single type-2A protein phosphatase. The catalytic subunit of type-2A protein phosphatase was phosphorylated by tyrosine-specific protein kinases. Phosphorylation was enhanced in the presence of the phosphatase inhibitor okadaic acid, consistent with an autodephosphorylation reaction. More than 90% of the activity of phosphatase 2A was lost when thioadenosine triphosphate was used to produce a thiophosphorylated protein resistant to autodephosphorylation. Phosphorylation in vitro occurred exclusively on Tyr307. Phosphorylation was catalyzed by p60v-src, p56lck, epidermal growth factor receptors, and insulin receptors. Transient deactivation of phosphatase 2A might enhance transmission of cellular signals through kinase cascades within cells.	BROWN UNIV, DIV BIOL & MED, BIOCHEM SECT, PROVIDENCE, RI 02912 USA	Brown University								AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; Chen J., UNPUB; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CICRELLI MF, 1988, J BIOL CHEM, V263, P2009; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KLARLUND JK, 1991, J BIOL CHEM, V266, P4052; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE EYC, 1979, WIN MIAM S, V16, P483; LEVINSON AD, 1980, J BIOL CHEM, V255, P1973; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARTENSEN TM, 1982, J BIOL CHEM, V257, P9648; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; REDDY SAG, 1990, J BIOL CHEM, V265, P7748; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SHRINER C, 1988, METHOD ENZYMOL, V159, P346; SILVA OBDC, 1987, FEBS LETT, V226, P176; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; TACHIBANA T, 1981, J AM CHEM SOC, V103, P2471; TAKEDA M, 1983, J BIOL CHEM, V258, P10453; TAMURA S, 1980, EUR J BIOCHEM, V104, P347, DOI 10.1111/j.1432-1033.1980.tb04435.x; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; USUI H, 1988, J BIOL CHEM, V263, P3752; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521	41	552	563	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1992	257	5074					1261	1264		10.1126/science.1325671	http://dx.doi.org/10.1126/science.1325671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1325671				2022-12-28	WOS:A1992JL05000028
J	MATSUMURA, M; FREMONT, DH; PETERSON, PA; WILSON, IA				MATSUMURA, M; FREMONT, DH; PETERSON, PA; WILSON, IA			EMERGING PRINCIPLES FOR THE RECOGNITION OF PEPTIDE ANTIGENS BY MHC CLASS-I MOLECULES	SCIENCE			English	Article							CYTOTOXIC LYMPHOCYTES-T; HISTOCOMPATIBILITY ANTIGEN; BINDING SITE; CELLS; IDENTIFICATION; HLA-B27; COMPLEX; HLA-A2	Class I major histocompatibility complex (MHC) molecules interact with self and foreign peptides of diverse amino acid sequences yet exhibit distinct allele-specific selectivity for peptide binding. The structures of the peptide-binding specificity pockets (subsites) in the groove of murine H-2K(b) as well as human histocompatibility antigen class I molecules have been analyzed. Deep but highly conserved pockets at each end of the groove bind the amino and carboxyl termini of peptide through extensive hydrogen bonding and, hence, dictate the orientation of peptide binding. A deep polymorphic pocket in the middle of the groove provides the chemical and structural complementarity for one of the peptide's anchor residues, thereby playing a major role in allele-specific peptide binding. Although one or two shallow pockets in the groove may also interact with specific peptide side chains, their role in the selection of peptide is minor. Thus, usage of a limited number of both deep and shallow pockets in multiple combinations appears to allow the binding of a broad range of peptides. This binding occurs with high affinity, primarily because of extensive interactions with the peptide backbone and the conserved hydrogen bonding network at both termini of the peptide. Interactions between the anchor residue (or residues) and the corresponding allele-specific pocket provide sufficient extra binding affinity not only to enhance specificity but also to endure the presentation of the peptide at the cell surface for recognition by T cells.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego	MATSUMURA, M (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Fremont, Daved/0000-0002-8544-2689	NCI NIH HHS [CA-09523, CA-97489] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Fersht A., 1985, ENZYME STRUCTURE MEC; FREMONT DH, 1992, SCIENCE, V257, pR30; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JANIN J, 1990, J BIOL CHEM, V265, P16027; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KLEIN J, 1986, NATURAL HIST MAJOR H; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; LANGLADE P, UNPUB; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, IN PRESS J BIOL CHEM; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO Y, UNPUB; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SAPER MA, IN PRESS CELL; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, J BIOL CHEM, V266, P3357; VANBLEEK GM, 1990, NATURE, V348, P213; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7	43	685	754	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					927	934		10.1126/science.1323878	http://dx.doi.org/10.1126/science.1323878			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1323878				2022-12-28	WOS:A1992JH82700025
J	GILLE, H; SHARROCKS, AD; SHAW, PE				GILLE, H; SHARROCKS, AD; SHAW, PE			PHOSPHORYLATION OF TRANSCRIPTION FACTOR P62TCF BY MAP KINASE STIMULATES TERNARY COMPLEX-FORMATION AT C-FOS PROMOTER	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; DIRECTED PROTEIN-KINASE; PROLIFERATIVE CELLS; LATE PHASE; S6 KINASE; ACTIVATION; IDENTIFICATION; P58CYCLIN; INSULIN	TRANSCRIPTION of the proto-oncogene c-fos is stimulated rapidly and transiently by serum growth factors and mitogens1. Critical for this response is the serum-response element which is bound in vivo in a ternary complex containing the transcription factors p67SRF and p62TCF (ref. 2). Disruption of the ternary complex correlates with impaired induction by serum and phorbol ester3,4. Mitogen-activated protein (MAP) kinase is a serine/threonine kinase which is activated 1-5 minutes after treatment of cells with mitogens and growth factors5-8 that induce re-entry into the cell cycle, making MAP kinase a candidate for the transmission of proliferative signals. Here we show that p62TCF is phosphorylated by MAP kinase in vitro and that phosphorylation results in enhanced ternary complex formation. Serum-starved Swiss 3T3 cells treated with epidermal growth factor, which induces MAP kinase in these cells9, are induced to express c-fos and yield p62TCF active in ternary complex formation. In contrast, treatment of Swiss 3T3 cells with insulin, which does not activate MAP kinase under these conditions9, does not lead to enhanced ternary complex formation nor does it induce c-fos transcription. Our results link the expression of the human c-fos proto-oncogene to signal transduction pathways known to be activated before its own induction.			GILLE, H (corresponding author), MAX PLANCK INST IMMUNBIOL, SPEMANN LABS, POSTFACH 1169, W-7800 FREIBURG, GERMANY.			SHAW, Peter/0000-0002-2598-4283				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUHROW SA, 1983, J BIOL CHEM, V258, P7824; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; FERRARI S, 1991, METHOD ENZYMOL, V200, P159; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HALL FL, 1991, J BIOL CHEM, V266, P17430; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIPSKIND RA, 1991, NATURE, V354, P31; HOSHI M, 1988, J BIOL CHEM, V263, P5396; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4	31	918	933	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1992	358	6385					414	417		10.1038/358414a0	http://dx.doi.org/10.1038/358414a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1322499				2022-12-28	WOS:A1992JF85300056
J	PATTNAIK, AK; BALL, LA; LEGRONE, AW; WERTZ, GW				PATTNAIK, AK; BALL, LA; LEGRONE, AW; WERTZ, GW			INFECTIOUS DEFECTIVE INTERFERING PARTICLES OF VSV FROM TRANSCRIPTS OF A CDNA CLONE	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; RNA-POLYMERASE; INFLUENZA-VIRUS; VACCINIA VIRUS; REPLICATION; EXPRESSION; AMPLIFICATION; MUTATIONS; PROTEINS; VECTORS	The generation of infectious defective interfering (DI) particles of vesicular stomatitis virus (VSV) entirely from cDNA clones is reported. Bacteriophage T7 RNA polymerase was used to direct the transcription of a complete negative-stranded genomic RNA from a cDNA clone of a VSV DI RNA in cells simultaneously expressing the five VSV proteins from separately transfected cDNA clones. The negative-stranded transcript was encapsidated with N protein, replicated by the VSV polymerase, and the replicated RNAs were assembled and budded to yield infectious DI virions. No helper VSV was required. Replication occurred at high levels and was assayed by direct biochemical means. An exact 3' terminus of the initial transcript, which was generated by autolytic cleavage using a ribozyme from hepatitis delta virus, was critical for replication.			PATTNAIK, AK (corresponding author), UNIV ALABAMA, SCH MED, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA.		Pattnaik, Asit K./X-1531-2019	Pattnaik, Asit K./0000-0002-9581-6787	NIAID NIH HHS [R37 AI18270, R37-AI12464, AI20181] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020181, R37AI012464, R37AI018270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON RF, 1988, J VIROL, V62, P3581, DOI 10.1128/JVI.62.10.3581-3588.1988; BALL LA, 1992, J VIROL, V66, P2335, DOI 10.1128/JVI.66.4.2335-2345.1992; COLLINS PL, 1991, P NATL ACAD SCI USA, V88, P9663, DOI 10.1073/pnas.88.21.9663; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; DZIANOTT AM, 1988, NUCLEIC ACIDS RES, V16, P10940, DOI 10.1093/nar/16.22.10940; EMERSON SU, 1972, J VIROL, V10, P297, DOI 10.1128/JVI.10.2.297-309.1972; EMERSON SU, 1975, J VIROL, V15, P1348, DOI 10.1128/JVI.15.6.1348-1356.1975; ENAMI M, 1990, P NATL ACAD SCI USA, V87, P3802, DOI 10.1073/pnas.87.10.3802; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HALTINER M, 1985, NUCLEIC ACIDS RES, V13, P1015, DOI 10.1093/nar/13.3.1015; KEENE JD, 1978, P NATL ACAD SCI USA, V75, P3225, DOI 10.1073/pnas.75.7.3225; KONARSKA MM, 1989, CELL, V57, P423, DOI 10.1016/0092-8674(89)90917-3; LUYTJES W, 1989, CELL, V59, P1107, DOI 10.1016/0092-8674(89)90766-6; MEIER E, 1984, J VIROL, V51, P515, DOI 10.1128/JVI.51.2.515-521.1984; MOYER SA, 1991, J VIROL, V65, P2170, DOI 10.1128/JVI.65.5.2170-2178.1991; PARK KH, 1991, P NATL ACAD SCI USA, V88, P5537, DOI 10.1073/pnas.88.13.5537; PATTNAIK AK, 1990, J VIROL, V64, P2948, DOI 10.1128/JVI.64.6.2948-2957.1990; PATTNAIK AK, 1991, P NATL ACAD SCI USA, V88, P1379, DOI 10.1073/pnas.88.4.1379; PATTON JT, 1984, J VIROL, V49, P303, DOI 10.1128/JVI.49.2.303-309.1984; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SORIA M, 1974, VIROLOGY, V61, P270, DOI 10.1016/0042-6822(74)90261-X; SULLENDER WM, 1991, J VIROL, V65, P5425, DOI 10.1128/JVI.65.10.5425-5434.1991; WERTZ GW, 1981, NUCLEIC ACIDS RES, V9, P6487, DOI 10.1093/nar/9.23.6487	26	246	270	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					1011	1020		10.1016/0092-8674(92)90619-N	http://dx.doi.org/10.1016/0092-8674(92)90619-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1318785				2022-12-28	WOS:A1992HY79200012
J	WENDT, CH; WEISDORF, DJ; JORDAN, MC; BALFOUR, HH; HERTZ, MI				WENDT, CH; WEISDORF, DJ; JORDAN, MC; BALFOUR, HH; HERTZ, MI			PARAINFLUENZA VIRUS RESPIRATORY-INFECTION AFTER BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARA-INFLUENZA VIRUS; CHILDREN; RIBAVIRIN; ADULTS; PNEUMONIA; LEUKEMIA; THERAPY	Background. Pneumonia complicates about half of all bone marrow transplantations, and in about a third of the cases no specific cause is identified. Although parainfluenza virus is a common cause of respiratory infection in normal children, its role in transplant recipients is unknown. Methods. We describe the incidence and clinical course of parainfluenza infection among the 1253 recipients of bone marrow transplants at our center from 1974 through 1990. We performed viral cultures on all such recipients who had manifestations of a viral infection or fever without apparent cause. Results. Among the 1253 patients, we found 27 (2.2 percent) who had parainfluenza virus infection as demonstrated by culture (12 of 580 adults and 15 of 673 children). Eight of these patients had only upper respiratory tract involvement, all of whom had positive nasopharyngeal cultures. Of the remaining 19, 8 had symptoms of both upper and lower respiratory tract involvement, and 11 had only lower respiratory involvement, of whom only 6 had positive nasopharyngeal cultures. Four required bronchoalveolar lavage for diagnosis. A median of nine days elapsed from the onset of symptoms until the culture became positive, and overall only 33 of 118 cultures obtained were positive. Respiratory failure developed in 6 of the 19 patients with lower respiratory tract involvement, and all 6 died. Conclusions. Parainfluenza virus is a cause of serious lower respiratory tract involvement in both adults and children who undergo bone marrow transplantation. Given the insensitivity of current culturing techniques, it may be underdiagnosed.	UNIV MINNESOTA,SCH MED,DEPT INTERNAL MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,BONE MARROW TRANSPLANT PROGRAM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Wendt, Chris/C-6823-2012		PHS HHS [P0-1 21737] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ATKINSON K, 1983, TRANSPLANT P, V15, P474; BREINIG MK, 1987, J INFECT DIS, V156, P273, DOI 10.1093/infdis/156.2.273; CRAWFORD SW, 1988, AM REV RESPIR DIS, V137, P682, DOI 10.1164/ajrccm/137.3.682; DELAGE G, 1979, J PEDIATR-US, V94, P426, DOI 10.1016/S0022-3476(79)80591-0; EGGLESTON M, 1987, INFECT CONT HOSP EP, V8, P215, DOI 10.1017/S0195941700065978; ENGLUND JA, 1988, ANN INTERN MED, V109, P203, DOI 10.7326/0003-4819-109-3-203; FRANK JA, 1983, AM J DIS CHILD, V137, P1172, DOI 10.1001/archpedi.1983.02140380032010; GARDNER PS, 1971, BMJ-BRIT MED J, V2, P7, DOI 10.1136/bmj.2.5752.7; GLEZEN WP, 1989, VIRAL INFECTIONS HUM, P493; Hall C B, 1987, Semin Respir Infect, V2, P48; HEILMAN CA, 1990, J INFECT DIS, V161, P402, DOI 10.1093/infdis/161.3.402; Henderson F W, 1987, Semin Respir Infect, V2, P112; HERTZ MI, 1989, MEDICINE, V68, P269, DOI 10.1097/00005792-198909000-00002; HERZOG KD, 1989, PEDIATR INFECT DIS J, V8, P534; HIERHOLZER JC, 1989, J CLIN MICROBIOL, V27, P1234; KIRSI JJ, 1984, ANTIMICROB AGENTS CH, V26, P466, DOI 10.1128/AAC.26.4.466; Knight V, 1987, Infect Dis Clin North Am, V1, P441; KROWKA MJ, 1985, CHEST, V87, P237, DOI 10.1378/chest.87.2.237; LJUNGMAN P, 1989, BONE MARROW TRANSPL, V4, P35; MCGLAVE P, 1987, J CLIN ONCOL, V5, P1033, DOI 10.1200/JCO.1987.5.7.1033; MCGLAVE PB, 1987, BLOOD, V70, P1325; MCINTOSH K, 1984, AM J DIS CHILD, V138, P305, DOI 10.1001/archpedi.1984.02140410083024; MCINTOSH K, 1985, MANUAL CLIN MICROBIO, P763; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; PETERSON PK, 1983, INFECT CONT HOSP EP, V4, P81, DOI 10.1017/S0195941700057805; REINES ED, 1988, MED CLIN N AM, V72, P691, DOI 10.1016/S0025-7125(16)30766-0; REINES ED, 1988, MED CLIN N AM, V72, pR9; RODRIGUEZ WJ, 1987, INFECT DIS CLIN N AM, V2, P425; SHIELDS AF, 1985, NEW ENGL J MED, V312, P529, DOI 10.1056/NEJM198502283120901; Siegel S., 1956, NONPARAMETRIC STAT, P116; WEISDORF D, 1990, BLOOD, V75, P1024, DOI 10.1182/blood.V75.4.1024.1024; WEISDORF DJ, 1988, BRIT J HAEMATOL, V69, P351, DOI 10.1111/j.1365-2141.1988.tb02373.x; WONG DT, 1982, J CLIN MICROBIOL, V16, P164, DOI 10.1128/JCM.16.1.164-167.1982	33	158	159	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					921	926		10.1056/NEJM199204023261404	http://dx.doi.org/10.1056/NEJM199204023261404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1311800				2022-12-28	WOS:A1992HL26100004
J	SINGER, SJ				SINGER, SJ			INTERCELLULAR COMMUNICATION AND CELL-CELL ADHESION	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; HELPER T-CELLS; GOLGI-APPARATUS; SEVENLESS PROTEIN; RECEPTOR; MEMBRANE; DROSOPHILA; ANTIGEN; MICROTUBULES; CONTACT	In developmental biology, binary cell-cell interactions often determine the fate of one or both cell partners. The two cells must adhere to one another to allow chemical signals to be transmitted in one or both directions across the regions of cell-cell contact. The molecular mechanisms of cell-cell adhesion and intercellular communication, even if they are mediated by different cell surface components, may be functionally integrated in several different ways. Studies of helper T cells with antigen-presenting B cells in culture have illuminated such binary interactions. The possible application of similar mechanisms to other binary developmental systems is briefly explored.			SINGER, SJ (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NIGMS NIH HHS [GM-15971] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015971] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANKELESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289; ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BELL GI, 1984, BIOPHYS J, V45, P1051, DOI 10.1016/S0006-3495(84)84252-6; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; CARPEN O, 1982, J IMMUNOL, V128, P2691; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DAVIS C G, 1990, New Biologist, V2, P410; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; GEIGER B, 1984, J CELL BIOL, V99, pS83, DOI 10.1083/jcb.99.1.83s; GEIGER B, 1979, P NATL ACAD SCI USA, V76, P4603, DOI 10.1073/pnas.76.9.4603; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; HARRIS W A, 1991, Current Biology, V1, P120, DOI 10.1016/0960-9822(91)90297-A; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HEIPLE JM, 1990, CELL MOTIL CYTOSKEL, V15, P260, DOI 10.1002/cm.970150408; HOLMES LB, 1977, DEV BIOL, V59, P164, DOI 10.1016/0012-1606(77)90251-2; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; KUPFER A, 1991, P NATL ACAD SCI USA, V88, P775, DOI 10.1073/pnas.88.3.775; KUPFER A, 1990, J MOL CELL IMMUNOL, V4, P317; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; KUPFER A, 1988, P NATL ACAD SCI USA, V85, P8216, DOI 10.1073/pnas.85.21.8216; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P39; LEPTIN M, 1987, EMBO J, V6, P1037, DOI 10.1002/j.1460-2075.1987.tb04856.x; LIPOWSKY R, 1991, NATURE, V349, P475, DOI 10.1038/349475a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCCLOSKEY MA, 1986, J CELL BIOL, V102, P2185, DOI 10.1083/jcb.102.6.2185; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; OSTER GF, 1989, J THEOR BIOL, V141, P463, DOI 10.1016/S0022-5193(89)80231-0; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; ROJO JM, 1989, P NATL ACAD SCI USA, V86, P3311, DOI 10.1073/pnas.86.9.3311; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SCHREINER GF, 1976, ADV IMMUNOL, V24, P38; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; SINGER SJ, 1988, T CELL RECEPTOR, P361; Singh S., 1976, Sugarcane Pathologists' Newsletter, P1; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TRELSTAD RL, 1970, J CELL BIOL, V45, P34, DOI 10.1083/jcb.45.1.34; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WEIS RM, 1982, J BIOL CHEM, V257, P6440	54	236	251	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1671	1677		10.1126/science.1313187	http://dx.doi.org/10.1126/science.1313187			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1313187				2022-12-28	WOS:A1992HK81200027
J	THOMAS, SM; DEMARCO, M; DARCANGELO, G; HALEGOUA, S; BRUGGE, JS				THOMAS, SM; DEMARCO, M; DARCANGELO, G; HALEGOUA, S; BRUGGE, JS			RAS IS ESSENTIAL FOR NERVE GROWTH FACTOR-INDUCED AND PHORBOL ESTER-INDUCED TYROSINE PHOSPHORYLATION OF MAP KINASES	CELL			English	Article							PROTEIN-KINASE; PC12 CELLS; TRANSFORMED FIBROBLASTS; SIGNAL TRANSDUCTION; 3T3 CELLS; P21; DIACYLGLYCEROL; REQUIREMENT; ONCOGENE; DIFFERENTIATION	Treatment of PC12 cells with nerve growth factor (NGF) induces a rapid increase in tyrosine phosphorylation of multiple cellular proteins. Expression of a dominant inhibitory Ras mutant specifically blocked NGF- and TPA-induced tyrosine phosphorylation of two proteins of approximately 42 and 44 kd. Conversely, expression of an oncogenic variant of Ras induced tyrosine phosphorylation of the same 42 and 44 kd proteins. The 44 kd protein was immunoprecipitated with an antibody directed against extracellular signal-regulated kinase 1/mitogen-activated protein kinase (MAPK) and the 42 kd protein comigrated with a 42 kd MAPK, indicating that at least one and probably both Ras-regulated phosphoproteins are MAPKs. In addition, MAPK activation, as measured by in vitro phosphorylation of myelin basic protein, was also regulated by Ras. Ras was not required for NGF-induced activation of Trk or tyrosine phosphorylation of PLC-gamma-1. Thus, NGF-induced tyrosine phosphorylation occurs both prior to and following Ras action, and Ras plays a critical role in the NGF- and TPA-induced tyrosine phosphorylation of MAPKs.	SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	THOMAS, SM (corresponding author), UNIV PENN,HOWARD HUGHES MED INST,DEPT MICROBIOL,PHILADELPHIA,PA 19104, USA.			D'Arcangelo, Gabriella/0000-0003-1575-1010	NCI NIH HHS [CA47572] Funding Source: Medline; NINDS NIH HHS [NS18218] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018218] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALLEMAIN GL, 1991, MOL CELL BIOL, V11, P1002; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BISHOP R, 1983, BIOCHEM BIOPH RES CO, V115, P536, DOI 10.1016/S0006-291X(83)80178-8; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CUADRADO A, 1990, BIOCHEM BIOPH RES CO, V170, P526, DOI 10.1016/0006-291X(90)92123-H; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALEGOUA S, 1990, CURRENT TOPICS MICRO; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P509; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MALLER J, 1991, Current Biology, V1, P334, DOI 10.1016/0960-9822(91)90104-5; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P133; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORI M, 1992, IN PRESS MOL CELL BI; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; RUGGIERI R, 1991, NATURE, V353, P390, DOI 10.1038/353390a0; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; THOMAS SM, 1991, MOL CELL BIOL, V11, P4739, DOI 10.1128/MCB.11.9.4739; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; VILA J, 1988, J CELL PHYSIOL, V135, P285, DOI 10.1002/jcp.1041350216; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	68	698	704	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1031	1040		10.1016/0092-8674(92)90075-N	http://dx.doi.org/10.1016/0092-8674(92)90075-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1312392				2022-12-28	WOS:A1992HK67400007
J	WOOD, KW; SARNECKI, C; ROBERTS, TM; BLENIS, J				WOOD, KW; SARNECKI, C; ROBERTS, TM; BLENIS, J			RAS MEDIATES NERVE GROWTH-FACTOR RECEPTOR MODULATION OF 3 SIGNAL-TRANSDUCING PROTEIN-KINASES - MAP KINASE, RAF-1, AND RSK	CELL			English	Article							CELL-PROLIFERATION; ONCOGENE PRODUCTS; PC12 CELLS; PHOSPHORYLATION; REQUIREMENT; ACTIVATION; TYROSINE; DIFFERENTIATION; STIMULATION; INHIBITION	p21c-ras plays a critical role in mediating tyrosine kinase-stimulated cell growth and differentiation. However, the pathways through which p21c-ras propagates these signals remain unknown. We report that in PC12 cells, expression of a dominant inhibitory mutant of ras, c-Ha-ras(Asn-17), antagonizes growth factor- and phorbol ester-induced activation of the erk-encoded family of MAP kinases, the 85-92 kd RSKs, and the kinase(s) responsible for hyperphosphorylation of the proto-oncogene product Raf-1. In addition, we find that expression of the activated ras oncogene is sufficient to stimulate these events. These data indicate that ras mediates nerve growth factor receptor and protein kinase C modulation of MAP kinases, RSKs, and Raf-1.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	WOOD, KW (corresponding author), HARVARD UNIV, DIV MED SCI, PROGRAM CELL & DEV BIOL, CAMBRIDGE, MA 02138 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA050661, R01CA043803] Funding Source: NIH RePORTER; NCI NIH HHS [CA43803, CA50661] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; IZUMI T, 1991, J BIOL CHEM, V266, P7933; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1991, MOL CELL BIOL, V11, P4739, DOI 10.1128/MCB.11.9.4739; THOMAS SM, 1992, CELL; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WILLIAMS NG, 1992, IN PRESS P NATL ACAD; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	55	913	924	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1041	1050		10.1016/0092-8674(92)90076-O	http://dx.doi.org/10.1016/0092-8674(92)90076-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1312393				2022-12-28	WOS:A1992HK67400008
J	SHPETNER, HS; VALLEE, RB				SHPETNER, HS; VALLEE, RB			DYNAMIN IS A GTPASE STIMULATED TO HIGH-LEVELS OF ACTIVITY BY MICROTUBULES	NATURE			English	Article							TEMPERATURE-SENSITIVE MUTANT; BRAIN CYTOPLASMIC DYNEIN; DROSOPHILA-MELANOGASTER; MECHANOCHEMICAL ENZYME; BINDING PROTEINS; TUMOR-METASTASIS; ACTIVATED ATPASE; GENE; IDENTIFICATION; TRANSLOCATION	DYNAMIN was initially identified in calf brain tissue as a protein of relative molecular mass 100,000 which induced nucleotide-sensitive bundling of microtubules 1. Purified dynamin showed only trace ATPase activity. But in combination with an activating factor removed during the purification, it exhibited microtubule-activated ATPase activity and dynamin-induced bundles showeD evidence of ATP-dependent force production 1. Dynamin is the product of the DrosophiLa gene shibire 2.3, which has been implicated in synaptic vesicle recycling 4,5 and, more generally, in the budding of endocytic vesicles from the plasma membrane 6,7 . Dynamin also shows 8 extensive homology with proteins that participate in vacuolar protein sorting 9 and spindle pole-body separation 10 in yeast, and in interferon-induced viral resistance 11,12 in mammals. All members of this family contain consensus sequence elements consistent with GTP binding near their amino termini, although none has been shown to have GTPase activity. We report here that dynamin is a specific GTPase which can be stimulated to very high levels of activity by microtubules.			SHPETNER, HS (corresponding author), WORCESTER FDN EXPTL BIOL INC, CELL BIOL GRP, SHREWSBURY, MA 01545 USA.							Agarwal R P, 1978, Methods Enzymol, V51, P376; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BLOOM GS, 1983, J CELL BIOL, V96, P1523, DOI 10.1083/jcb.96.6.1523; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURNS RG, 1981, EUR J BIOCHEM, V117, P515; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HENDERSON JF, 1973, NUCLEOTIDE METABOLIS, P18; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KOENIG JH, 1989, J NEUROSCI, V9, P1937; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PASCHAL BM, 1991, METHOD ENZYMOL, V196, P181; PENNINGROTH SM, 1977, J MOL BIOL, V115, P643, DOI 10.1016/0022-2836(77)90108-5; POLLARD TD, 1991, REV PHYSL, V53, P653; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STAEHELI P, 1988, MOL CELL BIOL, V8, P4524, DOI 10.1128/MCB.8.10.4524; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; VALLEE RB, 1986, METHOD ENZYMOL, V134, P104; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VIKSTROM KL, 1991, METHOD ENZYMOL, V196, P506; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	39	189	194	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1992	355	6362					733	735		10.1038/355733a0	http://dx.doi.org/10.1038/355733a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1311055				2022-12-28	WOS:A1992HE60400066
J	KAHTAN, S; GREENBERG, M				KAHTAN, S; GREENBERG, M			O LITTLE WOLVES OF LEEUWENHOEK	BRITISH MEDICAL JOURNAL			English	Article									WHITTINGTON HOSP,DEPT PRIMARY HLTH CARE,LONDON N19 5NF,ENGLAND; CUNY MT SINAI SCH MED,DEPT COMMUNITY MED,NEW YORK,NY 10029	University of London; University College London; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	GREENBERG, M (corresponding author), 74 N END RD,LONDON NW11 7SY,ENGLAND.							Ramazzini B., 1713, MORBIS ARTIFICUM; VANLEEUWENHOEK A, 1695, ARCANA NATURAE, P17	2	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1574	1574		10.1136/bmj.305.6868.1574	http://dx.doi.org/10.1136/bmj.305.6868.1574			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286394	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KD77100031
J	HILL, AVS; ELVIN, J; WILLIS, AC; AIDOO, M; ALLSOPP, CEM; GOTCH, FM; GAO, XM; TAKIGUCHI, M; GREENWOOD, BM; TOWNSEND, ARM; MCMICHAEL, AJ; WHITTLE, HC				HILL, AVS; ELVIN, J; WILLIS, AC; AIDOO, M; ALLSOPP, CEM; GOTCH, FM; GAO, XM; TAKIGUCHI, M; GREENWOOD, BM; TOWNSEND, ARM; MCMICHAEL, AJ; WHITTLE, HC			MOLECULAR ANALYSIS OF THE ASSOCIATION OF HLA-B53 AND RESISTANCE TO SEVERE MALARIA	NATURE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; T-CELL EPITOPES; MAJOR HISTOCOMPATIBILITY COMPLEX; CYTOTOXIC LYMPHOCYTES-T; CLASS-I MOLECULES; CIRCUMSPOROZOITE PROTEIN; LIVER-STAGE; VACCINE DEVELOPMENT; SURFACE-ANTIGENS; VIRAL-ANTIGEN	The protective association between the human leukocyte antigen HLA-B53 and severe malaria was investigated by sequencing of peptides eluted from this molecule followed by screening of candidate epitopes from pre-erythrocytic-stage antigens of Plasmodium falciparum in biochemical and cellular assays. Among malaria-immune Africans, HLA-B53-restricted cytotoxic T lymphocytes recognized a conserved nonamer peptide from liver-stage-specific antigen-1 (LSA-1), but no HLA-B53-restricted epitopes were identified in other antigens. These findings indicate a possible molecular basis for this HLA-disease association and support the candidacy of liver-stage-specific antigen-1 as a malaria vaccine component.	UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND; MRC LABS,BANJUL,SENEGAMBIA; UNIV TOKYO,INST MED SCI,MINAMI KU,TOKYO 108,JAPAN	University of Oxford; University of Tokyo	HILL, AVS (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.		Takiguchi, Masafumi/E-7468-2013; HILL, Adrian V>S>/C-1306-2008	Townsend, Alain/0000-0002-3702-0107	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; Amiel J.L, 1967, HISTOCOMPAT TEST, V1967, P79; ARNOT D, 1989, PARASITOL TODAY, V5, P138, DOI 10.1016/0169-4758(89)90077-X; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; CARRENO BM, 1992, J IMMUNOL, V148, P894; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CLYDE DF, 1973, AM J MED SCI, V266, P398, DOI 10.1097/00000441-197312000-00001; COWAN G, 1992, LANCET, V339, P1412, DOI 10.1016/0140-6736(92)91229-2; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELACRUZ VF, 1987, J BIOL CHEM, V262, P11935; DOOLAN DL, 1992, INFECT IMMUN, V60, P675, DOI 10.1128/IAI.60.2.675-682.1992; DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511; DOOLAN DL, 1991, INFECT IMMUN, V60, P765; DRUIHLE P, 1989, NEW STRATEGIES PARAS; ELLIS SA, 1985, HUM IMMUNOL, V13, P13, DOI 10.1016/0198-8859(85)90023-0; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; ELVIN J, IN PRESS J IMMUN MET; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9; GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199; GUERINMARCHAND C, 1987, NATURE, V329, P164, DOI 10.1038/329164a0; HARRIS R, 1969, NATURE, V221, P1062, DOI 10.1038/2211062a0; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; HAYASHI H, 1990, IMMUNOGENETICS, V32, P195, DOI 10.1007/BF02114973; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HOLLINGDALE MR, 1990, IMMUNOL LETT, V25, P71, DOI 10.1016/0165-2478(90)90094-7; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KHUSMITH S, 1991, SCIENCE, V252, P715, DOI 10.1126/science.1827210; KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0; LOCKYER M, 1990, PARASITOL TODAY, V6, P76, DOI 10.1016/0169-4758(90)90213-N; LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300; MCCUTCHAN TF, 1990, IMMUNOL LETT, V25, P23, DOI 10.1016/0165-2478(90)90085-5; MCGREGOR IA, 1968, MALARIA PRINCIPLES P, P559; MEIS JFGM, 1986, CELL TISSUE RES, V244, P345, DOI 10.1007/BF00219210; MELLOUK S, 1990, LANCET, V335, P721, DOI 10.1016/0140-6736(90)90832-P; MOELANS IIMD, 1991, MOL BIOCHEM PARASIT, V45, P193, DOI 10.1016/0166-6851(91)90086-L; NIXON DF, 1992, IMMUNOLOGY, V76, P515; NUSSENZWEIG RS, 1969, NATURE, V222, P488, DOI 10.1038/222488a0; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PERLMANN P, 1990, Immunology Letters, V25, P1; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SEDEGAH M, 1992, J IMMUNOL, V149, P966; SUHRBIER A, 1990, INFECT IMMUN, V58, P2834, DOI 10.1128/IAI.58.9.2834-2839.1990; SUHRBIER A, 1991, PARASITOL TODAY, V7, P160, DOI 10.1016/0169-4758(91)90120-D; SUTTON J, IN PRESS EUR J IMMUN; TIWARI JL, 1985, HLA DISEASE ASS; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; VANBLEEK GM, 1990, NATURE, V348, P213; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; WEISS WR, 1990, J EXP MED, V171, P1083; YAMAMOTO J, 1990, P NATL ACAD SCI USA, V87, P2583, DOI 10.1073/pnas.87.7.2583; YOSHIDA N, 1990, EXP PARASITOL, V71, P386, DOI 10.1016/0014-4894(90)90064-J; ZHU JD, 1991, MOL BIOCHEM PARASIT, V48, P223, DOI 10.1016/0166-6851(91)90117-O	65	596	618	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					434	439		10.1038/360434a0	http://dx.doi.org/10.1038/360434a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1280333				2022-12-28	WOS:A1992KA79700049
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ALERT ON CHANGES IN STANDARDIZED CAT ALLERGEN EXTRACT PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1328699				2022-12-28	WOS:A1992JW61600006
J	SAVARIT, D; DECOCK, KM; SCHUTZ, R; KONATE, S; LACKRITZ, E; BONDURAND, A				SAVARIT, D; DECOCK, KM; SCHUTZ, R; KONATE, S; LACKRITZ, E; BONDURAND, A			RISK OF HIV-INFECTION FROM TRANSFUSION WITH BLOOD NEGATIVE FOR HIV ANTIBODY IN A WEST AFRICAN CITY	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PREVALENCE; TRANSMISSION; AIDS	Objective-To estimate the risk of infection with HIV (HIV 1 or HIV 2, or both) from transfusion of a screened unit of blood in a high prevalence area in west Africa. Design-Retrospective cohort study for january-July 1991. Setting-National Blood Transfusion Centre, Abidjan, Cote d'Ivoire. Subjects-Repeat donors (5831 units of blood) and first time donors (5076 units) in the first five months of 1991. Main outcome measures-Prevalence and estimated incidence of HIV infection in repeat and first time donors; estimated rate of potentially infected, HIV antibody negative units; and rate of (false negative) potentially infected units assuming a laboratory test sensitivity of 99%. Results-Overall HIV prevalence was 11.0% in first time donors and 2.1% in repeat donors. In the first seven months of 1991, 29 HIV antibody positive (27 HIV 1, 1 HIV 2, 1 dually reactive) donors with a seronegative unit of blood earlier in the year were identified; 26 had donated blood eight weeks or less before their estimated dates of seroconversion and may have been infectious (minimum rate 26/5831 (4-5/1000 potentially infected units)). Estimated incidence of infection in repeat donors was 1.2-2.5%. Laboratory test insensitivity would result in an estimated 1.1/1000 false negative units from first time donors and 0.211000 units from regular donors. The overall rate of potentially infected units (all donors, seroconversions, and errors) was estimated at 5.4-10.6/1000. Conclusions-The risk of HIV infection from a single unit of blood remains substantial (5.4-10.6/1000 units). To prevent infection from blood transfusion in areas of high incidence and prevalence of HIV all but absolutely essential transfusions should be avoided, and donors with low incidence of HIV infection should be selected.	CTR NATL TRANSFUS SANGUINE,ABIDJAN,COTE IVOIRE; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; CTR DIS CONTROL,DIV PARASIT DIS,MALARIA BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Lackritz, Eve/0000-0002-5397-7291				ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; BROWN C, 1991, AIDS, V5, P89, DOI 10.1097/00002030-199101000-00013; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; CHIEWSILP P, 1991, LANCET, V338, P1341, DOI 10.1016/0140-6736(91)92650-Q; COUROUCE AM, 1990, REV FR TRANSFUS HEM, V33, P431, DOI 10.1016/S1140-4639(05)80060-7; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DECOCK KM, 1988, AM J EPIDEMIOL, V127, P1250, DOI 10.1093/oxfordjournals.aje.a114917; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; JULIEN AM, 1988, LANCET, V2, P1248; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MILLER HG, 1990, AIDS 2ND DECADE, P289; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; ZUCK TF, 1988, NEW ENGL J MED, V318, P511, DOI 10.1056/NEJM198802253180809; 1990, B WORLD HEALTH ORGAN, V68, P262	17	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					498	502		10.1136/bmj.305.6852.498	http://dx.doi.org/10.1136/bmj.305.6852.498			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1327367	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JL60900016
J	WILLIAMS, G; PATRICK, AW				WILLIAMS, G; PATRICK, AW			HUMAN INSULIN AND HYPOGLYCEMIA - BURNING ISSUE OR HOT AIR	BRITISH MEDICAL JOURNAL			English	Article							HYPOGLYCEMIA UNAWARENESS; AWARENESS; SYMPTOMS; IDDM				WILLIAMS, G (corresponding author), UNIV LIVERPOOL,DEPT MED,POB 147,LIVERPOOL L69 3BX,ENGLAND.							COLAGIURI S, 1992, LANCET, V339, P1432, DOI 10.1016/0140-6736(92)92028-E; CORP E, 1986, NEUROSCI LETT, V79, P17; COX DJ, 1991, PSYCHOSOM MED, V53, P453, DOI 10.1097/00006842-199107000-00010; DIAMOND MP, 1991, J CLIN ENDOCR METAB, V72, P1388, DOI 10.1210/jcem-72-6-1388; EGGER M, 1991, DIABETES CARE, V14, P1001, DOI 10.2337/diacare.14.11.1001; EGGER M, 1991, BMJ-BRIT MED J, V303, P617, DOI 10.1136/bmj.303.6803.617; EGGER M, 1991, BMJ-BRIT MED J, V303, P622, DOI 10.1136/bmj.303.6803.622; GALE EAM, 1989, LANCET, V2, P1264; GERICH JE, 1991, ENDOCR REV, V12, P356, DOI 10.1210/edrv-12-4-356; KERN W, 1990, DIABETES, V39, P1091, DOI 10.2337/diabetes.39.9.1091; KERR D, 1991, DIABETES, V40, P1057, DOI 10.2337/diabetes.40.8.1057; Lawrence RD, 1941, LANCET, V2, P602; LINDE B, 1991, TXB DIABETES, P371; MARAN A, 1992, DIABETIC MED S1, V9, pA11; PATRICK AW, 1991, LANCET, V338, P528, DOI 10.1016/0140-6736(91)91098-F; PATRICK AW, 1992, DIABETIC MED, V9, P579, DOI 10.1111/j.1464-5491.1992.tb01843.x; SCHWARTZ MW, 1990, AM J PHYSIOL, V259, pE378, DOI 10.1152/ajpendo.1990.259.3.E378; TEUSCHER A, 1987, LANCET, V2, P382; 1991, LANCET, V338, P950; 1991, BMJ, V303, P1265	20	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					355	357		10.1136/bmj.305.6849.355	http://dx.doi.org/10.1136/bmj.305.6849.355			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1294086	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JJ03200026
J	HAWKINS, PT; JACKSON, TR; STEPHENS, LR				HAWKINS, PT; JACKSON, TR; STEPHENS, LR			PLATELET-DERIVED GROWTH-FACTOR STIMULATES SYNTHESIS OF PTDLNS(3,4,5)P3 BY ACTIVATING A PTDLNS(4,5)P2 3-OH KINASE	NATURE			English	Article							PHOSPHATIDYLINOSITOL KINASE; INOSITOL; PHOSPHORYLATION; BINDING; CELLS	ALTHOUGH the hormone-stimulated synthesis of 3-phosphorylated inositol lipids is known to form an intracellular signalling system 1-5, there is no consensus on the crucial receptor-regulated event in this pathway and it is still not clear which of the intermediates represent potential output signals. We show here that the key step in the synthesis of 3-phosphorylated inositol lipids in 3T3 cells stimulated by platelet-derived growth factor is the activation of a phosphatidylinositol(4,5)-bisphosphate (3)-hydroxy (PtdIns(4,5)P2 3-OH) kinase. A similar conclusion has been applied to explain the actions of formyl-Met-Leu-Phe on neutrophils 6, and it may be that receptors that couple through intrinsic tyrosine kinases or through G proteins stimulate the same step in 3-phosphorylated inositol lipid metabolism. The close parallel between these two mechanisms for the activation of PtdIns(4,5)P2 3-OH kinase and those described for the activation of another key signalling enzyme, phospholipase C (ref. 7), focuses attention on the product of the PtdIns(4,5)P, 3-OH kinase, PtdIns(3,4,5)P3, as a possible new second messenger.			HAWKINS, PT (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,DEPT BIOCHEM,CAMBRIDGE CB2 4AT,ENGLAND.			stephens, len/0000-0002-2771-3487; Hawkins, Phillip/0000-0002-6979-0464				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BROWN KD, 1983, BIOCHEM J, V212, P465, DOI 10.1042/bj2120465; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; JACKSON TR, IN PRESS J BIOL CHEM; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Payne R. W., 1987, GENSTAT 5 REFERENCE; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	20	225	236	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					157	159		10.1038/358157a0	http://dx.doi.org/10.1038/358157a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1319558				2022-12-28	WOS:A1992JC58300054
J	KESSLER, DA				KESSLER, DA			THE BASIS OF THE FDAS DECISION ON BREAST IMPLANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KESSLER, DA (corresponding author), US FDA,ROCKVILLE,MD 20857, USA.								0	251	254	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1713	1715		10.1056/NEJM199206183262525	http://dx.doi.org/10.1056/NEJM199206183262525			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1309171	Bronze			2022-12-28	WOS:A1992HY62800032
J	EDLIN, BR; TOKARS, JI; GRIECO, MH; CRAWFORD, JT; WILLIAMS, J; SORDILLO, EM; ONG, KR; KILBURN, JO; DOOLEY, SW; CASTRO, KG; JARVIS, WR; HOLMBERG, SD				EDLIN, BR; TOKARS, JI; GRIECO, MH; CRAWFORD, JT; WILLIAMS, J; SORDILLO, EM; ONG, KR; KILBURN, JO; DOOLEY, SW; CASTRO, KG; JARVIS, WR; HOLMBERG, SD			AN OUTBREAK OF MULTIDRUG-RESISTANT TUBERCULOSIS AMONG HOSPITALIZED-PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-INFECTION; ASSOCIATION; SHELTER	Background. Since 1990 several clusters of multidrug-resistant tuberculosis have been identified among hospitalized patients with the acquired immunodeficiency syndrome (AIDS). We investigated one such cluster in a voluntary hospital in New York. Methods. We compared exposures among 18 patients with AIDS in whom tuberculosis resistant to isoniazid and streptomycin was diagnosed from January 1989 through April 1990 (the case patients) with exposures among 30 control patients who had AIDS and tuberculosis susceptible to isoniazid, streptomycin, or both. We also compared exposures among the 14 case patients hospitalized during the six months before the diagnosis of tuberculosis (the exposure period) with those among 44 control patients with AIDS matched for duration of hospitalization. Mycobacterium tuberculosis isolates were typed with analysis of restriction-fragment-length polymorphism (RFLP). Results. Case patients with drug-resistant tuberculosis were significantly more likely than controls with drug-susceptible tuberculosis to have been hospitalized during their exposure periods (14 of 18 vs. 10 of 30) (odds ratio, 7.0; 95 percent confidence interval, 1.6 to 36; P = 0.006). Case patients hospitalized during their exposure periods were significantly more likely to have been hospitalized on the same ward as a patient with infectious drug-resistant tuberculosis than were either controls with drug-susceptible tuberculosis hospitalized during their exposure periods or controls matched for duration of hospitalization (13 of 14 vs. 2 of 10 and 23 of 44) (odds ratio, 52; 95 percent confidence interval, 3.1 to 2474; P < 0.001; and odds ratio, infinity; 95 percent confidence interval, 2.4 to infinity; P = 0.005, respectively). Among those hospitalized on the same ward, the rooms of case patients were closer to that of the nearest patient with infectious tuberculosis than were the rooms of controls matched for duration of hospitalization. M. tuberculosis isolates from 15 of 16 case patients had identical patterns on RFLP analysis. Of 16 patients' rooms tested with air-flow studies, only 1 had the recommended negative-pressure ventilation. Conclusions. Multidrug-resistant tuberculosis is readily transmitted among hospitalized patients with AIDS. Physicians must be alert to this danger and must enforce adherence to the measures recommended to prevent nosocomial transmission of tuberculosis.	CTR DIS CONTROL,HOSP INFECT PROGRAM,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA 30333; COLUMBIA UNIV COLL PHYS & SURG,ST LUKES ROOSEVELT HOSP CTR,NEW YORK,NY 10032	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Columbia University; Mount Sinai St. Luke's; Mount Sinai West	EDLIN, BR (corresponding author), CTR DIS CONTROL,DIV HIV AIDS,MAILSTOP E-45,ATLANTA,GA 30333, USA.		Sordillo, Emilia Mia/AAF-3012-2021; Edlin, Brian R/F-2966-2018; Castro, Kenneth G/P-1882-2018	Sordillo, Emilia Mia/0000-0001-7787-3051; Edlin, Brian R/0000-0001-8172-8797; Castro, Kenneth G/0000-0001-7964-6354				BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DESPREZ RM, 1990, PRINCIPLES PRACTICE, P1881; DIPERRI G, 1989, LANCET, V2, P1502; ISEMAN MD, 1989, CLIN CHEST MED, V10, P341; Kent PT, 1985, PUBLIC HLTH MYCOBACT, P159; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; MCADAM JM, 1991, CHEST, V99, P792, DOI 10.1378/chest.99.3.792-c; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; PELLETIER AR, 1991, 40TH ANN C EP INT SE, P43; SALOMON N, 1991, 31ST INT C ANT AG CH, P152; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; VALWAY SE, 1992, 41ST ANN C EP INT SE, P30; 1985, MMWR, V34, P429; 1991, MMWR, V40, P585; [No title captured]; 1991, MMWR, V40, P129; 1990, MMWR S, V39, pRR17	23	743	762	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1514	1521		10.1056/NEJM199206043262302	http://dx.doi.org/10.1056/NEJM199206043262302			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1304721				2022-12-28	WOS:A1992HW97200002
J	KOUTSKY, LA; STEVENS, CE; HOLMES, KK; ASHLEY, RL; KIVIAT, NB; CRITCHLOW, CW; COREY, L				KOUTSKY, LA; STEVENS, CE; HOLMES, KK; ASHLEY, RL; KIVIAT, NB; CRITCHLOW, CW; COREY, L			UNDERDIAGNOSIS OF GENITAL HERPES BY CURRENT CLINICAL AND VIRAL-ISOLATION PROCEDURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS-INFECTION; TYPE-2 INFECTION; IMMUNE-RESPONSE; NATURAL-HISTORY; WESTERN BLOT; WOMEN; PREVALENCE; DIAGNOSIS; IMMUNOFLUORESCENCE; MANIFESTATIONS	Background. The current clinical strategy for diagnosing genital herpes simplex virus (HSV) infection in women relies on clinical findings plus the selective use of viral culture. The effectiveness of this approach for identifying women with genital herpes is unknown. Methods. We performed physical examinations, colposcopy, Pap smears, viral cultures, and HSV type-specific serologic assays of 779 randomly selected women attending a sexually transmitted disease clinic. Results. Evidence of HSV type 2 infection was detected in 363 women (47 percent), and 9 others (1 percent) had positive cultures indicative of urogenital or anal infection with HSV type 1. Of these 372 women, only 82 (22 percent) had symptoms. Fourteen women (4 percent) had viral shedding without symptoms, 60 (16 percent) had formerly had symptomatic episodes, and 216 (58 percent) had antibodies to HSV-2 with neither viral shedding nor a history of clinical episodes. Characteristic ulcerations of the external genitalia were present in only two thirds of the 66 women with positive HSV cultures; the others had atypical genital lesions or asymptomatic viral shedding. Isolation of HSV from a genitourinary tract specimen was the most sensitive (77 percent) test for confirming a first episode of infection. The detection of HSV-2-specific antibodies was the most sensitive (97 percent) way to confirm symptomatic reactivations of HSV-2 infection. HSV-2 serologic testing also identified the 290 women with asymptomatic HSV-2 infections (37 percent), including 14 (5 percent) who were shedding virus asymptomatically on the day of the examination. Conclusions. The current strategy for diagnosing genital HSV infection in women misses many cases. Newly developed type-specific serologic methods can identify women with recurrent genital HSV-2 infection, as well as those with unrecognized or subclinical infection.	UNIV WASHINGTON,SCH PUBL HLTH,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			, Holmes/K-6215-2019; Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL CANCER INSTITUTE [R01CA034493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI012192, R01AI020381] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34493] Funding Source: Medline; NIAID NIH HHS [AI-12192, AI-20381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1985, J MED VIROL, V17, P153, DOI 10.1002/jmv.1890170208; ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1987, J VIROL METHODS, V18, P159, DOI 10.1016/0166-0934(87)90121-2; BADER C, 1978, J INFECT DIS, V138, P897, DOI 10.1093/infdis/138.6.897; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BRYSON YJ, 1983, NEW ENGL J MED, V308, P916, DOI 10.1056/NEJM198304213081602; CONE RW, 1991, J INFECT DIS, V164, P757, DOI 10.1093/infdis/164.4.757; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; Davis W, 1980, IARC SCI PUBL, V32, P192; DORSKY DI, 1987, ANN INTERN MED, V107, P859, DOI 10.7326/0003-4819-107-6-859; ESCHENBACH DA, 1988, AM J OBSTET GYNECOL, V158, P819, DOI 10.1016/0002-9378(88)90078-6; FLEISS JL, 1981, STATISTICAL METHODS, P51; GUINAN ME, 1985, EPIDEMIOL REV, V7, P127, DOI 10.1093/oxfordjournals.epirev.a036279; GUINAN ME, 1981, NEW ENGL J MED, V304, P759, DOI 10.1056/NEJM198103263041305; HARDY DA, 1990, J INFECT DIS, V162, P1031, DOI 10.1093/infdis/162.5.1031; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KAUFMAN RH, 1973, CANCER RES, V33, P1446; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; LIPSON SM, 1987, J CLIN MICROBIOL, V25, P391, DOI 10.1128/JCM.25.2.391-394.1987; LYNCH PJ, 1970, CUTIS, V6, P79; MANN SL, 1984, J INFECT DIS, V149, P1026, DOI 10.1093/infdis/149.6.1026; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; MERTZ GL, 1984, JAMA-J AM MED ASSOC, V242, P1147; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; PAPANICOLAOU GN, 1963, ATLAS EXFOLIATIVE CY, P3; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; WADE JC, 1984, J INFECT DIS, V149, P750, DOI 10.1093/infdis/149.5.750; WHITLEY RJ, 1980, PEDIATRICS, V66, P489; 1991, HIV AIDS Q EPIDEMIOL	38	229	233	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1533	1539		10.1056/NEJM199206043262305	http://dx.doi.org/10.1056/NEJM199206043262305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1315930				2022-12-28	WOS:A1992HW97200005
J	PRUKSANANONDA, P; HALL, CB; INSEL, RA; MCINTYRE, K; PELLETT, PE; LONG, CE; SCHNABEL, KC; PINCUS, PH; STAMEY, FR; DAMBAUGH, TR; STEWART, JA				PRUKSANANONDA, P; HALL, CB; INSEL, RA; MCINTYRE, K; PELLETT, PE; LONG, CE; SCHNABEL, KC; PINCUS, PH; STAMEY, FR; DAMBAUGH, TR; STEWART, JA			PRIMARY HUMAN HERPESVIRUS-6 INFECTION IN YOUNG-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXANTHEM-SUBITUM; ANTIBODY; PREVALENCE; DNA; IDENTIFICATION; AMPLIFICATION; SEQUENCES; INFANTS; HBLV; RASH	Background. Human herpesvirus 6 (HHV-6) is a recently discovered virus that, on the basis of serologic evidence, appears to infect most children by the age of three years. However, the clinical manifestations of primary HHV-6 infection have not been well defined. Methods. We studied consecutive children two years old or younger who presented to an emergency ward with febrile illnesses. Our evaluation included the isolation of HHV-6 from peripheral-blood mononuclear cells, an immunofluorescent-antibody assay, the detection of HHV-6 by the polymerase chain reaction (PCR), and restriction-endonuclease-fragment profiles of HHV-6 isolates. Results. HHV-6 was isolated from 34 of 243 acutely ill children (14 percent). The children with viremia had irritability, high temperatures (mean, 39.7-degrees-C), and inflammation of tympanic membranes (in 21), but few other localizing signs. Two children were hospitalized, but all 34 recovered after an average of four days of fever. The rash characteristic of roseola, which has been associated with HHV-6 infection, was noted in only three children. In 29 children (85 percent), serum samples obtained during convalescence had at least a fourfold increase in IgG antibody titers; 4 infants less than three months old who presumably had maternal antibody did not have this increase. HHV-6 was isolated from blood obtained during convalescence in only one child, but in two thirds of the children the virus could be detected by PCR. The isolates had genomic heterogeneity, indicating the presence of multiple strains. Conclusions. Primary infection with HHV-6 is a major cause of acute febrile illness in young children. Such infection is associated with varied clinical manifestations, viremia, and the frequent persistence of the viral genome in mononuclear cells.	UNIV ROCHESTER,SCH MED,DEPT PEDIAT,601 ELMWOOD AVE,BOX 689,ROCHESTER,NY 14642; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; DUPONT MERCK PHARMACEUT,WILMINGTON,DE	University of Rochester; Centers for Disease Control & Prevention - USA				Pellett, Philip/0000-0002-8536-8343				ABLASHI DV, 1991, VIROLOGY, V184, P545, DOI 10.1016/0042-6822(91)90424-A; AGUT H, 1988, LANCET, V1, P712; ASANO Y, 1991, J PEDIATR-US, V118, P891, DOI 10.1016/S0022-3476(05)82200-0; ASANO Y, 1989, J PEDIATR-US, V114, P535, DOI 10.1016/S0022-3476(89)80689-4; ASANO Y, 1989, J PEDIATR-US, V115, P264, DOI 10.1016/S0022-3476(89)80078-2; AUBIN JT, 1991, J CLIN MICROBIOL, V29, P367, DOI 10.1128/JCM.29.2.367-372.1991; Breese Jr. BB., 1941, NEW YORK J MED, V41, P1854; BRIGGS M, 1988, LANCET, V1, P1058; BROWN NA, 1988, LANCET, V2, P396; DOWNING RG, 1987, LANCET, V2, P390; JARRETT RF, 1988, LEUKEMIA, V2, P496; KIKUTA H, 1989, J INFECT DIS, V160, P550, DOI 10.1093/infdis/160.3.550; KNOWLES WA, 1988, LANCET, V2, P912; KONDO K, 1990, J CLIN MICROBIOL, V28, P970, DOI 10.1128/JCM.28.5.970-974.1990; KRUEGER GRF, 1988, J VIROL METHODS, V21, P125, DOI 10.1016/0166-0934(88)90059-6; LINDQUESTER GJ, 1991, VIROLOGY, V182, P102, DOI 10.1016/0042-6822(91)90653-S; PELLETT PE, 1990, ADV EXP MED BIOL, V278, P9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SCHIRMER EC, 1991, P NATL ACAD SCI USA, V88, P5922, DOI 10.1073/pnas.88.13.5922; SUGA S, 1989, PEDIATRICS, V83, P1003; TAKAHASHI K, 1988, LANCET, V1, P1463; UEDA K, 1989, J INFECT DIS, V159, P750, DOI 10.1093/infdis/159.4.750; YAMANISHI K, 1988, LANCET, V1, P1065	24	213	219	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1992	326	22					1445	1450		10.1056/NEJM199205283262201	http://dx.doi.org/10.1056/NEJM199205283262201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV469	1315416				2022-12-28	WOS:A1992HV46900001
J	BERGSAGEL, DJ; FINEGOLD, MJ; BUTEL, JS; KUPSKY, WJ; GARCEA, RL				BERGSAGEL, DJ; FINEGOLD, MJ; BUTEL, JS; KUPSKY, WJ; GARCEA, RL			DNA-SEQUENCES SIMILAR TO THOSE OF SIMIAN VIRUS-40 IN EPENDYMOMAS AND CHOROID-PLEXUS TUMORS OF CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-BRAIN-TUMORS; B-LYMPHOTROPIC PAPOVAVIRUS; TRANSGENIC MICE; JC-VIRUS; PANCREATIC-ISLETS; POLYOMAVIRUS-JC; T-ANTIGEN; SV40; HAMSTERS; TISSUE	Background. Ependymomas and papillomas of the choroid plexus occur in early childhood. The ubiquitous human polyomaviruses, BK virus and JC virus, have been associated with the induction of these neoplasms in animal models. A related monkey polyomavirus, simian virus 40 (SV40), is highly tumorigenic in rodents and also induces choroid plexus papillomas. Methods. We tested the possibility that polyomaviruses were associated with these tumors in humans. Tumors from 31 children - 20 with choroid plexus neoplasms and 11 with ependymomas - were evaluated for the presence of polyomavirus T-antigen gene sequences by means of amplification with the polymerase chain reaction. Results. Ten of the 2O choroid plexus tumors and 10 of the 11 ependymomas contained amplification products that preferentially hybridized to probes specific for SV40 viral DNA rather than BK or JC viral DNA. In two specimens, DNA sequencing demonstrated that the amplified sequence was identical to the sequence of that region of the SV40 gene. In three other specimens, amplification with SV40-specific primers revealed a 574-bp segment of the SV40 viral gene. In 7 of 11 tumors examined by immunohistochemical staining, viral T antigen was expressed in the nuclei of the neoplastic cells. Conclusions. Half of the choroid plexus tumors and most of the ependymomas that we studied contained and expressed a segment of T-antigen gene related to SV40. These results suggest that SV40 or a closely related virus may have an etiologic role in the development of these neoplasms during childhood, as in animal models.	CHILDRENS HOSP MED CTR, DANA FARBER CANC INST,DIV PEDIAT ONCOL,D1620, 44 BINNEY ST, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DANA FARBER CANC INST, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Baylor College of Medicine; Baylor College of Medicine			Bergsagel, Daniel John/I-6464-2019	Butel, Janet/0000-0002-6876-3245	NATIONAL CANCER INSTITUTE [R01CA022555] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22555] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AICARDI J, 1969, ARCH FR PEDIATR, V26, P1103; BRADE L, 1980, J MED VIROL, V6, P301, DOI 10.1002/jmv.1890060405; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CHEN JD, 1989, J VIROL, V63, P2204, DOI 10.1128/JVI.63.5.2204-2214.1989; CORALLINI A, 1987, INT J CANCER, V39, P60, DOI 10.1002/ijc.2910390111; CORALLINI A, 1978, J NATL CANCER I, V61, P875; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DOUGHERTY RM, 1976, J GEN VIROL, V33, P61, DOI 10.1099/0022-1317-33-1-61; DUBENSKY TW, 1984, J VIROL, V50, P779, DOI 10.1128/JVI.50.3.779-783.1984; DUBENSKY TW, 1984, J VIROL, V50, P541, DOI 10.1128/JVI.50.2.541-546.1984; EDDY BE, 1961, P SOC EXP BIOL MED, V107, P191; EDDY BE, 1962, FED PROC, V21, P930; GARBER JE, 1990, CANCER-AM CANCER SOC, V66, P2658, DOI 10.1002/1097-0142(19901215)66:12<2658::AID-CNCR2820661232>3.0.CO;2-C; GARDNER SD, 1971, LANCET, V1, P1253; GEISSLER E, 1990, PROG MED VIROL, V37, P211; Gibson P E, 1983, Prog Clin Biol Res, V105, P119; GREENLEE JE, 1978, ANN NEUROL, V3, P479, DOI 10.1002/ana.410030604; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAUSEN HZ, 1987, CANCER, V59, P1692, DOI 10.1002/1097-0142(19870515)59:10<1692::AID-CNCR2820591003>3.0.CO;2-F; HEIDEMAN RL, 1989, PRINCIPLES PRACTICE, P505; Higuchi R, 1989, AMPLIFICATIONS, V2, P1; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; ISRAEL MA, 1978, VIROLOGY, V90, P187, DOI 10.1016/0042-6822(78)90302-1; KANDA T, 1986, J VIROL, V59, P531, DOI 10.1128/JVI.59.2.531-534.1986; KAWASAKI ES, 1990, PCR PROTOCOLS GUIDE, P153; KIRSCHSTEIN RL, 1962, NATURE, V195, P299, DOI 10.1038/195299b0; KOSAKA H, 1980, J NEUROSURG, V52, P367, DOI 10.3171/jns.1980.52.3.0367; KRIEG P, 1981, P NATL ACAD SCI-BIOL, V78, P6446, DOI 10.1073/pnas.78.10.6446; LANFORD RE, 1979, VIROLOGY, V97, P295, DOI 10.1016/0042-6822(79)90341-6; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LOEBER G, 1988, J VIROL, V62, P1730, DOI 10.1128/JVI.62.5.1730-1735.1988; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; Maniatis T., 1982, MOL CLONING; MCCANCE DJ, 1977, INFECT IMMUN, V18, P196, DOI 10.1128/IAI.18.1.196-202.1977; MEINKE W, 1979, NEUROLOGY, V29, P1590, DOI 10.1212/WNL.29.12.1590; PADGETT BL, 1971, LANCET, V1, P1257; PADGETT BL, 1976, PROG MED VIROL, V22, P1; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; PATER MM, 1980, VIRUSES NATURALLY OC, V7, P329; RABSON AS, 1962, J NATL CANCER I, V29, P765; ROBINOW M, 1984, J PEDIATR-US, V104, P404, DOI 10.1016/S0022-3476(84)81105-1; Scherneck S, 1979, Zentralbl Neurochir, V40, P121; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; TABUCHI K, 1978, INT J CANCER, V21, P12, DOI 10.1002/ijc.2910210104; TAVIS JE, 1989, J VIROL, V63, P901, DOI 10.1128/JVI.63.2.901-911.1989; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; Tooze J, 1980, DNA TUMOR VIRUSES; UCHIDA S, 1979, J NATL CANCER I, V63, P119; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WEISS AF, 1975, P NATL ACAD SCI USA, V72, P609, DOI 10.1073/pnas.72.2.609; WOLD WSM, 1978, P NATL ACAD SCI USA, V75, P454, DOI 10.1073/pnas.75.1.454; YOGO Y, 1990, J VIROL, V64, P3139, DOI 10.1128/JVI.64.6.3139-3143.1990; ZANG KD, 1979, NATURWISSENSCHAFTEN, V66, P59, DOI 10.1007/BF00369369; ZIMMERMANN W, 1981, ACTA VIROL, V25, P199	59	369	374	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					988	993		10.1056/NEJM199204093261504	http://dx.doi.org/10.1056/NEJM199204093261504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1312224				2022-12-28	WOS:A1992HM28500004
J	KIMURA, T; TANIZAWA, O; MORI, K; BROWNSTEIN, MJ; OKAYAMA, H				KIMURA, T; TANIZAWA, O; MORI, K; BROWNSTEIN, MJ; OKAYAMA, H			STRUCTURE AND EXPRESSION OF A HUMAN OXYTOCIN RECEPTOR	NATURE			English	Article							MOLECULAR CHARACTERIZATION; FUNCTIONAL EXPRESSION; BOVINE ENDOMETRIUM; CDNA; OOCYTES; CLONING; PARTURITION; PREGNANCY; PROTEIN; GENE	JUST before the onset of labour, uterine myometrium becomes extremely sensitive to oxytocin 1, for which it is a primary target tissue, because of a dramatic increase in the number of oxytocin receptors 2,3. We report here the structure and expression of the human oxytocin receptor complementary DNA isolated by expression cloning. The encoded receptor is a 388-amino-acid polypeptide with 7 transmembrane domains typical of G protein-coupled receptors. The oxytocin receptor, expressed in Xenopus oocytes, specifically responds to oxytocin and induces an inward membrane current. Messenger RNAs for the receptor are of two sizes, 3.6 kilobases in breast, and 4.4 kilobases in ovary, uterine endometrium and myometrium. The mRNA level in the myometrium is very high at term. We conclude that the increase in receptor number in the myometrium at labour is, at least in part, due to the increase in mRNA.	OSAKA BIOSCI INST,DEPT NEUROSCI,SUITA,OSAKA 565,JAPAN; NIMH,CELL BIOL LAB,BETHESDA,MD 20892; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC GENET,SUITA,OSAKA 565,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Osaka University	KIMURA, T (corresponding author), OSAKA UNIV,SCH MED,DEPT OBSTET & GYNECOL,1-1-50 FUKUSHIMA,FUKUSHIMA KU,OSAKA 553,JAPAN.		Brownstein, Michael/B-8609-2009	Mori, Kensaku/0000-0001-7853-9370				BANKOWSKI K, 1980, INT J PEPT PROT RES, V16, P382; CUNNINGHAM FG, 1989, WILLIAMS OBSTETRICS, P187; FUCHS AR, 1990, ENDOCRINOLOGY, V127, P629, DOI 10.1210/endo-127-2-629; FUCHS AR, 1984, AM J OBSTET GYNECOL, V150, P734, DOI 10.1016/0002-9378(84)90677-X; FUCHS AR, 1990, AM J OBSTET GYNECOL, V163, P1961, DOI 10.1016/0002-9378(90)90781-2; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HIRONO C, 1987, J PHYSIOL-LONDON, V382, P523, DOI 10.1113/jphysiol.1987.sp016382; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUGENIN RL, 1964, HELV CHIM ACTA, V47, P1934; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIMURA T, IN PRESS J STEROID B; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MORLEY SD, 1988, J MOL ENDOCRINOL, V1, P77, DOI 10.1677/jme.0.0010077; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERNIA C, 1989, J ENDOCRINOL, V121, P117, DOI 10.1677/joe.0.1210117; SIGEL E, 1990, J MEMBRANE BIOL, V117, P201, DOI 10.1007/BF01868451; SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	27	574	590	1	64	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					526	529		10.1038/356526a0	http://dx.doi.org/10.1038/356526a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1313946				2022-12-28	WOS:A1992HN23100060
J	GRIESHAMMER, U; SASSOON, D; ROSENTHAL, N				GRIESHAMMER, U; SASSOON, D; ROSENTHAL, N			A TRANSGENE TARGET FOR POSITIONAL REGULATORS MARKS EARLY ROSTROCAUDAL SPECIFICATION OF MYOGENIC LINEAGES	CELL			English	Article							FAST SKELETAL-MUSCLE; MOTONEURON PROJECTION PATTERNS; DIFFERENT SEGMENTAL LEVELS; EMBRYONIC CHICK HINDLIMB; HOMEODOMAIN-DNA COMPLEX; MYOSIN LIGHT CHAIN-1; GENE FAMILY; ENHANCER-BINDING; ACTIN PROMOTER; CELL LINEAGES	In transgenic mice, muscle-specific regulatory elements from the myosin light chain (MLC) 1/3 locus drive graded expression of a linked CAT reporter gene in selected fast muscles along the anteroposterior axis of the adult animal. The gradient of MLC-CAT transcripts is established early in development, during the generation of somites from the paraxial mesoderm and the activation of myogenic factor gene expression, and is not reflected in the expression of the endogenous MLC1 gene. At later embryonic stages, the gradient of MLC-CAT transcripts persists in intercostal and intervertebral muscles, but is not maintained in other axial muscles. Profiles of CAT transgene activity reveal that the gradient is generated during the maturation of increasingly caudal somites, opposite to the direction of somite development, and is retained in dissociated somite cultures. We propose that coexpression of myogenic factors is necessary but not sufficient to regulate expression of the MLC-CAT transgene, which is responsive to additional positional cues in the embryo.			GRIESHAMMER, U (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA.		SASSOON, David A/G-2502-2013	SASSOON, David A/0000-0001-6074-048X; Rosenthal, Nadia/0000-0002-7599-7365	NATIONAL INSTITUTE ON AGING [R01AG008920] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG08920] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAGNALL KM, 1989, DEVELOPMENT, V107, P931; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHEVALLIER A, 1979, J EMBRYOL EXP MORPH, V49, P73; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; CONDON K, 1990, DEV BIOL, V138, P256, DOI 10.1016/0012-1606(90)90196-P; COSSU G, 1987, CURR TOP DEV BIOL, V23, P185; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAUBAS P, 1985, NUCLEIC ACIDS RES, V13, P4623, DOI 10.1093/nar/13.13.4623; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DONOGHUE MJ, 1992, CELL, V69, P67, DOI 10.1016/0092-8674(92)90119-W; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GAUTHIER GF, 1979, J CELL BIOL, V81, P10, DOI 10.1083/jcb.81.1.10; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANCEJONES C, 1988, DEV BIOL, V126, P394, DOI 10.1016/0012-1606(88)90149-2; LANCEJONES C, 1988, DEV BIOL, V126, P408, DOI 10.1016/0012-1606(88)90150-9; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LOWEY S, 1971, NATURE, V234, P81, DOI 10.1038/234081a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; Meinhardt H., 1982, MODELS BIOL PATTERN; Miller J B, 1991, Neuromuscul Disord, V1, P7, DOI 10.1016/0960-8966(91)90038-T; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; OTT MO, 1991, DEVELOPMENT, V111, P1097; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; ROSENTHAL N, 1992, IN PRESS REGULATION; ROY RK, 1982, FEBS LETT, V149, P22, DOI 10.1016/0014-5793(82)81063-6; RUGH R, 1968, MOUSE ITS REPRODUCTI; RUTZ R, 1982, DEV BIOL, V90, P399, DOI 10.1016/0012-1606(82)90389-X; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEIDEL U, 1989, J BIOL CHEM, V264, P16109; STERN CD, 1987, DEVELOPMENT, V99, P261; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; VIVARELLI E, 1986, DEV BIOL, V117, P319, DOI 10.1016/0012-1606(86)90374-X; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WALSH K, 1988, MOL CELL BIOL, V8, P1800, DOI 10.1128/MCB.8.4.1800; WALSH K, 1987, J BIOL CHEM, V262, P9429; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WHALEN RG, 1982, MUSCLE DEV MOL CELLU, P25; WIGSTON DJ, 1985, J NEUROSCI, V5, P1208; WIGSTON DJ, 1982, NATURE, V299, P464, DOI 10.1038/299464a0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; [No title captured]	86	81	81	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					79	93		10.1016/0092-8674(92)90120-2	http://dx.doi.org/10.1016/0092-8674(92)90120-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1313337				2022-12-28	WOS:A1992HM44500008
J	JORGENSEN, JL; ESSER, U; FAZEKAS DE ST GROTH, B; REAY, PA; DAVIS, MM				JORGENSEN, JL; ESSER, U; FAZEKAS DE ST GROTH, B; REAY, PA; DAVIS, MM			MAPPING T-CELL RECEPTOR PEPTIDE CONTACTS BY VARIANT PEPTIDE IMMUNIZATION OF SINGLE-CHAIN TRANSGENICS	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; BETA-CHAIN; ANTIGEN RECEPTOR; JUNCTIONAL REGIONS; MHC MOLECULE; RECOGNITION; GENES; SPECIFICITY; DETERMINANT; USAGE	To test models of T-cell recognition, mice transgenic for T-cell receptor-alpha or beta-chain have been immunized with variant peptides that force changes in the resulting T-cell response. In particular, charge substitutions on the peptide often elicit reciprocal charges in the junctional (CDR3) sequences of T-cell receptor V(alpha) or V(beta) chains, indicating direct T-cell receptor-peptide contact, and allowing derivation of a topology for the T-cell receptor-MHC interaction. At one position on the peptide, variants transformed a homogeneous V(beta) response into a very heterogeneous one.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	JORGENSEN, JL (corresponding author), STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA.		de St Groth, Barbara Fazekas/O-3017-2017	de St Groth, Barbara Fazekas/0000-0001-6817-9690; Davis, Mark/0000-0001-6868-657X				ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; AEBISCHER T, 1990, EUR J IMMUNOL, V20, P523, DOI 10.1002/eji.1830200310; AJITKUMAR P, 1988, CELL, V54, P47, DOI 10.1016/0092-8674(88)90178-X; BOTSTEIN D, 1982, ANNU REV GENET, V16, P61, DOI 10.1146/annurev.ge.16.120182.000425; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHEN SZ, 1990, BIOTECHNIQUES, V8, P32; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FOX BS, 1987, J IMMUNOL, V139, P1578; FOX BS, 1988, NATURE, V331, P538, DOI 10.1038/331538a0; GASCOIGNE NRJ, 1984, NATURE, V310, P387, DOI 10.1038/310387a0; HEDRICK SM, 1988, ADV IMMUNOL, V43, P193; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; HUPPI KE, 1988, IMMUNOGENETICS, V27, P51, DOI 10.1007/BF00404444; JAMESON SC, 1991, J IMMUNOL, V147, P3185; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LAI MZ, 1990, J IMMUNOL, V144, P4851; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; ROCK KL, 1985, HYBRIDOMA TECHNOLOGY, P527; RODEWALD HR, 1989, J IMMUNOL, V143, P4238; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; SAITO T, 1987, NATURE, V329, P256, DOI 10.1038/329256a0; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHWARTZ RH, 1985, J IMMUNOL, V135, P2598; SORGER SB, 1990, J IMMUNOL, V144, P1127; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TAYLOR AH, 1990, J EXP MED, V172, P1643, DOI 10.1084/jem.172.6.1643; TJOELKER LW, 1990, P NATL ACAD SCI USA, V87, P7856, DOI 10.1073/pnas.87.20.7856; TOMONARI K, 1990, IMMUNOGENETICS, V32, P60, DOI 10.1007/BF01787331; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; WHITE J, 1989, J IMMUNOL, V143, P1822; WITHER J, 1991, J IMMUNOL, V146, P3513; YANAGI Y, 1990, J VIROL, V64, P5919, DOI 10.1128/JVI.64.12.5919-5926.1990; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0	51	530	534	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1992	355	6357					224	230		10.1038/355224a0	http://dx.doi.org/10.1038/355224a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1309938				2022-12-28	WOS:A1992GZ69400056
J	PILIPENKO, EV; GMYL, AP; MASLOVA, SV; SVITKIN, YV; SINYAKOV, AN; AGOL, VI				PILIPENKO, EV; GMYL, AP; MASLOVA, SV; SVITKIN, YV; SINYAKOV, AN; AGOL, VI			PROKARYOTIC-LIKE CIS ELEMENTS IN THE CAP-INDEPENDENT INTERNAL INITIATION OF TRANSLATION ON PICORNAVIRUS RNA	CELL			English	Article							ENCEPHALOMYOCARDITIS VIRUS-RNA; 5' NONCODING REGION; COMPLETE NUCLEOTIDE-SEQUENCE; ATTENUATED POLIOVIRUS STRAINS; EUKARYOTIC MESSENGER-RNA; HUMAN NEURO-BLASTOMA; MOUTH-DISEASE VIRUS; 5'-UNTRANSLATED REGION; INVITRO TRANSLATION; SECONDARY STRUCTURE	Initiation of translation on picornavirus RNAs is accomplished through internal binding of ribosomes to a complex cis-acting element. Here we show that efficient function of this element involves two appropriately spaced smaller elements: UUUCC and an AUG. This conclusion emerged f rom analysis of the genome structures of spontaneous revertants of mutant polio-viruses with extended insertions between the UUUCC and AUG motifs. It was confirmed by the results obtained with specially designed constructs. A similarity to the prokaryotic translation initiation mechanism, which involves the Shine-Dalgarno sequence, is emphasized, but in the picornavirus system the position of the UUUCC must be strictly fixed relative to upstream cis-acting elements, and the AUG may not necessarily serve as an initiation codon.	MV LOMONOSOV STATE UNIV, MOSCOW 119899, USSR	Lomonosov Moscow State University	PILIPENKO, EV (corresponding author), ACAD MED SCI USSR, INST POLIOMYELITIS & VIRAL ENCEPHALITIDES, MOSCOW 142782, USSR.		Agol, Vadim I./E-1941-2013; Gmyl, Anatoly/J-8367-2012	Svitkin, Yuri/0000-0003-3819-2143				AGOL VI, 1989, J VIROL, V63, P4034, DOI 10.1128/JVI.63.9.4034-4038.1989; AGOL VI, 1991, ADV VIRUS RES, V40, P103; BECK E, 1983, NUCLEIC ACIDS RES, V11, P7873, DOI 10.1093/nar/11.22.7873; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BIENKOWSKASZEWCZYK K, 1988, J VIROL, V62, P3068, DOI 10.1128/JVI.62.8.3068-3072.1988; BLINOV VM, 1988, DOKL AKAD NAUK SSSR+, V298, P1004; BROWN BA, 1979, VIROLOGY, V97, P396, DOI 10.1016/0042-6822(79)90350-7; CHANG KH, 1989, J GEN VIROL, V70, P3269, DOI 10.1099/0022-1317-70-12-3269; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; DELANGEL RM, 1989, P NATL ACAD SCI USA, V86, P8299; DORNER AJ, 1984, J VIROL, V50, P507, DOI 10.1128/JVI.50.2.507-514.1984; HAGENBUCHLE O, 1978, CELL, V13, P551, DOI 10.1016/0092-8674(78)90328-8; HUGHES PJ, 1989, J GEN VIROL, V70, P2943, DOI 10.1099/0022-1317-70-11-2943; IIZUKA N, 1989, J VIROL, V63, P5354, DOI 10.1128/JVI.63.12.5354-5363.1989; INOUE T, 1989, J GEN VIROL, V70, P919, DOI 10.1099/0022-1317-70-4-919; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUGE S, 1987, J VIROL, V61, P1478, DOI 10.1128/JVI.61.5.1478-1487.1987; KUHN R, 1990, J VIROL, V64, P4625; LAMONICA N, 1989, J VIROL, V63, P2357, DOI 10.1128/JVI.63.5.2357-2360.1989; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MUZYCHENKO AR, 1991, IN PRESS VIRUS RES; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1988, J VIROL, V62, P4486, DOI 10.1128/JVI.62.12.4486-4492.1988; PELLETIER J, 1988, J VIROL, V62, P2219, DOI 10.1128/JVI.62.7.2219-2227.1988; PESTOVA TV, 1991, IN PRESS J VIROL; PILIPENKO EV, 1990, NUCLEIC ACIDS RES, V18, P3371, DOI 10.1093/nar/18.11.3371; PILIPENKO EV, 1989, VIROLOGY, V168, P201, DOI 10.1016/0042-6822(89)90259-6; PILIPENKO EV, 1989, NUCLEIC ACIDS RES, V17, P5701, DOI 10.1093/nar/17.14.5701; RIVERA VM, 1988, VIROLOGY, V165, P42, DOI 10.1016/0042-6822(88)90656-3; Rueckert RR, 1985, VIROLOGY, P705; RYAN MD, 1990, J GEN VIROL, V71, P2291, DOI 10.1099/0022-1317-71-10-2291; SKINNER MA, 1989, J MOL BIOL, V207, P379, DOI 10.1016/0022-2836(89)90261-1; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SVITKIN YV, 1985, VIROLOGY, V147, P243, DOI 10.1016/0042-6822(85)90127-8; SVITKIN YV, 1990, VIROLOGY, V175, P103, DOI 10.1016/0042-6822(90)90190-3; SVITKIN YV, 1988, VIROLOGY, V166, P394, DOI 10.1016/0042-6822(88)90510-7; TOYODA H, 1984, J MOL BIOL, V174, P561, DOI 10.1016/0022-2836(84)90084-6; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; TRONO D, 1988, SCIENCE, V241, P445, DOI 10.1126/science.2839901; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364	46	245	260	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1992	68	1					119	131		10.1016/0092-8674(92)90211-T	http://dx.doi.org/10.1016/0092-8674(92)90211-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1310072				2022-12-28	WOS:A1992GZ58300014
J	BARKER, DJP; OSMOND, C; PANNETT, B				BARKER, DJP; OSMOND, C; PANNETT, B			WHY LONDONERS HAVE LOW DEATH RATES FROM ISCHEMIC-HEART-DISEASE AND STROKE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To explain the low death rates from cardiovascular disease in London. Setting-London and the other counties of England and Wales. Subjects-Women living in London during 1901-10 and people in London dying during 1968-78. Results-At the beginning of the twentieth century young women aged 15-34 in London had remarkably low death rates, largely because of low rates for tuberculosis and other infectious diseases and low mortality during childbirth. Their low death rates contrasted with the high rates in girls under 15 years. Conclusions-Large numbers of young women had migrated into London from agricultural counties in southern England and went into domestic service, where the diet was usually very good. Recent findings suggest that a mother's nutrition and health has a major effect on the risk of cardiovascular disease in the next generation. The low cardiovascular mortality in London is consistent with this, and contrasts with the high mortality from other common diseases.			BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				[Anonymous], 1913, CENSUS ENGLAND WALES, VIX; ARIOUAT J, IN PRESS NUTRITION H; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, IN PRESS DIABETOLOGI; BARKER DJP, IN PRESS BMJ; Barker DJP, 1992, FETAL INFANT ORIGINS; BOOTH C, 1903, IND LONDON, V4; BOOTH C, 1902, POVERTY, V1; BOOTH C, 1902, POVERTY LONDON, V3; BOOTH C, 1903, INDUSTRY, V5; CAMPBELL JM, 1932, MINISTRY HLTH REPORT, V68; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; GARDNER MJ, 1983, ATLAS MORTALITY SELE; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LAW CM, IN PRESS BMJ; Lumey L H, 1992, Paediatr Perinat Epidemiol, V6, P240, DOI 10.1111/j.1365-3016.1992.tb00764.x; PHIPPS K, IN PRESS DIABETOLOGI; WALL R, 1990, SOME INEQUALITIES RA; 1907, 65TH REG GEN BIR 1 S; 1913, 1911 REG GEN BIRTHS; 1919, 1915 19 LOND COUNT C, V3; 1931, NEW SURVEY LONDON LI, V2; 1910, 1909 10 LOC GOV BO S; 1913, CENSUS ENGLAND WALES, V7; 1919, 75TH REG GEN BIR 3 S; 1880, REGISTRAR GENERALS 1	29	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1551	1554		10.1136/bmj.305.6868.1551	http://dx.doi.org/10.1136/bmj.305.6868.1551			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286384	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KD77100021
J	BOUVET, P; BELASCO, JG				BOUVET, P; BELASCO, JG			CONTROL OF RNASE-E-MEDIATED RNA DEGRADATION BY 5'-TERMINAL BASE-PAIRING IN ESCHERICHIA-COLI	NATURE			English	Article							MESSENGER-RNA; ESCHERICHIA-COLI; RIBONUCLEASE-E; BACILLUS-SUBTILIS; PROCESSING ENZYME; PRIMER FORMATION; STABILITY; AMS; PLASMID; GENE	DESPITE the variety of messenger RNA half-lives in bacteria (0.5-30 min in Escherichia coli) and their importance in controlling gene expression, their molecular basis remains obscure. The life-time of an entire mRNA molecule can be determined by features near,its 5' end, but no 5' exoribonuclease has been identified in any prokaryotic organism1-6. A mutation that inactivates E. coli RNase E also increases the average lifetime of bulk E. coli mRNA and of many individual messages, suggesting that cleavage by this endonuclease may be the rate-determining step in the degradation of most mRNAs in E. coli7-16. We have investigated the substrate preference of RNase E in E. coli by using variants of RNA I, a small untranslated RNA whose swift degradation in vivo is initiated by RNase E cleavage at an internal site. We report here that RNase E has an unprecedented substrate specificity for an endoribonuclease, as it preferentially cleaves RNAs that have several unpaired nucleotides at the 5' end. The sensitivity of RNase E to 5'-terminal base pairing may explain how determinants near the 5' end can control rates of mRNA decay in bacteria.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; UNIV RENNES 1,BIOL & GENET DEV LAB,CNRS,UA 256,F-35042 RENNES,FRANCE	Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes			, Bouvet/AAC-8779-2020	Bouvet, Philippe/0000-0003-4524-2233				APIRION D, 1978, GENETICS, V90, P659; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BECHHOFER DH, 1987, P NATL ACAD SCI USA, V84, P498, DOI 10.1073/pnas.84.2.498; BECHHOFER DH, 1989, J BACTERIOL, V171, P5803, DOI 10.1128/jb.171.11.5803-5811.1989; BELASCO JG, 1986, CELL, V46, P245, DOI 10.1016/0092-8674(86)90741-5; CANNISTRARO VJ, 1985, J BACTERIOL, V161, P820, DOI 10.1128/JB.161.2.820-822.1985; CHEN LH, 1991, J BACTERIOL, V173, P4578, DOI 10.1128/jb.173.15.4578-4586.1991; DEUTSCHER MP, 1990, POSTTRANSCRIPTIONAL, P1; EMORY SA, 1992, GENE DEV, V6, P135, DOI 10.1101/gad.6.1.135; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; FORCHHAMMER J, 1972, J MOL BIOL, V71, P687, DOI 10.1016/S0022-2836(72)80032-9; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GORSKI K, 1985, CELL, V43, P461, DOI 10.1016/0092-8674(85)90176-X; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MORIKAWA N, 1969, NATURE, V223, P37, DOI 10.1038/223037a0; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; MORSE DE, 1969, NATURE, V223, P40, DOI 10.1038/223040a0; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; ROY MK, 1983, BIOCHIM BIOPHYS ACTA, V747, P200, DOI 10.1016/0167-4838(83)90098-5; SANDLER P, 1989, J BACTERIOL, V171, P6680, DOI 10.1128/jb.171.12.6680-6688.1989; SANDLER P, 1988, J MOL BIOL, V203, P905, DOI 10.1016/0022-2836(88)90116-7; TAMM J, 1983, NUCLEIC ACIDS RES, V11, P6381, DOI 10.1093/nar/11.18.6381; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TOMIZAWA J, 1981, P NATL ACAD SCI-BIOL, V78, P1421, DOI 10.1073/pnas.78.3.1421; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; YAMAMOTO T, 1975, J MOL BIOL, V92, P289, DOI 10.1016/0022-2836(75)90228-4	32	191	196	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					488	491		10.1038/360488a0	http://dx.doi.org/10.1038/360488a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1280335				2022-12-28	WOS:A1992KA79700067
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			TREATING BEFORE KNOWING	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ACUTE GLOMERULONEPHRITIS; GOODPASTURES-SYNDROME		TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GEN INTERNAL MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CLIN DECIS MAKING,BOSTON,MA 02111, USA.							COUSER WG, 1992, CECIL TXB MED, P551; Glassock RJ, 1991, KIDNEY, V4th, P1182; GLASSOCK RJ, 1991, KIDNEY, P1280; HOLDSWORTH S, 1985, Q J MED, V55, P75; JOHNSON JP, 1978, AM J MED, V64, P354, DOI 10.1016/0002-9343(78)90065-7; KEANE WF, 1988, IMMUNOLOGICAL DISEAS, V2, P1809; LEE HA, 1966, BMJ-BRIT MED J, V2, P1361, DOI 10.1136/bmj.2.5526.1361; MADAIO MP, 1983, NEW ENGL J MED, V309, P1299, DOI 10.1056/NEJM198311243092106; WIGGINS RC, 1992, TXB INTERNAL MED, P774	9	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1366	1369		10.1056/NEJM199211053271907	http://dx.doi.org/10.1056/NEJM199211053271907			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1302474				2022-12-28	WOS:A1992JW07700007
J	TARAGIN, MI; WILLETT, LR; WILCZEK, AP; TROUT, R; CARSON, JL				TARAGIN, MI; WILLETT, LR; WILCZEK, AP; TROUT, R; CARSON, JL			THE INFLUENCE OF STANDARD OF CARE AND SEVERITY OF INJURY ON THE RESOLUTION OF MEDICAL MALPRACTICE CLAIMS	ANNALS OF INTERNAL MEDICINE			English	Article						MALPRACTICE; SEVERITY OF ILLNESS INDEX; INSURANCE, LIABILITY; JURISPRUDENCE; PROFESSIONAL PRACTICE	PHYSICIANS	Objective: To explore how frequently physicians lose medical malpractice cases despite providing standard care and to assess whether severity of patient injury influences the frequency of plaintiff payment. Design: Retrospective cohort study. Setting: Physicians from the state of New Jersey insured by one insurance company from 1977 to 1992. Participants: A total of 12 829 physicians involved in 8231 closed malpractice cases. Measurements: Physician care and claim severity were prospectively determined by the insurance company using a standard process. Results: Physician care was considered defensible in 62% of the cases and indefensible in 25% of the cases, in almost half of which the physician admitted error. In the remaining 13% of cases, it was unclear whether physician care was defensible. The plaintiff received a payment in 43% of all cases. Payment was made 21 % of the time if physician care was considered defensible, 91% if considered indefensible, and 59% if considered unclear. The severity of the injury was classified as low, medium, or high in 28%, 47%, and 25% of the cases, respectively. Severity of injury had a small but significant association (P < 0.001) with the frequency of plaintiff payment (low severity, 39%; medium severity, 43%; and high severity, 47%). The severity of injury was not associated with the payment rate in cases resolved by a jury (low severity, 23%; medium severity, 25%; and high severity, 23%). Conclusions: In malpractice cases, physicians provide care that is usually defensible. The defensibility of the case and not the severity of patient injury predominantly influences whether any payment is made. Even in cases that require a jury verdict, the severity of patient injury has little effect on whether any payment is made. Our findings suggest that unjustified payments are probably uncommon.	UNIV MED & DENT NEW JERSEY, COOK COLL, NEW BRUNSWICK, NJ 08903 USA; NEW JERSEY MED INTERINSURANCE EXCHANGE, LAWRENCEVILLE, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	TARAGIN, MI (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DIV GEN INTERNAL MED, 97 PATERSON ST, NEW BRUNSWICK, NJ 08903 USA.							Boggs J S, 1987, J Fla Med Assoc, V74, P767; BOVBJERG RR, 1991, JAMA-J AM MED ASSOC, V265, P2836, DOI 10.1001/jama.265.21.2836; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; CHARLES SC, 1985, AM J PSYCHIAT, V142, P437; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; SAMUEL FE, 1986, LIABILITY THREAT SLO; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SLOAN FA, 1990, LAW SOC REV, V24, P997, DOI 10.2307/3053617; TARAGIN MI, 1992, IN PRESS AM J MED, P93; WEISS BD, 1986, J FAM PRACTICE, V23, P55; 1987, CONTINUING NEED LEGI; 1987, GAOHRD8755 GEN ACC O; 1989, AM MED NEWS     0106; 1987, GAOHRD8721 GEN ACC O; 1984, PHYSICIAN CHARACTERI; 1986, GAOHRD8650 GEN ACC O	18	118	118	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1992	117	9					780	784		10.7326/0003-4819-117-9-780	http://dx.doi.org/10.7326/0003-4819-117-9-780			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV424	1308760				2022-12-28	WOS:A1992JV42400013
J	LEIZOROVICZ, A; HAUGH, MC; CHAPUIS, FR; SAMAMA, MM; BOISSEL, JP				LEIZOROVICZ, A; HAUGH, MC; CHAPUIS, FR; SAMAMA, MM; BOISSEL, JP			LOW-MOLECULAR-WEIGHT HEPARIN IN PREVENTION OF PERIOPERATIVE THROMBOSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEEP-VEIN THROMBOSIS; LOW-DOSE HEPARIN; TOTAL HIP-REPLACEMENT; FATAL PULMONARY-EMBOLISM; UNFRACTIONATED HEPARIN; VENOUS THROMBOSIS; DOUBLE-BLIND; GENERAL-SURGERY; CLINICAL-TRIALS; KABI 2165	Objective-To determine whether prophylactic treatment with low molecular weight heparin reduces the incidence of thrombosis in patients who have had general or orthopaedic surgery. Design-Meta-analysis of results from 52 randomised, controlled clinical studies (29 in general surgery and 23 in orthopaedic surgery) in which low molecular weight heparin was compared with placebo, dextran, or unfractionated heparin. Subjects-Patients who had had general or orthopaedic surgery. Intervention-Once daily injection of a low molecular weight heparin compared with placebo, dextran, or unfractionated heparin. Main outcome measures-Incidence of deep venous thrombosis, pulmonary embolism, major haemorrhages, and death. Results-The results confirm that low molecular weight heparins are more efficacious for the prophylactic treatment of deep venous thrombosis than placebo (common odds ratio 0.31, 95% confidence interval 0.22 to 0.43; p<0.001) and dextran (0.44, 0.30 to 0.65; p<0.001). The results suggest that low molecular weight heparins are also more efficacious than unfractionated heparin (0.85, 0.74 to 0.97; p=0.02), with no significant difference in the incidence of major haemorrhages (1.06, 0.93 to 1.20; p=0.62). Conclusions-Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in preventing perioperative thrombosis. However, it remains to be shown in a suitably powered clinical trial whether low molecular weight heparin reduces the risk of fatal pulmonary embolism compared with heparin.	HOP HOTEL DIEU, CENT HEMATOL LAB, F-75181 PARIS 04, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	LEIZOROVICZ, A (corresponding author), UNITE PHARMACOL CLIN, BP 3041, F-69394 LYON 03, FRANCE.							ADOLF J, 1989, DEUT MED WOCHENSCHR, V114, P48, DOI 10.1055/s-2008-1066550; Barre J, 1987, J Mal Vasc, V12 Suppl B, P90; BAUMGARTNER A, 1989, VASA-J VASCULAR DIS, V18, P152; BERGQVIST D, 1988, BRIT J SURG, V75, P888, DOI 10.1002/bjs.1800750920; BERGQVIST D, 1986, BRIT J SURG, V73, P204, DOI 10.1002/bjs.1800730316; BERGQVIST D, 1987, JAMA-J AM MED ASSOC, V258, P324; BERGQVIST D, 1983, POSTOPERATIVE THROMB, P129; BINSACK T, 1986, THROMB RES, P83; BOISSEL JP, 1988, EUR J CLIN PHARMACOL, V34, P535, DOI 10.1007/BF00615213; BOISSEL JP, 1991, THROMB HAEMOSTASIS, V66, P368; BOISSEL JP, 1988, THROMB HAEMOSTASIS, V34, P535; BORSTAD E, 1988, ACTA OBSTET GYN SCAN, V67, P99, DOI 10.3109/00016348809004178; BREYER HG, 1987, THROMB HAEMOSTAS S, V7, P23; BRIEL RC, 1988, GEBURTSH FRAUENHEILK, V48, P160, DOI 10.1055/s-2008-1035716; BUCHANAN MR, 1985, BLOOD, V65, P198; CADE JF, 1984, THROMB RES, V35, P613, DOI 10.1016/0049-3848(84)90265-2; CAEN JP, 1988, THROMB HAEMOSTASIS, V59, P216; CARTER CJ, 1982, BLOOD, V59, P1239; CHIAPUZZO E, 1988, J INT MED RES, V16, P359, DOI 10.1177/030006058801600505; COLDITZ GA, 1986, LANCET, V2, P143; COLLET JP, 1991, EUR J CLIN PHARMACOL, V41, P267, DOI 10.1007/BF00314951; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DAHAN M, 1989, THROMB HAEMOSTASIS, V62, P519; DALEN JE, 1986, CHEST, V89, pS370, DOI 10.1378/chest.89.5_Supplement.370S; DECHAVANNE M, 1989, HAEMOSTASIS, V19, P5; DICKERSIN K, 1988, CONTROL CLIN TRIALS, V9, P76; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; ENCKE A, 1988, BRIT J SURG, V75, P1058; ERIKSSON BI, 1988, BRIT J SURG, V75, P1053, DOI 10.1002/bjs.1800751104; ERIKSSON BI, 1989, THROMB HAEMOSTASIS, V62, P470; ESQUIVEL CO, 1982, THROMB RES, V28, P389, DOI 10.1016/0049-3848(82)90120-7; FLEISS JL, 1973, STATISTICAL METHODS; FRICKER JP, 1988, EUR J CLIN INVEST, V18, P561, DOI 10.1111/j.1365-2362.1988.tb01268.x; FRYDMAN AM, 1988, J CLIN PHARMACOL, V28, P609, DOI 10.1002/j.1552-4604.1988.tb03184.x; HAAS S, 1985, THROMB HAEMOSTASIS, V54, P319; HAAS S, 1987, DRUG RES, V37, P839; HARTL P, 1990, THROMB RES, V57, P577, DOI 10.1016/0049-3848(90)90074-M; HEILMANN L, 1989, GEBURTSH FRAUENHEILK, V49, P803, DOI 10.1055/s-2008-1036089; HIRSH J, 1990, ACTA CHIR SCAND, P42; HOFFMANN R, 1987, HELV CHIR ACTA, V54, P521; HULL RD, 1986, CHEST, V89, pS374, DOI 10.1378/chest.89.5.374S; JORGENSEN PS, 1989, THROMB HAEMOSTASIS, V62, P525; KAKKAR VV, 1981, CLIN HAEMATOL, V10, P543; KAKKAR VV, 1985, BRIT J SURG, V72, P786, DOI 10.1002/bjs.1800721006; KAKKAR VV, 1989, AM J SURG, V157, P413, DOI 10.1016/0002-9610(89)90589-8; KOLLER M, 1986, THROMB HAEMOSTASIS, V56, P243; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LASSEN ML, 1989, THROMB HAEMOSTASIS, V62, P126; LASSEN MR, 1989, ARCH ORTHOP TRAUM SU, V108, P10, DOI 10.1007/BF00934150; LASSEN MR, 1988, BRIT J SURG, V75, P686, DOI 10.1002/bjs.1800750720; LECLERC J, 1991, THROMB HAEMOSTASIS, V65, P753; LEGAGNEUX F, 1987, THROMB HAEMOSTASIS, V58, P116; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; LEYVRAZ PF, 1983, NEW ENGL J MED, V309, P954, DOI 10.1056/NEJM198310203091605; LIEZOROVICZ A, 1991, BRIT J SURG, V78, P412, DOI 10.1002/bjs.1800780410; LOCKNER D, 1986, HAEMOSTASIS, V16, P8; Matzsch T, 1988, Acta Chir Scand Suppl, V543, P80; MATZSCH T, 1991, THROMB HAEMORRH DISO, V3, P25; MONREAL M, 1989, J TRAUMA, V29, P873, DOI 10.1097/00005373-198906000-00028; OCKELFORD PA, 1989, THROMB HAEMOSTASIS, V62, P1046; ONARHEIM H, 1986, ACTA CHIR SCAND, V152, P593; PEZZUOLI G, 1989, INT SURG, V74, P205; PINI M, 1989, INT ANGIOL, V8, P134; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; SAMAMA M, 1988, BRIT J SURG, V75, P128, DOI 10.1002/bjs.1800750213; SASAHARA AA, 1986, BRIT J SURG, V73, P697, DOI 10.1002/bjs.1800730906; SCHMITZHUEBNER U, 1984, KLIN WOCHENSCHR, V62, P349, DOI 10.1007/BF01716253; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SIMES RJ, 1987, STAT MED, V6, P11, DOI 10.1002/sim.4780060104; TABERNER DA, 1989, BRIT J SURG, V76, P933, DOI 10.1002/bjs.1800760920; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; TORHOLM C, 1991, J BONE JOINT SURG BR, V73, P434, DOI 10.1302/0301-620X.73B3.1670445; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; VALLE I, 1988, CURR MED RES OPIN, V11, P80, DOI 10.1185/03007998809110450; VERARDI S, 1988, INT ANGIOL, V7, P19; VOIGT J, 1986, ZBL CHIR, V111, P1296; 1991, ARCH INTERN MED, V151, P1612	78	333	339	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 17	1992	305	6859					913	920		10.1136/bmj.305.6859.913	http://dx.doi.org/10.1136/bmj.305.6859.913			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU649	1281030	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JU64900018
J	SCHLUEDERBERG, A; STRAUS, SE; PETERSON, P; BLUMENTHAL, S; KOMAROFF, AL; SPRING, SB; LANDAY, A; BUCHWALD, D				SCHLUEDERBERG, A; STRAUS, SE; PETERSON, P; BLUMENTHAL, S; KOMAROFF, AL; SPRING, SB; LANDAY, A; BUCHWALD, D			CHRONIC FATIGUE SYNDROME RESEARCH - DEFINITION AND MEDICAL OUTCOME ASSESSMENT	ANNALS OF INTERNAL MEDICINE			English	Article						FATIGUE SYNDROME, CHRONIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; DIAGNOSIS, DIFFERENTIAL; SLEEP DISORDERS	BARR VIRUS-INFECTION; FIBROMYALGIA; POPULATION	A workshop was held 18 to 19 March 1991 at the National Institutes of Health to address critical issues in research concerning the chronic fatigue syndrome (CFS). Case definition, confounding diagnoses, and medical outcome assessment by laboratory and other means were considered from the perspectives of key medical specialties involved in CFS research. It was recommended that published Centers for Disease Control (CDC) case-definition criteria be modified to exclude fewer patients from analysis because of a history of psychiatric disorder. Specific recommendations were made concerning the inclusion or exclusion of other major confounding diagnoses, and a standard panel of laboratory tests was specified for initial patient evaluation. The workshop emphasized the importance of recognizing other conditions that could explain the patient's symptoms and that may be treatable. It was viewed as essential for the investigator to screen for psychiatric disorder using a combination of self-report instruments followed by at least one structured interview to identity patients who should be excluded from studies or considered as a separate subgroup in data analysis. Because CFS is not a homogeneous abnormality and because there is no single pathogenic mechanism, research progress may depend upon delineation of these and other patient subgroups for separate data analysis. Despite preliminary data, no physical finding or laboratory test was deemed confirmatory of the diagnosis of CFS. For assessment of clinical status, investigators must rely on the use of standardized instruments for patient self-reporting of fatigue, mood disturbance, functional status, sleep disorder, global well-being, and pain. Further research is needed to develop better instruments for quantifying these domains in patients with CFS.	NIMH, BETHESDA, MD 20892 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; BRIGHAM & WOMENS HOSP, DIV GEN MED, BOSTON, MA 02115 USA; RUSH UNIV, MED CTR, DEPT IMMUNOL MICROBIOL, CHICAGO, IL 60612 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Brigham & Women's Hospital; Rush University; Harborview Medical Center; University of Washington; University of Washington Seattle	SCHLUEDERBERG, A (corresponding author), NIAID, DMID, VIROL BRANCH, ROOM 3A-16, SOLAR BLDG, BETHESDA, MD 20892 USA.							BAROFSKY I, 1991, REV INFECT DIS, V13, pS94; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BEYAERT R, 1991, CYTOKINE, V3, P284, DOI 10.1016/1043-4666(91)90496-Z; BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; BUCHWALD D, 1991, REV INFECT DIS, V13, pS12; BUCHWALD D, 1987, ARTHRITIS RHEUM, V30, P1132, DOI 10.1002/art.1780301007; CANNON JG, 1985, SCIENCE, V227, P1247, DOI 10.1126/science.3871966; COLBURN TR, 1976, ISA T, V15, P149; DEMITRACK MA, 1991, BIOL PSYCHIAT, V30, P747, DOI 10.1016/0006-3223(91)90231-A; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; ENDRES S, 1989, EUR J IMMUNOL, V19, P2327, DOI 10.1002/eji.1830191222; First M.B., 1989, STRUCTURED CLIN INTE; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOLDENBERG DL, 1990, ARTHRITIS RHEUM, V33, P381, DOI 10.1002/art.1780330311; HERBERMAN RB, 1991, REV INFECT DIS, V13, pS84; HOLMES GP, 1988, ANN INTERN MED, V109, P512; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HOLMES GP, 1991, REV INFECT DIS, V13, pS53; JONES JF, 1987, ANNU REV MED, V38, P195, DOI 10.1146/annurev.med.38.1.195; KATON W, 1992, IN PRESS ARCH INTERN; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; LANE TJ, 1991, AM J MED, V91, P335, DOI 10.1016/0002-9343(91)90150-V; LEWIS SF, 1991, REV INFECT DIS, V13, pS98; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; MILLER AH, 1986, J CLIN PSYCHIAT, V47, P529; PETERSON PK, 1991, MINN MED, V74, P21; PETERSON PK, 1990, AM J MED, V89, P554, DOI 10.1016/0002-9343(90)90172-A; REDMOND CK, 1991, REV INFECT DIS, V13, pS90; ROBINS LN, 1985, NIMH DIAGNOSTIC INTE; SCHULTE PA, 1991, REV INFECT DIS, V13, pS87; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STRAUS SE, 1988, J ALLERGY CLIN IMMUN, V81, P791, DOI 10.1016/0091-6749(88)90933-5; WOLFE F, 1989, Arthritis and Rheumatism, V32, pS47; 1989, NCCLS H42P NAT COMM	37	258	259	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					325	331		10.7326/0003-4819-117-4-325	http://dx.doi.org/10.7326/0003-4819-117-4-325			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1322076				2022-12-28	WOS:A1992JH46400010
J	MIYAZAKI, S; YUZAKI, M; NAKADA, K; SHIRAKAWA, H; NAKANISHI, S; NAKADE, S; MIKOSHIBA, K				MIYAZAKI, S; YUZAKI, M; NAKADA, K; SHIRAKAWA, H; NAKANISHI, S; NAKADE, S; MIKOSHIBA, K			BLOCK OF CA2+ WAVE AND CA2+ OSCILLATION BY ANTIBODY TO THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN FERTILIZED HAMSTER EGGS	SCIENCE			English	Article							SMOOTH-MUSCLE CELLS; PERIODIC INCREASE; CA-2+ RELEASE; FREE CALCIUM; GUINEA-PIG; TRISPHOSPHATE; EXPRESSION; PURIFICATION; RYANODINE; PROTEIN	The concentration of cytoplasmic free calcium (Ca2+) increases in various stimulated cells in a wave (Ca2+ wave) and in periodic transients (Ca2+ oscillations). These phenomena are explained by inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release (IICR) and Ca2+-induced Ca2+ release (CICR) from separate intracellular stores, but decisive evidence is lacking. A monoclonal antibody to the IP3 receptor inhibited both IICR and CICR upon injection of IP3 and Ca2+ into hamster eggs, respectively. The antibody completely blocked sperm-induced Ca2+ waves and Ca2+ oscillations. The results indicate that Ca2 release in fertilized hamster eggs is mediated solely by the IP3 receptor, and Ca2+-sensitized IICR, but not CICR, generates Ca2+ waves and Ca2+ oscillations.	JICHI MED SCH, DEPT BIOCHEM, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; OSAKA UNIV, INST PROT RES, DIV REGULAT MACROMOLEC FUNCT, SUITA, OSAKA 565, JAPAN; UNIV TOKYO, INST MED SCI, DEPT MOLEC NEUROBIOL, MINATO KU, TOKYO 108, JAPAN	Jichi Medical University; Osaka University; University of Tokyo	MIYAZAKI, S (corresponding author), TOKYO WOMENS MED COLL, DEPT PHYSIOL, 8-1 KAWADA CHO, SHINJUKU KU, TOKYO 162, JAPAN.		Nakanishi, Setsuko/G-5871-2015; Yuzaki, Michisuke/K-5328-2013; Mikoshiba, Katsuhiko/N-7943-2015	Nakanishi, Setsuko/0000-0003-4909-2113; Yuzaki, Michisuke/0000-0002-5750-3544; 				BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; COBBOLD PH, 1991, CELL CALCIUM, V12, P87, DOI 10.1016/0143-4160(91)90011-3; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IGUSA Y, 1986, J PHYSIOL-LONDON, V377, P193, DOI 10.1113/jphysiol.1986.sp016181; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Jaffe L. A., 1985, BIOL FERTILIZATION, P127; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; LONGO FJ, 1974, ANAT RECORD, V179, P27, DOI 10.1002/ar.1091790104; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAZAKI S, 1991, CELL CALCIUM, V12, P205, DOI 10.1016/0143-4160(91)90021-6; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WHITAKER M, 1990, DEVELOPMENT, V108, P525; WIER WG, 1991, CELL CALCIUM, V12, P241, DOI 10.1016/0143-4160(91)90024-9; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737	30	477	481	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1992	257	5067					251	255		10.1126/science.1321497	http://dx.doi.org/10.1126/science.1321497			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321497				2022-12-28	WOS:A1992JC58500042
J	JACOBUS, CH; HOLICK, MF; SHAO, Q; CHEN, TC; HOLM, IA; KOLODNY, JM; EL-HAJJ FULEIHAN, G; SEELY, EW				JACOBUS, CH; HOLICK, MF; SHAO, Q; CHEN, TC; HOLM, IA; KOLODNY, JM; EL-HAJJ FULEIHAN, G; SEELY, EW			HYPERVITAMINOSIS-D ASSOCIATED WITH DRINKING MILK	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Vitamin D has been added to milk in the United States since the 1930s to prevent rickets. We report the unusual occurrence of eight cases of vitamin D intoxication that appear to have been caused by excessive vitamin D fortification of dairy milk. Methods. Medical records were reviewed and a dietary questionnaire was sent to eight patients who had unexplained hypervitaminosis D. Vitamin D analyses with high-performance liquid chromatography were performed on samples of the patients' serum, the dairy milk they drank, and the vitamin D concentrate added to the milk. Results. All eight patients drank milk produced by a local dairy in amounts ranging from 1/2 to 3 cups (118 to 710 ml) daily. All had elevated serum 25-hydroxyvitamin D concentrations (mean [+/- SD], 731 +/- 434 nmol per liter [293 +/- 174 ng per milliliter]). Six of the eight patients had elevated serum vitamin D3 concentrations. Of the eight patients, seven had hypercalcemia and one had hypercalciuria but normocalcemia (mean serum calcium, 3.14 +/- 0.51 mmol per liter [12.6 +/- 2.1 mg per deciliter]). Analysis of the dairy's vitamin D-fortified milk revealed concentrations of vitamin D3 (cholecalciferol) that ranged from undetectable to as high as 232,565 IU per quart (245,840 IU per liter). An analysis of the concentrate that was used to fortify the milk, labeled as containing vitamin D2 (ergocalciferol), revealed that it contained vitamin D3. Conclusions. Hypervitaminosis D may result from drinking milk that is incorrectly and excessively fortified with vitamin D. Milk that is fortified with vitamin D must be carefully monitored.	NORWOOD HOSP, DEPT MED, NORWOOD, MA USA; BETH ISRAEL HOSP, DIV ENDOCRINOL, BOSTON, MA 02215 USA; CHILDRENS HOSP MED CTR, DIV ENDOCRINOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV ENDOCRINOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BOSTON CITY HOSP, DIV ENDOCRINOL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston Medical Center; Boston University				Holm, Ingrid/0000-0003-4712-8821; Chen, Tai/0000-0002-5704-5694; Holick, Michael/0000-0001-6023-9062	NIAMS NIH HHS [AR-36963] Funding Source: Medline; NICHD NIH HHS [R01-HD244499-04] Funding Source: Medline; NIDDK NIH HHS [T32DK-07516] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007516] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CLEMENS TL, 1990, PRINCIPLES PRACTICE, P417; EISMAN JA, 1977, ANAL BIOCHEM, V80, P298, DOI 10.1016/0003-2697(77)90648-0; HADDAD JG, 1971, J CLIN ENDOCR METAB, V33, P992, DOI 10.1210/jcem-33-6-992; HAYNES R C JR, 1990, P1496; HOLBROOK TL, 1991, AM J CLIN NUTR, V53, P741, DOI 10.1093/ajcn/53.3.741; HOLICK MF, 1992, NEW ENGL J MED, V326, P1178, DOI 10.1056/NEJM199204303261802; Holick MF, 1986, CLIN NUTR, V5, P121; Holick MF, 1989, ENDOCRINOLOGY, P902; Jeans PC, 1938, J PEDIATR-US, V13, P730, DOI 10.1016/S0022-3476(38)80162-1; LIGHTWOOD R, 1952, P ROY SOC MED, V45, P401; Napoli JL, 1984, VITAMIN D BASIC CLIN, P91; STAMP TCB, 1980, CLIN ENDOCRINOL META, V9, P81, DOI 10.1016/S0300-595X(80)80022-3; 1986, ADDITION VITAMINS MI; 1989, GRADE A PASTEURIZED, P243; 1956, BMJ, V2, P149	15	166	171	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1173	1177		10.1056/NEJM199204303261801	http://dx.doi.org/10.1056/NEJM199204303261801			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1313547				2022-12-28	WOS:A1992HR00800001
J	HEINEMANN, SH; TERLAU, H; STUHMER, W; IMOTO, K; NUMA, S				HEINEMANN, SH; TERLAU, H; STUHMER, W; IMOTO, K; NUMA, S			CALCIUM-CHANNEL CHARACTERISTICS CONFERRED ON THE SODIUM-CHANNEL BY SINGLE MUTATIONS	NATURE			English	Article							FUNCTIONAL EXPRESSION; ION PERMEATION; TEA BLOCKADE; TETRODOTOXIN; SELECTIVITY; SAXITOXIN; BLOCKERS; RECEPTOR; MUSCLE; PROBES	THE sodium channel, one of the family of structurally homologous voltage-gated ion channels 1, differs from other members, such as the calcium and the potassium channels, in its high selectivity for Na+. This selectivity presumably reflects a distinct structure of its ion-conducting pore. We have recently identified two clusters of predominantly negatively charged amino-acid residues, located at equivalent positions in the four internal repeats of the sodium channel as the main determinants of sensitivity to the blockers tetrodotoxin and saxitoxin 2. All site-directed mutations reducing net negative charge at these positions also caused a marked decrease in single-channel conductance 2. Thus these two amino-acid clusters probably form part of the extracellular mouth and/or the pore wall of the sodium channel. We report here the effects on ion selectivity of replacing lysine at position 1,422 in repeat III and/or alanine at position 1,714 in repeat IV of rat sodium channel II (ref. 3), each located in one of the two clusters, by glutamic acid, which occurs at the equivalent positions in calcium channels. These amino-acid substitutions, unlike other substitutions in the adjacent regions, alter ion-selection properties of the sodium channel to resemble those of calcium channels. This result indicates that lysine 1,422 and alanine 1,714 are critical in determining the ion selectivity of the sodium channel, suggesting that these residues constitute part of the selectivity filter of the channel.	KYOTO UNIV, FAC MED,DEPT MED CHEM, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED,DEPT MOLEC GENET, KYOTO 606, JAPAN	Kyoto University; Kyoto University	HEINEMANN, SH (corresponding author), MAX PLANCK INST BIOPHYS CHEM, MEMBRANBIOPHYS ABT, W-3400 GOTTINGEN, GERMANY.		Stuehmer, Walter/A-2176-2009	Stuehmer, Walter/0000-0002-0642-7764; Imoto, Keiji/0000-0002-2861-5985; Heinemann, Stefan H./0000-0002-4144-0251				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KOSTYUK PG, 1983, J MEMBRANE BIOL, V76, P83, DOI 10.1007/BF01871455; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMA S, 1989, HARVEY LECT, V83, P121; PUSCH M, 1990, EUR BIOPHYS J BIOPHY, V18, P327; PUSCH M, 1991, EUR BIOPHYS J, V20, P127, DOI 10.1007/BF01561134; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SALKOFF L, 1987, SCIENCE, V237, P744, DOI 10.1126/science.2441469; STUHMER W, 1987, EUR BIOPHYS J BIOPHY, V14, P131, DOI 10.1007/BF00253837; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; WHITE MM, 1990, MOL PHARMACOL, V37, P720; YAMAMOTO D, 1984, BIOPHYS J, V45, P337, DOI 10.1016/S0006-3495(84)84159-4; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	32	630	650	0	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 2	1992	356	6368					441	443		10.1038/356441a0	http://dx.doi.org/10.1038/356441a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1313551				2022-12-28	WOS:A1992HL83000066
J	MATHEWS, LS; VALE, WW; KINTNER, CR				MATHEWS, LS; VALE, WW; KINTNER, CR			CLONING OF A 2ND TYPE OF ACTIVIN RECEPTOR AND FUNCTIONAL-CHARACTERIZATION IN XENOPUS EMBRYOS	SCIENCE			English	Article							MESODERM INDUCTION; HOMOLOG; LAEVIS	A complementary DNA coding for a second type of activin receptor (ActRIIB) has been cloned from Xenopus laevis that fulfills the structural criteria of a transmembrane protein serine kinase. Ectodermal explants from embryos injected with activin receptor RNA show increased sensitivity to activin, as measured by the induction of muscle actin RNA. In addition, injected embryos display developmental defects characterized by inappropriate formation of dorsal mesodermal tissue. These results demonstrate that this receptor is involved in signal transduction and are consistent with the proposed role of activin in the induction and patterning of mesoderm in Xenopus embryos.	SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037	Salk Institute; Salk Institute					NICHD NIH HHS [HD-13275, HD-07343] Funding Source: Medline; NIDDK NIH HHS [DK-26741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; CHO KWY, 1991, CELL, V65, P1; COOKE J, 1989, DEVELOPMENT, V107, P229; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; KINTNER CR, 1985, J EMBRYOL EXP MORPH, V89, P37; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KINTNER CR, UNPUB; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SYMES K, 1987, DEVELOPMENT, V101, P339; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; YU R, UNPUB	25	219	235	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1702	1705		10.1126/science.1313188	http://dx.doi.org/10.1126/science.1313188			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1313188				2022-12-28	WOS:A1992HK81200037
J	THIEMANN, A; GRUNDER, S; PUSCH, M; JENTSCH, TJ				THIEMANN, A; GRUNDER, S; PUSCH, M; JENTSCH, TJ			A CHLORIDE CHANNEL WIDELY EXPRESSED IN EPITHELIAL AND NONEPITHELIAL CELLS	NATURE			English	Article							CYSTIC-FIBROSIS; RECEPTOR SHOWS; LINE T84; CONDUCTANCE; TRANSPORT; CLONING; GENE; CAMP	CHLORIDE channels have several functions, including the regulation of cell volume 1,2 stabilizing membrane potential 3,4, signal transduction 5,6 and transepithelial transport 7. The plasma membrane Cl- channels already cloned belong to different structural classes: ligand-gated channels 5,6, voltage-gated channels 8,9, and possibly transporters of the ATP-binding-cassette type (if the cystic fibrosis transmembrane regulator 10 is a Cl- channel 11-13). The importance of chloride channels is illustrated by the phenotypes that can result from their malfunction: cystic fibrosis, in which transepithelial transport is impaired, and myotonia 3, in which ClC-1, the principal skeletal muscle Cl- channel, is defective 9. Here we report the properties of ClC-2, a new member of the voltage-gated Cl- channel family. Its sequence is approximately 50% identical to either the Torpedo electroplax Cl- channel, ClC-0 (ref. 8), or the rat muscle Cl- channel, ClC-1 (ref. 9). Isolated initially from rat heart and brain, it is also expressed in pancreas, lung and liver, for example, and in pure cell lines of fibroblastic, neuronal, and epithelial origin, including tissues and cells affected by cystic fibrosis. Expression in Xenopus oocytes induces Cl- currents that activate slowly upon hyperpolarization and display a linear instantaneous current-voltage relationship. The conductivity sequence is Cl- greater-than-or-equal-to Br- > I-. The presence of ClC-2 in such different cell types contrasts with the highly specialized expression of ClC-1 (ref. 9) and also with the cloned cation channels, and suggests that its function is important for most cells.	UNIV HAMBURG,ZMNH,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	University of Hamburg			Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883; Jentsch, Thomas/0000-0002-3509-2553; Pusch, Michael/0000-0002-8644-8847				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; Higuchi R., 1989, PCR TECHNOLOGY, P61; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MILLER C, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P383; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; STRANGE K, 1991, AM J PHYSIOL, V260, pF225, DOI 10.1152/ajprenal.1991.260.2.F225; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	33	529	539	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					57	60		10.1038/356057a0	http://dx.doi.org/10.1038/356057a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1311421				2022-12-28	WOS:A1992HG60200054
J	JESSELL, TM; MELTON, DA				JESSELL, TM; MELTON, DA			DIFFUSIBLE FACTORS IN VERTEBRATE EMBRYONIC INDUCTION	CELL			English	Review							TYPE-2 ASTROCYTE DEVELOPMENT; CILIARY NEUROTROPHIC FACTOR; FIBROBLAST GROWTH-FACTOR; RETINOIC ACID RECEPTOR; CHICK LIMB BUD; TYROSINE KINASE RECEPTOR; EARLY XENOPUS EMBRYOS; PROTO-ONCOGENE INT-1; ACTIVIN-A; W-LOCUS		HARVARD UNIV, DEPT BIOCHEM, CAMBRIDGE, MA 02138 USA	Harvard University	JESSELL, TM (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ALTABA ARI, 1991, DEVELOPMENT, V112, P945; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COOKE J, 1989, CIBA F SYMP, V144, P187; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EICHELE G, 1987, J CELL BIOL, V105, P1917, DOI 10.1083/jcb.105.4.1917; ELLINGERZIEGELBAUER H, 1991, GENE DEV, V5, P94, DOI 10.1101/gad.5.1.94; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODIN I, 1990, DEVELOPMENT, V108, P357; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GURDON JB, 1985, P NATL ACAD SCI USA, V82, P139, DOI 10.1073/pnas.82.1.139; GURDON JB, 1987, DEVELOPMENT, V99, P285; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JACOBSON AG, 1966, SCIENCE, V152, P25, DOI 10.1126/science.152.3718.25; JONES CM, 1991, DEVELOPMENT, V111, P531; JONES EA, 1989, DEVELOPMENT, V107, P785; KAMEGAI M, 1990, NEURON, V4, P429, DOI 10.1016/0896-6273(90)90055-K; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LILLIEN LE, 1990, J CELL BIOL, V111, P635, DOI 10.1083/jcb.111.2.635; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MORRIS HR, 1988, BIOCHEM J, V249, P903, DOI 10.1042/bj2490903; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; NAWA H, 1990, NEURON, V4, P269, DOI 10.1016/0896-6273(90)90101-K; NAWA H, 1991, J NEUROCHEM, V56, P2147, DOI 10.1111/j.1471-4159.1991.tb03479.x; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; NIEUWKOOP PD, 1989, DEV GROWTH DIFFER, V32, P149; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAO MS, 1990, NEURON, V5, P899, DOI 10.1016/0896-6273(90)90350-O; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SLACK JMW, 1989, DEVELOPMENT, V107, P141; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SLACK JMW, 1991, DEVELOPMENT, V113, P661; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH SM, 1991, DEVELOPMENT, V111, P245; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H., 1938, EMBRYONIC DEV INDUCT; SUMMERBELL D, 1983, LIMB DEV REGENERAT A, P109; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1991, DEVELOPMENT, P113; TRAYNOR D, 1991, J BIOL CHEM, V266, P5291; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; YAMAMORI T, 1991, P NATL ACAD SCI USA, V88, P7298, DOI 10.1073/pnas.88.16.7298; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	142	302	315	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					257	270		10.1016/0092-8674(92)90469-S	http://dx.doi.org/10.1016/0092-8674(92)90469-S			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310256				2022-12-28	WOS:A1992HB35300007
J	SHUAI, K; SCHINDLER, C; PREZIOSO, VR; DARNELL, JE				SHUAI, K; SCHINDLER, C; PREZIOSO, VR; DARNELL, JE			ACTIVATION OF TRANSCRIPTION BY IFN-GAMMA - TYROSINE PHOSPHORYLATION OF A 91-KD DNA-BINDING PROTEIN	SCIENCE			English	Article							ALPHA-STIMULATED TRANSCRIPTION; INTERFERON-ALPHA; CYTOPLASMIC ACTIVATION; RECONSTITUTED INVITRO; GEL-ELECTROPHORESIS; POSITIVE REGULATOR; ISGF3; GENE; KINASE	Interferon-gamma (IFN-gamma) induces the transcription of the gene encoding a guanylate binding protein by activating a latent cytoplasmic factor, GAF (gamma-activated factor). GAF is translocated to the nucleus and binds a DNA element, the gamma-activated site. Through cross-linking and the use of specific antibodies GAF was found to be a 91-kilodalton DNA binding protein that was previously identified as one of four proteins in interferon-stimulated gene factor-3 (ISGF-3), a transcription complex activated by IFN-alpha. The IFN-gamma-dependent activation of the 91-kilodalton DNA binding protein required cytoplasmic phosphorylation of the protein on tyrosine. The 113-kilodalton ISGF-3 protein that is phosphorylated in response to IFN-alpha was not phosphorylated nor translocated to the nucleus in response to IFN-gamma. Thus the two different ligands result in tyrosine phosphorylation of different combinations of latent cytoplasmic transcription factors that then act at different DNA binding sites.			SHUAI, K (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; EVANS RK, 1986, P NATL ACAD SCI USA, V83, P5382, DOI 10.1073/pnas.83.15.5382; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1992, P NATL ACAD SCI USA, V89, P7846; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HARPUR AG, 1992, ONCOGENE, V7, P1347; HOWARD OMZ, 1992, ONCOGENE, V7, P895; HUTNER T, 1992, CELL, V70, P375; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAN KA, UNPUB; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, UNPUB; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P31; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	27	708	730	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1808	1812		10.1126/science.1281555	http://dx.doi.org/10.1126/science.1281555			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1281555				2022-12-28	WOS:A1992KB96400043
J	DRICKAMER, K				DRICKAMER, K			ENGINEERING GALACTOSE-BINDING ACTIVITY INTO A C-TYPE MANNOSE-BINDING PROTEIN	NATURE			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; SITE; RAT; HOMOLOGY; LECTIN	CALCIUM-DEPENDENT or C-type carbohydrate-recognition domains are homologous protein modules found in a variety of animal lectins1. Selective binding of sugars by these domains is essential for glycoprotein clearance, cell-cell adhesion and pathogen neutralization. Although various C-type carbohydrate-recognition domains share sequence identity ranging from 20 to 55%, their sugar-binding characteristics vary widely. The structure of a mannose-binding carbohydrate-recognition domain in complex with a saccharide ligand suggests that two glutamic acid-asparagine pairs are essential determinants of ligand binding by this domain2. In C-type lectins that bind galactose with higher affinity than mannose, one of these pairs is replaced by glutamine-aspartic acid. Here we shift the sequence of the mannose-binding protein to correspond to that found in galactose-binding domains in order to test the importance of these residues in sugar-binding selectivity. This simple switch in the position of a single amide group alters the binding activity of the domain so that galactose becomes the preferred ligand.			DRICKAMER, K (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.							BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1991, J BIOL CHEM, V266, P4810; Maniatis T., 1982, MOL CLONING; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; SIKDER SK, 1983, J BIOL CHEM, V258, P2520; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	18	443	467	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					183	186		10.1038/360183a0	http://dx.doi.org/10.1038/360183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1279438				2022-12-28	WOS:A1992JX75200068
J	LEAHY, DJ; HENDRICKSON, WA; AUKHIL, I; ERICKSON, HP				LEAHY, DJ; HENDRICKSON, WA; AUKHIL, I; ERICKSON, HP			STRUCTURE OF A FIBRONECTIN TYPE-III DOMAIN FROM TENASCIN PHASED BY MAD ANALYSIS OF THE SELENOMETHIONYL PROTEIN	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; CRYSTALLOGRAPHIC REFINEMENT; HEXABRACHION TENASCIN; ANOMALOUS DIFFRACTION; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; CELL ATTACHMENT; HUMAN CD4; RESOLUTION; FRAGMENTS	Fibronectin type III domains are found in many different proteins including cell surface receptors and cell adhesion molecules. The crystal structure of one such domain from the extracellular matrix protein tenascin was determined. The structure was solved by multiwavelength anomalous diffraction (MAD) phasing of the selenomethionyl protein and has been refined to 1.8 angstrom resolution. The folding topology of this domain is identical to that of the extracellular domains of the human growth hormone receptor, the second domain of CD4, and PapD. Although distinct, this topology is similar to that of immunoglobulin constant domains. An Arg-Gly-Asp (RGD) sequence that can function for cell adhesion is found in a tight turn on an exposed loop.	UNIV N CAROLINA, SCH DENT, DEPT PERIODONT, CHAPEL HILL, NC 27514 USA; DUKE UNIV, SCH MED, DEPT CELL BIOL, DURHAM, NC 27706 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University	LEAHY, DJ (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.				NCI NIH HHS [CA-47056] Funding Source: Medline; NIDCR NIH HHS [DE-07801] Funding Source: Medline; NIGMS NIH HHS [GM-34102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034102, R37GM034102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AUKHIL I, UNPUB; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOURDON MA, 1989, J CELL BIOL, V108, P1149, DOI 10.1083/jcb.108.3.1149; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CROMER DT, 1970, J CHEM PHYS, V53, P1891, DOI 10.1063/1.1674266; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FRIEDLANDER DR, 1988, J CELL BIOL, V107, P2329, DOI 10.1083/jcb.107.6.2329; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1975, P NATL ACAD SCI USA, V72, P2160, DOI 10.1073/pnas.72.6.2160; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JOSHI P, 1991, UNPUB J CELL BIOL, V115, pA134; LIGHTNER VA, 1990, J CELL SCI, V95, P263; NIES DE, 1991, J BIOL CHEM, V266, P2818; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	33	479	509	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 6	1992	258	5084					987	991		10.1126/science.1279805	http://dx.doi.org/10.1126/science.1279805			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1279805				2022-12-28	WOS:A1992JW79600033
J	LIAO, YL; COOPER, RS; GHALI, JK; SZOCKA, A				LIAO, YL; COOPER, RS; GHALI, JK; SZOCKA, A			SURVIVAL RATES WITH CORONARY-ARTERY DISEASE FOR BLACK-WOMEN COMPARED WITH BLACK-MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; LONG-TERM SURVIVAL; HEART-DISEASE; OPERATIVE MORTALITY; FOLLOW-UP; BYPASS; SURGERY; CASS; PROGNOSIS; WHITE	Objective.-To evaluate the influence of gender on the prognosis of coronary heart disease among black patients. Design.-Cohort study based on a consecutive sample from a hospital registry, with a mean follow-up of 4 years. Setting.-An inner-city public hospital in Chicago, III. Patients.-The study included 1719 consecutive black patients (780 men and 939 women) who had any one of the following events: cardiac catheterization for presumed coronary heart disease, hospitalization for acute myocardial infarction, or coronary artery bypass grafting. Results.-Hospital and operative mortality rates following acute myocardial infarction and coronary artery bypass grafting were similar between the two sexes. The relative risks for cardiac death in women vs men were 0.88 (95% confidence interval [CI], 0.60 to 1.28), 0.79 (95% CI, 0.53 to 1.17), and 0.79 (95% CI, 0.34 to 1.85) for coronary artery disease, acute myocardial infarction, and coronary artery bypass grafting, respectively, after adjusting for age, history of diabetes, hypertension, angina pectoris and myocardial infarction, number of diseased vessels, and ejection fraction. Compared with patients of the same sex with normal angiograms, relative risk estimates were 5.0, 10.1, and 6.3 for women and were 1.8, 4.0, and 2.0 for men in the same three groups of patients, respectively. Conclusions.-Survival with coronary artery disease in black women is similar to that observed in black men, but relative to members of the same sex without the disease, the prognosis for women is considerably worse than for men.			LIAO, YL (corresponding author), LOYOLA UNIV,MED CTR,DEPT PREVENT MED & EPIDEMIOL,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.				NHLBI NIH HHS [R01HL36723] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GARDNER TJ, 1985, ANN SURG, V201, P780, DOI 10.1097/00000658-198506000-00016; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; HALL RJ, 1983, CIRCULATION, V68, P20; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; Henning R, 1981, Eur Heart J, V2, P65; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; KANNEL WB, 1987, CORONARY HEART DISEA, P208; KENNEDY JW, 1981, CIRCULATION, V63, P793, DOI 10.1161/01.CIR.63.4.793; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KILLEN DA, 1982, ANN THORAC SURG, V34, P559, DOI 10.1016/S0003-4975(10)63003-2; LACROIX AZ, 1989, AM J EPIDEMIOL, V129, P669, DOI 10.1093/oxfordjournals.aje.a115183; LAIRDMEETER K, 1984, EUR HEART J, V5, P35, DOI 10.1093/oxfordjournals.eurheartj.a061549; LANGFORD HG, 1984, AM HEART J, V108, P797, DOI 10.1016/0002-8703(84)90674-4; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MACMAHON B, 1983, AM J PUBLIC HEALTH, V73, P1247, DOI 10.2105/AJPH.73.11.1247; MAYNARD C, 1987, AM J CARDIOL, V60, P513, DOI 10.1016/0002-9149(87)90296-7; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MAYNARD C, 1986, CIRCULATION, V74, P64, DOI 10.1161/01.CIR.74.1.64; OBERMAN A, 1984, AM HEART J, V108, P688, DOI 10.1016/0002-8703(84)90656-2; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; SANDLER H, 1968, AM HEART J, V75, P325, DOI 10.1016/0002-8703(68)90089-6; SIMMONS BE, 1987, AM J CARDIOL, V59, P547, DOI 10.1016/0002-9149(87)91167-2; THOM TJ, 1987, CORONARY HEART DISEA, P33; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; 1988, SAS P179 SAS I INC T, P49	33	31	31	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1867	1871		10.1001/jama.268.14.1867	http://dx.doi.org/10.1001/jama.268.14.1867			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JR439	1285782				2022-12-28	WOS:A1992JR43900034
J	WEISNER, C; SCHMIDT, L				WEISNER, C; SCHMIDT, L			GENDER DISPARITIES IN TREATMENT FOR ALCOHOL-PROBLEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN; DEPENDENCE; PREVALENCE; HEALTH	Objective.-To examine women's access to treatment for alcohol problems in terms of the prevalence, characteristics, and treatment-seeking patterns of problem drinkers in a range of alcohol-specific and nonspecialized health care systems. Design.-In-person survey. Setting.-A Northern California county. Participants.-Consecutive samples of admissions in public alcohol treatment (n=381), drug treatment (n=210), mental health treatment (n=406), emergency health services (n=2626), primary health clinics (n=394), and adults in the county general population (n=3069). Primary Outcome Measures.-Prevalence and relative risk (RR) of problem drinking and rates of alcohol-related treatment episodes. Results.-Rates of problem drinking were higher among men than women across all samples. However, after accounting for gender differences in general population rates, women in all of the non-alcohol-specific clinical samples were at greater risk than men for problem drinking (eg, RR=5.6 for women and RR=2.1 for men in the mental health sample). Men reported a greater variety in types of services sought in past alcohol-related treatment encounters, but women experienced greater symptom severity. Conclusions.-Female problem drinkers were more likely than male problem drinkers to use non-alcohol-specific health care settings, particularly mental health treatment services, and to report greater symptom severity. Future research on women's access to services for alcohol problems should consider a range of health care systems and gender differences in seeking help.	UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT SOCIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley	WEISNER, C (corresponding author), ALCOHOL RES GRP,2000 HEARST AVE,BERKELEY,CA 94709, USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P30AA005595, P50AA005595] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-05595] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ARMITAGE P, 1971, STATISTICAL METHODS; Baily S, 1990, Drug Alcohol Rev, V9, P125, DOI 10.1080/09595239000185181; BECKMAN LJ, 1986, J STUD ALCOHOL, V47, P135, DOI 10.15288/jsa.1986.47.135; BLUME SB, 1986, JAMA-J AM MED ASSOC, V256, P1467; BLUME SB, 1982, ALCOHOLISM CLIN PSYC, pCH13; CAETANO R, 1990, ALCOHOL ALCOHOLISM, V25, P303, DOI 10.1093/oxfordjournals.alcalc.a045004; CAETANO R, 1988, STUDY DIMENSIONS DEP; CELENTANO DD, 1980, J CHRON DIS, V33, P383, DOI 10.1016/0021-9681(80)90048-X; Cherpitel C, 1989, DRINKING CASUALTIES, P288; CHERPITEL CS, 1989, PRIMARY CARE STUDY; CHERPITEL CS, 1991, ALCOHOL ALCOHOLISM, V5, P627; Clark WB, 1982, ALCOHOL CONSUMPTION, P3; Clark WB, 1991, ALCOHOL AM DRINKING; CURLEE J, 1970, J PSYCHOL, V74, P239, DOI 10.1080/00223980.1970.9923735; FERRENCE RG, 1980, SERVICES ALCOHOLICS; FERRENCE RG, 1980, RES ADV ALCOHOL DRUG, V5, P69; Fillmore K.M., 1984, ALCOHOL PROBLEMS WOM, P7; FURST C, 1981, UTILIZATION ALCOHOL; GLASS IB, 1988, BRIT J ADDICT, V83, P1105; GOMBERG E, 1974, WOMEN THERAPY, pCH7; HILTON M, 1991, ALCOHOL AM DRINKING, P256; HORN JL, 1970, Q J STUD ALCOHOL, V31, P40; Jones K R, 1979, Med Care, V17, P1; MARSH JC, 1982, J SOC ISSUES, V38, P1, DOI 10.1111/j.1540-4560.1982.tb00114.x; MCINTOSH ID, 1982, INT J ADDICT, V17, P609, DOI 10.3109/10826088209053007; MECHANIC D, 1979, J HEALTH SOC BEHAV, V20, P387, DOI 10.2307/2955413; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; REED BG, 1987, J PSYCHOACTIVE DRUGS, V19, P151, DOI 10.1080/02791072.1987.10472399; RODIN J, 1990, AM PSYCHOL, V45, P1018, DOI 10.1037/0003-066X.45.9.1018; ROMAN PM, 1988, ADM881574US DEP HLTH; ROOM R, 1988, 14TH ANN ALC EP S BE; RUSH B, 1983, CAN J PUBLIC HEALTH, V74, P270; SANDMAIER M, 1980, INVISIBLE ALCOHOLICS; SCHMIDT L, 1992, HOSP COMMUNITY PSYCH, V43, P245; SCHMIDT L, 1988, COSTA COUNTRY MENTAL; SCHUCKIT M A, 1979, American Journal of Psychiatry, V136, P611; STEPHENS C, 1987, COSTA COUNTY 4 HOSPI; THOM B, 1986, BRIT J ADDICT, V81, P777; Weisner C, 1987, Recent Dev Alcohol, V5, P203; WEISNER C, IN PRESS AM J DRUG A; WEISNER C, IN PRESS J STUD ALCO; WEISNER C, 1988, COMMUNITY RESPONSE S; WILSNACK SC, 1991, AM J PUBLIC HEALTH, V81, P305, DOI 10.2105/AJPH.81.3.305; ZUNG BJ, 1982, PSYCHIAT FORUM, V11, P32; 1990, HIGHLIGHTS 1989 NATI; 1990, BROADENING BASE ALCO, P23; 1991, C ASSESSING FUTURE R	47	233	234	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1872	1876		10.1001/jama.268.14.1872	http://dx.doi.org/10.1001/jama.268.14.1872			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JR439	1328695				2022-12-28	WOS:A1992JR43900035
J	FARCI, P; ALTER, HJ; GOVINDARAJAN, S; WONG, DC; ENGLE, R; LESNIEWSKI, RR; MUSHAHWAR, IK; DESAI, SM; MILLER, RH; OGATA, N; PURCELL, RH				FARCI, P; ALTER, HJ; GOVINDARAJAN, S; WONG, DC; ENGLE, R; LESNIEWSKI, RR; MUSHAHWAR, IK; DESAI, SM; MILLER, RH; OGATA, N; PURCELL, RH			LACK OF PROTECTIVE IMMUNITY AGAINST REINFECTION WITH HEPATITIS-C VIRUS	SCIENCE			English	Article							NON-B-HEPATITIS; EXPERIMENTALLY INFECTED CHIMPANZEES; TRANSFUSION-ASSOCIATED HEPATITIS; NON-A-HEPATITIS; VIRAL-HEPATITIS; ENVELOPE PROTEIN; LONG-TERM; POSTTRANSFUSION HEPATITIS; CROSS-CHALLENGE; HUMAN CARRIERS	Some individuals infected with hepatitis C virus (HCV) experience multiple episodes of acute hepatitis. It is unclear whether these episodes are due to reinfection with HCV or to reactivation of the original virus infection. Markers of viral replication and host immunity were studied in five chimpanzees sequentially inoculated over a period of 3 years with different HCV strains of proven infectivity. Each rechallenge of a convalescent chimpanzee with the same or a different HCV strain resulted in the reappearance of viremia, which was due to infection with the subsequent challenge virus. The evidence indicates that HCV infection does not elicit protective immunity against reinfection with homologous or heterologous strains, which raises concerns for the development of effective vaccines against HCV.	NIH,WARREN G MARGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892; RANCHO LOS AMIGOS MED CTR,DOWNEY,CA 90242; GEORGETOWN UNIV,DEPT MICROBIOL,DIV MOLEC VIROL & IMMUNOL,ROCKVILLE,MD 20852; ABBOTT LABS,EXPTL BIOL RES,N CHICAGO,IL 60064	National Institutes of Health (NIH) - USA; Georgetown University; Abbott Laboratories	FARCI, P (corresponding author), NIAID,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BETHESDA,MD 20892, USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; Aach RD, 1978, VIRAL HEPATITIS, P383; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1978, LANCET, V1, P459; Alter HJ, 1978, VIRAL HEPATITIS, P359; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BENN S, 1985, SCIENCE, V230, P949, DOI 10.1126/science.2997922; BRADLEY DW, 1980, J MED VIROL, V6, P185, DOI 10.1002/jmv.1890060302; BRADLEY DW, 1979, J MED VIROL, V3, P253, DOI 10.1002/jmv.1890030403; BRADLEY DW, 1981, J INFECT DIS, V143, P210, DOI 10.1093/infdis/143.2.210; BROTMAN B, 1985, J INFECT DIS, V151, P618, DOI 10.1093/infdis/151.4.618; BURK KH, 1984, HEPATOLOGY, V4, P808, DOI 10.1002/hep.1840040502; BUUKH J, 1992, P NATL ACAD SCI USA, V89, P187; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CRASKE J, 1978, LANCET, V2, P1051; DIENES HP, 1990, J HEPATOL, V10, P77, DOI 10.1016/0168-8278(90)90076-4; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; Eder G, 1988, VIRAL HEPATITIS LIVE, P550; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FARCI P, 1992, J INFECT DIS, V165, P1006, DOI 10.1093/infdis/165.6.1006; FARCI P, UNPUB; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; GALBRAITH RM, 1979, LANCET, V1, P951; GOVINDARAJAN S, UNPUB; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HIJIKATA M, 1991, BIOCHEM BIOPH RES CO, V175, P220, DOI 10.1016/S0006-291X(05)81223-9; HIJIKATA M, 1990, JPN J CANCER RES, V81, P1195, DOI 10.1111/j.1349-7006.1990.tb02676.x; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; HOLLINGER FB, 1980, J INFECT DIS, V142, P400, DOI 10.1093/infdis/142.3.400; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; HRUBY MA, 1978, JAMA-J AM MED ASSOC, V240, P1355; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KNODELL RG, 1976, LANCET, V1, P557; KORETZ RL, 1985, GASTROENTEROLOGY, V88, P1251, DOI 10.1016/S0016-5085(85)80087-1; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; MOSLEY JW, 1977, NEW ENGL J MED, V296, P75, DOI 10.1056/NEJM197701132960204; NORKRANS G, 1980, JAMA-J AM MED ASSOC, V243, P1056, DOI 10.1001/jama.243.10.1056; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; PRINCE AM, 1992, J INFECT DIS, V165, P438, DOI 10.1093/infdis/165.3.438; PURCELL RH, 1985, HEPATOLOGY, V5, P1091, DOI 10.1002/hep.1840050606; REALDI G, 1982, GUT, V23, P270, DOI 10.1136/gut.23.4.270; RIZZETTO M, 1986, PROG LIVER DIS, V8, P417; SEEFF LB, 1978, VIRAL HEPATITIS, P371; SHIMIZU YK, 1990, P NATL ACAD SCI USA, V87, P6441, DOI 10.1073/pnas.87.16.6441; TABOR E, 1984, TRANSFUSION, V24, P224, DOI 10.1046/j.1537-2995.1984.24384225027.x; TAEBOR E, 1979, J INFECT DIS, V140, P789; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TAKEUCHI K, 1990, GENE, V91, P287, DOI 10.1016/0378-1119(90)90102-W; TAKEUCHI K, 1990, J GEN VIROL, V71, P3027, DOI 10.1099/0022-1317-71-12-3027; TSIQUAYE KN, 1979, LANCET, V1, P1135; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YOSHIZAWA H, 1981, GASTROENTEROLOGY, V81, P107; 883109225	64	663	705	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					135	140		10.1126/science.1279801	http://dx.doi.org/10.1126/science.1279801			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1279801				2022-12-28	WOS:A1992JQ61900036
J	NAKAMURA, Y; KOMATSU, N; NAKAUCHI, H				NAKAMURA, Y; KOMATSU, N; NAKAUCHI, H			A TRUNCATED ERYTHROPOIETIN RECEPTOR THAT FAILS TO PREVENT PROGRAMMED CELL-DEATH OF ERYTHROID-CELLS	SCIENCE			English	Article							BONE-MARROW; CLONING; EXPRESSION; GENE; MEGAKARYOCYTES; ESTABLISHMENT; GROWTH; LINE; RAT	A form of the human erythropoietin receptor (EPOR) was identified in which the cytoplasmic region is truncated by alternative splicing. The truncated form of the receptor (EPOR-T) is the most prevalent form of EPOR in early-stage erythroid progenitor cells, but the full-length EPOR (EPOR-F) becomes the most prevalent form in late-stage progenitors. EPOR-T can transduce a mitogenic signal. However, cells transfected with EPOR-T are more prone to programmed cell death than those expressing EPOR-F. EPOR-F may transduce a signal to prevent programmed cell death that is independent of the mitogenic signal, and alternative splicing of the EPOR gene may have an important role in erythropoiesis.	INST PHYS & CHEM RES RIKEN, TSUKUBA LIFE SCI CTR, CELL GROWTH & DIFFERENTIAT LAB, 3-1-1 KOYADAI, TSUKUBA, JAPAN	RIKEN			Nakamura, Yukio/A-5263-2016	Nakamura, Yukio/0000-0001-8056-4946				BERRIDGE MV, 1988, BLOOD, V72, P970; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FERNANDEZBOTRAN R, 1991, J EXP MED, V174, P673, DOI 10.1084/jem.174.3.673; FRASER JK, 1989, EXP HEMATOL, V17, P10; GREGORY CJ, 1976, J CELL PHYSIOL, V89, P289, DOI 10.1002/jcp.1040890212; HEATH DS, 1976, BLOOD, V47, P777; JONES SS, 1990, BLOOD, V76, P31; KOMATSU N, 1991, CANCER RES, V51, P341; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LANDSCHULZ KT, 1989, BLOOD, V73, P1476; LOKEN MR, 1987, BLOOD, V69, P255; MAOUCHE L, 1991, BLOOD, V78, P2557; NOGUCHI CT, 1991, BLOOD, V78, P2548; OKUNO Y, 1990, CANCER, V66, P1544, DOI 10.1002/1097-0142(19901001)66:7<1544::AID-CNCR2820660719>3.0.CO;2-9; PARACIOS R, 1985, CELL, V41, P727; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WINKELMANN JC, 1990, BLOOD, V76, P24; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; [No title captured]	21	161	166	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1992	257	5073					1138	1141		10.1126/science.257.5073.1138	http://dx.doi.org/10.1126/science.257.5073.1138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1324524				2022-12-28	WOS:A1992JJ88400039
J	KYRIAKIS, JM; APP, H; ZHANG, XF; BANERJEE, P; BRAUTIGAN, DL; RAPP, UR; AVRUCH, J				KYRIAKIS, JM; APP, H; ZHANG, XF; BANERJEE, P; BRAUTIGAN, DL; RAPP, UR; AVRUCH, J			RAF-1 ACTIVATES MAP KINASE-KINASE	NATURE			English	Article							THREONINE PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; T-CELL ACTIVATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INSULIN; PATHWAYS; CASCADE	THE normal cellular homologue of the acutely transforming oncogene v-raf is c-raf-1, which encodes a serine/threonine protein kinase that is activated by many extracellular stimuli1. The physiological substrates of the protein c-Raf-1 are unknown. The mitogen-activated protein (MAP) kinases Erk1 and 2 are also activated by mitogens through phosphorylation of Erk tyrosine and threonine residues catalysed by a protein kinase of relative molecular mass 50,000, MAP kinase-kinase (MAPK-K)2-7. Here we report that MAPK-K as well as Erk1 and 2 are constitutively active in v-raf-transformed cells. MAPK-K partially purified from v-raf-transformed cells or from mitogen-treated cells3 can be deactivated by phosphatase 2A. c-Raf-1 purified after mitogen stimulation can reactivate the phosphatase 2A-inactivated MAPK-K over 30-fold in vitro. c-Raf-1 reactivation of MAPK-K coincides with the selective phosphorylation at serine/threonine residues of a polypeptide with M(r) 50,000 which coelutes precisely on cation-exchange chromatography with the MAPK-K activatable by c-Raf-1. These results indicate that c-Raf-1 is an immediate upstream activator of MAPK-K in vivo. To our knowledge, MAPK-K is the first physiological substrate of the c-raf-1 protooncogene product to be identified.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Brown University	KYRIAKIS, JM (corresponding author), MASSACHUSETTS GEN HOSP,MED SERV,DIABET UNIT,149 13TH ST,BOSTON,MA 02129, USA.							AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALLEMAIN GL, 1992, MOL CELL BIOL, V12, P2222; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GROVE JR, 1987, SCIENCE, V238, P530; HSI ED, 1989, J BIOL CHEM, V264, P10836; JONES SW, 1989, J BIOL CHEM, V264, P7747; KYRIAKIS JM, 1990, BIOCHIM BIOPHYS ACTA, V1054, P73, DOI 10.1016/0167-4889(90)90207-T; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKEDA M, 1988, J BIOL CHEM, V258, P10455; TROPPMAIR J, IN PRESS ONCOGENE	26	1189	1208	0	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					417	421		10.1038/358417a0	http://dx.doi.org/10.1038/358417a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1322500				2022-12-28	WOS:A1992JF85300057
J	HINGORANI, AD; DOLLERY, CT; OAKLEY, CM; BLOOM, SR; COHEN, J				HINGORANI, AD; DOLLERY, CT; OAKLEY, CM; BLOOM, SR; COHEN, J			HAMMERSMITH STAFF ROUNDS - POSTINFECTIOUS MYOCARDITIS	BRITISH MEDICAL JOURNAL			English	Discussion							ENDOMYOCARDIAL BIOPSY; CARDIOMYOPATHY				HINGORANI, AD (corresponding author), HAMMERSMITH HOSP,DEPT MED,LONDON W12 0HS,ENGLAND.			Hingorani, Aroon/0000-0001-8365-0081				Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; CHOW LC, 1988, ANN INTERN MED, V109, P535, DOI 10.7326/0003-4819-109-7-535; DEE GW, 1985, NEW ENGL J MED, V312, P885; ELHAGRASSY MMO, 1980, LANCET, V1, P1160; FENOGLIO JJ, 1983, NEW ENGL J MED, V308, P12, DOI 10.1056/NEJM198301063080103; JIN O, 1990, CIRCULATION, V82, P8, DOI 10.1161/01.CIR.82.1.8; MASON JW, 1980, AM J CARDIOL, V45, P1037, DOI 10.1016/0002-9149(80)90174-5; MONTAGUE T, 1990, CHEST, V1, P190; NIPPOLDT TB, 1982, MAYO CLIN PROC, V57, P407; OAKLEY CM, 1988, OXFORD TSB MED; PARILLO JE, 1984, CIRCULATION, V69, P93; PETERS NS, 1991, J ROY SOC MED, V84, P1; REMES J, 1990, EUR HEART J, V11, P182, DOI 10.1093/oxfordjournals.eurheartj.a059675; Saphir O, 1941, ARCH PATHOL, V32, P1000; SHANES JG, 1987, CIRCULATION, V75, P401, DOI 10.1161/01.CIR.75.2.401; ZEECHENG CS, 1984, J AM COLL CARDIOL, V3, P63, DOI 10.1016/S0735-1097(84)80431-3	16	3	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1676	1678		10.1136/bmj.304.6843.1676	http://dx.doi.org/10.1136/bmj.304.6843.1676			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1321685	Bronze, Green Published			2022-12-28	WOS:A1992JB93900027
J	BURNASHEV, N; KHODOROVA, A; JONAS, P; HELM, PJ; WISDEN, W; MONYER, H; SEEBURG, PH; SAKMANN, B				BURNASHEV, N; KHODOROVA, A; JONAS, P; HELM, PJ; WISDEN, W; MONYER, H; SEEBURG, PH; SAKMANN, B			CALCIUM-PERMEABLE AMPA-KAINATE RECEPTORS IN FUSIFORM CEREBELLAR GLIAL-CELLS	SCIENCE			English	Article							FUNCTIONAL EXPRESSION; GLUTAMATE; ASTROCYTES; CHANNELS; CULTURES; MORPHOLOGY; <H-3>GABA; CLONING; FAMILY	Glutamate-operated ion channels (GluR channels) of the L-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-kainate subtype are found in both neurons and glial cells of the central nervous system. These channels are assembled from the GluR-A, -B, -C, and -D subunits; channels containing a GluR-B subunit show an outwardly rectifying current-voltage relation and low calcium permeability, whereas channels lacking the GluR-B subunit are characterized by a doubly rectifying current-voltage relation and high calcium permeability. Most cell types in the central nervous system coexpress several subunits, including GluR-B. However, Bergmann glia in rat cerebellum do not express GluR-B subunit genes. In a subset of cultured cerebellar glial cells, likely derived from Bergmann glial cells, GluR channels exhibit doubly rectifying current-voltage relations and high calcium permeability, whereas GluR channels of cerebellar neurons have low calcium permeability. Thus, differential expression of the GluR-B subunit gene in neurons and glia is one mechanism by which functional properties of native GluR channels are regulated.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY; ALL UNION BIOTECHNOL RES INST, MOSCOW 117246, USSR; UNIV HEIDELBERG, CTR MOLEC BIOL, W-6900 HEIDELBERG, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg			Wisden, William/A-4071-2011; Burnashev, Nail/G-4056-2013	Wisden, William/0000-0003-4743-0334; Monyer, Hannah/0000-0002-9332-5749; Jonas, Peter/0000-0001-5001-4804				BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; GRANDES P, 1991, EUR J NEUROSCI, V3, P1370, DOI 10.1111/j.1460-9568.1991.tb00070.x; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JOHNSTONE SR, 1986, DEV BRAIN RES, V24, P63, DOI 10.1016/0165-3806(86)90173-2; JONAS P, IN PRESS J PHYSL LON; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LEVI G, 1983, DEV BRAIN RES, V10, P227, DOI 10.1016/0165-3806(83)90139-6; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; ORTEGA A, 1991, NEUROSCIENCE, V41, P335, DOI 10.1016/0306-4522(91)90331-H; OZAWA S, 1991, J NEUROPHYSIOL, V66, P2, DOI 10.1152/jn.1991.66.1.2; RAFF MC, 1983, J NEUROSCI, V3, P1289; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SOMOGYI P, 1990, NEUROSCIENCE, V35, P9, DOI 10.1016/0306-4522(90)90116-L; SONTHEIMER H, 1988, GLIA, V1, P328, DOI 10.1002/glia.440010505; TEICHBERG VI, 1991, FASEB J, V5, P3086, DOI 10.1096/fasebj.5.15.1660422; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; WYLLIE DJA, 1992, J PHYSIOL-LONDON, V446, pP598	27	383	386	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1992	256	5063					1566	1570		10.1126/science.1317970	http://dx.doi.org/10.1126/science.1317970			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317970				2022-12-28	WOS:A1992HY07500032
J	PAULMICHL, M; LI, Y; WICKMAN, K; ACKERMAN, M; PERALTA, E; CLAPHAM, D				PAULMICHL, M; LI, Y; WICKMAN, K; ACKERMAN, M; PERALTA, E; CLAPHAM, D			NEW MAMMALIAN CHLORIDE CHANNEL IDENTIFIED BY EXPRESSION CLONING	NATURE			English	Article							CANINE KIDNEY-CELLS; CYSTIC-FIBROSIS; XENOPUS OOCYTES; ION CHANNELS; CONDUCTANCE; MEMBRANE; PROTEINS; DISEASE; VOLUME	ION channels selectively permeable to chloride ions regulate cell functions as diverse as excitability and control of cell volume 1-5. Using expression cloning techniques, a complementary DNA from an epithelial cell line has been isolated, sequenced and its putative structure examined by site-directed mutagenesis. This cDNA, encoding a 235-amino-acid protein, gave rise to a chloride-selective outward current when expressed in Xenopus oocytes. The expressed, outwardly rectifying chloride current was calcium-insensitive and was blocked by nucleotides applied to the cell surface. Mutation of a putative nucleotide-binding site resulted in loss of nucleotide block but incurred dependence on extracellular calcium concentration. The unusual sequence of this putative channel protein suggests a new class of ion channels not related to other previously cloned chloride channels 6-11.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,BOSTON,MA 02115	Mayo Clinic; Harvard University			Clapham, David/R-5974-2019	Wickman, Kevin/0000-0002-5179-9540; Clapham, David/0000-0002-4459-9428				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; GUY HR, 1985, BIOPHYS J, V47, P61, DOI 10.1016/S0006-3495(85)83877-7; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; Hille B, 1984, IONIC CHANNELS EXCIT; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KOLB HA, 1985, PFLUG ARCH EUR J PHY, V403, P262, DOI 10.1007/BF00583597; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANG F, 1986, PFLUG ARCH EUR J PHY, V407, P158, DOI 10.1007/BF00580668; Lang F., 1990, Comparative Physiology, V4, P1; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; Maniatis T., 1982, MOL CLONING; PAULMICHL M, 1989, PFLUG ARCH EUR J PHY, V413, P456, DOI 10.1007/BF00594173; PAULMICHL M, 1988, FEBS LETT, V234, P263, DOI 10.1016/0014-5793(88)80094-2; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SOLC CK, 1991, AM J PHYSIOL, V261, P658; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WANGEMANN P, 1986, PFLUGERS ARCH, V407, pS141; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	30	335	348	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					238	241		10.1038/356238a0	http://dx.doi.org/10.1038/356238a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1313151				2022-12-28	WOS:A1992HJ94400057
J	SIMON, MN; PELEGRINI, O; VERON, M; KAY, RR				SIMON, MN; PELEGRINI, O; VERON, M; KAY, RR			MUTATION OF PROTEIN KINASE-A CAUSES HETEROCHRONIC DEVELOPMENT OF DICTYOSTELIUM	NATURE			English	Article							AMINO-ACID-SEQUENCE; REGULATORY SUBUNIT; CYCLIC-AMP; CAENORHABDITIS-ELEGANS; CELL-DIFFERENTIATION; SIGNAL TRANSDUCTION; DISCOIDEUM; REQUIREMENTS; MUTANTS; FORMS	IN heterochronic mutants the relative timing of developmental events is altered compared with the wild type. This generally results in a disordered embryo 1,2, though heterochronic mutations may also be an important source of evolutionary variation 3. In the rapidly developing (rde) mutants of Dictyostelium, stalk and spore cells differentiate before morphogenesis is complete. We have traced the lesion in one class of these mutants to the regulatory subunit of cyclic AMP-dependent protein kinase (pk-A). Inactivation of this protein results in the unrestrained activity of the catalytic subunit, so prematurely triggering terminal cell differentiation.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	SIMON, MN (corresponding author), INST PASTEUR,UNITE BIOCHIM CELLULAIRE,CNRS,URA 1129,F-75724 PARIS 15,FRANCE.			Kay, Robert R/0000-0001-9836-7967				ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; BONNER JT, 1982, AM NAT, V119, P530, DOI 10.1086/283930; DEGUNZBURG J, 1982, EMBO J, V1, P1063, DOI 10.1002/j.1460-2075.1982.tb01297.x; DEGUNZBURG J, 1984, BIOCHEMISTRY-US, V23, P3805, DOI 10.1021/bi00312a003; DEVREOTES PN, 1979, J CELL BIOL, V80, P300, DOI 10.1083/jcb.80.2.300; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; INNIS MA, 1990, PCR PROTOCOLS; KAY RR, 1989, DEVELOPMENT, V105, P753; KESSIN RH, 1977, CELL, V10, P703, DOI 10.1016/0092-8674(77)90104-0; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KURET J, 1988, J BIOL CHEM, V263, P9149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERKLE RK, 1984, CELL DIFFER DEV, V14, P257, DOI 10.1016/0045-6039(84)90014-9; MUTZEL R, 1988, BIOCHEMISTRY-US, V27, P481, DOI 10.1021/bi00401a069; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; NEWELL PC, 1988, J CELL SCI, V89, P123; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; REYMOND CD, 1987, NUCLEIC ACIDS RES, V15, P8118, DOI 10.1093/nar/15.19.8118; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; SONNEBORN DR, 1963, DEV BIOL, V7, P79, DOI 10.1016/0012-1606(63)90108-8; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAYLOR SS, 1990, REV BIOCH, V59, P971; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0	27	121	123	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					171	172		10.1038/356171a0	http://dx.doi.org/10.1038/356171a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1312226				2022-12-28	WOS:A1992HH73100066
J	FOWLER, KB; STAGNO, S; PASS, RF; BRITT, WJ; BOLL, TJ; ALFORD, CA				FOWLER, KB; STAGNO, S; PASS, RF; BRITT, WJ; BOLL, TJ; ALFORD, CA			THE OUTCOME OF CONGENITAL CYTOMEGALOVIRUS-INFECTION IN RELATION TO MATERNAL ANTIBODY STATUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; INCLUSION DISEASE; VIRUS INFECTION; PREGNANCY; INFANTS; GROWTH	Background. Intrauterine transmission of cytomegalovirus (CMV) can occur whether a mother has prior immunity or acquires CMV for the first time during pregnancy. The degree of protection afforded an infected infant by the presence of antibody in the mother before conception is uncertain. Methods. We compared the outcomes of CMV-infected infants born to mothers who acquired primary CMV infection during pregnancy (primary-infection group) with those of CMV-infected infants born to mothers with immunity (recurrent-infection group). Screening for viruria identified 197 newborns with congenital CMV infection. Stored serum samples were used to categorize maternal infection as either primary or recurrent. We followed 125 infants from the primary-infection group and 64 from the recurrent-infection group. Serial medical, audiologic, psychometric, and eye examinations were used to identify sequelae of CMV infection. Results. Only infants in the primary-infection group had symptomatic CMV infection at birth (18 percent). After a mean follow-up of 4.7 years, one or more sequelae were seen in 25 percent of the primary-infection group and in 8 percent of the recurrent-infection group. Thirteen percent of infants whose mothers had primary infection during pregnancy had mental impairment (IQ less-than-or-equal-to 70), as compared with none of those whose mothers had recurrent CMV infections. Sensorineural hearing loss was found in 15 percent of those in the primary-infection group and in only 5 percent of those in the recurrent-infection group. Bilateral hearing loss was identified only among children in the primary-infection group (8 percent). Conclusions. The presence of maternal antibody to CMV before conception provides substantial protection against damaging congenital CMV infection in the newborn. Primary maternal infection during pregnancy is associated with more severe sequelae of congenital CMV infection.	UNIV ALABAMA, DEPT PSYCHOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	FOWLER, KB (corresponding author), UNIV ALABAMA, DEPT PEDIAT, 1600 7TH AVE S, SUITE 752, BIRMINGHAM, AL 35294 USA.			Pass, Robert/0000-0003-2029-0247	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000032] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0032, M01 RR000032] Funding Source: Medline; NICHD NIH HHS [HD10699] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHLFORS K, 1981, NEW ENGL J MED, V305, P284; BERENBERG W, 1970, PEDIATRICS, V46, P403; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; CAMPOS N, 1988, COMPUT METH PROG BIO, V27, P223, DOI 10.1016/0169-2607(88)90086-7; DAHLE AJ, 1979, J SPEECH HEAR DISORD, V44, P220, DOI 10.1044/jshd.4402.220; DEMMLER GJ, 1991, REV INFECT DIS, V13, P315, DOI 10.1093/clinids/13.2.315; GOLDENBERG RL, 1985, AM J OBSTET GYNECOL, V152, P980, DOI 10.1016/0002-9378(85)90543-5; GRIFFITHS PD, 1982, J INFECT DIS, V145, P647, DOI 10.1093/infdis/145.2.647; HANSHAW JB, 1976, NEW ENGL J MED, V295, P468, DOI 10.1056/NEJM197608262950902; KUMAR ML, 1973, NEW ENGL J MED, V288, P1370, DOI 10.1056/NEJM197306282882603; Matthews D.E., 1988, USING UNDERSTANDING, P67; MCCRACKE.GH, 1969, AM J DIS CHILD, V117, P522, DOI 10.1001/archpedi.1969.02100030524005; MEDEARIS DN, 1964, B JOHNS HOPKINS HOSP, V114, P181; MEDEARIS DN, 1982, NEW ENGL J MED, V306, P985, DOI 10.1056/NEJM198204223061609; MELISH ME, 1973, AM J DIS CHILD, V126, P190, DOI 10.1001/archpedi.1973.02110190168011; PACKMAN S, 1991, P443; PASS RF, 1990, PEDIATR INFECT DIS J, V9, P465, DOI 10.1097/00006454-199007000-00003; PASS RF, 1980, PEDIATRICS, V66, P758; REYNOLDS DW, 1974, NEW ENGL J MED, V290, P291, DOI 10.1056/NEJM197402072900601; REYNOLDS DW, 1973, NEW ENGL J MED, V289, P1, DOI 10.1056/NEJM197307052890101; RUTTER D, 1985, LANCET, V2, P1182; Stagno S, 1981, Birth Defects Orig Artic Ser, V17, P31; STAGNO S, 1985, J CLIN MICROBIOL, V21, P930, DOI 10.1128/JCM.21.6.930-935.1985; STAGNO S, 1982, NEW ENGL J MED, V306, P945, DOI 10.1056/NEJM198204223061601; STAGNO S, 1977, PEDIATRICS, V59, P669; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; STAGNO S, 1977, NEW ENGL J MED, V296, P1254, DOI 10.1056/NEJM197706022962203; STAGNO S, 1990, INFECT DIS, P241; WELLER TH, 1962, NEW ENGL J MED, V266, P1233, DOI 10.1056/NEJM196206142662401; 1987, SAS STAT GUIDE PERSO, P519	30	780	806	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					663	667		10.1056/NEJM199203053261003	http://dx.doi.org/10.1056/NEJM199203053261003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1310525				2022-12-28	WOS:A1992HG11700003
J	MOSER, CC; KESKE, JM; WARNCKE, K; FARID, RS; DUTTON, PL				MOSER, CC; KESKE, JM; WARNCKE, K; FARID, RS; DUTTON, PL			NATURE OF BIOLOGICAL ELECTRON-TRANSFER	NATURE			English	Article							PHOTOSYNTHETIC REACTION CENTERS; BACTERIAL REACTION CENTERS; RHODOPSEUDOMONAS-VIRIDIS; CHARGE SEPARATION; FREE-ENERGY; RHODOBACTER-SPHAEROIDES; DELAYED FLUORESCENCE; TRANSFER RATES; MOLECULES; RECOMBINATION	Powerful first-order analysis of intraprotein electron transfer is developed from electron-transfer measurements both in biological and in chemical systems. A variation of 20 angstrom in the distance between donors and acceptors in protein changes the electron-transfer rate by 10(12)-fold. Protein presents a uniform electronic barrier to electron tunnelling and a uniform nuclear characteristic frequency, properties similar to an organic glass. Selection of distance, free energy and reorganization energy are sufficient to define rate and directional specificity of biological electron transfer, meeting physiological requirements in diverse systems.	UNIV PENN, DEPT BIOCHEM & BIOPHYS, JOHNSON RES FDN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Moser, Christopher C/O-6559-2014	Moser, Christopher C/0000-0003-4814-8568				ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ANTOLOVICH M, 1991, J PHYS CHEM-US, V95, P1933, DOI 10.1021/j100158a010; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; CARITHERS RP, 1975, BIOCHIM BIOPHYS ACTA, V387, P194, DOI 10.1016/0005-2728(75)90103-6; CHANCE B, 1960, P NATL ACAD SCI USA, V46, P19, DOI 10.1073/pnas.46.1.19; CHANG CH, 1986, FEBS LETT, V205, P82, DOI 10.1016/0014-5793(86)80870-5; CHIDSEY CED, 1984, BIOCHIM BIOPHYS ACTA, V766, P424, DOI 10.1016/0005-2728(84)90258-5; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; COWAN JA, 1988, ANN NY ACAD SCI, V550, P68, DOI 10.1111/j.1749-6632.1988.tb35324.x; DEVAULT D, 1980, Q REV BIOPHYS, V13, P387, DOI 10.1017/S003358350000175X; DEVAULT D, 1966, BIOPHYS J, V6, P825, DOI 10.1016/S0006-3495(66)86698-5; DRACHEVA SM, 1988, EUR J BIOCHEM, V171, P253, DOI 10.1111/j.1432-1033.1988.tb13784.x; FOX LS, 1990, SCIENCE, V247, P1069, DOI 10.1126/science.247.4946.1069; FRANZEN S, 1990, J PHYS CHEM-US, V94, P5135, DOI 10.1021/j100375a068; GAINES GL, 1991, J AM CHEM SOC, V113, P719, DOI 10.1021/ja00002a076; Gamow G, 1928, Z PHYS, V51, P204, DOI 10.1007/BF01343196; GIANGIACOMO KM, 1989, P NATL ACAD SCI USA, V86, P2658, DOI 10.1073/pnas.86.8.2658; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HOLTEN D, 1978, BIOCHIM BIOPHYS ACTA, V501, P112, DOI 10.1016/0005-2728(78)90100-7; HOLZAPFEL W, 1990, P NATL ACAD SCI USA, V87, P5168, DOI 10.1073/pnas.87.13.5168; HOLZAPFEL W, 1989, CHEM PHYS LETT, V160, P1, DOI 10.1016/0009-2614(89)87543-8; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; JORAN AD, 1987, NATURE, V327, P508, DOI 10.1038/327508a0; JORTNER J, 1976, J CHEM PHYS, V64, P4860, DOI 10.1063/1.432142; KNAPP S, 1991, J AM CHEM SOC, V113, P4010, DOI 10.1021/ja00010a064; LEVICH VG, 1959, DOKL AKAD NAUK SSSR+, V124, P123; LOCKHART DJ, 1990, J PHYS CHEM-US, V94, P6987, DOI 10.1021/j100381a015; MACQUEEN DB, 1991, J AM CHEM SOC, V113, P7470, DOI 10.1021/ja00020a003; MARCUS RA, 1956, J CHEM PHYS, V24, P966, DOI 10.1063/1.1742723; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MCLENDON G, 1988, ACCOUNTS CHEM RES, V21, P160, DOI 10.1021/ar00148a005; MEADE TJ, 1989, J AM CHEM SOC, V111, P4353, DOI 10.1021/ja00194a030; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MICHELBEYERLE ME, 1988, BIOCHIM BIOPHYS ACTA, V932, P52, DOI 10.1016/0005-2728(88)90139-9; MILLER JR, 1984, J AM CHEM SOC, V106, P5057, DOI 10.1021/ja00330a004; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; PARSON WW, 1990, BIOCHIM BIOPHYS ACTA, V1017, P251, DOI 10.1016/0005-2728(90)90192-7; PARSON WW, 1975, BIOCHIM BIOPHYS ACTA, V387, P265, DOI 10.1016/0005-2728(75)90109-7; PERKINS TA, 1990, J PHYS CHEM-US, V94, P8745, DOI 10.1021/j100388a001; SCHENCK CC, 1982, BIOCHIM BIOPHYS ACTA, V680, P44, DOI 10.1016/0005-2728(82)90315-2; SHOPES RJ, 1987, BIOCHIM BIOPHYS ACTA, V893, P409, DOI 10.1016/0005-2728(87)90093-4; SHOPES RJ, 1987, PHOTOSYNTH RES, V12, P165, DOI 10.1007/BF00047946; SHOPES RJ, 1985, BIOCHIM BIOPHYS ACTA, V806, P348, DOI 10.1016/0005-2728(85)90242-7; SHUVALOV VA, 1983, FEBS LETT, V160, P51, DOI 10.1016/0014-5793(83)80934-X; TAKAHASHI E, 1991, FEBS LETT, V283, P140, DOI 10.1016/0014-5793(91)80572-K; THERIEN MJ, 1991, ADV CHEM SER, V228, P191; TIEDE DM, 1988, PHOTOSYNTHETIC BACTE, P13; WASIELEWSKI MR, 1985, J AM CHEM SOC, V107, P1080, DOI 10.1021/ja00290a066; WASIELEWSKI MR, 1989, TETRAHEDRON, V45, P4785, DOI 10.1016/S0040-4020(01)85152-8; WASIELEWSKI MR, 1985, PORPHYRINS EXCITED S, P154	50	1646	1670	5	323	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 27	1992	355	6363					796	802		10.1038/355796a0	http://dx.doi.org/10.1038/355796a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1311417				2022-12-28	WOS:A1992HF63600045
J	BROOK, JD; MCCURRACH, ME; HARLEY, HG; BUCKLER, AJ; CHURCH, D; ABURATANI, H; HUNTER, K; STANTON, VP; THIRION, JP; HUDSON, T; SOHN, R; ZEMELMAN, B; SNELL, RG; RUNDLE, SA; CROW, S; DAVIES, J; SHELBOURNE, P; BUXTON, J; JONES, C; JUVONEN, V; JOHNSON, K; HARPER, PS; SHAW, DJ; HOUSMAN, DE				BROOK, JD; MCCURRACH, ME; HARLEY, HG; BUCKLER, AJ; CHURCH, D; ABURATANI, H; HUNTER, K; STANTON, VP; THIRION, JP; HUDSON, T; SOHN, R; ZEMELMAN, B; SNELL, RG; RUNDLE, SA; CROW, S; DAVIES, J; SHELBOURNE, P; BUXTON, J; JONES, C; JUVONEN, V; JOHNSON, K; HARPER, PS; SHAW, DJ; HOUSMAN, DE			MOLECULAR-BASIS OF MYOTONIC-DYSTROPHY - EXPANSION OF A TRINUCLEOTIDE (CTG) REPEAT AT THE 3' END OF A TRANSCRIPT ENCODING A PROTEIN-KINASE FAMILY MEMBER	CELL			English	Article							MUSCULAR-DYSTROPHY; CHROMOSOME-19; LOCUS; MEMBRANE; LINKAGE; REGION; MAP; DNA	Using positional cloning strategies, we have identified a CTG triplet repeat that undergoes expansion in myotonic dystrophy patients. This sequence is highly variable in the normal population. PCR analysis of the interval containing this repeat indicates that unaffected individuals have between 5 and 27 copies. Myotonic dystrophy patients who are minimally affected have at least 50 repeats, while more severely affected patients have expansion of the repeat containing segment up to several kilobase pairs. The CTG repeat is transcribed and is located in the 3' untranslated region of an mRNA that is expressed in tissues affected by myotonic dystrophy. This mRNA encodes a polypeptide that is a member of the protein kinase family.	UNIV WALES COLL MED, INST MED GENET, CARDIFF CF4 4XN, S GLAM, WALES; CHARING CROSS & WESTMINSTER MED SCH, DEPT ANAT, LONDON W6 8RF, ENGLAND	Cardiff University; Imperial College London	BROOK, JD (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.		Buxton, Jessica L/I-4033-2014; Buxton, Jessica/L-9849-2019	Buxton, Jessica L/0000-0002-0918-9335; Snell, Russell/0000-0002-8166-4014; johnson, keith/0000-0002-8578-5921; Brook, John David/0000-0002-5946-6740; Stanton, Vincent/0000-0002-2205-6000	NHGRI NIH HHS [HG 00299] Funding Source: Medline; NHLBI NIH HHS [HL-41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000299] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BROOK JD, 1991, J MED GENET, V28, P84, DOI 10.1136/jmg.28.2.84; BROOK JD, 1991, HUM GENET, V87, P65, DOI 10.1007/BF01213095; BROOK JD, 1992, IN PRESS GENOMICS; BRUNNER HG, 1989, GENOMICS, V5, P589, DOI 10.1016/0888-7543(89)90027-X; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; BUTTERFIELD DA, 1974, BIOCHEMISTRY-US, V13, P5078, DOI 10.1021/bi00722a003; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; DYKEN PR, 1973, NEUROLOGY, V23, P465, DOI 10.1212/WNL.23.5.465; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARLEY HG, 1991, HUM GENET, V87, P73, DOI 10.1007/BF01213096; Harper P.S., 1989, MYOTONIC DYSTROPHY; HARPER PS, 1972, LANCET, V2, P53; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; HULL KL, 1976, J PHYSIOL-LONDON, V254, P169, DOI 10.1113/jphysiol.1976.sp011227; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; JANSEN G, IN PRESS GENOMICS; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; KORNELUK RG, 1989, GENOMICS, V5, P596, DOI 10.1016/0888-7543(89)90028-1; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; RENAUD JF, 1986, NATURE, V319, P678, DOI 10.1038/319678a0; ROSES AD, 1973, P NATL ACAD SCI USA, V70, P1855, DOI 10.1073/pnas.70.6.1855; ROSES AD, 1974, NATURE, V250, P245, DOI 10.1038/250245a0; SEILER D, 1970, SCHWEIZ MED WSCHR, V100, P1374; SHUTLER G, 1992, IN PRESS GENOMICS; SMEETS H, 1990, AM J HUM GENET, V46, P492; TSIFIDIS C, 1991, AM J HUM GENET, V49, P961; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	44	2076	2137	2	78	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					799	808		10.1016/0092-8674(92)90154-5	http://dx.doi.org/10.1016/0092-8674(92)90154-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1310900				2022-12-28	WOS:A1992HF44000019
J	MCCLATCHEY, AI; VANDENBERGH, P; PERICAKVANCE, MA; RASKIND, W; VERELLEN, C; MCKENNAYASEK, D; RAO, K; HAINES, JL; BIRD, T; BROWN, RH; GUSELLA, JF				MCCLATCHEY, AI; VANDENBERGH, P; PERICAKVANCE, MA; RASKIND, W; VERELLEN, C; MCKENNAYASEK, D; RAO, K; HAINES, JL; BIRD, T; BROWN, RH; GUSELLA, JF			TEMPERATURE-SENSITIVE MUTATIONS IN THE III-IV-CYTOPLASMIC LOOP REGION OF THE SKELETAL-MUSCLE SODIUM-CHANNEL GENE IN PARAMYOTONIA-CONGENITA	CELL			English	Article							RAT-BRAIN; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; CDNA SEQUENCE; CLONED CDNA; INACTIVATION; DROSOPHILA; MYOTONIA	Paramyotonia congenita (PMC), a dominant disorder featuring cold-induced myotonia (muscle stiffness), has recently been genetically linked to a candidate gene, the skeletal muscle sodium channel gene SCN4A. We have now established that SCN4A is the disease gene in PMC by identifying two different single-base coding sequence alterations in PMC families. Both mutations affect highly conserved residues in the III-IV cytoplasmic loop, a portion of the sodium channel thought to pivot in response to membrane depolarization, thereby blocking and inactivating the channel. Abnormal function of this cytoplasmic loop therefore appears to produce the Na+ current abnormality and the unique temperature-sensitive clinical phenotype in this disorder.	MASSACHUSETTS GEN HOSP,DAY NEUROMUSCULAR RES,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; CATHOLIC UNIV LOUVAIN,CLIN UNIV ST LUC,DEPT NEUROL,B-1200 BRUSSELS,BELGIUM; DUKE UNIV,DEPT MED,DIV NEUROSURG,DURHAM,NC 27706; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV CONNECTICUT,CTR HLTH,DEPT NEUROL,FARMINGTON,CT 06032; SEATTLE VET AFFAIRS HOSP,DIV NEUROL,SEATTLE,WA 98195	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Duke University; University of Washington; University of Washington Seattle; University of Connecticut	MCCLATCHEY, AI (corresponding author), MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET LAB,BOSTON,MA 02129, USA.		Haines, Jonathan/C-3374-2012	Haines, Jonathan/0000-0002-4351-4728	NINDS NIH HHS [NS22224, NS24279, NS26630] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS026630, P01NS024279, R01NS022224] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; CANNON SC, 1991, NEURON, V6, P619, DOI 10.1016/0896-6273(91)90064-7; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; ENGEL AG, 1986, MYOLOGY, P1843; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GUSELLA J, 1979, P NATL ACAD SCI USA, V76, P5239, DOI 10.1073/pnas.76.10.5239; HOSHI T, 1990, SCIENCE, V250, P506; IAZZO PA, 1991, NEUROMUSC DISORDERS, V1, P47; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P116; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KOCH MC, 1991, J MED GENET, V28, P583, DOI 10.1136/jmg.28.9.583; KOCH MC, 1991, IN PRESS HUM GENET; LEHMANNHORN F, 1990, MUSCLE NERVE, V13, P528, DOI 10.1002/mus.880130609; LEHMANNHORN F, 1987, MUSCLE NERVE, V10, P363, DOI 10.1002/mus.880100414; LEHMANNHORN F, 1987, MUSCLE NERVE, V10, P633, DOI 10.1002/mus.880100709; LEHMANNHORN F, 1991, PFLUG ARCH EUR J PHY, V418, P297, DOI 10.1007/BF00370530; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MCCLATCHEY AI, 1992, IN PRESS AM J HUM GE; MOORMAN JR, 1990, SCIENCE, V250, P688; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PTACEK LJ, 1991, AM J HUM GENET, V49, P851; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1991, AM J HUM GENET, V49, P378; RASKIND WH, 1991, AM J HUM GENET, V48, P335; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROJAS CV, 1991, IN PRESS NATURE; SALKOFF L, 1987, NUCLEIC ACIDS RES, V15, P8569, DOI 10.1093/nar/15.20.8569; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P11; SEIZINGER BR, 1986, NATURE, V322, P664; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; VANDENBERGH P, 1991, NEUROLOGY S1, V41, P419; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937	44	222	228	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					769	774		10.1016/0092-8674(92)90151-2	http://dx.doi.org/10.1016/0092-8674(92)90151-2			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1310898				2022-12-28	WOS:A1992HF44000016
J	LEWIS, MJ; PELHAM, HRB				LEWIS, MJ; PELHAM, HRB			LIGAND-INDUCED REDISTRIBUTION OF A HUMAN KDEL RECEPTOR FROM THE GOLGI-COMPLEX TO THE ENDOPLASMIC-RETICULUM	CELL			English	Article							LUMINAL ER PROTEINS; GIANT HELA-CELLS; BREFELDIN-A; THIAMINE PYROPHOSPHATASE; MEMBRANE-PROTEIN; YEAST; ANTIBODIES; IDENTIFICATION; LOCALIZATION; COMPARTMENT	Resident luminal endoplasmic reticulum (ER) proteins carry a targeting signal (usually KDEL in animal cells) that allows their retrieval from later stages of the secretory pathway. In yeast, the receptor that promotes this selective retrograde transport has been identified as the product of the ERD2 gene. We describe here the properties of a human homolog of this protein (hERD2). Overproduction of hERD2 improves retention of a protein with a weakly recognized variant signal (DDEL). Moreover, overexpression of KDEL or DDEL ligands causes a redistribution of hERD2 from the Golgi apparatus to the ER. Mutation of hERD2 alters the ligand specificity of this effect, implying that it interacts directly with the retained proteins. Ligand control of receptor movement may limit retrograde flow and thus minimize fruitless recycling of secretory proteins.			LEWIS, MJ (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							BRETSCHER MS, 1983, P NATL ACAD SCI-BIOL, V80, P454, DOI 10.1073/pnas.80.2.454; BRETSCHER MS, 1983, EMBO J, V2, P599, DOI 10.1002/j.1460-2075.1983.tb01469.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DAILEY L, 1985, J VIROL, V54, P739, DOI 10.1128/JVI.54.3.739-749.1985; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARIUZZA RA, 1983, J MOL BIOL, V170, P1055, DOI 10.1016/S0022-2836(83)80206-X; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; PUDDINGTON L, 1986, J CELL BIOL, V102, P2147, DOI 10.1083/jcb.102.6.2147; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SARASTE J, 1991, IN PRESS J CELL SCI; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; VAN PN, 1989, J BIOL CHEM, V264, P17494; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0	34	340	345	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					353	364		10.1016/0092-8674(92)90476-S	http://dx.doi.org/10.1016/0092-8674(92)90476-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1310258				2022-12-28	WOS:A1992HB35300014
J	SIMONETTI, RG; CAMMA, C; FIORELLO, F; COTTONE, M; RAPICETTA, M; MARINO, L; FIORENTINO, G; CRAXI, A; CICCAGLIONE, A; GIUSEPPETTI, R; STROFFOLINI, T; PAGLIARO, L				SIMONETTI, RG; CAMMA, C; FIORELLO, F; COTTONE, M; RAPICETTA, M; MARINO, L; FIORENTINO, G; CRAXI, A; CICCAGLIONE, A; GIUSEPPETTI, R; STROFFOLINI, T; PAGLIARO, L			HEPATITIS-C VIRUS-INFECTION AS A RISK FACTOR FOR HEPATOCELLULAR-CARCINOMA IN PATIENTS WITH CIRRHOSIS - A CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C VIRUS; LIVER NEOPLASMS; HEPATITIS, VIRAL, NON-A, NON-B; HEPATITIS-B; LIVER CIRRHOSIS	POST-TRANSFUSION HEPATITIS; NON-B-HEPATITIS; CHRONIC NON-A; BLOOD-DONORS; ANTIBODIES; PREVALENCE; ETIOLOGY; ALCOHOL	Objective: To determine whether chronic hepatitis C virus (HCV) infection is an independent risk factor for hepatocellular carcinoma and whether it increases the cirrhosis-related risk for hepatocellular carcinoma. Design: Two pair-matched case-control studies. Setting: A referral-based hospital. Patients: In study I, 212 patients with hepatocellular carcinoma (197 of whom had known underlying cirrhosis) were compared with controls who had chronic nonhepatic diseases. In study II, the 197 patients with hepatocellular carcinoma and cirrhosis were compared with 197 pair-matched controls who had cirrhosis but not hepatocellular carcinoma. Measurements: Levels of antibody to HCV (anti-HCV), hepatitis B surface antigen (HBsAg), and antibody to hepatitis B core antigen (anti-HBc) were assayed, and alcohol abuse was assessed by history. Main Results: In study I, 151 patients (71%) with hepatocellular carcinoma were anti-HCV positive compared with 11 controls (5%) with chronic nonhepatic diseases (odds ratio, 42; 95% Cl, 22 to 95). Multivariate analysis showed that anti-HCV was an independent risk factor for hepatocellular carcinoma (odds ratio, 69; Cl, 15 to 308). The analysis also showed that HBsAg (odds ratio, 8.7; Cl, 1.5 to 50) and anti-HBc (odds ratio, 4.2 (Cl, 1.7 to 11) were risk factors for hepatocellular carcinoma. No statistically significant interaction was found between anti-HCV and the markers of HBV infection. In study II, 146 patients (74%) with hepatocellular carcinoma and cirrhosis were anti-HCV positive compared with 122 patients (62%) with cirrhosis alone (odds ratio, 1.8; Cl, 1.1 to 2.8). Multivariate analysis confirmed that anti-HCV (odds ratio, 2.0; Cl, 1.3 to 32) and HBsAg (odds ratio, 2.0; Cl, 1.0 to 4.2) were independent risk factors for hepatocellular carcinoma. Conclusions: Hepatitis C virus infection is a risk factor for hepatocellular carcinoma, apparently by inducing cirrhosis and, to a lesser extent, by enhancing the risk in patients with cirrhosis. Hepatitis C virus infection acts independently of HBV infection (another risk factor) and of alcohol abuse, age, or gender.	UNIV PALERMO, IST MED GEN & PNEUMOL, I-90134 PALERMO, ITALY; IST SUPER SANITA, I-00161 ROME, ITALY	University of Palermo; Istituto Superiore di Sanita (ISS)			Giuseppetti, Roberto/AAA-6508-2021; CICCAGLIONE, ANNA RITA/M-2956-2015; Craxi, Antonio/K-9529-2016	Giuseppetti, Roberto/0000-0001-9958-164X; CICCAGLIONE, ANNA RITA/0000-0002-3791-3781; Cottone, Mario/0000-0003-1523-7556; Craxi, Antonio/0000-0002-4480-9544; CAMMA', CALOGERO/0000-0002-9224-1914				ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; ALTER HJ, 1990, J GASTROEN HEPATOL, V5, P78, DOI 10.1111/j.1440-1746.1990.tb01783.x; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BOSCH FX, 1989, FALK SYMP, V51, P3; BRESLOW N, 1982, BIOMETRICS, V38, P661, DOI 10.2307/2530047; Breslow N, 1980, STATISTICAL METHODS, V32; BRUIX J, 1989, LANCET, V2, P1004; CAPORASO N, 1991, J HEPATOL, V12, P367, DOI 10.1016/0168-8278(91)90841-X; CHIARAMONTE M, 1990, ASPETTI EPIDEMIOLOGI, P11; COLOMBO M, 1989, LANCET, V2, P1006; DAZZA MC, 1990, LANCET, V335, P1216, DOI 10.1016/0140-6736(90)92733-X; ESTEBAN JI, 1989, LANCET, V2, P294; GILLIAM JH, 1984, ANN INTERN MED, V101, P794, DOI 10.7326/0003-4819-101-6-794; HASAN F, 1990, HEPATOLOGY, V12, P589, DOI 10.1002/hep.1840120323; JOHNSON PJ, 1987, J HEPATOL, V4, P140, DOI 10.1016/S0168-8278(87)80021-1; KAKLAMANI E, 1991, JAMA-J AM MED ASSOC, V265, P1974, DOI 10.1001/jama.265.15.1974; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KIYOSAWA K, 1987, AM J GASTROENTEROL, V78, P777; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LEVRERO M, 1991, J HEPATOL, V12, P60, DOI 10.1016/0168-8278(91)90910-4; LONDON WT, 1981, HUM PATHOL, V12, P1085, DOI 10.1016/S0046-8177(81)80329-2; MAGRIN S, 1991, J GASTROENTEROL, V23, P312; OKUDA K, 1986, DIGEST DIS SCI, V31, pS133; PAGLIARO L, 1983, HEPATO-GASTROENTEROL, V30, P48; RESNICK RH, 1983, DIGEST DIS SCI, V28, P908, DOI 10.1007/BF01317042; SANCHEZTAPIAS JM, 1990, ANN INTERN MED, V112, P921, DOI 10.7326/0003-4819-112-12-921; SANCHIS J, 1990, 1990 P INT S VIR HEP, P439; SIMONETTI RG, 1989, LANCET, V2, P1338; SIMONETTI RG, 1991, DIGEST DIS SCI, V36, P962, DOI 10.1007/BF01297149; SIRCHIA G, 1990, VOX SANG, V59, P26, DOI 10.1111/j.1423-0410.1990.tb02109.x; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; TREMOLADA F, 1990, LANCET, V335, P300, DOI 10.1016/0140-6736(90)90129-S; VARGAS V, 1990, ANN INTERN MED, V112, P232, DOI 10.7326/0003-4819-112-3-232_2; VILLA E, 1988, CANCER-AM CANCER SOC, V62, P611, DOI 10.1002/1097-0142(19880801)62:3<611::AID-CNCR2820620328>3.0.CO;2-0; WEINER AJ, 1990, LANCET, V336, P695, DOI 10.1016/0140-6736(90)92194-M; WEJSTAL R, 1987, SCAND J GASTROENTERO, V22, P1115, DOI 10.3109/00365528708991968; YARRISH RL, 1980, INT J CANCER, V26, P711, DOI 10.1002/ijc.2910260603; YU MC, 1990, JNCI-J NATL CANCER I, V82, P1038, DOI 10.1093/jnci/82.12.1038; ZAMAN SN, 1985, LANCET, V1, P1357; 1988, SAS STAT USERS GUIDE, P189	40	357	360	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					97	102		10.7326/0003-4819-116-2-97	http://dx.doi.org/10.7326/0003-4819-116-2-97			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1309286				2022-12-28	WOS:A1992GZ35600001
J	HEALY, B				HEALY, B			BETTER TREATMENT FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1992	267	2					209	209						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY046	1309267				2022-12-28	WOS:A1992GY04600005
J	OVEREND, A; HALL, WW; GODWIN, PGR				OVEREND, A; HALL, WW; GODWIN, PGR			DOES EARWAX LOSE ITS PATHOGENS ON YOUR AURISCOPE OVERNIGHT	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To describe the organisms cultured from general practitioners' auriscope earpieces; and to explore general practitioners' perceptions of the possibility of cross infection from contaminated auriscope earpieces and of how their auriscope earpieces are cleaned. Design-Microbiological survey of auriscope ear-pieces in two general practices and a semistructured questionnaire sent to 105 general practitioners. Setting-General practitioners served by one district general hospital microbiology laboratory in the north of England. Results-Organisms were cultured from 41 (93%) of 44 auriscope earpieces, of which 14 (32%) carried potential pathogens; four (9%) were heavily contaminated. Of the 85 (81%) general practitioners who responded, 72 (85%) believed that contaminated auriscope earpieces could cause serious infection, 66 (78%) did not clean earpieces between patients, and 70 (82%) thought that patients would mind if they knew that dirty earpieces were used. Conclusions-Almost a third of auriscope ear-pieces were contaminated by pathogenic bacteria. Although general practitioners suspected this, most did not ensure that a clean earpiece was used for each patient.	TOWNHEAD SURG,SETTLE BD24 9JA,N YORKSHIRE,ENGLAND; AIREDALE DIST GEN HOSP,KEIGHLEY,W YORKSHIRE,ENGLAND		HALL, WW (corresponding author), TOWNHEAD SURG,SETTLE BD24 9JA,N YORKSHIRE,ENGLAND.							AYLIFFE GAJ, 1992, CONTROL HOSPITAL INF; BROOK I, 1985, AM J OTOLARYNG, V6, P111, DOI 10.1016/S0196-0709(85)80048-X; CASSISI N, 1977, ANN OTO RHINOL LARYN, V86, P1; CHAI TJ, 1980, CHEMOTHERAPY, V18, P638; HORDER J, 1986, J ROY COLL GEN PRACT, V36, P517; LENNETTE EH, 1980, MANUAL CLIN MICROBIO; MARCY SM, 1985, PEDIATR INFECT DIS J, V4, P192; MARCY SM, 1985, PEDIATR INFECT DIS J, V4, pS27, DOI 10.1097/00006454-198505010-00007; Roethlisberger F. J., 1939, MANAGEMENT WORKER; Rosenstock I., 1979, HEALTH PSYCHOL, P161; SHETH KJ, 1986, PEDIATRICS, V77, P920; STONE M, 1984, ANN OTO RHINOL LARYN, V93, P183, DOI 10.1177/000348948409300217; 1992, PRACTICE PLUS DIAGNO; 1990, INTRUCTION LEAFLET D	14	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1571	1573		10.1136/bmj.305.6868.1571	http://dx.doi.org/10.1136/bmj.305.6868.1571			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286392	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KD77100029
J	WEITZMAN, M; GORTMAKER, SL; SOBOL, AM; PERRIN, JM				WEITZMAN, M; GORTMAKER, SL; SOBOL, AM; PERRIN, JM			RECENT TRENDS IN THE PREVALENCE AND SEVERITY OF CHILDHOOD ASTHMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHANGING PATTERNS; BEHAVIOR PROBLEMS; NEW-ZEALAND; CHILDREN; MORTALITY; HOSPITALIZATION; RATES; HEALTH; RISKS	Objective.-To examine changes in the prevalence and distribution of childhood asthma and its relationship with various measures of children's health and functioning between 1981 and 1988. It was hypothesized that there would be an increase in the prevalence of asthma, especially among black children, and that available measures would suggest a deterioration in the health and functioning of children with asthma over this period. Design.-Analyses of data from the Child Health Supplements to the National Health Interview Survey. Setting and Sample.-Nationally representative random sample of 15 224 children aged 0 to 17 years in 1981 and 17 110 in 1988. Main Outcome Measures.-Changes in (1) the prevalence and distribution of asthma, and (2) among children with asthma, the percentage of children hospitalized, days spent in bed, school days lost in the year prior to survey, and parent ratings and reports of children's overall health status and behavior problems. Results.-The estimated prevalence of childhood asthma increased from 3.1% in 1981 to 4.3% in 1988 (P<.0001), with similar increases for children, adolescents, and both sexes. Increases occurred among white children (2.7% to 4.1%; P<.0001) but not black children (5.3% vs 5.1%; not significant). Among those with asthma in 1988 compared with 1981, there was better overall health status (11% vs 24% fair/poor; P<.0001) and fewer with 30 or more days spent in bed in the last year (3.9% vs 7.2%; P<.04). We also observed trends toward a lower rate of hospitalization in the last year (10% vs 14%; P=.07), fewer school days missed (2% vs 6% with >30 days; P=.08), and a lower rate of extreme behavior problem scores (13% vs 18%; P=.09) in 1988 compared with 1981. Reductions were similar among both black and white children. Conclusions.-These results indicate that the estimated prevalence of asthma among children in the United States increased by almost 40%, and that although the increase occurred exclusively among white children, the prevalence of asthma still remains higher in black children than in white children. There was no support for increasing asthma severity and functional impact among either black or white children with asthma in 1988 compared with 1981. These findings provide no evidence to support the beliefs that asthma prevalence is increasing largely among black children or that the severity of asthma among most children in the United States is increasing.	UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642; HARVARD UNIV,SCH PUBL HLTH,DEPT BEHAV SCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114	University of Rochester; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Perrin, James/0000-0002-1810-3708				ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; BUIST AS, 1990, JAMA-J AM MED ASSOC, V264, P1719, DOI 10.1001/jama.264.13.1719; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURT ML, 1989, ARCH DIS CHILD, V64, P1452; BURT ML, 1987, J EPIDEMIOL COMMUNIT, V41, P185; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CYPRESS BK, 1983, VITAL HLTH STAT 13, V75, P13; EVANS R, 1987, CHEST, V91, P652; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GORTMAKER SL, 1990, PEDIATRICS, V85, P267; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MCCORMICK MC, 1990, J PEDIATR-US, V117, P687, DOI 10.1016/S0022-3476(05)83322-0; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; MULLALLY DI, 1984, ANN ALLERGY, V53, P15; NEWACHECK PW, 1986, AM J PUBLIC HEALTH, V76, P178, DOI 10.2105/AJPH.76.2.178; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; PERRIN JM, 1991, AJDC, V145, P415; PETERSON JL, 1986, J MARRIAGE FAM, V48, P295, DOI 10.2307/352397; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; SLY RM, 1988, ANN ALLERGY, V60, P433; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; SUDMAN S, 1976, APPL SAMPLING, P69; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEITZMAN M, 1986, J CHRON DIS, V39, P799, DOI 10.1016/0021-9681(86)90082-2; WEITZMAN M, 1990, PEDIATRICS, V85, P505; WEITZMAN M, 1992, PEDIATRICS, V90, P342; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1982, VITAL HLTH STAT 10, V14, P1; 1989, STATISTICAL ABSTRACT, P462; 1990, PHS901232 NAT CTR HL, P16; 1973, PHS DHEW HRA741511 P, P1	40	285	287	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2673	2677		10.1001/jama.268.19.2673	http://dx.doi.org/10.1001/jama.268.19.2673			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JX680	1304735				2022-12-28	WOS:A1992JX68000029
J	SPIEGELHALTER, DJ; GORE, SM; FITZPATRICK, R; FLETCHER, AE; JONES, DR; COX, DR				SPIEGELHALTER, DJ; GORE, SM; FITZPATRICK, R; FLETCHER, AE; JONES, DR; COX, DR			QUALITY-OF-LIFE MEASURES IN HEALTH-CARE .3. RESOURCE-ALLOCATION	BRITISH MEDICAL JOURNAL			English	Article							TECHNICAL SOLUTION; POLITICAL PROBLEM; QALYS		DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX1 1NF,ENGLAND; ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND; UNIV LEICESTER,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE1 7RH,ENGLAND; UNIV OXFORD NUFFIELD COLL,OXFORD OX1 1NF,ENGLAND	Imperial College London; University of Leicester; University of Oxford	SPIEGELHALTER, DJ (corresponding author), INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							Allen D, 1989, Int J Health Plann Manage, V4, P261, DOI 10.1002/hpm.4740040403; BERWICK DM, 1992, BRIT MED J, V304, P235, DOI 10.1136/bmj.304.6821.235; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; BROOKS RG, 1991, HEALTH POLICY, V18, P37, DOI 10.1016/0168-8510(91)90142-K; BUXTON MJ, 1992, MEASURES QUALITY LIF, P41; Cairns J, 1992, Health Econ, V1, P76, DOI 10.1002/hec.4730010111; CARRHILL RA, 1989, SOC SCI MED, V29, P469, DOI 10.1016/0277-9536(89)90296-7; CARRHILL RA, 1991, INT J HEALTH SERV, V21, P351, DOI 10.2190/HPLM-EGXV-BWKY-5XBN; CARRHILL RA, 1991, HLTH SERVICE J, V101, P25; COAST J, 1992, BMJ-BRIT MED J, V305, P87, DOI 10.1136/bmj.305.6845.87; COX DR, 1992, J ROY STAT SOC A STA, V155, P353, DOI 10.2307/2982889; CUBBON J, 1991, J MED ETHICS, V17, P181, DOI 10.1136/jme.17.4.181; DEAN M, 1991, LANCET, V337, P480, DOI 10.1016/0140-6736(91)93408-2; DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; DOWIE J, 1991, HPA9158 NEW S WAL HL; DRUMMOND MF, 1987, J CHRON DIS, V40, P605, DOI 10.1016/0021-9681(87)90021-X; FITZPATRICK R, 1992, BRIT MED J, V305, P1074, DOI 10.1136/bmj.305.6861.1074; Fletcher Astrid, 1992, British Medical Journal, V305, P1145; HARRIS J, 1991, J MED ETHICS, V17, P185, DOI 10.1136/jme.17.4.185; Keeney R.L., 1976, DECISIONS MULTIPLE O; KKRISTIANSEN IS, 1991, BMJ, V302, P1119; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; NORMAND C, 1991, BRIT MED J, V303, P1572, DOI 10.1136/bmj.303.6817.1572; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; ROSSER R, 1992, MEASURES QUALITY LIF, P81; SMITH A, 1987, LANCET, V1, P1134; SMITH R, 1991, BRIT MED J, V303, P1561, DOI 10.1136/bmj.303.6817.1561; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; WAGSTAFF A, 1991, J HLTH EC, V5, P1; WALKER P, 1992, MEASURES QUALITY LIF; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; WILLIAMS A, 1991, INT J HEALTH SERV, V21, P365, DOI 10.2190/WFMX-Y3VX-4UN8-8XMP; Williams A, 1992, MEASURES QUALITY LIF, P21; 1992, LANCET, V340, P148; 1987, ENGLISH LIFE TABLES	37	70	73	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1205	1209		10.1136/bmj.305.6863.1205	http://dx.doi.org/10.1136/bmj.305.6863.1205			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JY777	1304741	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JY77700025
J	JOHNSON, E				JOHNSON, E			MEMORY CIRCUIT AND SCHIZOPHRENIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							1992, AM J PSYCHIAT, V149, P890	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1518	1518						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1325568				2022-12-28	WOS:A1992JN25600007
J	GEGNER, JA; GRAHAM, DR; ROTH, AF; DAHLQUIST, FW				GEGNER, JA; GRAHAM, DR; ROTH, AF; DAHLQUIST, FW			ASSEMBLY OF AN MCP RECEPTOR, CHEW, AND KINASE CHEA COMPLEX IN THE BACTERIAL CHEMOTAXIS SIGNAL TRANSDUCTION PATHWAY	CELL			English	Article							DIRECTED CROSS-LINKING; ESCHERICHIA-COLI; PROTEIN-PHOSPHORYLATION; METHYLESTERASE; SITE; OVEREXPRESSION; DEMETHYLATION; ATTRACTANTS; METHYLATION; REPELLENTS	We examined the binding interactions of the methylation-dependent chemotaxis receptors Tsr and Tar with the chemotaxis-specific protein kinase CheA and the coupling factor CheW. Receptor directly bound CheW, but receptor-CheA binding was dependent upon the presence of CheW. These observations in combination with our previous identification of a CheW-CheA complex suggest that CheW physically links the kinase to the receptor. The ternary complex of receptor, CheW, and CheA is both kinetically and thermodynamically stable at physiological concentrations. Stability is not significantly altered by changes associated with attractant or repellent binding to the receptor. Such binding greatly modulates the kinase activity of CheA. Our results demonstrate that modulation of the kinase activity does not require association-dissociation of the ternary complex. This suggests that the receptor signal is transduced through conformational changes in the ternary complex rather than through changes in the association of the kinase CheA with receptor and/or CheW.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA	University of Oregon; University of Oregon					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007759, R01GM033677, R37GM033677] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07759, GM33677] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; KEHRY MR, 1985, J BACTERIOL, V161, P105, DOI 10.1128/JB.161.1.105-112.1985; KEHRY MR, 1985, J BACTERIOL, V163, P983, DOI 10.1128/JB.163.3.983-990.1985; KLEENE SJ, 1979, P NATL ACAD SCI USA, V76, P6309, DOI 10.1073/pnas.76.12.6309; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LUPAS A, 1989, J BIOL CHEM, V264, P17337; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MESIBOV R, 1972, J BACTERIOL, V112, P315, DOI 10.1128/JB.112.1.315-326.1972; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NINFA EG, 1991, J BIOL CHEM, V266, P9764; Osborn M J, 1974, Methods Enzymol, V31, P642; ROLLINS C, 1981, CELL, V25, P333, DOI 10.1016/0092-8674(81)90051-9; SANDERS DA, 1989, J BACTERIOL, V171, P6271, DOI 10.1128/jb.171.11.6271-6278.1989; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEGALL JE, 1982, NATURE, V296, P855, DOI 10.1038/296855a0; SIMMS SA, 1985, J BIOL CHEM, V260, P161; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STEWART RC, 1988, J BACTERIOL, V170, P5728, DOI 10.1128/jb.170.12.5728-5738.1988; STOCK A, 1987, J BIOL CHEM, V262, P535; TSANG N, 1973, SCIENCE, V181, P60, DOI 10.1126/science.181.4094.60; TSO WW, 1974, J BACTERIOL, V118, P560, DOI 10.1128/JB.118.2.560-576.1974	35	317	320	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					975	982		10.1016/0092-8674(92)90247-A	http://dx.doi.org/10.1016/0092-8674(92)90247-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1326408				2022-12-28	WOS:A1992JN78100012
J	BYRNE, TN				BYRNE, TN			CURRENT CONCEPTS - SPINAL-CORD COMPRESSION FROM EPIDURAL METASTASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BACK PAIN; COMPUTED-TOMOGRAPHY; GADOLINIUM-DTPA; EARLY DIAGNOSIS; DISEASE; TUMORS; MYELOGRAPHY; MANAGEMENT; CANCER; DEXAMETHASONE		YALE COMPREHENS CANC CTR, NEUROONCOL UNIT, NEW HAVEN, CT USA; YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06510 USA	Yale University; Yale University								ABRAMS HL, 1950, CANCER, V3, P74, DOI 10.1002/1097-0142(1950)3:1<74::AID-CNCR2820030111>3.0.CO;2-7; ARGUELLO F, 1990, CANCER, V65, P98, DOI 10.1002/1097-0142(19900101)65:1<98::AID-CNCR2820650121>3.0.CO;2-K; BARRON KD, 1959, NEUROLOGY, V9, P91, DOI 10.1212/WNL.9.2.91; Batson OV, 1940, ANN SURG, V112, P138, DOI 10.1097/00000658-194007000-00016; BLEYER WA, 1988, CURR PROB CANCER, V12, P185; BYRNE TN, 1990, CONT NEUROLOGY SERIE, V33; CALKINS AR, 1986, NEUROSURGERY, V19, P614, DOI 10.1227/00006123-198610000-00018; CARMODY RF, 1989, RADIOLOGY, V173, P225, DOI 10.1148/radiology.173.1.2675185; COMAN DR, 1951, CANCER, V4, P610, DOI 10.1002/1097-0142(195105)4:3<610::AID-CNCR2820040312>3.0.CO;2-Q; CONSTANS JP, 1983, J NEUROSURG, V59, P111, DOI 10.3171/jns.1983.59.1.0111; DELATTRE JY, 1989, J NEUROSURG, V70, P920, DOI 10.3171/jns.1989.70.6.0920; FINDLAY GFG, 1984, J NEUROL NEUROSUR PS, V47, P761, DOI 10.1136/jnnp.47.8.761; GILBERT RW, 1978, ANN NEUROL, V3, P40, DOI 10.1002/ana.410030107; GRAUS F, 1985, P AN M AM SOC CLIN, V4, P269; GREENBERG HS, 1980, ANN NEUROL, V8, P361, DOI 10.1002/ana.410080404; HADDAD P, 1976, CANCER, V38, P1862, DOI 10.1002/1097-0142(197610)38:4<1862::AID-CNCR2820380467>3.0.CO;2-8; HARRINGTON KD, 1988, CLIN ORTHOP RELAT R, P177; HARRINGTON KD, 1984, J NEUROSURG, V61, P107, DOI 10.3171/jns.1984.61.1.0107; HASHIZUME Y, 1983, ACTA NEUROPATHOL, V61, P219, DOI 10.1007/BF00691989; HOLLIS PH, 1986, J NEUROSURG, V64, P253, DOI 10.3171/jns.1986.64.2.0253; KATO A, 1985, J NEUROSURG, V63, P260, DOI 10.3171/jns.1985.63.2.0260; KIM RY, 1990, RADIOLOGY, V176, P279, DOI 10.1148/radiology.176.1.2353102; KLEIN SL, 1991, J NEUROSURG, V74, P70, DOI 10.3171/jns.1991.74.1.0070; LEWIS DW, 1986, PEDIATRICS, V78, P438; LI KC, 1988, MAGN RESON IMAGING, V6, P547, DOI 10.1016/0730-725X(88)90129-4; MANABE S, 1989, SPINE, V14, P1308, DOI 10.1097/00007632-198912000-00007; OROURKE T, 1986, J CLIN ONCOL, V4, P576, DOI 10.1200/JCO.1986.4.4.576; PORTENOY RK, 1987, NEUROLOGY, V37, P134, DOI 10.1212/WNL.37.1.134; PORTENOY RK, 1989, CANCER, V64, P2207, DOI 10.1002/1097-0142(19891201)64:11<2207::AID-CNCR2820641104>3.0.CO;2-9; POSNER JB, 1987, MED CLIN N AM, V71, P185; POSNER JB, 1977, ANN NEUROL, V2, P409, DOI 10.1002/ana.410020511; REDMOND J, 1988, J CLIN ONCOL, V6, P154, DOI 10.1200/JCO.1988.6.1.154; RODICHOK LD, 1986, ANN NEUROL, V20, P696, DOI 10.1002/ana.410200608; RODICHOK LD, 1981, AM J MED, V70, P1181, DOI 10.1016/0002-9343(81)90825-1; RODRIGUEZ M, 1980, MAYO CLIN PROC, V55, P442; RUFF, 1990, CANCER, V66, P935; RUFF RL, 1989, CANCER-AM CANCER SOC, V63, P2234, DOI 10.1002/1097-0142(19890601)63:11<2234::AID-CNCR2820631130>3.0.CO;2-T; SIEGAL T, 1989, SPINE, V14, P223, DOI 10.1097/00007632-198902000-00015; SIEGAL T, 1985, NEUROSURGERY, V17, P424, DOI 10.1227/00006123-198509000-00005; SIEGAL T, 1991, NEUROLOGY, V41, P574, DOI 10.1212/WNL.41.4.574; SMOKER WRK, 1987, AM J ROENTGENOL, V149, P1241, DOI 10.2214/ajr.149.6.1241; STARK RJ, 1982, BRAIN, V105, P189, DOI 10.1093/brain/105.1.189; SUNDARESAN N, 1989, J CLIN ONCOL, V7, P1485, DOI 10.1200/JCO.1989.7.10.1485; SZE G, 1988, AM J NEURORADIOL, V9, P153; SZE G, 1988, RADIOLOGY, V167, P217, DOI 10.1148/radiology.167.1.3347725; SZE G, 1988, AM J NEURORADIOL, V9, P847; USHIO Y, 1977, NEUROLOGY, V27, P422, DOI 10.1212/WNL.27.5.422; VECHT CJ, 1989, NEUROLOGY, V39, P1255, DOI 10.1212/WNL.39.9.1255; WEISSMAN DE, 1985, J CLIN ONCOL, V3, P1541, DOI 10.1200/JCO.1985.3.11.1541; WEISSMAN DE, 1988, J CLIN ONCOL, V6, P543, DOI 10.1200/JCO.1988.6.3.543; YOUNG RF, 1980, J NEUROSURG, V53, P741, DOI 10.3171/jns.1980.53.6.0741; ZIMMERMAN RA, 1988, RADIOL CLIN N AM, V26, P965	52	257	271	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					614	619						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1296600				2022-12-28	WOS:A1992JK20400007
J	ZHANG, XK; LEHMANN, J; HOFFMANN, B; DAWSON, MI; CAMERON, J; GRAUPNER, G; HERMANN, T; TRAN, P; PFAHL, M				ZHANG, XK; LEHMANN, J; HOFFMANN, B; DAWSON, MI; CAMERON, J; GRAUPNER, G; HERMANN, T; TRAN, P; PFAHL, M			HOMODIMER FORMATION OF RETINOID X-RECEPTOR INDUCED BY 9-CIS RETINOIC ACID	NATURE			English	Article							THYROID-HORMONE; RESPONSIVE ELEMENT; GENE; IDENTIFICATION; BINDING; ISOFORM; GAMMA	RETINOID response pathways are mediated by two classes of receptors, the retinoic acid receptors (RARs)1-6 and the retinoid X receptors (RXRs)7-11. A central question is whether distinct response pathways are regulated by these two classes of receptors. The observation that the stereoisomer 9-cis-retinoic acid binds with high affinity to RXRs12,13 suggested that this retinoid has a distinct role in controlling RXR activity, but it was almost simultaneously discovered that RXRs function as auxiliary receptors for RARs and related receptors, and are essential for DNA binding and function of those receptors9,10,14-17. Hence, although RARs seem to operate effectively only as heterodimeric RAR/RXR complexes, RXRs themselves apparently function predominantly, if not exclusively, as auxiliary receptors. Here we report that 9-cis-retinoic acid induces RXR homodimer formation. Our results demonstrate a new mechanism for retinoid action by which a ligand-induced homodimer mediates a distinct retinoid response pathway.	LA JOLLA CANC RES FDN,CTR CANC,10901 N TORREY PINES RD,LA JOLLA,CA 92037; SRI INT,DIV LIFE SCI,MENLO PK,CA 94025	Sanford Burnham Prebys Medical Discovery Institute; SRI International								BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HERMANN T, IN PRESS MOL ENDOCR; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1734; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	30	563	575	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					587	591		10.1038/358587a0	http://dx.doi.org/10.1038/358587a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1323763				2022-12-28	WOS:A1992JH82900061
J	SILVA, AJ; PAYLOR, R; WEHNER, JM; TONEGAWA, S				SILVA, AJ; PAYLOR, R; WEHNER, JM; TONEGAWA, S			IMPAIRED SPATIAL-LEARNING IN ALPHA-CALCIUM-CALMODULIN KINASE-II MUTANT MICE	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY PROTEIN; RABBIT FOLLOWING STIMULATION; HIPPOCAMPAL-LESIONS; SYNAPTIC TRANSMISSION; LASTING POTENTIATION; PERFORANT PATH; DENTATE AREA; RAT-BRAIN	Although long-term potentiation (LTP) has been studied as the mechanism for hippocampus-dependent learning and memory, evidence for this hypothesis is still incomplete. The mice with a mutation in the alpha-calcium-calmodulin-dependent kinase II (alpha-CaMKII), a synaptic protein enriched in the hippocampus, are appropriate for addressing this issue because the hippocampus of these mice is deficient in LTP but maintains intact postsynaptic mechanisms. These mutant mice exhibit specific learning impairments, an indication that alpha-CaMKII has a prominent role in spatial learning, but that it is not essential for some types of non-spatial learning. The data considerably strengthen the contention that the synaptic changes exhibited in LTP are the basis for spatial memory.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV COLORADO,INST BEHAV GENET,BOULDER,CO 80309	Massachusetts Institute of Technology (MIT); University of Colorado System; University of Colorado Boulder	SILVA, AJ (corresponding author), MIT,HOWARD HUGHES MED INST,CTR CANC RES,CAMBRIDGE,MA 02139, USA.		Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494				BEKKERS JH, 1990, COLD SPRING HARBOR S, V50; BENSON DL, 1991, J NEUROSCI, V11, P1540; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CASTRO CA, 1989, NATURE, V342, P545, DOI 10.1038/342545a0; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DAVIS M, 1992, TRENDS PHARMACOL SCI, V13, P35, DOI 10.1016/0165-6147(92)90014-W; DAVIS S, 1992, J NEUROSCI, V12, P21; DOUGLAS RJ, 1964, PSYCHON SCI, V1, P187, DOI 10.3758/BF03342856; Eccles, 2013, PHYSL SYNAPSES; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FOREMAN NP, 1983, PHYSIOL BEHAV, V30, P711, DOI 10.1016/0031-9384(83)90167-1; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HEBB DO, 1949, ORG BEHAVIOR; KEITH JR, 1990, PSYCHOBIOLOGY, V18, P251; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KIMBLE DP, 1963, J COMP PHYSIOL PSYCH, V56, P273, DOI 10.1037/h0048903; LEATON RN, 1981, J COMP PHYSIOL PSYCH, V95, P813, DOI 10.1037/h0077832; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALLINOW R, 1989, SCIENCE, V245, P862; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OGORMAN S, 1991, SCIENCE, V251, P135; PAYLOR R, UNPUB; ROBERTS WW, 1986, J COMP PHYSIOL PSYCH, V55, P695; SCHWARTZKROIN PA, 1975, BRAIN RES, V89, P107, DOI 10.1016/0006-8993(75)90138-9; SILVA AJ, 1992, SCIENCE, V257, P204; STAUBLI U, 1989, BEHAV NEUROSCI, V103, P54, DOI 10.1037/0735-7044.103.1.54; SUTHERLAND R J, 1991, Society for Neuroscience Abstracts, V17, P483; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TEITELBAUM H, 1963, J COMP PHYSIOL PSYCH, V56, P284, DOI 10.1037/h0047052; UPCHURCH M, 1988, PHARMACOL BIOCHEM BE, V29, P325, DOI 10.1016/0091-3057(88)90164-5; UPCHURCH M, 1988, BEHAV GENET, V18, P55, DOI 10.1007/BF01067075; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; WHISHAW IQ, 1984, BEHAV BRAIN RES, V11, P123, DOI 10.1016/0166-4328(84)90135-9	40	1048	1087	2	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					206	211		10.1126/science.1321493	http://dx.doi.org/10.1126/science.1321493			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JC585	1321493				2022-12-28	WOS:A1992JC58500027
J	SPERBER, SJ; HENDLEY, JO; HAYDEN, FG; RIKER, DK; SORRENTINO, JV; GWALTNEY, JM				SPERBER, SJ; HENDLEY, JO; HAYDEN, FG; RIKER, DK; SORRENTINO, JV; GWALTNEY, JM			EFFECTS OF NAPROXEN ON EXPERIMENTAL RHINOVIRUS COLDS - A RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							BRADYKININ; INFECTION; ASPIRIN; FIBROBLASTS; KININS	Objective: To determine whether naproxen, a propionic acid inhibitor of cyclooxygenase, alters the course of experimental rhinovirus colds. Design: A randomized, double-blind, controlled trial. Setting: Rhinovirus challenge model in volunteers cloistered in individual hotel rooms. Volunteers: Eighty-seven healthy young adults with serum neutralizing antibody titers of less-than-or-equal-to 1:2 to the challenge virus; 79 were evaluable. Intervention: Thirty-nine participants received naproxen (loading dose, 400 mg or 500 mg followed by 200 mg or 500 mg three times daily for 5 days). Forty participants received placebo. Treatment was started 6 hours after viral challenge. Measurements: Daily measurement of viral titers, symptoms, nasal mucus production, and nasal tissue use; incidence of infection and illness; and measurement of homotypic serum neutralizing antibody responses. Results: Viral titers and serum homotypic antibody responses were similar in the naproxen and placebo groups. Significant reductions in headache, malaise, myalgia, and cough occurred in the naproxen group. A 29% reduction was noted in the total (5-day) symptom score in the naproxen group (95% Cl, 16% to 42%). Conclusion: Naproxen treatment did not alter virus shedding or serum neutralizing antibody responses in participants with experimental rhinovirus colds, but it had a beneficial effect on the symptoms of headache, malaise, myalgia, and cough. Prostaglandins may be among the inflammatory mediators that play a role in the pathogenesis of rhinovirus colds.	UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, NEW BRUNSWICK, NJ USA; RICHARDSON VICKS USA, SHELTON, CT USA	University of Virginia; Rutgers State University New Brunswick; Rutgers State University Medical Center			Riker, Donald/AAR-8380-2020					BAREIS DL, 1983, P NATL ACAD SCI-BIOL, V80, P2514, DOI 10.1073/pnas.80.9.2514; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; FARR BM, 1990, J INFECT DIS, V162, P1173, DOI 10.1093/infdis/162.5.1173; GAFFEY MJ, 1987, AM REV RESPIR DIS, V135, P241; GAFFEY MJ, 1987, AM REV RESPIR DIS, V136, P556, DOI 10.1164/ajrccm/136.3.556; GAFFEY MJ, 1988, ANTIMICROB AGENTS CH, V32, P1644, DOI 10.1128/AAC.32.11.1644; GRAHAM NMH, 1990, J INFECT DIS, V162, P1277, DOI 10.1093/infdis/162.6.1277; GWALTNEY JM, 1980, J INFECT DIS, V142, P811, DOI 10.1093/infdis/142.6.811; GWALTNEY JM, 1989, DIAGNOSTIC PROCEDURE, P604; HAYDEN FG, 1982, ANTIMICROB AGENTS CH, V21, P892, DOI 10.1128/AAC.21.6.892; HEAVEY DJ, 1985, NATURE, V318, P186, DOI 10.1038/318186a0; HIGGINS PG, 1990, ANTIVIR RES, V14, P339, DOI 10.1016/0166-3542(90)90052-9; HONG SCL, 1976, J BIOL CHEM, V251, P5814; HORI Y, 1986, EUR J PHARMACOL, V132, P47, DOI 10.1016/0014-2999(86)90007-5; HSIA J, 1989, B NEW YORK ACAD MED, V65, P45; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; Katsu M, 1978, Kansenshogaku Zasshi, V52, P148; LEIKAUF GD, 1985, AM J PHYSIOL, V248, pF48, DOI 10.1152/ajprenal.1985.248.1.F48; MONCADA S, 1979, BRIT J PHARMACOL, V66, pP96; NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; SPERBER SJ, 1989, B NEW YORK ACAD MED, V65, P145; STANLEY ED, 1975, JAMA-J AM MED ASSOC, V231, P1248, DOI 10.1001/jama.231.12.1248; TODD PA, 1990, DRUGS, V40, P91, DOI 10.2165/00003495-199040010-00006; TURNER RB, 1982, J INFECT DIS, V145, P849, DOI 10.1093/infdis/145.6.849; WHALLEY ET, 1979, J PHARM PHARMACOL, V31, P486, DOI 10.1111/j.2042-7158.1979.tb13565.x	26	74	76	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					37	41		10.7326/0003-4819-117-1-37	http://dx.doi.org/10.7326/0003-4819-117-1-37			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1317694				2022-12-28	WOS:A1992JA43500006
J	HONG, SC; CHELOUCHE, A; LIN, RH; SHAYWITZ, D; BRAUNSTEIN, NS; GLIMCHER, L; JANEWAY, CA				HONG, SC; CHELOUCHE, A; LIN, RH; SHAYWITZ, D; BRAUNSTEIN, NS; GLIMCHER, L; JANEWAY, CA			AN MHC INTERACTION SITE MAPS TO THE AMINO-TERMINAL HALF OF THE T-CELL RECEPTOR ALPHA-CHAIN VARIABLE DOMAIN	CELL			English	Article							CLASS-II MHC; ANTIGEN-BINDING SITE; BETA-CHAIN; MONOCLONAL-ANTIBODY; FOREIGN ANTIGEN; DIRECTED MUTAGENESIS; JUNCTIONAL REGIONS; RECOGNITION; SPECIFICITY; MOLECULES	We have used cloned T cell receptor (TCR) genes from closely related CD4 T cell lines to probe the interaction of the TCR with several specific major histocompatibility complex (MHC) class II ligands. Complementarity determining region 3 (CDR3) equivalents of both alpha and beta-TCR chains are required for antigen-MHC recognition. Our data provide novel information about the rotational orientation of TCR-MHC contacts in that exchange of the amino terminal portion of the TCR alpha-chain containing the putative CDR1 and CDR2 regions results in both gain and loss of MHC class II specificity by the resulting receptor. These two TCRs differ primarily in recognition of polymorphisms in the second hypervariable region of the MHC class II alpha-chain. These results document the involvement of CDR1 and/or CDR2 of the TCR alpha-chain in MHC recognition and suggest a rotational orientation of this TCR to its MHC ligand.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV RHEUMATOL, NEW YORK, NY 10032 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA	Columbia University; Harvard University; Harvard T.H. Chan School of Public Health	HONG, SC (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014579, R37AI014579] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-14579] Funding Source: Medline; NIGMS NIH HHS [GM39275] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; AJITKUMAR P, 1988, CELL, V54, P47, DOI 10.1016/0092-8674(88)90178-X; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ASHWELL JD, 1986, J IMMUNOL, V136, P389; BARBER LD, 1991, J IMMUNOL, V147, P2346; BERKOWITZ N, 1992, J IMMUNOL, V148, P309; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUERSTEDDE JM, 1989, J EXP MED, V169, P1645, DOI 10.1084/jem.169.5.1645; BUERSTEDDE JM, 1988, J EXP MED, V167, P473, DOI 10.1084/jem.167.2.473; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; COHN LE, 1986, P NATL ACAD SCI USA, V83, P747, DOI 10.1073/pnas.83.3.747; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DAVIS CB, 1989, J EXP MED, V169, P2239, DOI 10.1084/jem.169.6.2239; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELLABONA P, 1991, EUR J IMMUNOL, V21, P209, DOI 10.1002/eji.1830210131; DEMOTZ S, 1991, P NATL ACAD SCI USA, V88, P8730, DOI 10.1073/pnas.88.19.8730; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; ECKELS DD, 1990, HUM IMMUNOL, V27, P240, DOI 10.1016/0198-8859(90)90054-S; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; ESCH TR, 1989, CELL IMMUNOL, V123, P226, DOI 10.1016/0008-8749(89)90282-7; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GLIMCHER LH, 1987, IMMUNOL TODAY, V8, P274, DOI 10.1016/0167-5699(87)90188-5; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; HEDRICK SM, 1988, ADV IMMUNOL, V43, P193; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JANEWAY CA, 1982, BEHRING I MITT, V70, P200; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KARR RW, 1990, J EXP MED, V172, P273, DOI 10.1084/jem.172.1.273; KAYE J, 1988, NATURE, V336, P580, DOI 10.1038/336580a0; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KLEIN J, 1986, NATURAL HIST MAJOR H; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAI MZ, 1990, J IMMUNOL, V144, P4851; LANG B, 1990, HUM IMMUNOL, V27, P378, DOI 10.1016/0198-8859(90)90088-7; LECHLER RI, 1990, IMMUNOL TODAY, V11, P83, DOI 10.1016/0167-5699(90)90033-6; LEE JM, 1991, J IMMUNOL, V146, P2952; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOMBARDI G, 1991, J IMMUNOL, V147, P2034; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MELLINS E, 1990, P NATL ACAD SCI USA, V87, P4785, DOI 10.1073/pnas.87.12.4785; NAKAGAWA TY, 1991, EUR J IMMUNOL, V21, P2851, DOI 10.1002/eji.1830211129; NALEFSKI EA, 1990, J BIOL CHEM, V265, P8842; PANINABORDIGNON P, 1989, COLD SPRING HARB SYM, V54, P445; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PORTOLES P, 1989, J MOL CELL IMMUNOL, V4, P129; PORTOLES P, 1989, J IMMUNOL, V142, P4169; PORTOLES P, 1989, EUR J IMMUNOL, V19, P83, DOI 10.1002/eji.1830190114; ROJO JM, 1988, J IMMUNOL, V140, P1081; ROJO JM, 1989, EUR J IMMUNOL, V19, P2061, DOI 10.1002/eji.1830191114; ROSLONIEC EF, 1989, J IMMUNOL, V143, P50; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SAITO T, 1987, NATURE, V329, P256, DOI 10.1038/329256a0; SORGER SB, 1990, IMMUNOGENETICS, V31, P118, DOI 10.1007/BF00661222; STAERZ UD, 1985, J IMMUNOL, V134, P3994; VONBOEHMER H, 1989, IMMUNOL TODAY, V10, P57, DOI 10.1016/0167-5699(89)90307-1; VONBOEHMER H, 1979, EUR J IMMUNOL, V9, P592, DOI 10.1002/eji.1830090804; WEI BY, 1991, INT IMMUNOL, V3, P833, DOI 10.1093/intimm/3.8.833; WILSON DB, 1968, J EXP MED, V128, P1157, DOI 10.1084/jem.128.5.1157; WINOTO A, 1986, NATURE, V324, P679, DOI 10.1038/324679a0; YAGI JJ, 1990, J IMMUNOL, V144, P892; Zinkernagel R.M., 1979, ADV IMMUNOL, V27, P52	73	96	96	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					999	1009		10.1016/0092-8674(92)90618-M	http://dx.doi.org/10.1016/0092-8674(92)90618-M			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1318787	hybrid			2022-12-28	WOS:A1992HY79200011
J	HIBBS, JR; FRICKHOFEN, N; ROSENFELD, SJ; FEINSTONE, SM; KOJIMA, S; BACIGALUPO, A; LOCASCIULLI, A; TZAKIS, AG; ALTER, HJ; YOUNG, NS				HIBBS, JR; FRICKHOFEN, N; ROSENFELD, SJ; FEINSTONE, SM; KOJIMA, S; BACIGALUPO, A; LOCASCIULLI, A; TZAKIS, AG; ALTER, HJ; YOUNG, NS			APLASTIC-ANEMIA AND VIRAL-HEPATITIS - NON-A, NON-B, NON-C	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS; HEMOPHILIACS; SERUM	Objective. - To test the hypothesis that the rare, often fatal, syndrome of hepatitis-associated aplasia is associated with hepatitis C virus infection. Design. - Case series. Setting. - Tertiary referral centers in the United States, Japan, Italy, and Germany. Patients. - Twenty-eight patients with onset of aplastic anemia within 90 days after seeking medical attention for jaundice, or having serum transaminase levels 150% or more of normal (hepatitis-associated aplasia patients) and three patients who developed aplastic anemia following liver transplantation for non-A, non-B hepatitis. Outcome Measures. - Presence of hepatitis C in serum, bone marrow, and liver samples, detected by the polymerase chain reaction; antibody testing; and percentage of activated peripheral cytotoxic T lymphocytes determined by immunophenotyping. Results. - Hepatitis ribonucleic acid was present in the serum samples of 10 (36%) patients with hepatitis-associated aplasia. However, hepatitis C virus viremia was associated with transfusions received after the onset of aplasia: seven (58%) of 12 patients with hepatitis-associated aplasia who had received 21 or more units of blood products at the time of serum sampling were viremic, compared with only three (19%) of 16 patients with hepatitis-associated aplasia who had received 20 or less units of blood products (P < .05). Hepatitis C virus was not found in blood and bone marrow samples of three National Institutes of Health case patients tested at the time of diagnosis. None of three livers from non-A, non-B hepatitis patients who developed aplastic anemia after liver transplantation contained hepatitis C virus ribonucleic acid. Activated CD8+ T lymphocytes were elevated three- to 20-fold early in the course of hepatitis-associated aplasia. Conclusions. - Our results implicate a novel, non-A, non-B, and non-C agent in both hepatitis-associated aplasia and fulminant hepatitis.	US FDA,CTR BIOL EVALUAT & RES,DIV VIROL,KENSINGTON,MD; NIH,DEPT TRANSFUS MED,BETHESDA,MD 20892; NAGOYA HOSP 1ST,JAPANESE RED CROSS,CHILDRENS MED CTR,DIV HEMATOL ONCOL,NAGOYA,JAPAN; SAN MARTINO HOSP,DIV HEMATOL 2,CTR BONE MARROW TRANSPLANT,GENOA,ITALY; UNIV ULM,DEPT MED 3,W-7900 ULM,GERMANY; HOSP SAN GERARDO,DIV PEDIAT HEMATOL,MILAN,ITALY; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; University of Genoa; IRCCS AOU San Martino IST; Ulm University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	HIBBS, JR (corresponding author), NHLBI,CLIN HEMATOL BRANCH,10-7C103,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F35HL008279] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08279-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; FOON KA, 1984, ANN INTERN MED, V100, P657, DOI 10.7326/0003-4819-100-5-657; GARSON JA, 1990, LANCET, V336, P1022, DOI 10.1016/0140-6736(90)92487-3; HAGLER L, 1975, MEDICINE, V54, P139, DOI 10.1097/00005792-197554020-00003; Hardy WD, 1980, FELINE LEUKEMIA VIRU; ISSARAGRISIL S, 1991, BLOOD, V77, P2166; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KURTZMAN GJ, 1989, BLOOD, V74, P71; LINET MS, 1985, ARCH INTERN MED, V145, P635, DOI 10.1001/archinte.145.4.635; LINET MS, 1989, LEUKEMIA RES, V13, P3, DOI 10.1016/0145-2126(89)90025-8; NAKAO S, 1989, BLOOD, V74, P1235; PERRILLO RP, 1981, JAMA-J AM MED ASSOC, V245, P494, DOI 10.1001/jama.245.5.494; PHILLIPS MJ, 1991, NEW ENGL J MED, V324, P455, DOI 10.1056/NEJM199102143240705; POL S, 1990, ANN INTERN MED, V113, P435; Sambrook J, 1989, MOL CLONING LABORATO; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; TZAKIS AG, 1988, NEW ENGL J MED, V319, P393, DOI 10.1056/NEJM198808183190702; ULRICH PP, 1990, J CLIN INVEST, V86, P1609, DOI 10.1172/JCI114882; WANG WC, 1986, AM J MED SCI, V291, P304, DOI 10.1097/00000441-198605000-00003; YOUNG NS, 1986, BRIT J HAEMATOL, V62, P1, DOI 10.1111/j.1365-2141.1986.tb02893.x; YOUNG NS, 1990, JAMA-J AM MED ASSOC, V263, P3065, DOI 10.1001/jama.263.22.3065; YOUNG NS, 1992, CECILS TXB MED, P831; ZELDIS JB, 1983, AM J MED, V74, P64, DOI 10.1016/0002-9343(83)91119-1; ZOUMBOS NC, 1985, NEW ENGL J MED, V312, P257, DOI 10.1056/NEJM198501313120501; [No title captured]	31	96	99	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2051	2054						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1313118				2022-12-28	WOS:A1992HM65000030
J	KAUFMAN, PD; RIO, DC				KAUFMAN, PD; RIO, DC			P-ELEMENT TRANSPOSITION INVITRO PROCEEDS BY A CUT-AND-PASTE MECHANISM AND USES GTP AS A COFACTOR	CELL			English	Article							TRANSPOSABLE ELEMENT; BACTERIOPHAGE-MU; STRAND TRANSFER; DROSOPHILA; DNA; PROTEIN; VECTORS; TRANSFORMATION; INTEGRATION; PRODUCT	We have developed an in vitro reaction system for Drosophila P element transposition. Transposition products were recovered by selection in E. coli, and contained simple P element insertions flanked by 8 bp target site duplications as observed in vivo. Transposition required Mg+2 and partially purified P element transposase. Unlike other DNA rearrangement reactions, P element transposition in vitro used GTP as a cofactor; deoxyGTP, dideoxyGTP, or the nonhydrolyzable GTP analogs GMP-PNP or GMP-PCP were also used. Transposon DNA molecules cleaved at the P element termini were able to transpose, but those lacking 3'-hydroxyl groups were inactive. These biochemical data are consistent with genetic data suggesting that P element transposition occurs via a "cut-and-paste" mechanism.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)				Kaufman, Paul/0000-0003-3089-313X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD022857] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22857] Funding Source: Medline; NIGMS NIH HHS [GM47394] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg DE, 1989, MOBILE DNA; BERG DE, 1989, MOBILE DNA, P185; BOUROUIS M, 1983, EMBO J, V2, P1099, DOI 10.1002/j.1460-2075.1983.tb01552.x; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CRAIG NL, 1990, CELL, V62, P399, DOI 10.1016/0092-8674(90)90001-U; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; Engels W.R, 1989, MOBILE DNA, P437; ENGELS WR, 1984, SCIENCE, V226, P1194, DOI 10.1126/science.6095450; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GLOOR GB, 1991, SCIENCE, V253, P1110, DOI 10.1126/science.1653452; HANIFORD DB, 1991, CELL, V64, P171; ICHIKAWA H, 1990, J BIOL CHEM, V265, P18829; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KAUFMAN PD, 1991, NUCLEIC ACIDS RES, V19, P6336, DOI 10.1093/nar/19.22.6336; KAUFMAN PD, 1989, CELL, V59, P359, DOI 10.1016/0092-8674(89)90297-3; KAUFMAN PD, 1991, P NATL ACAD SCI USA, V88, P2613, DOI 10.1073/pnas.88.7.2613; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PAL SK, 1988, J BACTERIOL, V170, P3554, DOI 10.1128/jb.170.8.3554-3560.1988; PALL ML, 1985, CURR TOP CELL REGUL, V25, P1; Pato ML, 1989, MOBILE DNA, P23; RIO DC, 1988, P NATL ACAD SCI USA, V85, P8929, DOI 10.1073/pnas.85.23.8929; RIO DC, 1990, ANNU REV GENET, V24, P543; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; RIO DC, 1991, TRENDS GENET, V7, P282, DOI 10.1016/0168-9525(91)90176-Q; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; THOMPSON JF, 1989, MOBILE DNA, P1; TSUBOTA SI, 1991, P NATL ACAD SCI USA, V88, P693, DOI 10.1073/pnas.88.3.693; [No title captured]	44	124	135	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					27	39		10.1016/0092-8674(92)90116-T	http://dx.doi.org/10.1016/0092-8674(92)90116-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1313335				2022-12-28	WOS:A1992HM44500004
J	FERRIS, CD; CAMERON, AM; HUGANIR, RL; SNYDER, SH				FERRIS, CD; CAMERON, AM; HUGANIR, RL; SNYDER, SH			QUANTAL CALCIUM RELEASE BY PURIFIED RECONSTITUTED INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; LIPID VESICLES; TRISPHOSPHATE; PHOSPHATES; EXPRESSION; MECHANISM; FLUX	RELEASE of intracellular Ca2+ by inositol 1,4,5-trisphosphate (InsP3) occurs through specific receptor proteins 1 which are ligand-activated Ca2+ channels 2. Changes in intracellular Ca2+ regulate many cellular functions 3. This Ca2+ release is a discontinuous quantal process in which successive increments of InsP3 transiently release precise amounts of Ca2+ (refs 4-6). Possible explanations of quantal Ca2+ release have included rapid degradation of InsP3, reciprocity of Ca2+ release and sequestration, desensitization of InsP3 receptors 7, or actions of InsP3 on discrete compartments of Ca2+ with variable sensitivity to InsP3 (ref. 4). We successfully reconstituted InsP3-induced Ca2+ flux in vesicles containing only purified InsP3 receptor protein 2. The reconstituted vesicles retain the regulatory features of the InsP3 receptor, including phosphorylation sites 8 and modulation of Ca2+ release by adenine nucleotides 9. Using these reconstituted vesicles, we show here that quantal flux of Ca2+ elicited by InsP3 is a fundamental property of its receptor.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FERRIS CD, 1991, REV PHYSL, V54, P469; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1982, J BIOL CHEM, V257, P9372; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; ROSS CA, 1991, SOC NEUR ABSTR; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530	24	131	131	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					350	352		10.1038/356350a0	http://dx.doi.org/10.1038/356350a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1312682				2022-12-28	WOS:A1992HK79400068
J	DRISCOLL, J; FINLEY, D				DRISCOLL, J; FINLEY, D			A CONTROLLED BREAKDOWN - ANTIGEN PROCESSING AND THE TURNOVER OF VIRAL-PROTEINS	CELL			English	Review							MAJOR HISTOCOMPATIBILITY COMPLEX; UBIQUITIN; IDENTIFICATION; PROTEASE; CELLS				DRISCOLL, J (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115, USA.			Driscoll, James/0000-0001-8364-0617				ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GERMAIN RN, 1991, NATURE, V353, P605, DOI 10.1038/353605a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GUARINO LA, 1990, P NATL ACAD SCI USA, V87, P409, DOI 10.1073/pnas.87.1.409; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; IJZERMANS JNM, 1989, IMMUNOBIOLOGY, V179, P456, DOI 10.1016/S0171-2985(89)80049-X; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KNIGHT E, 1991, J IMMUNOL, V146, P2280; LOEB KR, 1992, IN PRESS J BIOL CHEM; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; RODRIGUEZ JM, 1991, VIROLOGY, V186, P40; SARGENT CA, 1989, P NATL ACAD SCI USA, V86, P1968, DOI 10.1073/pnas.86.6.1968; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R	34	61	65	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					823	825		10.1016/0092-8674(92)90024-7	http://dx.doi.org/10.1016/0092-8674(92)90024-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1312390				2022-12-28	WOS:A1992HH74800002
J	HOTH, M; PENNER, R				HOTH, M; PENNER, R			DEPLETION OF INTRACELLULAR CALCIUM STORES ACTIVATES A CALCIUM CURRENT IN MAST-CELLS	NATURE			English	Article							INOSITOL TRISPHOSPHATE; CA-2+ RELEASE; INFLUX; ENTRY; PHOSPHATES; MESSENGERS; IONOMYCIN; CHANNELS; MN-2+	IN many cell types, receptor-mediated Ca2+ release from internal stores is followed by Ca2+ influx across the plasma membrane 1-3. The sustained entry of Ca2+ is thought to result partly from the depletion of intracellular Ca2+ pools 4,5. Most investigations have characterized Ca2+ influx indirectly by measuring Ca2+-activated currents 6-9 or using Fura-2 quenching by Mn2+, which in some cells enters the cells by the same influx pathway 10,11 But only a few studies have investigated this Ca2+ entry pathway more directly 12-14. We have combined patch-clamp and Fura-2 measurements to monitor membrane currents in mast cells under conditions where intracellular Ca2+ stores were emptied by either inositol 1,4,5-trisphosphate, ionomycin, or excess of the Ca2+ chelator EGTA. The depletion of Ca2+ pools by these independent mechanisms commonly induced activation of a sustained calcium inward current that was highly selective for Ca2+ ions over Ba2+, Sr2+ and Mn2+. This Ca2+ current, which we term I(CRAC) (calcium release-activated calcium), is not voltage-activated and shows a characteristic inward rectification. It may be the mechanism by which electrically nonexcitable cells maintain raised intracellular Ca2+ concentrations and replenish their empty Ca2+ stores after receptor stimulation.			HOTH, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM, W-3400 GOTTINGEN, GERMANY.			Hoth, Markus/0000-0001-7080-4643; Penner, Reinhold/0000-0002-5366-1537				ALBERT PR, 1984, J BIOL CHEM, V259, P5350; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CULLEN PJ, 1988, FEBS LETT, V228, P57, DOI 10.1016/0014-5793(88)80584-2; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KASS GEN, 1990, J BIOL CHEM, V265, P17486; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LIU CM, 1978, J BIOL CHEM, V253, P5892; LLANO I, 1987, PFLUG ARCH EUR J PHY, V409, P499, DOI 10.1007/BF00583807; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P131, DOI 10.1113/jphysiol.1989.sp017831; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUHLEN FV, 1991, P NATL ACAD SCI USA, V88, P926, DOI 10.1073/pnas.88.3.926; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466	26	1500	1530	4	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1992	355	6358					353	356		10.1038/355353a0	http://dx.doi.org/10.1038/355353a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA591	1309940				2022-12-28	WOS:A1992HA59100069
J	BUCHWALD, D; CHENEY, PR; PETERSON, DL; HENRY, B; WORMSLEY, SB; GEIGER, A; ABLASHI, DV; SALAHUDDIN, SZ; SAXINGER, C; BIDDLE, R; KIKINIS, R; JOLESZ, FA; FOLKS, T; BALACHANDRAN, N; PETER, JB; GALLO, RC; KOMAROFF, AL				BUCHWALD, D; CHENEY, PR; PETERSON, DL; HENRY, B; WORMSLEY, SB; GEIGER, A; ABLASHI, DV; SALAHUDDIN, SZ; SAXINGER, C; BIDDLE, R; KIKINIS, R; JOLESZ, FA; FOLKS, T; BALACHANDRAN, N; PETER, JB; GALLO, RC; KOMAROFF, AL			A CHRONIC ILLNESS CHARACTERIZED BY FATIGUE, NEUROLOGIC AND IMMUNOLOGICAL DISORDERS, AND ACTIVE HUMAN HERPESVIRUS TYPE-6 INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						FATIGUE SYNDROME, CHRONIC; HERPESVIRUS-6, HUMAN; NEUROLOGIC MANIFESTATIONS; FATIGUE; IMMUNOLOGICAL DISEASES	BARR VIRUS-INFECTION; CHRONIC MONONUCLEOSIS SYNDROME; NATURAL-KILLER CELLS; MAGNETIC-RESONANCE; HUMAN-LYMPHOCYTES; SYNDROME AIDS; HUMAN-DISEASE; T-CELLS; HHV-6; HBLV	Objective: To conduct neurologic, immunologic, and virologic studies in patients with a chronic debilitating illness of acute onset. Design: Cohort study with comparison to matched, healthy control subjects. Patients: We studied 259 patients who sought care in one medical practice; 29% of the patients were regularly bedridden or shut-in. Main Outcome Measures: Detailed medical history, physical examination, conventional hematologic and chemistry testing, magnetic resonance imaging (MRI) studies lymphocyte phenotyping studies, and assays for active infection of patients' lymphocytes with human herpesvirus type 6 (HHV-6). Main Results: Patients had a higher mean (+/- SD) CD4/CD8 T-cell ratio than matched healthy controls (3.16 +/- 1.5 compared with 2.3 +/- 1.0, respectively; P < 0.003). Magnetic resonance scans of the brain showed punctate, subcortical areas of high signal intensity consistent with edema or demyelination in 78% of patients (95% Cl, 72% to 86%) and in 21% of controls (Cl, 11% to 36%) (P < 10(-9)). Primary cell culture of lymphocytes showed active replication of HHV-6 in 79 of 113 patients (70%; Cl, 61% to 78%) and in 8 of 40 controls (20%; Cl, 9% to 36%) (P < 10(-8)), a finding confirmed by assays using monoclonal antibodies specific for HHV-6 proteins and by polymerase chain reaction assays specific for HHV-6 DNA. Conclusions: Neurologic symptoms, MRI findings, and lymphocyte phenotyping studies suggest that the patients may have been experiencing a chronic, immunologically mediated inflammatory process of the central nervous system. The active replication of HHV-6 most likely represents reactivation of latent infection, perhaps due to immunologic dysfunction. Our study did not directly address whether HHV-6, a lymphotropic and gliotropic virus, plays a role in producing the symptoms or the immunologic and neurologic dysfunction seen in this illness. Whether the findings in our patients, who came from a relatively small geographic area, will be generalizable to other patients with a similar syndrome remains to be seen.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED, 75 FRANCIS ST, BOSTON, MA 02115 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA; WASHOE CTY SHERIFFS DIV, DIV FORENS SCI, RENO, NV 89512 USA; CYTOMETRY ASSOCIATES, SAN DIEGO, CA 92121 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV SO CALIF, HUNTINGTON MEM HOSP, AIDS RES LAB, PASADENA, CA 91105 USA; NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA; STOCKTON RADIOL MED GRP, STOCKTON, CA 95204 USA; CTR DIS CONTROL, DIV VIROL, ATLANTA, GA 30333 USA; UNIV KANSAS, MED CTR, DEPT MICROBIOL, KANSAS CITY, KS 66103 USA; SPECIALTY LABS INC, SANTA MONICA, CA 90009 USA	Harvard University; Brigham & Women's Hospital; Harborview Medical Center; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern California; Huntington Memorial Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centers for Disease Control & Prevention - USA; University of Kansas; University of Kansas Medical Center			Ablashi, Dharam/AAE-8934-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032246, R01AI027314, R01AI026788] Funding Source: NIH RePORTER; NIAID NIH HHS [U01AI32246, R01AI27314, R01AI26788] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; ABLASHI DV, 1991, VIROLOGY, V184, P545, DOI 10.1016/0042-6822(91)90424-A; ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; AOKI T, 1987, NAT IMMUN CELL GROW, V6, P116; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; AWAD IA, 1987, NEUROSURGERY, V20, P222, DOI 10.1227/00006123-198702000-00004; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BHAGAVATI S, 1988, NEW ENGL J MED, V318, P1141, DOI 10.1056/NEJM198805053181801; BRADLEY WG, 1984, NONINVASIVE MED IMAG, V1, P35; BUCHWALD D, 1990, J CLIN IMMUNOL, V10, P335, DOI 10.1007/BF00917479; BUCHWALD D, 1991, REV INFECT DIS, V13, pS12; BUCHWALD D, 1987, ARTHRITIS RHEUM, V30, P1132, DOI 10.1002/art.1780301007; BUCHWALD D, 1987, JAMA-J AM MED ASSOC, V257, P2303, DOI 10.1001/jama.257.17.2303; CALIGIURI M, 1987, J IMMUNOL, V139, P3306; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; COYLE PK, 1990, ANN NEUROL, V28, P243; CUNNINGHAM L, 1990, J GEN VIROL, V71, P1399, DOI 10.1099/0022-1317-71-6-1399; DALE JK, 1989, ANN INTERN MED, V110, P92, DOI 10.7326/0003-4819-110-1-92; DEFREITAS E, 1991, P NATL ACAD SCI USA, V88, P2922, DOI 10.1073/pnas.88.7.2922; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; FOLKS T, 1986, J IMMUNOL, V136, P4049; FRENKEL N, 1990, P NATL ACAD SCI USA, V87, P748, DOI 10.1073/pnas.87.2.748; FRENKEL N, 1990, J VIROL, V64, P4598, DOI 10.1128/JVI.64.9.4598-4602.1990; GOLDENBERG DL, 1987, JAMA-J AM MED ASSOC, V257, P2782, DOI 10.1001/jama.257.20.2782; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; GUPTA S, 1991, SCAND J IMMUNOL, V33, P319, DOI 10.1111/j.1365-3083.1991.tb01777.x; HEIER LA, 1989, AM J NEURORADIOL, V10, P929; HENDERSON DA, 1959, NEW ENGL J MED, V260, P757, DOI 10.1056/NEJM195904092601506; HENLE W, 1979, DIAGNOSTIC PROCEDURE, P441; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JENKINS R, 1991, POST VIRAL FATIGUE S; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; JOSEPHS SF, 1991, LANCET, V337, P1346, DOI 10.1016/0140-6736(91)93018-5; JOSEPHS SF, 1986, SCIENCE, V234, P601, DOI 10.1126/science.3020691; JUNGREIS CA, 1988, RADIOLOGY, V169, P101, DOI 10.1148/radiology.169.1.3420242; KIBLER R, 1985, J CLIN IMMUNOL, V5, P46, DOI 10.1007/BF00915168; KIRKPATRICK JB, 1987, RADIOLOGY, V162, P509, DOI 10.1148/radiology.162.2.3797666; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; KOMAROFF AL, 1990, AM J CLIN PATHOL, V93, P836; KOMAROFF AL, 1988, CLIN RES, V36, pA743; KOMAROFF AL, 1987, HOSP PRACT, V22, P71; KOMAROFF AL, 1988, J VIROL METHODS, V21, P3, DOI 10.1016/0166-0934(88)90047-X; Krueger G R, 1991, In Vivo, V5, P287; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; LEVY JA, 1990, VIROLOGY, V178, P113, DOI 10.1016/0042-6822(90)90384-4; LEVY JA, 1990, LANCET, V335, P1047, DOI 10.1016/0140-6736(90)92628-U; LLOYD AR, 1989, MED J AUSTRALIA, V151, P122, DOI 10.5694/j.1326-5377.1989.tb139594.x; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MURDOCH JC, 1988, NEW ZEAL MED J, V101, P511; POSKANZER DC, 1957, NEW ENGL J MED, V257, P356, DOI 10.1056/NEJM195708222570802; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SALIT IE, 1985, CAN MED ASSOC J, V133, P659; SAXINGER C, 1988, J VIROL METHODS, V21, P199, DOI 10.1016/0166-0934(88)90066-3; SHELOKOV A, 1957, NEW ENGL J MED, V257, P345, DOI 10.1056/NEJM195708222570801; SIGURDSSON B, 1956, LANCET, V270, P766; SIGURDSSON B, 1950, AM J HYG, V52, P222, DOI 10.1093/oxfordjournals.aje.a119421; STRAUS SE, 1988, J INFECT DIS, V157, P405, DOI 10.1093/infdis/157.3.405; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; SZE G, 1986, AM J NEURORADIOL, V7, P381; TOBI M, 1982, LANCET, V1, P61; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584; WHITESIDE TL, 1989, CLIN IMMUNOL IMMUNOP, V53, P1, DOI 10.1016/0090-1229(89)90096-2; YOUSEF GE, 1988, LANCET, V1, P146; ZIMMERMAN RD, 1986, AM J ROENTGENOL, V146, P443, DOI 10.2214/ajr.146.3.443; 1957, BRIT MED J, V2, P895	70	279	287	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1992	116	2					103	113		10.7326/0003-4819-116-2-103	http://dx.doi.org/10.7326/0003-4819-116-2-103			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ356	1309285				2022-12-28	WOS:A1992GZ35600002
J	GODLEE, F				GODLEE, F			MEDICINAL-PLANTS - ANOTHER MANS POISON	BRITISH MEDICAL JOURNAL			English	Article																		FELLOWS LE, 1922, NEW DRUGS NATURAL SO; FLINT M, 1991, BIOL RESOURCES DEV C; SCALISE JA, 1988, VET HUM TOXICOL, V30, P426	3	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1583	1585		10.1136/bmj.305.6868.1583	http://dx.doi.org/10.1136/bmj.305.6868.1583			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286403	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KD77100042
J	GRACE, PA				GRACE, PA			DOCTORS DIFFER OVER THE GERMAN CROWN-PRINCE	BRITISH MEDICAL JOURNAL			English	Item About an Individual											GRACE, PA (corresponding author), ROYAL COLL SURG IRELAND,BEAUMONT HOSP,DEPT SURG,DUBLIN 9,IRELAND.							Mackenzie M, 1888, FATAL ILLNESS FREDER; MASSIE RK, 1992, DREDNOUGHT, P38; PONSONBY F, 1928, LETT EMPRESS FREDERI; THOMSON SC, 1939, J LARYNGOL OTOL, V54, P61; THOREK M, 1945, J INT COLL SURG, V8, P555; VONBISMARK O, 1898, BISMARK MAN STATESMA, P331; 1888, BMJ, V2, P836	7	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1536	1538		10.1136/bmj.305.6868.1536	http://dx.doi.org/10.1136/bmj.305.6868.1536			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286375	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992KD77100012
J	ELLERBROCK, TV; LIEB, S; HARRINGTON, PE; BUSH, TJ; SCHOENFISCH, SA; OXTOBY, MJ; HOWELL, JT; ROGERS, MF; WITTE, JJ				ELLERBROCK, TV; LIEB, S; HARRINGTON, PE; BUSH, TJ; SCHOENFISCH, SA; OXTOBY, MJ; HOWELL, JT; ROGERS, MF; WITTE, JJ			HETEROSEXUALLY TRANSMITTED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AMONG PREGNANT-WOMEN IN A RURAL FLORIDA COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEXUAL-BEHAVIOR; UNITED-STATES; TRANSMISSION; CRACK; RISK; EPIDEMIOLOGY; AIDS; HIV	Background. In the United States, an increasing proportion of women infected with the human immunodeficiency virus (HIV) live in nonmetropolitan areas. Little is known, however, about the risk factors for HIV transmission in women outside large cities. Methods. We interviewed and tested 1082 (99.8 percent) of 1084 consecutive pregnant women who registered for prenatal care at a public health clinic in western Palm Beach County, Florida. This rural agricultural area of about 36,000 people is known to have a high prevalence of HIV infection. Results. The seroprevalence of HIV was 5.1 percent (52 of 1011 women). Black women who were neither Haitian nor Hispanic had the highest rate of infection (8.3 percent [48 of 575]). Only 4 of 1009 women (0.4 percent) reported ever injecting drugs, and the 4 were HIV-sero-negative; however, 14 of 43 users of "crack" cocaine (33 percent) had HIV infection. At prenatal registration, 131 of 983 women (13 percent) tested positive for gonorrhea, chlamydial infection, or syphilis. By multivariate logistic-regression analysis, HIV infection was found to be independently associated with having used crack cocaine (odds ratio, 3.3; P<0.001), having had more than two sexual partners (odds ratio, 4.6; P<0.001), being black but neither Hispanic nor Haitian (odds ratio, 11; P<0.001), having had sexual intercourse with a high-risk partner (odds ratio, 5.6; P<0.001), and testing positive for syphilis (odds ratio, 3.1; P = 0.015). Nevertheless, 11 of the 52 HIV-infected women (21 percent) reported a total of only two to five sexual partners and no known high-risk partners, had never used crack cocaine, and had no positive tests for sexually transmitted disease. Conclusions. In the rural community we studied, most of the women with HIV infection acquired it through heterosexual contact. The increasing seroprevalence of HIV and the increasing incidence of syphilis and use of crack cocaine mean that other women may be at similar risk of acquiring heterosexually transmitted HIV infection.	FLORIDA STATE DEPT HLTH & REHABIL SERV,DIST 9 OFF,W PALM BEACH,FL; FLORIDA STATE DEPT HLTH & REHABIL SERV,AIDS PROGRAM,TALLAHASSEE,FL		ELLERBROCK, TV (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,1600 CLIFTON RD NE,MAILSTOP E-45,ATLANTA,GA 30333, USA.							ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; BOWEN GS, 1990, FAM PLANN PERSPECT, V22, P62, DOI 10.2307/2135510; CARLSON RG, 1991, J PSYCHOACTIVE DRUGS, V23, P11, DOI 10.1080/02791072.1991.10472570; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; CHIPHANGWI I, 1990, 6TH INT C AIDS SAN F, V1, P158; DARROW WW, 1988, 4TH P INT C AIDS STO, V1, P273; DEBUONO BA, 1990, NEW ENGL J MED, V322, P821, DOI 10.1056/NEJM199003223221206; DEHOVITZ J, 1991, 7TH INT C AIDS FLOR, V2, P320; EDLIN B, 1991, 7TH INT C AIDS FLOR, V2, P68; ELLERBROCK TV, 1991, JAMA-J AM MED ASSOC, V265, P2971, DOI 10.1001/jama.265.22.2971; FRIEDMAN SR, 1988, 4TH INT C AIDS ABSTR, V2, P396; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; LAGA M, 1990, 6TH INT C AIDS SAN F, V1, P158; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; Lieb S, 1988, J Fla Med Assoc, V75, P301; MATI J, 1991, 7TH INT C AIDS FLOR, V2, P319; NARKUNAS JP, 1989, 5TH P INT C AIDS MON, P101; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; PUCCIO PS, 1991, DRUG OTHER SUBSTANCE; ROLFS RT, 1990, JAMA-J AM MED ASSOC, V264, P1432, DOI 10.1001/jama.264.11.1432; SMITH TW, 1991, FAM PLANN PERSPECT, V23, P102, DOI 10.2307/2135820; WASSER S, 1991, 119TH ANN M AM PUBL, P6; Wilkinson Alec., 1989, BIG SUGAR SEASONS CA; 1991, CENSUS POPULATION HO	25	104	105	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1704	1709		10.1056/NEJM199212103272402	http://dx.doi.org/10.1056/NEJM199212103272402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1308669	Bronze			2022-12-28	WOS:A1992KA89700002
J	TRIAS, J; JARLIER, V; BENZ, R				TRIAS, J; JARLIER, V; BENZ, R			PORINS IN THE CELL-WALL OF MYCOBACTERIA	SCIENCE			English	Article							PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; TUBERCULOSIS; INFECTION; MEMBRANE; BARRIER	The cell wall of mycobacteria is an efficient permeability barrier that makes mycobacteria naturally resistant to most antibiotics. Liposome swelling assays and planar bilayer experiments were used to investigate the diffusion process of hydrophilic molecules through the cell wall of Mycobacterium chelonae and identify the main hydrophilic pathway. A 59-kilodalton cell wall protein formed a water-filled channel with a diameter of 2.2 nanometers and an average single-channel conductance equal to 2.7 nanosiemens in 1 M potassium chloride. These results suggest that porins can be found in the cell wall of a Gram-positive bacterium. A better knowledge of the hydrophilic pathways should help in the design of more effective antimycobacterial agents.	UNIV PARIS 06,BACTERIOL VIROL LAB,F-75634 PARIS 13,FRANCE; UNIV WURZBURG,LEHRSTUHL BIOTECHNOL,W-8700 WURZBURG,GERMANY	UDICE-French Research Universities; Sorbonne Universite; University of Wurzburg				Benz, Roland/0000-0002-9510-9265				BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0; DRAPER P, 1982, BIOL MYCOBACTERIA, P9; HIRSCHFIELD GR, 1990, J BACTERIOL, V172, P1005, DOI 10.1128/jb.172.2.1005-1013.1990; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; JARLIER V, 1991, ANTIMICROB AGENTS CH, V35, P1937, DOI 10.1128/AAC.35.9.1937; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; Minnikin DE, 1987, CHEMOTHERAPY TROPICA, P19; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; TRIAS J, UNPUB; WHEELER PR, 1988, BRIT MED BULL, V44, P547, DOI 10.1093/oxfordjournals.bmb.a072267; YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308; 1982, TUBERCLE, V63, P157	16	164	173	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1479	1481		10.1126/science.1279810	http://dx.doi.org/10.1126/science.1279810			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279810				2022-12-28	WOS:A1992JZ62500027
J	CAUX, C; DEZUTTERDAMBUYANT, C; SCHMITT, D; BANCHEREAU, J				CAUX, C; DEZUTTERDAMBUYANT, C; SCHMITT, D; BANCHEREAU, J			GM-CSF AND TNF-ALPHA COOPERATE IN THE GENERATION OF DENDRITIC LANGERHANS CELLS	NATURE			English	Article							COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; IDENTIFICATION; PROLIFERATION; VIABILITY; BLOOD	DENDRITIC cells comprise a system of highly efficient antigen-presenting cells which initiate immune responses such as the sensitization of T cells restricted by major histocompatibility complex molecules, the rejection of organ transplants and the formation of T-cell-dependent antibodies. Dendritic cells are found in many non-lymphoid tissues, such as skin (Langerhans cells) and mucosa, and they migrate after antigen capture through the afferent lymph or the bloodstream to lymphoid organs, where they efficiently present antigen to T cells1. Dendritic cells are difficult to isolate and, although they originate from bone marrow2,3 their site of maturation and the conditions that direct their growth and differentiation are still poorly characterized. Granulocyte macrophage-colony stimulating factor (GM-CSF) favours the outgrowth of dendritic cells from mouse peripheral blood4. Here we extend this finding to man and demonstrate that cooperation between GM-CSF and tumour necrosis factor-alpha (TNF-alpha) is crucial for the generation of human dendritic/Langerhans cells from CD34+ haematopoietic progenitors. The availability of large numbers of these cells should now facilitate the understanding of their role in immunological regulation and disorder.	HOP EDOUARD HERRIOT, INSERM, U346, F-69437 LYON 03, FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	CAUX, C (corresponding author), SCHERING PLOUGH CORP, IMMUNOL RES LAB, 27 CHEMIN PEUPLIERS, BP 11, F-69571 DARDILLY, FRANCE.		Caux, Christophe/G-2851-2013; dezutter-dambuyant, colette/F-5962-2013	Caux, Christophe/0000-0003-2438-833X; dezutter-dambuyant, colette/0000-0002-3866-4537				CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CAUX C, 1990, BLOOD, V75, P2292; CAUX C, 1991, BLOOD, V78, P635; CROW MK, 1982, CLIN EXP IMMUNOL, V49, P338; DEZUTTERDAMBUYANT C, 1989, HYBRIDOMA, V8, P199, DOI 10.1089/hyb.1989.8.199; DEZUTTERDAMBUYANT C, 1985, J INVEST DERMATOL, V84, P465, DOI 10.1111/1523-1747.ep12272371; DJEU JY, 1992, TUMOR NECROSIS FACTO, P531; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GHIARA P, 1987, J IMMUNOL, V139, P3676; HART DNJ, 1988, J EXP MED, V168, P157, DOI 10.1084/jem.168.1.157; HEUFLER C, 1988, J EXP MED, V167, P700, DOI 10.1084/jem.167.2.700; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; KNIGHT SC, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P145; KOCH F, 1990, J EXP MED, V171, P159, DOI 10.1084/jem.171.1.159; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; LUGER TA, 1989, ACTA DERM-VENEREOL, V69, P61; MALIK STA, 1992, TUMOR NECROSIS FACTO, P407; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; ROMANI N, 1989, J INVEST DERMATOL, V93, P600, DOI 10.1111/1523-1747.ep12319727; SORNASSE T, 1992, J EXP MED, V175, P15, DOI 10.1084/jem.175.1.15; STEINMAN RM, 1974, J EXP MED, V139, P1431, DOI 10.1084/jem.139.6.1431; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; VANDERIJN M, 1984, HUM IMMUNOL, V9, P201, DOI 10.1016/0198-8859(84)90025-9; VANVOORHIS WC, 1982, J EXP MED, V155, P1172, DOI 10.1084/jem.155.4.1172; VANVOORHIS WC, 1983, J EXP MED, V158, P174, DOI 10.1084/jem.158.1.174; WITMERPACK MD, 1987, J EXP MED, V166, P1484, DOI 10.1084/jem.166.5.1484	29	1426	1480	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1992	360	6401					258	261		10.1038/360258a0	http://dx.doi.org/10.1038/360258a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1279441				2022-12-28	WOS:A1992JY96000051
J	NIKAIDO, H; SAIER, MH				NIKAIDO, H; SAIER, MH			TRANSPORT PROTEINS IN BACTERIA - COMMON THEMES IN THEIR DESIGN	SCIENCE			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; COLI LACTOSE CARRIER; AMINO-ACID-RESIDUES; ESCHERICHIA-COLI; BINDING-PROTEIN; MALTOSE TRANSPORT; OUTER-MEMBRANE; MANNITOL PERMEASE; ATP HYDROLYSIS; LAC PERMEASE	Bacterial transport proteins mediate passive and active transport of small solutes across membranes. Comparison of amino acid sequences shows strong conservation not only among bacterial transporters, but also between them and many transporters of animal cells; thus the study of bacterial transporters is expected to contribute to our understanding of transporters in more complex cells. During the last few years, structures of three bacterial outer membrane transporters were solved by x-ray crystallography. Much progress has also occurred in the biochemical and molecular genetic studies of transporters in the cytoplasmic membranes of bacteria, and a unifying design among membrane transporters is gradually emerging. Common structural motives and evolutionary origins among transporters with diverse energy-coupling mechanisms suggest that many transporters contain a central module forming a transmembrane channel through which the solute may pass. Energy-coupling mechanisms can be viewed as secondary features added on to these fundamental translocation units.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	NIKAIDO, H (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.		Wood, David W/B-2992-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702, R01AI014176] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-14176, AI-21702, AI-9044] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AERTS T, 1990, J BIOL CHEM, V265, P8675; ALLOING G, 1990, MOL MICROBIOL, V4, P633, DOI 10.1111/j.1365-2958.1990.tb00632.x; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P9083; BAUER K, 1989, J BIOL CHEM, V264, P16393; BENZ R, 1987, J MEMBRANE BIOL, V100, P21, DOI 10.1007/BF02209137; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BOTFIELD MC, 1990, RES MICROBIOL, V141, P328, DOI 10.1016/0923-2508(90)90006-C; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BROOKER RJ, 1990, RES MICROBIOL, V141, P309, DOI 10.1016/0923-2508(90)90004-A; BROOKER RJ, 1990, J BIOL CHEM, V265, P4155; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; BUHR A, 1992, J BIOL CHEM, V267, P3847; BUHR A, COMMUNICATION; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DASSA E, COMMUNICATION; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8947; DEAN DA, 1989, P NATL ACAD SCI USA, V86, P9134, DOI 10.1073/pnas.86.23.9134; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P218; ERNI B, 1986, BIOCHEMISTRY-US, V25, P305, DOI 10.1021/bi00350a004; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; GARAVITO RM, 1980, J CELL BIOL, V86, P127; GRENIER FC, 1986, J CELL BIOCHEM, V31, P97, DOI 10.1002/jcb.240310203; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; HENDERSON PJF, 1990, RES MICROBIOL, V141, P316, DOI 10.1016/0923-2508(90)90005-B; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; KABACK HR, 1986, ANN NY ACAD SCI, V456, P291; KING SC, 1989, J BIOL CHEM, V264, P7390; KING SC, 1990, J BIOL CHEM, V265, P3153; KING SC, 1990, J BIOL CHEM, V265, P9645; KING SC, 1990, J BIOL CHEM, V265, P9638; KLAWITTER S, COMMUNICATION; LENGELER JW, 1990, PHILOS T ROY SOC B, V326, P489, DOI 10.1098/rstb.1990.0027; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P6721, DOI 10.1021/bi00241a013; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P6716, DOI 10.1021/bi00241a012; LUCKEY M, 1980, BIOCHEM BIOPH RES CO, V93, P166, DOI 10.1016/S0006-291X(80)80261-0; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MALONEY PC, 1990, RES MICROBIOL, V141, P374, DOI 10.1016/0923-2508(90)90015-I; MANYAN R, 1988, J BACTERIOL, V170, P1290; MARGER MD, IN PRESS TRENDS BIOC; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; MITCHELL P, 1990, RES MICROBIOL, V141, P286, DOI 10.1016/0923-2508(90)90002-8; MITCHELL PETER, 1967, COMPR BIO CHEM, V22, P167; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; NEWMAN MJ, 1980, J BIOL CHEM, V255, P583; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; NIKAIDO H, 1985, J MEMBRANE BIOL, V85, P87, DOI 10.1007/BF01872008; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; POSTLE K, 1990, MOL MICROBIOL, V4, P2027; POSTMA PW, 1981, J BACTERIOL, V147, P382, DOI 10.1128/JB.147.2.382-389.1981; RACKER E, 1979, ARCH BIOCHEM BIOPHYS, V198, P470, DOI 10.1016/0003-9861(79)90521-6; REIZER A, 1991, J MOL EVOL, V33, P179, DOI 10.1007/BF02193633; REIZER J, 1992, PROTEIN SCI, V1, P722, DOI 10.1002/pro.5560010604; ROEPE PD, 1990, RES MICROBIOL, V141, P290, DOI 10.1016/0923-2508(90)90003-9; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P5682, DOI 10.1021/bi00319a003; RUIJTER GJG, 1992, J BACTERIOL, V174, P2843, DOI 10.1128/JB.174.9.2843-2850.1992; RUSSELL RRB, 1992, J BIOL CHEM, V267, P4631; RUTZ JM, IN PRESS SCIENCE; SAIER MH, 1990, RES MICROBIOL, V141, P281, DOI 10.1016/0923-2508(90)90001-7; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SCHILTZ E, 1991, EUR J BIOCHEM, V199, P587, DOI 10.1111/j.1432-1033.1991.tb16158.x; SCHNETZ K, 1990, J BIOL CHEM, V265, P13464; SEN K, 1990, P NATL ACAD SCI USA, V87, P743, DOI 10.1073/pnas.87.2.743; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P4046, DOI 10.1021/bi00362a009; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; TRIAS J, 1989, ANTIMICROB AGENTS CH, V33, P1201, DOI 10.1128/AAC.33.8.1202; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P9478, DOI 10.1021/bi00103a013; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WHITE DW, 1990, J BACTERIOL, V172, P1509, DOI 10.1128/jb.172.3.1509-1515.1990; WILSON DB, 1978, ANNU REV BIOCHEM, V47, P933, DOI 10.1146/annurev.bi.47.070178.004441; WRUBEL W, 1990, J BACTERIOL, V172, P5374, DOI 10.1128/jb.172.9.5374-5381.1990; WU LF, 1990, MOL MICROBIOL, V4, P1219, DOI 10.1111/j.1365-2958.1990.tb00698.x	91	176	178	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					936	942		10.1126/science.1279804	http://dx.doi.org/10.1126/science.1279804			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1279804				2022-12-28	WOS:A1992JW79600022
J	ROSENBLATT, RA; WHITCOMB, ME; CULLEN, TJ; LISHNER, DM; HART, LG				ROSENBLATT, RA; WHITCOMB, ME; CULLEN, TJ; LISHNER, DM; HART, LG			WHICH MEDICAL-SCHOOLS PRODUCE RURAL PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WAMI PROGRAM PARTICIPANTS; SPECIALTY DISTRIBUTIONS; UNITED-STATES; PRIMARY CARE; EDUCATION; AREAS; NONPARTICIPANTS; CURRICULUM; POLICY; CHOICE	Objective.-To examine the hypothesis that medical schools vary systematically and predictably in the proportion of their graduates who enter rural practice. Design.-The December 1991 version of the American Medical Association Physician Masterfile was used to examine the rural and urban practice locations of physicians who graduated from American medical schools between 1976 and 1985. Selected characteristics of the medical schools-including location, ownership, and funding-were linked to the Physician Masterfile. Main Outcome Measures.-The percentage of the graduates from each medical school who were practicing in rural areas in December 1991, disaggregated by physician specialty. Results.-Of the practicing graduates from our study, 12.6% were located in rural counties; family physicians were much more likely than members of other specialties to select rural practice, particulady in the smallest and most isolated rural counties. Women were much less likely than men to enter rural practice. Medical schools varied greatly in the percentage of their graduates who entered rural practice, ranging from 41.2% to 2.3% of the graduating classes studied. Twelve medical schools accounted for over one quarter of the physicians entering rural practice in this time period. Four variables were strongly associated with a tendency to produce rural graduates: location in a rural state, public ownership, production of family physicians, and smaller amounts of funding from the National Institutes of Health. Discussion.-The organization, location, and mission of medical schools is closely related to the propensity of their graduates to select rural practice. Increasing policy coordination among medical schools and state and federal governmental entities would most effectively address residual problems of rural physician shortages.			ROSENBLATT, RA (corresponding author), UNIV WASHINGTON,SCH MED,WAMI RURAL HLTH RES CTR,DEPT FAMILY MED,HQ-30,SEATTLE,WA 98195, USA.				NIAMS NIH HHS [HAR000017-03] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADKINS RJ, 1987, J MED EDUC, V62, P810; BARTLETT AA, 1992, PHYSICS TODAY    JAN, P67; Boulger J G, 1991, J Rural Health, V7, P105, DOI 10.1111/j.1748-0361.1991.tb00713.x; Brazeau N K, 1990, Fam Med, V22, P350; BRUCE TA, 1990, ACAD MED, V65, pS10, DOI 10.1097/00001888-199012000-00026; BURFIELD WB, 1986, J MED EDUC, V61, P545; Butler M. A., 1990, RURAL URBAN CONTINUU; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; COOPER JK, 1977, AM J PUBLIC HEALTH, V67, P756, DOI 10.2105/AJPH.67.8.756; CORDES SM, 1978, W J MED, V189, P75; DOR A, 1989, 65009 URB I WORK PAP; FRENZEN PD, 1991, AM J PUBLIC HEALTH, V81, P1141, DOI 10.2105/AJPH.81.9.1141; GARRARD J, 1977, J MED EDUC, V52, P802; GINSBURG PB, 1990, HEALTH AFFAIR, V9, P178, DOI 10.1377/hlthaff.9.1.178; HAUG MR, 1980, J MED EDUC, V55, P333; Hewitt Maria, 1989, DEFINING RURAL AREAS; IMBEMBO AL, 1986, SURGERY, V100, P72; Jacoby I, 1991, J Rural Health, V7, P427; JOHNSON KG, 1975, J MED EDUC, V50, P38; JOHNSON V, 1980, AM J RURAL HLTH, V5, P1; KEGELFLOM P, 1977, J MED EDUC, V52, P204; Kindig D A, 1991, J Rural Health, V7, P313; KINDIG DA, 1990, ACAD MED, V65, pS15, DOI 10.1097/00001888-199012000-00027; KINDIG DA, 1989, HEALTH AFFAIR, V8, P63, DOI 10.1377/hlthaff.8.2.63; LANKFORD PM, 1977, J MED EDUC, V52, P982; LEROY L, 1977, HLTH PROFESSIONS ED; MORGAN JL, 1986, J MED EDUC, V61, P11; NEWHOUSE JP, 1982, JAMA-J AM MED ASSOC, V247, P2392, DOI 10.1001/jama.247.17.2392; PAIVA REA, 1982, J MED EDUC, V57, P666; PETERSDORF RG, 1990, ACAD MED S, pS65; Pusey WA, 1925, J AMER MED ASSOC, V84, P281, DOI 10.1001/jama.1925.26620300002013; RABINOWITZ HK, 1988, NEW ENGL J MED, V319, P480, DOI 10.1056/NEJM198808253190805; RABINOWITZ HK, 1986, J MED EDUC, V61, P598; ROBACK G, 1990, PHYSICIAN CHARACTERI; ROSENBLATT RA, 1991, WESTERN J MED, V154, P43; ROWLEY BD, 1991, JAMA-J AM MED ASSOC, V266, P933, DOI 10.1001/jama.266.7.933; Schmittling G, 1991, Fam Med, V23, P297; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; SCHWARTZ WB, 1980, NEW ENGL J MED, V303, P1032, DOI 10.1056/NEJM198010303031803; TARLOV AR, 1980, NEW ENGL J MED, V303, P1058, DOI 10.1056/NEJM198010303031811; VERBY JE, 1991, JAMA-J AM MED ASSOC, V266, P110, DOI 10.1001/jama.266.1.110; WILLOUGHBY TL, 1981, J MED EDUC, V56, P717; Yett D E, 1974, Inquiry, V11, P125; ZUIDEMA GD, 1982, SURG CLIN N AM, V62, P603; 1978, MANPOWER POLICY PRIM; 1988, PHS 1ST COUNC GRAD M, P1; 1992, MED SCH ADM REQUIREM, P192; 1978, US DHEW HRA7811 HLTH; 1990, GAOHRD90128 NAT HLTH	49	148	148	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1559	1565		10.1001/jama.268.12.1559	http://dx.doi.org/10.1001/jama.268.12.1559			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1308662				2022-12-28	WOS:A1992JN25600026
J	SAMPSON, HA; MENDELSON, L; ROSEN, JP				SAMPSON, HA; MENDELSON, L; ROSEN, JP			FATAL AND NEAR-FATAL ANAPHYLACTIC REACTIONS TO FOOD IN CHILDREN AND ADOLESCENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; MAST-CELLS; ALLERGY; INFANTS; RELEASE; MICE	Background and Methods. Reports of fatal or near-fatal anaphylactic reactions to foods in children and adolescents are rare. We identified six children and adolescents who died of anaphylactic reactions to foods and seven others who nearly died and required intubation. All the cases but one occurred in one of three metropolitan areas over a period of 14 months. Our investigations included a review of emergency medical care reports, medical records, and depositions by witnesses to the events, as well as interviews with parents (and some patients). Results. Of the 13 children and adolescents (age range, 2 to 17 years), 12 had asthma that was well controlled. All had known food allergies, but had unknowingly ingested the foods responsible for the reactions. The reactions were to peanuts (four patients), nuts (six patients), eggs (one patient), and milk (two patients), all of which were contained in foods such as candy, cookies, and pastry. The six patients who died had symptoms within 3 to 30 minutes of the ingestion of the allergen, but only two received epinephrine in the first hour. All the patients who survived had symptoms within 5 minutes of allergen ingestion, and all but one received epinephrine within 30 minutes. The course of anaphylaxis was rapidly progressive and uniphasic in seven patients; biphasic, with a relatively symptom-free interval in three; and protracted in three, requiring intubation for 3 to 21 days. Conclusions. Dangerous anaphylactic reactions to food occur in children and adolescents. The failure to recognize the severity of these reactions and to administer epinephrine promptly increases the risk of a fatal outcome.	UNIV CONNECTICUT,HARTFORD HOSP,HARTFORD,CT 06112; JOHNS HOPKINS UNIV,SCH MED,DIV PEDIAT ALLERGY & IMMUNOL,BALTIMORE,MD 21205	Hartford Hospital; University of Connecticut; Johns Hopkins University					NCRR NIH HHS [RR00052] Funding Source: Medline; NIAID NIH HHS [AI24439] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1987, PEDIATRICS, V79, P683; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; HA TY, 1987, EXP CELL BIOL, V5, P63; HIDE DW, 1983, BRIT J CLIN PRACT, V37, P285; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SLOAN AE, 1986, J ALLERGY CLIN IMMUN, V78, P127, DOI 10.1016/0091-6749(86)90002-3; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; STARNES HF, 1990, J IMMUNOL, V145, P4185; TAKEISHI T, 1991, J CLIN INVEST, V88, P598, DOI 10.1172/JCI115344; VECCHIARELLI A, 1992, CLIN EXP ALLERGY, V22, P365, DOI 10.1111/j.1365-2222.1992.tb03097.x; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	19	1266	1306	1	98	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					380	384		10.1056/NEJM199208063270603	http://dx.doi.org/10.1056/NEJM199208063270603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1294076				2022-12-28	WOS:A1992JG35600003
J	BORTIN, MM; HOROWITZ, MM; GALE, RP; BARRETT, AJ; CHAMPLIN, RE; DICKE, KA; GLUCKMAN, E; KOLB, HJ; MARMONT, AM; MRSIC, M; SOBOCINSKI, KA; WEINER, RS; RIMM, AA				BORTIN, MM; HOROWITZ, MM; GALE, RP; BARRETT, AJ; CHAMPLIN, RE; DICKE, KA; GLUCKMAN, E; KOLB, HJ; MARMONT, AM; MRSIC, M; SOBOCINSKI, KA; WEINER, RS; RIMM, AA			CHANGING TRENDS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA IN THE 1980S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VERSUS-HOST DISEASE; CYTOMEGALO-VIRUS INFECTION; TOTAL-BODY IRRADIATION; T-CELL DEPLETION; ACUTE NONLYMPHOBLASTIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; INTRAVENOUS IMMUNE GLOBULIN; ACUTE GRAFT; INCREASING UTILIZATION; APLASTIC-ANEMIA	Objective.-To identify changes in practice and outcome of bone marrow transplants for leukemia in the 1980s. Design.-Comparison of key explanatory and outcome variables in five 2-year cohorts, from 1980 through 1981 to 1988 through 1989, using a large database of detailed clinical information. Patients.-Recipients (7788) of bone marrow transplants for acute lymphoblastic, acute myelogenous, or chronic myelogenous leukemia reported to the International Bone Marrow Transplant Registry, Milwaukee, Wis, by 185 transplant teams worldwide. Results.-Linear increases occurred during the periods 1980 through 1981 to 1988 through 1989 as follows with 95% confidence intervals: (1) transplants for chronic myelogenous leukemia from 14%+/-2% to 35%+/-2%; (2) transplants from unrelated donors from 1%+/-1% to 7%+/-1%; (3) preparative regimens without radiation from 3%+/-1% to 30%+/-2%; and (4) use of methotrexate plus cyclosporine to prevent graft-vs-host disease from 2%+/-1% to 55%+/-2%. Among recipients of human lymphocyte antigen-identical sibling bone marrow, the 2-year probability of treatment-related mortality decreased by 6% to 22%. The probability of relapse decreased from 46%+/-6% to 38%+/-6% in intermediate leukemia but did not change appreciably in early or advanced leukemia. Probabilities of leukemia-free survival improved from 51%+/-4% to 57%+/-3% in early leukemia, from 28%+/-4% to 36%+/-5% in intermediate leukemia, and from 12%+/-4% to 18%+/-5% in advanced leukemia. A separate analysis of a homogenous population of patients indicated that improvements in outcome in the 1980s were due to improvements in transplant practice rather than improved patient selection. Conclusions.-Modest increases in leukemia-free survival rates occurred after human lymphocyte antigen-identical sibling bone marrow transplants in the 1980s. Improvements were due primarily to reductions in treatment-related mortality with little or no change in relapse risk. More effective antileukemia strategies and continued reductions in treatment-related toxic effects are needed.	MED COLL WISCONSIN, INT BONE MARROW TRANSPLANT REGISTRY, POB 26509, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DIV CANC & BLOOD DIS, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DIV BIOSTAT CLIN EPIDEMIOL, MILWAUKEE, WI 53226 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA 90024 USA; ROYAL POSTGRAD MED SCH, LONDON W12 0HS, ENGLAND; MD ANDERSON CANC CTR, HOUSTON, TX USA; CTR CANC PREVENT & TREATMENT, HOUSTON, TX USA; HOP ST LOUIS, F-75010 PARIS, FRANCE; UNIV MUNICH, W-8000 MUNICH 2, GERMANY; OSPED SAN MARTINO GENOVA, GENOA, ITALY; UNIV CROATIA, ZAGREB, CROATIA; UNIV FLORIDA, GAINESVILLE, FL 32611 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; University of California System; University of California Los Angeles; Imperial College London; University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Munich; University of Genoa; IRCCS AOU San Martino IST; State University System of Florida; University of Florida			horowitz, Mary/ABH-2173-2021; eliane, Gluckman/AAA-5024-2021		NCI NIH HHS [P01-CA-40053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPERLEY JF, 1986, BONE MARROW TRANSPL, V1, P53; ASH RC, 1989, BLOOD, V74, pA163; ATKINSON K, 1991, EXP HEMATOL, V19, P578; BIGGS JC, 1986, TRANSPLANT P, V18, P253; BLUME KG, 1987, BLOOD, V69, P1015; BORTIN MM, 1989, TRANSPLANTATION, V48, P453, DOI 10.1097/00007890-198909000-00021; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; BORTIN MM, 1986, TRANSPLANTATION, V42, P229, DOI 10.1097/00007890-198609000-00001; BROCHSTEIN JA, 1987, NEW ENGL J MED, V317, P1618, DOI 10.1056/NEJM198712243172602; CLIFT R, 1989, BONE MARROW TRANSPL, V4, P445; CLIFT RA, 1987, BONE MARROW TRANSPL, V2, P243; Cochran W.G., 2007, SAMPLING TECHNIQUES; DEEG HJ, 1985, BLOOD, V65, P1325, DOI 10.1182/blood.V65.6.1325.bloodjournal6561325; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; FORMAN SJ, 1987, TRANSPLANT P, V19, P2605; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GOTTLIEB DJ, 1989, BLOOD, V74, P2335; GRATWOHL A, 1987, Bone Marrow Transplantation, V2, P15; HERZIG RH, 1985, SEMIN ONCOL, V12, P184; HOROWITZ MM, 1989, BONE MARROW TRANSPL, V4, P221; KLINTMALM G, 1985, SCAND J INFECT DIS, V17, P157, DOI 10.3109/inf.1985.17.issue-2.06; MARMONT AM, 1991, BLOOD, V78, P2120, DOI 10.1182/blood.V78.8.2120.bloodjournal7882120; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; NAVARI RM, 1984, AM J MED, V76, P564, DOI 10.1016/0002-9343(84)90274-2; PETERSEN FB, 1987, SCAND J INFECT DIS, V19, P559, DOI 10.3109/00365548709032423; PRENTICE HG, 1984, LANCET, V1, P472; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; RINGDEN O, 1986, BONE MARROW TRANSPL, V1, P41; SANTOS GW, 1983, NEW ENGL J MED, V309, P1347, DOI 10.1056/NEJM198312013092202; STORB R, 1985, BLOOD, V66, P698; STORB R, 1986, BLOOD, V68, P119; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; STORB R, 1970, TRANSPLANTATION, V9, P240, DOI 10.1097/00007890-197003000-00007; THOMAS ED, 1982, INT J RADIAT ONCOL, V8, P817, DOI 10.1016/0360-3016(82)90083-9; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TORLONTANO G, 1981, EUR BONE MARROW TRAN, P41; TORRES A, 1989, BLUT, V58, P63, DOI 10.1007/BF00320650; TUTSCHKA PJ, 1986, VOX SANG, V51, P87, DOI 10.1111/j.1423-0410.1986.tb02014.x; WALDMANN H, 1984, LANCET, V2, P483; WINSTON DJ, 1987, ANN INTERN MED, V106, P12, DOI 10.7326/0003-4819-106-1-12	40	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					607	612						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF473	1321298				2022-12-28	WOS:A1992JF47300024
J	HAUGHN, L; GRATTON, S; CARON, L; SEKALY, RP; VEILLETTE, A; JULIUS, M				HAUGHN, L; GRATTON, S; CARON, L; SEKALY, RP; VEILLETTE, A; JULIUS, M			ASSOCIATION OF TYROSINE KINASE P56(LCK) WITH CD4 INHIBITS THE INDUCTION OF GROWTH THROUGH THE ALPHA-BETA T-CELL RECEPTOR	NATURE			English	Article							ANTIGEN RECEPTOR; LYMPHOCYTES-T; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; CROSS-LINKING; L3T4 MOLECULE; ACTIVATION; P56LCK; EXPRESSION; COMPLEX	THE membrane glycoprotein CD4 enhances antigen-mediated activation of T cells restricted by class II molecules of the major histocompatibility complex (MHC)1-3. This positive function has been attributed to the protein tyrosine kinase p56lck (ref. 4), which is noncovalently associated with the cytoplasmic portion of CD45,6, and is activated on CD4 aggregation7. Antigen presentation by MHC class II molecules coaggregates CD4 and the T-cell antigen receptor (TCR-alpha-beta-CD3)8. Thus, the mutual specificity of CD4 and TCR-alpha-beta for the MHC-antigen complex results in the juxtaposition of p56lck and TCRalpha-beta-CD39-13. In contrast, antibodies can abrogate antigen-induced14-17, as well as anti induced18-20 T-cell activation, indicating that CD4 might also transduce negative signals. The molecular basis for this opposing function remains unclear. Here we show that the CD4-p56lck complex prohibits the induction of activation signals through the TCR-CD3 complex when not specifically included in the signalling process. This negative effect does not require anti-CD4 treatment, indicating that the induction of distinct negative signals is probably not involved. Rather, the results demonstrate that the CD4-p56lck complex provides prerequisite signals for antigen-receptor-induced T-cell growth and thus characterize a molecular mechanism for functional constraints imposed on T-cell activation by the MHC.	MCGILL UNIV, DEPT MICROBIOL & IMMUNOL, 3775 UNIV ST, MONTREAL H3A 2B4, QUEBEC, CANADA; MCGILL UNIV, DEPT MED, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA; INST RECH CLIN MONTREAL, IMMUNOL LAB, MONTREAL H2W 1R7, QUEBEC, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL H3G 1Y6, QUEBEC, CANADA	McGill University; McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ANDERSON P, 1987, J IMMUNOL, V139, P678; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CAMBIER JC, 1988, SCAND J IMMUNOL, V27, P59, DOI 10.1111/j.1365-3083.1988.tb02323.x; CHUCK RS, 1990, P NATL ACAD SCI USA, V87, P5021, DOI 10.1073/pnas.87.13.5021; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1987, EUR J IMMUNOL, V17, P529, DOI 10.1002/eji.1830170415; FINKEL TH, 1989, J IMMUNOL, V142, P3006; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; Ledbetter J A, 1990, Semin Immunol, V2, P99; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MOLDWIN RL, 1987, J IMMUNOL, V139, P657; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; OWENS T, 1987, P NATL ACAD SCI USA, V84, P9209, DOI 10.1073/pnas.84.24.9209; PIERRES A, 1984, J IMMUNOL, V132, P2775; ROSOFF PM, 1987, CELL, V49, P845, DOI 10.1016/0092-8674(87)90622-2; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SPRINGER TA, 1980, MONOCLONAL ANTIBODIE, P185; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WASSMER P, 1985, J IMMUNOL, V135, P2237; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0	45	147	150	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1992	358	6384					328	331		10.1038/358328a0	http://dx.doi.org/10.1038/358328a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1322497				2022-12-28	WOS:A1992JE68400063
J	ROTROSEN, D; YEUNG, CL; LETO, TL; MALECH, HL; KWONG, CH				ROTROSEN, D; YEUNG, CL; LETO, TL; MALECH, HL; KWONG, CH			CYTOCHROME-B558 - THE FLAVIN-BINDING COMPONENT OF THE PHAGOCYTE NADPH OXIDASE	SCIENCE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; AMINO-ACID-SEQUENCE; HUMAN-NEUTROPHILS; NADPH-CYTOCHROME-P-450 REDUCTASE; FLAVOPROTEIN COMPONENT; GLUTATHIONE-REDUCTASE; DIPHENYLENE IODONIUM; GENERATING OXIDASE; PLASMA-MEMBRANE	The phagocyte respiratory burst oxidase is a flavin-adenine dinucleotide (FAD)-dependent dehydrogenase and an electron transferase that reduces molecular oxygen to superoxide anion, a precursor of microbicidal oxidants. Several proteins required for assembly of the oxidase have been characterized, but the identity of its flavin-binding component has been unclear. Oxidase activity was reconstituted in vitro with only the purified oxidase proteins p47phox, p67phox, Rac-related guanine nucleotide (GTP)-binding proteins, and membrane-bound cytochrome b558. The reconstituted oxidase required added FAD, and FAD binding was localized to cytochrome b558. Alignment of the amino acid sequence of the beta-subunit of cytochrome b558 (gp91phox) with other flavoproteins revealed similarities to the nicotinamide adenine dinucleotide phosphate (reduced) (NADPH)-binding domains. Thus flavocytochrome b558 is the only obligate electron transporting component of the NADPH oxidase.			ROTROSEN, D (corresponding author), NIAID,HOST DEF LAB,BETHESDA,MD 20892, USA.			Malech, Harry/0000-0001-5874-5775				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1977, BLOOD, V50, P517; BIRKTOFT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P6166, DOI 10.1073/pnas.79.20.6166; BORREGAARD N, 1984, J BIOL CHEM, V259, P47; Branden C., 1991, INTRO PORTEIN STRUCT, pChapter 10; BREDT DS, 1986, NATURE, V25, P7906; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CROSS AR, 1982, BIOCHEM J, V208, P759, DOI 10.1042/bj2080759; DINAUER MC, 1989, J CLIN INVEST, V84, P2012, DOI 10.1172/JCI114393; DOUSSIERE J, 1986, BIOCHEM BIOPH RES CO, V139, P85, DOI 10.1016/S0006-291X(86)80083-3; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; GABIG TG, 1984, BIOCHEM BIOPH RES CO, V118, P430, DOI 10.1016/0006-291X(84)91321-4; GABIG TG, 1983, J BIOL CHEM, V258, P6352; GABIG TG, 1984, J CLIN INVEST, V73, P701, DOI 10.1172/JCI111262; GREEN TR, 1988, J BIOL CHEM, V263, P5617; HANIU M, 1986, BIOCHEMISTRY-US, V25, P7906, DOI 10.1021/bi00372a018; HANIU M, 1989, BIOCHEMISTRY-US, V28, P8639, DOI 10.1021/bi00447a054; HARPER AM, 1984, BIOCHEM J, V219, P519, DOI 10.1042/bj2190519; KAKINUMA K, 1987, J BIOL CHEM, V262, P12316; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; NONAKA Y, BIOCHEM BIOPH RES CO, V145, P1239; OHNO Y, 1986, BLOOD, V67, P1132; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROTROSEN D, UNPUB; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SCHAPIRO BL, 1991, NEW ENGL J MED, V325, P1786, DOI 10.1056/NEJM199112193252506; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, 14TH ANN PHAG WORKSH; SHERIFF S, 1981, J MOL BIOL, V145, P441, DOI 10.1016/0022-2836(81)90214-X; SMITH RM, 1989, J BIOL CHEM, V264, P1958; UMEI T, 1991, J BIOL CHEM, V266, P6019; UMEI T, 1986, J BIOL CHEM, V261, P5229; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; YEA CM, 1990, BIOCHEM J, V265, P95, DOI 10.1042/bj2650095	48	359	362	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1459	1462		10.1126/science.1318579	http://dx.doi.org/10.1126/science.1318579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1318579				2022-12-28	WOS:A1992HX33700040
J	TRUOG, RD; BRETT, AS; FRADER, J				TRUOG, RD; BRETT, AS; FRADER, J			THE PROBLEM WITH FUTILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICAL INTENSIVE-CARE; FAMILY; RESUSCITATE; PATIENT; ORDERS; POLICY; ETHICS		UNIV PITTSBURGH,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	TRUOG, RD (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.		Frader, Joel/A-8610-2010					AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; [Anonymous], 1990, CRIT CARE MED, V18, P1435; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BRAITHWAITE S, 1986, ANN INTERN MED, V104, P711, DOI 10.7326/0003-4819-104-5-711; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; CALLAHAN D, 1991, HASTINGS CENT REP, V21, P30, DOI 10.2307/3562999; CAPRON AM, 1991, HASTINGS CENT REP, V21, P26, DOI 10.2307/3562887; DANIS M, 1988, CRIT CARE MED, V16, P594, DOI 10.1097/00003246-198806000-00006; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DANIS M, 1987, CRIT CARE MED, V15, P138, DOI 10.1097/00003246-198702000-00012; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P417, DOI 10.1001/jama.266.3.417; ELSTEIN AS, 1976, SCIENCE, V194, P696, DOI 10.1126/science.982034; HACKLER JC, 1990, JAMA-J AM MED ASSOC, V264, P1281, DOI 10.1001/jama.264.10.1281; HIPPOCRATES, 1977, ETHICS MED HIST PERS, P6; LANTOS JD, 1989, AM J MED, V87, P81; LAPUMA J, 1987, WESTERN J MED, V146, P633; MEISEL A, 1989, RIGHT DIE, P104; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; PARIS JJ, 1990, NEW ENGL J MED, V322, P1012, DOI 10.1056/NEJM199004053221420; POSES RM, 1989, CRIT CARE MED, V17, P827, DOI 10.1097/00003246-198908000-00021; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; 1983, PRESIDENTS COMMISSIO, P188; 1991, NY TIMES        0705, pA8; 1986, DO NOT RESISCIATE OR, P96; 1986, DO NOT RESUSCITATE O, P83; 1987, GUIDELINES TERMINATI, P112; 1974, JAMA-J AM MED ASSOC, V227, P864; 1987, GUIDELINES TERMINATI, P32; 1991, JAMA-J AM MED ASSOC, V265, P1868	36	302	305	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1560	1564		10.1056/NEJM199206043262310	http://dx.doi.org/10.1056/NEJM199206043262310			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1285741				2022-12-28	WOS:A1992HW97200010
J	JOHNSON, E				JOHNSON, E			CRAVING NOT SUFFICIENT OR NECESSARY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2293	2293						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1314314				2022-12-28	WOS:A1992HR01500006
J	CZEIZEL, AE; DUDAS, I				CZEIZEL, AE; DUDAS, I			PREVENTION OF THE 1ST OCCURRENCE OF NEURAL-TUBE DEFECTS BY PERICONCEPTIONAL VITAMIN SUPPLEMENTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLIC-ACID SUPPLEMENTATION; RECURRENCE; FOLATE	Background. The risk of recurrent, neural-tube defects is decreased in women who take folic acid or multivitamins containing folic acid during the periconceptional period. The extent to which such supplementation can reduce the first occurrence of defects is not known. Methods. We conducted a randomized,controlled trial of periconceptional multivitamin supplementation to test the efficacy of this treatment in reducing the incidence of a first occurrence of neural-tube defects. Women planning a pregnancy (in most cases their first) were randomly assigned to receive a single tablet of a vitamin supplement (containing 12 vitamins, including 0.8 mg of folic acid; 4 minerals; and 3 trace elements) or a trace-element supplement (containing copper, manganese, zinc, and a very low dose of vitamin C ) daily for at least one month before conception and until the date of the second missed menstrual period or later. Results. Pregnancy was confirmed in 4753 women. The outcome of the pregnancy (whether the fetus or infant had a neural-tube defect or congenital malformation) was known in 2104 women who received the vitamin supplement and in 2052 who received the trace-element supplement. Congenital malformations were,significantly more prevalent in the group receiving the trace-element supplement than in the vitamin-supplement group (22.9 per 1000 vs. 13.3 per 1000, P = 0.02). There were six cases of neural-tube defects in the group receiving the trace-element supplement, as compared with none in the vitamin-supplement group (P = 0.029). The prevalence of cleft lip with or without cleft palate was not reduced by periconceptional vitamin supplementation. Conclusions. Periconceptional vitamin use decreases the incidence of a first occurrence of neural-tube defects.	WHO,COLLABORATING CTR COMMUNITY CONTROL HEREDITARY DIS,NATL INST HYG,DEPT HUMAN GENET & TERATOL,BUDAPEST,HUNGARY	World Health Organization	CZEIZEL, AE (corresponding author), OKI,GYALI UT 2-6,H-1966 BUDAPEST,HUNGARY.							BOWER C, 1992, J EPIDEMIOL COMMUN H, V46, P157, DOI 10.1136/jech.46.2.157; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; CZEIZEL A, 1970, BRIT J PREV SOC MED, V24, P205; CZEIZEL A, 1988, J MED GENET, V25, P2, DOI 10.1136/jmg.25.1.2; CZEIZEL AE, 1992, ARCH GYNECOL OBSTET, V251, P181, DOI 10.1007/BF02718384; CZEIZEL AE, 1984, AETIOLOGICAL STUDIES; CZEIZEL AE, 1988, MULTIPLE CONGENITAL; DUDAS I, 1992, TERATOLOGY, V45, P335, DOI 10.1002/tera.1420450402; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; MILLS JL, 1989, NEW ENGL J MED, V321, P430, DOI 10.1056/NEJM198908173210704; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; SMITHELLS RW, 1989, LANCET, V2, P498; SMITHELLS RW, 1980, LANCET, V1, P339; TOLAROVA M, 1982, LANCET, V2, P217; VERGEL RG, 1990, PRENATAL DIAG, V10, P149, DOI 10.1002/pd.1970100303; 1991, LANCET, V338, P131	17	2340	2425	1	129	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1992	327	26					1832	1835		10.1056/NEJM199212243272602	http://dx.doi.org/10.1056/NEJM199212243272602			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD714	1307234				2022-12-28	WOS:A1992KD71400002
J	BIKKINA, M; LARSON, MG; LEVY, D				BIKKINA, M; LARSON, MG; LEVY, D			PROGNOSTIC IMPLICATIONS OF ASYMPTOMATIC VENTRICULAR ARRHYTHMIAS - THE FRAMINGHAM HEART-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						EXTRASYSTOLE; CORONARY DISEASE; ARRHYTHMIA; MYOCARDIAL INFARCTION	ACUTE MYOCARDIAL-INFARCTION; SUDDEN-DEATH; HEALTHY-SUBJECTS; DISEASE; HYPERTROPHY; FREQUENT; COMPLEX; ECTOPY; RISK; MASS	Objective: To evaluate the prevalence and prognostic significance of asymptomatic complex or frequent ventricular premature beats detected during ambulatory electrocardiographic (ECG) monitoring. Design: Cohort study with a follow-up period of 4 to 6 years. Setting: Population-based. Participants: Surviving patients of the original Framingham Heart Study cohort and offspring of original cohort members (2727 men and 3306 women). Measurements: One-hour ambulatory electrocardiography. Results: The age-adjusted prevalence of complex or frequent arrhythmia (more than 30 ventricular premature complexes per hour or multiform premature complexes, ventricular couplets, ventricular tachycardia, or R-on-T ventricular premature complexes) was 12% (95% Cl, 11% to 13%) in the 2425 men without clinically evident coronary heart disease and 33% (Cl, 24% to 42%) in the 302 men with coronary heart disease. The corresponding values in women (3064 without disease and 242 with disease) were 12% (Cl, 11 % to 13%) and 26% (Cl, 9% to 43%). After adjusting for age and traditional risk factors for coronary heart disease in a Cox proportional hazards model, men without coronary heart disease who had complex or frequent ventricular arrhythmias were at increased risk for both all-cause mortality (relative risk, 2.30; Cl, 1.65 to 3.20) and the occurrence of myocardial infarction or death from coronary heart disease (relative risk, 2.12; Cl, 1.33 to 3.38). In men with coronary heart disease and in women with and without coronary heart disease, complex or frequent arrhythmias were not associated with an increased risk for either outcome. Conclusions: In men who do not have clinically apparent coronary heart disease, the incidental detection of ventricular arrhythmias is associated with a twofold increase in the risk for all-cause mortality and myocardial infarction or death due to coronary heart disease. The preventive and therapeutic implications of these findings await further investigation.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA; NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Harvard University; Beth Israel Deaconess Medical Center			Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254				[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1973, JAMA, V223, P1116; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; BIGGER JT, 1977, PROG CARDIOVASC DIS, V19, P255, DOI 10.1016/0033-0620(77)90005-6; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CATS VM, 1979, AM J CARDIOL, V44, P1257, DOI 10.1016/0002-9149(79)90438-7; CHIANG BN, 1969, ANN INTERN MED, V70, P1159, DOI 10.7326/0003-4819-70-6-1159; CONNOLLY SJ, 1992, AM J CARDIOL, V69, P308, DOI 10.1016/0002-9149(92)90225-N; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DESOYZA N, 1978, AM J MED, V64, P377, DOI 10.1016/0002-9343(78)90215-2; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; ELKON KB, 1977, S AFR MED J, V52, P564; FEIGENBAUM H, 1981, ECHOCARDIOGR-J CARD, P51; FISHER FD, 1973, CIRCULATION, V47, P712, DOI 10.1161/01.CIR.47.4.712; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HINKLE LE, 1969, AM J CARDIOL, V24, P629, DOI 10.1016/0002-9149(69)90451-2; HORAN MJ, 1984, JAMA-J AM MED ASSOC, V251, P380; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KENNEDY HL, 1985, NEW ENGL J MED, V312, P193, DOI 10.1056/NEJM198501243120401; KENNEDY HL, 1980, ANN INTERN MED, V92, P179, DOI 10.7326/0003-4819-92-2-179; KENNEDY HL, 1976, AM J CARDIOL, V38, P141, DOI 10.1016/0002-9149(76)90140-5; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KOPPES GM, 1980, AM J CARDIOL, V46, P322, DOI 10.1016/0002-9149(80)90079-X; KOTLER MN, 1973, CIRCULATION, V47, P959, DOI 10.1161/01.CIR.47.5.959; LEVY D, 1988, AM J CARDIOL, V62, P147, DOI 10.1016/0002-9149(88)91383-5; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1987, AM J CARDIOL, V59, P836, DOI 10.1016/0002-9149(87)91102-7; LEVY D, 1987, AM J CARDIOL, V60, P560, DOI 10.1016/0002-9149(87)90305-5; LICHSTEIN E, 1983, CIRCULATION, V67, P5; LIE KI, 1975, CIRCULATION, V52, P755, DOI 10.1161/01.CIR.52.5.755; LOWN B, 1971, CIRCULATION, V44, P130, DOI 10.1161/01.CIR.44.1.130; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; MIALL WE, 1983, BMJ-BRIT MED J, V287, P1249; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MOSS AJ, 1974, CIRCULATION, V49, P460, DOI 10.1161/01.CIR.49.3.460; MOSS AJ, 1980, PROG CARDIOVASC DIS, V23, P33, DOI 10.1016/0033-0620(80)90004-3; OLSSON G, 1984, CIRCULATION, V69, P1129, DOI 10.1161/01.CIR.69.6.1129; PELL S, 1961, JAMA-J AM MED ASSOC, V175, P463, DOI 10.1001/jama.1961.03040060037008; RABKIN SW, 1981, AM HEART J, V101, P135, DOI 10.1016/0002-8703(81)90655-4; RODSTEIN M, 1971, CIRCULATION, V44, P617, DOI 10.1161/01.CIR.44.4.617; RUBERMAN W, 1977, NEW ENGL J MED, V297, P750, DOI 10.1056/NEJM197710062971404; SWERDLOW CD, 1983, NEW ENGL J MED, V308, P1436, DOI 10.1056/NEJM198306163082402; TALAJIC M, 1991, CAN J CARDIOL, V7, P96; 1991, SAS P217 SAS I INC T; 1989, SAS STAT USERS GUIDE, V1; [No title captured]	51	150	158	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					990	996		10.7326/0003-4819-117-12-990	http://dx.doi.org/10.7326/0003-4819-117-12-990			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1280018				2022-12-28	WOS:A1992KB98000003
J	NABAVI, N; FREEMAN, GJ; GAULT, A; GODFREY, D; NADLER, LM; GLIMCHER, LH				NABAVI, N; FREEMAN, GJ; GAULT, A; GODFREY, D; NADLER, LM; GLIMCHER, LH			SIGNALING THROUGH THE MHC CLASS-II CYTOPLASMIC DOMAIN IS REQUIRED FOR ANTIGEN PRESENTATION AND INDUCES B7 EXPRESSION	NATURE			English	Article							CELL ACTIVATION ANTIGEN-B7; T-CELLS; COSTIMULATORY SIGNAL; RESTRICTED ANTIGEN; MOLECULES; RECEPTOR; TRANSLOCATION; INTERLEUKIN-2; INDUCTION; PROVIDES	CLASS II major histocompatibility complex (MHC) molecules function as antigen-presenting elements as well as signal transducers on B lymphocytes. We previously reported that a B lymphoma cell transfectant, 5C2, expressing genetically engineered I-A(k) molecules with truncated cytoplasmic domains was severely impaired in both antigen presentation and in anti-Ia-induced intracytoplasmic signalling1-5. These two functions could be restored by preculturing 5C2 cells with cyclic AMP analogues6,7. Here we demonstrate that impaired signal transduction by truncated class II molecules results in a deficiency in induction of the newly defined B-cell accessory molecule B7 (ref. 8), which can be reversed by restoration of B7 expression. These data imply that contact of the T-cell antigen receptor with MHC/antigen ligand results in signal transmission through the class II cytoplasmic domain. This signal, which can be mimicked by dibutyryl cAMP, induces expression of B7, resulting in effective antigen presentation. The fact that crosslinking of surface class II MHC also induces B7 expression on normal resting human B cells9 supports this contention.	HARVARD UNIV,SCH PUBL HLTH,665 HUNTINGTON AVE,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; ROCHE RES CTR,DEPT IMMUNOPHARMACOL,NUTLEY,NJ 07110; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR BIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Roche Holding; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Godfrey, Dale/0000-0002-3009-5472				CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHEN ZZ, 1987, J IMMUNOL, V138, P2345; DAMLE NK, 1991, EUR J IMMUNOL, V21, P1277, DOI 10.1002/eji.1830210527; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; NABAVI N, 1989, J IMMUNOL, V142, P1444; POLLOK KE, 1991, J IMMUNOL, V146, P1633; REISER H, 1992, P NATL ACAD SCI USA, V89, P271, DOI 10.1073/pnas.89.1.271; STPIERRE Y, 1991, J IMMUNOL, V147, P2875; STPIERRE Y, 1989, J IMMUNOL, V143, P808; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297; YOKOCHI T, 1982, J IMMUNOL, V128, P823	20	336	359	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					266	268		10.1038/360266a0	http://dx.doi.org/10.1038/360266a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1279442				2022-12-28	WOS:A1992JY96000054
J	WHITE, RJ; LIKAVEC, MJ				WHITE, RJ; LIKAVEC, MJ			CURRENT CONCEPTS - THE DIAGNOSIS AND INITIAL MANAGEMENT OF HEAD-INJURY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COMA; METABOLISM; TRAUMA				WHITE, RJ (corresponding author), CASE WESTERN RESERVE UNIV,METROHEALTH MED CTR,DEPT SURG,DIV NEUROSURG,3395 SCRANTON RD,CLEVELAND,OH 44109, USA.							ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1990, BRIT MED J, V300, P1515, DOI 10.1136/bmj.300.6738.1515; BULLOCK R, 1990, BRIT MED J, V300, P1576, DOI 10.1136/bmj.300.6739.1576; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Frankowski R. H., 1985, CENTRAL NERVOUS SYST, P33; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; GENNARELLI TA, 1990, CRANIOSPINAL TRAUMA, P11; GIANNOTTA SL, 1990, CRANIOSPINAL TRAUMA, P25; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; Jennett B., 1990, CRANIOSPINAL TRAUMA, P1; LEVEN HS, 1990, J NEUROSURG, V73, P699; LIVINGSTON RB, 1960, MED PHYSL BIOPHYSICS, P892; MARSHALL LE, 1990, CRANIOSPINAL TRAUMA, P37; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MILLER DJ, 1981, CLIN NEUROSURG, V29, P103; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OCONNOR DC, 1967, HIST NEUROLOGICAL SU, P1; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PLUM F, 1980, CONT NEUROLOGY SERIE, V19, P1; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; TEASDALE G, 1974, LANCET, V2, P81; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WHITE RJ, 1985, EMERGENCY DISASTER M, P418; WHITE RJ, 1982, EMERGENCY SURGERY TR, P153; 1988, ADV TRAUMA LIFE SUPP, P131	34	37	38	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1507	1511						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1306057				2022-12-28	WOS:A1992JY16500008
J	WILLETT, WC; HUNTER, DJ; STAMPFER, MJ; COLDITZ, G; MANSON, JE; SPIEGELMAN, D; ROSNER, B; HENNEKENS, CH; SPEIZER, FE				WILLETT, WC; HUNTER, DJ; STAMPFER, MJ; COLDITZ, G; MANSON, JE; SPIEGELMAN, D; ROSNER, B; HENNEKENS, CH; SPEIZER, FE			DIETARY-FAT AND FIBER IN RELATION TO RISK OF BREAST-CANCER - AN 8-YEAR FOLLOW-UP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN; CONSUMPTION; DISEASE; CARCINOGENESIS; QUESTIONNAIRE; REDUCTION; NUTRITION; HEALTH; RATS	Objective.-To address the hypotheses that dietary fat increases and fiber decreases the risk of breast cancer. Design.-Prospective cohort study with dietary assessment at baseline, using a validated, self-administered food frequency questionnaire. Setting/Participants.-89 494 women in the Nurses' Health Study who were 34 through 59 years of age in 1980 and who were followed up for 8 years (>95% complete). Results.-1439 incident cases of breast cancer were diagnosed, including 774 among postmenopausal women. After adjustment for age, established risk factors, and total energy intake, we observed no evidence of any positive association between total fat intake and breast cancer incidence (relative risks [RRs] for increasing quintiles of fat intake were 1.0, 0.85, 0.96, 0.91, and 0.90; 95% confidence interval for highest vs lowest quintile, 0.77 to 1.07). Among postmenopausal women alone, corresponding RRs were 1.0, 0.89, 1.00, 0.95, and 0.91. Comparing extreme deciles of total fat intake (greater-than-or-equal-to 49% vs <29% of total energy intake), the RR was 0.86 (95% confidence interval, 0.67 to 1.08). A similar absence of any positive association was observed without adjustment for energy intake; for tumors less than 2 cm as well as 2 cm or greater in diameter; for saturated, monounsaturated, and polyunsaturated fat; and after excluding the first 4 years of follow-up. Also, we found no suggestion of any positive association when using a more detailed and precise dietary questionnaire completed in 1984 (666 subsequent cases), even when women consuming less than 25% of energy from fat were used as the comparison group. No suggestion of a protective effect of dietary fiber was observed (RRs for increasing quintiles were 1.0, 0.95, 0.93, 1.02, and 1.02). Conclusions.-These data provide evidence against both an adverse influence of fat intake and a protective effect of fiber consumption by middle-aged women on breast cancer incidence over 8 years. Nevertheless, the positive association between intake of animal fat and risk of colon cancer observed in many studies provides ample reason to limit this source of energy.	HARVARD UNIV, SCH MED, DEPT PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University	WILLETT, WC (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA50597, CA40356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356, R01CA050597] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appleton B S, 1986, Adv Exp Med Biol, V206, P99; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Birt D F, 1986, Adv Exp Med Biol, V206, P69; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; BOYAR AP, 1988, NUTR CANCER, V11, P93, DOI 10.1080/01635588809513975; COHEN LA, 1991, JNCI-J NATL CANCER I, V83, P496, DOI 10.1093/jnci/83.7.496; COHEN LA, 1990, MED HYPOTHESES, V31, P83, DOI 10.1016/0306-9877(90)90002-V; FREEDMAN LS, 1990, CANCER RES, V50, P5710; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V134, P714; GOLDIN BR, 1982, NEW ENGL J MED, V307, P1542, DOI 10.1056/NEJM198212163072502; GOODWIN PJ, 1987, JNCI-J NATL CANCER I, V79, P473; GRAHAM S, 1982, AM J EPIDEMIOL, V116, P68, DOI 10.1093/oxfordjournals.aje.a113403; HEBERT JR, 1988, AM J CLIN NUTR, V47, P1068, DOI 10.1093/ajcn/47.6.1068; HOWE GR, 1991, J NATL CANCER I, V83, P336, DOI 10.1093/jnci/83.5.336; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; HUNTER DJ, 1991, AM J EPIDEMIOL, V134, P715; JONES DY, 1987, JNCI-J NATL CANCER I, V79, P465; KNEKT P, 1990, AM J CLIN NUTR, V52, P903, DOI 10.1093/ajcn/52.5.903; KUSHI LH, 1992, J NATL CANCER I, V84, P1092, DOI 10.1093/jnci/84.14.1092; MICOZZI MS, 1985, YEARB PHYS ANTHROPOL, V28, P175; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRENTICE R, 1990, J NATL CANCER I, V82, P129, DOI 10.1093/jnci/82.2.129; PRENTICE RL, 1988, JNCI-J NATL CANCER I, V80, P802, DOI 10.1093/jnci/80.11.802; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; ROELS OA, 1958, J NUTR, V65, P115, DOI 10.1093/jn/65.1.115; ROSE DP, 1987, JNCI-J NATL CANCER I, V78, P623; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEPHEN AM, 1990, AM J CLIN NUTR, V52, P457, DOI 10.1093/ajcn/52.3.457; STRYKER WS, 1991, J AM DIET ASSOC, V91, P172; SUN M, 1988, SCIENCE, V239, P17, DOI 10.1126/science.3336770; SWANSON CA, 1988, CANCER RES, V48, P5363; VALAORAS VG, 1969, INT J CANCER, V4, P350, DOI 10.1002/ijc.2910040312; VATTEN LJ, 1990, BRIT J CANCER, V61, P881, DOI 10.1038/bjc.1990.197; WELSCH CW, 1983, J NATL CANCER I, V70, P215; WELSCH CW, 1992, CANCER RES, V52, pS2040; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W, 1990, NUTRITIONAL EPIDEMIO; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1990, CANCER CAUSE CONTROL, V1, P103, DOI 10.1007/BF00053190; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1989, DIET HLTH; 1963, DEPT AGR HDB, V8	47	352	356	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2037	2044		10.1001/jama.268.15.2037	http://dx.doi.org/10.1001/jama.268.15.2037			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1328696				2022-12-28	WOS:A1992JT52000026
J	SURBONE, A				SURBONE, A			TRUTH TELLING TO THE PATIENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SURBONE, A (corresponding author), SANTA CHIARA HOSP,DEPT ONCOL,VIA ROMA 67,PISA,ITALY.							BOERI S, 1992, PANORAMA, V1349, P38; MOSCONI P, 1991, ANN ONCOL, V2, P273, DOI 10.1093/oxfordjournals.annonc.a057936; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; PELLEGRINO ED, 1987, JAMA-J AM MED ASSOC, V258, P1939, DOI 10.1001/jama.258.14.1939; SABBIONI MEE, 1991, ANN ONCOL, V2, P234; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; Yourcenar M., 1974, MEMOIRES HADRIEN SUI; ZITTOUN R, 1990, PSYCHOSOCIAL ASPECTS, P27; 1984, ANN INTERN MED, V101, P129; 1991, UFFICIALE FEDERAZION, V41, P1; 1991, JAMA-J AM MED ASSOC, V265, P391; 1992, 12 CORS FORM TEM BIO; 1992, ORGANO UFFICIALE FED, V40, P4; 1990, ANN ORDINE MED PROVI, P28; 1992, ORGANO UFFICIALE FED, V26, P16; 1990, ANN ORDINE MED PROVI, P27; 1992, ORGANO UFFICIALE FED, V30, P17; 1987, GUIDA ESERCIZIO PROF, P66; 1984, TRIBUNALE DIRITTI MA	19	91	91	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1661	1662						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1309178				2022-12-28	WOS:A1992JQ37600012
J	SEELEY, T				SEELEY, T			ESTROGEN REPLACEMENT THERAPY AFTER HYSTERECTOMY	BRITISH MEDICAL JOURNAL			English	Article							WOMEN	Objective-To identify those women who might benefit from oestrogen replacement after hysterectomy. Design-Targeted health screening. Setting-Large group practice. Subjects-All women aged under 50 who had had a hysterectomy. Main outcome measures-Concentration of follicle stimulating hormone, symptom profile, uptake of oestrogen replacement therapy. Results-145 of 1953 women aged 32-49 had had a hysterectomy. 35 of the 41 with bilateral oophorectomy and 27 of 104 with one or more ovaries conserved were taking oestrogen replacement. 62 of the 68 who had ovaries conserved and were not taking oestrogen replacement attended for review, of whom 14 had a follicle stimulating hormone concentration greater-than-or-equal-to 20 IU/l. 16 of the 19 women identified as potentially able to benefit from oestrogen replacement started treatment and were still on treatment at six months of follow up. Conclusion-Systematic review of women who had had a hysterectomy identified an important group who would potentially benefit from oestrogen replacement therapy.			SEELEY, T (corresponding author), NORTHGATE HOUSE,BRIDGNORTH WV16 4BU,SHROPS,ENGLAND.							BARLOW DH, 1989, BRIT J OBSTET GYNAEC, V96, P1192, DOI 10.1111/j.1471-0528.1989.tb03195.x; SIDDLE N, 1987, FERTIL STERIL, V47, P94; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434; TINDALL V, 1987, JEFFCOATES PRINCIPLE; WHITEHEAD M, 1992, HORMONE REPLACEMENT	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					811	812		10.1136/bmj.305.6857.811	http://dx.doi.org/10.1136/bmj.305.6857.811			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1301029	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JT25600026
J	MULLAN, F; POLITZER, RM; LEWIS, CT; BASTACKY, S; RODAK, J; HARMON, RG				MULLAN, F; POLITZER, RM; LEWIS, CT; BASTACKY, S; RODAK, J; HARMON, RG			THE NATIONAL-PRACTITIONER-DATA-BANK - REPORT FROM THE 1ST YEAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											MULLAN, F (corresponding author), US PHS,5600 FISHERS LN,ROOM 8-05,ROCKVILLE,MD 20857, USA.							DOBIN L, 1985, NEW ENGL J MED, V313, P1156; GRAY J, 1992, MED EC          0120, P126; HUGHS D, 1990, MED PROFESSIONAL LIA; IGLEHART J, 1987, NEW ENGL J MED, V316, P961; NOBLE K, 1988, NY TIMES        0313, P30; Noble Kenneth B, 1988, N Y Times Web, P31; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; ROBACK G, 1992, PHYSICIAN CHARACTERI; SPERNAK S, 1991, PHS913474 US DEP HLT; YESSIAN M, 1986, 0A1018600064 US DEP; 1992, FSMB NEWS RELEASE OF; 1990, ACCREDITATION MANUAL; 1987, HRD8755 GEN ACC OFF; 1988, PROFESSIONAL LIABILI; 1991, NATIONAL PRACTITIONE; 1989, IMMUNITY PEER REV PA; 1988, 1988 1989 YB DIRECTO	17	29	29	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					73	79		10.1001/jama.268.1.73	http://dx.doi.org/10.1001/jama.268.1.73			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1296591				2022-12-28	WOS:A1992JA16500026
J	MASSAGUE, J				MASSAGUE, J			RECEPTORS FOR THE TGF-BETA FAMILY	CELL			English	Review							GROWTH; INHIBITION; KINASE; CELLS				MASSAGUE, J (corresponding author), MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.			Massague, Joan/0000-0001-9324-8408				ANDRES JL, 1992, J BIOL CHEM, V267, P5927; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	22	716	773	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1067	1070		10.1016/0092-8674(92)90627-O	http://dx.doi.org/10.1016/0092-8674(92)90627-O			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1319842				2022-12-28	WOS:A1992JA43100002
J	NISHIGUCHI, S; KUROKI, T; UEDA, T; FUKUDA, K; TAKEDA, T; NAKAJIMA, S; SHIOMI, S; KOBAYASHI, K; OTANI, S; HAYASHI, N; SHIKATA, T				NISHIGUCHI, S; KUROKI, T; UEDA, T; FUKUDA, K; TAKEDA, T; NAKAJIMA, S; SHIOMI, S; KOBAYASHI, K; OTANI, S; HAYASHI, N; SHIKATA, T			DETECTION OF HEPATITIS-C VIRUS-ANTIBODY IN THE ABSENCE OF VIRAL-RNA IN PATIENTS WITH AUTOIMMUNE HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C VIRUS; AUTOIMMUNE DISEASES; RNA, VIRAL; FALSE POSITIVE REACTIONS; RECOMBINANT IMMUNOBLOT ASSAY	NON-A; GENOME; PROTEIN; ASSAY	Objective: To determine whether laboratory findings showing antibodies to hepatitis C virus (HCV) in patients with autoimmune hepatitis represent false-positive results and to identify possible explanations for true-positive results in these patients. Design: Cross-sectional. Setting. University-based hospital. Patients: Fifty-two patients with non-A, non-B chronic hepatitis as a control group and 26 patients with classic chronic active autoimmune hepatitis. Measurements: Comparison of the results of five kinds of assays of HCV antibodies and HCV RNA. Main Results: Of 52 patients with non-A, non-B chronic hepatitis, HCV antibodies (anti-HCV) were detected in 42 patients (81%; 95% Cl, 67% to 90%) by a first-generation enzyme-linked immunosorbent assay (ELISA-I), in 39 patients (75%) by Sp42 ELISA, in 37 patients (71 %) by RIA-I, in 49 patients (94%) by ELISA-II, and in 48 patients (92%) by RIBA-II. We found HCV RNA in 47 patients (90%; Cl, 79% to 97%). Of the 26 patients with autoimmune hepatitis, anti-HCV were detected in 23 patients (88%; Cl, 70% to 98%) by ELISA-I, in 12 (46%) by both RIA-I and Sp42 ELISA, in 20 (77%) by ELISA-II, and in 9 (35%) by RIBA-II. However, HCV RNA was found in only five of these patients (19%; Cl, 7% to 39%). None of our patients, including controls, had antibodies to superoxide dismutase. Of the 21 patients who had autoimmune hepatitis that was completely responsive to steroid therapy, 18 had anti-HCV by ELISA-I, but 13 of these patients had negative results by RIBA-II, and only two patients had HCV RNA. Of the five patients who did not respond to steroid treatment, all had anti-HCV by ELISA-I, four had negative results by RIBA-II, and three had HCV RNA. Conclusions: Testing for HCV antibodies in patients with autoimmune hepatitis frequently elicits positive results when the ELISA-I or ELISA-II tests are used. Most of these appear to represent false-positive results because HCV RNA is usually absent from the serum. Such false positivity may result from previous infection with HCV or from cross-reaction of an epitope of HCV. Other patients with apparent autoimmune hepatitis who fail to respond to corticosteroid therapy may actually have chronic hepatitis C (or other non-A, non-B hepatitis) infection.	NIHON UNIV, SCH MED, TOKYO 101, JAPAN	Nihon University	NISHIGUCHI, S (corresponding author), OSAKA UNIV, SCH MED, DEPT INTERNAL MED 3, 1-5-7 ASAHI MACHI, ABENO KU, OSAKA 545, JAPAN.							BASSETTI D, 1991, LANCET, V337, P912; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; ESTEBAN JI, 1989, LANCET, V2, P294; FUSCONI M, 1990, LANCET, V336, P823, DOI 10.1016/0140-6736(90)93297-3; GARSON JA, 1990, LANCET, V336, P1022, DOI 10.1016/0140-6736(90)92487-3; IKEDA Y, 1990, LANCET, V335, P1345, DOI 10.1016/0140-6736(90)91228-3; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; OKAMOTO H, 1990, JPN J EXP MED, V60, P223; QUERY CC, 1987, CELL, V51, P211, DOI 10.1016/0092-8674(87)90148-6; ROBERTSON DAF, 1987, LANCET, V2, P9; TAKAHASHI T, 1990, ACTA HEPATOL JPN, V31, P1380; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; VENTO S, 1991, LANCET, V337, P1183, DOI 10.1016/0140-6736(91)92858-Y; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q	19	94	110	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					21	25		10.7326/0003-4819-116-1-21	http://dx.doi.org/10.7326/0003-4819-116-1-21			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1309200				2022-12-28	WOS:A1992GX15700004
J	JOHNSON, EM				JOHNSON, EM			MOUSE MODEL OF GAUCHER DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, EM (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.								0	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					447	447						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1320132				2022-12-28	WOS:A1992JD47200005
J	JOHNSON, EM				JOHNSON, EM			PRENATAL COCAINE EXPOSURE AND SIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, EM (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							OLSEN GD, 1992, J PHARM EXPT THE MAY	1	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					447	447						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1320132				2022-12-28	WOS:A1992JD47200004
